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Dr. Lichtor is a practicing neurosurgeon. He has a 
number of research interests, and his brain tumor work 
is largely focused on the development of a DNA vaccine 
for treatment of primary and metastatic intracerebral 
tumors. In particular Dr. Lichtor has shown that vac-
cines prepared by transfer of DNA from the tumor into 
a highly immunogenic cell line can encompass the array 
of tumor antigens that characterize the patient’s neoplasm. Poorly im-
munogenic tumor antigens, characteristic of malignant cells, can become 
strongly antigenic if they are expressed by highly immunogenic cells. The 
introduction of the vaccine directly into the tumor bed of animals with 
an intracerebral tumor stimulates a systemic cellular anti-tumor immune 
response associated with a prolongation of survival. It is hopeful that this 
vaccine strategy will be efficacious in the treatments of patients with brain 
tumors. Dr. Lichtor is a member of the neurosurgery faculty at Rush Uni-
versity Medical Center in Chicago, Illinois.
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Although technical advances have resulted in marked improvements in the ability to diag‐
nose and surgically treat primary and metastatic brain tumors, the incidence and mortality
rates of these tumors is increasing. Particularly affected are young adults and the elderly. The
present standard treatment modalities following surgical resection including cranial irradia‐
tion and systemic or local chemotherapy each have limited efficacy and serious adverse side
effects. Furthermore the relatively few long-term survivors are inevitably left with cognitive
deficits and other disabilities. The difficulties in treating malignant gliomas can be attributed
to several factors. Glial tumors are inherently resistant to radiation and standard cytotoxic
chemotherapies. The existence of blood-brain and blood-tumor barriers impede drug delivery
to the tumor and adjacent brain infiltrated with tumor. In addition the low therapeutic index
between tumor sensitivity and toxicity to normal brain severely limits the ability to systemi‐
cally deliver therapeutic doses of drugs or radiation therapy to the tumor. New treatment
strategies for the management of patients with these tumors are urgently needed.
A number of emerging treatment strategies currently being developed are outlined in this
book. In particular advances in the molecular biology of brain tumors including the evolu‐
tion of stem cell biology, microRNAs along with angiogenesis and tumor invasion patterns
are reviewed in this book. Another emerging strategy in the treatment of brain tumors in‐
volves the stimulation of an immunologic response against the neoplastic cells. Although in
most instances proliferating tumors do not provoke anti-tumor cellular immune responses,
the hope is that the immune system can be called into play to destroy malignant cells. In
addition the tumors display a particular resistance to radiation therapy and chemotherapy.
Some of the mechanisms that enable antigenic neoplasms to escape host immunity or devel‐
op a resistance to radiation therapy or chemotherapy are reviewed in this book. Hopefully
this information coupled with advances in the understanding of the pathophysiology and
molecular biology of brain tumors which are outlined in this book will translate into novel
therapeutic treatment strategies with an emphasis on molecular targeting that should lead to
the prolongation of survival without a decline in cognitive functions or other side effects in
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Angiogenesis and Tumor Invasion
Chapter 1
Brain Tumor Invasion and Angiogenesis
Almos Klekner
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/50198
1. Introduction
It is a well-known fact that effectiveness of oncotherapy in brain tumors remains under the
expectations in comparison to anaplastic tumors of other organs. Knowing the very modest
survival rates enormous efforts of neuro-oncological researches has been made, but only
partial success is produced. Beside the extremely high proliferation rate of high grade glio‐
ma cells researches established the highly intensive invasiveness and angiogenesis as the
main reasons of treatment failure. In this chapter the main molecular mechanisms of brain
tumor invasion and angiogenesis will be discussed followed by the hopeful treatment possi‐
bilities that are already in studies and will be achievable in the near-future.
2. General a spects of glioma invasion
Malignant gliomas are the most common primary brain tumors. They are associated with
the shortest survival time explained by their early recurrence due to their deep invasion of
the normal brain, which makes them practically impossible to remove completely. Invasive
anaplastic gliomas are almost invariably fatal, recurring close to the resection margin in al‐
most all cases. Interestingly, primary brain tumors have a strong tendency to invade their
environment, but with rare exceptions, do not metastasize outside the brain. [1-3].
To understand the invasion behaviour of gliomas, the cellular and molecular events of peri‐
tumoral infiltration have to be discussed. The most important medium for this process is the
extracellular matrix (ECM). The ECM comprises a considerable proportion of the normal
brain volume. The extracellular space (ECS) of the healthy brain tissue volume is approxi‐
matley 20%. The extracellular volume fraction in the majority of primary brain tumors is sig‐
nificantly increased, representing about 48% of the total tumor tissue volume especially in
© 2013 Klekner; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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high grade gliomas. The structure and compounds of the ECM of the brain tissue have
many specific differences from other human organs. The ECM of the brain contains mainly
macromolecules like glycosaminoglycans (GAGs) and proteoglycans (PGs), and only mod‐
erately express fibrillary glycoproteins (e.g. collagens, fibronectin, elastin or reticulin). The
compounds of ECM glycoproteins play a crucial role in peritumoral invasion forming struc‐
tural elements for cellular attachment and migration. There is much evidence that ECM
components can modulate brain tumor growth, proliferation, and invasion by many differ‐
ent mechanisms. Thus extracellular matrix plays a pivotal role in the tumorous infiltration of
the surrounding tissue. The presence and functions of hyaluronic acid (hyaluronan, HA),
PGs and various types of GAGs have already been intensively investigated to clarify the
molecular mechanisms of invasion, and a positive correlation has been established many
times. To allow cell adhesion and migration, the ECM components interact with specific re‐
ceptors on the cell membrane, such as integrins, CD44, or CD168. Some proteases and syn‐
thases also strongly influence invasiveness because of their capacity to alter the actual levels
of the ECM molecules or to degrade the pericellular network. [4-16]
Using the ECM macromolecules to their active movement, glioma cells infiltrate the enviro‐
ment and form it similar to the tumor tissue. The process of the peritumoral invasion de‐
pends on the confrontation zone of the tumor cells and the non-neoplastic cells and ECM.
Glioma cells express mainly adhesion receptors and proteases, while host cells produce
macromolecules to maintain original structure and to inhibit invading cell movement. Since
brain ECM has no strong fibrillar, collagen-rich network, the brain parenchyma remains
soft, that can not hinder significantly the migration of tumor cells.
In case of glial cell tumors there are two main factors that significantly promote peritumoral
infiltration. First is the normal structure of the brain parenchyma composed mainly by tracts
in the white matter and basement membranes, which are suitable for guiding cell migration.
Second is the increased ability of glia cells to migration. Both factors are special for the brain
and they can be easily understood knowing the connection of development, structure and
function. [17, 18]
From neuro-oncological point of view the increased glioma cell mobility and extensive peri‐
tumoral infiltration leads to the following problems:
a. A. Total extirpation of a low grade tumor is not an easy and evident technical tool of
therapy. This is one main reason why these tumors are “semi-benign” tumors. Thus in
spite of the macroscopically radical surgical removal, the recurrence rate of these tu‐
mors is very high, and full recovery is not a general event.
b. B. In case of high grade tumors, neither open surgery, nor stereotactic radiosurgery can
achieve radical tumor removal. This experience can explain the local recurrence that ap‐
pears in almost every case.
c. C. Local chemotherapeutical treatment (intraparenchymal or post operatively adminis‐
tered intracavital drug) has low effectiveness.
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3. Molecular aspects of glioma invasion
Molecules that are responsible for the cell migration are divided in three groups:
1. Cell-membrane associated molecules (receptors and adhesion molecules).
2. Extracellular matrix (ECM) components (targets for the receptors).
3. Enzymes that are synthesizing or lysating the ECM components.
3.1. Cell-membrane associated molecules (receptors and adhesion molecules)
Molecules with evident role in peritumoral invasion are located either on the cell surface, or
form transmembrane structure. The main representatives of this group are the receptors and
adhesion molecules as detailed below.
The Ig superfamily contains molecules in the cell membrane consisted of immunoglobulin-
like and fibronectin type III domains involved in cell–cell adhesion. The superfamily in‐
cludes the integrins, a variety of cell adhesion molecules (CAMs) with distinct ligand-
binding specificities, namely ICAM (intercellular), NCAM (neural), Ep-CAM (epithelial), L1-
CAM, VCAM (vascular), ALCAM (activated leukocyte), and JAM (junctional adhesion
molecule), among others. [19]
The integrins are the most common molecules that serve for glioma cells to adhere to ECM.
These molecules are heterodimeric transmembrane glycoproteins consisting of non-cova‐
lently linked α and β chains, which both determine ligand binding strength and specificity.
Eight distinct α and 18 β chains combine to form about 24 different heterodimers. They can
interact with two groups of ligands: some of the ECM proteins, such as fibrinogen, fibronec‐
tin, vitronectin, and cell surface molecules, that are members of the immunoglobulin super‐
family. Regarding the many different heterodimers, each cell type maintains a specific and
activation-dependent integrin repertoire and consequence ligand preference. The cytoplas‐
mic integrin domains connect to signalling proteins and to the actin-cytoskeleton mediating
intracellular signal transduction and cell movement. This function definietly demonstrate
the dynamics of cell–ECM interaction as cells move along a substrate. Thus, integrins are
prominently important mediators for cell adhesion and migration. They also interact with
growth hormone receptors and contribute to cell–cell contacts due to direct interactions with
counterpart cell receptors. On the other hand, focal contacts mainly depend on the ECM-
compartment and on the cell type. Different integrins are known to be involved in that proc‐
ess. Integrin α5β1 binds to fibronectin, α6β1 or β4 binds to laminin, αvβ3 binds to
fibronectin, vitronectin and tenascin-C and α2β1 binds to fibrillar collagen. Some of the in‐
tegrins are directly connected to malignant behavior of gliomas. Neutralizing antibodies to
β1- and αvβ5-integrin lead to decreased glioma migration in vitro. It was also demonstrated,
that tenascin increases in vitro motility of human gliomas through interaction with β1-integ‐
rins. Inhibition of β1-integrins leads also to decreased motility, whereas inhibition of αv-in‐
tegrin causes increased motility. The integrin αvβ3 plays a central role in glioma invasion.
Increased expression of integrin αvβ3 results in increased motility of glioma cells with a de‐
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3. Molecular aspects of glioma invasion
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1. Cell-membrane associated molecules (receptors and adhesion molecules).
2. Extracellular matrix (ECM) components (targets for the receptors).
3. Enzymes that are synthesizing or lysating the ECM components.
3.1. Cell-membrane associated molecules (receptors and adhesion molecules)
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like and fibronectin type III domains involved in cell–cell adhesion. The superfamily in‐
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binding specificities, namely ICAM (intercellular), NCAM (neural), Ep-CAM (epithelial), L1-
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molecule), among others. [19]
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lently linked α and β chains, which both determine ligand binding strength and specificity.
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tin, vitronectin, and cell surface molecules, that are members of the immunoglobulin super‐
family. Regarding the many different heterodimers, each cell type maintains a specific and
activation-dependent integrin repertoire and consequence ligand preference. The cytoplas‐
mic integrin domains connect to signalling proteins and to the actin-cytoskeleton mediating
intracellular signal transduction and cell movement. This function definietly demonstrate
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growth hormone receptors and contribute to cell–cell contacts due to direct interactions with
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compartment and on the cell type. Different integrins are known to be involved in that proc‐
ess. Integrin α5β1 binds to fibronectin, α6β1 or β4 binds to laminin, αvβ3 binds to
fibronectin, vitronectin and tenascin-C and α2β1 binds to fibrillar collagen. Some of the in‐
tegrins are directly connected to malignant behavior of gliomas. Neutralizing antibodies to
β1- and αvβ5-integrin lead to decreased glioma migration in vitro. It was also demonstrated,
that tenascin increases in vitro motility of human gliomas through interaction with β1-integ‐
rins. Inhibition of β1-integrins leads also to decreased motility, whereas inhibition of αv-in‐
tegrin causes increased motility. The integrin αvβ3 plays a central role in glioma invasion.
Increased expression of integrin αvβ3 results in increased motility of glioma cells with a de‐
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crease in apoptosis sensitivity. Furthermore, inhibition of integrin αvβ3 decreases glioma
cell motility. Integrins αvβ3 and αvβ6 interacting with tenascin was proved to mediate ad‐
hesion rather than migration. Expression of β5-integrin is correlated with in vitro invasive‐
ness and migration of human glioma cells. However α-actin expression and linkage of
integrins to the cytoskeleton is related to glioma aggressiveness and poor prognosis in WHO
II and III astrocytoma. [20-33]
Integrins mediate also activation of focal adhesion kinase (FAK) that associates with β1-
and β3-integrins, which can trigger FAK phosphorylation. It is a non receptor tyrosine kin‐
ase overexpressed in invasive glioma cells, and its expression correlates with tumor
recurrence and invasiveness in many tumor types. FAK is activated either by integrin medi‐
ated adhesion to ECM or by growth factor stimulation and it induces cell migration. Induc‐
tion of FAK can protect cells from apoptosis. [34-41]
The neural cell adhesion molecule (NCAM) is expressed mainly by developing neurons. It
is downregulated during embryogenesis and re-expressed again once differentiation is initi‐
ated. Overexpression of NCAM decreases glioma cell motility in vitro. In drug-resistant
glioma cell lines NCAM expression is reduced and integrin-expression is increased that help
to explain decreased chemosensitivity in invading glioma. [42- 45]
CD44 is the most important HA-receptor expressed by every nucleated cells in vertebrates.
CD44 is a transmembrane glycoprotein belonging to the immunoglobulin receptor super‐
family. Besides the standard form (CD44s), multiple splice variants encoded by variable
exons v1–10 (CD44v1–10) can be identified depending on the cell differentiation and activa‐
tion state. Interactions of CD44 with numerous other molecules, such as collagens, laminins
and fibronectin, have been proved in vitro. CD44 is consisted of four functional domains:
amino terminal domain, stem structure, transmembrane domain and cytoplasmic domain.
The amino terminal domain can link to the ECM components such as HA and other GAGs.
The stem structure domain binds the amino-terminal domain and transmembrane domain.
The transmembrane region is probable responsible for the association of CD44 with lipid
rafts. The cytoplasmic domain of CD44 is connected to the cytoskeleton via ankyrin and oth‐
er proteins that is necessary to cell adhesion and motiliy. CD44 can be cleaved to two parts,
and both the extracellular and intracellular components of CD44 promote cell migration.
CD44 also interacts with various regulatory mediators to cell signaling pathways. Through
these connections CD44 promotes MMP-mediated matrix degradation, tumor cell growth,
migration and invasion and its expression correlates well with invasion potential of glioblas‐
toma. [46-54]
The receptor for hyaluronate-mediated motility (RHAMM) is also a HA-binding protein
expressed on the cell surface and also in the cytoplasm, cytoskeleton and nucleus. Interac‐
tion of HA with RHAMM induces many cellular signaling pathways in connection to pro‐
tein kinase-C, FAK, MAP kinases, NFκB, RAS, phosphatidylinositol kinase (PI3K), tyrosine
kinases and cytoskeletal components. CD44 and RHAMM probably have redundant or
overlapping functions, but it is evident that interactions of HA with CD44 and RHAMM are
necessary for tumorigenesis and tumor progression. [55-58]
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Syndecans are a family of transmembrane heparan sulphate proteoglycans with four mem‐
bers, syndecans 1 to 4. Syndecans are co-receptors by binding their ECM ligands in conjunc‐
tion with other receptors, mainly integrins. Through their heparan sulphate side chains,
syndecans may further take part in other ligand binding, like VEGF, fibronectin and antith‐
rombin-1. Linking syndecan to fibronectin is modulated by tenascin-C. Syndecan-1, -3, and
syndecan -2, -4 bild two different structural subgroups. Syndecan-1 is expressed generally in
fibroblasts and epithelial cells (especially in keratinocytes), but normally there is only a
moderate presence in endothel and neural cells. Syndecan-3 dominates in neural cells, but
not in epithelial cells, and syndecan-4 can be found mainly in epithel cells and fibroblasts,
while it is poorly expressed by endothel and neural cells. Syndecans have four main func‐
tion: 1. activation of growth hormon receptors; 2. cell adhesion to ECM components such as
collagens type I, III, V, fibronectin, thrombospondin and tenascin; 3. cell-to-cell adhesion
(e.g. syndecan-4 and integrin linkage takes part in intercellular interactions; 4. tumor sup‐
pression (anti-invasive effect by keeping tumor cells together) or tumor progression (de‐
pending on tumor histology and growth phase). [59-62]
Cadherin superfamily is also an important group of adhesion molecules regarding glioma
invasion. Cadherins are transmembrane proteins compound of several tandemly repeated
cadherin domains that interact in calcium-dependent homophilic cell–cell contacts. The cad‐
herin superfamily consists of more than 100 different members, with E- (epithelial) and N-
(neural) and P-cadherin, most intensively expressed in epithelial and neural tissues,
respectively. Desmosomal cadherins (desmoglein and desmocollin) provide a linkage to the
intermediate filament network through connection with cytosolic proteins (desmoplakin,
plakoglobin and plakophilin). Adherens junctions play a pivotal role in embryonic develop‐
ment as well as in the maintenance of tissue architecture in adults. Cadherins are linked to
the actin-cytoskeleton network through catenins (α-, β-catenin, plakoglobin and p120ctn),
thereby providing molecular lines of communication to other cell–cell junctions and to cell-
substratum junctions. Cadherin cluster forms a transmembrane core of adherens junctions at
sites of the cell–cell contacts. During tumor progression decreased cadherin function is cor‐
related with de-differentiation, metastasis and poor prognosis. In glioblastoma N-cadherin
cleavage is regulated by ADAM-10 that promotes tumor cell migration. Furthermore, aber‐
rantly processed proN-cadherin promotes cell migration and invasion in vitro, and in hu‐
man glioma the level of proN-cadherin is elevated that directly correlates with the invasion
potential. [63-68]
Dystroglycan is a transmembrane glycoprotein expressed mainly in sceletal muscle cells,
but it can be also found in brain tissue as well. Its main function is to creat contact between
the ECM macromolecules and the intracellular cytosceleton. It is linked intracellularly to
dystrophin, a protein coded on the X-chromosome (lack of dystrophin causes the herediter
muscle disease named dystrophia musculorum Duchenne). Dystroglycan is a heterodimeric
complex consisting of non-covalently associated α and β subunits. The α-subunit connects
α2-laminin, agrin and perlecan (components of the lamina basalis), the β-subunit is the
transmembrane part that binds to dystrophin. Overexpression of dystroglycan decreased
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crease in apoptosis sensitivity. Furthermore, inhibition of integrin αvβ3 decreases glioma
cell motility. Integrins αvβ3 and αvβ6 interacting with tenascin was proved to mediate ad‐
hesion rather than migration. Expression of β5-integrin is correlated with in vitro invasive‐
ness and migration of human glioma cells. However α-actin expression and linkage of
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er proteins that is necessary to cell adhesion and motiliy. CD44 can be cleaved to two parts,
and both the extracellular and intracellular components of CD44 promote cell migration.
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these connections CD44 promotes MMP-mediated matrix degradation, tumor cell growth,
migration and invasion and its expression correlates well with invasion potential of glioblas‐
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expressed on the cell surface and also in the cytoplasm, cytoskeleton and nucleus. Interac‐
tion of HA with RHAMM induces many cellular signaling pathways in connection to pro‐
tein kinase-C, FAK, MAP kinases, NFκB, RAS, phosphatidylinositol kinase (PI3K), tyrosine
kinases and cytoskeletal components. CD44 and RHAMM probably have redundant or
overlapping functions, but it is evident that interactions of HA with CD44 and RHAMM are
necessary for tumorigenesis and tumor progression. [55-58]
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications6
Syndecans are a family of transmembrane heparan sulphate proteoglycans with four mem‐
bers, syndecans 1 to 4. Syndecans are co-receptors by binding their ECM ligands in conjunc‐
tion with other receptors, mainly integrins. Through their heparan sulphate side chains,
syndecans may further take part in other ligand binding, like VEGF, fibronectin and antith‐
rombin-1. Linking syndecan to fibronectin is modulated by tenascin-C. Syndecan-1, -3, and
syndecan -2, -4 bild two different structural subgroups. Syndecan-1 is expressed generally in
fibroblasts and epithelial cells (especially in keratinocytes), but normally there is only a
moderate presence in endothel and neural cells. Syndecan-3 dominates in neural cells, but
not in epithelial cells, and syndecan-4 can be found mainly in epithel cells and fibroblasts,
while it is poorly expressed by endothel and neural cells. Syndecans have four main func‐
tion: 1. activation of growth hormon receptors; 2. cell adhesion to ECM components such as
collagens type I, III, V, fibronectin, thrombospondin and tenascin; 3. cell-to-cell adhesion
(e.g. syndecan-4 and integrin linkage takes part in intercellular interactions; 4. tumor sup‐
pression (anti-invasive effect by keeping tumor cells together) or tumor progression (de‐
pending on tumor histology and growth phase). [59-62]
Cadherin superfamily is also an important group of adhesion molecules regarding glioma
invasion. Cadherins are transmembrane proteins compound of several tandemly repeated
cadherin domains that interact in calcium-dependent homophilic cell–cell contacts. The cad‐
herin superfamily consists of more than 100 different members, with E- (epithelial) and N-
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thereby providing molecular lines of communication to other cell–cell junctions and to cell-
substratum junctions. Cadherin cluster forms a transmembrane core of adherens junctions at
sites of the cell–cell contacts. During tumor progression decreased cadherin function is cor‐
related with de-differentiation, metastasis and poor prognosis. In glioblastoma N-cadherin
cleavage is regulated by ADAM-10 that promotes tumor cell migration. Furthermore, aber‐
rantly processed proN-cadherin promotes cell migration and invasion in vitro, and in hu‐
man glioma the level of proN-cadherin is elevated that directly correlates with the invasion
potential. [63-68]
Dystroglycan is a transmembrane glycoprotein expressed mainly in sceletal muscle cells,
but it can be also found in brain tissue as well. Its main function is to creat contact between
the ECM macromolecules and the intracellular cytosceleton. It is linked intracellularly to
dystrophin, a protein coded on the X-chromosome (lack of dystrophin causes the herediter
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the growth rate of glioma cell lines so it was found to be involved in the progression of pri‐
mary brain tumors. [69-71]
3.2. Extracellular Matrix (ECM) components (targets for the receptors)
Various components of brain ECM, like GAGs and PGs are overexpressed in gliomas. These
molecules are binding sites for tumor cell receptors or they can inhibit cell migration, so
they take an important part in peritumoral glioma invasion, and consequently could also
serve as targets for anti-tumor therapy.
Proteoglycans (PGs) are composed of a protein core and glycosaminoglycan side chains
(GAGs). GAGs are carbohydrate polymers containing N-acethylglucosamine or N-acethyl‐
galactosamine and uronic acid (glycuronacid or iduronacid).
Depending on the GAG side chains the main types of PGs are chondroitin-sulphate (gly‐
curonacid  and  N-acethylgalactosamine  polymer  and  protein  core),  dermatan-sulphates
(former  name  chondroitin-sulphate-B,  composed  of  iduronacid  and  N-acethylgalactosa‐
mine  polymer  and  protein  core),  heparansulphate  (glycuronacid  and  N-sulphoglucosa‐
mine  polymer  and  protein  core)  and  keratansulphate  (galactose  and  N-
acethylgalactosamine  polymer  and  protein  core).  Hyaluronic  acid  (hyaluronan,  HA)  is
consisted of only GAGs (glycuronacid and N-acethylglucosamin polymer) that has no co‐
valent bind to a protein, so it is not a PG by definition, but due to its tight relation to the
PGs in general it is discussed together with them.
One of the most frequent adhesion glycoprotein in the ECM is fibronectin. It has a pivotal
role in cell attachment, migration, differentiation and proliferation. Although its protein
fragment is coded by only one gene, more isoform exits due to alternative splicing. The
main cell surface receptors for fibronectin are the integrins, but it can also bind collagens,
fibrin and heparan-sulphates. It is structured of two different subunits linked by disulphid
bridges to each other. Fibronectin appears in two different forms: the solubile molecule can
be found in the plasma, produced by hepatocytes, it accumulates at wessel wall damage and
has an evident role in clot-building. The insolubile form of fibronectin is expressed by fibro‐
blasts and mainly localized in the intercellular ECM. In tumor stroma production of fibro‐
nectin is reduced and its degradation is increased. Paralel to these changes on tumor cell
surface, the expression of the fibronectin receptor α5β1 integrin is also decreased. ECM com‐
ponents such as fibronectin and collagen type IV are mostly produced by the host tissue and
are associated dominantly with the vessel walls in gliomas. Fibronectin is mainly degraded
by MMP-2 that is specifically active in gliomas explaining partly the moderate presence of
extracellular fibronectin in glioma ECM. [72-74]
Another common component of the ECM is the molecular family of laminins. This glyco‐
protein has many variants, and it is the main component of lamina basalis. It is thought to
take part in cell differentiation, adhesion, migration and cell survival. Each molecule of lam‐
inin consits three different chains (α, β, and γ chain) which has 5, 4 and 3 genetic variants,
respectively. Recently at least fifteen different chain-combinations have been detected in hu‐
man tissues. In the lamina basalis laminins promote cell-to-cell linkage, and it forms a spe‐
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cific network with connection to enactin, fibronectin and perlecan. These molecules can also
bind to cell surface receptors such as integrins or dystroglycans, etc. Laminins regulate glio‐
ma cell adhesion to ECM proteins in specific manner leading to cell proliferation or cell mi‐
gration and up-regulation of laminin is associated with the invasiveness activity. [75-77]
Agrin is also an ECM forming PG with the capability to collect acetylcholin receptors. Nor‐
mally it is indispensible in developing neuromuscular junctions during embryogenesis. Ag‐
rin is secretaed at the end of the moto-neurons, and it is also a main component of
membrana basalis in various human organs taking part in cell-ECM interactions. Together
with neurocan, tenascin-C and versican it is responsible for the peritumoral infiltration of
gliomas. [78]
Hyaluronan(HA) is a non-sulphated, linear, high-molecularweight GAG. It differs evidently
of other GAGs, because of its extremely large molecular weight (103–104 kDa) composed of
10,000 or more disaccharide repeating units, the lack of sulfate groups or epimerized uronic
acid residues and because HA is synthesized at the inner face of the plasma membrane as a
free linear polymer without any protein core. It has a significant waterbinding capacity, so it
controls the water content of the brain interstitium. HA comprises a substantial fraction of
brain ECM and is involved in many physiological and pathological processes. In normal
ECM, HA sustain tissue homeostasis, biomechanical integrity, structure and some kind of
tissue cohesion. In malignant tumor tissues, HA transmit signals into cytoplasm and induces
cell proliferation, motility and invasion. HA binds tenascins, lecticans, the cell surface recep‐
tors including CD44, RHAMM or ICAM-1, which together contribute to ECM organization
and cell–matrix interaction. Through elevating the level of MMP-9 HA also promotes peritu‐
moral invasion by activating the protease system. Glial tumors have increased amounts of
HA which facilitates invasion activity of glioma cells. [79-84]
Lecticans comprise also a family of chondroitin sulphate proteoglycans with four members
(brevican, versican, neurocan, and aggrecan), whereby brevican and neurocan are brain-spe‐
cific molecules. Lecticans contain HA and tenascin binding sites and thus mediates linkage
in protein–PG-GAG networks. [85-86]
Brain enriched hyaluronan binding (BEHAB) molecule,also known as brevican, a brain-
specific chondroitin sulfate PG shows dramatic upregulation in gliomas and it is also in‐
duced during periods of increased glial cell motility in development and following brain
injury. Gliomas express unique brevican isoforms and the processing of this specific isoform
is important for its proinvasive role. In experimentally induced tumors brevican accumu‐
lates at the invasive borders and it associates with high infiltrative profiles. Furthermore,
brevican up-regulation correlates well with short survival periods of patients with high
grade gliomas. Brevican expression in gliomas is restricted to membrane localization, and its
presence in high-grade gliomas suggests that it plays a significant role in glioma progres‐
sion. Brevican promotes activation of epidermal growth factor receptor (EGFR), increases
the synthesis of cell adhesion molecules and facilitate fibronectin microfibrill presence on
the cell membrane. The effect of brevican on glioma cells motility is mediated not only via
EGFR signaling but also by fibronectin-dependent adhesion, and increased expression of
CAMs. This motogenic signals could not be worked in the normal neural ECM, where fibro‐
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nectin is almost absent but it is effective in the microenvironment of glioma cells, which co-
express large amounts of brevican and fibronectin in vivo. This interaction explains the
distinct ability of these tumors spreading in the central nervous system. Overexpression of
brain-specific isoforms of brevican proved to be correlated with ability to peritumoral inva‐
sion of gliomas. [73, 87-89]
Neurocan is a large brain specific chondroitin-sulphate PG that interacts with heparan-sul‐
phate proteoglycan (HSPG) molecules, such as syndecan-3 and glypican-1. It has influence
on cell adhesion and migration. Neurocan has two HSPG-binding domain with different af‐
finity. In cell culture neurit outgrowth is increased by C-terminal part of neurocan. HSPGs
serve also as cell-surface receptors for neurocan, and connection of neurocan to the HSPGs is
necessary for the neurit growth. It was found on clinical samples that higher expression of
neurocan is associated with the invasive activity of astrocytomas. [89-90]
The ECM glycoprotein tenascin, which forms a hexabrachion structure, can be detected in
both the ECM and the perivascular tissues of high-grade gliomas. Tenascin R, a brain-specif‐
ic member of the tenascin family comprising also tenascin C, X, and W, is a homotrimer
with both lectican and integrin binding sites forming an adhesion link between the ECM
and cells. The developed brain does not contains tenascin, but in normal brain tissue distin‐
guishable deposits of this glycoprotein can be found in the glia limitans externa, and some
tenascin was also detected in the ECS of white matter. Theres is a positive correlation be‐
tween tenascin production and the malignancy or angiogenesis of astrocytomas and there is
a prognostic utility of its immunohistochemical detection in ependymomas. The accumula‐
tion of tenascin in the ECS in high grade glial tumors can be one of the major factors leading
to the critical increase in ECS tortuosity and the simultaneous enlargement of the ECS. It has
been arised that the ECM distribution is modified at the brain-tumor zone of confrontation
and the presence of tenascin in this zone represents a negative prognostic factor in pediatric
ependymomas. Tenascin-C is overexpressed in both low and high grade astrocytomas as
well. In cultured brain-tissue tenascin-C is produced by the endothelial cells. It takes an im‐
portant part in various cellular mechanisms like heamagglutination, T-cell immunsuppres‐
sion, angiogenesis, chondrogenesis and it also has some antiadhesive effect. Tenascin
subunits contain EGF- and fibronectin-like repeated sequences that are responsible for the
growth inducing effect. Tenascin-C enhances migration of endothelial cells and phosphory‐
lation of focal adhesion kinase (FAK). Tenascin-C signaling is mainly mediated by integrin-
β1 which interacts with FAK. Tenascin-C is produced by the glioma cells rather than by the
invaded brain and it improves aggressive behaviour and invasion activity of grade II astro‐
cytoma cells in vitro and in vivo. Furthermore, expression of tenascin-C can be used as prog‐
nostic factor in grade II astrocytomas showing correlation with ability of tumor recurrence.
Beside this, low tenascin-C expression was found to be associated with prolonged average
survival time in glioblastomas and highest tenascin-C expression could be detected at the
border of the malignant gliomas. [91-104]
Versican (also known as VCAN or CSPG2), a chondroitin sulfate PG, is one of the main
components of the ECM, expressed almost in all human tissues. Versican takes part in nor‐
mal tissue development, but its increased expression can be also detected in most malignan‐
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cies. Elevated versican production occurs in either the tumor cells or the stromal cells
surrounding the tumor. Increased versican expression strongly correlates with poor out‐
comes for many different tumor types. Versican regulates a wide variety of intracellular
processes including cell adhesion, proliferation, apoptosis, migration and invasion via the
chondroitin and dermatan sulfate side chains. In addition, the versican G1 and G3 domains
can interact with various intracellular or extracellular molecules. In addition to HA, versican
associates with tenascin-R, fibulin-1 and -2, fibrillin-1, fibronectin, P- and L-selectin, and
many chemokines. It also binds to cell surface proteins including epidermal growth factor
receptor (EGFR), CD44, and integrin β1.
A number of proteinase families are capable of generating the proteolytic fragments of versi‐
can. Matrix metalloproteinase (MMP)-1, -2, -3, -7, and -9, ADAMTS-1, -4, -5 and -9 cleave
versican and generates proteolytic fragments.The accumulation of proteolytic fragments of
versican play an important role in cancer progression. The regulation of G1 and G3 versican
levels by proteases is known to be important in regulating cancer cell motility and metasta‐
sis. Through the EGF-like motifs in the G3 domain versican can stimulate cell proliferation
and its G1 domain destabilizes cell adhesion and promotes cell growth. Versican expression
is associated with a high rate of proliferation and it is localized in HA-rich tissues and also
accumulated in perivascular elastic tissues involved in peritumoral invasion. These features
of versican make it a proliferative, anti-adhesive and pro-migratory molecule that facilitates
tumor cell motility. In clinical samples the association of versican to invasiveness of astrocy‐
toma could be evidently demonstrated. On the other side, the decreased expression of versi‐
can V0 and V1 isoforms in glioma ECM can be related to the marked local invasivity and
rarity of extracranial metastasis of gliomas. [105-111]
3.3. Enzymes that are synthesizing or lysating the ECM components
Matrix metalloproteinases (MMPs) are the most common proteases that degrade ECM to
create the space for invading glioma cells. MMPs belong to the zinc-dependent endopepti‐
dase together with adamalysins, serralysins and astacins. MMPs take part in remodelling af‐
ter tissue damage, cell migration, differentiation and angiogenesis. At least 28 different
types of MMPs are identified composing a protease family that is able to degrade practically
every component of the ECM. Due to their function, MMPs also play evident role of activat‐
ing mechanism by cleavage metabolits of inactive molecules. MMPs are overexpressed in
glioma cells compared with normal brain tissue. MMP-2, MMP-3 and MMP-9 activity corre‐
lates well with glioma cell migration and invasion. [46, 112, 113]
Cathepsin-B is a cystein protease involved in protein degradation primarily within intracel‐
lular lysosomes but it takes evidently part in degradation of ECM-proteins. In order to be
able to interact with ECM proteins, the lysosomal enzyme is secreted from its intracellular
localization. Thus cathepsin B appears on the surface of glioma cells, where the enzyme can
interact with the surrounding matrix components. Cathepsin-B is overexpressed in gliomas.
Downregulation of cathepsin B in human glioma cells leads to decreased invasiveness in
matrigel-assay and coculture experiments. Furthermore, downregulation of cathepsin-L in
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human glioma cells correlates with decreased invasiveness and increased sensitivity to
apoptotic stimuli. [114-118]
4. Invasion process of tumor cells
Knowing the invasion potential of primary brain tumors, many of the molecular mecha‐
nisms of peritumoral infiltration have been already studied and some of the invasion proc‐
esses have been defined. During malignant transformation, invasiveness is determined by
the complex functions of tumor cells of distinct histological types. A four-step model of in‐
vasion has been applied, that is also valid for brain tumors. This model contains the follow‐
ing steps: 1) the tumor cells at the invasive site detach from the growing primary tumor
mass; 2) they adhere to the extracellular matrix (ECM) via specific recebptors; 3) proteases
secreted by the glioma cells locally degrade the ECM components, forming a pathway mi‐
gration into the surrounding tissue, and 4) tumor cell movement due to cytosceletal process‐
es. Each step of the peritumoral invasion requires a harmonized cooperation of numerous
molecules resulted in active cellular movement into the normal brain parenchyma. [119, 120]
The detachment of invading glioma cells from the primary tumor mass is a complex process
comprising the following steps: 1) Destabilization and disorganization of the cadherin medi‐
ated junctions that hold the primary mass together. 2) Decrease expression of cell adhesion
molecule which provides adhesion to the primary tumor mass. This leads to a reduction in
gap junction formation. Cell–cell communication is necessary for growth control and differ‐
entiation, and it is mainly achieved through gap junctions. Increased malignancy of gliomas
is accociated with reduced in situ gap junction formation, and invasion of gliomas. 3) Cleav‐
age of CD44, which anchors the primary mass to the ECM. This process is mediated by met‐
alloproteinase ADAM. [119-123]
Tumor cell adherence to the ECM components is mediated by specific cell surface or trans‐
membrane receptors like integrins binding to laminins, fibronectins and collagens or CD44
to hyaluronan.
Degradation of ECM components occurs due to the local enhancement and activation of
protease suc as MMPs, hyaluronidase, cathepsins and chondroitin suphatase.
Due to migration the glioma cell must interact with the surrounding ECM, which forms a
mechanical barrier to the cells, and serves as a substratum for traction for the moving cells.
For cell movement changes in cell morphology occur: the cell becomes polarized and mem‐
brane protrusions develop, including the extensions at the leading edge of pseudopodia, la‐
mellipodia, filopodia, and invadopodia. These extensions contain filamentous actin and
various structural and signaling molecules. The formation of membrane anchors needs cy‐
toskeletal contraction, which finally results a cell forward displacement. Glioma cell motility
and contractility also require A and B isoforms of myosin II. Myosin II is the major source of
cytoplasmic contractile force. Myosin II allows glioma cells to squeeze through pores small‐
er than their nuclear diameter, which is especially important for gliomas because the human
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brain tissue has particularly narrow extracellular spaces. The connection of ECM macromo‐
lecules and cytosceleton is mediated by dystroglycans. [69, 124]
5. The possible agents for antiinvasive therapy
Tumor cell invasion into the surrounding brain tissue is mainly responsible for the failure of
radical surgical resection and successful treatment, with tumor recurrence as microdissemi‐
nated disease. ECM related molecules and their receptors predominantly participate in the
invasion process, including the cell adhesion to the surrounding microenvironment and cell
migration. Determination of the key molecules of invasion process can help toprovide possi‐
ble targets for antiinvasive therapy. Regarding peritumoral infiltration activity of glioma
cells, the following molecules are supposed to serve as antitumor agents.
Cilengitide is a cyclic peptide targeting the RGD-motif of integrins blocking αvβ3- and
αvβ5-integrin mediated interaction between endothelial cells and ECM. By targeting these
integrins cilengitide could inhibit both glioma invasion and angiogenesis. Cilengitide causes
significant regression of glioma xenograftsand induces apoptosis in U87 glioma cells cul‐
tured on tenascin and vitronectin. In clinical trials targeting glioma invasion, in a random‐
ized phase II study cilengitide proved to be safe and was associated with a median survival
of 10 months in recurrent glioma patients. The North American Brain Tumor Consortium
(NABTC) study aimed to determine cilengitide penetration rate into GBM in human pa‐
tients. This study confirmed that cilengitide is effectively delivered into primary human
GBM tumors with good retention. The effect of combination therapy, such as cilengitide
with XRT or with another chemotherapeutic agent, is likely to be cumulative. [125-129]
Knowing the evident role of versican proteolytic fragments in cancer progression, its possi‐
ble role as target for anti-cancer therapy has been arised. Although there are only a few re‐
sults regarding anti-versican therapy in glioma patients, some possible agents are notable to
mention for their potential future role.The tyrosine kinase inhibitor genistein has been
shown to block versican expression in malignant mesothelioma cell lines and in vascular
smooth muscle cells. Versican G3 fragments facilitate cancer cell growth, invasion and meta‐
stasis through EGFR signaling. The selective EGF receptor inhibitor, AG1478 prevents G3
fragment enhanced cell growth, migration, invasion and chemical resistance in vitro. Galar‐
din, an antibody against the ADAMTS specific versican cleavage site inhibits glioma cell mi‐
gration. GM6001, a MMP and ADAMT proteases inhibitor, also decreases cancer cell
invasion and metastasis in several kinds of carcinoma. Other protease inhibitors such as cat‐
echin gallate esters, present in natural sources (green tea) selectively inhibit ADAMTS-1, -4
and -5 catabolism. [130-137]
Tumor  formation  of  the  pericellular  matrix  with  HA  and  versican  can  be  inhibited  by
treatment with HA oligomers, which can block the interaction between HA and versican,
serving as inhibitors of cancer dissemination. Furthermore, disruption of the HA CD44 in‐
teraction  with  HA  oligomers  could  also  inhibit  the  growth  of  B16F16  melanoma  cells,
Therefore the application of HA oligomers can be an effective agent for inhibiting the for‐
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mation  of  vesicant-HA-CD44  complexes,  providing  valuable  targets  against  tumor  pro‐
gression. [138-140]
Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) has evident anti-invasive effect on HA-
induced glioma invasion. In glioma cells emodin inhibits the TGFbeta and FGF-2 induced
expression of syndecan-1. It decreses the expression of MMP-2 and MMP-9 at both tran‐
scriptional and translational levels suggesting that emodin can be a clinically valuable anti-
cancer agent against glioma invasion. [141, 142]
Since increased MMP levels are associated with glioma invasion and angiogenesis, marima‐
stat, an orally active drug that can reduce MMP levels in patients with gliomas could inhibit
growing of tumor. A phase II study evaluated marimastat combined with temozolomide
(TMZ) in patients with recurrent malignant glioma and good outcome was documented, but
joint and tendon pain was reported in 47% of patients. [143, 144]
6. General aspects of angiogenesis
Rapidly growing tumors need to develop their own vasculature. The hypervascularisation
of high grade gliomas can be visualized well on radioimaging and it can be a preoperative
characteristic of glioblastoma. Furthermore, glioma angiogenesis is necessary for tumor ex‐
pansion and survival, so its inhibition could be a potential tool in anti-tumor therapy.
There are two main angiogenic and invasive glioma phenotypes. Clusters of glioma cells
perform single cell infiltrations into normal parenchyma independent of vasculature. An‐
other group of glioma cells can be found around newly developed vessels in the normal
brain parenchyma near to the tumor margin. These two different angiogenic and invasive
phenotypes  are  called  angiogenesis-dependent  and  angiogenesis  independent  invasions.
High  grade  astrocytomas  content  both  invasion  phenotypes  in  a  mixture  of  subclones
present in different intratumoral regions.  Molecular mechanisms of single cell  migration
were detailed above, but the role of neo-angiogenesis forms also a very important way to
glioma expansion. [145]
In expanding, highly proliferate gliomas angiogenesis is activated when the pro-angiogenic
stimuli dominates over the anti-angiogenic stimuli. These stimuli are mediated by factors se‐
creted from glioma, endothelial or microglia cells, or arise from the extracellular matrix or
other environmental sources like hypoxia induced cell productions. The pro- and anti-angio‐
genic forces are influenced strongly by tissue hypoxia and genetic alterations. The summa‐
tion of these stimulileads to the so-called “angiogenic switch” in glioma angiogenesis.The
most effective activator of angiogenesis in brain tumors is hypoxia that downregulates anti-
angiogenic pathways and induces many pro-angiogenic ones. A well-known pathway is the
HIF-1/VEGF-A pathway, which play a significant role in endothelial cell proliferation and
migration. Another pathway mediator is interleukin-8, which is produced by microglia cells
as a reaction to hypoxia. It is important to mention, that genetic instability of high grade
gliomas provides the way of angiogenesis independently of hypoxia (such as chronic HIF
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activation via phosphoinositide 3-kinase (PI3K) or mitogenactivated protein kinase (MAPK)
pathways. [146-152]
After activating the “angiogenic switch”, the tumor produces new vessels. The modes of
new blood vessel formation in glioma occur by one of three different methods: 1) angiogene‐
sis; 2) vasculogenesis; or 3) arteriogenesis. Angiogenesis is the formation of new blood ves‐
sels by rerouting or remodeling existing tumor vessels, and is supposed to be the main
stream of neo-angiogenesis. Vasculogenesis means de novo production of blood vessels
from circulating marrow-derived endothelial progenitor cells originally as the method of
vasculature development in embryonic process. Since these progenitor cells have been also
identified in tumors, they role in tumor angiogenesis cannot be denied. Vasculogenesis is
probably regulated by tumor-secreted stromal-derived factor 1 under the control of the hy‐
poxia-induced transcription factor hypoxia-inducible factor 1α (HIF1α). Arteriogenesis is
the third mode of arteriolar networks formation representing a moderate proportion of tu‐
mor angiogenesis. [153-156]
6.1. Neoangiogenesis
The most significant way to form new blood vessels in gliomas is neoangiogenesis. Forma‐
tion of new vessels from native vessels begins with breaking down the original vessel wall.
The process of blood vessel breakdown is composed of three main phases. The first event in
forming new vessels from existing ones is the disintegration of the vessel wall. Angiopoie‐
tin-1 (Ang-1) and its receptor Tie-2 play a pivotal role in this phase. Normally, Ang-1 binds
to Tie-2 achieving a close association between pericytes and endothelial cells that is necessa‐
ry for vasculature stability. In rapidly proliferating tumors like glioblastoma, tissue hypoxia
increases and it induces Ang-2 upregulation in endothelial cells whereas Ang-1 is accumu‐
lated tumor cells. Increased Ang-2 expression, which is an antagonist of Tie-2, leads to the
initial regression of blood vessels. Beside these, matrix-metalloproteinase (MMP)-2 expres‐
sion is induced via Tie-2 signaling, and in conjunction with VEGF promotes angiogenesis.
The second phase is the breakdown of ECM to provide place for the migration of endothel
cells to form new blood vessels. Following dissolution of native vessel wall, degradation of
the vessel basement membrane and relating ECM is the necessary condition for endothelial
cells for invasion the surrounding microenvironment. MMPs play an integral role in this
phase. In case of glioma angiogenesis, the collagenases MMP-2 and MMP-9 are involved in
this process and their expression correlates with a poor prognosis in gliomas. Expression of
MMP-2 and MMP-9 is also induced by hypoxia and through their proteolytic activity inter‐
action of endothelial cells and tumor-ECM contents like VEGF and fibroblast growth factor
(FGF) occurs. [157-166]
The third phase to form new blood vessels is the migration of endothelial cells. After disso‐
lution of the basement membrane of the blood vessels and decomponent ECM, endothelial
cells begins to proliferate and migrate toward tumor cells that expresses pro-angiogenic fac‐
tors. Due to this process cell surface adhesion and migration molecules, such as integrins
and CD44 upregulates.The activated endothelial cells secrets platelet-derived growth factor
(PDGF) that induces pericytes to participate in creating a new basement membrane. For this
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activation via phosphoinositide 3-kinase (PI3K) or mitogenactivated protein kinase (MAPK)
pathways. [146-152]
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reason beside migration of endothelial cells, pericyte migration also occurs as a necessary
event of vasculogenesis. [167-169]
At the end of tumor blood vessel formation a significant change occurs in the extracellular
environment, caused by increased expression of embryonic ECM molecules, such as tenas‐
cin-C. Elevation of VEGF and Ang-2 levels can be also detected, that probably explains the
leakiness and pathologic structure of the new vessels. The result of glioma angiogenesis are
highly tortuous dilated vessels and lots of small diameter vessels with alterations in endo‐
thelial cell adhesion molecule expression and disrupted basement membrane. [170-174]
7. Molecular aspects of glioma angiogenesis
Angiogenesis is mainly induced through growth hormone receptors, especially through the
vascular endothel growth factor receptor (VEGFR). This is a transmembrane receptor with
an extracellular antibody-binding domain (for vascular endothel growth factor (VEGF)) and
an intracellular tyrosin kinase domain stimulating the PI3K/Akt pathway. In tumor angio‐
genesis the effect of VEGFR can be increased either by receptor overexpression on the cell
surface or by mutation of the receptor that without a hormone-ligand or by only a moderate
ligand connection it keeps on a permanent stimulus.
Regarding glioma angiogenesis not only VEGFR but the hormone ligand VEGF has also an
evident role in the process. There are more types of VEGF. Specifically, VEGF-A is upregu‐
lated in glioblastoma and it is produced by many cell types, such as tumor cells, stromal,
and inflammatory cells. VEGF-A is primarily induced by tissue hypoxia and it regulates en‐
dothelial cell survival, proliferation, permeability and migration mainly through the VEGF-
receptor 2 (VEGFR2). VEGF can also be derived from the tumor-ECM. Beside the increased
amount of VEGF, the receptors VEGF-R1, VEGF-R2 and VEGF-R3 are upregulated on endo‐
thelial cells in glioma in comparison to normal brain. [175- 182]
Other growth factors have also influence on angiogenesis. Epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF) and platelet derived gfrowth factor (PDGF) facili‐
tates VEGF expression. The result of pathologic increased VEGF signaling in tumors is im‐
mature, highly permeable blood vessels with deteriorated blood-brain-barrier (BBB)
function and subsequent parenchymal edema. In glioma, bFGF is expressed by tumor cells
and endothelial cells but it can be also accumulated and stored in the extracellular matrix of
glioma. [183-186]
In rapidly proliferating anaplastic gliomas oxigene supply remains constantly under the ne‐
cessity, thus hypoxia remains a permanent stimuli for angiogenic factors. It seems to induce
not only the secretion of growth factors, but also interleukin-8 (Il-8), a chemokine released
by microglia, and Il-8 is expressed in adult glioma at levels correlating to tumor grade. In
glioma the interleukin-8 mediated angiogenesis is regulated by the tumor suppressor pro‐
tein ING4 through the transcription factor NFĸB. [187-189]
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Interestingly, there are some molecules involved in neuronal pattering during embryogen‐
esis  that  have  similar  functions  in  vascular  pattern  during  tumor  angiogenesis.  One  of
these molecules is the semaphorin, that induces signal pathway through neuropilins and
plexins. Neuropilins are expressed on vascular endothelial cells and function as receptors
for  VEGF.  Their  activation  leads  to  pro-angiogenic  responses  even in  the  absent  of  the
classical  VEGF-R2 signaling  and blocking neuropilin-1  can decrease  tumor  angiogenesis
and growth. [183, 190-192]
Beside growth factors and their receptors, there are some ECM components that are overex‐
pressed in glioma vessels in comparison to normal brain tissue, and have some stimulating
effect on angiogenesis. One of the most important ECM proteins with an evident role in an‐
giogenesis is tenascin-C, which is normally not expressed in the adult brain, but in glioma it
can be found at the invading tumor border in the region of angiogenesis. Tenascin-C facili‐
tates endothelial cell migration and induces VEGF expression and focal adhesion kinase
phosphorylation, which are both important for angiogenesis. Another ECM protein in‐
volved in angiogenesis is fibronectin. The oncofetal form of fibronectin is typically only ex‐
pressed during embryogenesis, but it is also produced in GBM, and it is localized to the
tumor vessels. Laminin-8 a member of the laminin family in ECM is expressed in vascular
basement membrane of GBM. Its blocking in an animal model of GBM resulted in decreased
tumor microvessel density and increased survival. Versican is also an important ECM com‐
ponent of the tumor angiogenesis process. The versican G3 domain facilitates endothelial
cell adhesion, proliferation, and migration in vitro and blood vessel formation in nude
mouse tumors. Furthermore, G3-domain expressing cells produce increased levels of fibro‐
nectin and VEGF, suggesting their common functions in angiogenesis. [193-197]
8. The possible agents for anti-angiogenic therapy
Since VEGFR play the most significant role in tumor angiogenesis, its inhibition bears the
most effective possibility for decrease tumor growth. The VEGFR is a transmembrane tu‐
mor cell  receptor,  so  blocking antibodies  could close down its  effect.  On the other  side
blocking the intracellular  tyrosine-kinase domain could also inhibit  the activation of  the
signaling pathways. The latest way came into the front in past few years, when small-mo‐
lecular tyrosine kinase inhibitors proved to be effective in vitro against glioma cell lines.
Beside these, blocking the VEG-factor itself can also definitely decrease the stimulating ef‐
fect of the receptor.
8.1. VEGF-blocking
The most known VEGF neutralizing antibody is the bevacizumab that is already a possible
tool of the oncotherapy for glioblastoma. In recurrent glioma patients treated with bevacizu‐
mab combined with the chemotherapy agent irinotecan the median survival can be pro‐
longed. As the result of a significant antitumor effect 63% radiographic response, 6-month
progression-free survival in 32% of GBM patients could be achieved. Based on these favora‐
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ble observations further clinical trials have been initiated to combine bevacizumab with te‐
mozolomide, the current standard of care for newly diagnosed glioblastoma patients.
Another clinical trial suggests that the presence of tumor hypoxia markers predicts probable
radiographic response and better survival of patients treated with combinant chemotherapy
of bevacizumab and irinotecan. Gliomas treated with bevacizumab often appear as nonen‐
hancing infiltrating laesions on MRI proving the reduced vascularity beside the ongoing in‐
vasion, so induction of anti-angiogenic therapy combined with anti-invasive therapy seems
to be a possible treatment method in the future. [198-203]
8.2. VEGF-receptor blocking
Anti-angiogenic therapy with VEGF receptor inhibitor sunitinib normalizates tumor vascu‐
lature, so it elevates intratumoral level of temozolomide due to the improved vessel func‐
tions. Cediranib is a pan-VEGFR tyrosine kinase inhibitor, while enzastaurin is a protein
kinase-C inhibitor. Both agents are already in studies. Sorafenib is a multikinase inhibitor,
that suppresses angiogenesis by inhibiting VEGFR and PDGFR activities in endothelial cells.
Sorafenib-treated mice showed significant suppression of glioblastoma cell proliferation, in‐
creased apoptosis and autophagy, and reduction of angiogenesis in vivo, phase II trials of
sorafenib in patients with malignant gliomas were inducted. Imatinib is a kinase inhibitor
of PDGFR, c-kit, and bcr-abl. In vitro studies of imatinib on glioma cell proliferation de‐
scribe, that it is cytostatic agent at low concentration whereas at high concentrations it has
cytotoxic effect. Imatinib monotherapy against malignant gliomas has failed to show any
significant clinical benefits probable because of the moderate drug penetration across BBB
and the inhibition of PDGFR alone can be insufficient to inhibit growth of malignant glio‐
mas. In spite of these its use in combination therapy is still an interesting theme. [204-211]
8.3. Other target molecules for anti-angiogenic therapy
Tenascin-C is mainly expressed in hyperplastic vessels and it promotes migration of endo‐
thelial cells in astrocytic tumors. Therefore, blocking tenascin with an antibody to inhibit an‐
giogenesis seems biologically reasonable, so a tenascin-specific antibody radiolabeled with
I-131 was tested in patients with high-grade gliomas. The phase II studies with tenascin-
blocking antibody in malignant glioma reported about a slight increase in survival time.
[101, 195, 212-214]
Another ECM protein that has anti-angiogenic effect in glioma is secreted protein acidic and
rich in cysteine (SPARC), also known as osteonectin or BM-40. Osteonectin takes part in a
number of basic biologic functions, including migration, proliferation, and survival. Expres‐
sion of SPARC in the nervous system is restricted normally to the angiogenic microvascula‐
ture, such as in the region of locus coeruleus and retinal astrocytes, but is not expressed in
the cerebral cortex. In contrast, osteonectin is present in both tumor cells and endothelial
cells in gliomas of all grades, and it is also expressed by endothelial cells and astrocytes in
the adjacent tissue. Osteonectin suppresses tumor angiogenesis via inhibition of VEGF ex‐
pression and secretion. [215-221]
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8.4. Endogenous anti-angiogenic factors
A number of endogenous anti-angiogenic factors have been described that play pivotal role
in tumor angiogenesis. Identifying these factors could offer some anti-cancer agent for neu‐
ro-oncological therapies. One of the best known endogenous anti-angiogenic proteins is an‐
giostatin. It is mainly derived from degradation of plasminogen by proteases cathepsin-D
and MMPs. In vivo studies in mice proved that angiostatin inhibits glioma angiogenesis and
growth. The thrombospondins (TSPs) are another family of proteins that serves as an anti-
angiogenic factor. In normal tissue TSP1 is produced by platelets, endothelial cells, and
smooth muscle cells. Similar to angiostatin, endostatin is also an anti-angiogenic molecule
created in glioblastoma basement membrane by proteolytic cleavage of collagen-18 by elas‐
tase, cathepsin-L, and specific MMPs. The endostatin-mediated signaling has more angio‐
genic inhibitory mechanism by binding to a5b1 integrin, inhibition of VEGF-R2, reduction of
focal adhesion kinase-mediated endothelial cell migration, and suppression of pro-angio‐
genic MMP-2. A further factor is the angiogenesis inhibitor-1 (BAI1), also known as vascu‐
lostatin, that is produced only in glial cells and neurons of normal brain but not in blood
vessels. Since vasculostatin is defnietly reduced in glioblastomas, its role in suppressing an‐
giogenesis is glioma is strongly supposed. [222-231]
9. Conclusion
There are no simple and evidently succesful protocols for therapy of primary brain tumors.
The intensive proliferation activity, the significant peritumoral infiltration and increased an‐
giogenesis altogether are responsible for the extremely high recurrence rate of gliomas. The
failure of recently administered chemotherapy arises the requirement of combination thera‐
py. Thus besides searching a highly specific tumor marker, establishing the molecular spec‐
trum of these tumors can be suggested. Supporting this theory, the mRNA expression
pattern of the invasion-related molecules was found to be highly specific for various differ‐
ent histological tumor groups. So determination of the genetic signature of invasion of a
glioma is thought to help in screening exact molecules as targets for individual chemothera‐
py. [89] Furthermore, complexity of oncotherapy with combination of antiproliferation, anti‐
invasive and antiangiogenic drugs could bring benefits in treatment effectiveness against
brain tumors in the future.
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1. Introduction
Glial tumors, within neuroepitelial-derived lesions, are the most common intra-assial neo‐
plastic histotypes. Gliomas account for about 45% of all primary central nervous system
(CNS) tumors and 77% of all malignant primary CNS tumors. Gliomas can originate from
neural stem cells, progenitor cells, or from de-differentiated mature neural cells transformed
into cancer stem cells. Although brain tumors constitute only a small proportion of overall
human malignancies, they carry high rates of morbidity and mortality. Mortality is still close
to 100% and the average survival of patients with glioblastoma multiforme (GBM) is less
than 1 year when classical treatment is used. Recent progresses in multimodal treatment has
led to only a slight increase in average survival up to 15-18 months [1]. The effectiveness of
the actual chemotherapeutic approach and multimodal targeted therapies remains modest
in gliomas.
Gliomas are divided into different subtypes based on cell line from which they originate.
Gliomas include astrocytomas, glioblastomas, oligodendrogliomas, ependymomas and oth‐
er histological subtypes. The most common gliomas are astrocytomas, oligodendrogliomas
and ependymomas. Since 1993, the 4-level grading system proposed by the World Health
Organization (WHO), was the most widely accepted and widespread. It is based on histo‐
logic features: nuclear atypia, presence of mitoses, endothelial proliferation. Grade I gliomas
are benign with a slow proliferation rate and include pylocitic astrocytoma most common in
pediatric age. Grade II gliomas are characterized by a high degree of cellular differentiation
and grow diffusely into the normal brain parenchyma and are prone to malignant progres‐
sion. They include astrocytoma, oligodendroglioma and oligoastrocytoma. Grade III lesions
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include anaplastic astrocytoma, anaplastic oligoastrocytoma and anaplastic oligodendro‐
glioma. These tumors show a higher cellular density and a notable presence of atypia and
mitotic cells. Grade IV tumors are the most malignant and also the most frequent gliomas
and include glioblastoma and gliosarcoma. These tumors presented microvascular prolifera‐
tions and pseudopalisading necrosis.
Conventional brain tumor treatments include surgery, radiation therapy and chemotherapy.
Surgical treatment is invasive but represents the first approach for the vast majority of brain
tumors due to difficulties arising in early stage detection. However, gross total removal is
not always achievable in relation to the location of the tumor, to preserve vital nervous or
vascular structures. Aggressive treatment modalities have extended the median survival
from 4 months to 1 year, but the survival is often associated with significant impairment in
the quality of life. Radiation therapy and chemotherapy are non-invasive options often used
as adjuvant therapy, but may also be effective for curing early-stage tumors. Radiotherapy
seems to be related only to a prolonged progression-free survival, with better control of seiz‐
ures, but with no substantial differences in overall survival. Besides, patients treated with
radiotherapy, have high risk to develop some complications such as post radiation leukoen‐
cephalopathy, that is characterized by dementia, gait disturbance, incontinence, deficit in at‐
tention and executive functions. In patients with recurrent GBM, the 6-months progression-
free survival is only 21% after treatment with temozolomide [2]. The effectiveness of
systemic chemotherapy is limited by toxic effects on healthy cells, generally resulting in
morbidity or mortality of the patient. Moreover, the presence of the blood-brain barrier
(BBB) limits the passage of a wide variety of anticancer agents. The high incidence of recur‐
rence and poor prognosis of malignant gliomas compel the development of more powerful
anti-cancer treatments. Action of alkylating agents, one of the most common class of chemo‐
therapeutic drugs employed, is limited by activation of methylguanine-methyltransferase.
The compromise of the quality of remaining life as well as the limited success of current
treatment options in shrinking tumors, raise increasing concerns about the adverse effects of
cancer treatment on brain function.
Glioma cell invasion into normal tissue is thought to be a multi-factorial process, consisting
of cell interactions with extracellular matrix (ECM) and with adjacent cells, as well as accom‐
panying biochemical processes supportive of active cell movement. Tumor cell invasion re‐
quires four distinct steps: (1) detachment of invading cells from the primary tumor mass, (2)
adhesion to ECM, (3) degradation of ECM, and (4) cell motility and contractility. However,
growth of tumors necessitates, also, the recruitment of a new blood supply. Angiogenesis,
represent a key event in the progression of malignant gliomas. Tumor angiogenesis involves
multiple cellular processes including endothelial cell proliferation, migration, reorganization
of ECM and tube formation.
The advent of molecular studies allowed a new evaluation of the biology of gliomas with, a
level of precision that promises interesting advances toward the development of specific
and effective therapies. The introduction of molecularly targeted agents is one of the most
significant advances in cancer therapy in recent years. Targeted therapies block activation of
oncogenic pathways, either at the ligand-receptor interaction level or by inhibiting down‐
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stream signal transduction pathways, thereby inhibiting growth and progression of cancer.
Because of their specificity, targeted therapies should theoretically have better efficacy and
safety profiles than systemic cytotoxic chemotherapy or radiotherapy.
In  this  chapter  we  evaluated  the  invasion  and  angiogenesis  in  the  glioma  progression.
Moreover, new pharmacological agents on the basis of the more recent literature will be
evaluated.
2. Gliomas
Approximately 50% of primary brain tumors are gliomas,  arising from astrocytes,  oligo‐
dendrocytes, or their precursors and ependymal cells. Gliomas are classified from I to IV
according  to  the  WHO  malignancy  scale.  Gliomas  are  divided  into  different  subtypes
based  on  cell  line  from  which  they  originate.  The  WHO  classification  of  CNS  tumors,
now in its fourth edition, is the universal standard for classifying and grading brain neo‐
plasms. Analysis of tumour differentiation, cellularity, cytonuclear atypia, mitotic activity,
microvascular proliferation, and necrosis further enables grading of the tumour as grade
2 (diffuse infiltrating low-grade gliomas), 3 (anaplastic gliomas), or 4 (glioblastomas) with
increasing  aggressiveness.  Unfortunately,  WHO morphological  classification  is  based on
subjective criteria, lacks reproducibility, and remains imperfect in its ability to predict in‐
dividual  outcomes.  The most  recent  WHO classification introduced a number of  signifi‐
cant  changes  that  include  both  additions  and  redefinitions  or  clarifications  of  existing
entities.  Three new tumor types were added to  the glioma section.  The first  of  these is
angiocentric  glioma.  Angiocentric  gliomas are slowly growing solid hemispheric  tumors
of children and young adults. They are strongly epileptogenic, with 95% of patients pre‐
senting  with  intractable  seizures.  These  tumors  are  characterized histologically  by  elon‐
gated  bipolar  glial  tumor  cells  and  by  their  striking  perivascular  growth  pattern.
Angiocentric  gliomas  have  a  low  proliferative  potential  (MIB-1  between  1%  -  5%)  and
have been designated as WHO grade I  neoplasms. The second, pilomyxoid astrocytoma
(PMA),  is  now formally  considered as  a  distinct  more  aggressive  variant  of  PA.  PMAs
typically occur at an earlier mean age and are associated with more aggressive behavior
than Pas (pilocytic astrocytomas). PMAs are composed of bipolar (piloid or hairlike) cells
that  lie  within  a  distinct  myxoid  background  matrix.  PMAs  are  currently  considered
WHO grade II neoplasms. Atypical choroid plexus papilloma (CPP) is the third new tu‐
mor.  Cellular  atypia and increased mitotic  activity are reflected in more aggressive bio‐
logic behavior, with earlier metastases and higher recurrence rates than CPP. An aCPP is
designated as a WHO grade II neoplasm. The 2007 WHO version recognized, also, papil‐
lary  glioneuronal  tumor  (PGNT),  rosette-forming  glioneuronal  tumor  (RGNT)  of  the
fourth ventricle, and the extraventricular form of neurocytoma. PGNT is a rare relatively
well-circumscribed  clinically  indolent  tumor  that  is  exclusively  found  in  the  cerebral
hemispheres.  PGNTs  are  biphasic  tumors,  with  both  astrocytic  and  neuronal  elements.
The histologic hallmark of  PGNT is  the presence of  hyalinized vascular pseudopapillae.
Although PGNT was not  formally assigned a WHO grade in the 2007 revision,  this  tu‐
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mor generally behaves in a benign grade I fashion. RGNTs are rare slow-growing tumors
of  young  and  middle-aged  adults.  RGNTs  contain  both  neurocytic  and  astrocytic  ele‐
ments.  Their  histologic  hallmark  is  the  formation  of  neurocytic  perivascular  pseudoro‐
settes.  RGNTs  are  designated  as  WHO  grade  I  neoplasms.  The  term  “central
neurocytoma” describes a neuronal tumor with preferential location in the lateral ventri‐
cle  body.  These  tumors  comprise  fibrillary  areas  mimicking neuropil  plus  collections  of
uniform round cells that have immunohistochemical and ultrastructural evidence of neu‐
ronal differentiation. A low proliferation rate is typical. Similar neoplasms have been re‐
ported outside the ventricular system, and the WHO 2007 designated the term “EVNCT”
(extraventricular  neurocytoma)  for  these  uncommon  tumors.  Because  the  only  distin‐
guishing  feature  is  location  EVNCTs  are  included  in  the  same  histopathologic  code  as
central  neurocytoma.  Both  central  and  extraventricular  neurocytomas  are  designated  as
WHO  grade  II  neoplasms.  Two  new  tumors  of  the  pineal  region  were  codified  in  the
WHO 2007 classification, papillary tumor of the pineal region (PTPR) and pineal paren‐
chymal tumor of intermediate differentiation (PPTID). PTPR is a rare neuroepithelial  tu‐
mor that  arises  from the  subcommissural  organ and exhibits  ependymal  differentiation.
Macroscopically, PTPRs are indistinguishable from pineocytomas. Microscopically, the tu‐
mors  are  easily  distinguished.  PTPRs  show  papillary  architecture  with  pseudostratified
columnar  epithelium.  Ultrastructural  features  suggesting  ependymal  differentiation  are
present.  Immunohistochemistry is  positive for cytokeratins.  While grading of PTPRs has
yet  to  be  defined,  most  neuropathologists  consider  these  as  WHO  grade  II  or  III  neo‐
plasms. PPTID is a newly recognized tumor intermediate in malignancy between pineo‐
cytoma and pineoblastoma. Mild-to-moderate nuclear atypia and low-to-moderate mitotic
activity  result  in  either  WHO  grade  II  or  III.  PPTIDs  have  a  much  more  aggressive
course than pineocytomas and may warrant adjuvant therapy. PPTIDs are more common
than  previously  recognized,  accounting  for  up  to  20%  of  all  pineal  parenchymal  neo‐
plasms.  Recent  reports  emphasize  their  large  size  and  focal  invasion  of  adjacent  struc‐
tures as features that distinguish them from pineocytoma [3].
According to  WHO low grade  gliomas  include  diffuse  astrocytomas  (fibrillar,  gemistio‐
cytic,  protoplasmatic,  mixed),  grade II  oligodendrogliomas and oligoastrocytomas.  Diag‐
nosis  of  anaplastic  glioma  is  based  on  the  presence  of  mitotic  activity,  while  vascular
proliferation and necrosis are typical features of GBM. The definition of low grade glio‐
ma does not refer perhaps to I grade astrocytomas, that differ from other gliomas in rela‐
tion to their  biological  behaviour,  prognosis and genetic  profile [4].  Low grade gliomas,
tend  perhaps  to  dedifferentiate:  a  global  therapeutic  approach,  related  to  gross  total  (>
90%) surgical removal, radiotherapy e chemiotherapy with temozolamide, leads only to a
slight  prolongation of  overall  survival,  calculated from 3  to  7  years  [5].  This  variability
depends from various factors:  age at  diagnosis,  tumor volume, tumor crossing the mid‐
line,  neurological  deficits  before treatment and tumor’s histology [6].  Anyway, mortality
is  near  to  100% and only 35% of  patients  with glioblastoma multiforme have a median
survival of one year or more.
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2.1. Genetics of malignant gliomas
Cancers originate as the result of hereditary or somatic alterations in genes that control criti‐
cal biological processes. The accumulation of such genetic damage over time permits the
survival and progressive transformation of abnormal cell populations that eventually lead
to the formation of a tumor. Consistent with their high malignant potential, gliomas exhibit
a vast array of well-documented genetic changes that likely contribute to their phenotype.
Gliomagenesis is characterized by several biological events, such as activated growth factor
receptor signaling pathways, downregulation of many apoptotic mechanisms and unbal‐
ance among proangiogenic and antiangiogenic factors. Several growth factor receptors, such
epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDRGF),
C-Kit, vascular endhotelial growth factor receptor (VEGFR) and others growth factors recep‐
tors, are overexpressed, amplified and/or mutated in gliomas. Features of the glioma cells
are the loss of tumor suppressor genes, which are critical for the cell growth, differentiation
and function.
The TP53 tumor suppressor gene was identified as the main driver of chromosome 17 altera‐
tions in glioblastoma, and further studies indicated that p53 plays a critical role in monitor‐
ing the genome for DNA damage and can control cell cycle arrest to permit DNA repair or
can trigger apoptosis to eliminate the damaged cell [7]. It acts as a transcriptional activator
and it repress the transcription of other genes, such as IL-6, c-fos, c-jun and other oncogenes.
The levels of p53 increase in G1 and S phases of the cell cycle. Cells transfected with the nor‐
mal gene p53 block their growth in G1, suppressing the passage S-phase. The expression of
the p53 gene cause apoptosis (programmed cell death). The effects of its mutation are the
loss of cell cycle regulation, through the inactivation of p16ink-4a, the super expression of cy‐
cline dependent kinase 4 Cdk4 and Cdk6 and of ubiquitin ligase Mdm2 and Mdm4. A simi‐
lar mechanism is created after mutation of retinoblastoma (Rb), a tumor suppressor gene.
Probably, TP53 is a gene responsible for the progression from low-grade to high-grade glio‐
mas, but its mutation is an early event. Many glioma cell lines expressing p53 mutations.
The mutated form of p53 has a crucial role in the regulation of neovascularization. It induces
increased levels of VEGF and FGFβ through an activation of the transcription of the corre‐
sponding genes. The deletion of NFKBIA (encoding nuclear factor of κ-light polypeptide
gene enhancer in B-cells inhibitor-α), an inhibitor of the EGFR-signaling pathway, promotes
tumorigenesis in glioblastomas that do not have alterations of EGFR. Bredel et al. analyzed
790 human GBMs for deletions, mutations, or expression of NFKBIA and EGFR. they stud‐
ied the tumor-suppressor activity of NFKBIA in tumor-cell culture and compared the molec‐
ular results with the outcome of GBM in 570 affected persons. NFKBIA is often deleted but
not mutated in GBM [8].
Epidermal growth factor receptor mutations include amplifications, point mutations and de‐
letions, with the most common alteration being the variant III deletion of the extracellular
domain (EGFR-vIII mutant) [9]. Platelet-derived growth factor receptor and its ligands
PDGF-A and PDGF-B are also commonly over-expressed in some glioma cells, raising the
possibility of autocrine or paracrine activation [10]. Other RTK genes, such as ERBB2, anoth‐
er member of the EGF receptor family, and MET, which encodes the hepatocyte growth fac‐
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mor generally behaves in a benign grade I fashion. RGNTs are rare slow-growing tumors
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settes.  RGNTs  are  designated  as  WHO  grade  I  neoplasms.  The  term  “central
neurocytoma” describes a neuronal tumor with preferential location in the lateral ventri‐
cle  body.  These  tumors  comprise  fibrillary  areas  mimicking neuropil  plus  collections  of
uniform round cells that have immunohistochemical and ultrastructural evidence of neu‐
ronal differentiation. A low proliferation rate is typical. Similar neoplasms have been re‐
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mor that  arises  from the  subcommissural  organ and exhibits  ependymal  differentiation.
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yet  to  be  defined,  most  neuropathologists  consider  these  as  WHO  grade  II  or  III  neo‐
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cytoma and pineoblastoma. Mild-to-moderate nuclear atypia and low-to-moderate mitotic
activity  result  in  either  WHO  grade  II  or  III.  PPTIDs  have  a  much  more  aggressive
course than pineocytomas and may warrant adjuvant therapy. PPTIDs are more common
than  previously  recognized,  accounting  for  up  to  20%  of  all  pineal  parenchymal  neo‐
plasms.  Recent  reports  emphasize  their  large  size  and  focal  invasion  of  adjacent  struc‐
tures as features that distinguish them from pineocytoma [3].
According to  WHO low grade  gliomas  include  diffuse  astrocytomas  (fibrillar,  gemistio‐
cytic,  protoplasmatic,  mixed),  grade II  oligodendrogliomas and oligoastrocytomas.  Diag‐
nosis  of  anaplastic  glioma  is  based  on  the  presence  of  mitotic  activity,  while  vascular
proliferation and necrosis are typical features of GBM. The definition of low grade glio‐
ma does not refer perhaps to I grade astrocytomas, that differ from other gliomas in rela‐
tion to their  biological  behaviour,  prognosis and genetic  profile [4].  Low grade gliomas,
tend  perhaps  to  dedifferentiate:  a  global  therapeutic  approach,  related  to  gross  total  (>
90%) surgical removal, radiotherapy e chemiotherapy with temozolamide, leads only to a
slight  prolongation of  overall  survival,  calculated from 3  to  7  years  [5].  This  variability
depends from various factors:  age at  diagnosis,  tumor volume, tumor crossing the mid‐
line,  neurological  deficits  before treatment and tumor’s histology [6].  Anyway, mortality
is  near  to  100% and only 35% of  patients  with glioblastoma multiforme have a median
survival of one year or more.
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Cancers originate as the result of hereditary or somatic alterations in genes that control criti‐
cal biological processes. The accumulation of such genetic damage over time permits the
survival and progressive transformation of abnormal cell populations that eventually lead
to the formation of a tumor. Consistent with their high malignant potential, gliomas exhibit
a vast array of well-documented genetic changes that likely contribute to their phenotype.
Gliomagenesis is characterized by several biological events, such as activated growth factor
receptor signaling pathways, downregulation of many apoptotic mechanisms and unbal‐
ance among proangiogenic and antiangiogenic factors. Several growth factor receptors, such
epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDRGF),
C-Kit, vascular endhotelial growth factor receptor (VEGFR) and others growth factors recep‐
tors, are overexpressed, amplified and/or mutated in gliomas. Features of the glioma cells
are the loss of tumor suppressor genes, which are critical for the cell growth, differentiation
and function.
The TP53 tumor suppressor gene was identified as the main driver of chromosome 17 altera‐
tions in glioblastoma, and further studies indicated that p53 plays a critical role in monitor‐
ing the genome for DNA damage and can control cell cycle arrest to permit DNA repair or
can trigger apoptosis to eliminate the damaged cell [7]. It acts as a transcriptional activator
and it repress the transcription of other genes, such as IL-6, c-fos, c-jun and other oncogenes.
The levels of p53 increase in G1 and S phases of the cell cycle. Cells transfected with the nor‐
mal gene p53 block their growth in G1, suppressing the passage S-phase. The expression of
the p53 gene cause apoptosis (programmed cell death). The effects of its mutation are the
loss of cell cycle regulation, through the inactivation of p16ink-4a, the super expression of cy‐
cline dependent kinase 4 Cdk4 and Cdk6 and of ubiquitin ligase Mdm2 and Mdm4. A simi‐
lar mechanism is created after mutation of retinoblastoma (Rb), a tumor suppressor gene.
Probably, TP53 is a gene responsible for the progression from low-grade to high-grade glio‐
mas, but its mutation is an early event. Many glioma cell lines expressing p53 mutations.
The mutated form of p53 has a crucial role in the regulation of neovascularization. It induces
increased levels of VEGF and FGFβ through an activation of the transcription of the corre‐
sponding genes. The deletion of NFKBIA (encoding nuclear factor of κ-light polypeptide
gene enhancer in B-cells inhibitor-α), an inhibitor of the EGFR-signaling pathway, promotes
tumorigenesis in glioblastomas that do not have alterations of EGFR. Bredel et al. analyzed
790 human GBMs for deletions, mutations, or expression of NFKBIA and EGFR. they stud‐
ied the tumor-suppressor activity of NFKBIA in tumor-cell culture and compared the molec‐
ular results with the outcome of GBM in 570 affected persons. NFKBIA is often deleted but
not mutated in GBM [8].
Epidermal growth factor receptor mutations include amplifications, point mutations and de‐
letions, with the most common alteration being the variant III deletion of the extracellular
domain (EGFR-vIII mutant) [9]. Platelet-derived growth factor receptor and its ligands
PDGF-A and PDGF-B are also commonly over-expressed in some glioma cells, raising the
possibility of autocrine or paracrine activation [10]. Other RTK genes, such as ERBB2, anoth‐
er member of the EGF receptor family, and MET, which encodes the hepatocyte growth fac‐
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tor receptor, have also been found to be mutated in GBMs [9]. RTKs mediate cell growth and
proliferation via downstream effectors such as Ras and phosphatidylinositide-3-kinase
(PI3K). Activity of these proteins is tightly regulated, especially by the tumor suppressors
Nf1 and Pten. The PI3K pathway is another essential survival pathway for a variety of can‐
cer cells. The tumor suppressor Pten (phosphatase and tensin homologue on chromosome
10) negatively regulates the PI3K pathway by dephosphorylating phosphatidylinositol-3,4,5-
triphosphate (PIP3) back to phosphatidylinositol-4,5-biphosphate (PIP2) [11]. Mutations in
PTEN frequently involve the phosphatase domain, and mutations in PI3K typically involve
the catalytic (p110α) and regulatory (p85α) domains.
Classically, GBM has been described as result endpoint from two main gliomagenesis path‐
ways [12-13]. Primary GBM shows amplification of the EGFR, deletion or mutation of homo‐
zygous cyclin-dependent kinase (CDK) inhibitor p16INK4A/(CDKN2A), alterations in
tumor-suppressor PTEN on chromosome 10, and deletion in the INK4a gene with loss of
p14 and p16 [14-15]. Progression from low-grade to high-grade astrocytomas involves inac‐
tivating mutations of tumor-suppressor gene TP53 and elevated expression of PDGF ligands
and receptors, accumulation of genetic alteration of retinoblastoma-associated cell cycle reg‐
ulatory pathways, including deletion or mutations of cyclin-dependent kinase inhibitor
p16INK4A/(CDKN2A) or the retinoblastoma susceptibility locus 1 (pRB1), as well as ampli‐
fication or overexpression of cyclin-dependent kinase 4 (CDK4) and human double minute 2
(HDM2). Evolution to secondary GBM is associated with deletion of chromosome 10, which
includes tumor-suppressor phosphatase and tensin homologue (PTEN). PTEN phosphatase
were identified as the tumor suppressors lost on chromosomes 19 and 10, respectively. p16
can slow down cell cycle progression, whereas PTEN is a negative regulator of the phos‐
phoinositide 3-kinase (PI3K) pathway, [16] a major signaling pathway that stimulates cellu‐
lar proliferation in response to growth factor stimulation. Interestingly, only 1 copy of the
gene is mutated in the tumors, suggesting that the mutations do not result in a simple loss of
function. The mutation is very specific and leads to a single amino acid change (arginine 132
usually becomes histidine) in the IDH1 active site, whereby the enzyme loses its ability to
catalyze conversion of isocitrate to α-ketoglutarate. It was proposed that this might have an
indirect oncogenic effect through the activation of the hypoxia-inducible factor pathway,
[17] a critical step in the metabolic adaptation of tumors to anaerobic growth and for the for‐
mation of new blood vessels through the angiogenic process.
Recently, attention has been focused on the role of an enzyme, isocitrate dehydrogenase 1
(IDH1), present in cytoplasm and peroxisomes, catalyzing the oxidative decarboxylation of
isocitrate to alpha-ketoglutarate, reducing NADP+ to NADPH. Studies performed with seri‐
ated biopsies from gliomas, revealed that mutation of IDH1 is always found before TP53
mutation or, in case of oligodendrogliomas, before their typical deletions of chromosomes
1p and 19q. Moreover, mutation of IDH1 is quite specific, since it is extremely rare in I grade
gliomas, non glioma brain tumors and in other cancers. Yan et al. studied genetic alterations
of both IDH1 and of its related gene, IDH2. Genomic analysis, showed mutation of amino
acid 132 of IDH1 in over 70% of patients with both low or high grade gliomas, and many of
the cases negative for IDH1 mutations, had mutation involving amino acid 172 of IDH2 [18].
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Studies suggest that mutant IDH1 loses its normal enzymatic activity in tumors while gain‐
ing a new pro-oncogenic activity, leading to the production of an onco-metabolite [18-20].
Other studies characterizing the genomic make-up of human glioblastoma have provided
further insight into the genetic changes, core pathways and molecular subtypes underlying
this disease [20-22]. Based on their gene expression profiles, The Cancer Genome Atlas Net‐
work (TCGA) further classified GBMs into four subtypes termed: proneural, neural, classi‐
cal, and mesenchymal [9]. While the status of gene expression and mutation in EGFR, NF1,
PDGFA, and IDH1 were defining components of these subtypes, it was also found that re‐
sponse to therapies was different for each subtype, suggesting that personalized treatment
based on genomic alterations could lead to a more favorable outcome for this disease [23].
3. Molecular biology of glioma invasion
The cellular and molecular events that initiate and promote malignant glioma development
are not completely understood. Vasculogenesis and angiogenesis potentially play distinct
roles in the etiology of primary and recurrent malignant gliomas, suggesting that patient
therapy should perhaps be tailored specifically against the predominant vasculature path‐
way at a given specific stage of gliomagenesis [24]. Cerebral gliomas show a unique pattern
of invasion and, with rare exceptions, do not metastasize outside of the brain. Invading glio‐
ma cells normally migrate to distinct anatomical structures. These structures include the
basement membrane (BM) of blood vessels, the subependymal space, the glial limitans ex‐
terna, and parallel and intersecting nerve fiber tracts in the white matter. Invasion of tumor
cells into normal tissue is thought to be a multifactorial process, consisting of cell interac‐
tions with ECM and with adjacent cells, as well as accompanying biochemical processes
supportive of active cell movement. Several cell types aim active movement during various
stages of embryonal development, during wound healing, and in the course of immune re‐
sponses. This innate activity is regulated in a very rigid manner, suggesting that the reap‐
pearance of a motile phenotype in cancer cells results from the loss or cessation of normal
inhibitory controls [25]. Critical factors in tumor cell invasion, include the detachment of in‐
vading cells from the primary tumor mass, the synthesis and deposition of ECM compo‐
nents by tumor cells and mesenchymal cells, the release of ECM-degrading activities for
remodeling interstitial space, and the expression of adhesion molecules on glioma cell surfa‐
ces that specifically recognize and adhere to ECM components.
The detachment of invading glioma cells from the primary tumor mass involves several
events, including, destabilization and disorganization of the cadherin-mediated junctions
that hold the primary mass together, loss of expression of neural cell adhesion molecule,
which promotes adhesion to the primary tumor mass through homophilic binding, cleavage
of CD44, which anchors the primary mass to the ECM by the metalloproteinase ADAM.
Cadherin superfamily are important adhesion molecules associated with glioma invasion.
Cadherins (E-, P-, and N-cadherin) form adherent junctions and may function as suppres‐
sors of tumor growth and invasion. Desmosomal cadherins interact heterotypically and pro‐
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tor receptor, have also been found to be mutated in GBMs [9]. RTKs mediate cell growth and
proliferation via downstream effectors such as Ras and phosphatidylinositide-3-kinase
(PI3K). Activity of these proteins is tightly regulated, especially by the tumor suppressors
Nf1 and Pten. The PI3K pathway is another essential survival pathway for a variety of can‐
cer cells. The tumor suppressor Pten (phosphatase and tensin homologue on chromosome
10) negatively regulates the PI3K pathway by dephosphorylating phosphatidylinositol-3,4,5-
triphosphate (PIP3) back to phosphatidylinositol-4,5-biphosphate (PIP2) [11]. Mutations in
PTEN frequently involve the phosphatase domain, and mutations in PI3K typically involve
the catalytic (p110α) and regulatory (p85α) domains.
Classically, GBM has been described as result endpoint from two main gliomagenesis path‐
ways [12-13]. Primary GBM shows amplification of the EGFR, deletion or mutation of homo‐
zygous cyclin-dependent kinase (CDK) inhibitor p16INK4A/(CDKN2A), alterations in
tumor-suppressor PTEN on chromosome 10, and deletion in the INK4a gene with loss of
p14 and p16 [14-15]. Progression from low-grade to high-grade astrocytomas involves inac‐
tivating mutations of tumor-suppressor gene TP53 and elevated expression of PDGF ligands
and receptors, accumulation of genetic alteration of retinoblastoma-associated cell cycle reg‐
ulatory pathways, including deletion or mutations of cyclin-dependent kinase inhibitor
p16INK4A/(CDKN2A) or the retinoblastoma susceptibility locus 1 (pRB1), as well as ampli‐
fication or overexpression of cyclin-dependent kinase 4 (CDK4) and human double minute 2
(HDM2). Evolution to secondary GBM is associated with deletion of chromosome 10, which
includes tumor-suppressor phosphatase and tensin homologue (PTEN). PTEN phosphatase
were identified as the tumor suppressors lost on chromosomes 19 and 10, respectively. p16
can slow down cell cycle progression, whereas PTEN is a negative regulator of the phos‐
phoinositide 3-kinase (PI3K) pathway, [16] a major signaling pathway that stimulates cellu‐
lar proliferation in response to growth factor stimulation. Interestingly, only 1 copy of the
gene is mutated in the tumors, suggesting that the mutations do not result in a simple loss of
function. The mutation is very specific and leads to a single amino acid change (arginine 132
usually becomes histidine) in the IDH1 active site, whereby the enzyme loses its ability to
catalyze conversion of isocitrate to α-ketoglutarate. It was proposed that this might have an
indirect oncogenic effect through the activation of the hypoxia-inducible factor pathway,
[17] a critical step in the metabolic adaptation of tumors to anaerobic growth and for the for‐
mation of new blood vessels through the angiogenic process.
Recently, attention has been focused on the role of an enzyme, isocitrate dehydrogenase 1
(IDH1), present in cytoplasm and peroxisomes, catalyzing the oxidative decarboxylation of
isocitrate to alpha-ketoglutarate, reducing NADP+ to NADPH. Studies performed with seri‐
ated biopsies from gliomas, revealed that mutation of IDH1 is always found before TP53
mutation or, in case of oligodendrogliomas, before their typical deletions of chromosomes
1p and 19q. Moreover, mutation of IDH1 is quite specific, since it is extremely rare in I grade
gliomas, non glioma brain tumors and in other cancers. Yan et al. studied genetic alterations
of both IDH1 and of its related gene, IDH2. Genomic analysis, showed mutation of amino
acid 132 of IDH1 in over 70% of patients with both low or high grade gliomas, and many of
the cases negative for IDH1 mutations, had mutation involving amino acid 172 of IDH2 [18].
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cal, and mesenchymal [9]. While the status of gene expression and mutation in EGFR, NF1,
PDGFA, and IDH1 were defining components of these subtypes, it was also found that re‐
sponse to therapies was different for each subtype, suggesting that personalized treatment
based on genomic alterations could lead to a more favorable outcome for this disease [23].
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The cellular and molecular events that initiate and promote malignant glioma development
are not completely understood. Vasculogenesis and angiogenesis potentially play distinct
roles in the etiology of primary and recurrent malignant gliomas, suggesting that patient
therapy should perhaps be tailored specifically against the predominant vasculature path‐
way at a given specific stage of gliomagenesis [24]. Cerebral gliomas show a unique pattern
of invasion and, with rare exceptions, do not metastasize outside of the brain. Invading glio‐
ma cells normally migrate to distinct anatomical structures. These structures include the
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terna, and parallel and intersecting nerve fiber tracts in the white matter. Invasion of tumor
cells into normal tissue is thought to be a multifactorial process, consisting of cell interac‐
tions with ECM and with adjacent cells, as well as accompanying biochemical processes
supportive of active cell movement. Several cell types aim active movement during various
stages of embryonal development, during wound healing, and in the course of immune re‐
sponses. This innate activity is regulated in a very rigid manner, suggesting that the reap‐
pearance of a motile phenotype in cancer cells results from the loss or cessation of normal
inhibitory controls [25]. Critical factors in tumor cell invasion, include the detachment of in‐
vading cells from the primary tumor mass, the synthesis and deposition of ECM compo‐
nents by tumor cells and mesenchymal cells, the release of ECM-degrading activities for
remodeling interstitial space, and the expression of adhesion molecules on glioma cell surfa‐
ces that specifically recognize and adhere to ECM components.
The detachment of invading glioma cells from the primary tumor mass involves several
events, including, destabilization and disorganization of the cadherin-mediated junctions
that hold the primary mass together, loss of expression of neural cell adhesion molecule,
which promotes adhesion to the primary tumor mass through homophilic binding, cleavage
of CD44, which anchors the primary mass to the ECM by the metalloproteinase ADAM.
Cadherin superfamily are important adhesion molecules associated with glioma invasion.
Cadherins (E-, P-, and N-cadherin) form adherent junctions and may function as suppres‐
sors of tumor growth and invasion. Desmosomal cadherins interact heterotypically and pro‐
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vide a linkage to the intermediate filament network through association with cytosolic
proteins (desmoplakin, plakoglobin). Cadherins are linked to the actin-cytoskeleton via cate‐
nins (α-, β-catenin, plakoglobin), thereby establishing molecular lines of communication to
other cell-cell junctions and to cell-substratum junctions [26]. During glioma progression de‐
creased cadherin function is correlated with de-differentiation, metastasis and poor progno‐
sis [27]. Due to its participation in processes such as morphological differentiation and
contact inhibition of growth and motility, cadherins may function as suppressors of tumor
growth and invasion [25]. Perego and co-worker, showed that only glioma cells with imma‐
ture adherens junctions are capable of migrating and invading through poly-1-lysine coated
filters. In the process of maturation of adhesions, the Lin-7 protein forms a complex with
cadherin and β-catenin [28].
The second step is a decline in the expression of connexin 43, which leads to a reduction in
gap junction formation. Connexin 43 is the most abundant gap junction protein in CNS and
is expressed primarily in astrocytes [29]. Cell-cell communication is important in growth
control and differentiation, and it is partly achieved using gap junctions and via second
messengers [30]. Decreased gap junction formation may result in fewer inhibitory signals,
facilitating uncontrolled cell division and de-differentiation [31]. Has been demonstrated
that reduced gap junction formation is correlated with increased motility of glioma cells in
vitro [32]. Increased malignancy of glioma specimens correlates with reduced in situ gap
junction formation as well as reduced connexin 43 expression [33]. The third event is cleav‐
age of CD44, which anchors the primary mass to ECM, by the metalloproteinase ADAM.
CD44 is a transmembrane glycoprotein belonging to the immunoglobulin receptor super‐
family, which interacts with hyaluronic acid as its ligand. Monoclonal antibodies directed
against CD44 decrease intracerebral invasion of glioma cells in vivo and through matrigel
matrices in vitro [34]. CD44 can be cleaved by ADAM 10 and 17, and both the extracellular
and intracellular cleaved components of CD44 promote cell migration [35].
3.1. Integrins
Integrins are heterodimeric transmembrane cell surface receptors that play a key role in the
crosstalk between the cell and its surrounding stroma. Integrins regulate cell adhesion, mi‐
gration, differentiation, proliferation, and survival during physiological and pathological
conditions, including inflammation and cancer. Upon ligation to extracellular ligands (ma‐
trix proteins such as collagens, laminins, vitronectins and fibronectins), integrins activate
downstream signaling pathways in concert with growth factor receptors, including PDGFR,
EGFR and VEGFR. Preclinical data indicate that integrins play a key role in cancer initiation
and progression.
Integrins contain two distinct chains, calls subunit α (alpha) and β (beta). Have been identi‐
fied about 18 α and 8 β subunits. The integrin subunits penetrate the plasma membrane and
typically have very short cytoplasmic domains of about 40-70 amino acids. Outside the plas‐
ma membrane, α and β chains protrude to a length of about 23 nm, the last 5 of which -
thanks to the termination of each chain formed dall'NH2 - a region used to form bonds to
the ECM. The molecular mass of the subunits of the integrin may range from 90 kD to 160
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kD. The β subunits have 4 cysteine-rich repeat sequences. Both the α subunit β both bind
many divalent cations. There are many ways to classify the integrins. For example, a sub‐
class of the chains α has a structural domain in more inserted at the network termination
NH2, the so-called alpha-domain A. The integrins that possess this characteristic usually
form collagen (α1β1 integrins, and α2β1), or act as adhesion molecules between cell and cell
(β2 integrin family). This domain α-1 is the active site for links to various integrins. Those
who do not carry this domain, however, have a domain A in their active site, but this is in
the β chain. In both cases, the domains A are connected to three active sites consisting of
divalent cations. One of these is permanently occupied by physiological concentrations of
divalent cations, and binds to a calcium ion or magnesium. The other two sites are occupied
by cations when establishing ties - at least for the bonds involving an amino acid, aspartic
acid, typically - in their interaction sites. An amino acid characterized in the active site of the
integrin many proteins ECM, as part of the amino acid sequence Arginine-Glycine-Aspartic
acid. The two main functions of integrins are cell adhesion to ECM and signal transduction
from the ECM to the cell. They interact with two large groups of ligands: a variety of ECM
proteins, such as fibronectin, vitronectin, fibrinogen, and cell surface molecules, that are
members of the immunoglobulin supergene family, such as intracellular adhesion molecules
(ICAM-1, ICAM-2) and vascular cell adhesion molecule (VCAM-1). In particular, the integ‐
rin ανβ3, which binds to fibronectin, vitronectin, and tenascin-C in ECM, is thought to play
a central role in glioma invasion [36]. Increased expression of integrin ανβ3 leads to in‐
creased motility in human glioma cells with a concomitant decrease in apoptosis sensitivity.
Integrins combine the ECM out of the cell to the cytoskeleton (in particular microfilaments)
within the cell. What site can bind the ECM is usually decided by the integrin α and β subu‐
nit which is composed of the same integrin. Bonds between the integrin are fibronectin, vi‐
tronectin, collagen, and laminin. The connection between the cell and the ECM makes the
cell able to withstand the forces tie rods without being thrown out of the ECM. The connec‐
tions between the integrin and the links in the ECM and microfilaments inside the cell are
indirect: they are connected by proteins "armor" as talin, paxillin, and alpha-actinin. These
act by regulating the kinase such as FAK (focal adhesion kinase - focal adhesion kinase) and
the family of Src kinases to phosphorylated substrates such as the p130CAS or recruiting
signal adapters such as Crk. The connection of the cell to the extracellular matrix is a basic
requirement to form a multicellular organism. Integrins link the cytoskeleton to the extracel‐
lular matrix, and are recognized to be key regulators of tissue structure. They provide adhe‐
sive, migratory, and survival cues to tumor cells and to cells of the tumor
microenvironment, including angiogenic endothelial cells. The integrins ανβ3 and ανβ5,
among others, are highly expressed not only on the tumor vasculature and angiogenic endo‐
thelial cells, but also on tumor cells, including gliomas. Consequently, integrins have been
considered as a promising therapeutic target in cancer. Monoclonal antibodies and peptide-
based integrin inhibitors are being investigated for their potential therapeutic activity in var‐
ious tumor types. This strategy is in advanced stage clinical development in glioblastoma, a
highly vascular primary brain tumor [37].
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vide a linkage to the intermediate filament network through association with cytosolic
proteins (desmoplakin, plakoglobin). Cadherins are linked to the actin-cytoskeleton via cate‐
nins (α-, β-catenin, plakoglobin), thereby establishing molecular lines of communication to
other cell-cell junctions and to cell-substratum junctions [26]. During glioma progression de‐
creased cadherin function is correlated with de-differentiation, metastasis and poor progno‐
sis [27]. Due to its participation in processes such as morphological differentiation and
contact inhibition of growth and motility, cadherins may function as suppressors of tumor
growth and invasion [25]. Perego and co-worker, showed that only glioma cells with imma‐
ture adherens junctions are capable of migrating and invading through poly-1-lysine coated
filters. In the process of maturation of adhesions, the Lin-7 protein forms a complex with
cadherin and β-catenin [28].
The second step is a decline in the expression of connexin 43, which leads to a reduction in
gap junction formation. Connexin 43 is the most abundant gap junction protein in CNS and
is expressed primarily in astrocytes [29]. Cell-cell communication is important in growth
control and differentiation, and it is partly achieved using gap junctions and via second
messengers [30]. Decreased gap junction formation may result in fewer inhibitory signals,
facilitating uncontrolled cell division and de-differentiation [31]. Has been demonstrated
that reduced gap junction formation is correlated with increased motility of glioma cells in
vitro [32]. Increased malignancy of glioma specimens correlates with reduced in situ gap
junction formation as well as reduced connexin 43 expression [33]. The third event is cleav‐
age of CD44, which anchors the primary mass to ECM, by the metalloproteinase ADAM.
CD44 is a transmembrane glycoprotein belonging to the immunoglobulin receptor super‐
family, which interacts with hyaluronic acid as its ligand. Monoclonal antibodies directed
against CD44 decrease intracerebral invasion of glioma cells in vivo and through matrigel
matrices in vitro [34]. CD44 can be cleaved by ADAM 10 and 17, and both the extracellular
and intracellular cleaved components of CD44 promote cell migration [35].
3.1. Integrins
Integrins are heterodimeric transmembrane cell surface receptors that play a key role in the
crosstalk between the cell and its surrounding stroma. Integrins regulate cell adhesion, mi‐
gration, differentiation, proliferation, and survival during physiological and pathological
conditions, including inflammation and cancer. Upon ligation to extracellular ligands (ma‐
trix proteins such as collagens, laminins, vitronectins and fibronectins), integrins activate
downstream signaling pathways in concert with growth factor receptors, including PDGFR,
EGFR and VEGFR. Preclinical data indicate that integrins play a key role in cancer initiation
and progression.
Integrins contain two distinct chains, calls subunit α (alpha) and β (beta). Have been identi‐
fied about 18 α and 8 β subunits. The integrin subunits penetrate the plasma membrane and
typically have very short cytoplasmic domains of about 40-70 amino acids. Outside the plas‐
ma membrane, α and β chains protrude to a length of about 23 nm, the last 5 of which -
thanks to the termination of each chain formed dall'NH2 - a region used to form bonds to
the ECM. The molecular mass of the subunits of the integrin may range from 90 kD to 160
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kD. The β subunits have 4 cysteine-rich repeat sequences. Both the α subunit β both bind
many divalent cations. There are many ways to classify the integrins. For example, a sub‐
class of the chains α has a structural domain in more inserted at the network termination
NH2, the so-called alpha-domain A. The integrins that possess this characteristic usually
form collagen (α1β1 integrins, and α2β1), or act as adhesion molecules between cell and cell
(β2 integrin family). This domain α-1 is the active site for links to various integrins. Those
who do not carry this domain, however, have a domain A in their active site, but this is in
the β chain. In both cases, the domains A are connected to three active sites consisting of
divalent cations. One of these is permanently occupied by physiological concentrations of
divalent cations, and binds to a calcium ion or magnesium. The other two sites are occupied
by cations when establishing ties - at least for the bonds involving an amino acid, aspartic
acid, typically - in their interaction sites. An amino acid characterized in the active site of the
integrin many proteins ECM, as part of the amino acid sequence Arginine-Glycine-Aspartic
acid. The two main functions of integrins are cell adhesion to ECM and signal transduction
from the ECM to the cell. They interact with two large groups of ligands: a variety of ECM
proteins, such as fibronectin, vitronectin, fibrinogen, and cell surface molecules, that are
members of the immunoglobulin supergene family, such as intracellular adhesion molecules
(ICAM-1, ICAM-2) and vascular cell adhesion molecule (VCAM-1). In particular, the integ‐
rin ανβ3, which binds to fibronectin, vitronectin, and tenascin-C in ECM, is thought to play
a central role in glioma invasion [36]. Increased expression of integrin ανβ3 leads to in‐
creased motility in human glioma cells with a concomitant decrease in apoptosis sensitivity.
Integrins combine the ECM out of the cell to the cytoskeleton (in particular microfilaments)
within the cell. What site can bind the ECM is usually decided by the integrin α and β subu‐
nit which is composed of the same integrin. Bonds between the integrin are fibronectin, vi‐
tronectin, collagen, and laminin. The connection between the cell and the ECM makes the
cell able to withstand the forces tie rods without being thrown out of the ECM. The connec‐
tions between the integrin and the links in the ECM and microfilaments inside the cell are
indirect: they are connected by proteins "armor" as talin, paxillin, and alpha-actinin. These
act by regulating the kinase such as FAK (focal adhesion kinase - focal adhesion kinase) and
the family of Src kinases to phosphorylated substrates such as the p130CAS or recruiting
signal adapters such as Crk. The connection of the cell to the extracellular matrix is a basic
requirement to form a multicellular organism. Integrins link the cytoskeleton to the extracel‐
lular matrix, and are recognized to be key regulators of tissue structure. They provide adhe‐
sive, migratory, and survival cues to tumor cells and to cells of the tumor
microenvironment, including angiogenic endothelial cells. The integrins ανβ3 and ανβ5,
among others, are highly expressed not only on the tumor vasculature and angiogenic endo‐
thelial cells, but also on tumor cells, including gliomas. Consequently, integrins have been
considered as a promising therapeutic target in cancer. Monoclonal antibodies and peptide-
based integrin inhibitors are being investigated for their potential therapeutic activity in var‐
ious tumor types. This strategy is in advanced stage clinical development in glioblastoma, a
highly vascular primary brain tumor [37].
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The malignancy of glioma is dependent on diffusive properties of tumor cells that may in‐
vade widely as single cells anywhere in the brain. Integrins are the family of adhesive recep‐
tors that promote invasiveness of glioma. These heterodimeric transcellular membrane
receptors are composed of two subunits, α and β, and are the major receptors for the ECM
proteins. Immunohistopathological studies revealed an upregulation of α2β1, α3β1, α5β1,
α6β1, and αvβ3 integrins on GBM when compared with normal brain [38].
Glioblastoma commonly displays enhanced expression of several integrins along with their
ECM ligands: αvβ3 and αvβ5 (tenascin and vitronectin receptors), α5β1 (fibronectin recep‐
tor), α2β1 (collagens receptor), and α3β1, α6β4, and α6β1 (laminins receptors). Numerous
studies have focused on the αv integrin family. The integrins αvβ3 and αvβ5 are markers of
glioblastoma malignancy and influence a variety of processes in glioblastoma progression in
vivo, including proliferation, apoptosis, and angiogenesis. Furthermore, cilengitide, an αvβ3
and αvβ5 integrins antagonist, extends mouse survival by delaying the tumor growth and is
nowadays in clinical trial for recurrent malignant glioma. Two other integrins, α5β1 and
α3β1, have been shown to be implicated in glioma cell adhesion and migration in vitro. The
α6 integrin subunit associates with β1 or β4 subunits to form functional heterodimers that
selectively bind laminins. The α6β4 integrin is essential for the organization and mainte‐
nance of epithelial hemidesmosomes that link the intermediate filaments with the extracellu‐
lar matrix. The major ligand of α6β4 is the laminin-332, while α6β1 is a well-characterized
laminin-111 receptor. Overexpression of α6β1 integrin has been associated with the progres‐
sion of many epithelial tumors. Several studies concerning gliomas and the α6β1 ligand
laminin-111 have been reported in the literature. Using immunohistochemistry studies,
Gingras et al. showed that α6 integrin was strongly expressed in glioblastoma tissue, where‐
as it was weakly expressed in normal brain [39]. Previtali et al. confirmed that the expres‐
sion of α6 was increased in glioblastoma and in other central nervous system tumors, such
as meningioma, astrocytoma, and neuroblastoma, when compared with the autologous nor‐
mal tissue counterpart [40]. In glioblastoma biopsies, laminin-111 is highly expressed on tu‐
mor blood vessels, but also within the brain tumor as punctuate deposits and at the tumor
invasion front. In vitro, glioma cells can both secrete laminin-111 and induce its expression
in normal brain tissue. Moreover, laminin-111 is one of the most permissive substrates for
adhesion and migration of glioma cells in vitro. Additionally, over laminin-111, migrating
glioma cells are protected from apoptosis [41].
In malignant glioma, and in particular in GBM, overexpression of αvβ3 integrin is well
documented. The integrin αvβ3, which binds to fibronectin, vitronectin, and tenascin-C in
ECM, is thought to play a central role in glioma invasion [36]. Increased expression of integ‐
rin αvβ3 leads to increased motility in human glioma cells with a concomitant decrease in
apoptosis sensitivity. Importantly, αvβ3 integrin is expressed both on angiogenic endothe‐
lial cells and on tumor cells. Conversely, inhibition of integrin αvβ3 decreases glioma cell
motility [42]. Several factors expressed in glioma cells have been found to regulate integrin
expression. Particularly, uPA secreted by glioma cells has been shown to upregulate integrin
αvβ3 expression by autocrine mechanism [43]. Furthermore, decreasing the in vivo expres‐
sion of the β1 subunit by an antisense strategy in the intracranial C6 glioma model leads to
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an inhibition of glioma associated angiogenesis at the invasive edge of the tumors [44].
Down-regulated β1 integrin protein levels in vivo probably affect interactions of glioma
cells with ECM components, leading to reduced migration along vascular basement mem‐
branes. The integrin α6β1 plays an important role for the regulation of glioma-initiating cells
in the perivascular niche. This integrin mediates the interaction of glioma-initiating cells to
laminin, an extracellular matrix protein expressed in basement membranes, including those
supporting endothelial cells. This interaction provides an anchorage for glioma-initiating
cells within the perivascular niche and supports their tumorigenic potential [37].
Brown  et  al.  evaluate  the  role  of  α9β1  integrin  interaction  with  nerve  growth  factor
(NGF)  in  glioma  progression,  they  selected  the  two  most  malignant  glioblastoma  cell
lines: LN229, which expresses α9β1, and LN18,in which does not. Presence of the α9 in‐
tegrin subunit on LN229 and absence on LN18 cell  lines were verified using several as‐
says  such  as  monoclonal  antibody  adhesion  microarray,  Western  blot  analysis  of  cell
lysates, flow cytometry, and immunocytostaining [38]. Very high expression of the α9 in‐
tegrin  subunit  was  observed  only  on  the  LN229  cell  line.  Western  blot  analysis,  using
polyclonal anti-α9 antibody, showed the absence of this integrin subunit on normal astro‐
cytes.  The expression of α9β1 integrin on LN229 and lack of it  on LN18 was confirmed
by  flow  cytometry  and  immunocytostaining  analysis.  The  investigation  of  cellular  re‐
sponses  following binding of  NGF to  α9β1 integrin  on LN229 and LN18 cells  required
evaluation of the level of two other NGF receptors, TrkA and p75NTR. Western blot analy‐
sis  of  cell  lysates  and  immunocytostaining  revealed  negligible  expression  of  TrkA  on
both types of cells, and a stable expression of p75NTR  in comparison with PC12 neuronal
cells used as a positive control. Interestingly, the level of p75NTR appeared to be lower on
LN18 cells, which are α9β1 integrin deficient, than on LN229 cells, which are α9β1 integ‐
rin positive. This correlation was previously observed in the mRNA level of SW480 cells
transfected with α9 integrin subunit. Cells transfected with the α9 subunit showed a po‐
tent  increase of  p75NTR,  whereas mock-transfected cells  had a significantly lower expres‐
sion of this NGF receptor. The opposite situation occurred for TrkA, suggesting that this
specific high affinity NGF receptor has a functional complementary association with α9β1
integrin.  Several  factors  expressed in  glioma cells  have  been  found to  regulate  integrin
expression.  Glioma expression of  focal  adhesion kinase,  a  nonreceptor cytoplasmic tyro‐
sine kinase, has been shown to increase phosphorylation of the enhancer of filamentation
1,  which  in  turn  stimulates  PDGF-mediated  stimulation  of  glioma  integrin  adhesion  to
ECM [45].
3.2. Proteases
Extracellular proteolytic enzymes are critical for the invasive properties of malignant neo‐
plasms [46]. Barrier to invasion do not appear as restrictive within CNS parenchyma and
matrix substrates most responsible for impeding tumor migration have not been identified
[47]. Nonetheless, there is a strong evidence that the expression of specific extracellular ma‐
trix proteases promotes invasive behavior by gliomas. These include the matrix metallopro‐
teinases (MMPs), the urokinase-dependent plasminogen activating cascade, and cathepsin
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The malignancy of glioma is dependent on diffusive properties of tumor cells that may in‐
vade widely as single cells anywhere in the brain. Integrins are the family of adhesive recep‐
tors that promote invasiveness of glioma. These heterodimeric transcellular membrane
receptors are composed of two subunits, α and β, and are the major receptors for the ECM
proteins. Immunohistopathological studies revealed an upregulation of α2β1, α3β1, α5β1,
α6β1, and αvβ3 integrins on GBM when compared with normal brain [38].
Glioblastoma commonly displays enhanced expression of several integrins along with their
ECM ligands: αvβ3 and αvβ5 (tenascin and vitronectin receptors), α5β1 (fibronectin recep‐
tor), α2β1 (collagens receptor), and α3β1, α6β4, and α6β1 (laminins receptors). Numerous
studies have focused on the αv integrin family. The integrins αvβ3 and αvβ5 are markers of
glioblastoma malignancy and influence a variety of processes in glioblastoma progression in
vivo, including proliferation, apoptosis, and angiogenesis. Furthermore, cilengitide, an αvβ3
and αvβ5 integrins antagonist, extends mouse survival by delaying the tumor growth and is
nowadays in clinical trial for recurrent malignant glioma. Two other integrins, α5β1 and
α3β1, have been shown to be implicated in glioma cell adhesion and migration in vitro. The
α6 integrin subunit associates with β1 or β4 subunits to form functional heterodimers that
selectively bind laminins. The α6β4 integrin is essential for the organization and mainte‐
nance of epithelial hemidesmosomes that link the intermediate filaments with the extracellu‐
lar matrix. The major ligand of α6β4 is the laminin-332, while α6β1 is a well-characterized
laminin-111 receptor. Overexpression of α6β1 integrin has been associated with the progres‐
sion of many epithelial tumors. Several studies concerning gliomas and the α6β1 ligand
laminin-111 have been reported in the literature. Using immunohistochemistry studies,
Gingras et al. showed that α6 integrin was strongly expressed in glioblastoma tissue, where‐
as it was weakly expressed in normal brain [39]. Previtali et al. confirmed that the expres‐
sion of α6 was increased in glioblastoma and in other central nervous system tumors, such
as meningioma, astrocytoma, and neuroblastoma, when compared with the autologous nor‐
mal tissue counterpart [40]. In glioblastoma biopsies, laminin-111 is highly expressed on tu‐
mor blood vessels, but also within the brain tumor as punctuate deposits and at the tumor
invasion front. In vitro, glioma cells can both secrete laminin-111 and induce its expression
in normal brain tissue. Moreover, laminin-111 is one of the most permissive substrates for
adhesion and migration of glioma cells in vitro. Additionally, over laminin-111, migrating
glioma cells are protected from apoptosis [41].
In malignant glioma, and in particular in GBM, overexpression of αvβ3 integrin is well
documented. The integrin αvβ3, which binds to fibronectin, vitronectin, and tenascin-C in
ECM, is thought to play a central role in glioma invasion [36]. Increased expression of integ‐
rin αvβ3 leads to increased motility in human glioma cells with a concomitant decrease in
apoptosis sensitivity. Importantly, αvβ3 integrin is expressed both on angiogenic endothe‐
lial cells and on tumor cells. Conversely, inhibition of integrin αvβ3 decreases glioma cell
motility [42]. Several factors expressed in glioma cells have been found to regulate integrin
expression. Particularly, uPA secreted by glioma cells has been shown to upregulate integrin
αvβ3 expression by autocrine mechanism [43]. Furthermore, decreasing the in vivo expres‐
sion of the β1 subunit by an antisense strategy in the intracranial C6 glioma model leads to
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an inhibition of glioma associated angiogenesis at the invasive edge of the tumors [44].
Down-regulated β1 integrin protein levels in vivo probably affect interactions of glioma
cells with ECM components, leading to reduced migration along vascular basement mem‐
branes. The integrin α6β1 plays an important role for the regulation of glioma-initiating cells
in the perivascular niche. This integrin mediates the interaction of glioma-initiating cells to
laminin, an extracellular matrix protein expressed in basement membranes, including those
supporting endothelial cells. This interaction provides an anchorage for glioma-initiating
cells within the perivascular niche and supports their tumorigenic potential [37].
Brown  et  al.  evaluate  the  role  of  α9β1  integrin  interaction  with  nerve  growth  factor
(NGF)  in  glioma  progression,  they  selected  the  two  most  malignant  glioblastoma  cell
lines: LN229, which expresses α9β1, and LN18,in which does not. Presence of the α9 in‐
tegrin subunit on LN229 and absence on LN18 cell  lines were verified using several as‐
says  such  as  monoclonal  antibody  adhesion  microarray,  Western  blot  analysis  of  cell
lysates, flow cytometry, and immunocytostaining [38]. Very high expression of the α9 in‐
tegrin  subunit  was  observed  only  on  the  LN229  cell  line.  Western  blot  analysis,  using
polyclonal anti-α9 antibody, showed the absence of this integrin subunit on normal astro‐
cytes.  The expression of α9β1 integrin on LN229 and lack of it  on LN18 was confirmed
by  flow  cytometry  and  immunocytostaining  analysis.  The  investigation  of  cellular  re‐
sponses  following binding of  NGF to  α9β1 integrin  on LN229 and LN18 cells  required
evaluation of the level of two other NGF receptors, TrkA and p75NTR. Western blot analy‐
sis  of  cell  lysates  and  immunocytostaining  revealed  negligible  expression  of  TrkA  on
both types of cells, and a stable expression of p75NTR  in comparison with PC12 neuronal
cells used as a positive control. Interestingly, the level of p75NTR appeared to be lower on
LN18 cells, which are α9β1 integrin deficient, than on LN229 cells, which are α9β1 integ‐
rin positive. This correlation was previously observed in the mRNA level of SW480 cells
transfected with α9 integrin subunit. Cells transfected with the α9 subunit showed a po‐
tent  increase of  p75NTR,  whereas mock-transfected cells  had a significantly lower expres‐
sion of this NGF receptor. The opposite situation occurred for TrkA, suggesting that this
specific high affinity NGF receptor has a functional complementary association with α9β1
integrin.  Several  factors  expressed in  glioma cells  have  been  found to  regulate  integrin
expression.  Glioma expression of  focal  adhesion kinase,  a  nonreceptor cytoplasmic tyro‐
sine kinase, has been shown to increase phosphorylation of the enhancer of filamentation
1,  which  in  turn  stimulates  PDGF-mediated  stimulation  of  glioma  integrin  adhesion  to
ECM [45].
3.2. Proteases
Extracellular proteolytic enzymes are critical for the invasive properties of malignant neo‐
plasms [46]. Barrier to invasion do not appear as restrictive within CNS parenchyma and
matrix substrates most responsible for impeding tumor migration have not been identified
[47]. Nonetheless, there is a strong evidence that the expression of specific extracellular ma‐
trix proteases promotes invasive behavior by gliomas. These include the matrix metallopro‐
teinases (MMPs), the urokinase-dependent plasminogen activating cascade, and cathepsin
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B. Wild-Bode et al. [48] found that MMP-2 and MMP-3 levels and MMP-2/MMP-9 activity
correlated with glioma cell migration and invasion. NF-jB, uPA, low-density lipoprotein re‐
ceptor-related protein 1, and insulin-like growth factor binding protein-2 are known to upre‐
gulate MMP expression. Induced expression of tissue inhibitor of metalloproteinases-3
(TIMP-3), a putative inhibitor of MMP activity, has been shown to suppress infiltration and
also to induce apoptosis in cancer cell lines. MMPs play an important role in human brain
tumor invasion, probably due to an imbalance between the production of MMPs and tissue
inhibitor of metalloproteinases-1 (TIMP-1) by the tumor cells. MMP-1 is the crucial enzyme
able to initiate breakdown of the interstitial collagen types; in this way, it activates the other
MMPs, which allows the glioma cells to infiltrate normal brain tissue.
Matrix metalloproteinases comprise a large family of zinc-dependent endoproteinases, col‐
lectively capable of degrading all ECM components. A total of 23 families of MMPs are
known and these are numbered in the sequence of their discovery [49]. Originally, MMPs
were classified according to their respective substrate specificity, now they are divided into
eight structural subgroups, five of which are secreted and three of which are transmem‐
brane MMPs. A signal peptide leads them to the secretory pathway. Then, these enzymes
can be secreted from the cell or anchored to the plasma membrane, thereby confining their
catalytic activity to the extracellular space or to the cell surface, respectively. Their function
is to degrade different protein components of the ECM and of basement membranes, there‐
fore they are essential for the interaction of individual cells with their surrounding and for
the development and function of multicellular organisms [50]. Between the various sub‐
strates of MMPs we include collagens, non collagens glicoproteins, proteoglycans and other
ECM components like tenascin, fibronectin and laminin, which often show tumor specific
expression are also substrates [51]. The proteolytic activities of MMPs influence essential cel‐
lular processes like cell proliferation, migration and adhesion, as well as many fundamental
physiological events involving tissue remodeling, such as angiogenesis, bone development,
wound healing, and uterine and mammary involution [52]. However, the increasing expres‐
sion of this enzymes is associated with many pathological conditions [53-54] such as rheu‐
matoid arthritis, cardiovascular diseases or cancer progression [55]. MMP expression and
activity can be regulated at different levels including gene transcription, proenzyme activa‐
tion and endogenous inhibition, which act in a coordinated manner to confine the diverse
MMP proteolytic activities to those conditions and locations where they are necessary. Un‐
fortunately, these restrictive regulatory mechanisms are frequently lost in multiple patho‐
logical conditions [56]. MMPs expression is induced by different factors like EGF, TGF-β,
PDGF, and various inflammation’s mediated, included TNFα and IL-1β.
MMPs or matrixins are synthesized as zymogens, inactive pro-enzymes (pro-MMPs), with
the zinc ion, essential for MMP activity, hidden by a cysteine-sulphydryl residue situated
near the C-terminal end of the peptide. The pro-enzyme’s activations starts breaking the in‐
teraction cysteine-zinc exposing, in this way the catalytic site. The fully active enzyme is
generated by proteolytic cleavage of the pro-peptide domain of the partially active inter‐
mediate enzyme [50]. Once active, MMPs are regulated by interactions with endogenous in‐
hibitors including α2-macroglobulin, thrombospondin-2, tissue inhibitors of metallopro-
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teinases (TIMPs) and RECK (reversion-inducing cysteine-rich protein with kazal motifs)
[49]. Numerous studies have investigated the expression of selected MMPs in human GBM
cell lines. As it has already been reported that there are differences in the expression pat‐
terns of MMPs in different cell-lines [57]. A number of different techniques have been used
to detect protease expression patterns. This may have led to dissimilar conclusions, due to
disparate sensitivities and due to comparing mRNA expression with protein expression or
protein activity. Variations in MMP expression may be due to in vitro selection processes or
karyotype evolution, where the transcription of either the enzyme and/or its inhibitor may
be affected which ultimately leads to an imbalance in the MMP-regulatory network [57].
MMP-9’s production is dependent on a regulation by extracellular signal-regulated kinase
(ERK), PKCα/NF-κB and jun amino-terminal kinase (JNK) signaling cascades. Glioblastomas
are highly hypoxic and hypoxia upregulates MMP-2 mRNA expression in U87, U251, U373
and LN18 glioblastoma cell-lines by activation of the HIF-1α transcription factor, thereby en‐
hancing their invasive potential. Migration and invasion of U87 and T98G GBM cells is also
facilitated by NO, which can be found in high concentrations in glioblastoma tissue. NO
stimulates MMP-1 expression and activity. EGF raises MMP14 expression in U251 cells, but
does not influence MMP-15, -16 or MMP-24. MMP-2 expression and secretion is induced by
IL-6 in U87 cells. However, IL-6 action seems to be cell-line specific, since U343 cells were
not affected [57].
The inflammatory cytokine TNF-α and the immune-suppressive cytokine TGF-β have been
implicated in migration and invasion of glioma cells in vitro. In U251 and in U373 cells,
TNF-α stimulated the expression of MMP-9 and MMP-19. MMP-1 mRNA expression was
significantly increased in U373 cells by TNF-α, whereas its expression in U251 cells re‐
mained unaffected. This may be due to the high basal level of MMP-1 expression displayed
by U251 cells, where a further increase is not possible, or else it could also be a cell- line spe‐
cific effect. Such an effect has been observed for MMP-1, -2, -3 and MMP-7 regulation by
TNF-α and TGF-β1, which only caused a marked induction of expression in some GBM cell-
lines. TNF-α enhances the invasiveness of T98G cells through an induction of MMP-3, but
has no effect on MMP-1, -2 or MMP-9. However, in U251 cells TNF-α inhibits MMP-2 and
decreases invasiveness into the extracellular matrix. In A172 cells, TNF-α induces gene ex‐
pression and protein secretion of MMP-9. TGF-β1 alone had no effect on MMP-9 production.
However, when it was added together with TNF-α a significant dose-dependent inhibition
of MMP-9 secretion was observed. TGF-β1 displayed inconsistent effects on adhesion and
invasiveness, depending on the cell-line examined. The invasive potential of U138 cells was
markedly reduced, whereas U373 cell invasion remained unchanged. TGF-β1 caused a sig‐
nificant induction of MMP-11 and MMP-24 expression in U373 cells, whereas there was no
impact on MMP expression in U251 cells. In U87 and LN229 cells, TGF-β upregulates
MMP-2. Thus, the transcriptional modulation of MMP genes in response to TNF-α or TGF-β
is not consistent, but extremely cell-line specific [57]. Elevated levels of several MMPs were
also found in malignant glioma tissue samples. MMP-1 expression was increased in surgical
specimens of GBM compared to low grade astrocytomas and normal brain. This increased
expression is probably due to a single nucleotide polymorphism in the MMP-1 promoter at
position-1607, creating a functional binding site for members of the ETS family of transcrip‐
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B. Wild-Bode et al. [48] found that MMP-2 and MMP-3 levels and MMP-2/MMP-9 activity
correlated with glioma cell migration and invasion. NF-jB, uPA, low-density lipoprotein re‐
ceptor-related protein 1, and insulin-like growth factor binding protein-2 are known to upre‐
gulate MMP expression. Induced expression of tissue inhibitor of metalloproteinases-3
(TIMP-3), a putative inhibitor of MMP activity, has been shown to suppress infiltration and
also to induce apoptosis in cancer cell lines. MMPs play an important role in human brain
tumor invasion, probably due to an imbalance between the production of MMPs and tissue
inhibitor of metalloproteinases-1 (TIMP-1) by the tumor cells. MMP-1 is the crucial enzyme
able to initiate breakdown of the interstitial collagen types; in this way, it activates the other
MMPs, which allows the glioma cells to infiltrate normal brain tissue.
Matrix metalloproteinases comprise a large family of zinc-dependent endoproteinases, col‐
lectively capable of degrading all ECM components. A total of 23 families of MMPs are
known and these are numbered in the sequence of their discovery [49]. Originally, MMPs
were classified according to their respective substrate specificity, now they are divided into
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strates of MMPs we include collagens, non collagens glicoproteins, proteoglycans and other
ECM components like tenascin, fibronectin and laminin, which often show tumor specific
expression are also substrates [51]. The proteolytic activities of MMPs influence essential cel‐
lular processes like cell proliferation, migration and adhesion, as well as many fundamental
physiological events involving tissue remodeling, such as angiogenesis, bone development,
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matoid arthritis, cardiovascular diseases or cancer progression [55]. MMP expression and
activity can be regulated at different levels including gene transcription, proenzyme activa‐
tion and endogenous inhibition, which act in a coordinated manner to confine the diverse
MMP proteolytic activities to those conditions and locations where they are necessary. Un‐
fortunately, these restrictive regulatory mechanisms are frequently lost in multiple patho‐
logical conditions [56]. MMPs expression is induced by different factors like EGF, TGF-β,
PDGF, and various inflammation’s mediated, included TNFα and IL-1β.
MMPs or matrixins are synthesized as zymogens, inactive pro-enzymes (pro-MMPs), with
the zinc ion, essential for MMP activity, hidden by a cysteine-sulphydryl residue situated
near the C-terminal end of the peptide. The pro-enzyme’s activations starts breaking the in‐
teraction cysteine-zinc exposing, in this way the catalytic site. The fully active enzyme is
generated by proteolytic cleavage of the pro-peptide domain of the partially active inter‐
mediate enzyme [50]. Once active, MMPs are regulated by interactions with endogenous in‐
hibitors including α2-macroglobulin, thrombospondin-2, tissue inhibitors of metallopro-
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teinases (TIMPs) and RECK (reversion-inducing cysteine-rich protein with kazal motifs)
[49]. Numerous studies have investigated the expression of selected MMPs in human GBM
cell lines. As it has already been reported that there are differences in the expression pat‐
terns of MMPs in different cell-lines [57]. A number of different techniques have been used
to detect protease expression patterns. This may have led to dissimilar conclusions, due to
disparate sensitivities and due to comparing mRNA expression with protein expression or
protein activity. Variations in MMP expression may be due to in vitro selection processes or
karyotype evolution, where the transcription of either the enzyme and/or its inhibitor may
be affected which ultimately leads to an imbalance in the MMP-regulatory network [57].
MMP-9’s production is dependent on a regulation by extracellular signal-regulated kinase
(ERK), PKCα/NF-κB and jun amino-terminal kinase (JNK) signaling cascades. Glioblastomas
are highly hypoxic and hypoxia upregulates MMP-2 mRNA expression in U87, U251, U373
and LN18 glioblastoma cell-lines by activation of the HIF-1α transcription factor, thereby en‐
hancing their invasive potential. Migration and invasion of U87 and T98G GBM cells is also
facilitated by NO, which can be found in high concentrations in glioblastoma tissue. NO
stimulates MMP-1 expression and activity. EGF raises MMP14 expression in U251 cells, but
does not influence MMP-15, -16 or MMP-24. MMP-2 expression and secretion is induced by
IL-6 in U87 cells. However, IL-6 action seems to be cell-line specific, since U343 cells were
not affected [57].
The inflammatory cytokine TNF-α and the immune-suppressive cytokine TGF-β have been
implicated in migration and invasion of glioma cells in vitro. In U251 and in U373 cells,
TNF-α stimulated the expression of MMP-9 and MMP-19. MMP-1 mRNA expression was
significantly increased in U373 cells by TNF-α, whereas its expression in U251 cells re‐
mained unaffected. This may be due to the high basal level of MMP-1 expression displayed
by U251 cells, where a further increase is not possible, or else it could also be a cell- line spe‐
cific effect. Such an effect has been observed for MMP-1, -2, -3 and MMP-7 regulation by
TNF-α and TGF-β1, which only caused a marked induction of expression in some GBM cell-
lines. TNF-α enhances the invasiveness of T98G cells through an induction of MMP-3, but
has no effect on MMP-1, -2 or MMP-9. However, in U251 cells TNF-α inhibits MMP-2 and
decreases invasiveness into the extracellular matrix. In A172 cells, TNF-α induces gene ex‐
pression and protein secretion of MMP-9. TGF-β1 alone had no effect on MMP-9 production.
However, when it was added together with TNF-α a significant dose-dependent inhibition
of MMP-9 secretion was observed. TGF-β1 displayed inconsistent effects on adhesion and
invasiveness, depending on the cell-line examined. The invasive potential of U138 cells was
markedly reduced, whereas U373 cell invasion remained unchanged. TGF-β1 caused a sig‐
nificant induction of MMP-11 and MMP-24 expression in U373 cells, whereas there was no
impact on MMP expression in U251 cells. In U87 and LN229 cells, TGF-β upregulates
MMP-2. Thus, the transcriptional modulation of MMP genes in response to TNF-α or TGF-β
is not consistent, but extremely cell-line specific [57]. Elevated levels of several MMPs were
also found in malignant glioma tissue samples. MMP-1 expression was increased in surgical
specimens of GBM compared to low grade astrocytomas and normal brain. This increased
expression is probably due to a single nucleotide polymorphism in the MMP-1 promoter at
position-1607, creating a functional binding site for members of the ETS family of transcrip‐
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tion factors. MMP-1 was expressed throughout the tumor section, particularly in the highly
cellular areas of the GBM [57]. Many studies have demonstrated an intimate association be‐
tween MMP-9 and tumor invasiveness. Different analyses for MMP-9 were negative in NB
tissue, showed weak signals in LGA and strong expression in GBM [57]. MMP-9 is strongly
expressed in blood vessels at proliferating margins, as well as tumor cells, this suggests a
role in the regulation of tumor neoangiogenesis [58]. Other proteases that could be related
with the development of highly invasive glial tumor are MMP-11, MMP-12, MMO-14,
MMP-15, MMP-19, MMP-24, MMP-25.
A second proteolytic system that interfaces with MMPs is the urokinase pathway of plasmi‐
nogen activation. This system includes urokinase (also known as urokinase-type plasmino‐
gen activator, uPA), the urokinase receptor (uPAR), and plasminogen. Urokinase is secreted
as a single chain, inactive proenzyme that is activated by cleavage upon binding to its cell
surface receptor uPAR. Activated uPA then converts plasminogen into plasmin, a serine
protease that promotes cellular migration by the degradation of extracellular matrix pro‐
teins, activation of other matrix proteases and activation of cell surface receptors that trans‐
duce intracellular signaling for migration. Plasmin activates protease activated receptor 1
(PAR1), which is normally expressed in human astrocytes, is activated in many malignan‐
cies including GBMs, and is associated with increased invasive properties [59]. Thus, uPA
and plasminogen activation can occur in the immediate vicinity of the cell membrane or, fol‐
lowing cleavage of the uPAR GPI anchor, at greater distance in the extracellular matrix. An
important biologic regulator of this cascade is plasminogen activator–inhibitor 1 (PAI1),
which promotes the internalization of uPA bound uPAR [60]. uPAR has roles in cellular mi‐
gration distinct from its ability to activate plasminogen though its interactions with integ‐
rins, signaling through G-protein coupled receptors, and caveolin binding [61]. There is a
convincing correlative relationship between uPAR and uPA expression and malignant pro‐
gression in a variety of tumor types [62]. Both neoplastic cells and stromal cells contribute to
the overall activity of these pathways. In co-cultures of malignant gliomas and reactive as‐
trocytes, most uPA and uPAR activity was derived from reactive astrocytes, whereas plas‐
minogen was expressed in largest amounts by glioma cells [63]. Levels of uPA mRNA and
its enzymatic activity are higher in human anaplastic astrocytomas and GBMs than in low
grade astrocytomas and normal human brain and uPA mRNA levels have an inverse corre‐
lation with survival periods [64]. uPAR levels are significantly higher in GBMs and anaplas‐
tic astrocytomas that normal brain and low grade gliomas, with uPAR mRNA localizing to
both glioma cells and endothelial cells [65]. The finding of uPAR expression at the leading
edge of neoplastic infiltration and within remodeling hyperplastic blood vessels suggested
that it may be playing a role in invasion and tissue remodeling. mRNA levels of both uPA
and uPAR genes are increased in high grade gliomas possibly suggesting increased gene
transcription [66]. In the CNS, reactive astrocytes in the vicinity of invading gliomas appear
to contribute for a substantial proportion of extracellular MMP activity, both by their secre‐
tion of pro-MMP2 and the components of the plasminogen activating system, uPA and uP‐
AR [63]. Reactive astrocytes have also been shown to promote the invasive capabilities of
glioma cells in vitro, presumably resulting from enhanced extracellular MMP-2 activity.
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The cathepsins are a family of lysosomal cysteine proteases. These proteases are synthesized
as inactive pro-enzymes that are activated by autocatalytic activity initiated by low pH or by
other proteases including cathepsin D, uPA, and pepsin. Natural regulators of cathepsins
are the cystatins, which are critical, in their inhibitory properties. Cathepsins are secreted in‐
to the extracellular space where they degrade extracellular matrix components required for
invasive properties in neoplastic disease. Best studied for their roles in glioma tumorigenesis
and invasion are cathepsins B, D, H, L, and S. Each of these cathepsin subtypes have higher
protein levels in high grade astrocytomas than low grade tumors or normal brain and enzy‐
matic activities, in general, correlate with protein expression [67-68]. The role of cathepsins
in tumor invasion has been supported by the finding that tumor cells at the invading edge
of gliomas express high levels of cathepsins, especially cathepsin B [69]. In addition, protein
and enzymatic levels of cathepsins B, D, L, H, and S were found to correlate with the ability
of glioblastoma cells to migrate in vitro. Once in the extracellular compartment, cathepsin B
physically interacts with a protein complex at the outer cell membrane containing annexin
II, p11, tPA and plasminogen [70]. Its close proximity to both the plasminogen activating
cascade and MMPs is critical for regulation of their combined proteolytic functions. Upon
activation, cathepsin B has its own proteolytic activity on extracellular matrix components,
but also activates the cascade to convert plasminogen to plasmin and is able to activate se‐
lected MMPs [71].
3.3. Extracellular matrix
The ECM affects numerous functions and processes within the brain. During brain develop‐
ment, the ECM modulates the migration of glial and neuronal precursor cells, guides axonal
growth cones, synapse formation and cell proliferation. The roles played by the ECM in neo‐
plastic transformation are complex and only now beginning to be uncovered. ECM is a com‐
plex network of different collagens, proteoglycans, hyaluronic acid, laminin, fibronectin,
and many other glycoproteins, including proteolytic enzymes involved in degradation and
remodelling of the ECM [72]. Extracellular matrix exists in two forms: interstitial matrix that
fills in the intercellular space and the more specialized BM, which is a thin sheet of extracel‐
lular matrix underlying the epithelium. ECM provides the microenvironment for the cells
and serves as a tissue scaffold, guiding cell migration during embryonic development and
wound repair. Integrins are a class of adhesion molecules that have a major role in the adhe‐
sion and subsequent invasion of tumor cells. ECM proteins such as fibronectin, laminins or
collagens form distinct protein networks that show tissue-specific variation in composition
and architecture. Cell responses to contact with these networks depend on the cell’s reper‐
toire of ECM receptors. Connections from the matrix through these receptors determine the
organization of cytoskeletal structures and the localization and activation of signaling mole‐
cules leading to unique tissue specific cell functions. Changes in these ECM components are
felt to modulate brain tumor growth, proliferation and invasion, although specific interac‐
tions and exact mechanisms are unknown. Cell adhesion is the binding of the cells to each
other and to the ECM through cell adhesion molecules such as integrins, selectins, cadher‐
ins, the Ig (immunoglobulin) superfamily and lymphocyte homing receptors. Cell adhesion
mediates cell attachment, migration, and signalling to and from the extracellular matrix. Ad‐
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(PAR1), which is normally expressed in human astrocytes, is activated in many malignan‐
cies including GBMs, and is associated with increased invasive properties [59]. Thus, uPA
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which promotes the internalization of uPA bound uPAR [60]. uPAR has roles in cellular mi‐
gration distinct from its ability to activate plasminogen though its interactions with integ‐
rins, signaling through G-protein coupled receptors, and caveolin binding [61]. There is a
convincing correlative relationship between uPAR and uPA expression and malignant pro‐
gression in a variety of tumor types [62]. Both neoplastic cells and stromal cells contribute to
the overall activity of these pathways. In co-cultures of malignant gliomas and reactive as‐
trocytes, most uPA and uPAR activity was derived from reactive astrocytes, whereas plas‐
minogen was expressed in largest amounts by glioma cells [63]. Levels of uPA mRNA and
its enzymatic activity are higher in human anaplastic astrocytomas and GBMs than in low
grade astrocytomas and normal human brain and uPA mRNA levels have an inverse corre‐
lation with survival periods [64]. uPAR levels are significantly higher in GBMs and anaplas‐
tic astrocytomas that normal brain and low grade gliomas, with uPAR mRNA localizing to
both glioma cells and endothelial cells [65]. The finding of uPAR expression at the leading
edge of neoplastic infiltration and within remodeling hyperplastic blood vessels suggested
that it may be playing a role in invasion and tissue remodeling. mRNA levels of both uPA
and uPAR genes are increased in high grade gliomas possibly suggesting increased gene
transcription [66]. In the CNS, reactive astrocytes in the vicinity of invading gliomas appear
to contribute for a substantial proportion of extracellular MMP activity, both by their secre‐
tion of pro-MMP2 and the components of the plasminogen activating system, uPA and uP‐
AR [63]. Reactive astrocytes have also been shown to promote the invasive capabilities of
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growth cones, synapse formation and cell proliferation. The roles played by the ECM in neo‐
plastic transformation are complex and only now beginning to be uncovered. ECM is a com‐
plex network of different collagens, proteoglycans, hyaluronic acid, laminin, fibronectin,
and many other glycoproteins, including proteolytic enzymes involved in degradation and
remodelling of the ECM [72]. Extracellular matrix exists in two forms: interstitial matrix that
fills in the intercellular space and the more specialized BM, which is a thin sheet of extracel‐
lular matrix underlying the epithelium. ECM provides the microenvironment for the cells
and serves as a tissue scaffold, guiding cell migration during embryonic development and
wound repair. Integrins are a class of adhesion molecules that have a major role in the adhe‐
sion and subsequent invasion of tumor cells. ECM proteins such as fibronectin, laminins or
collagens form distinct protein networks that show tissue-specific variation in composition
and architecture. Cell responses to contact with these networks depend on the cell’s reper‐
toire of ECM receptors. Connections from the matrix through these receptors determine the
organization of cytoskeletal structures and the localization and activation of signaling mole‐
cules leading to unique tissue specific cell functions. Changes in these ECM components are
felt to modulate brain tumor growth, proliferation and invasion, although specific interac‐
tions and exact mechanisms are unknown. Cell adhesion is the binding of the cells to each
other and to the ECM through cell adhesion molecules such as integrins, selectins, cadher‐
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hesion complexes include focal adhesions, adherens junctions, tight junctions, desmosomes,
hemi-desmosomes, and gap junctions. The best characterized adhesion molecules are the in‐
tegrins and the best characterized adhesion complexes are focal adhesions. The extracellular
ligands that anchor these adhesions include laminin, fibronectin, vitronectin, and various
collagens. Focal adhesions can be considered both as sensors of force and as sites that origi‐
nate cytoskeletal forces through anchored actin-microfilament bundles. Focal adhesions
have many SH2-containing components (Src kinases, PI3K, SHP-2), as well as many tyro‐
sine-phosphorylated molecules (focal adhesion kinase paxillin, tensin, caveolin).
Syndecans are a family of transmembrane heparin sulphate proteoglycans with four mem‐
bers, syndecans 1 to 4. Syndecans function mainly as co-receptors by binding to their ECM
ligands in conjunction with other receptors, notably integrins. Through their heparin sul‐
phate side chains, syndecans may further engage directly in ligand binding. Dystroglycans
are heterodimeric complexes consisting of non-covalently associated α and β subunits with
extracellular ligand-binding and transmembrane functions, respectively. Dystroglycans are
a part of the larger dystrophin-associated protein (DAP) complex that connects basement
membranes to the cytoskeleton, particularly via α2 laminins and perlecan. Ig superfamily
members consist of immunoglobulin-like and fibronectin type III domains involved in ho‐
mophilic and heterophilic cell–cell adhesion. The superfamily includes a variety of cell ad‐
hesion molecules (CAMs) with distinct ligand-binding specificities, including ICAM
(intercellular), NCAM (neural), Ep-CAM (epithelial), L1-CAM, VCAM (vascular), ALCAM
(activated leukocyte), and JAM (junctional adhesion molecule), among others. Cadherins are
transmembrane proteins consisting of several tandemly repeated cadherin domains that me‐
diate calcium-dependent homophilic cell-cell contacts. The cadherin superfamily comprises
a total of more than 100 different members, with E- (epithelial) and N-cadherin (neural)
most widely expressed in epithelial and neural tissues, respectively [73].
By convention, ECM components are biochemically classified fibrillar proteins (collagens),
glycoproteins (laminins, fibronectin, tenascins), and several classes of proteo- glycans (hep‐
aran sulfate-, chondroitin sulfate-, dermatan sulfate-, and keratan sulfate proteoglycans).
The latter mainly consist of large glycosaminoglycan (GAG) chains, covalently linked to ex‐
tra- cellular or membrane bound core proteins. In contrast to other tissues, the ECM in the
CNS lacks fibrillar proteins under physiological conditions. Instead the neural ECM is rich
in glycoproteins and proteoglycans. It has been estimated that the neural ECM makes up
about 20% of the CNS parenchyma [74]. The brain ECM is mainly deposited by astrocytes
and oligodendrocytes and comprises an estimated 20% of the brain volume in adults. The
main ECM components are hyaluronic acid (HA), tenascin R, and lecticans, which intercon‐
nect with each other noncovalently and form molecular networks filling the intercellular
space. HA is a non-sulphated, linear, high-molecular weight glycosaminoglycan which, due
to its water-binding capacity, controls the high water content of the brain interstitium. Be‐
sides tenascins and lecticans, HA binds to cell surface receptors including CD44 and
ICAM-1, which together contribute to both ECM organization and cell-matrix interaction. It
represents the major component of neuropil ECM and is widely distributed in the adult and
embryonic brain. Malignant gliomas contain higher amounts of HA than low-grade gliomas
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in situ and in vitro, while the perivascular location in glioma biopsy suggests additional
production by vascular stromal cells [75].
The tenascins (TN) are a family of large multimeric ECM proteins consisting of repeated
structural modules including heptad repeats, epidermal growth factor (EGF)-like repeats, fi‐
bronectin type III repeats, and a globular domain shared with the fibrinogens. The TN are
presumably involved in the morphogenesis of many organs and tissues [76-77]. The original
tenascin discovered was TN-C, partially because of its overexpression in tumours and, infer‐
ring from cell biological studies, it has been proposed as an adhesion-modulating protein
[77]. TN-C (also called neuronectin, brachinectin, myotendinous antigen, hexabrachion, glio‐
ma-mesenchymal extracellular matrix antigen, cytotactin, J1 protein, GP250 protein) has a
characteristic hexabrachion structure, with as many as six arms linked to a central knob
formed by disulfide bonding of cysteines in the NH2-terminal ends of polypeptides. TN-C
initially appears during embryonic neural crest cell development, and it is present during
brain and spinal cord organogenesis, being correlated with developmental phenomena such
as cell proliferation, migration, and ECM remodelling. In addition, TN-C is transiently
present in the dense mesenchyma surrounding several developing organs and tissues, in‐
cluding the nervous system [76-77]. Enhanced TN-C expression was detected among tu‐
mour cells, around individual cells as a fibrillary network, and around vascular channels
[78]. A direct relation between the presence of TN-C and the degree of malignancy of glio‐
mas has been reported, being TN-C reported to be expressed 5-fold higher in GBM as com‐
pared with AA and 10-fold higher as compared with juvenile pylocitic astrocytoma [79-80].
Endothelial cells in vitro attach to TN-C substrata, where they elongate, extend, and have
interconnecting process. These features are lacking when endothelial cells growth on other
matrix proteins, such as fibronectin, collagen, or laminin. The attachment of endothelial cells
to TN-C is mediated by annexin and integrins, including ανβ3 integrin, which is required
for angiogenesis [79-81]. Tenascin R, another brain-specific member of the tenascin family, is
a homotrimer with both lectican and integrin binding sites forming an adhesion bridge be‐
tween the ECM and cells. Lecticans comprise a family of chondroitin sulphate proteoglycans
with four members (brevican, versican, neurocan, and aggrecan), whereby brevican and
neurocan are brain-specific. Lecticans contain HA and tenascin R binding sites and thus act
as link molecules in protein–proteoglycan–glycosaminoglycan networks. Compared with
peripheral interstitial tissues, a distinctive feature of the brain ECM is the absence of fibrillar
collagen networks, which results in a low stiffness of the brain parenchyma. In a restricted
expression pattern, fibrillar collagens I and III are, however, deposited by leptomeningeal
cells, pericytes, and smooth muscle cells in blood vessels and the brain meninges, including
the pia mater.
Fibronectin (FN) is a member of a family of glycoproteins that show many biological func‐
tions, including normal cell adhesion, growth, and migration. FN is involved in many cellu‐
lar processes, including tissue repair, embryogenesis, blood clotting, and cell migration/
adhesion. Both decreased expression and elevated degradation of FN have been shown to be
responsible for some of the morphological changes observed in tumors and tumor-derived
cell lines. As a peripheral protein, FN mainly acts as a bridge to link the cell surface and
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in glycoproteins and proteoglycans. It has been estimated that the neural ECM makes up
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and oligodendrocytes and comprises an estimated 20% of the brain volume in adults. The
main ECM components are hyaluronic acid (HA), tenascin R, and lecticans, which intercon‐
nect with each other noncovalently and form molecular networks filling the intercellular
space. HA is a non-sulphated, linear, high-molecular weight glycosaminoglycan which, due
to its water-binding capacity, controls the high water content of the brain interstitium. Be‐
sides tenascins and lecticans, HA binds to cell surface receptors including CD44 and
ICAM-1, which together contribute to both ECM organization and cell-matrix interaction. It
represents the major component of neuropil ECM and is widely distributed in the adult and
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tenascin discovered was TN-C, partially because of its overexpression in tumours and, infer‐
ring from cell biological studies, it has been proposed as an adhesion-modulating protein
[77]. TN-C (also called neuronectin, brachinectin, myotendinous antigen, hexabrachion, glio‐
ma-mesenchymal extracellular matrix antigen, cytotactin, J1 protein, GP250 protein) has a
characteristic hexabrachion structure, with as many as six arms linked to a central knob
formed by disulfide bonding of cysteines in the NH2-terminal ends of polypeptides. TN-C
initially appears during embryonic neural crest cell development, and it is present during
brain and spinal cord organogenesis, being correlated with developmental phenomena such
as cell proliferation, migration, and ECM remodelling. In addition, TN-C is transiently
present in the dense mesenchyma surrounding several developing organs and tissues, in‐
cluding the nervous system [76-77]. Enhanced TN-C expression was detected among tu‐
mour cells, around individual cells as a fibrillary network, and around vascular channels
[78]. A direct relation between the presence of TN-C and the degree of malignancy of glio‐
mas has been reported, being TN-C reported to be expressed 5-fold higher in GBM as com‐
pared with AA and 10-fold higher as compared with juvenile pylocitic astrocytoma [79-80].
Endothelial cells in vitro attach to TN-C substrata, where they elongate, extend, and have
interconnecting process. These features are lacking when endothelial cells growth on other
matrix proteins, such as fibronectin, collagen, or laminin. The attachment of endothelial cells
to TN-C is mediated by annexin and integrins, including ανβ3 integrin, which is required
for angiogenesis [79-81]. Tenascin R, another brain-specific member of the tenascin family, is
a homotrimer with both lectican and integrin binding sites forming an adhesion bridge be‐
tween the ECM and cells. Lecticans comprise a family of chondroitin sulphate proteoglycans
with four members (brevican, versican, neurocan, and aggrecan), whereby brevican and
neurocan are brain-specific. Lecticans contain HA and tenascin R binding sites and thus act
as link molecules in protein–proteoglycan–glycosaminoglycan networks. Compared with
peripheral interstitial tissues, a distinctive feature of the brain ECM is the absence of fibrillar
collagen networks, which results in a low stiffness of the brain parenchyma. In a restricted
expression pattern, fibrillar collagens I and III are, however, deposited by leptomeningeal
cells, pericytes, and smooth muscle cells in blood vessels and the brain meninges, including
the pia mater.
Fibronectin (FN) is a member of a family of glycoproteins that show many biological func‐
tions, including normal cell adhesion, growth, and migration. FN is involved in many cellu‐
lar processes, including tissue repair, embryogenesis, blood clotting, and cell migration/
adhesion. Both decreased expression and elevated degradation of FN have been shown to be
responsible for some of the morphological changes observed in tumors and tumor-derived
cell lines. As a peripheral protein, FN mainly acts as a bridge to link the cell surface and
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ECM. Therefore, the absence or reduction of FN in tumor cells may reduce the adhesion be‐
tween tumor cells and matrix components, and decrease the matrix's control of cell differen‐
tiation, proliferation, and migration. As a major protein in blood and as component of the
wound provisional matrix, plasma FN contributes to tissue repair and neuronal survival fol‐
lowing cerebral ischemia [82]. Fibronectin structure is rod-like, composed of three different
types of homologous, repeating modules, types I, II, and III. These modules comprise func‐
tional domains that mediate interactions with other ECM components, with cell surface re‐
ceptors and with FN itself. Twelve type I modules make up the amino-terminal and
carboxy-terminal region of the molecule, and are involved mainly in fibrin and collagen
binding. Only two type II modules are found in FN. They are instrumental in binding colla‐
gen. The most abundant module in FN is type III, which contains the RGD-FN receptor rec‐
ognition sequence along with binding sites for other integrins and heparin. Depending on
the tissue type and/or cellular conditions, the FN molecule is made up of 15-17 type III mod‐
ules. In addition, there is a module that does not fall into any of these categories, called II‐
ICS. This module, along with EDB and EDA is regulated through alternative splicing of FN
pre-mRNA. FN is an important component in the ECM of gliomas, largely in the vessel wall
[83]. Expression of FN has been characterized in human GBM and in a number of astrocyto‐
ma and glioblastoma cell lines. In a study of pediatric GBM, a marked positive staining of
FN in walls of small and medium size vessels was demonstrated. FN expression was seen in
perivascular sheets, where it looked like a fine irregular network [83]. Knott et al. found that
when normal brain tissues were invaded by glioma, ECM components such as LN, FN, and
collagen type IV may are available and that tumor cells may express specific integrins, de‐
pending on the change of the interior environment, to interact with these ECM components,
and enhance tumor cell invasion [84]. In vitro experiments have proven that components of
ECM, LN and FN, can strongly stimulate the migration of glioma cells, which occurs after
glioma cells express the relevant surface receptors [85]. Although there are many in vitro
and in vivo models for FN-promoted invasion and transmigration [85], the uniqueness of
these findings may be attributed to interaction between tumor cells and vascular endothelial
cells (VECs), as changes of tumoral microenvironment molecules can affect tumor status and
progression. Recently it has been demonstrated that FN expression is correlated with glioma
migration and glioma malignancy [86]. More recently, FN has been reported to mantain ex‐
tracellular matrix rigidity to promote structural rigidity, motility, and proliferation of estab‐
lished glioma cell lines in vitro [87]. The inhibition of FN expression in glioma cells, using
short hairpin RNA-mediated silencing of gene expression, delayed cell proliferation in vitro.
This delayed growth is explained, in part, by the observed reduced expression of integrin ß1
FN receptor, which was restored by the inhibition of proteosomal activity [88].
LM are a group of adhesion structural glycoproteins found in all BM as an integral part of
the glia limitans externa [89]. LM the first neurite outgrowth promoting ECM identified is
an adhesion glycoprotein associated with the development and regeneration of neuroecto‐
dermal tissues [89]. LM is distributed beneath vascular endothelial cells, around vascular
smooth muscle cells, in the glia limitans, and beneath choroid plexus epithelial cells and
plays a role in migration, neurite outgrowth, proliferation, and differentiation [90]. LM con‐
stitute the preferred substrate for growth of astrocytes and neurons, and have been found in
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all BM and in hyperplastic blood vessels in gliomas, gliosarcomas, and meningiomas [89].
Reactive astrocytes in situ, glioma cells in situ, as well as glioma cells lines, have been re‐
ported to express LM. Variants of LM may be expressed by astrocytes or neurons under dif‐
ferent situations which adds to the complexity of the function and regulation of these large
molecules in the CNS [91].
Type IV collagen (C-IV), the principal collagenous constituent of most BM, is mainly present
in capillaries and large blood vessels. C-IV is associated with laminin, entactin, and the hep‐
aran sulphate proteoglycans perlecan. C-IV is found in areas of the normal brain, such as,
beneath vascular endothelial cells, around vascular smooth muscle cells, in the glia limitans,
and beneath choroid plexus epithelial cells. GBM cells are able of synthesising C-IV in vitro
[72]. Bjerkvig et al. [92], demonstrated that C-IV was strongly expressed in tumour sphe‐
roids from rat glioma cell lines BT4C. In vitro the presence of C-IV in tumour vessels has
been used to demonstrate vascular abnormalities in gliomas, such as BM duplication and
disruption, as well as increased vascular density [93]. Recent studies have shown that GBM
cells around areas of vascular proliferation, are also able to synthesise C-IV localised to the
subendothelial BM of blood vessels [72].
4. Angiogenesis
Physiological angiogenesis, the formation of new blood vessels from pre-existing ones, is a
strictly regulated fine-tuned process. The local balance between inducers and inhibitors of
angiogenesis is critical in determining the generation or not of new vessels. Whenever this
balance is perturbed pathological, uncontrolled, excessive angiogenesis occurs. Angiogene‐
sis is a process that plays an essential role in cancer development. Coagulation and inflam‐
mation also play an important role in tumorigenesis. Their expression is controlled by over-
or under-expression of certain genes [94]. Although a plethora of molecules can act as
inducers of angiogenesis such as acidic fibroblast growth factor (aFGF), basic fibroblast
growth factor (bFGF), transforming growth factor alpha and beta (TGF-a and -h), tumor ne‐
crosis factor alpha (TNFα) and interleukin-8 (IL-8), the major growth factors specific for vas‐
cular endothelium include members of the vascular endothelium growth factor (VEGF) and
angiopoietin families, and at least one member of the large ephrin family.
Angiogenesis is believed to be the primary method of vessel formation in gliomas. Malig‐
nant gliomas are characterized by extensive microvascular proliferation. Neovascularization
in brain tumors correlates directly with their biological aggressiveness, degree of malignan‐
cy and clinical recurrence and inversely with the post-operative survival of patients affected
by gliomas. Among all solid tumors, GBM has been reported to be the most angiogenic by
displaying the highest degree of vascular proliferation and endothelial cell hyperplasia.
Such intense vascularization might be responsible for the peritumoral edema, one of the
pathological features of GBM [95]. The presence of endothelial glomeruloid-like prolifera‐
tion and of positive immunoreaction at level of BM of tumor vascular channel are predictive
of active tumor invasiveness [83]. Diffuse astrocytomas tend to progress from grade II to
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ECM. Therefore, the absence or reduction of FN in tumor cells may reduce the adhesion be‐
tween tumor cells and matrix components, and decrease the matrix's control of cell differen‐
tiation, proliferation, and migration. As a major protein in blood and as component of the
wound provisional matrix, plasma FN contributes to tissue repair and neuronal survival fol‐
lowing cerebral ischemia [82]. Fibronectin structure is rod-like, composed of three different
types of homologous, repeating modules, types I, II, and III. These modules comprise func‐
tional domains that mediate interactions with other ECM components, with cell surface re‐
ceptors and with FN itself. Twelve type I modules make up the amino-terminal and
carboxy-terminal region of the molecule, and are involved mainly in fibrin and collagen
binding. Only two type II modules are found in FN. They are instrumental in binding colla‐
gen. The most abundant module in FN is type III, which contains the RGD-FN receptor rec‐
ognition sequence along with binding sites for other integrins and heparin. Depending on
the tissue type and/or cellular conditions, the FN molecule is made up of 15-17 type III mod‐
ules. In addition, there is a module that does not fall into any of these categories, called II‐
ICS. This module, along with EDB and EDA is regulated through alternative splicing of FN
pre-mRNA. FN is an important component in the ECM of gliomas, largely in the vessel wall
[83]. Expression of FN has been characterized in human GBM and in a number of astrocyto‐
ma and glioblastoma cell lines. In a study of pediatric GBM, a marked positive staining of
FN in walls of small and medium size vessels was demonstrated. FN expression was seen in
perivascular sheets, where it looked like a fine irregular network [83]. Knott et al. found that
when normal brain tissues were invaded by glioma, ECM components such as LN, FN, and
collagen type IV may are available and that tumor cells may express specific integrins, de‐
pending on the change of the interior environment, to interact with these ECM components,
and enhance tumor cell invasion [84]. In vitro experiments have proven that components of
ECM, LN and FN, can strongly stimulate the migration of glioma cells, which occurs after
glioma cells express the relevant surface receptors [85]. Although there are many in vitro
and in vivo models for FN-promoted invasion and transmigration [85], the uniqueness of
these findings may be attributed to interaction between tumor cells and vascular endothelial
cells (VECs), as changes of tumoral microenvironment molecules can affect tumor status and
progression. Recently it has been demonstrated that FN expression is correlated with glioma
migration and glioma malignancy [86]. More recently, FN has been reported to mantain ex‐
tracellular matrix rigidity to promote structural rigidity, motility, and proliferation of estab‐
lished glioma cell lines in vitro [87]. The inhibition of FN expression in glioma cells, using
short hairpin RNA-mediated silencing of gene expression, delayed cell proliferation in vitro.
This delayed growth is explained, in part, by the observed reduced expression of integrin ß1
FN receptor, which was restored by the inhibition of proteosomal activity [88].
LM are a group of adhesion structural glycoproteins found in all BM as an integral part of
the glia limitans externa [89]. LM the first neurite outgrowth promoting ECM identified is
an adhesion glycoprotein associated with the development and regeneration of neuroecto‐
dermal tissues [89]. LM is distributed beneath vascular endothelial cells, around vascular
smooth muscle cells, in the glia limitans, and beneath choroid plexus epithelial cells and
plays a role in migration, neurite outgrowth, proliferation, and differentiation [90]. LM con‐
stitute the preferred substrate for growth of astrocytes and neurons, and have been found in
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all BM and in hyperplastic blood vessels in gliomas, gliosarcomas, and meningiomas [89].
Reactive astrocytes in situ, glioma cells in situ, as well as glioma cells lines, have been re‐
ported to express LM. Variants of LM may be expressed by astrocytes or neurons under dif‐
ferent situations which adds to the complexity of the function and regulation of these large
molecules in the CNS [91].
Type IV collagen (C-IV), the principal collagenous constituent of most BM, is mainly present
in capillaries and large blood vessels. C-IV is associated with laminin, entactin, and the hep‐
aran sulphate proteoglycans perlecan. C-IV is found in areas of the normal brain, such as,
beneath vascular endothelial cells, around vascular smooth muscle cells, in the glia limitans,
and beneath choroid plexus epithelial cells. GBM cells are able of synthesising C-IV in vitro
[72]. Bjerkvig et al. [92], demonstrated that C-IV was strongly expressed in tumour sphe‐
roids from rat glioma cell lines BT4C. In vitro the presence of C-IV in tumour vessels has
been used to demonstrate vascular abnormalities in gliomas, such as BM duplication and
disruption, as well as increased vascular density [93]. Recent studies have shown that GBM
cells around areas of vascular proliferation, are also able to synthesise C-IV localised to the
subendothelial BM of blood vessels [72].
4. Angiogenesis
Physiological angiogenesis, the formation of new blood vessels from pre-existing ones, is a
strictly regulated fine-tuned process. The local balance between inducers and inhibitors of
angiogenesis is critical in determining the generation or not of new vessels. Whenever this
balance is perturbed pathological, uncontrolled, excessive angiogenesis occurs. Angiogene‐
sis is a process that plays an essential role in cancer development. Coagulation and inflam‐
mation also play an important role in tumorigenesis. Their expression is controlled by over-
or under-expression of certain genes [94]. Although a plethora of molecules can act as
inducers of angiogenesis such as acidic fibroblast growth factor (aFGF), basic fibroblast
growth factor (bFGF), transforming growth factor alpha and beta (TGF-a and -h), tumor ne‐
crosis factor alpha (TNFα) and interleukin-8 (IL-8), the major growth factors specific for vas‐
cular endothelium include members of the vascular endothelium growth factor (VEGF) and
angiopoietin families, and at least one member of the large ephrin family.
Angiogenesis is believed to be the primary method of vessel formation in gliomas. Malig‐
nant gliomas are characterized by extensive microvascular proliferation. Neovascularization
in brain tumors correlates directly with their biological aggressiveness, degree of malignan‐
cy and clinical recurrence and inversely with the post-operative survival of patients affected
by gliomas. Among all solid tumors, GBM has been reported to be the most angiogenic by
displaying the highest degree of vascular proliferation and endothelial cell hyperplasia.
Such intense vascularization might be responsible for the peritumoral edema, one of the
pathological features of GBM [95]. The presence of endothelial glomeruloid-like prolifera‐
tion and of positive immunoreaction at level of BM of tumor vascular channel are predictive
of active tumor invasiveness [83]. Diffuse astrocytomas tend to progress from grade II to
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grade III tumors with a time interval of several years, whereas, progression of grade III to
grade IV is more rapid, typically 2 years. Primary and secondary GBMs are morphologically
indistinguishable and show their histologic hallmarks, i.e., “glomeruloid” microvascular
tufts and necrosis. Glioma vasculature is structurally and functionally abnormal and it cor‐
relates and leads to vasogenic edema, increased interstitial pressure, and heterogeneous de‐
livery of oxygen and drugs [96].
Neoangiogenesis may be quantified post-operatively in brain tumors by the evaluation on
surgical samples of the so-called microvessel density (MVD), which reflects the number of
vessels per mm2 within representative histological sections. Specifically, MVD is assessed in
formalin-fixed and paraffin-embedded tissue sections through standard immunohistochem‐
istry; in detail, the vessels present in the histological sections are preliminarly highlighted
with peroxidase-conjugated antibodies against endothelial markers and then they are count‐
ed at light microscopy. Antibodies against several endothelial markers, such as Factor VIII,
CD31, CD34 and endoglin, may be used for the quantification of MVD, with different sensi‐
tivity and specificity. For instance, following the use of antibodies against pan-endothelial
markers (Factor VIII, CD31, CD34), all the vessels present in the histological section are
stained, with no distinction between pre-existing and newly-formed vessels [97]. As a conse‐
quence, pan-endothelial cannot be considered as optimal markers for the quantification of
neoangiogenesis. In contrast, endoglin (CD105), a 180-kDa transmembrane homodimeric
glycoprotein that belongs to the TGF receptor complex [98], appears as an endothelial mark‐
er which more specifically allows the detection of vessels related to neoangiogenic process
in brain tumors [97, 99-101]. Indeed, this protein is predominantly expressed by the cycling
endothelial cells in the vessels of tumors [102]; even more the antibody against endoglin pre‐
fentially binds the activated endothelial cells of peri- and intra-tumor vessels that are actual‐
ly involved in tumor neoangiogenesis, while a negative/weak immunoreaction for endoglin
is evidenced in the vascular endothelium of normal tissues [97, 102]. Besides, in comparative
studies, antibodies against endoglin have been demonstrated to be more specific in the de‐
tection of newly formed vessels in meningiomas [97], as well as in astrocytic [100] or oligo‐
dendroglial [101] neoplasias in comparison to those binding pan-endothelial markers. In
addition, when MVD was assessed by using endoglin as a marker of angiogenesis, it ap‐
peared to be significantly correlated to the growth fraction and histological grade of menin‐
giomas, and it was shown to have a prognostic impact on the overall survival and
recurrence risk of these neoplasias [97]. Thus, we suggest the use of anti-endoglin antibodies
instead of that of antibodies against pan-endothelial markers for the quantification of angio‐
genesis in brain tumors. Besides, the demonstration of endoglin expression in tumour ves‐
sels may also open therapeutic prespectives. Indeed, it has been recently shown that
monoclonal antibodies against endoglin are able to induce tumour growth regression
through the inhibition of the endothelial cells proliferation and angiogenesis itself [103].
The first phase in forming new blood vessels from existing vessels is the dissolution of as‐
pects of native vessels. Glioma cells first accumulate around the existing cerebral blood ves‐
sels and lift off the astrocytic foot processes, which leads to the disruption of the normal
contact between endothelial cells and the basement membrane [104]. The affected endothe‐
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lial cells express angiopoietins resulting in destabilization of the vessel wall and decreased
pericyte coverage. The angiopoietins are endothelial growth factors and their signal trans‐
duction pathway passes via the Tie2 receptor tyrosine kinase expressed on endothelial cells.
In particular, Ang-1 and -2, have been implicated in glioma angiogenesis [105]. Ang-1 medi‐
ated activation of Tie2 is required for stabilization, remodeling and maturation of blood ves‐
sels, promotes angiogenesis and tumor growth and is associated with an increased number
of highly branched vessels. Ang-1 induces phosphorylation of Tie2 and the p85 subunit of
PI3K and increases PI3K activity in a dose-dependent manner, leading to endothelial cell
survival via Akt signaling. In addition, Ang-1 stimulates endothelial cell migration via a
PI3K-dependent activation of focal adhesion kinase (FAK), which has a key role in regulat‐
ing dynamic changes in actin cytoskeletal organisation during cell migration. The biological
effect of Ang-2 may depend on VEGF level. In the presence of endogenous VEGF, Ang-2
promotes vessel dilatation, remodelling of the basal lamina, proliferation and migration of
endothelial cells, and stimulates sprouting of new blood vessels. In the absence of VEGF ac‐
tivity, Ang-2 becomes anti-angiogenic by promoting endothelial cell death and the regres‐
sion of vessels [105]. Binding of Ang-2 to the Tie2 receptor on endothelial cells antagonizes
this receptor’s phosphorylation, thereby disrupting contacts between endothelial and peri‐
endothelial support cells and disengaging pericytes from the tumor vessels during initiation
of vessel sprouting or regression. Increased expression of Ang-2 on GBM microvasculature
appears early during glioma angiogenesis. Ang-2 and Tie2 expression are absent in the nor‐
mal brain vasculature but are induced in tumor endothelium of coopted tumor vessels prior
to their regression. Treatment of glioma cell derived mouse xenografts with a dominant neg‐
ative form of Tie2 results in a significant decrease in tumor growth [106]. Maintenance of an
optimal number of pericytes is necessary for successful angiogenesis in stabilizing newly
formed vessels from further sprouting and to support adequate blood flow. Ang-2 may act
as an antagonist to Tie2 phosphorylation, leading to destabilization of blood vessels. There‐
fore, Ang-2 represents a checkpoint for Ang-1/Tie2-mediated angiogenesis [107]. In brain tu‐
mor growth it’s possible observe two vascular phases. In the first, the vessels are native
cerebral vessels, which are co-opted by tumor cells, while in the second phase, there is true
neovascularization arising from existing vessels. During the transition period between these
two phases, hypoxia driven HIF-1 expression occurs which results in VEGF secretion and in
the induction of neovascularization. In stage IV, angiogenesis adjacent to the necrotic area is
triggered in response to increased expression of HIF-1α and VEGF. For the newly sprouting
vessel is essential the deposition of proangiogenic matrix. This involves breakdown of the
vascular basement membrane and extracellular matrix through the action of cathepsin B,
matrix metalloproteases and other enzymes as well as the expression of matrix proteins such
as fibronectin, laminin, tenascin-C and vitronectin [108]. Degradation of the vessel basement
membrane and surrounding ECM, which also facilitates the invasion of endothelial cells, is
an integral part of the ongoing angiogenic process. The matrix metalloproteinase family en‐
zymes that degrade components of ECM consist of four groups according to their sub‐
strates: collagenases, gelatinases, stromelysins, and membrane-associated MMPs.
Gelatinases-A (MMP-2) and gelatinases-B (MMP-9) are highly expressed in astrocytomas,
and their expression levels, especially those of MMP-9, correlate with the histological grade
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grade III tumors with a time interval of several years, whereas, progression of grade III to
grade IV is more rapid, typically 2 years. Primary and secondary GBMs are morphologically
indistinguishable and show their histologic hallmarks, i.e., “glomeruloid” microvascular
tufts and necrosis. Glioma vasculature is structurally and functionally abnormal and it cor‐
relates and leads to vasogenic edema, increased interstitial pressure, and heterogeneous de‐
livery of oxygen and drugs [96].
Neoangiogenesis may be quantified post-operatively in brain tumors by the evaluation on
surgical samples of the so-called microvessel density (MVD), which reflects the number of
vessels per mm2 within representative histological sections. Specifically, MVD is assessed in
formalin-fixed and paraffin-embedded tissue sections through standard immunohistochem‐
istry; in detail, the vessels present in the histological sections are preliminarly highlighted
with peroxidase-conjugated antibodies against endothelial markers and then they are count‐
ed at light microscopy. Antibodies against several endothelial markers, such as Factor VIII,
CD31, CD34 and endoglin, may be used for the quantification of MVD, with different sensi‐
tivity and specificity. For instance, following the use of antibodies against pan-endothelial
markers (Factor VIII, CD31, CD34), all the vessels present in the histological section are
stained, with no distinction between pre-existing and newly-formed vessels [97]. As a conse‐
quence, pan-endothelial cannot be considered as optimal markers for the quantification of
neoangiogenesis. In contrast, endoglin (CD105), a 180-kDa transmembrane homodimeric
glycoprotein that belongs to the TGF receptor complex [98], appears as an endothelial mark‐
er which more specifically allows the detection of vessels related to neoangiogenic process
in brain tumors [97, 99-101]. Indeed, this protein is predominantly expressed by the cycling
endothelial cells in the vessels of tumors [102]; even more the antibody against endoglin pre‐
fentially binds the activated endothelial cells of peri- and intra-tumor vessels that are actual‐
ly involved in tumor neoangiogenesis, while a negative/weak immunoreaction for endoglin
is evidenced in the vascular endothelium of normal tissues [97, 102]. Besides, in comparative
studies, antibodies against endoglin have been demonstrated to be more specific in the de‐
tection of newly formed vessels in meningiomas [97], as well as in astrocytic [100] or oligo‐
dendroglial [101] neoplasias in comparison to those binding pan-endothelial markers. In
addition, when MVD was assessed by using endoglin as a marker of angiogenesis, it ap‐
peared to be significantly correlated to the growth fraction and histological grade of menin‐
giomas, and it was shown to have a prognostic impact on the overall survival and
recurrence risk of these neoplasias [97]. Thus, we suggest the use of anti-endoglin antibodies
instead of that of antibodies against pan-endothelial markers for the quantification of angio‐
genesis in brain tumors. Besides, the demonstration of endoglin expression in tumour ves‐
sels may also open therapeutic prespectives. Indeed, it has been recently shown that
monoclonal antibodies against endoglin are able to induce tumour growth regression
through the inhibition of the endothelial cells proliferation and angiogenesis itself [103].
The first phase in forming new blood vessels from existing vessels is the dissolution of as‐
pects of native vessels. Glioma cells first accumulate around the existing cerebral blood ves‐
sels and lift off the astrocytic foot processes, which leads to the disruption of the normal
contact between endothelial cells and the basement membrane [104]. The affected endothe‐
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lial cells express angiopoietins resulting in destabilization of the vessel wall and decreased
pericyte coverage. The angiopoietins are endothelial growth factors and their signal trans‐
duction pathway passes via the Tie2 receptor tyrosine kinase expressed on endothelial cells.
In particular, Ang-1 and -2, have been implicated in glioma angiogenesis [105]. Ang-1 medi‐
ated activation of Tie2 is required for stabilization, remodeling and maturation of blood ves‐
sels, promotes angiogenesis and tumor growth and is associated with an increased number
of highly branched vessels. Ang-1 induces phosphorylation of Tie2 and the p85 subunit of
PI3K and increases PI3K activity in a dose-dependent manner, leading to endothelial cell
survival via Akt signaling. In addition, Ang-1 stimulates endothelial cell migration via a
PI3K-dependent activation of focal adhesion kinase (FAK), which has a key role in regulat‐
ing dynamic changes in actin cytoskeletal organisation during cell migration. The biological
effect of Ang-2 may depend on VEGF level. In the presence of endogenous VEGF, Ang-2
promotes vessel dilatation, remodelling of the basal lamina, proliferation and migration of
endothelial cells, and stimulates sprouting of new blood vessels. In the absence of VEGF ac‐
tivity, Ang-2 becomes anti-angiogenic by promoting endothelial cell death and the regres‐
sion of vessels [105]. Binding of Ang-2 to the Tie2 receptor on endothelial cells antagonizes
this receptor’s phosphorylation, thereby disrupting contacts between endothelial and peri‐
endothelial support cells and disengaging pericytes from the tumor vessels during initiation
of vessel sprouting or regression. Increased expression of Ang-2 on GBM microvasculature
appears early during glioma angiogenesis. Ang-2 and Tie2 expression are absent in the nor‐
mal brain vasculature but are induced in tumor endothelium of coopted tumor vessels prior
to their regression. Treatment of glioma cell derived mouse xenografts with a dominant neg‐
ative form of Tie2 results in a significant decrease in tumor growth [106]. Maintenance of an
optimal number of pericytes is necessary for successful angiogenesis in stabilizing newly
formed vessels from further sprouting and to support adequate blood flow. Ang-2 may act
as an antagonist to Tie2 phosphorylation, leading to destabilization of blood vessels. There‐
fore, Ang-2 represents a checkpoint for Ang-1/Tie2-mediated angiogenesis [107]. In brain tu‐
mor growth it’s possible observe two vascular phases. In the first, the vessels are native
cerebral vessels, which are co-opted by tumor cells, while in the second phase, there is true
neovascularization arising from existing vessels. During the transition period between these
two phases, hypoxia driven HIF-1 expression occurs which results in VEGF secretion and in
the induction of neovascularization. In stage IV, angiogenesis adjacent to the necrotic area is
triggered in response to increased expression of HIF-1α and VEGF. For the newly sprouting
vessel is essential the deposition of proangiogenic matrix. This involves breakdown of the
vascular basement membrane and extracellular matrix through the action of cathepsin B,
matrix metalloproteases and other enzymes as well as the expression of matrix proteins such
as fibronectin, laminin, tenascin-C and vitronectin [108]. Degradation of the vessel basement
membrane and surrounding ECM, which also facilitates the invasion of endothelial cells, is
an integral part of the ongoing angiogenic process. The matrix metalloproteinase family en‐
zymes that degrade components of ECM consist of four groups according to their sub‐
strates: collagenases, gelatinases, stromelysins, and membrane-associated MMPs.
Gelatinases-A (MMP-2) and gelatinases-B (MMP-9) are highly expressed in astrocytomas,
and their expression levels, especially those of MMP-9, correlate with the histological grade
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of tumor. MMP-2 and MMP-9 expression is strongly induced by hypoxia, and these two
molecules appear to have a synergistic effect on basement membrane degradation [109]. The
inhibitors of MMPs are called tissue inhibitors of metalloproteinases (TIMPs), which are
comprised of TIMP-1, TIMP-2, TIMP-3, and TIMP-4. The interactions between these proteas‐
es and their inhibitors play important roles in cell morphogenesis, angiogenesis, tissue re‐
modeling, tissue repair, tumor metastasis, cirrhosis, and arthritis. After breakdown of the
basement membrane, endothelial cells proliferate and migrate toward the tumor cells ex‐
pressing pro-angiogenic compounds. The activation of endothelial cells results in increased
expression of cell adhesion receptors, such as integrins ανβ3 and α5β1, and in increased cell
survival, proliferation, and migration responses. In addition to migration of endothelial
cells, migration of pericytes is an important part of tumor vessel formation. Platelet-derived
growth factor secretion by activated endothelial cells recruits pericytes to the site of newly
sprouting vessels and aids in establishing a new basement membrane [110].
The discovery of hypoxia inducible factor-1 (HIF-1) and the observation that hypoxia-in‐
duced HIF-1α expression in pseudopalisading cells, in tumoral necrotic areas, was concomi‐
tant with the expression of one of its target genes, VEGF, established a biological link
between hypoxia and angiogenesis [111]. The most potent activator of angiogenic mecha‐
nisms in brain tumors is tissue hypoxia. One well-studied pathway is the HIF-1/VEGF-A
pathway, which leads to endothelial cell proliferation and migration. HIF is a heterodimeric
DNA-binding complex composed of two basic helix-loop-helix proteins of the PAS family
(PER, AHR, ARNT and SIM family): the constitutive HIF-1b and one of either hypoxia-indu‐
cible a-subunits, HIF-1a or HIF-2a. In hypoxia, the a/b heterodimer binds to a core pentanu‐
cleotide sequence (RCGTG) in the hypoxia response elements (HREs) of target genes. The
hypoxic microenvironment (1–2% O2) caused by the increased oxygen consumption of hy‐
perplasia and/or hypertrophy and the decreased oxygen delivery due to the increase in dif‐
fusion distance was assumed to contribute to the angiogenic switch. An important link
between hypoxia and angiogenesis was the discovery that the expression of the potent vas‐
cular endothelial growth factor was induced by hypoxia [112]. VEGF, which regulates tumor
edema and blood vessel formation, is an example of a gene regulated by an HIF-1 though an
HRE. Angiogenesis is essential for development, wound healing, tissue or organ regenera‐
tion, but it is also part of pathological processes, such as cancer and certain retinopathies. It
is an intricate multistep and temporally ordered process that involves a great number of
genes, modifiers and pathways. Many of these genes are directly induced by HIF-1a, such as
nitric oxide synthases, angiogenic and vascular growth factors and genes regulating matrix
metabolism (urokinasetype plasminogen activator receptor; uPAR) [113]. Immunohisto‐
chemical expression of HIF-1α clearly correlated with the degree of glioma malignancies
and predicted survival among patients with malignant gliomas and the degree of necrosis
on MRI. In a recent study, has been demonstrated that SN38, the active metabolite of CPT11,
exhibited an antiangiogenic effect. SN38 inhibited HIF-1α and VEGF mRNA and protein ex‐
pression of glioma cells in a dose- and time-dependent manner [114]. Metronomic CPT11
treatment of gliomas exhibited growth inhibitory effects without systemic toxicity, that is,
through comparison of body weight loss that was not observed by conventional CPT11
treatment. Tumor tissues treated with metronomic CPT11 exhibited decreased expression of
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HIF-1α protein and pimonidazole expression, which were indicative of areas of hypoxia by
immunohistochemistry.
4.1. Mediators of glioma angiogenesis
Glioma angiogenesis is mediated by the release of angiogenic cytokines by the tumor cells.
Numerous, different cytokines have been identified so far which are able to induce angio‐
genesis (Figure 1). This cytokine production is either the result of overexpressing angiogenic
factors through genetic alterations or is triggered by hypoxia.
Figure 1. Representation of angiogenesis mediators in gliomas.
In the phosphatidylinositol-30 kinase (PI3K)/Akt and Ras/mitogen-activated protein kinase
(MAPK) converge many angiogenic growth factors, including vascular endothelial growth
factor (VEGF). These pathways modulate important cellular processes in angiogenesis, in‐
cluding endothelial cell proliferation, survival, migration, invasion, tube formation and ex‐
tracellular matrix degradation.
CXCR = C-X-C chemokine receptor, CYR6.1 = cysteine-rich angiogenic inducer 61, CTGF =
connective tissue growth factor, EGF = epidermal growth factor, FGF = fibroblast growth
factor, HGF = hepatocyte growth factor, IL-6 = interleukin-6, IL-8 = interleukin-8, MMP =
matrix metalloproteinases, PDGF = platelet-derived growth factor, PI3K = PI3 kinase, SF =
scatter factor, TGF-a = transforming growth factor-alpha, TGF-ß = transforming growth fac‐
tor-beta.
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of tumor. MMP-2 and MMP-9 expression is strongly induced by hypoxia, and these two
molecules appear to have a synergistic effect on basement membrane degradation [109]. The
inhibitors of MMPs are called tissue inhibitors of metalloproteinases (TIMPs), which are
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growth factor secretion by activated endothelial cells recruits pericytes to the site of newly
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4.1.1. VEGF, VEGF-receptors and VEGF pathway
The VEGF family of growth factors and their receptors are the most important mediators of
glioma angiogenesis. The VEGF family includes six glycoproteins referred to as VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor. The VEGF acts as a major
vascular permeability factor and as a mitogen/survival promoter for endothelial cells [115,
116]. VEGF-A and its receptors are the best characterized signaling pathway in angiogenesis
and binds to two receptor tyrosine kinases (RTK) – VEGFR-1 (Flt-1) and VEGFR-2 (KDR,
Flk-1) [117]. It is generally agreed that VEGFR-2 is the major receptor mediating the mito‐
genic, angiogenic and permeability-enhancing effects of VEGF-A. Recent evidence has sug‐
gested that VEGFR-1 participates in haematopoiesis and in the recruitment of monocytes
and other bone marrow derived cells to promote tumor angiogenesis [118]. In addition,
VEGFR-1 is involved in the activation of MMPs associated with matrix degradation and in
the production of growth factors from endothelial cells. VEGF-A gene expression is up-regu‐
lated by hypoxia, mediated by the transcription factor HIF and the product of the von Hip‐
pel–Lindau (VHL) tumor suppressor gene. Other transcription factors capable of up-
regulating VEGF transcription include the ETS-1 proto-oncogene and STAT-3. ETS proteins
activate many genes involved in angiogenesis, including those that regulate VEGFR-1 and
VEGFR-2, integrin b3, some MMPs and urokinase-type plasminogen activator (uPA). ETS-1
is expressed more frequently in GBM being most prominently observed in the glomeruloid
tufts of GBM [119]. VEGF promotes endothelial proliferation via the activation of the MAPK
pathway. VEGF also enhances vascular permeability through the MAPK signaling cascade
by rearranging cadherin/catenin complexes and loosening adhering junctions between en‐
dothelial cells [120]. The VEGF-A is secreted by tumor cells as well as by stromal and in‐
flammatory cells. VEGF-A can be linked in the extracellular matrix through the interaction
with proteoglycans or glycosaminoglycans. The expression of the receptors VEGFR1 and
VEGFR2 is regulated on the endothelial cells in gliomas. VEGF-A activation causes endothe‐
lial cell differentiation into a “tip” cell and a VEGF-A gradient induces “stalk” cell prolifera‐
tion along an opening in the BM in forming of a new vessel sprout [121]. The ligands for
VEGF3 (VEGF-C&D) are expressed by multiple cell types that surround the angiogenic ves‐
sels, suggesting the existence of a novel pro-angiogenic paracrine signaling pathways in
these neoplasms. In addition to transcription factors, VEGF expression is also probably cor‐
relates with many other growth factors and their specific receptors, including transforming
growth factor (TGF)-b, platelet-derived growth factor (PDGF)-B, epidermal growth factor
(EGF), basic fibroblast growth factors (FGF). VEGF promotes endothelial proliferation via
activation of the MAPK pathway. The activation of MAPK/ERK is associated with inhibition
of the Jun-N terminal kinase (JNK) pathway in mediating the anti-apoptotic effect of VEGF.
The PI3K/Akt pathway is of central importance in VEGF signaling. Activated VEGFR-2 me‐
diates the phosphorylation of Akt, which potently inhibits endothelial cell apoptosis by in‐
terfering with various apoptosis signaling pathways. Akt also promotes endothelial cell
migration, and increases the expression of HIF, leading to enhanced VEGF expression [122].
VEGF stimulates endothelial production of urokinase-type plasminogen activator (uPA),
which induces conversion of plasminogen to plasmin, causing the breakdown of ECM com‐
ponents and leading to ECM remodeling [123]. The end result of VEGF signaling in tumors
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is the production of immature, highly permeable blood vessels with subsequent poor main‐
tenance of BBB and parenchymal edema [96, 124]. Alternatively, the angiogenic effect of
VEGF can be mediated through integrins, a1b1, a2b1 and avb3, which promote cell migra‐
tion, proliferation and matrix remodeling.
4.1.2. FGF and FGF receptors
The FGF family of proteins and their receptors are overexpressed in various types of cancer.
Binding of FGF to its receptor causes transphosphorylation and activation of intrinsic tyro‐
sine kinase, which results in signal transduction. Both acidic FGF (aFGF) and basic FGF
(bFGF) are up-regulated in GBM [125] and are responsible for resistance of endothelial cells
to apoptosis. Basic fibroblast growth factor (bFGF) is expressed by vascular cells and, focal‐
ly, by the tumor cells. The receptors for bFGF include FGFR1, expressed by the tumor cells
and the tumor endothelial cells and the FGFR2 expressed only by the tumor cells. The anti-
apoptotic effect of bFGF is mediated by increased expression of Bcl-XL and Bcl-2 via the
MEK-dependent signaling pathway. In addition, bFGF stimulates the expression of VEGFR
in endothelial cells.145 Similar to VEGF, aFGF and bFGF induce endothelial cell prolifera‐
tion and migration. Furthermore, FGF activation leads to remodeling of ECM and degrada‐
tion of the basement membrane by inducing production of plasminogen activator,
collagenase and MMP in endothelial cells [127].
4.1.3. PDGF Family
PDGF-B and platelet-derived growth factor b receptor (PDGFRb) have important roles in
the development and differentiation of the vessel wall [128]. PDGF is a mitogen for multiple
cells of mesenchymal and neuroectodermal origin that acts through the PDGF receptors α
and β. PDGF-B is required for recruitment of pericytes and maturation of the microvascula‐
ture. PDGFR-β is expressed on endothelial cells of astroglial tumors and that PDGF expres‐
sion correlates with astroglial malignancy and angiogenic activity
PDGF contributes indirectly to tumor angiogenesis acting as a potent mitogenic and che‐
motactic  stimulus for angiogenesis  associated stromal cells,  such as smooth muscle cells
or pericytes. However, PDGF’s effects on angiogenesis are mediated partly by VEGF. The
angiogenic effects of PDGF are mediated through PI3K/Akt, MAPK/ERK and STAT3 sig‐
nalling [129].
4.1.4. Molecules of the inflammatory cascade
Molecules of the inflammatory cascade act indirectly on angiogenesis via modulating ex‐
pression of direct angiogenic factors. Interleukin-8 (IL-8) is a potent chemoattractant. But re‐
cent data suggest that it has a critical role in glial tumor angiogenesis and progression. High
expression levels of PGES-1 (Prostaglandine E 1 Sinthase) and IL-8 in malignant gliomas
cells and microglial cells, strongly correlated with grading tumor, are been demonstrated
[130]. IL-8 expression is first observed in low grade astrocytoma in perivascular tumor areas
expressing inflammatory cytokines. In malignant gliomas, IL-8 further localizes in oxygen-
Gliomas Biology: Angiogenesis and Invasion
http://dx.doi.org/10.5772/53487
61
4.1.1. VEGF, VEGF-receptors and VEGF pathway
The VEGF family of growth factors and their receptors are the most important mediators of
glioma angiogenesis. The VEGF family includes six glycoproteins referred to as VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor. The VEGF acts as a major
vascular permeability factor and as a mitogen/survival promoter for endothelial cells [115,
116]. VEGF-A and its receptors are the best characterized signaling pathway in angiogenesis
and binds to two receptor tyrosine kinases (RTK) – VEGFR-1 (Flt-1) and VEGFR-2 (KDR,
Flk-1) [117]. It is generally agreed that VEGFR-2 is the major receptor mediating the mito‐
genic, angiogenic and permeability-enhancing effects of VEGF-A. Recent evidence has sug‐
gested that VEGFR-1 participates in haematopoiesis and in the recruitment of monocytes
and other bone marrow derived cells to promote tumor angiogenesis [118]. In addition,
VEGFR-1 is involved in the activation of MMPs associated with matrix degradation and in
the production of growth factors from endothelial cells. VEGF-A gene expression is up-regu‐
lated by hypoxia, mediated by the transcription factor HIF and the product of the von Hip‐
pel–Lindau (VHL) tumor suppressor gene. Other transcription factors capable of up-
regulating VEGF transcription include the ETS-1 proto-oncogene and STAT-3. ETS proteins
activate many genes involved in angiogenesis, including those that regulate VEGFR-1 and
VEGFR-2, integrin b3, some MMPs and urokinase-type plasminogen activator (uPA). ETS-1
is expressed more frequently in GBM being most prominently observed in the glomeruloid
tufts of GBM [119]. VEGF promotes endothelial proliferation via the activation of the MAPK
pathway. VEGF also enhances vascular permeability through the MAPK signaling cascade
by rearranging cadherin/catenin complexes and loosening adhering junctions between en‐
dothelial cells [120]. The VEGF-A is secreted by tumor cells as well as by stromal and in‐
flammatory cells. VEGF-A can be linked in the extracellular matrix through the interaction
with proteoglycans or glycosaminoglycans. The expression of the receptors VEGFR1 and
VEGFR2 is regulated on the endothelial cells in gliomas. VEGF-A activation causes endothe‐
lial cell differentiation into a “tip” cell and a VEGF-A gradient induces “stalk” cell prolifera‐
tion along an opening in the BM in forming of a new vessel sprout [121]. The ligands for
VEGF3 (VEGF-C&D) are expressed by multiple cell types that surround the angiogenic ves‐
sels, suggesting the existence of a novel pro-angiogenic paracrine signaling pathways in
these neoplasms. In addition to transcription factors, VEGF expression is also probably cor‐
relates with many other growth factors and their specific receptors, including transforming
growth factor (TGF)-b, platelet-derived growth factor (PDGF)-B, epidermal growth factor
(EGF), basic fibroblast growth factors (FGF). VEGF promotes endothelial proliferation via
activation of the MAPK pathway. The activation of MAPK/ERK is associated with inhibition
of the Jun-N terminal kinase (JNK) pathway in mediating the anti-apoptotic effect of VEGF.
The PI3K/Akt pathway is of central importance in VEGF signaling. Activated VEGFR-2 me‐
diates the phosphorylation of Akt, which potently inhibits endothelial cell apoptosis by in‐
terfering with various apoptosis signaling pathways. Akt also promotes endothelial cell
migration, and increases the expression of HIF, leading to enhanced VEGF expression [122].
VEGF stimulates endothelial production of urokinase-type plasminogen activator (uPA),
which induces conversion of plasminogen to plasmin, causing the breakdown of ECM com‐
ponents and leading to ECM remodeling [123]. The end result of VEGF signaling in tumors
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications60
is the production of immature, highly permeable blood vessels with subsequent poor main‐
tenance of BBB and parenchymal edema [96, 124]. Alternatively, the angiogenic effect of
VEGF can be mediated through integrins, a1b1, a2b1 and avb3, which promote cell migra‐
tion, proliferation and matrix remodeling.
4.1.2. FGF and FGF receptors
The FGF family of proteins and their receptors are overexpressed in various types of cancer.
Binding of FGF to its receptor causes transphosphorylation and activation of intrinsic tyro‐
sine kinase, which results in signal transduction. Both acidic FGF (aFGF) and basic FGF
(bFGF) are up-regulated in GBM [125] and are responsible for resistance of endothelial cells
to apoptosis. Basic fibroblast growth factor (bFGF) is expressed by vascular cells and, focal‐
ly, by the tumor cells. The receptors for bFGF include FGFR1, expressed by the tumor cells
and the tumor endothelial cells and the FGFR2 expressed only by the tumor cells. The anti-
apoptotic effect of bFGF is mediated by increased expression of Bcl-XL and Bcl-2 via the
MEK-dependent signaling pathway. In addition, bFGF stimulates the expression of VEGFR
in endothelial cells.145 Similar to VEGF, aFGF and bFGF induce endothelial cell prolifera‐
tion and migration. Furthermore, FGF activation leads to remodeling of ECM and degrada‐
tion of the basement membrane by inducing production of plasminogen activator,
collagenase and MMP in endothelial cells [127].
4.1.3. PDGF Family
PDGF-B and platelet-derived growth factor b receptor (PDGFRb) have important roles in
the development and differentiation of the vessel wall [128]. PDGF is a mitogen for multiple
cells of mesenchymal and neuroectodermal origin that acts through the PDGF receptors α
and β. PDGF-B is required for recruitment of pericytes and maturation of the microvascula‐
ture. PDGFR-β is expressed on endothelial cells of astroglial tumors and that PDGF expres‐
sion correlates with astroglial malignancy and angiogenic activity
PDGF contributes indirectly to tumor angiogenesis acting as a potent mitogenic and che‐
motactic  stimulus for angiogenesis  associated stromal cells,  such as smooth muscle cells
or pericytes. However, PDGF’s effects on angiogenesis are mediated partly by VEGF. The
angiogenic effects of PDGF are mediated through PI3K/Akt, MAPK/ERK and STAT3 sig‐
nalling [129].
4.1.4. Molecules of the inflammatory cascade
Molecules of the inflammatory cascade act indirectly on angiogenesis via modulating ex‐
pression of direct angiogenic factors. Interleukin-8 (IL-8) is a potent chemoattractant. But re‐
cent data suggest that it has a critical role in glial tumor angiogenesis and progression. High
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deprived cells surrounding necrosis. IL-8, however, stimulates angiogenesis via the interac‐
tion with the CXC chemokine receptor 1 (CXCR1), CXCR2 and Duffy antigen receptor for
cytokines (DARC). DARC expression has been detected on tumour-associated endothelial
cells, whereas CXCR1 and CXCR2 are found on infiltrating leukocytes near blood vessels.
Macrophages are known to produce high levels of IL-8, which has a tumorigenic activity, by
inducing tumor growth and angiogenesis; IL-8 is an inflammatory chemoattractant respond‐
ing to the tumor microenvironment. Tumor pseudopalisading cells secrete HIF which indu‐
ces IL-8 secretion. On the basis of preliminary results, the role of IL-8 as crucial angiogenesis
mediator within HIF-1α pathway and crosstalk between hypoxia-induced high levels of
HIF-1α and VEGF expression has been demonstrated.
The cyclooxygenase isoforms (COX-1 and COX-2) catalyze the synthesis of prostaglandins
from arachidonic acid. While COX-1 is ubiquitously expressed in a wide range of tissues,
COX-2 is cytokine inducible. COX-2 is expressed in human glioma cells where its expression
correlates with malignancy, being highest in glioblastoma. The anti-angiogenic efficacy of
COX-2 inhibitors is currently explained first by downregulation of VEGF, which results in
blocking of endothelial cell proliferation and induction of endothelial cell apoptosis and sec‐
ond by inhibition of integrin function and signaling.
Tumor necrosis factor-α (TNF-α) is a potent proinflammatory cytokine with a quite complex
role in endothelial cell survival and migration. It has impact on endothelial cell survival and
migration via its TNF-receptor 1 and 2 which are both expressed on endothelial cells.
Membrane type 1-matrix metalloproteinase (MT1-MMP) expressed by the tip cell of an en‐
dothelial sprout opens up the surrounding matrix and is only later down-regulated when
stalk cells come into contact with pericytes. Re-established contact between endothelial cells
and pericytes induces expression of tissue inhibitor of metalloproteinases-2 (TIMP-2) in en‐
dothelial cells and TIMP-3 in pericytes in switching off the proteolytic phenotype in endo‐
thelial cells [131]. MT1-MMPs on the endothelial cell surface are also required for the
subsequent step in the angiogenesis cascade of tube formation by playing a role in endothe‐
lial intracellular vacuole and lumen formation. The vessel lumen is tightly sealed by adjoin‐
ing endothelial cells held together by tight and adherens junctions. A basement membrane is
then produced by endothelial cells in cooperation with surrounding cells in providing struc‐
tural support and maintaining endothelial cell quiescence. The BM is built up of scaffolding
laminins and essential components such as collagen IV, perlecan, nidogens, and collagen
XVIII [132-133]. During the maturation of new capillaries, pruning of excess or unneeded
vessels for optimal perfusion is proposed to represent an adjustment to oxygen surplus
while the surrounding ECM exerts mechanical strain providing traction and orientation for
angiogenic microvessels [134].
Many other proangiogenic factors are upregulated in gliomas and this aspect might explain
the failure of many actual antiangiogenic therapeutic strategies in gliomas management.
TGF-b and its receptors are highly expressed in malignant gliomas, especially in areas of
vascular hyperplasia and around necrotic regions. In glioma cells, the angiogenic effect of
TGF-b is probably mediated through the enhanced expression of VEGF. TGF-b also pro‐
motes angiogenesis via the integrin signaling pathway. TGF-b upregulates expression of
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ανβ3 integrin that, in turn, binds to MMP-2, which leads to degradation of the ECM and en‐
hanced endothelial cell invasion [135]. An important role has absolved by IL-1beta, IL-6,
TNF-alpha and stromal-cell-derived factor (SDF)-1 alpha [46].
5. Microglia
Glioma tissues as obtained by surgical resection contain also a considerable amount of non-
transformed cells. The majority of these cells are tumor-associated macrophages (TAMs)
[136-137]. Resident macrophages of the brain are termed microglia. These cells invade the
brain early in development and differentiate into so-called resident, ramified microglia.
These tumor-associated microglia displayed an ameboid morphology similar to that descri‐
bed in other pathologies. Since microglia share many properties with macrophages found in
non-neuronal tissues including the blood, it was possible that glioma-associated microglia
could be recruited de novo from the microglial population resident in the brain, or alterna‐
tively, migrate into brain tumors from the periphery. To address this question, Badie and
Schartner [138] used CD45 labeling of cells in rodent tumor models to distinguish brain mi‐
croglia (CD45 low) from peripheral macrophages (CD45 high). They used CD11b/c as a gen‐
eral marker for macrophages and sorted the CD11b/c2 positive cells into two populations
showing high and low CD45 expression. From this, they concluded that the macrophages
are primarily found within tumors, while microglia was detected in all brain tissue. Thus,
the precise origin of tumor microglia remains to be determined. Regardless of origin, we can
define any glioma-associated monocytic cell with macrophage characteristics as a tumor-as‐
sociated microglia. Candidate chemoattractants of tumor-associated microglia include mon‐
ocyte chemotactic protein-3(MCP-3), colony-stimulating factor 1 (CSF-1), granulocyte-
colony stimulatory factor (G-CSF), and hepathocyte growth factor/scatter factor: each of
these has been shown to be released by gliomas and microglia are known to express recep‐
tors for these chemoattractant growth factors [139-140].
TAMs promote cancer progression through several mechanisms, including promotion of an‐
giogenesis, induction of tumour growth, and enhancement of tumour cell migration and in‐
vasion. The hypoxic stress in the tumour mass leads to the expression of inflammatory
molecules, which promote the recruitment of macrophages followed by conversion to the
M2 phenotype. TAMs are capable to modulate and induce neovascularization and functions
related to stroma formation. When TAMs are activated, in response to specific stimuli, these
cells can express a repertoire of substances that promote angiogenesis. Growth factors such
as acidic fibroblasts growth factor (aFGF/FGF1), basic fibroblasts growth factor (bFGF/
FGF2), vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor
(GM-CSF), transforming growth factor-α, insulin-like growth factor-1, platelet derived
growth factor (PDGF), tumour growth factor-β (TGF-β) and other monokines (e.g. tumour
necrosis factor-α (TNF-α), interleukin-1, interleukin-6, interleukin-8, substance P, prosta‐
glandins, interferons and thrombospondin which are released by tumour cells leads to the
activation of macrophages and have the capability to influence the angiogenic process [141].
Therefore, macrophages recruited in situ represent an indirect pathway of amplification of
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angiogenesis, in concert with angiogenic molecules directly produced by tumor cells. In ex‐
perimental in vitro studies, glioma cell lines seem produce high levels of a monocyte-macro‐
phages-derived cytokine, IL-8, that induces formation of tube-like structures by human
microvascular endothelial cells [142]. We previously demonstrated significant increase in
IL-8 protein level in astrocytic cultures treated with PGE2. The ability of PGE2 to increase
IL-8 expression in glioma cells has a significant biological impact on tumorigenesis, as
shown by increased growth and reduced apoptosis in PGE2-treated cells [143]. Macrophag‐
es can exert a dual influence on blood vessel formation. On the one hand macrophages pro‐
duce proangiogenic molecules on the other hand they can express anti-angiogenic molecules
and damage the integrity of blood vessels. In general the pro-angiogenic functions of TAMs
prevail [144].
Angiogenesis is also facilitated by TAM-derived proteases released in tumours, as extracel‐
lular proteolysis is an absolute requirement for new blood vessel formation. Macrophages
can express proteases to release a number of pro-angiogenic molecules bound to heparan
sulfate in proteoglycans, and fragment of fibrin and collagen, which facilitate angiogenesis.
Among these, matrix metalloproteases (MMPs 1, 2, 3, 9 and 12), plasmin, urokinase plasmi‐
nogen activator and receptor are the prominent ones which promotes tumour directed an‐
giogenesis. MMPs are a family of matrix degrading enzymes including collagenase
(MMP-1), gelatinase A (MMP-2), stromelysin (MMP-3), matrilysin (MMP-7), gelatinase B
(MMP-9), and other MMPs. TAMs have been reported to correlate with the metastatic po‐
tential of a variety of human cancers, and they have also been shown to be a major source of
MMP-9. In addition, urokinase-type plasminogen activator is a serine protease synthesized
by TAMs in various human tumour types [145]. TAMs were shown to express CXCL8,
which like VEGF, binds heparin in the ECM and stimulate angiogenesis [146]. Thus TAMs
have the capacity to affect each phase of the angiogenic process, including degradation of
the extracellular matrix, endothelial cell proliferation and endothelial cell migration. TAMs
can also secrete cysteine-type lysosomal proteases and a wide variety of growth factors that
can stimulate cancer growth.
New blood vessels in tumours are usually disorganized and prone to collapse, resulting in
areas of inadequate perfusion and hypoxia (low oxygen tension). Additionally, rapid tu‐
mour cell proliferation in some areas may outpace the rate of new blood vessel growth,
causing hypoxic areas to form [147]. The level of TAMs in tumours appears to be affected by
hypoxia, a trait commonly found in these tissues. TAM numbers are generally higher in tu‐
mours containing high overall levels of hypoxia, as seen in primary human breast carcino‐
mas and various animal tumours. Hypoxic tumours secrete higher amounts of
chemoattractants and/or other factors that enhance monocyte attachment to and migration
through the tumour vasculature. Once targeted to hypoxic sites, TAM functions are greatly
affected by hypoxia-related factors. Because macrophages are phagocytes, they may also be
attracted to hypoxic, perinecrotic areas along a trail of necrotic debris emanating from dead
cells. Hypoxia also entraps TAMs by decreasing their mobility in a number of ways. One
such approach involves the hypoxic up-regulation of the enzyme mitogen-activated protein
kinase phosphatase (MKP-1) by macrophages. This is important because various chemoat‐
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications64
tractant receptors, including those for CCL2, VEGF, and endothelin 2, stimulate cell migra‐
tion by phosphorylating the signaling enzymes MEK, ERK1/2, and p38 MAPK. Up-
regulated MKP-1 rapidly dephosphorylates these molecules in TAMs, thus terminating the
chemotactic response of TAMs to these chemokines [148]. Hypoxia also inhibits macrophage
expression of the chemokine receptors CCR2 and CCR5 [149], further helping to immobilize
TAMs. Hypoxia also induces a profound change in the phenotype of macrophages, promot‐
ing increased expression of a wide range of genes.
This is brought about by the hypoxic up-regulation of such transcription factors as hypoxia-
inducible factors, HIF-1α and HIF-2α. TAMs respond to hypoxia by up-regulating a broad
array of genes encoding proteins that promote the proliferation, invasion, and metastasis of
tumour cells as well as tumour angiogenesis. Genes coding for M-CSF, a growth factor that
promotes the survival and differentiation of macrophages, is over expressed in some human
tumours, and elevated M-CSF levels correlate with high TAM numbers and poor prognosis
[150]. Hypoxic macrophages are also likely to promote the invasive and/or metastatic behav‐
ior of tumour cells by releasing such pro-invasive factors as macrophage inhibitory factor
[151]. Macrophage inhibitory factor is known to modulate the activities of a number of cell
types in tumours, including stimulation of tumour cell motility [152]. This may involve indi‐
rect effects such as macrophage inhibitory factor-stimulated release of matrix metalloprotei‐
nase 9, which in turn degrades components of the basement membrane and extracellular
matrix, thereby increasing the motility of tumour cells.
In a cultured mouse brain slice model, the invasion and growth of glioma cells was com‐
pared between normal and microglia-depleted slices. Glioma cell invasion was significantly
reduced in microglia depleted slices relative to control slices [153]. The impact of microglia
on glioma migration might relate to the production of membrane type 1 metalloprotease
(MT1-MMP or MMP-14) that are produced by microglia in response to soluble factors re‐
leased from glioma cells. Glioma cells also release metalloproteases 2 that is fully activated
by MT1-MMP released from microglia. The consequent degradation of the extracellular ma‐
trix has been postulated to enhance the invasion of glioma cells into the brain parenchyma.
The importance of microglia for glioma growth was further substantiated by studying ani‐
mals in which microglia was depleted. The microglia-depletion in vivo was achieved by us‐
ing the CD11b-HSVTK mouse model. Seven days after intracerebral glioma inoculation,
ganciclovir (a specific substrate for the viral thymidine kinase HSVTK) was infused via
mini-pumps into the tumor area for a further 7 days. To restrict the effect of ganciclovir on
the intrinsic microglial population, the mice were irradiated before bone marrow transplant‐
ed with wild-type monocytes. The ganciclovir treatment led to a considerable depletion of
microglia and to an 80% reduction in glioma volume [153].
CD68 is a monoclonal mouse antibody that labels human monocytes and macrophages. The
antigen recognized by CD68 is absent from resting microglia but readily detectable in phag‐
ocytic microglia, perivascular cells and brain macrophages. In a recent study, the presence of
CD68 positive cells neighboring of neoplastic cells, contiguous to necrotic and hypoxic areas
within neoplastic tissue has been evidenced. The presence of TAMs that passed through ves‐
sel wall also in low-grade astrocytomas was, also, observed [154]. In anaplastic cases, neo‐
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the extracellular matrix, endothelial cell proliferation and endothelial cell migration. TAMs
can also secrete cysteine-type lysosomal proteases and a wide variety of growth factors that
can stimulate cancer growth.
New blood vessels in tumours are usually disorganized and prone to collapse, resulting in
areas of inadequate perfusion and hypoxia (low oxygen tension). Additionally, rapid tu‐
mour cell proliferation in some areas may outpace the rate of new blood vessel growth,
causing hypoxic areas to form [147]. The level of TAMs in tumours appears to be affected by
hypoxia, a trait commonly found in these tissues. TAM numbers are generally higher in tu‐
mours containing high overall levels of hypoxia, as seen in primary human breast carcino‐
mas and various animal tumours. Hypoxic tumours secrete higher amounts of
chemoattractants and/or other factors that enhance monocyte attachment to and migration
through the tumour vasculature. Once targeted to hypoxic sites, TAM functions are greatly
affected by hypoxia-related factors. Because macrophages are phagocytes, they may also be
attracted to hypoxic, perinecrotic areas along a trail of necrotic debris emanating from dead
cells. Hypoxia also entraps TAMs by decreasing their mobility in a number of ways. One
such approach involves the hypoxic up-regulation of the enzyme mitogen-activated protein
kinase phosphatase (MKP-1) by macrophages. This is important because various chemoat‐
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tractant receptors, including those for CCL2, VEGF, and endothelin 2, stimulate cell migra‐
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inducible factors, HIF-1α and HIF-2α. TAMs respond to hypoxia by up-regulating a broad
array of genes encoding proteins that promote the proliferation, invasion, and metastasis of
tumour cells as well as tumour angiogenesis. Genes coding for M-CSF, a growth factor that
promotes the survival and differentiation of macrophages, is over expressed in some human
tumours, and elevated M-CSF levels correlate with high TAM numbers and poor prognosis
[150]. Hypoxic macrophages are also likely to promote the invasive and/or metastatic behav‐
ior of tumour cells by releasing such pro-invasive factors as macrophage inhibitory factor
[151]. Macrophage inhibitory factor is known to modulate the activities of a number of cell
types in tumours, including stimulation of tumour cell motility [152]. This may involve indi‐
rect effects such as macrophage inhibitory factor-stimulated release of matrix metalloprotei‐
nase 9, which in turn degrades components of the basement membrane and extracellular
matrix, thereby increasing the motility of tumour cells.
In a cultured mouse brain slice model, the invasion and growth of glioma cells was com‐
pared between normal and microglia-depleted slices. Glioma cell invasion was significantly
reduced in microglia depleted slices relative to control slices [153]. The impact of microglia
on glioma migration might relate to the production of membrane type 1 metalloprotease
(MT1-MMP or MMP-14) that are produced by microglia in response to soluble factors re‐
leased from glioma cells. Glioma cells also release metalloproteases 2 that is fully activated
by MT1-MMP released from microglia. The consequent degradation of the extracellular ma‐
trix has been postulated to enhance the invasion of glioma cells into the brain parenchyma.
The importance of microglia for glioma growth was further substantiated by studying ani‐
mals in which microglia was depleted. The microglia-depletion in vivo was achieved by us‐
ing the CD11b-HSVTK mouse model. Seven days after intracerebral glioma inoculation,
ganciclovir (a specific substrate for the viral thymidine kinase HSVTK) was infused via
mini-pumps into the tumor area for a further 7 days. To restrict the effect of ganciclovir on
the intrinsic microglial population, the mice were irradiated before bone marrow transplant‐
ed with wild-type monocytes. The ganciclovir treatment led to a considerable depletion of
microglia and to an 80% reduction in glioma volume [153].
CD68 is a monoclonal mouse antibody that labels human monocytes and macrophages. The
antigen recognized by CD68 is absent from resting microglia but readily detectable in phag‐
ocytic microglia, perivascular cells and brain macrophages. In a recent study, the presence of
CD68 positive cells neighboring of neoplastic cells, contiguous to necrotic and hypoxic areas
within neoplastic tissue has been evidenced. The presence of TAMs that passed through ves‐
sel wall also in low-grade astrocytomas was, also, observed [154]. In anaplastic cases, neo‐
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plastic cells seem to be guided towards microglia. These data, can reinforced the hypothesis
that macrophage infiltration could be closely associated with neovascularization and malig‐
nancy in human gliomas. Matrix metalloprotease activity is also regulated by the CX3CL1/
CX3CR1 signaling pathway. For example, matrix metalloproteases 2, 9, and 14 are upregu‐
lated in microglia following activation of CX3CL1/CX3CR1signaling. Notably, CX3CR1 is
upregulated in glioma associated microglia [155] and polymorphisms in the chemokine re‐
ceptor CX3CR1 have been associated with prognosis among patients with glioma. The com‐
mon CX3CR1 allele (termed V249I) was a favorable prognostic factor. Patients who had only
this CX3CR1 allele had a more than 1.5 longer mean survival time. This common allele was
associated with reduced microglial cell infiltration in primary tumor biopsies [155].
In a previous study has been demonstrated, in a series of GBM, the presence of laminin, fi‐
bronectin and type IV collagen in hyper-plastic vessels, in and around vascular channel, in
vascular walls and at level of BM associated with endothelial glomerulus-like proliferations
[83]. Laminin within the BM can bind to both endothelial cells and tumor cells and is in‐
volved in angiogenesis and tumor growth. We can hypothesized that in pilocytic astrocyto‐
ma, the ECM integrity cause a reduced macrophagic/microglial migration. In this view, an
incompetent control of interactions occurs between microglial adhesive molecules and ECM
substrates. In low-grade astrocytomas is achievable that low macrophage/microglial recruit‐
ment is also correlated with a lower vascular neo-angiogenesis. This relationship may influ‐
ence microglial morphology, blocking microglial migration and phagocytosis [154]. To
support these findings, a recent study showed an increase of CD68 positive cells which cor‐
related with trends toward worse event-free survival [156].
6. Therapeutic strategies for malignant gliomas
The treatment of brain cancer is one of the most difficult challenge in neurosurgery and on‐
cology. Malignant gliomas involve, in their progression, multiple aberrant signaling path‐
ways and the blood-brain barrier (BBB) restricts the delivery of many chemotherapeutic
agents. Current conventional treatments protocols include maximally safe surgical resection
followed by fractionated radiation therapy of the tumor and surrounding brain parenchyma
and systemic chemotherapy. However, radiation therapy is limited to a largely palliative
role, and chemotherapy has provided only a modest benefit in clinical outcome. There are
several factors underlying the disappointing results in brain cancer therapeutics including
limited tumor cell drug uptake, intracellular drug metabolism, inherent tumor sensitivity to
chemotherapy, and cellular mechanisms of resistance. The BBB protects the brain from tox‐
ins and fluctuations in systemic chemical concentrations, but it also excludes many thera‐
peutic agents. Multimodal therapeutic approaches and molecular-based targeted therapies
are modern and complex strategies potentially very efficacious and applicable to up-regu‐
late the selectivity of therapeutic effects and down-regulate systemic toxicity and side effect
toward peritumoral and safe brain tissue. Developments in molecular biology have led to a
clearer understanding of the mechanisms of tumor development and resistance to therapy.
As a results, new treatment strategies are emerging that target steps in the molecular patho‐
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genesis of brain gliomas. An optimal realization of a system that overcomes the problems
associated with developing effective brain tumor treatments requires the identification of
neoplastic markers, and understanding their evolution over time, and the development of
technology for the biomarker-targeted delivery of multiple therapeutic agents, and for the
simultaneous capability of avoiding biological and biophysical barriers. In this complex phe‐
nomenon it is fundamental to improve specific selective drugs delivery systems: in this way,
drugs, antisense oligonucleotides (AONs), small interference RNAs, engineered monoclonal
antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB.
Glioma gene expression and its development during gliomagenesis may help to better un‐
derstand the role of important molecules involved in tumor-safe brain parenchyma relation‐
ships. These molecules, such as ECM proteases, cell adhesion molecules, and their related
signaling pathways, show an important role in glioma cell migration and invasion and
could selectively attack to inhibit the glioma invasive rim. Various small molecule inhibitors
and antibodies has been developed, and is continuing to be developed, to target key compo‐
nents of the signal transduction machinery, with a particular focus on growth factors and
their corresponding receptors and canonical downstream signal transduction intermediates.
Many of these inhibitors have potential for the treatment of glioblastoma. Testing some of
these inhibitors, as well as using genetic approaches to untangling these signaling networks
in well-designed model systems (including both highly representative xenograft models and
mouse genetic models), is beginning to provide an emerging picture of the targetable molec‐
ular phenotype of glioblastoma.
Angiogenesis is tightly correlated with the histological grading and prognosis of gliomas.
Glioma vasculature is structurally and functionally abnormal, leading to vasogenic edema,
increased interstitial pressure, and heterogeneous delivery of oxygen and drugs. VEGF is
the key factor implicated in the angiogenesis of gliomas. It acts as a major vascular permea‐
bility factor and as a mitogen/survival promoter for endothelial cells. VEGF expression is
stimulated by hypoxia, acidosis, and many growth factors (EGFR, PDGFR, HGFR, CKit, in‐
sulin-like growth factor receptor), and their downstream signaling pathways (PI3K–Akt,
Ras–MAPK) are commonly activated in gliomas. However, many other proangiogenic fac‐
tors are upregulated in gliomas, and this might explain how gliomas may escape a specific
antiangiogenic therapy. Antiangiogenic therapy is able to normalize the structure and func‐
tion of abnormal neovasculature [96]. The normalization hypothesis states that antiangio‐
genic therapies may augment the effects of chemotherapy and radiotherapy by normalizing
tumor vessels. Furthermore, normalizing tumor vessels might also reduce hypoxia, and thus
make the tumor cells more sensitive to chemotherapy and radiation therapy [96].
6.1. Molecular targeted therapy
Elevated expression or mutation of receptors and intracellular downstream effectors has
been demonstrated in gliomas. These pathways are controlled by several growth factors
linked to tyrosine kinase. Specific targeting of these signaling pathways that lead to altered
cellular proliferation and cell migration and invasion could provide new molecularly target‐
ed options for glioma treatment. The introduction of molecularly targeted agents is one of
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ma, the ECM integrity cause a reduced macrophagic/microglial migration. In this view, an
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support these findings, a recent study showed an increase of CD68 positive cells which cor‐
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cology. Malignant gliomas involve, in their progression, multiple aberrant signaling path‐
ways and the blood-brain barrier (BBB) restricts the delivery of many chemotherapeutic
agents. Current conventional treatments protocols include maximally safe surgical resection
followed by fractionated radiation therapy of the tumor and surrounding brain parenchyma
and systemic chemotherapy. However, radiation therapy is limited to a largely palliative
role, and chemotherapy has provided only a modest benefit in clinical outcome. There are
several factors underlying the disappointing results in brain cancer therapeutics including
limited tumor cell drug uptake, intracellular drug metabolism, inherent tumor sensitivity to
chemotherapy, and cellular mechanisms of resistance. The BBB protects the brain from tox‐
ins and fluctuations in systemic chemical concentrations, but it also excludes many thera‐
peutic agents. Multimodal therapeutic approaches and molecular-based targeted therapies
are modern and complex strategies potentially very efficacious and applicable to up-regu‐
late the selectivity of therapeutic effects and down-regulate systemic toxicity and side effect
toward peritumoral and safe brain tissue. Developments in molecular biology have led to a
clearer understanding of the mechanisms of tumor development and resistance to therapy.
As a results, new treatment strategies are emerging that target steps in the molecular patho‐
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications66
genesis of brain gliomas. An optimal realization of a system that overcomes the problems
associated with developing effective brain tumor treatments requires the identification of
neoplastic markers, and understanding their evolution over time, and the development of
technology for the biomarker-targeted delivery of multiple therapeutic agents, and for the
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antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB.
Glioma gene expression and its development during gliomagenesis may help to better un‐
derstand the role of important molecules involved in tumor-safe brain parenchyma relation‐
ships. These molecules, such as ECM proteases, cell adhesion molecules, and their related
signaling pathways, show an important role in glioma cell migration and invasion and
could selectively attack to inhibit the glioma invasive rim. Various small molecule inhibitors
and antibodies has been developed, and is continuing to be developed, to target key compo‐
nents of the signal transduction machinery, with a particular focus on growth factors and
their corresponding receptors and canonical downstream signal transduction intermediates.
Many of these inhibitors have potential for the treatment of glioblastoma. Testing some of
these inhibitors, as well as using genetic approaches to untangling these signaling networks
in well-designed model systems (including both highly representative xenograft models and
mouse genetic models), is beginning to provide an emerging picture of the targetable molec‐
ular phenotype of glioblastoma.
Angiogenesis is tightly correlated with the histological grading and prognosis of gliomas.
Glioma vasculature is structurally and functionally abnormal, leading to vasogenic edema,
increased interstitial pressure, and heterogeneous delivery of oxygen and drugs. VEGF is
the key factor implicated in the angiogenesis of gliomas. It acts as a major vascular permea‐
bility factor and as a mitogen/survival promoter for endothelial cells. VEGF expression is
stimulated by hypoxia, acidosis, and many growth factors (EGFR, PDGFR, HGFR, CKit, in‐
sulin-like growth factor receptor), and their downstream signaling pathways (PI3K–Akt,
Ras–MAPK) are commonly activated in gliomas. However, many other proangiogenic fac‐
tors are upregulated in gliomas, and this might explain how gliomas may escape a specific
antiangiogenic therapy. Antiangiogenic therapy is able to normalize the structure and func‐
tion of abnormal neovasculature [96]. The normalization hypothesis states that antiangio‐
genic therapies may augment the effects of chemotherapy and radiotherapy by normalizing
tumor vessels. Furthermore, normalizing tumor vessels might also reduce hypoxia, and thus
make the tumor cells more sensitive to chemotherapy and radiation therapy [96].
6.1. Molecular targeted therapy
Elevated expression or mutation of receptors and intracellular downstream effectors has
been demonstrated in gliomas. These pathways are controlled by several growth factors
linked to tyrosine kinase. Specific targeting of these signaling pathways that lead to altered
cellular proliferation and cell migration and invasion could provide new molecularly target‐
ed options for glioma treatment. The introduction of molecularly targeted agents is one of
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the most significant advances in cancer therapy in recent years. Targeted therapies block ac‐
tivation of oncogenic pathways, either at the ligand–receptor interaction level or by inhibit‐
ing downstream signal transduction pathways, thereby inhibiting growth and progression
of cancer. Because of their specificity, targeted therapies should theoretically have better ef‐
ficacy and safety profiles than systemic cytotoxic chemotherapy or radiotherapy. The main
rationale for using antiangiogenic therapies in glioblastoma is to normalize the vasculature,
restoring the selective permeability of the blood-brain barrier.
6.1.1. VEGF, VEGF-receptors and VEGF pathway
VEGF-A is a member of the VEGF family that acts as a key proangiogenic factor because of
its specificity to endothelial cells and the multitude of responses that it can elicit. These in‐
clude ECM degradation, endothelial cell proliferation, migration and tube formation, and
expression of other proangiogenic factors, such as urokinase-type plasminogen activator,
plasminogen activator inhibitor-1, urokinase-type plasminogen activator receptor, and ma‐
trix metalloproteinase-1. Overexpression of VEGF-A occurs in response to hypoxia, PDGF,
EGF, transforming growth factor-h, interleukin-1h, and tumor necrosis factor-a. The best-
studied receptor is VEGFR-2, a potent tyrosine kinase that mediates endothelial cell signal‐
ing through the activation of Ras/Raf/MEK/MAPK, PI3K/AKT/PKB, and protein kinase C
pathways. Has been suggested that blocking VEGF pathways may normalize tumor vascu‐
lature and improve chemotherapy delivery, allowing higher drug concentrations [157].
Several strategies for targeting VEGF have been proposed, such as VEGFR TKI, anti-VEGF-
A and VEGFR-2 monoclonal antibodies, antisense oligonucleotides, and ribozymes. The
best-studied drugs in gliomas have been vatalanib (PTK787/ZK222584), ZD6474, sorafenib
(BAY 43-9006), sunitinib (SU11248), and cediranib (AZD2171). Difficulties include defining
the optimal biological dose of drugs that are rarely toxic, determining the relevance of com‐
binations with cytotoxic chemotherapy and radiotherapy, and elucidating adequate surro‐
gate markers.
Vatalanib is a VEGFR-1 and VEGFR-2 TKI that showed activity in glioma cell lines and xen‐
ograft models [158]. A phase I study of vatalanib, and c-kit in patients with newly diagnosed
GBM receiving radiation, temozolomide, and an enzyme-inducing anti-epileptic drug in or‐
der to determine the MTD of vatalanib in this patient population was evaluated. Vatalanib
was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases). Other
grade 3/4 toxicities included leukopenia, lymphopenia, neutropenia, and hand-foot syn‐
drome. Of the 13 patients evaluable for a radiographic response, 2 had a partial response
and 9 had stable disease. Vatalanib significantly increased PlGF and sVEGFR1 in plasma cir‐
culation and decreased sVEGFR2 and sTie2. Vatalanib was well tolerated and this study
demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients.
Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angio‐
genic therapies [159].
ZD6474 is a VEGFR-2 TKI with additional VEGR-3 and EGFR inhibition properties. In vivo
models showed a broader spectrum of action, suggesting an antiangiogenic and anti-VEGFR
preponderant effect [160]. In a glioma xenograft study, ZD6474 decreased tumor volume,
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lowered the tumor cell proliferation index (Ki-67), and increased tumor cell apoptosis. How‐
ever, microvascular density, a typical marker of angiogenic activity, surprisingly increased,
raising doubts on the antiangiogenic effects of the drug [161].
The effect of ZD6474, was also evaluated in combination with either radiotherapy or temo‐
zolomide. ZD6474 in combination with radiotherapy significantly decreased tumour area by
66% compared with controls whereas the combination with temozolomide decreased tu‐
mour area by 74% [162].
Recently, the AEE788, a reversible TK inhibitor that inhibits EGFR and VEGFR, in recurrent
glioblastoma patients, was evaluated [163]. Continuous, once-daily AEE788 was associated
with unacceptable toxicity and minimal activity for the treatment of recurrent glioblastoma.
The study was, therefore, discontinued prematurely.
Cediranib (AZD2171) is a potent, orally available, small-molecule inhibitor of VEGF-recep‐
tor (VEGFR) tyrosine kinase activity that  rapidly normalizes tumor blood vessels  in pa‐
tients with glioblastoma, leading to a clinical improvement in cerebral edema [164]. In a
recent  study,  drug  effects  were  evaluated  over  time  through the  use  of  magnetic  reso‐
nance imaging techniques (including analysis of perfusion, permeability, and relative ves‐
sel  size)  and assessment of  circulating progenitor  cells,  circulating endothelial  cells,  and
plasma levels of several proangiogenic proteins. Results suggest that cediranib leads to a
normalization of vasculature and decreased edema; however, such effects disappear over‐
time,  which is  accompanied by an increase in  circulating basic  fibroblast  growth factor,
stromal  cell-derived  factor-1a,  and  circulating  endothelial  cells.  In  mouse  models,  im‐
provement  in  edema  was  associated  with  increased  survival,  despite  continued  tumor
growth  [165].  The  first  clinical  data  of  the  REGAL  trial  of  cediranib  plus  lomustine
(CCNU) to investigate  whether  preclinical  findings will  translate  into improvements  for
patients with recurrent glioma have been negative [166].
Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors,
was evaluated for treatment of patients with recurrent glioblastoma and anaplastic astrocy‐
toma (AA). For AA patients, the most common side effects were fatigue, diarrhea, hand-foot
syndrome, neutropenia, thrombocytopenia, and nausea. In the GBM cohort, the most com‐
mon side effects were fatigue, diarrhea, neutropenia, and thrombocytopenia. Median overall
survival was 12.1 months (AA) and 12.6 months (GBM). Nonetheless, sunitinib did not dem‐
onstrate significant anti-glioma activity in patients with recurrent malignant astrocytic glio‐
mas [167]. Recent preclinical studies suggest that treating GBM with a combination of
targeted chemotherapy and radiotherapy may enhance the anti-tumor effects of both thera‐
pies. In a recent study, have been evaluated the effects of combination therapy in a mouse
gliomamodel that utilizes a PDGF-IRES-Cre-expressing retrovirus to infect adult glial pro‐
genitors in mice carrying conditional deletions of Pten and p53. The addition of sunitinib to
low-dose radiation caused a modest, but significant delay in tumor growth. However, no
significant survival benefit was seen as tumors progressed in 100% of animals. Histological
analysis revealed a reduction in vascular proliferation and a marked increase in brain inva‐
sion. The results showed that the addition of Sunitinib to radiotherapy fails to significantly
alter survival in GBM despite enhancement of the effects of radiation [168].
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the most significant advances in cancer therapy in recent years. Targeted therapies block ac‐
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lowered the tumor cell proliferation index (Ki-67), and increased tumor cell apoptosis. How‐
ever, microvascular density, a typical marker of angiogenic activity, surprisingly increased,
raising doubts on the antiangiogenic effects of the drug [161].
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survival was 12.1 months (AA) and 12.6 months (GBM). Nonetheless, sunitinib did not dem‐
onstrate significant anti-glioma activity in patients with recurrent malignant astrocytic glio‐
mas [167]. Recent preclinical studies suggest that treating GBM with a combination of
targeted chemotherapy and radiotherapy may enhance the anti-tumor effects of both thera‐
pies. In a recent study, have been evaluated the effects of combination therapy in a mouse
gliomamodel that utilizes a PDGF-IRES-Cre-expressing retrovirus to infect adult glial pro‐
genitors in mice carrying conditional deletions of Pten and p53. The addition of sunitinib to
low-dose radiation caused a modest, but significant delay in tumor growth. However, no
significant survival benefit was seen as tumors progressed in 100% of animals. Histological
analysis revealed a reduction in vascular proliferation and a marked increase in brain inva‐
sion. The results showed that the addition of Sunitinib to radiotherapy fails to significantly
alter survival in GBM despite enhancement of the effects of radiation [168].
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In gliomas, despite evidence of activity in preclinical models, clinical development of beva‐
cizumab was delayed initially because of the fear of central nervous system hemorrhage
[169]. Bevacizumab is a monoclonal antibody against VEGF inhibiting angiogenesis by pre‐
venting receptor activation. Phase II clinical trials using bevacizumab in both newly diag‐
nosed and recurrent high-grade glioma showed promising results. Bevacizumab has been
shown to be safe and tolerable in malignant gliomas. In the recurrent disease setting, bevaci‐
zumab alone might be sufficient for a clinical benefit and is currently approved as a single
agent for this indication. In a phase II study was evaluated the efficacy and safety of bevaci‐
zumab in Japanese patients with recurrent malignant glioma. The 6-month progression-free
survival rate in the 29 patients with recurrent glioblastoma was 33.9% and the median pro‐
gression-free survival was 3.3 months. The 1-year survival rate was 34.5% with a median
overall survival of 10.5 months. There were eight responders (all partial responses) giving
an objective response rate of 27.6%. The disease control rate was 79.3% [170].
Norden et al. [171] analyzed the pattern of recurrence in patients treated with bevacizumab
and irinotecan, and their observations suggest that bevacizumab might more efficiently sup‐
press enhancing tumor recurrence than infiltrative tumor growth. A single-institution phase
II trial using the humanized monoclonal VEGF antibody bevacizumab combined with irino‐
tecan in malignant gliomas has been reported [172]. No central nervous system hemorrhag‐
es were observed. The 6-month PFS rates were 30% and 56% in grade 4 and grade 3 gliomas,
respectively, comparing favorably with historical controls. In a similar study, bevacizumab
plus irinotecan in recurrent malignant gliomas improves responses, progression-free surviv‐
al, and overall survival compared with historical data. Karnofsky performance status of at
least 80% was a predictive factor for response and overall survival [173].
In a recent research was evaluated concurrent bevacizumab with hypofractionated stereo‐
tactic radiation therapy (HSRT) for the treatment of recurrent malignant gliomas. Despite
the promising initial response seen with the addition of HSRT to bevacizumab as salvage
treatment for recurrent gliomas, approximately half of patients ultimately still experience
failure within the radiation field. The rate of local failure with the addition of HSRT seems
to be lower than that seen with bevacizumab alone in the salvage setting [174].
Several studies of bevacizumab in combination with metronomic dosing of temozolomide or
etoposide or with daily erlotinib in recurrent glioma patients are ongoing.
6.1.2. Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR, ErbB1, HER1) is a tyrosine kinase receptor that is
abnormally activated in 70% of solid cancers. EGFR overexpression and immunoreactivity
are more common in primary tumors than in secondary glioblastomas. Activation of EGFR
pathways in cancer cells has been linked to increased motility, adhesion, invasion, and pro‐
liferation of tumor cells as well as inhibition of apoptosis and induction of angiogenesis.
The EGFR transmembrane protein comprises three domains: the extracellular domain, the
transmembrane domain, and the cytoplasmic domain, which harbors the tyrosine kinase ac‐
tivity. Ligand binding (amphiregulin, EGF, transforming growth factor TGF-β, decorin, be‐
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tacellulin, epiregulin, neuroregulin) to the extracellular domain of a monomer results in its
homo- or heterodimerization, inducing phosphorylation of the tyrosine kinase domain, acti‐
vating several signaling pathways, in particular: phosphatidylinositol 3’-kinase/Akt/
mammalian target of rapamycin (mTOR), Ras/mitogen-activated protein kinase (MAPK),
phospholipase C (PLC)/protein kinase C (PKC), and (d) c-Src [175]. These activated path‐
ways are involved in several cell biological processes, including cell proliferation, angiogen‐
esis, migration/adhesion, survival, and differentiation. Approximately 50% of glioblastomas
overexpress EGFR and 25% express a constitutively active mutated form of EGFR. This acti‐
vation occurs through several molecular mechanisms: protein overexpression, reported in
~60% of cases; gene amplification, reported in ~40% of cases; truncated transcripts encoding
for a constitutionally active receptor, reported in ~20% (mainly EGFRvIII) of cases; and mu‐
tation of the extracellular domain (15%) [175]. These alterations, which are quite frequently
combined in the same tumor, activate the EGFR downstream signaling pathways, promot‐
ing the oncogenic process. Therefore, several strategies have been developed in order to
block the EGFR signaling pathway, including small molecule tyrosine kinase inhibitors
(TKIs), monoclonal antibodies, toxin-linked conjugates, and vaccine therapies. However,
caution is needed with EGFR inhibitors, because hypoxia and low glucose levels might con‐
vert the cytotoxic effects of EGFR inhibition into a cytoprotective effect.
Two main EGFR small molecule TKIs have been evaluated in gliomas: gefitinib and erloti‐
nib. These small molecules, which are orally delivered, block the ATP pocket of the EGFR
intracellular tyrosine kinase domain and thus inhibit activation of downstream signaling
pathways.
Growth factor pathway expression using epidermal growth factor receptor (EGFR), mutant
EGFR (EGFRvIII), platelet derived growth factor receptor (PDGFR), C-Kit and C-Abl togeth‐
er with phosphatase and tensin homolog (PTEN) expression and downstream activation of
AKT and phosphorylated ribosomal protein S6 (P70S6K) was analysed in 26 primary glioma
cultures treated with the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and imatinib.
Response for each culture was compared with the EGFR/PDGFR immunocytochemical
pathway profile using hierarchical cluster analysis (HCA) and principal component analysis
(PCA). Erlotinib response was not strongly associated with high expression of the growth
factor pathway components. Increased EGFR expression was associated with gefitinib re‐
sponse; increased PDGFR-α expression was associated with imatinib response. The results
of this in vitro study suggest gefitinib and imatinib may have therapeutic potential in glio‐
mas with a corresponding growth factor receptor expression profile [176].
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor that inhib‐
its cell growth and induces apoptosis in human glioma cells. Gefitinib also induces death of
H4 cells with characteristics of the intrinsic apoptotic pathway, including Bax mitochondrial
translocation, mitochondrial outer membrane permeabilization, cytochrome c cytosolic re‐
lease, and caspase-9/caspase-3 activation. Gefitinib caused Bad dephosphorylation, and in‐
creased its binding preference to Bcl-2 and Bcl-xL. The dephosphorylation of Bad in
gefitinib-treated cells was accompanied by reduced intracellular cyclic AMP content and
protein kinase A (PKA) activity. Adenylyl cyclase activator forskolin attenuated, but PKA
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ing the oncogenic process. Therefore, several strategies have been developed in order to
block the EGFR signaling pathway, including small molecule tyrosine kinase inhibitors
(TKIs), monoclonal antibodies, toxin-linked conjugates, and vaccine therapies. However,
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EGFR (EGFRvIII), platelet derived growth factor receptor (PDGFR), C-Kit and C-Abl togeth‐
er with phosphatase and tensin homolog (PTEN) expression and downstream activation of
AKT and phosphorylated ribosomal protein S6 (P70S6K) was analysed in 26 primary glioma
cultures treated with the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and imatinib.
Response for each culture was compared with the EGFR/PDGFR immunocytochemical
pathway profile using hierarchical cluster analysis (HCA) and principal component analysis
(PCA). Erlotinib response was not strongly associated with high expression of the growth
factor pathway components. Increased EGFR expression was associated with gefitinib re‐
sponse; increased PDGFR-α expression was associated with imatinib response. The results
of this in vitro study suggest gefitinib and imatinib may have therapeutic potential in glio‐
mas with a corresponding growth factor receptor expression profile [176].
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor that inhib‐
its cell growth and induces apoptosis in human glioma cells. Gefitinib also induces death of
H4 cells with characteristics of the intrinsic apoptotic pathway, including Bax mitochondrial
translocation, mitochondrial outer membrane permeabilization, cytochrome c cytosolic re‐
lease, and caspase-9/caspase-3 activation. Gefitinib caused Bad dephosphorylation, and in‐
creased its binding preference to Bcl-2 and Bcl-xL. The dephosphorylation of Bad in
gefitinib-treated cells was accompanied by reduced intracellular cyclic AMP content and
protein kinase A (PKA) activity. Adenylyl cyclase activator forskolin attenuated, but PKA
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inhibitor H89 augmented, gefitinib-induced Bad dephosphorylation, Bax mitochondrial
translocation, caspase-9/caspase-3 activation, and viability loss. Inactivation of PKA sensi‐
tized H4, T98G, and U87 cells to gefitinib cytotoxicity, Bad dephosphorylation in serine-112,
and caspase-9/caspase-3 activation [177].
In a recent study, the molecular effects of the tyrosine kinase inhibitor gefitinib on the EGFR
signaling pathway in human glioblastoma were investigated. Resected glioblastoma tissues
exhibited high concentrations of gefitinib, 20 times higher than respective plasma. However,
no significant effect on 12 pathway constituents was detected. In contrast, in vitro treatment
of a glioblastoma cell line, BS-153, with endogenous EGFRwt amplification and EGFRvIII
expression resulted not only in dephosphorylation of the EGFR, but also of key regulators in
the pathway such as AKT. Treating established xenografts of the same cell line as an in vivo
model showed dephosphorylation of the EGFR without affecting downstream signal trans‐
ductors, similar to the human glioblastoma. Taken together, gefitinib reaches high concen‐
trations in the tumor tissue and efficiently dephosphorylates its target [178]. A phase II
study was designed to assess the safety and efficacy of gefitinib given with and following
radiation therapy in children newly diagnosed with a poor prognosis brainstem glioma. The
observation that a subset of children with this generally fatal tumor experienced long-term
progression-free survival, coupled with recent observations regarding the molecular fea‐
tures of brainstem gliomas, raises the possibility that prospective molecular characterization
may allow enrichment of treatment responders and improvement in outcome results in fu‐
ture studies of biologically targeted agents [179].
Comparative analysis of tissue obtained from patients before and after the start of treatment
suggested that EGFR phosphorylation and downstream signaling were not markedly inhib‐
ited after treatment was started. Two main mechanisms of resistance to small molecule TKIs
have been proposed. First, Stommel et al. [180] showed that several RTKs could be activated
simultaneously in gliomas maintaining activation of RTKs downstream signaling pathways.
Thus, inhibition of one single activated RTK is insufficient and could be easily bypassed by
other activated RTKs [181]. Second, in addition to RTK activation, growth factor receptor
downstream signaling pathways can be activated through a mutation of ras or PTEN or an
amplification of PI3K, inducing redundant activation of the signaling pathways [182].
Haas-Kogan et al. reported that glioblastoma patients whose tumor overexpressed and am‐
plified EGFR gene had a better tumor response to small TKIs than patients whose glioblasto‐
ma did not have these molecular abnormalities. In addition, these investigators showed that
low phospho-PKB/Akt level is associated with a good tumor response to erlotinib [183].
The combination of EGFR inhibitors with inhibitors of mTOR, a distal target of the growth
factor receptor signaling cascade (temsirolimus, sirolimus, everolimus), is a promising strat‐
egy. It became clear that the mechanisms of sensitivity and resistance in gliomas differ from
other types of tumors, such as lung cancer, in that the sensitivity in gliomas does not seem to
be linked to tyrosine kinase domain mutations. In order to achieve higher dosages than pre‐
viously used in clinical trials, we conducted a phase I trial to determine the maximum toler‐
ated dose (MTD) for the combination of erlotinib and sirolimus for the treatments of
recurrent malignant gliomas. The MTD was determined to be 150 mg daily for erlotinib and
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5 mg daily (after a 15 mg loading dose) for sirolimus. The dose-limiting toxicity s included
rash and mucositis, hypophosphatemia, altered mental status, and neutropenia. The combi‐
nation oferlotinib and sirolimus is difficult to tolerate at dosages higher than previously re‐
ported in phase II trials [184].
Ongoing trials of gefitinib, erlotinib, and other EGFR TKIs, such as lapatinib, as well as fur‐
ther tissue analysis of finished trials, may clarify whether selection of patients based on
EGFR overexpression, EGFRvIII, pAKT, and/or PTEN expression could improve results.
Other attempts to overcome resistance include trials combining EGFR TKI with cytotoxic
chemotherapy and radiotherapy as well as the use of new agents that are capable of inhibit‐
ing EGFRvIII-overexpressing cell lines in vitro, such as HKI-272 (an irreversible EGFR TKI)
and AEE788 [185].
A phase 2 study assessed the efficacy and safety of concurrent radiation therapy (RT) and
temozolomide with pharmacodynamic dose escalation of erlotinib in patients with newly
diagnosed GBM. Twenty-seven patients were treated in this study. Twenty-two (81%) pa‐
tients came off study for progressive disease (18 [67%]) or adverse events (4 [15%]). Eighteen
patients (67%) have died. Median progression-free survival was 2.8 months, and the median
overall survival was 8.6 months. Erlotinib co-administered with RT and temozolomide was
not efficacious and had an unacceptable toxicity [186].
Recently,  an EGFR murine humanized monoclonal  antibody,  cetuximab was developed.
Little is known about the efficacy of cetuximab in glioma patients. Recently, a phase I/II
study combining cetuximab, radiation, and temozolomide was initiated in order to assess
the safety and efficacy of this combination as first-line treatment for primary glioblasto‐
ma patients [187].
6.1.3. Platelet-derived growth factor receptor PDGFR
PDGFs are a growth factor family composed of four different polypeptide chains (PDGF-A,
PDGF-B, PDGF-C, and PDGF-D) that exert their cellular effects through two types of protein
tyrosine kinase receptors: PDGFR-a and PDGFR-h. Ligand binding induces receptor dimeri‐
zation, activation, and autophosphorylation of the tyrosine kinase domain, which results in
activation of several signal transduction pathways, including Ras-MAPK, PI3K, Src family
kinase, signal transducers and activators of transcription factors (Stat), and phospholipase
Cg. Overexpression of PDGF and PDGFR has been shown to play a role in the development
of cancer through autocrine stimulation of cancer cells, development of angiogenesis, and
control of tumor interstitial pressure. Animal gliomagenesis models have suggested that
PDGFR pathways not only play a role in proliferation but also have effects on cell differen‐
tiation through dedifferentiation of mature cells, prevention of glial cell differentiation, and
even promotion of cancer stem cells [188]. Inhibition of PDGFR was correlated with de‐
creased phosphorylated extracellular signal-regulated kinase and pAKT levels, suggesting
inhibition of MAPK and PI3K pathways. PDGFR and PDGF are frequently expressed in
gliomas, particularly in secondary glioblastomas and seems to be associated with a poorer
prognosis.
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other types of tumors, such as lung cancer, in that the sensitivity in gliomas does not seem to
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5 mg daily (after a 15 mg loading dose) for sirolimus. The dose-limiting toxicity s included
rash and mucositis, hypophosphatemia, altered mental status, and neutropenia. The combi‐
nation oferlotinib and sirolimus is difficult to tolerate at dosages higher than previously re‐
ported in phase II trials [184].
Ongoing trials of gefitinib, erlotinib, and other EGFR TKIs, such as lapatinib, as well as fur‐
ther tissue analysis of finished trials, may clarify whether selection of patients based on
EGFR overexpression, EGFRvIII, pAKT, and/or PTEN expression could improve results.
Other attempts to overcome resistance include trials combining EGFR TKI with cytotoxic
chemotherapy and radiotherapy as well as the use of new agents that are capable of inhibit‐
ing EGFRvIII-overexpressing cell lines in vitro, such as HKI-272 (an irreversible EGFR TKI)
and AEE788 [185].
A phase 2 study assessed the efficacy and safety of concurrent radiation therapy (RT) and
temozolomide with pharmacodynamic dose escalation of erlotinib in patients with newly
diagnosed GBM. Twenty-seven patients were treated in this study. Twenty-two (81%) pa‐
tients came off study for progressive disease (18 [67%]) or adverse events (4 [15%]). Eighteen
patients (67%) have died. Median progression-free survival was 2.8 months, and the median
overall survival was 8.6 months. Erlotinib co-administered with RT and temozolomide was
not efficacious and had an unacceptable toxicity [186].
Recently,  an EGFR murine humanized monoclonal  antibody,  cetuximab was developed.
Little is known about the efficacy of cetuximab in glioma patients. Recently, a phase I/II
study combining cetuximab, radiation, and temozolomide was initiated in order to assess
the safety and efficacy of this combination as first-line treatment for primary glioblasto‐
ma patients [187].
6.1.3. Platelet-derived growth factor receptor PDGFR
PDGFs are a growth factor family composed of four different polypeptide chains (PDGF-A,
PDGF-B, PDGF-C, and PDGF-D) that exert their cellular effects through two types of protein
tyrosine kinase receptors: PDGFR-a and PDGFR-h. Ligand binding induces receptor dimeri‐
zation, activation, and autophosphorylation of the tyrosine kinase domain, which results in
activation of several signal transduction pathways, including Ras-MAPK, PI3K, Src family
kinase, signal transducers and activators of transcription factors (Stat), and phospholipase
Cg. Overexpression of PDGF and PDGFR has been shown to play a role in the development
of cancer through autocrine stimulation of cancer cells, development of angiogenesis, and
control of tumor interstitial pressure. Animal gliomagenesis models have suggested that
PDGFR pathways not only play a role in proliferation but also have effects on cell differen‐
tiation through dedifferentiation of mature cells, prevention of glial cell differentiation, and
even promotion of cancer stem cells [188]. Inhibition of PDGFR was correlated with de‐
creased phosphorylated extracellular signal-regulated kinase and pAKT levels, suggesting
inhibition of MAPK and PI3K pathways. PDGFR and PDGF are frequently expressed in
gliomas, particularly in secondary glioblastomas and seems to be associated with a poorer
prognosis.
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Clinical studies using the tyrosine kinase inhibitor, imatinib mesylate, in malignant gliomas,
have shown no major inhibition of tumor growth or extension of survival for patients, un‐
like those in chronic myeloid leukemia and gastrointestinal stromal tumors. Phase I data in
malignant gliomas have suggested that use of enzyme-inducing drugs significantly affects
drug metabolization [189]. However, preliminary phase II results of single-agent imatinib
have found only limited efficacy in unselected patients [189-190].
The effects of imatinib on the PDGFR downstream signaling pathways as well as on other
cellular functions in human glioblastoma cells were studied. Western blot analysis demon‐
strated that imatinib was more effective in inhibiting the activated rather than the quiescent
forms of the target proteins. Furthermore, the imatinib treatment induced the sustained acti‐
vation of extracellular signal-regulated kinase (ERK 1/2) signaling as well as components of
other downstream signaling pathways, such as PI3K/Akt, STAT3 and p38MAPK. Further
analysis indicated that the activation of ERK induced by the imatinib treatment was related
to the S-phase re-entry of the cell cycle in one of the three glioma cells. Imatinib significantly
inhibited cell migration but not cell growth. The combination treatment of imatinib with a
MEK or PI3K inhibitor resulted in significant growth inhibition but did not inhibit cell mi‐
gration beyond the inhibition achieved with the imatinib treatment alone [191. In a recent
study has been demonstrated that long-term culture with imatinib mesylate against PDGFR
and c-Kit (stem cell factor receptor) resulted in reduced cancer stem cell ability in glioblasto‐
ma cells through cell differentiation. Derived from RG glioblastoma cells co-cultured with
imatinib for 3 months, RG-IM cells showed distinct properties of cell cycle distribution and
morphology in addition to significantly decreased ability to form aggregates and colonies in
vitro and tumorigenicity in vivo. Furthermore, decreased expression of stem cell markers,
i.e., CD133, Oct-3/4, nestin, and Bmi1, and increased terminal neural cell markers, GFAP,
Tuj1, etc., were identified in RG-IM at the mRNA level [192]. Conversely, using a combina‐
tion of imatinib and hydroxyurea achieved better results compared with imatinib alone or
historical controls [193]. It has been hypothesized that imatinib potentializes hydroxyurea
cytotoxic effects through a decrease in tumor interstitial pressure (which would increase hy‐
droxyurea delivery to tumor cells) and a decrease in DNA repair secondary to imatinib-in‐
duced reduction of Rad 51 expression. The combination of imatinib, hydroxyurea, and
vatalanib, a VEGFR inhibitor, was well tolerated in a phase I trial and has been suggested as
a possible multitargeted regimen for GBM [194].
Sorafenib is an orally available antiangiogenic agent that inhibits tumor cell growth and pro‐
liferation by blocking the action of intracellular and receptor kinases, including PDGFR,
RAF kinase, VEGFR2, and c-KIT. In human glioblastoma cell lines, sorafenib inhibited pro‐
liferation synergistically in combination with bortezomib, a proteosome inhibitor, and rot‐
tlerin, an experimental inhibitor of protein kinase C[195-196]. A phase II trial found that
first-line TMZ and radiotherapy followed by TMZ plus sorafenib was tolerated by patients
with glioblastoma, although preliminary efficacy data for this regimen were similar to data
for standard therapy [197]. It has been postulated that sorafenib and protracted, daily temo‐
zolomide may provide complementary therapeutic benefit among recurrent GBM patients.
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The conclusions of this study showed that sorafenib can be safely administered with daily
temozolomide with a regimen with limited activity for recurrent GBM [198].
Tandutinib is an orally active inhibitor of PDGFR, FLT3, and c-KIT tyrosine kinase activity.
Although no preclinical data have been reported for tandutinib in glioblastoma, 2 early-
phase trials are assessing tandutinib in recurrent or progressive glioblastoma as monothera‐
py or combined with bevacizumab. In a novel study, targeted PDGFR-A mediated tumor
growth in vitro and in vivo using the tyrosine kinase inhibitor,tandutinib (MLN-518), which
strongly inhibits PDGFR-A has been evaluated. Although PDGFR-A inhibition by this agent
resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced
tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360
mg/kg) in vivo [199].
6.1.4. P13K and related pathways
Overactivation of the PI3K/AKT/mTOR pathway seems to play a key role in the down‐
stream signaling pathways promoting growth and survival in several types of tumor cells,
including glioma. Activation of such a pathway is triggered by stimulation of growth factor
receptors (including EGFR, PDGFR, fibroblast growth factor receptor, and insulin-like
growth factor-I receptor) and the Ras pathway, leading to activation of PI3K. Activated PIP3
promotes phosphorylation of AKT through translocation near the cell membrane and activa‐
tion of PDK1 and PDK2. pAKT promotes phosphorylation of several downstream effectors,
including MDM2, p21/p27, Bad, FKHR, nuclear factor-nB, caspase-9, glycogen synthase kin‐
ase-3h, and mTOR. mTOR plays a key role in downstream signaling of the PI3K/AKT path‐
way through the regulation of cellular catabolism, anabolism, proliferation, cell cycle
control, autophagy, angiogenesis, and apoptosis.
In vitro studies have suggested that mTOR activity is particularly highly activated in cells
with deficient PTEN function, including glioma cell lines. Alterations of PTEN expression
are frequent in high-grade gliomas, with PTEN mutations being present in 15% to 40% of
primary glioblastomas [200]. Preclinical studies in gliomas have suggested that PTEN-defi‐
cient tumors show enhanced sensitivity to mTOR inhibition; this provided the rationale for
clinical trials of mTOR inhibitors in glioblastomas [201].
Temsirolimus (CCI-779) is a lipid soluble analog of rapamycin that inhibits mTOR by bind‐
ing to FKBP-12, resulting in cell cycle arrest and decreased growth of several human cancer
cell lines. In a mouse model of PDGF-B driven low-grade gliomas the use of CCI-779 dem‐
onstrated dramatic anti-proliferative effect in these tumors [202]. Again, data from other
studies, demonstrated that the blockade of mTOR with CCI-779 resulted in regional apopto‐
sis and conversion in the character of surviving tumor cells from astrocytoma to oligoden‐
droglioma in a mouse model of Akt+KRas-induced GBMs [203]. In a recent research, a
combination of perifosine and CCI-779 to inhibit Akt and mTOR respectively was adopted.
In vivo, perifosine and CCI-779 showed synergy in inhibiting the PI3K/mTOR axis corre‐
sponding with decreased tumor proliferation and induction of apoptosis [204].
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Clinical studies using the tyrosine kinase inhibitor, imatinib mesylate, in malignant gliomas,
have shown no major inhibition of tumor growth or extension of survival for patients, un‐
like those in chronic myeloid leukemia and gastrointestinal stromal tumors. Phase I data in
malignant gliomas have suggested that use of enzyme-inducing drugs significantly affects
drug metabolization [189]. However, preliminary phase II results of single-agent imatinib
have found only limited efficacy in unselected patients [189-190].
The effects of imatinib on the PDGFR downstream signaling pathways as well as on other
cellular functions in human glioblastoma cells were studied. Western blot analysis demon‐
strated that imatinib was more effective in inhibiting the activated rather than the quiescent
forms of the target proteins. Furthermore, the imatinib treatment induced the sustained acti‐
vation of extracellular signal-regulated kinase (ERK 1/2) signaling as well as components of
other downstream signaling pathways, such as PI3K/Akt, STAT3 and p38MAPK. Further
analysis indicated that the activation of ERK induced by the imatinib treatment was related
to the S-phase re-entry of the cell cycle in one of the three glioma cells. Imatinib significantly
inhibited cell migration but not cell growth. The combination treatment of imatinib with a
MEK or PI3K inhibitor resulted in significant growth inhibition but did not inhibit cell mi‐
gration beyond the inhibition achieved with the imatinib treatment alone [191. In a recent
study has been demonstrated that long-term culture with imatinib mesylate against PDGFR
and c-Kit (stem cell factor receptor) resulted in reduced cancer stem cell ability in glioblasto‐
ma cells through cell differentiation. Derived from RG glioblastoma cells co-cultured with
imatinib for 3 months, RG-IM cells showed distinct properties of cell cycle distribution and
morphology in addition to significantly decreased ability to form aggregates and colonies in
vitro and tumorigenicity in vivo. Furthermore, decreased expression of stem cell markers,
i.e., CD133, Oct-3/4, nestin, and Bmi1, and increased terminal neural cell markers, GFAP,
Tuj1, etc., were identified in RG-IM at the mRNA level [192]. Conversely, using a combina‐
tion of imatinib and hydroxyurea achieved better results compared with imatinib alone or
historical controls [193]. It has been hypothesized that imatinib potentializes hydroxyurea
cytotoxic effects through a decrease in tumor interstitial pressure (which would increase hy‐
droxyurea delivery to tumor cells) and a decrease in DNA repair secondary to imatinib-in‐
duced reduction of Rad 51 expression. The combination of imatinib, hydroxyurea, and
vatalanib, a VEGFR inhibitor, was well tolerated in a phase I trial and has been suggested as
a possible multitargeted regimen for GBM [194].
Sorafenib is an orally available antiangiogenic agent that inhibits tumor cell growth and pro‐
liferation by blocking the action of intracellular and receptor kinases, including PDGFR,
RAF kinase, VEGFR2, and c-KIT. In human glioblastoma cell lines, sorafenib inhibited pro‐
liferation synergistically in combination with bortezomib, a proteosome inhibitor, and rot‐
tlerin, an experimental inhibitor of protein kinase C[195-196]. A phase II trial found that
first-line TMZ and radiotherapy followed by TMZ plus sorafenib was tolerated by patients
with glioblastoma, although preliminary efficacy data for this regimen were similar to data
for standard therapy [197]. It has been postulated that sorafenib and protracted, daily temo‐
zolomide may provide complementary therapeutic benefit among recurrent GBM patients.
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The conclusions of this study showed that sorafenib can be safely administered with daily
temozolomide with a regimen with limited activity for recurrent GBM [198].
Tandutinib is an orally active inhibitor of PDGFR, FLT3, and c-KIT tyrosine kinase activity.
Although no preclinical data have been reported for tandutinib in glioblastoma, 2 early-
phase trials are assessing tandutinib in recurrent or progressive glioblastoma as monothera‐
py or combined with bevacizumab. In a novel study, targeted PDGFR-A mediated tumor
growth in vitro and in vivo using the tyrosine kinase inhibitor,tandutinib (MLN-518), which
strongly inhibits PDGFR-A has been evaluated. Although PDGFR-A inhibition by this agent
resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced
tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360
mg/kg) in vivo [199].
6.1.4. P13K and related pathways
Overactivation of the PI3K/AKT/mTOR pathway seems to play a key role in the down‐
stream signaling pathways promoting growth and survival in several types of tumor cells,
including glioma. Activation of such a pathway is triggered by stimulation of growth factor
receptors (including EGFR, PDGFR, fibroblast growth factor receptor, and insulin-like
growth factor-I receptor) and the Ras pathway, leading to activation of PI3K. Activated PIP3
promotes phosphorylation of AKT through translocation near the cell membrane and activa‐
tion of PDK1 and PDK2. pAKT promotes phosphorylation of several downstream effectors,
including MDM2, p21/p27, Bad, FKHR, nuclear factor-nB, caspase-9, glycogen synthase kin‐
ase-3h, and mTOR. mTOR plays a key role in downstream signaling of the PI3K/AKT path‐
way through the regulation of cellular catabolism, anabolism, proliferation, cell cycle
control, autophagy, angiogenesis, and apoptosis.
In vitro studies have suggested that mTOR activity is particularly highly activated in cells
with deficient PTEN function, including glioma cell lines. Alterations of PTEN expression
are frequent in high-grade gliomas, with PTEN mutations being present in 15% to 40% of
primary glioblastomas [200]. Preclinical studies in gliomas have suggested that PTEN-defi‐
cient tumors show enhanced sensitivity to mTOR inhibition; this provided the rationale for
clinical trials of mTOR inhibitors in glioblastomas [201].
Temsirolimus (CCI-779) is a lipid soluble analog of rapamycin that inhibits mTOR by bind‐
ing to FKBP-12, resulting in cell cycle arrest and decreased growth of several human cancer
cell lines. In a mouse model of PDGF-B driven low-grade gliomas the use of CCI-779 dem‐
onstrated dramatic anti-proliferative effect in these tumors [202]. Again, data from other
studies, demonstrated that the blockade of mTOR with CCI-779 resulted in regional apopto‐
sis and conversion in the character of surviving tumor cells from astrocytoma to oligoden‐
droglioma in a mouse model of Akt+KRas-induced GBMs [203]. In a recent research, a
combination of perifosine and CCI-779 to inhibit Akt and mTOR respectively was adopted.
In vivo, perifosine and CCI-779 showed synergy in inhibiting the PI3K/mTOR axis corre‐
sponding with decreased tumor proliferation and induction of apoptosis [204].
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Recently, was reported that the combination of focal RT and mammalian target of rapamy‐
cin (mTOR) inhibition using clinically relevant concentrations of temsirolimus (CCI-779)
prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. In
vitro, the mTOR inhibitor CCI-779 exerted marked anti-invasive effects, irrespective of the
phosphatase and tensin homolog deleted on chromosome 10 status and counteracted the
proinvasive effect of sublethal irradiation. In this study, the G-protein signaling 4 (RGS4)
was identified as a novel target of mTOR inhibition and a key driver of glioblastoma inva‐
siveness, sensitive to the anti-invasive properties of CCI-779 [205]. A phase II study of tem‐
sirolimus was conducted in children and adolescents with high-grade glioma,
neuroblastoma or rhabdomyosarcoma. Temsirolimus administered weekly at the dose of 75
mg/m(2) did not meet the primary objective efficacy threshold in children with high-grade
glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable dis‐
ease merits further evaluation in combination therapy [206].
Prompted by in vitro evidence of synergism between mTOR inhibitors and EGFR TKI, ongo‐
ing clinical research is concentrating efforts on such combinations, including trials of temsir‐
olimus, everolimus (RAD001), or sirolimus (rapamycin) combined with gefitinib, erlotinib,
or AEE788. A phase I study combining gefitinib and sirolimus in malignant gliomas found
no significant pharmacokinetic interaction between the two drugs. Preliminary results of a
study using gefitinib and everolimus in unselected recurrent glioblastoma patients were re‐
cently presented. Using modified radiographic criteria, responses were found in 31% of pa‐
tients, including partial and minor responses. However, median OS and PFS were not
different from historical controls [207].
Enzastaurin suppress proliferation and induced apoptosis via a caspase-dependent mecha‐
nism in glioblastoma cells in vitro and inhibited growth of human glioblastoma xenografts,
which was accompanied by decreased phosphorylation of downstream signaling molecules,
including GSK-3b [208]. Enzastaurin is a potent a PKC/PI3K/AKT inhibitor, that reduces an‐
giogenesis and has direct cytotoxic activity against glioma cells in preclinical studies. In a
novel study, therapy was well tolerated with thrombosis, thrombocytopenia, hemorrhage,
and elevated alanine aminotransferase as the most commonly observed drug-associated
grade 3 or higher toxicities. The 6-month PFS was 7% for patients with glioblastoma and
16% for patients with anaplastic glioma. Enzastaurin showed, an anti-glioma activity in pa‐
tients with recurrent high-grade glioma, but does not appear to have enough single-agent
activity to be useful as monotherapy [209].
A recent study was conducted in patients with recurrent glioblastoma or newly diagnosed
disease that was not treatable with standard (chemo)radiotherapy. In this phase 1 research,
the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogen‐
ic) enzastaurin in combination with single-agent temozolomide, was evaluated. The recom‐
mended dose for enzastaurin in combination with standard 4-weekly temozolomide is
therefore 500 mg OD. Temozolomide did not appear to effect enzastaurin exposures at the
250 mg or 500 mg OD dose levels [210].
In vivo models showed that enzastaurin combined with radiotherapy synergistically re‐
duced tumor volume, radiation-induced satellite tumor formation, upregulation of VEGF
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expression, neovascularization, and GSK-3b phosphorylation [211]. An open-label, single-
arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT)
to treat glioblastoma multiforme (GBM) and gliosarcoma was reported. Progression-free
survival (PFS), toxicity, and correlations between efficacy and molecular markers analyzed
from tumor tissue samples were also evaluated. The treatment regimen was well tolerated.
Overall survival (median, 74 weeks) and progression-free survival (median, 36 weeks) re‐
sults from the current trial were comparable to those from a prior phase II study using erlo‐
tinib and were significantly better than those from 2 other previous studies that used
thalidomide or cis-retinoic acid, all in combination with temozolomide plus RT [212].
In a phase II study of enzastaurin in patients with recurrent heavily pretreated glioblastoma,
an interim analysis showed that objective radiographic responses occurred in ~20% of pa‐
tients. The subsequent phase III trial comparing lomustine and enzastaurin at first or second
recurrence was the firstphase III trial to evaluate a targeted therapy for recurrent glioblasto‐
ma. However, a planned interim analysis found that enzastaurin treatment did not signifi‐
cantly increase PFS, leading to enrolment being halted [213].
6.1.5. SRC and SRC-family kinases
SRC and SFKs are frequently activated in glioblastoma cell lines and patient samples. SRC
and SFKs are promiscuous regulators of multiple signaling pathways regulating cell growth,
proliferation, adhesion, migration, and invasion, which are important processes in tumor in‐
vasion and metastasis. In particular, SFKs mediate signaling from growth factor receptors
that are commonly overexpressed in GBM. Recently, SRC and FYN (an SFK) were shown to
mediate oncogenic EGFR and EGFRvIII signaling in a rodent GBM model [214].
Dasatinib is a potent inhibitor of SRC and SFK tyrosine kinase activity. Preclinical studies in
a wide variety of solid tumor cell lines, including prostate, breast and glioma, have shown
that dasatinib acts as a cytostatic agent, inhibiting the processes of cell proliferation, inva‐
sion and metastasis. Dasatinib also inhibits the activity of osteoclasts, which have a major
role in the development of metastatic bone lesions. Dasatinib also has inhibitory activity
against c-KIT and PDGFR.
In GBM cells, dasatinib inhibited migration and induced autophagic cell death, and autoph‐
agy was increased by combining dasatinib with TMZ [214-215]. In vivo, dasatinib inhibited
invasion, promoted tumor regression, induced apoptosis in EGFRvIII-expressing glioblasto‐
mas, and enhanced the activity of anti-EGFR antibodies.19 Recently, it has been showed that
dasatinib interacts synergistically with JSI-124, an STAT3/JAK pathway inhibitor. Depletion
of Src and STAT3 by siRNA inhibits cell proliferation and migration, suggesting that Src and
STA3 play a key role in these cellular responses [216].
Recently the efficacy of dasatinib, in patients with recurrent GBM after bevacizumab failure,
was explored. Adult patients were treated with dasatinib 70-100 mg twice daily in combina‐
tion with bevacizumab (n = 14). Of the thirteen evaluable patients, none had a complete or
partial response and only one patient had stable disease after an 8 week interval. Median
progression-free survival (PFS) was 28 days. Median overall survival was 78 days. The
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Recently, was reported that the combination of focal RT and mammalian target of rapamy‐
cin (mTOR) inhibition using clinically relevant concentrations of temsirolimus (CCI-779)
prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. In
vitro, the mTOR inhibitor CCI-779 exerted marked anti-invasive effects, irrespective of the
phosphatase and tensin homolog deleted on chromosome 10 status and counteracted the
proinvasive effect of sublethal irradiation. In this study, the G-protein signaling 4 (RGS4)
was identified as a novel target of mTOR inhibition and a key driver of glioblastoma inva‐
siveness, sensitive to the anti-invasive properties of CCI-779 [205]. A phase II study of tem‐
sirolimus was conducted in children and adolescents with high-grade glioma,
neuroblastoma or rhabdomyosarcoma. Temsirolimus administered weekly at the dose of 75
mg/m(2) did not meet the primary objective efficacy threshold in children with high-grade
glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable dis‐
ease merits further evaluation in combination therapy [206].
Prompted by in vitro evidence of synergism between mTOR inhibitors and EGFR TKI, ongo‐
ing clinical research is concentrating efforts on such combinations, including trials of temsir‐
olimus, everolimus (RAD001), or sirolimus (rapamycin) combined with gefitinib, erlotinib,
or AEE788. A phase I study combining gefitinib and sirolimus in malignant gliomas found
no significant pharmacokinetic interaction between the two drugs. Preliminary results of a
study using gefitinib and everolimus in unselected recurrent glioblastoma patients were re‐
cently presented. Using modified radiographic criteria, responses were found in 31% of pa‐
tients, including partial and minor responses. However, median OS and PFS were not
different from historical controls [207].
Enzastaurin suppress proliferation and induced apoptosis via a caspase-dependent mecha‐
nism in glioblastoma cells in vitro and inhibited growth of human glioblastoma xenografts,
which was accompanied by decreased phosphorylation of downstream signaling molecules,
including GSK-3b [208]. Enzastaurin is a potent a PKC/PI3K/AKT inhibitor, that reduces an‐
giogenesis and has direct cytotoxic activity against glioma cells in preclinical studies. In a
novel study, therapy was well tolerated with thrombosis, thrombocytopenia, hemorrhage,
and elevated alanine aminotransferase as the most commonly observed drug-associated
grade 3 or higher toxicities. The 6-month PFS was 7% for patients with glioblastoma and
16% for patients with anaplastic glioma. Enzastaurin showed, an anti-glioma activity in pa‐
tients with recurrent high-grade glioma, but does not appear to have enough single-agent
activity to be useful as monotherapy [209].
A recent study was conducted in patients with recurrent glioblastoma or newly diagnosed
disease that was not treatable with standard (chemo)radiotherapy. In this phase 1 research,
the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogen‐
ic) enzastaurin in combination with single-agent temozolomide, was evaluated. The recom‐
mended dose for enzastaurin in combination with standard 4-weekly temozolomide is
therefore 500 mg OD. Temozolomide did not appear to effect enzastaurin exposures at the
250 mg or 500 mg OD dose levels [210].
In vivo models showed that enzastaurin combined with radiotherapy synergistically re‐
duced tumor volume, radiation-induced satellite tumor formation, upregulation of VEGF
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expression, neovascularization, and GSK-3b phosphorylation [211]. An open-label, single-
arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT)
to treat glioblastoma multiforme (GBM) and gliosarcoma was reported. Progression-free
survival (PFS), toxicity, and correlations between efficacy and molecular markers analyzed
from tumor tissue samples were also evaluated. The treatment regimen was well tolerated.
Overall survival (median, 74 weeks) and progression-free survival (median, 36 weeks) re‐
sults from the current trial were comparable to those from a prior phase II study using erlo‐
tinib and were significantly better than those from 2 other previous studies that used
thalidomide or cis-retinoic acid, all in combination with temozolomide plus RT [212].
In a phase II study of enzastaurin in patients with recurrent heavily pretreated glioblastoma,
an interim analysis showed that objective radiographic responses occurred in ~20% of pa‐
tients. The subsequent phase III trial comparing lomustine and enzastaurin at first or second
recurrence was the firstphase III trial to evaluate a targeted therapy for recurrent glioblasto‐
ma. However, a planned interim analysis found that enzastaurin treatment did not signifi‐
cantly increase PFS, leading to enrolment being halted [213].
6.1.5. SRC and SRC-family kinases
SRC and SFKs are frequently activated in glioblastoma cell lines and patient samples. SRC
and SFKs are promiscuous regulators of multiple signaling pathways regulating cell growth,
proliferation, adhesion, migration, and invasion, which are important processes in tumor in‐
vasion and metastasis. In particular, SFKs mediate signaling from growth factor receptors
that are commonly overexpressed in GBM. Recently, SRC and FYN (an SFK) were shown to
mediate oncogenic EGFR and EGFRvIII signaling in a rodent GBM model [214].
Dasatinib is a potent inhibitor of SRC and SFK tyrosine kinase activity. Preclinical studies in
a wide variety of solid tumor cell lines, including prostate, breast and glioma, have shown
that dasatinib acts as a cytostatic agent, inhibiting the processes of cell proliferation, inva‐
sion and metastasis. Dasatinib also inhibits the activity of osteoclasts, which have a major
role in the development of metastatic bone lesions. Dasatinib also has inhibitory activity
against c-KIT and PDGFR.
In GBM cells, dasatinib inhibited migration and induced autophagic cell death, and autoph‐
agy was increased by combining dasatinib with TMZ [214-215]. In vivo, dasatinib inhibited
invasion, promoted tumor regression, induced apoptosis in EGFRvIII-expressing glioblasto‐
mas, and enhanced the activity of anti-EGFR antibodies.19 Recently, it has been showed that
dasatinib interacts synergistically with JSI-124, an STAT3/JAK pathway inhibitor. Depletion
of Src and STAT3 by siRNA inhibits cell proliferation and migration, suggesting that Src and
STA3 play a key role in these cellular responses [216].
Recently the efficacy of dasatinib, in patients with recurrent GBM after bevacizumab failure,
was explored. Adult patients were treated with dasatinib 70-100 mg twice daily in combina‐
tion with bevacizumab (n = 14). Of the thirteen evaluable patients, none had a complete or
partial response and only one patient had stable disease after an 8 week interval. Median
progression-free survival (PFS) was 28 days. Median overall survival was 78 days. The
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study demonstrated that Dasatinib in conjunction with bevacizumab does not appear to
have activity in patients with recurrent, heavily pretreated GBM [217].
NVP-AEW541is an inhibitor of insulin-like growth factor-I receptor (IGF-IR) kinase activity
on growth and signaling in a panel of glioma cell lines. NVP-AEW541 blocked phosphoryla‐
tion of IGF-IR in a dose- and time-dependent manner and inhibited proliferation and clono‐
genicity. NVP-AEW541 also induced loss of mitochondrial membrane potential and release
of cytochrome c and apoptosis-inducing factor (AIF) from mitochondria. Combined treat‐
ment with dasatinib and NVP-AEW541 induced significantly more apoptosis than either
agent alone in glioma cells, but not non-neoplastic astrocytes, and synergistically inhibited
clonogenic survival. Mechanistic studies indicated that combination of NVP-AEW541 and
dasatinib significantly reduced pERK and pAkt and markedly increased AIF release, Bax oli‐
gomerization and loss of mitochondrial potential compared to each agent alone. These data
indicate that activation of Bax plays a critical role in mediating NVP-AEW541 and dasatinib-
induced apoptosis, and suggest the potential value of combining IGFR inhibition with other
classes of tyrosine kinase inhibitors to potentiate therapeutic efficacy [218].
6.1.6. Integrin inhibitors
Integrins are transmembrane receptors for the ECM that play a role in cell adhesion and cell
migration, namely, in endothelial cell migration, adhesion, and proliferation during angio‐
genesis. Cilengitide is a cyclic arginine– glycine–aspartic acid containing peptide that binds
to and inhibits αvβ3 and αvβ5 integrins, which are specifically involved in angiogenesis.
Cilengitide induces apoptosis in U87 glioma cells by preventing adherence to vitronectin
and tenascin, matrix protein mediators of brain tumor invasion, and growth [219]. In a
phase I study (n = 51) of recurrent high grade glioma patients, cilengitide was well tolerated
and was demonstrated to have some activity. An objective response was observed in five
patients, with two patients demonstrating prolonged complete responses [220]. The most
notable trial to date was a randomized phase II study of cilengitide, which was associated
with a median survival of 10 months in recurrent glioma patients [221].
A novel study was designed to evaluate the efficacy and tumor delivery of cilengitide in pa‐
tients with recurrent glioblastoma. The study accrued 30 patients with recurrent glioblasto‐
ma and, after recovery from surgery, patients were treated with cilengitide (2000 mg i.v.
twice weekly, maximum of 2 years of treatment). The results confirm drug delivery and pos‐
sibly retention in tumor. This study provides evidence that with established dosing, cilengi‐
tide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent
glioblastoma is modest [222].
In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard
temozolomide  and  radiation  demonstrate  consistent  antitumor  activity  and  a  favorable
safety profile.  Preliminary results of a phase II trial of cilengitide added to radiotherapy
and temozolomide conducted in 52 patients with newly diagnosed glioblastomas suggest‐
ed efficacy in a subgroup of patients, with little or no additional toxicity [223]. A multi‐
center, phase I/IIa study, investigated the efficacy and safety of cilengitide in combination
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications78
with standard chemoradiotherapy in newly diagnosed glioblastoma. Patients were treat‐
ed  with  cilengitide  (500  mg)  administered  twice  weekly  intravenously  in  addition  to
standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was con‐
tinued  until  disease  progression  or  for  up  to  35  weeks.  The  conclusions  demonstrated
that the combination of cilengitide with temozolomide and radiotherapy was well tolerat‐
ed, with no additional toxicity [224]. In a recent study, the mechanisms of cilengitide-in‐
duced cytotoxicity in glioma cells  was evaluated.  The final  data showed that cilengitide
treatment  induced  cell  detachment  in  glioma  cells  plated  on  vitronectin  in  a  dose-de‐
pendent  manner  and  decreased  cell  viability  with  increasing  doses.  Moreover,  the  au‐
thors evidenced that the treatment of glioma cells with cilengitide induced autophagy in
these cells, as demonstrated by puncta LC3-GFP appearance, the increased expression of
LC3II, and increased acidic vacuole formation. Some level of cell apoptosis was observed
in the cilengitide-treated cells only after 48 hours of treatment, following the induction of
autophagy. The pretreatment of the cells  with cilengitide could increase the level of  au‐
tophagy  induced  by  γ-irradiation  and  significantly  decreased  the  viability  of  the  cells
[225].  Nabors  et  al.  examined,  in  a  randomized phase 2  trial,  the  safety and efficacy of
cilengitide when combined with radiation and temozolomide for patients with newly di‐
agnosed glioblastoma multiforme. The authors showed that cilengitide was well tolerated
when  combined  with  standard  chemoradiation  and  may  improve  survival  for  patients
newly diagnosed with glioblastoma multiforme regardless of MGMT methylation status.
The authors concluded that,  from an efficacy and safety standpoint,  future trials  of  this
agent in this population should use the 2000 mg dose [226].
6.2. Antisense strategy
Several approaches are available to manipulate gene expression at the DNA or RNA stage of
protein synthesis. In eukaryotic organism, pre-mRNA is transcribed in the nucleus, introns
are spliced out and then the mature mRNA is exported from the nucleus to cytoplasm. The
small subunit of the ribosome usually starts by binding to one end of the mRNA and is
joined there by other eukaryotic initiation factors, forming the initiation complex. This mul‐
ti-enzymatic complex scans along the mRNA strand until it reaches a start codon, and then
the large subunit of ribosome attaches to the small subunit so that the translation of a pro‐
tein begins. This process, by which the information of a gene is converted into protein, is
referred to as “gene expression”.
Several approaches are available to specifically manipulate gene expression at the DNA or
RNA stage of protein synthesis. An interesting molecular targeting strategy is the introduc‐
tion of single-stranded antisense oligonucleotides, specific molecules involved in cell prolif‐
eration and cell death, to modify gene expression at the translational level. Antisense
oligonucleotides (AONs) are short synthetic single-stranded DNA-sequences, 13-25 nucleo‐
tides long, that bind to and induce the cleavage of homologous stretches of mRNA sequen‐
ces. These result in targeted destruction of mRNA and correction of genetic aberrations.
AONs thus can act as drug molecules and potentially rectify many disease conditions. RNA
and DNA based oligonucleotides are the most prevalent and most practical antisense drugs.
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study demonstrated that Dasatinib in conjunction with bevacizumab does not appear to
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agent alone in glioma cells, but not non-neoplastic astrocytes, and synergistically inhibited
clonogenic survival. Mechanistic studies indicated that combination of NVP-AEW541 and
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tide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent
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In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard
temozolomide  and  radiation  demonstrate  consistent  antitumor  activity  and  a  favorable
safety profile.  Preliminary results of a phase II trial of cilengitide added to radiotherapy
and temozolomide conducted in 52 patients with newly diagnosed glioblastomas suggest‐
ed efficacy in a subgroup of patients, with little or no additional toxicity [223]. A multi‐
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small subunit of the ribosome usually starts by binding to one end of the mRNA and is
joined there by other eukaryotic initiation factors, forming the initiation complex. This mul‐
ti-enzymatic complex scans along the mRNA strand until it reaches a start codon, and then
the large subunit of ribosome attaches to the small subunit so that the translation of a pro‐
tein begins. This process, by which the information of a gene is converted into protein, is
referred to as “gene expression”.
Several approaches are available to specifically manipulate gene expression at the DNA or
RNA stage of protein synthesis. An interesting molecular targeting strategy is the introduc‐
tion of single-stranded antisense oligonucleotides, specific molecules involved in cell prolif‐
eration and cell death, to modify gene expression at the translational level. Antisense
oligonucleotides (AONs) are short synthetic single-stranded DNA-sequences, 13-25 nucleo‐
tides long, that bind to and induce the cleavage of homologous stretches of mRNA sequen‐
ces. These result in targeted destruction of mRNA and correction of genetic aberrations.
AONs thus can act as drug molecules and potentially rectify many disease conditions. RNA
and DNA based oligonucleotides are the most prevalent and most practical antisense drugs.
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Interactions of RNA based AONs with target mRNA inhibit gene expression by interfering
with protein translation without necessarily altering mRNA stability. AONs inhibit mRNA
function by several mechanisms including modulation of splicing and inhibiting protein
translation by disrupting ribosome assembly.
Two different and adjunctive antisense-based approaches to modulate gene expression in‐
to cancer cells are RNA interference (RNAi) and ribozymes. RNAi is mainly responsible
for the post-transcriptional regulation of gene expression but is involved in transcription‐
al  regulation.  RNAi  is  a  process  within  living  cells  that  moderates  the  activity  of  their
genes. RNA interference plays a fundamental role in diverse eukaryotic functions includ‐
ing viral  defence,  chromatin  remodeling,  genome rearrangement,  developmental  timing,
brain morphogenesis, and stem cell maintenance. The power of RNAi lies in the key dis‐
covery  that  endogenous  RNAi  gene  silencing  machinery  can  be  hijacked  to  artificially
regulate genes of interest. The selective effect of RNAi on gene expression makes it a val‐
uable research tool, both in cell culture and in living organisms because synthetic double-
stranded RNA (dsRNA) introduced into cells can induce suppression of specific genes of
interest.
Ribozymes are small oligo-ribo-nucleotides which have a specific base sequence with natu‐
ral self-splicing activity. This activity can be directed against virtually any RNA target by
the inclusion of an antisense region into the ribozyme. Some ribozymes have a self-cleavage
catalytic action while other ones are true catalysts and can carry out RNA slicing by transes‐
terification (splicesome) and peptidyl transfer (in ribosomes). A major disadvantage of ribo‐
zymes at present is that, being ribonucleic acids, they are particularly sensitive to nuclease
degradation. Ribozymes are not generally being considered as agents which may be exoge‐
nously administered. Whilst it should be possible to develop nuclease-resistant ribonucleo‐
tide analogues, present strategies employing ribozymes achieve their delivery by genetic
means, in the form of mini-gene constructs. Ribozymes are now utilized to study gene func‐
tion in HIV disease and in cancer research.
6.2.1. Antisense oligonucleotides
The choice  of  the  target  is  crucial  to  the  potential  success  of  the  therapeutic  approach.
The most interesting targets are involved in apoptosis, cell proliferation, neoangiogenesis
and invasion.
In tumorigenic mice generated by subcutaneous injection of glioma cell lines, overexpres‐
sion of antisense VEGF (C6-VEGF(-/-) mice) significantly suppressed tumor growth, de‐
creased angiogenesis and reduced tumoral edema. Further studies by electron microscope
revealed that tumor-induced hyperpermeability was mediated by formation of vesiculo-va‐
cuolar organelles (VVO), specifically reducing the number of vesicle and caveolae in VVO,
and this effect was partially blocked by antisense VEGF [227].
Recently was evaluated the suitability of folate-PAMAM dendrimer conjugates for efficient
EGFR AON delivery into glioma cells, wherein they release the AON from the FA-PAMAM
to knock down EGFR expression in C6 glioma cells, both in vitro and in vivo. Folic acid was
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coupled to the surface amino groups of G5-PAMAM dendrimer (G5D) through a 1-[3-(dime‐
thylamino)propyl]-3-ethylcarbodiimide bond, and AONs corresponding to rat EGFR were
then complexed with FA-PAMAM. The AON transfection rates mediated by FA-PAMAM
and PAMAM resulting in greater suppression of EGFR expression and glioma cell growth
[228]. In a previous study, was demonstrated that antisense-EGFR transfection inhibited the
growth and transforming phenotype of U87MG cells. In this research, the co-transfection of
U87MG cells with wild-type PTEN and antisense EGFR constructs could inhibit the cellular
growth by 91.7% [229].
Inhibition of PKC-α expression by a synthetic AON inhibits proliferation of C6 glioma cells.
In addition, inhibition of PKC-α expression, has also showed growth inhibition of trans‐
formed U-87 cells transfected with antisense anti-PKC-α oligonucleotide [230]. PKC- α anti‐
sense oligonucleotide treatment in GBM and in A172 GBM cells was accompanied by
reduction in PKC-α levels and the induction of wild-type p53 and insulin-like growth factor-
binding protein-3 (IGFBP3) 24-72 h after treatment. Increased IGFBP3 levels were accompa‐
nied by increased mRNA levels. Recombinant human IGFBP3 induced an apoptotic effect
that was similar to the PKC- α antisense oligonucleotide, and its effect was blocked by IGF-I
[231]. Other potential therapeutic targets are human C-raf kinase and c-Ki-RAS proteins and
signal transduction kinase proteins, involved in the control of proliferation, cellular migra‐
tion and differentiation, and cytoskeletal rearrangements.
In a murine model, was showed the down-regulation of proliferation rate of C6 glioma cells
transfected with antisense AKT2 cDNA construct. Parental C6 cells and C6 cells, transfected
with antisense construct, were implanted through lipofectamine complexes. Dominant-neg‐
ative (DN-AKT2) and antisense AKT2 constructs (AS-AKT2) were transfected into rat C6
glioma cells with elevated endogenous AKT2 expression. AKT2 expression was inhibited in
C6 cells transfected with AS-AKT2 but did not significantly change in cells transfected with
DN-AKT2. The cell migration distance was reduced in cells transfected with DN-AKT2 or
AS-AKT2 compared to the control cells and gelatin zymography showed that the produc‐
tion of MMP2 and MMP9 was inhibited in transfected cells [232]. Edwards et al. targeted the
phosphatidylinositol 3-kinase/protein kinase B (PKB)/Akt and the Ras/MAPK pathway for
their involvement in cell survival and cell proliferation. The glioblastoma cell lines U87MG,
SF-188, and U251MG were transiently transfected with an antisense oligonucleotide target‐
ing ILK (ILKAS) alone or in combination with the Raf-1 inhibitor GW5074 or with the MEK
inhibitor U0126. Glioblastoma cells transfected with ILKAS exhibited reduced levels of ILK
and phosphorylated PKB/Akt on Ser473. These results confirmed that combinations target‐
ing ILK and components of the Ras/MAPK pathway result in synergy and could potentially
be more effective against glioblastoma cancer than monotherapy [233].
During progression of human gliomas, the expression of capillary BM laminins containing
α4 chain switches from the predominant laminin-9 into lanimin-8. Effects of antisense inhib‐
ition of laminin-8 expression in glioma therapy through an in vitro model using human
GBM cell lines M059K and U-87MG co-cultured with normal human brain microvascular
endothelial cells (HBMVEC) have been observed. Laminin-8 and its receptor, integrins α3β1
and α6β1, are important for the functioning of endothelial cell BMs, which play a role in the
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maintenance of the BBB. Laminin-8 plays an important role in glioma cell invasiveness, in
combination with other proteins associated with glioma progression, such as tenascin-C,
MMP-2 and MMP-9. In this study was demonstrated a significant reduction of invasion of
co-cultures through Matrigel and through the use of morpholino oligos against α4 and β1
chains of laminin-8 [234]. The downregulation of laminin α4 chain using AONs inhibits the
motility of human glioma cells was shown. Laminin α4 chain appears to be an important
factor in glioma migration and invasion, both in vitro and in vivo [235].
The antisense modulation of Bcl-2 expression could increase the effectiveness of convention‐
al chemotherapeutic agent. Antisense human bcl-2 cDNA was transfected into human ma‐
lignant glioma cells. The effects of bcl-2 protein down-regulation on glioma cell
morphology, in vitro tumor growth, and tumorigenicity in nude mice, as well as chemosen‐
sitivity to cisplatin, were studied. Expression of antisense bcl-2 cDNA decreased bcl-2 pro‐
tein by more than sixfold. Antisense bcl-2 stable transfectants (AS-bcl-2) showed profound
morphological change, marked retarded cell growth in vitro and significantly increased cy‐
totoxicity of cisplatin [236]. Phase I and II studies are also being done to test G3139 in combi‐
nation with docetaxel in patients with advanced breast cancer, hormone-refractory prostate
cancer, and other solid tumors. By using AONs against the first six codons of the human
Bcl-2 gene transfected into malignant glioma cells (Jon52 and Roc GBM cell lines), has been
demonstrated a decrease in cell growth and an increase in apoptotic death [237]. There is a
link between resistance to chemotherapy in glioblastoma and expression of antiapoptotic
bcl-2 family members, including bcl-XL. Anti-bcl-XL AONs (ISIS 16009, ISIS 16967) in
M059K GBM cell lines have been used and demonstrated a valid correlation between reduc‐
tion of bcl-XL protein expression, induction of intrinsic apoptotic pathway and enhance‐
ment of cytotoxic responses to paclitaxel treatment, resulting in a chemosensitizing effect of
anti-bcl-XL therapy [238].
7. Conclusion
Cerebral gliomas remain essentially resistant to traditional cancer therapy. Radiation thera‐
py is limited to a largely palliative role, and chemotherapy has provided only a modest ben‐
efit in the clinical outcome. Ideally we would analyze tumor tissue in order to confirm
adequate concentrations of our agents; however, the difficulties of accessing brain tumor
samples compared with other tumor samples in systemic cancers make this a difficult task.
This also impedes our validation of biological effects in vivo, a crucial step in the assessment
of new interventions and therapies.
Understanding the genetic bases of gliomas and of the invasive behavior may suggest new
molecular targets to overcome the mechanisms of multi-drug-resistance of the actual thera‐
peutic approaches and to attack at the same time different crucial biological events of glio‐
magenesis. In recent years, basic and preclinical studies have revealed multiple new
mechanisms of gliomagenesis and corresponding targets for treatment. Glioma gene expres‐
sion and its development during gliomagenesis will may help to better understand the role
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of important molecules involved in tumor-safe brain parenchyma relationships. These mole‐
cules, such as ECM proteases, cell adhesion molecules and their related signaling pathways
show an important role in glioma cell migration and invasion and could be selectively attack
to inhibit the glioma invasive rim. Targeted therapies are adopted to disrupt the function of
their targets or deliver toxins to tumor cells expressing the target. However, drugs targeting
single molecules show a limited efficacy, because multiple abnormalities are simultaneously
present in glioma patients. It is clear that the complexity and cross-talk between signal trans‐
duction pathways limits the potential efficacy of targeting a single receptor or molecule. As
a result of a tested preclinical study, clusterin, eukaryotic initiation factor-4E (eIF-4E), integ‐
rins, metalloproteinases and other key molecules (involved in invasion and angiogenesis)
might be possible future interesting molecular targets in glioma therapy. Targeting of multi‐
ple signaling pathways by multitargeted kinase inhibitors or combinations of single-target‐
ed kinase inhibitors may increase treatment efficacies. Parallel to this is the task of
determining the unique molecular and genetic profiles of individual patient tumors so that
the most effective therapies can be selected for those individuals. Targeted agents are likely
to have the greatest potential when used in combination to increase the activity of standard
chemotherapies, broadening the range of pathways inhibited by treatment and/or counter‐
acting mechanisms of resistance. In addition, as for classic cytotoxic agents, an intact BBB
may represent an important impediment limiting the efficacy of targeted therapies.
Nanotechnology provides a unique opportunity to combat cancer on the molecular scale
through careful engineering of nanomedicines to specifically interact with cancer cells and
inhibit cancer cell function. It is also possible to take into neoplastic tissue, novel selective
contrast enhancement molecules to visualize brain tumors and to study in vivo all of their
characteristics, such as cellular proliferation, angiogenesis, necrosis, tumor-safe tissue inter‐
face, and edema. There are significant opportunities to investigate the use of nuclear imag‐
ing techniques such as positron emission tomography (PET) and single-photon emission
computed tomography (SPECT) for development of radiolabeled nanoparticles targeting
cancer. The versatility, sensitivity and tomographic imaging capabilities of these imaging
modalities will provide excellent opportunities for future development of targeted nanopar‐
ticle formulations. The surface of nanoparticles can be modified to achieve targeted delivery
and improved biocompatibility. Compounds may also be encapsulated within the interior
core of nanoparticles for multiple functions. Nanoparticle-based delivery systems could in‐
crease the overcoming of the BBB by the use of drugs with a targeted-cell specificity modali‐
ty. This approach permits the use of a lower dose of drug, a selective drug delivery to target
tumor cells, both into the central core of tumor and into the distal foci of tumor cells within
areas often characterized from integrity of the BBB [239-240]. Considerable effort has been
made toward the research and development of multifunctional nano-particle systems for
cancer targeted imaging and therapy. Theranostic nanomedicine represent an integrated
nanotherapeutic system, which can diagnose, deliver targeted therapy, and monitor the re‐
sponse to therapy. This integration of diagnostic imaging capability with therapeutic inter‐
ventions is critical to addressing the challenges of brain tumor hetereogeneity and
adaptation. As a platform technology, nanomedicine has the advantage of being able to tar‐
get multiple tumor markers and deliver multiple agents simultaneously for synergy in ad‐
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maintenance of the BBB. Laminin-8 plays an important role in glioma cell invasiveness, in
combination with other proteins associated with glioma progression, such as tenascin-C,
MMP-2 and MMP-9. In this study was demonstrated a significant reduction of invasion of
co-cultures through Matrigel and through the use of morpholino oligos against α4 and β1
chains of laminin-8 [234]. The downregulation of laminin α4 chain using AONs inhibits the
motility of human glioma cells was shown. Laminin α4 chain appears to be an important
factor in glioma migration and invasion, both in vitro and in vivo [235].
The antisense modulation of Bcl-2 expression could increase the effectiveness of convention‐
al chemotherapeutic agent. Antisense human bcl-2 cDNA was transfected into human ma‐
lignant glioma cells. The effects of bcl-2 protein down-regulation on glioma cell
morphology, in vitro tumor growth, and tumorigenicity in nude mice, as well as chemosen‐
sitivity to cisplatin, were studied. Expression of antisense bcl-2 cDNA decreased bcl-2 pro‐
tein by more than sixfold. Antisense bcl-2 stable transfectants (AS-bcl-2) showed profound
morphological change, marked retarded cell growth in vitro and significantly increased cy‐
totoxicity of cisplatin [236]. Phase I and II studies are also being done to test G3139 in combi‐
nation with docetaxel in patients with advanced breast cancer, hormone-refractory prostate
cancer, and other solid tumors. By using AONs against the first six codons of the human
Bcl-2 gene transfected into malignant glioma cells (Jon52 and Roc GBM cell lines), has been
demonstrated a decrease in cell growth and an increase in apoptotic death [237]. There is a
link between resistance to chemotherapy in glioblastoma and expression of antiapoptotic
bcl-2 family members, including bcl-XL. Anti-bcl-XL AONs (ISIS 16009, ISIS 16967) in
M059K GBM cell lines have been used and demonstrated a valid correlation between reduc‐
tion of bcl-XL protein expression, induction of intrinsic apoptotic pathway and enhance‐
ment of cytotoxic responses to paclitaxel treatment, resulting in a chemosensitizing effect of
anti-bcl-XL therapy [238].
7. Conclusion
Cerebral gliomas remain essentially resistant to traditional cancer therapy. Radiation thera‐
py is limited to a largely palliative role, and chemotherapy has provided only a modest ben‐
efit in the clinical outcome. Ideally we would analyze tumor tissue in order to confirm
adequate concentrations of our agents; however, the difficulties of accessing brain tumor
samples compared with other tumor samples in systemic cancers make this a difficult task.
This also impedes our validation of biological effects in vivo, a crucial step in the assessment
of new interventions and therapies.
Understanding the genetic bases of gliomas and of the invasive behavior may suggest new
molecular targets to overcome the mechanisms of multi-drug-resistance of the actual thera‐
peutic approaches and to attack at the same time different crucial biological events of glio‐
magenesis. In recent years, basic and preclinical studies have revealed multiple new
mechanisms of gliomagenesis and corresponding targets for treatment. Glioma gene expres‐
sion and its development during gliomagenesis will may help to better understand the role
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of important molecules involved in tumor-safe brain parenchyma relationships. These mole‐
cules, such as ECM proteases, cell adhesion molecules and their related signaling pathways
show an important role in glioma cell migration and invasion and could be selectively attack
to inhibit the glioma invasive rim. Targeted therapies are adopted to disrupt the function of
their targets or deliver toxins to tumor cells expressing the target. However, drugs targeting
single molecules show a limited efficacy, because multiple abnormalities are simultaneously
present in glioma patients. It is clear that the complexity and cross-talk between signal trans‐
duction pathways limits the potential efficacy of targeting a single receptor or molecule. As
a result of a tested preclinical study, clusterin, eukaryotic initiation factor-4E (eIF-4E), integ‐
rins, metalloproteinases and other key molecules (involved in invasion and angiogenesis)
might be possible future interesting molecular targets in glioma therapy. Targeting of multi‐
ple signaling pathways by multitargeted kinase inhibitors or combinations of single-target‐
ed kinase inhibitors may increase treatment efficacies. Parallel to this is the task of
determining the unique molecular and genetic profiles of individual patient tumors so that
the most effective therapies can be selected for those individuals. Targeted agents are likely
to have the greatest potential when used in combination to increase the activity of standard
chemotherapies, broadening the range of pathways inhibited by treatment and/or counter‐
acting mechanisms of resistance. In addition, as for classic cytotoxic agents, an intact BBB
may represent an important impediment limiting the efficacy of targeted therapies.
Nanotechnology provides a unique opportunity to combat cancer on the molecular scale
through careful engineering of nanomedicines to specifically interact with cancer cells and
inhibit cancer cell function. It is also possible to take into neoplastic tissue, novel selective
contrast enhancement molecules to visualize brain tumors and to study in vivo all of their
characteristics, such as cellular proliferation, angiogenesis, necrosis, tumor-safe tissue inter‐
face, and edema. There are significant opportunities to investigate the use of nuclear imag‐
ing techniques such as positron emission tomography (PET) and single-photon emission
computed tomography (SPECT) for development of radiolabeled nanoparticles targeting
cancer. The versatility, sensitivity and tomographic imaging capabilities of these imaging
modalities will provide excellent opportunities for future development of targeted nanopar‐
ticle formulations. The surface of nanoparticles can be modified to achieve targeted delivery
and improved biocompatibility. Compounds may also be encapsulated within the interior
core of nanoparticles for multiple functions. Nanoparticle-based delivery systems could in‐
crease the overcoming of the BBB by the use of drugs with a targeted-cell specificity modali‐
ty. This approach permits the use of a lower dose of drug, a selective drug delivery to target
tumor cells, both into the central core of tumor and into the distal foci of tumor cells within
areas often characterized from integrity of the BBB [239-240]. Considerable effort has been
made toward the research and development of multifunctional nano-particle systems for
cancer targeted imaging and therapy. Theranostic nanomedicine represent an integrated
nanotherapeutic system, which can diagnose, deliver targeted therapy, and monitor the re‐
sponse to therapy. This integration of diagnostic imaging capability with therapeutic inter‐
ventions is critical to addressing the challenges of brain tumor hetereogeneity and
adaptation. As a platform technology, nanomedicine has the advantage of being able to tar‐
get multiple tumor markers and deliver multiple agents simultaneously for synergy in ad‐
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dressing the challenges of cancer hetereogeneity and adaptative resistance. Nanoparticle
drug delivery vehicles have shown the ability to encapsulate a variety of therapeutic agents
such as small molecules (hydrophilic and/or hydrophobic), peptides, protein-based drugs,
and nucleic acids. By encapsulating these molecules inside a nanocarrier, the solubility and
stability of the drugs can be improved, providing an opportunity to reevaluate potential
drugs previously ignored because of poor pharmacokinetics. Encapsulated molecules can be
released from nanocarriers in a controlled manner over time to maintain a drug concentra‐
tion within a therapeutic window or the release can be triggered by some stimulus unique to
the delivery site [241]. The surface of the nanocarrier can be engineered to increase the blood
circulation half-life and influence the bio-distribution, while attachment of targeting ligands
to the surface can result in enhanced uptake by target tissues.
On the basis of the data collected and of the limits of actual standard therapeutic protocol,
we think that targeted therapy represents an interesting approach to modify the biological
development of gliomas, probably trying to modulate crucial pathways of gliomagenesis
during precocious steps of tumor progression and more molecular targets of the same path‐
way or of two different pathways.
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drugs previously ignored because of poor pharmacokinetics. Encapsulated molecules can be
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the delivery site [241]. The surface of the nanocarrier can be engineered to increase the blood
circulation half-life and influence the bio-distribution, while attachment of targeting ligands
to the surface can result in enhanced uptake by target tissues.
On the basis of the data collected and of the limits of actual standard therapeutic protocol,
we think that targeted therapy represents an interesting approach to modify the biological
development of gliomas, probably trying to modulate crucial pathways of gliomagenesis
during precocious steps of tumor progression and more molecular targets of the same path‐
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1. Introduction
Malignant gliomas are not only the most frequent primary brain tumor in the adult pop‐
ulation,  but  also  the  most  aggressive.  Despite  recent  therapeutic  advances,  they  remain
associated with  high morbidity  and mortality.  determinant  of  key biological  features  of
these tumors, like their response, resistance, and patterns of recurrence when challenged
by standard and new therapeutic options. Glioblastoma multiforme (GBM), the most ag‐
gressive  of  the  astrocytic  neoplasms,  is  characterized  by  both  necrosis  as  well  as  high
rates of endothelial proliferation and neo-vascularization. that generates a high consump‐
tion of oxygen and nutrients, thus leading to local hypoxia. The latter activates a cascade
of  signaling  pathways  leading  to:  1)  angiogenesis,  2)  enhanced  motility/invasion,  3)
changes in metabolism, and 4)  the ability to survive oxidative stress.  This  is  a  dynamic
and multifactorial process whose outcome, either death or survival,  is dependent on the
timing and the rates of each of these processes,  as well  as on the molecular characteris‐
tics of the tumor. Therefore,  hypoxia-induced enhancement of motility/invasion may de‐
termine  the  outcome  and  response  to  therapy  of  a  particular  GBM.  We  seek  a  better
understanding of  the  molecular  and phenotypic  effects  of  local  hypoxia  in  GBM.  Here,
we review the definition of hypoxia and its  molecular and phenotypic effects on cancer
cells in general and then turn our attention to its impact on malignant glioma cells.  We
also  examine  the  interplay  between  anti-angiogenesis,  survival,  and  enhanced  motility,
and explore  potential  therapeutic  implications.  We close  with unresolved questions  and
potential future directions.
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2. Malignant gliomas
2.1. Overview of gliomas
Central nervous system (CNS) neoplasms are a diverse group that varies widely in terms of
clinical presentation, aggressiveness, and response to therapy, with distinctions in histology
and cellular composition being largely responsible for these differences (Brat and Mapstone
2003). Of the many different types of brain tumors, gliomas are the most frequent primary
brain tumors in adults (Ricard, Idbaih et al. 2012). Lower grade tumors, such as grades I and
II, are commonly well-differentiated with limited amounts of increased cell density and oth‐
er abnormalities. Grade III astrocytomas are anaplastic and have increased vessel and cell
density, cellular atypia, and increased mitotic activity. GBM, grade IV, is characterized by
the presence of necrosis and endothelial proliferation (Brat and Mapstone 2003; Westphal
and Lamszus 2011).
2.2. Significance of malignant gliomas
The annual incidence of malignant gliomas is approximately 4 to 5 per 100 thousand and
this group accounts for approximately 70% of the total number of new cases of malignant
primary brain tumors diagnosed in the United States each year (Wen and Kesari 2008; Wen,
Macdonald et al. 2010). The overall incidence of gliomas is higher among males as compared
to females (7.2 per 100,000 persons-years in males versus 5.0 per 100,000-person years in fe‐
males) and it is also highest among Caucasians, as compared to other ethnic groups (Peak
and Levin 2010). Malignant gliomas can occur in any age group however the incidence in‐
creases in the fifth decade of life and peaks at about 65 years of age (Brat and Mapstone
2003). GBM is the most aggressive glioma. Stupp and colleagues reported that patients treat‐
ed with concomitant and adjuvant Temozolomide and radiotherapy had overall survival
(OS) rates of 27.2 and 9.8 percent at 2 and 5 years, respectively (Stupp, Mason et al. 2005;
Stupp, Hegi et al. 2009).
3. Hypoxia
3.1. Definition of hypoxia
Oxygen plays a central role in cell biology and human cells require constant and adequate
supply of oxygen. Oxygen functions as the terminal electron acceptor in the process of mito‐
chondrial respiration, the process by which ATP is generated for use in most biochemical
reactions (Semenza 2012; Semenza 2012). Hypoxia is a term used to describe reduced levels
of oxygen and can be defined as a condition in which the oxygen pressure in the environ‐
ment is less than 5 to 10 mmHg (Lu and Kang 2010). Hypoxia typically ranges from 0.1 per‐
cent to 3 percent oxygen, with exact definitions varying according to individual researchers
(Wang, Jiang et al. 1995; Semenza 1998; Ke and Costa 2006; Palazon, Aragones et al. 2012).
Normoxia for tissue culture experiments is considered approximately 21 percent oxygen. to
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meet consumption. For example, a local environment including a large number of metabol‐
ically active cancer cells may be hypoxic when the oxygen supply is not enhanced; to pre‐
vent hypoxia, supply must be increased. Factors that contribute to hypoxia include low
partial pressure of oxygen in the blood, reduced ability of blood to carry oxygen, reduced
tissue perfusion, increased diffusion distances, or inability of cells to use oxygen (Hockel
and Vaupel 2001). Hypoxia is threatening to the normal cellular environment and a series of
highly regulated and coordinated response-mechanisms are necessary in order for cells to
survive in hypoxic environments (Wheaton and Chandel 2011).
3.2. Hypoxia and tumor cells
One of the characteristics of cancer cells is deregulated, high cellular proliferation that ulti‐
mately results in structurally and functionally abnormal blood vessels that are unable to
provide an adequate amount of oxygen to meet the increased metabolic demands of prolif‐
eration, which ultimately results in hypoxia (Vaupel, Kallinowski et al. 1989; Harris 2002;
Semenza 2012). Although indirect evidence for hypoxia in human tumors was first reported
in the 1950s, Peter Vaupel and colleagues were among the first researchers to demonstrate
direct evidence of hypoxia in human cancers, as well as linking hypoxia with increased
metastasis and poor prognosis in patients with squamous tumors of the head and neck, cer‐
vical cancers, and breast cancers (Thomlinson and Gray 1955; Hockel, Schlenger et al. 1999;
Hockel and Vaupel 2001; Harris 2002).
Tumor cells generally respond to hypoxia in 1 of 2 ways: either cellular proliferation is re‐
stricted and apoptosis and necrosis may occur or the tumor cells adapt to the stress of the
hypoxic environment and become more aggressive (Vaupel 2008). This adaptation towards
a more aggressive phenotype is accomplished by regulating the expression of various genes
that have critical roles in cellular events, which include cellular proliferation, differentiation,
tumor glycolysis, angiogenesis, and metastasis and invasion (Vaupel 2004; Lu and Kang
2010; Semenza 2012). Additionally, tumor cells not only acquire more invasive and metastat‐
ic properties in response to hypoxia, but also become more resistant to standard treatments,
such as chemotherapies and radiation therapies (Semenza 2012). Hypoxia-associated resist‐
ance to radiation therapy can occur when the partial pressure of oxygen in a tumor is less
than 25-30 mmHg. The mechanism of this resistance is thought to be multi-factorial, howev‐
er some proposed possibilities include decreased oxygen concentrations, higher levels of
heat shock proteins, and the presence of cells with decreased apoptotic potential (Hockel
and Vaupel 2001). Hypoxia-induced resistance to chemotherapy is likely affected by inhibi‐
tion of cellular proliferation, decreased effectiveness of some agents in the setting of hypo‐
xia, tissue acidosis, and/or the loss of apoptotic potential of cells (Hockel and Vaupel 2001).
4. Molecular signals of hypoxia
Hypoxia-inducible factor (HIF) is a transcription factor that plays a critical a central role in
mediating the ability to adapt to low-oxygen concentrations (Wang, Jiang et al. 1995; Semen‐
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and Lamszus 2011).
2.2. Significance of malignant gliomas
The annual incidence of malignant gliomas is approximately 4 to 5 per 100 thousand and
this group accounts for approximately 70% of the total number of new cases of malignant
primary brain tumors diagnosed in the United States each year (Wen and Kesari 2008; Wen,
Macdonald et al. 2010). The overall incidence of gliomas is higher among males as compared
to females (7.2 per 100,000 persons-years in males versus 5.0 per 100,000-person years in fe‐
males) and it is also highest among Caucasians, as compared to other ethnic groups (Peak
and Levin 2010). Malignant gliomas can occur in any age group however the incidence in‐
creases in the fifth decade of life and peaks at about 65 years of age (Brat and Mapstone
2003). GBM is the most aggressive glioma. Stupp and colleagues reported that patients treat‐
ed with concomitant and adjuvant Temozolomide and radiotherapy had overall survival
(OS) rates of 27.2 and 9.8 percent at 2 and 5 years, respectively (Stupp, Mason et al. 2005;
Stupp, Hegi et al. 2009).
3. Hypoxia
3.1. Definition of hypoxia
Oxygen plays a central role in cell biology and human cells require constant and adequate
supply of oxygen. Oxygen functions as the terminal electron acceptor in the process of mito‐
chondrial respiration, the process by which ATP is generated for use in most biochemical
reactions (Semenza 2012; Semenza 2012). Hypoxia is a term used to describe reduced levels
of oxygen and can be defined as a condition in which the oxygen pressure in the environ‐
ment is less than 5 to 10 mmHg (Lu and Kang 2010). Hypoxia typically ranges from 0.1 per‐
cent to 3 percent oxygen, with exact definitions varying according to individual researchers
(Wang, Jiang et al. 1995; Semenza 1998; Ke and Costa 2006; Palazon, Aragones et al. 2012).
Normoxia for tissue culture experiments is considered approximately 21 percent oxygen. to
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meet consumption. For example, a local environment including a large number of metabol‐
ically active cancer cells may be hypoxic when the oxygen supply is not enhanced; to pre‐
vent hypoxia, supply must be increased. Factors that contribute to hypoxia include low
partial pressure of oxygen in the blood, reduced ability of blood to carry oxygen, reduced
tissue perfusion, increased diffusion distances, or inability of cells to use oxygen (Hockel
and Vaupel 2001). Hypoxia is threatening to the normal cellular environment and a series of
highly regulated and coordinated response-mechanisms are necessary in order for cells to
survive in hypoxic environments (Wheaton and Chandel 2011).
3.2. Hypoxia and tumor cells
One of the characteristics of cancer cells is deregulated, high cellular proliferation that ulti‐
mately results in structurally and functionally abnormal blood vessels that are unable to
provide an adequate amount of oxygen to meet the increased metabolic demands of prolif‐
eration, which ultimately results in hypoxia (Vaupel, Kallinowski et al. 1989; Harris 2002;
Semenza 2012). Although indirect evidence for hypoxia in human tumors was first reported
in the 1950s, Peter Vaupel and colleagues were among the first researchers to demonstrate
direct evidence of hypoxia in human cancers, as well as linking hypoxia with increased
metastasis and poor prognosis in patients with squamous tumors of the head and neck, cer‐
vical cancers, and breast cancers (Thomlinson and Gray 1955; Hockel, Schlenger et al. 1999;
Hockel and Vaupel 2001; Harris 2002).
Tumor cells generally respond to hypoxia in 1 of 2 ways: either cellular proliferation is re‐
stricted and apoptosis and necrosis may occur or the tumor cells adapt to the stress of the
hypoxic environment and become more aggressive (Vaupel 2008). This adaptation towards
a more aggressive phenotype is accomplished by regulating the expression of various genes
that have critical roles in cellular events, which include cellular proliferation, differentiation,
tumor glycolysis, angiogenesis, and metastasis and invasion (Vaupel 2004; Lu and Kang
2010; Semenza 2012). Additionally, tumor cells not only acquire more invasive and metastat‐
ic properties in response to hypoxia, but also become more resistant to standard treatments,
such as chemotherapies and radiation therapies (Semenza 2012). Hypoxia-associated resist‐
ance to radiation therapy can occur when the partial pressure of oxygen in a tumor is less
than 25-30 mmHg. The mechanism of this resistance is thought to be multi-factorial, howev‐
er some proposed possibilities include decreased oxygen concentrations, higher levels of
heat shock proteins, and the presence of cells with decreased apoptotic potential (Hockel
and Vaupel 2001). Hypoxia-induced resistance to chemotherapy is likely affected by inhibi‐
tion of cellular proliferation, decreased effectiveness of some agents in the setting of hypo‐
xia, tissue acidosis, and/or the loss of apoptotic potential of cells (Hockel and Vaupel 2001).
4. Molecular signals of hypoxia
Hypoxia-inducible factor (HIF) is a transcription factor that plays a critical a central role in
mediating the ability to adapt to low-oxygen concentrations (Wang, Jiang et al. 1995; Semen‐
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za 1998). One of the primary cellular events in response to the initial exposure to hypoxia is
activation of hypoxia-inducible factor 1 (HIF-1), a hetero-dimeric basic helix-loop-helix pro‐
tein, composed of 2 subunits: HIF-1α, which is up-regulated in an oxygen-dependent man‐
ner, and HIF-1β, which is constitutively expressed (Semenza 2000; Lee, Bae et al. 2004; Zhu,
Zhou et al. 2011). Over-expression of HIF-1α is seen in many cancer types associated with a
poor prognosis, like malignancies of the brain, oropharynx, breast, cervix, ovary, and uterus
(Semenza 2003; Lu and Kang 2010).
Hypoxia-inducible factor-2 alpha (HIF-2α) is another mammalian protein that appears to
play  a  role  in  the  cellular  response  to  hypoxia  (Hu,  Wang  et  al.  2003;  Semenza  2012).
HIF-2α  is  structurally  similar  to  HIF-1α,  sharing  48  percent  of  the  overall  amino  acid
identity (Hu, Wang et al. 2003; Ke and Costa 2006). Unlike HIF-1α, which is ubiquitous‐
ly  expressed,  HIF-2α  is  mainly  expressed  in  the  lung,  endothelium,  and  carotid  body
(Kaur,  Khwaja  et  al.  2005;  Ke and Costa  2006).  recently  been discovered;  its  splice  var‐
iants appear to play a role as negative regulators of HIF-1 (Gu, Moran et al. 1998; Maki‐
no,  Cao  et  al.  2001;  Ke  and  Costa  2006).  Other  important  transcription  factors  that  are
activated  by  hypoxia  include  cyclic-AMP-response  element-binding  protein  (CREB),  nu‐
clear  factor-κB  (NF-κB),  activating  protein-1  (AP-1),  and  metal-responsive  transcription
factor-1 (MTF-1) (Harris 2002; Vaupel 2004).
4.1. Mechanisms of hypoxia-induced signaling
Under normal oxygen conditions, HIF-1α is hydroxylated by prolyl hydroxylase (PHD).
This hydroxylation leads to the recognition and binding of von Hippel-Lindau (VHL),
which is part of an E3 ubiquitin ligase complex that targets HIF-1α for degradation through
a proteasomal pathway (Wheaton and Chandel 2011; Semenza 2012). hypoxic conditions,
the hydroxylation of the HIF-1α subunit by PHD is inhibited and, therefore, HIF-1α is stabi‐
lized, resulting in its translocation to the cell nucleus where it dimerizes with the HIF-1β
subunit and forms the active HIF-1. Activation of HIF-1 subsequently results in the recruit‐
ment of transcriptional co-activators and this complex then binds to consensus hypoxia-re‐
sponsive elements (HREs) within the promoter regions of target genes and initiates the
transcription of a variety of hypoxia-responsive genes (Vaupel 2004). These genes can be
grouped into 4 functional categories (see Figure), namely, survival/proliferation, metabo‐
lism, angiogenesis, and invasion/metastasis (Lu and Kang 2010).
4.2. Effects on cell proliferation and survival
Increased rates of cell proliferation and decreased rates of cell death are 2 of the defining dif‐
ferences between neoplastic cells and normal cells. HIF-1 plays an important role in cellular
proliferation. Iyer et al. demonstrated that cells deficient in HIF-1α have reduced rates of cel‐
lular proliferation as compared to wild-type cells under both normoxic and hypoxic condi‐
tions, with the degree of reduction worsened in hypoxia (Iyer, Kotch et al. 1998; Feldser,
Agani et al. 1999). Additionally, several growth factors that contribute to increased cell pro‐
liferation are also HIF-1 target genes. insulin-like growth factor-2 (IGF2) and transforming-
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growth factor-alpha (TGF-α) (Feldser, Agani et al. 1999; Krishnamachary, Berg-Dixon et al.
2003). Binding of these factors to their receptors, namely insulin-like growth factor recep‐
tor-1 (IGFR1) and epidermal growth-factor receptor (EGFR), respectively, leads to autocrine
signaling, resulting in both increased cell proliferation and survival as well as increased ex‐
pression of HIF-1 (Semenza 2003; Ke and Costa 2006). These autocrine signaling pathways
are necessary for cancer progression (Semenza 2003).
4.3. Effects on metabolism
The uptake of glucose by metastatic cancer cells is markedly increased as compared to non-
cancer cells and under hypoxic conditions cells switch from the oxygen-dependent metabol‐
ic pathway, the tricarboxylic acid (TCA) cycle, to the oxygen-independent pathway,
glycolysis (Dang and Semenza 1999; Ke and Costa 2006). HIF-1 plays an active role in this
metabolic response to hypoxia by up-regulating the expression of glycolytic enzymes, such
as aldolase A, phosphoglycerate kinase 1, and lactate dehydrogenase, that convert glucose
to lactate (Vaupel 2004). HIF-1 also induces the over-expression of glucose transporters,
namely GLUT1 and GLUT3, that facilitate the uptake of glucose by the cells (Chen, Pore et
al. 2001; Ke and Costa 2006; Semenza 2012). While it is well known that HIF-1 stimulates
glycolysis, it has also been demonstrated that it can actively repress mitochondrial function
and oxygen consumption by inducing pyruvate dehydrogenase kinase 1 (PDK1). Papan‐
dreou et al nicely demonstrated that HIF-1-dependent block of oxygen utilization results in
increased oxygen availability and in decreased cell death when total oxygen is limiting (Pa‐
pandreou, Cairns et al. 2006). In a feedback loop, this leads to a shut-down of the formation
of mitochondrial acetyl-CoA and oxidative phosphorylation (OXPHOS), which in turn re‐
duces the generation of mitochondrial Reactive Oxygen Species (ROS) and contributes to the
generation of lactate that can be used to acidify the microenvironment leading to increase
invasion and migration. Additionally, a very elegant study by Guzy et al. (2005 Cell metabo‐
lism) found that functionality of complex III of the mitochondrial electron transport chain
(ETC) is required for the hypoxic stabilization of HIF-1α and HIF-2α and that an increase in
ROS links this complex to HIF-alpha stabilization (Guzy, Hoyos et al. 2005). This important
study linked an oxygen-dependent pathway to the stabilization of HIF-1. Thus, while HIF-1
controls glycolysis and shuts-down OXPHOS, functional mitochondria play a role in the
regulation of HIF-1.
4.4. Effects on angiogenesis
Lee et. al demonstrated that inhibition of HIF-1 activity by either anthracycline chemothera‐
py or acriflavine prevents tumor vascularization in mouse models, thus lending support to
the idea that HIF-1 activity is critical in tumor vascularization (Lee, Qian et al. 2009; Lee,
Zhang et al. 2009; Semenza 2012). Angiogenesis is a complex process by which the vascular
system is formed through growth of new capillaries from pre-existing vessels (Wang, Fei et
al. 2004). In addition, although there is great diversity in the factors and signals that contrib‐
ute to angiogenesis, the chemical signal that appears to play the most critical role in the
process is Vascular Endothelial Growth Factor, or VEGF. VEGF is a pro-angiogenic growth
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za 1998). One of the primary cellular events in response to the initial exposure to hypoxia is
activation of hypoxia-inducible factor 1 (HIF-1), a hetero-dimeric basic helix-loop-helix pro‐
tein, composed of 2 subunits: HIF-1α, which is up-regulated in an oxygen-dependent man‐
ner, and HIF-1β, which is constitutively expressed (Semenza 2000; Lee, Bae et al. 2004; Zhu,
Zhou et al. 2011). Over-expression of HIF-1α is seen in many cancer types associated with a
poor prognosis, like malignancies of the brain, oropharynx, breast, cervix, ovary, and uterus
(Semenza 2003; Lu and Kang 2010).
Hypoxia-inducible factor-2 alpha (HIF-2α) is another mammalian protein that appears to
play  a  role  in  the  cellular  response  to  hypoxia  (Hu,  Wang  et  al.  2003;  Semenza  2012).
HIF-2α  is  structurally  similar  to  HIF-1α,  sharing  48  percent  of  the  overall  amino  acid
identity (Hu, Wang et al. 2003; Ke and Costa 2006). Unlike HIF-1α, which is ubiquitous‐
ly  expressed,  HIF-2α  is  mainly  expressed  in  the  lung,  endothelium,  and  carotid  body
(Kaur,  Khwaja  et  al.  2005;  Ke and Costa  2006).  recently  been discovered;  its  splice  var‐
iants appear to play a role as negative regulators of HIF-1 (Gu, Moran et al. 1998; Maki‐
no,  Cao  et  al.  2001;  Ke  and  Costa  2006).  Other  important  transcription  factors  that  are
activated  by  hypoxia  include  cyclic-AMP-response  element-binding  protein  (CREB),  nu‐
clear  factor-κB  (NF-κB),  activating  protein-1  (AP-1),  and  metal-responsive  transcription
factor-1 (MTF-1) (Harris 2002; Vaupel 2004).
4.1. Mechanisms of hypoxia-induced signaling
Under normal oxygen conditions, HIF-1α is hydroxylated by prolyl hydroxylase (PHD).
This hydroxylation leads to the recognition and binding of von Hippel-Lindau (VHL),
which is part of an E3 ubiquitin ligase complex that targets HIF-1α for degradation through
a proteasomal pathway (Wheaton and Chandel 2011; Semenza 2012). hypoxic conditions,
the hydroxylation of the HIF-1α subunit by PHD is inhibited and, therefore, HIF-1α is stabi‐
lized, resulting in its translocation to the cell nucleus where it dimerizes with the HIF-1β
subunit and forms the active HIF-1. Activation of HIF-1 subsequently results in the recruit‐
ment of transcriptional co-activators and this complex then binds to consensus hypoxia-re‐
sponsive elements (HREs) within the promoter regions of target genes and initiates the
transcription of a variety of hypoxia-responsive genes (Vaupel 2004). These genes can be
grouped into 4 functional categories (see Figure), namely, survival/proliferation, metabo‐
lism, angiogenesis, and invasion/metastasis (Lu and Kang 2010).
4.2. Effects on cell proliferation and survival
Increased rates of cell proliferation and decreased rates of cell death are 2 of the defining dif‐
ferences between neoplastic cells and normal cells. HIF-1 plays an important role in cellular
proliferation. Iyer et al. demonstrated that cells deficient in HIF-1α have reduced rates of cel‐
lular proliferation as compared to wild-type cells under both normoxic and hypoxic condi‐
tions, with the degree of reduction worsened in hypoxia (Iyer, Kotch et al. 1998; Feldser,
Agani et al. 1999). Additionally, several growth factors that contribute to increased cell pro‐
liferation are also HIF-1 target genes. insulin-like growth factor-2 (IGF2) and transforming-
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growth factor-alpha (TGF-α) (Feldser, Agani et al. 1999; Krishnamachary, Berg-Dixon et al.
2003). Binding of these factors to their receptors, namely insulin-like growth factor recep‐
tor-1 (IGFR1) and epidermal growth-factor receptor (EGFR), respectively, leads to autocrine
signaling, resulting in both increased cell proliferation and survival as well as increased ex‐
pression of HIF-1 (Semenza 2003; Ke and Costa 2006). These autocrine signaling pathways
are necessary for cancer progression (Semenza 2003).
4.3. Effects on metabolism
The uptake of glucose by metastatic cancer cells is markedly increased as compared to non-
cancer cells and under hypoxic conditions cells switch from the oxygen-dependent metabol‐
ic pathway, the tricarboxylic acid (TCA) cycle, to the oxygen-independent pathway,
glycolysis (Dang and Semenza 1999; Ke and Costa 2006). HIF-1 plays an active role in this
metabolic response to hypoxia by up-regulating the expression of glycolytic enzymes, such
as aldolase A, phosphoglycerate kinase 1, and lactate dehydrogenase, that convert glucose
to lactate (Vaupel 2004). HIF-1 also induces the over-expression of glucose transporters,
namely GLUT1 and GLUT3, that facilitate the uptake of glucose by the cells (Chen, Pore et
al. 2001; Ke and Costa 2006; Semenza 2012). While it is well known that HIF-1 stimulates
glycolysis, it has also been demonstrated that it can actively repress mitochondrial function
and oxygen consumption by inducing pyruvate dehydrogenase kinase 1 (PDK1). Papan‐
dreou et al nicely demonstrated that HIF-1-dependent block of oxygen utilization results in
increased oxygen availability and in decreased cell death when total oxygen is limiting (Pa‐
pandreou, Cairns et al. 2006). In a feedback loop, this leads to a shut-down of the formation
of mitochondrial acetyl-CoA and oxidative phosphorylation (OXPHOS), which in turn re‐
duces the generation of mitochondrial Reactive Oxygen Species (ROS) and contributes to the
generation of lactate that can be used to acidify the microenvironment leading to increase
invasion and migration. Additionally, a very elegant study by Guzy et al. (2005 Cell metabo‐
lism) found that functionality of complex III of the mitochondrial electron transport chain
(ETC) is required for the hypoxic stabilization of HIF-1α and HIF-2α and that an increase in
ROS links this complex to HIF-alpha stabilization (Guzy, Hoyos et al. 2005). This important
study linked an oxygen-dependent pathway to the stabilization of HIF-1. Thus, while HIF-1
controls glycolysis and shuts-down OXPHOS, functional mitochondria play a role in the
regulation of HIF-1.
4.4. Effects on angiogenesis
Lee et. al demonstrated that inhibition of HIF-1 activity by either anthracycline chemothera‐
py or acriflavine prevents tumor vascularization in mouse models, thus lending support to
the idea that HIF-1 activity is critical in tumor vascularization (Lee, Qian et al. 2009; Lee,
Zhang et al. 2009; Semenza 2012). Angiogenesis is a complex process by which the vascular
system is formed through growth of new capillaries from pre-existing vessels (Wang, Fei et
al. 2004). In addition, although there is great diversity in the factors and signals that contrib‐
ute to angiogenesis, the chemical signal that appears to play the most critical role in the
process is Vascular Endothelial Growth Factor, or VEGF. VEGF is a pro-angiogenic growth
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factor that is secreted by many cells, including mesenchymal, stromal, and especially tumor
cells. VEGF induces the migration of the endothelial precursor cells to sites of angiogenesis
and is also responsible for the proliferation and differentiation of these cells (Ahluwalia and
Gladson 2010). (Kaur, Khwaja et al. 2005). Interestingly, HIF-1 activates the transcription of
VEGF by binding to the HRE in its promoter region (Forsythe, Jiang et al. 1996; Kaur, Khwa‐
ja et al. 2005). Hypoxia also increases VEGF production by stabilizing its mRNA; this effect
is mediated by the 3’ un-translated region of the mRNA (Onesto, Berra et al. 2004; Kaur,
Khwaja et al. 2005). Moreover, HIF-1 up-regulates the expression of additional key mole‐
cules that induce angiogenesis, including stromal-derived factor 1 (SDF1), placental growth
factor (PGF), platelet-derived growth factor B (PDGFB), and angiopoietin (ANGPT) 1 and 2
(Rey and Semenza 2010; Semenza 2012). These pro-angiogenic genes increase vascular den‐
sity, thus supplying oxygen and nutrients to metabolically demanding tumor cells (Ke and
Costa 2006).
4.5. Effects of hypoxia on tumor invasion and motility
Metastasis is a complex process that consists of a series of highly regulated, rate-limiting
steps  in  which  tumor  cells  gain  more  invasive  properties.  Metastasis  begins  with  a
change  in  tumor  plasticity  in  a  process  called  epithelial-mesenchymal  transition  (EMT).
During this  process there is  a loss of  epithelial  cell  characteristics and a gain of  mesen‐
chymal gene expression. In short, this process is characterized by the down-regulation of
epithelial (E)-cadherin, involved in adherence junctions and endothelial stabilization, and
the up-regulation of mesenchymal (N)-cadherin, which allows cells to become more mo‐
tile (Lu and Kang 2010; van Zijl, Krupitza et al. 2011). the repression of (E)-cadherin (Im‐
ai,  Horiuchi  et  al.  2003;  Krishnamachary,  Zagzag  et  al.  2006;  Yang,  Wu et  al.  2008;  Lu
and Kang 2010).  Next,  tumor cells  begin to disrupt the integrity of  the basement mem‐
brane. This is accomplished via a proteolytic cascade that is put into motion by HIF-1α-
dependent  up-regulation  of  enzymes  such  as  cathepsin  D  (CTSD),  urokinase-type
plasminogen-activator  receptor  (uPAR),  and  matrix  metalloproteinase-2  (MMP2)  (Krish‐
namachary, Berg-Dixon et al. 2003; Lu and Kang 2010). Once the basement membrane is
disrupted, tumor cells eventually penetrate the walls of blood vessels in order to become
circulating tumor cells (CTCs) in a process known as intravasation (Lu and Kang 2010).
(Gupta, Nguyen et al. 2007; Lu and Kang 2010). Hypoxia-induced expression of VEGF al‐
so increases the chance of intravasation through the effects of VEGF on increased micro-
vascular permeability and interstitial  fluid pressure (Sullivan and Graham 2007;  Lu and
Kang 2010).
Motility is also an important concept in the process of metastasis. Once the cell-cell junc‐
tions have been broken down by the down-regulation of (E)-cadherin, the cells are quick‐
ly able to reassemble the actin cytoskeleton into protrusive and invasive structures, such
as lamellipodia and filopodia,  that help them to migrate through the degraded extracel‐
lular matrix (ECM), into the blood vessels, and ultimately to their target location (Fathal‐
lah-Shaykh  2005).  Actin-Related  Protein  2/3  (Arp2/3),  which  is  composed  of  2  actin
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related proteins and 5 structural subunits, is controlled by the Scar/WAVE complex, also
known as the WANP complex,  and is essential  to the rapid assembly of actin networks
that  make up lamellipodia (Machesky 2008).  Additionally,  the up-regulation of  the cap‐
ping protein increases the protrusion activity of invasive tumor cells (Yamaguchi, Wyck‐
off  et  al.  2005).  The  formation  of  filopodia  is  controlled  by  proteins  such  as  fascin,
diaphanous, and Mena/VASP (Machesky 2008).
5. Hypoxia and malignant gliomas
5.1. HIF in gliomas
In addition to decreased oxygen tension in brain and GBM tissues, the expression of HIF
in gliomas can be affected by the activation of oncogenes, namely epidermal growth fac‐
tor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), and/or the loss
of  tumor  suppressor  function  through  p53  and  phosphatase  and  tensin  homolog  gene
(PTEN)  (Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). EGFR affects the expression
of HIF by activating a series  of  pathways,  the first  of  which is  the Phosphatidylinositol
3-kinases  (PI(3)K)  pathway,  which  ultimately  leads  to  increased  HIF-1α  protein  levels
(Clarke,  Smith et  al.  2001;  Kaur,  Khwaja et  al.  2005).  EGFR amplification found in glio‐
blastoma, as well as among other tumors, is also associated with a poor prognosis (Fred‐
erick, Wang et al. 2000; Kaur, Khwaja et al. 2005). Platelet-derived growth factor (PDGF)
has 3 isoforms and 2 receptors and of  these,  the PDGFA isoform and the PDFGR-α re‐
ceptor  are  over-expressed  by  glial  tumor  cells  (Brat  and  Mapstone  2003).  Furthermore,
PDGF is thought to enhance the transcription and secretion of VEGF (Brat and Mapstone
2003).  The  PTEN  gene,  located  on  chromosome 10,  is  a  tumor  suppressor  gene  that  is
mutated in 20 to 40 percent of glioblastoma (Li,  Yen et al.  1997; Cantley and Neel 1999;
Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). Loss of function of the PTEN gene in
gliomas is associated with increased HIF-1α expression as well  as tumor vascularization
and Zundel et al.  showed that over-expression of the gene in gliomas is associated with
reduction in HIF-1α expression (Zundel, Schindler et al.  2000; Kaur, Khwaja et al.  2005).
The p53 gene, mutated in approximately 50% of gliomas and believed to be the ”guardi‐
an of the genome,” exerts a key role in hypoxia by enhancing the degradation of HIF-1α,
by  promoting  the  interaction  of  the  latter  with  MDM2,  which  enhances  ubiquitination
(Hollstein,  Sidransky  et  al.  1991).  Thus,  expression  of  wild-type  p53  down-regulates
VEGF and therefore leads to inhibition of angiogenesis (Brat and Mapstone 2003; Hunter,
Brat  et  al.  2003;  Kaur,  Khwaja et  al.  2005).  Interestingly,  HIF-1α stabilizes p53 by direct
physical interaction. p53 activity is lost in gliomas by multiple mechanisms; mutations of
p53 are common in gliomas (Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). In addi‐
tion,  the MDM2 protein,  which enhances p53 degradation by ubiquitination,  is  over-ex‐
pressed in gliomas (Reifenberger, Liu et al. 1993; Brat and Mapstone 2003). Furthermore,
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factor that is secreted by many cells, including mesenchymal, stromal, and especially tumor
cells. VEGF induces the migration of the endothelial precursor cells to sites of angiogenesis
and is also responsible for the proliferation and differentiation of these cells (Ahluwalia and
Gladson 2010). (Kaur, Khwaja et al. 2005). Interestingly, HIF-1 activates the transcription of
VEGF by binding to the HRE in its promoter region (Forsythe, Jiang et al. 1996; Kaur, Khwa‐
ja et al. 2005). Hypoxia also increases VEGF production by stabilizing its mRNA; this effect
is mediated by the 3’ un-translated region of the mRNA (Onesto, Berra et al. 2004; Kaur,
Khwaja et al. 2005). Moreover, HIF-1 up-regulates the expression of additional key mole‐
cules that induce angiogenesis, including stromal-derived factor 1 (SDF1), placental growth
factor (PGF), platelet-derived growth factor B (PDGFB), and angiopoietin (ANGPT) 1 and 2
(Rey and Semenza 2010; Semenza 2012). These pro-angiogenic genes increase vascular den‐
sity, thus supplying oxygen and nutrients to metabolically demanding tumor cells (Ke and
Costa 2006).
4.5. Effects of hypoxia on tumor invasion and motility
Metastasis is a complex process that consists of a series of highly regulated, rate-limiting
steps  in  which  tumor  cells  gain  more  invasive  properties.  Metastasis  begins  with  a
change  in  tumor  plasticity  in  a  process  called  epithelial-mesenchymal  transition  (EMT).
During this  process there is  a loss of  epithelial  cell  characteristics and a gain of  mesen‐
chymal gene expression. In short, this process is characterized by the down-regulation of
epithelial (E)-cadherin, involved in adherence junctions and endothelial stabilization, and
the up-regulation of mesenchymal (N)-cadherin, which allows cells to become more mo‐
tile (Lu and Kang 2010; van Zijl, Krupitza et al. 2011). the repression of (E)-cadherin (Im‐
ai,  Horiuchi  et  al.  2003;  Krishnamachary,  Zagzag  et  al.  2006;  Yang,  Wu et  al.  2008;  Lu
and Kang 2010).  Next,  tumor cells  begin to disrupt the integrity of  the basement mem‐
brane. This is accomplished via a proteolytic cascade that is put into motion by HIF-1α-
dependent  up-regulation  of  enzymes  such  as  cathepsin  D  (CTSD),  urokinase-type
plasminogen-activator  receptor  (uPAR),  and  matrix  metalloproteinase-2  (MMP2)  (Krish‐
namachary, Berg-Dixon et al. 2003; Lu and Kang 2010). Once the basement membrane is
disrupted, tumor cells eventually penetrate the walls of blood vessels in order to become
circulating tumor cells (CTCs) in a process known as intravasation (Lu and Kang 2010).
(Gupta, Nguyen et al. 2007; Lu and Kang 2010). Hypoxia-induced expression of VEGF al‐
so increases the chance of intravasation through the effects of VEGF on increased micro-
vascular permeability and interstitial  fluid pressure (Sullivan and Graham 2007;  Lu and
Kang 2010).
Motility is also an important concept in the process of metastasis. Once the cell-cell junc‐
tions have been broken down by the down-regulation of (E)-cadherin, the cells are quick‐
ly able to reassemble the actin cytoskeleton into protrusive and invasive structures, such
as lamellipodia and filopodia,  that help them to migrate through the degraded extracel‐
lular matrix (ECM), into the blood vessels, and ultimately to their target location (Fathal‐
lah-Shaykh  2005).  Actin-Related  Protein  2/3  (Arp2/3),  which  is  composed  of  2  actin
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related proteins and 5 structural subunits, is controlled by the Scar/WAVE complex, also
known as the WANP complex,  and is essential  to the rapid assembly of actin networks
that  make up lamellipodia (Machesky 2008).  Additionally,  the up-regulation of  the cap‐
ping protein increases the protrusion activity of invasive tumor cells (Yamaguchi, Wyck‐
off  et  al.  2005).  The  formation  of  filopodia  is  controlled  by  proteins  such  as  fascin,
diaphanous, and Mena/VASP (Machesky 2008).
5. Hypoxia and malignant gliomas
5.1. HIF in gliomas
In addition to decreased oxygen tension in brain and GBM tissues, the expression of HIF
in gliomas can be affected by the activation of oncogenes, namely epidermal growth fac‐
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Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). Loss of function of the PTEN gene in
gliomas is associated with increased HIF-1α expression as well  as tumor vascularization
and Zundel et al.  showed that over-expression of the gene in gliomas is associated with
reduction in HIF-1α expression (Zundel, Schindler et al.  2000; Kaur, Khwaja et al.  2005).
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Brat  et  al.  2003;  Kaur,  Khwaja et  al.  2005).  Interestingly,  HIF-1α stabilizes p53 by direct
physical interaction. p53 activity is lost in gliomas by multiple mechanisms; mutations of
p53 are common in gliomas (Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). In addi‐
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Hypoxia, Angiogenesis and Mechanisms for Invasion of Malignant Gliomas
http://dx.doi.org/10.5772/53298
111
loss of p14ARF function in gliomas leads to MDM2-mediated enhanced degradation of p53
(Nakamura, Watanabe et al. 2001; Brat and Mapstone 2003).
5.2. Hypoxia, angiogenesis, and GBM
GBM are highly cellular astrocytic neoplasms; they are histologically characterized by an
area  of  central  necrosis  surrounded by  a  highly  cellular  rim of  viable  tumor  (Brat  and
Mapstone 2003; Giese, Bjerkvig et al. 2003). GBM also display areas of microvascular hy‐
perplasia as well as areas of necrosis with the appearance of tumor cells pseudo-palisad‐
ing around the necrotic centers.  The areas of microvascular hyperplasia are examples of
accelerated  angiogenesis  and are  thought  to  influence  the  biological  behavior  of  malig‐
nant gliomas by favoring aggressive neoplastic growth. angiogenesis in the surrounding
hypoxic  areas.  In  fact,  the  VEGF  concentrations  in  glioblastoma  are  200  to  300  times
greater than serum concentrations (Takano, Yoshii  et  al.  1996;  Brat and Mapstone 2003).
The pseudo-palisading cells have also been shown to over-express HIF-1 and also to se‐
crete  other  pro-angiogenic  factors  in  addition  to  VEGF,  such  as  interleukin  8  (IL-8)
(Rong, Durden et al.  2006; Onishi, Ichikawa et al.  2011). It is also important to note that
newly  formed  blood  vessels  in  malignant  gliomas  generally  have  increased  diameters,
are  highly  permeable,  have  thickened basement  membranes,  and have  highly  prolifera‐
tive endothelial cells (Lopes 2003; Onishi, Ichikawa et al. 2011).
5.3. Hypoxia and invasiveness of GBM
As discussed earlier, cancer cell migration and invasion consists of a series of highly coordi‐
nated steps including dissociation of cellular adhesions, remodeling of the actin cytoskele‐
ton, proteolytic degradation of the ECM, and formation of new adhesions. Brain invasion is
a characteristic feature of malignant gliomas. In vivo studies of glioblastoma have shown
that tumor hypoxia results in increased cell migration (Plasswilm, Tannapfel et al. 2000).
Once again, the pseudopalisading cells found around the necrotic cores in GBM, which up-
regulate HIF-1, appear to be hypoxic and migrating away from the necrotic core (Elstner,
Holtkamp et al. 2007; Onishi, Ichikawa et al. 2011). discovery has revealed that the protein
MINK, which inactivates ADF/cofilin by phosphorylation, is up-regulated in glioma cells as
compared to normal brain cells (Fathallah-Shaykh 2005). Additionally, under hypoxic condi‐
tions, glioblastoma induce the expression of c-Met, which stimulates gliomas cells to secrete
urokinase plasminogen activator (uPA), which converts circulating plasminogen into plas‐
min. The latter helps promote invasion by degrading ECM proteins as well as by activating
matrix metalloproteins, including MMP2, up-regulated in glioma cells (Fathallah-Shaykh
2005; Martens, Schmidt et al. 2006; Eckerich, Zapf et al. 2007; Onishi, Ichikawa et al. 2011).
5.4. Hypoxia and cell survival in GBM
Microarray analysis of cultured glioma cells revealed over-expression of molecules that pro‐
tect them from reactive oxygen species (ROS) and endoplasmic reticulum (ER)-induced
apoptosis (Fathallah-Shaykh 2005). ROS, generated by the rapid multiplication of cancer
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cells, cause a release of cytochrome c leading to apoptosis (Filomeni, Aquilano et al. 2003;
Petrosillo, Ruggiero et al. 2003; Fathallah-Shaykh 2005). Glioma cells appear to acquire pro‐
tective mechanisms against ROS-induced apoptosis. First, by up-regulating protective en‐
zymes such as AKR1A1 and AKR1C1, which belong to the aldo-keto reductase enzyme
super-family (Sanli and Blaber 2001; Fathallah-Shaykh 2005). Second, by up-regulating sev‐
eral antioxidants, some of which include PDG, TALDO1, AFG3L1, ANT2, GSTP1, and
PRDX1 (Berggren, Husbeck et al. 2001; Nonn, Berggren et al. 2003; Fathallah-Shaykh 2005).,
nuclear factor κВ (NF- κВ) has been reported to be constitutively activated in cultured glio‐
ma cells and GBM surgical samples (Bharti and Aggarwal 2002; Robe, Bentires-Alj et al.
2004; Wang, Zhang et al. 2004; Fathallah-Shaykh 2005).
The  ER,  one  of  the  cells  largest  organelles,  is  responsible  for  folding,  glysolating,  and
sorting proteins to their  correct  destinations,  as  well  as  for synthesizing lipids and cho‐
lesterol  components  of  the  cell  membrane.  When  homeostasis  is  disrupted  in  the  ER,
mis-folded  and un-folded  proteins  can  accumulate  with  the  ER lumen,  resulting  in  ER
stress,  which shuts off  protein synthesis leading to apoptosis.  This response is  beneficial
to the cell as a safeguard against carcinogenesis because mis-folded proteins may acquire
aberrant functions. On the other hand, bypassing this response is an important milestone
in  the  development  of  cancer.  Glioma cells  appear  to  acquire  pathways  that  help  them
recover  from ER stress  and avoid  apoptosis.  A normal  ER stress-induced response  ulti‐
mately leads to inactivation of the eukaryotic initiation factor 2 (eIF-2α), which shuts off
protein  synthesis.  By  up-regulating  activating  transcription  factor  4  (ATF4),  malignant
glioma  cells  appear  to  bypass  the  ER  stress-induced  protein  synthesis  inhibition.  ATF4
induces the growth arrest and DNA damage-inducible protein (GADD34), which dephos‐
phorylates eIF2α, causing protein synthesis recovery (Connor, Weiser et al.  2001; Novoa,
Zeng et al. 2001; Brush, Weiser et al. 2003; Fathallah-Shaykh 2005).
6. Linking hypoxia, invasion, and angiogenesis
6.1. Hypoxia, invasion, and angiogenesis in malignant gliomas
Hypoxia, invasion, and angiogenesis are interrelated through a variety of molecular path‐
ways and feedback loops. divide and increase in number, they often out-grow their diffu‐
sion-limited oxygen supplies and hypoxia results. Once the tumor micro-environment
becomes hypoxic, cellular and molecular signaling pathways are initiated in order to pro‐
mote overall tumor survival. These adaptive responses include: 1) increasing cellular resist‐
ance to hypoxia, 2) favoring metabolic pathways that are optimal in hypoxia, 3) increasing
motility and invasive properties in order to seek new oxygen supplies, and 4) initiating an‐
giogenesis in order to create a new vascular supply, or a combination of these responses.
(Shimizu, Eguchi et al. 1995). Therefore, there is evidence that local oxygen concentrations
modulate a switch between proliferative phenotype and an invasive in GBM cells; this is
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called the “Go or Grow” mechanism (Giese, Kluwe et al. 1996; Giese, Loo et al. 1996; Hatzi‐
kirou, Basanta et al. 2012).
When considering angiogenesis as the adaptive mechanism in glial cells, it is necessary to
evaluate the relationship between the rate of angiogenesis and the rate of cellular division. If
cellular division proceeds at a rate faster than angiogenesis, then oxygen supply cannot
meet metabolic demands causing not only local necrosis, but also dissemination of tumor
cells by enhanced brain invasion. On the other hand, if angiogenesis proceeds at a rate faster
than cellular division then oxygen supplies are sufficient to meet metabolic demands and no
necrosis occurs, which is characteristic of anaplastic astrocytoma.
6.2. Anti-angiogenic agents as treatment for malignant gliomas
Both prospective and retrospective clinical trials have shown that Bevacizumab, an anti-an‐
giogenic agent, is effective as a single-agent against recurrent glioblastoma as compared to
historical controls of salvage chemotherapy (Friedman, Prados et al. 2009; Kreisl, Kim et al.
2009; Raizer, Grimm et al. 2010). The Roche-sponsored AVAglio international multicenter
phase III clinical trial, comparing standard of care to standard of care plus Bevacizumab for
the treatment of newly-diagnosed GBM, is completed; the results will be presented at The
Society for Neuro-Oncology 2012 meeting. It is noteworthy that Bevacizumab has a positive
significant impact on progression-free survival times (Norden, Drappatz et al. 2009; van den
Bent, Vogelbaum et al. 2009; Keunen, Johansson et al. 2011).
Interestingly, in vivo GBM models have shown that anti-angiogenic agents enhance tumor
cell migration/invasion. Keunen and colleagues studied a human GBM xenograft model, de‐
rived from patient tumor spheroids, in rats. The results revealed that Bevacizumab induces
vascular remodeling that leads to increased tumor cell invasion into normal brain parenchy‐
ma, associated with a hypoxic tumor microenvironment and a glycolytic metabolism (Keu‐
nen, Johansson et al. 2011). Plasswilm et al. implanted cultured glioma cells in a chicken
embryo model and showed that local hypoxia promotes tumor spread and the development
of secondary tumor cell bulks (Plasswilm, Tannapfel et al. 2000).
6.3. Implications for treatment of malignant gliomas
Treatment with Bevacizumab also has important implications for how tumor progression is
defined. Traditionally, tumor progression has been measured according to the MacDonald
criteria which define progression by increase in contrast enhancement. However, as a result
of blood-brain barrier stabilization secondary to anti-angiogenic agents, contrast enhance‐
ment is no longer a reliable measure of progression. Therefore, the Response Assessment in
Neuro-Oncology (RANO) Working Group developed the RANO criteria as a means to ad‐
dress potential progression by non-enhancing T2/FLAIR (fluid attenuated inversion recov‐
ery) lesions as well as by increases in contrast enhancement in malignant gliomas (Province,
Han et al. 2011). The use of anti-angiogenic agents, namely Bevacizumab, has also raised
many questions about patterns of recurrence in malignant gliomas. Additionally, although
there is some conflicting data on this subject secondary to poor study design and low study
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power, there is evidence that patients who are treated with Bevacizumab exhibit more dif‐
fuse or distant recurrence patterns as compared to those who do not receive Bevacizumab.
Once again, the possibility of more diffuse and distant recurrence patterns may be explained
by the “Go or Grow” mechanism, as explained above, with further supporting evidence de‐
rived from the glioblastoma xenograft model, also detailed above (Keunen, Johansson et al.
2011; Hatzikirou, Basanta et al. 2012).
Hypoxia-mediated enhancement of brain invasion has profound biological and clinical im‐
plications on GBM, in particular in the context of  treatment with anti-angiogenic drugs.
Recall that necrosis is a hallmark of GBM; thus, one can safely assume that, by the time of
the initial clinical presentation, GBM cells have already invaded the surrounding brain pa‐
renchyma because of local hypoxia. This feature of GBM may limit the effectiveness of lo‐
cal  therapeutic  options,  like  radiation  therapy  and  surgical  resection.  Furthermore,  one
could argue that,  though anti-angiogenic  drugs prolong progression free survival  times,
they  may  create  a  more  aggressive  and  invasive  tumor  by  hypoxia-mediated  enhance‐
ment of motility,  which delays clinical progression. These patients may experience a so-
called “honeymoon period,” in which they may appear stable; however, once they recur,
the rate  of  progression of  Bevacizumab-treated tumors may be very acute  secondary to
the large volume of invaded brain. This rationale may explain the limited effects of Beva‐
cizumab on overall survival times.
7. Future directions
The Figure depicts the effects of HIF-1α on key cellular functions. Though some of the sig‐
naling molecules are known, we seem to be only looking at the tip of the iceberg. More re‐
search is needed to fit the pieces of the puzzle. What other molecules are activated by
hypoxia to influence the 4 phenotypes shown in the Figure? How do they relate to HIF-1?
Are there feedback loops between the phenotypes? That is, does motility affect metabolism
and vice versa? We have presented a succinct view of the molecular basis of the four pheno‐
types; however, a detailed analysis is not within the scope of this chapter.
Although preclinical studies have revealed a molecular link between hypoxia, angiogenesis,
and invasion, the clinical implications of these relationships are still not well known and fu‐
ture studies are needed. Drawing from what has already been established regarding the ef‐
fects of anti-angiogenic agents on increased migration and invasion in malignant gliomas, a
plausible direction for future therapeutic development would include blocking not only an‐
giogenesis but also invasion and migration. motility agents in malignant GBM will result in
significant improvement in PFS as well as overall survival times by blocking two of the pri‐
mary mechanisms for their survival.
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fects of anti-angiogenic agents on increased migration and invasion in malignant gliomas, a
plausible direction for future therapeutic development would include blocking not only an‐
giogenesis but also invasion and migration. motility agents in malignant GBM will result in
significant improvement in PFS as well as overall survival times by blocking two of the pri‐
mary mechanisms for their survival.




From this chapter, it is our hope that the reader has gained an understanding of the exten‐
sive role of hypoxia in brain tumors, with specific regard to its role in angiogenesis, inva‐
sion, metabolism, and overall survival of the tumor. Furthermore, although the use of anti-
angiogenic agents as therapeutic options for malignant gliomas has provided some
promising results, it has also revealed the need for further molecular research into the mech‐
anisms for invasion of malignant gliomas, especially as it relates to the hypoxic environ‐
ments created by anti-angiogenic drugs. Hopefully, this combination of efforts to decrease
both angiogenesis and invasion will result in the development of more promising therapeu‐
tic agents to treat this disease.
Figure 1. Cartoon illustrating signaling and degradation of HIF-1α in hypoxia. Under normal oxygen supply, one of the
two proline residues (Pro-402, Pto-564) in HIF-1α is hydroxylated by prolyl hydroxylase. Once hydroxylated HIF-1α is
recognized by VHL, an E3 ubiquitin (Ub) ligase, which targets HIF-1α for degradation through the proteasomal path‐
way. In hypoxic conditions, hydroxylation is inhibited causing the accumulation of HIF-1α, which translocates to nu‐
cleus where it associates with HIF-1β then binds to the HIF responsive Element (HRE) of target genes activating their
transcription. The HIF targeting genes modulate cell survival, metabolism, angiogenesis, and tumor invasion. PGK:
phosphoglycerate kinase, LDH: lactate dehydrogenase.
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From this chapter, it is our hope that the reader has gained an understanding of the exten‐
sive role of hypoxia in brain tumors, with specific regard to its role in angiogenesis, inva‐
sion, metabolism, and overall survival of the tumor. Furthermore, although the use of anti-
angiogenic agents as therapeutic options for malignant gliomas has provided some
promising results, it has also revealed the need for further molecular research into the mech‐
anisms for invasion of malignant gliomas, especially as it relates to the hypoxic environ‐
ments created by anti-angiogenic drugs. Hopefully, this combination of efforts to decrease
both angiogenesis and invasion will result in the development of more promising therapeu‐
tic agents to treat this disease.
Figure 1. Cartoon illustrating signaling and degradation of HIF-1α in hypoxia. Under normal oxygen supply, one of the
two proline residues (Pro-402, Pto-564) in HIF-1α is hydroxylated by prolyl hydroxylase. Once hydroxylated HIF-1α is
recognized by VHL, an E3 ubiquitin (Ub) ligase, which targets HIF-1α for degradation through the proteasomal path‐
way. In hypoxic conditions, hydroxylation is inhibited causing the accumulation of HIF-1α, which translocates to nu‐
cleus where it associates with HIF-1β then binds to the HIF responsive Element (HRE) of target genes activating their
transcription. The HIF targeting genes modulate cell survival, metabolism, angiogenesis, and tumor invasion. PGK:
phosphoglycerate kinase, LDH: lactate dehydrogenase.
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1. Introduction
Investigation on tumor angiogenesis has taken a discontinuous path through history. Studies
on blood vessels of the human body are documented for the first time in the 17th century BC
by the description of a heartbeat. The Ebers Papyrus (16th century BC) reports how the heart
is connected to arteries and primarily describes the high vascularization of tumors. Later,
Hippocrates (460-370 BC) made a description that should have a great impact on cancer
research: He interpreted the vessels around a malignant tumor as claws of a crab and therefore
named the disease ‘karkinos’. From there on tumor vessels had been described with no
conceptional impact on therapeutic approaches. In 1971, Judah Folkman kicked a stone with
his landmark papers on tumor-induced angiogenesis, thereby promoting a completely new
view on cancer biology and therapy. He showed evidence that the tumor is not able to grow
beyond a certain barrier without a network of newly recruited microvessels, stating that the
tumor stimulates the proliferation of host endothelial cells via secreted factors. Folkman
concluded that tumor growth is an angiogenesis-dependent process and thus anti-angioge‐
netic approaches could be a promising new therapy. [1, 2].
Since then the field of angiogenesis developed dynamically, becoming an actual research
avalanche in the past decades. Key molecules and their receptors have been identified, certain
hierarchies in signaling have been unveiled and angiogenesis is named as one of the ten
hallmarks of cancer development [3]. However, the therapeutic approach to brain tumors is
more complicated and has been hampered for tumor heterogeneity, delivery of drugs to the
central nervous system and neurotoxic side-effects still represent the main challenges.
Furthermore, the role of participating cells remains to be unraveled, i.e. whether interactions
between host and tumor cells are required for vessel formation [4, 5, 6].
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Blood vessels deliver oxygen and nutrients and are crucially needed for cell survival, cell
function  and  evacuating  carbon  dioxide  and  metabolic  waste.  All  cells  of  the  human
body reside in a 100 µm-radius to a capillary blood vessel. The close connection between
brain  and  vessels  is  seen  during  brain  development  and  axon  growth,  insofar  as  the
same guidance molecules are recruited for axon targeting and vessel growth [7].  In par‐
ticular  proliferating  cells  in  a  tissue  depend  strongly  on  continuous  blood  supply  and
have  an  immanent  aptitude  to  foster  angiogenesis.  They  create  a  microenvironment  of
contact-dependent (short-range) and secreted (long-range) factors which promote the gen‐
eration  and  growth  of  blood  vessels.  Thus,  it  is  tempting  to  speculate  that  neoplasms
have  to  evolve  angiogenic  abilities  to  induce  neovasculature  in  order  to  develop  and
progress  in  size  [8,  9,  10].  Beside normal  development,  physiological  tissue remodeling,
tumor  growth,  metastasis  and  inflammation,  angiogenesis  is  associated  with  a  wide
range of other pathologies such as cardio-vascular and ocular diseases [11].
Figure 1. Vessel scheme showing the three main cellular components. The inner layer consists of endothelial cells,
lining the inside (lumen) of the vessel. The tube is covered on the outer side by pericytes and smooth muscle cells. The
relation of endothelial cells and pericytes is specifically in the brain with a ratio of 1:1. In between is a layer of extracel‐
lular matrix tissue known as basal lamina.
During development, two physiological processes of vessel growth can be distinguished: First
angiogenesis as the sprouting of vessels and capillaries from pre-existing ones, and second
vasculogenesis which describes the process of de novo formation of vessels from bone marrow-
derived progenitor cells. In the mature state in adulthood new vessels are believed to be formed
solely through angiogenesis. In contrast, tumor cell proliferation appears in an uncontrolled
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manner with replicative immortality and sustained angiogenesis is reinforced by vasculogen‐
esis. While in physiological processes e.g. wound healing, angiogenesis is merely active
transiently, an “angiogenic switch” is almost always turned on in tumor development. It
appears plausible that the angiogenic switch is redox dependent and controlled by counter‐
balancing positive and negative factors, either inducing or blocking angiogenesis [12, 13]. The
angiogenesis-inducing factors, such as vascular endothelial growth factor-A (VEGF-A), acidic
and basic fibroblast growth factors (FGF1/2), bind to their corresponding receptors on
endothelial cells. VEGF-A is one of the major players in embryonic vasculo- and angiogenesis
as well as in endothelial cell survival. The expression of VEGF-A and FGF-1/-2 can be chron‐
ically upregulated by hypoxia and oncogenes. However, the blood vessels produced by
chronically dominant proangiogenic factors show characteristic morphological aberrations:
The tumor-induced neovasculature is marked by a high-density capillary microvessel network
with extreme vessel branching, auto-looping, tortous, disorganized and enlarged vessels.
2. Identification of key angiogenic factors
Several hypotheses have been raised regarding the importance of tumor-induced angiogenesis
in development and metastasis of tumors. Dr. Folkman summarized the work of insightful
investigators at that time, such as Algire and Chalkley [14], Warren [15], and Greenblatt and
Shubik [16], who first termed the process of ’tumor angiogenesis’. Thus, Folkman coined the
concept of treating solid tumors by inhibiting angiogenesis.
Folkman’s visionary hypotheses consisted of the ideas that primary tumors remain dormant
in terms of angiogenesis up to a maximum size of approximately 1-2 mm in diameter. Tumor
growth beyond that avascular state, switches angiogenesis on by perverting the circumvent
mature host blood vessels to start sprouting towards and probably infiltrate the tumors. This
process creates a network of new capillaries within and around the tumorbulk. This idea of an
angiogenic switch was supported by an orphan vascular growth factor [17] produced by
tumors, which has been initially termed ’tumor angiogenesis factor’ (TAF) [18]. Therefore it
would seem plausible to affect the tumor growth by diminishing or even preventing angio‐
genesis via blocking TAF or its receptors. This ’dormancy-inducing‘ therapeutic approach was
thought not to be curative in the common sense but suggested the prevention of further tumor
expansion. At best it would result in sustained regression of established tumor bulks to a size
of 1-2 mm in diameter so that survival is possible through diffusion and a blood vessel supply
is not necessary.
During the following decade Folkman’s ideas though very logical and envisioned but still
hypothetical attracted little scientific interest. The situation challenged with the identification
and cloning of the first pro-angiogenic factor in the mid 1980s when Sing et al. isolated the
basic fibroblast growth factor (bFGF/FGF-2) from chondrosarcoma [19]. The authors showed
that bFGF is a tumor-derived growth factor, which can induce angiogenesis in different models
[20]. bFGF belongs to a group of structurally related signaling molecules, all binding fibroblast
growth factor receptors (aFGF/FGF-1, FGFRs). Up to now, the FGFR-family consists of four
Brain Tumor–Induced Angiogenesis: Approaches and Bioassays
http://dx.doi.org/10.5772/53182
127
Blood vessels deliver oxygen and nutrients and are crucially needed for cell survival, cell
function  and  evacuating  carbon  dioxide  and  metabolic  waste.  All  cells  of  the  human
body reside in a 100 µm-radius to a capillary blood vessel. The close connection between
brain  and  vessels  is  seen  during  brain  development  and  axon  growth,  insofar  as  the
same guidance molecules are recruited for axon targeting and vessel growth [7].  In par‐
ticular  proliferating  cells  in  a  tissue  depend  strongly  on  continuous  blood  supply  and
have  an  immanent  aptitude  to  foster  angiogenesis.  They  create  a  microenvironment  of
contact-dependent (short-range) and secreted (long-range) factors which promote the gen‐
eration  and  growth  of  blood  vessels.  Thus,  it  is  tempting  to  speculate  that  neoplasms
have  to  evolve  angiogenic  abilities  to  induce  neovasculature  in  order  to  develop  and
progress  in  size  [8,  9,  10].  Beside normal  development,  physiological  tissue remodeling,
tumor  growth,  metastasis  and  inflammation,  angiogenesis  is  associated  with  a  wide
range of other pathologies such as cardio-vascular and ocular diseases [11].
Figure 1. Vessel scheme showing the three main cellular components. The inner layer consists of endothelial cells,
lining the inside (lumen) of the vessel. The tube is covered on the outer side by pericytes and smooth muscle cells. The
relation of endothelial cells and pericytes is specifically in the brain with a ratio of 1:1. In between is a layer of extracel‐
lular matrix tissue known as basal lamina.
During development, two physiological processes of vessel growth can be distinguished: First
angiogenesis as the sprouting of vessels and capillaries from pre-existing ones, and second
vasculogenesis which describes the process of de novo formation of vessels from bone marrow-
derived progenitor cells. In the mature state in adulthood new vessels are believed to be formed
solely through angiogenesis. In contrast, tumor cell proliferation appears in an uncontrolled
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications126
manner with replicative immortality and sustained angiogenesis is reinforced by vasculogen‐
esis. While in physiological processes e.g. wound healing, angiogenesis is merely active
transiently, an “angiogenic switch” is almost always turned on in tumor development. It
appears plausible that the angiogenic switch is redox dependent and controlled by counter‐
balancing positive and negative factors, either inducing or blocking angiogenesis [12, 13]. The
angiogenesis-inducing factors, such as vascular endothelial growth factor-A (VEGF-A), acidic
and basic fibroblast growth factors (FGF1/2), bind to their corresponding receptors on
endothelial cells. VEGF-A is one of the major players in embryonic vasculo- and angiogenesis
as well as in endothelial cell survival. The expression of VEGF-A and FGF-1/-2 can be chron‐
ically upregulated by hypoxia and oncogenes. However, the blood vessels produced by
chronically dominant proangiogenic factors show characteristic morphological aberrations:
The tumor-induced neovasculature is marked by a high-density capillary microvessel network
with extreme vessel branching, auto-looping, tortous, disorganized and enlarged vessels.
2. Identification of key angiogenic factors
Several hypotheses have been raised regarding the importance of tumor-induced angiogenesis
in development and metastasis of tumors. Dr. Folkman summarized the work of insightful
investigators at that time, such as Algire and Chalkley [14], Warren [15], and Greenblatt and
Shubik [16], who first termed the process of ’tumor angiogenesis’. Thus, Folkman coined the
concept of treating solid tumors by inhibiting angiogenesis.
Folkman’s visionary hypotheses consisted of the ideas that primary tumors remain dormant
in terms of angiogenesis up to a maximum size of approximately 1-2 mm in diameter. Tumor
growth beyond that avascular state, switches angiogenesis on by perverting the circumvent
mature host blood vessels to start sprouting towards and probably infiltrate the tumors. This
process creates a network of new capillaries within and around the tumorbulk. This idea of an
angiogenic switch was supported by an orphan vascular growth factor [17] produced by
tumors, which has been initially termed ’tumor angiogenesis factor’ (TAF) [18]. Therefore it
would seem plausible to affect the tumor growth by diminishing or even preventing angio‐
genesis via blocking TAF or its receptors. This ’dormancy-inducing‘ therapeutic approach was
thought not to be curative in the common sense but suggested the prevention of further tumor
expansion. At best it would result in sustained regression of established tumor bulks to a size
of 1-2 mm in diameter so that survival is possible through diffusion and a blood vessel supply
is not necessary.
During the following decade Folkman’s ideas though very logical and envisioned but still
hypothetical attracted little scientific interest. The situation challenged with the identification
and cloning of the first pro-angiogenic factor in the mid 1980s when Sing et al. isolated the
basic fibroblast growth factor (bFGF/FGF-2) from chondrosarcoma [19]. The authors showed
that bFGF is a tumor-derived growth factor, which can induce angiogenesis in different models
[20]. bFGF belongs to a group of structurally related signaling molecules, all binding fibroblast
growth factor receptors (aFGF/FGF-1, FGFRs). Up to now, the FGFR-family consists of four
Brain Tumor–Induced Angiogenesis: Approaches and Bioassays
http://dx.doi.org/10.5772/53182
127
members: FGFR1, FGFR2, FGFR3 and FGFR4. Alternate splicing of FGFR1-3 gives rise to ‘b’
and ‘c’ variants resulting in seven FGFR-subtypes that can be present on the cell surface. Beside
monitoring critical functions during normal development of vertebrates and invertebrates [21,
22], FGF-1 and FGF-2 take part in the promotion of endothelial cell and fibroblast proliferation
and organizes endothelial cells into tube-like structures. As FGF is quite ubiquitous in the
human body it is thought to have a higher angiogenic potential than other angiogenic factors
(VEGF, PDGF) [23].
The interest in the research field of angiogenesis actually started to grow in the mid and late
1970s when the group of Dvorak et al. [24, 25] published their paper on one pro-angiogenic
factor originally discovered in the late 1970s as a protein secreted by tumors that could increase
the permeability of the microvasculature to plasma proteins [26], thus termed vascular
permeability factor (VPF). It is the founding member of the later termed vascular endothelial
growth factor- (VEGF-) family, a group of closely related cytokines (VEGF, VEGF-B, VEGF-C,
VEGF-D, PDGF, VEGF-F) identified by Ferrera and colleagues [27, 28]with functions in the
physiological and pathological processes of vasculogenesis, angiogenesis and lymphangio‐
genesis. VPF/VEGF (or VEGF-A) is the most important: It is essential for developmental
vasculogenesis and angiogenesis, it increases the permeability of microvasculature to plasma
proteins, a characteristic especially known for tumor vasculature in the beginning of tumor
stroma generation [29]. VEGF is clinically relevant due to its widespread overexpression in
different human cancers and is a candidate for evaluating the prognosis of individual patients.
Unlike FGF, which is nonselective for endothelium and stimulates division in many different
cell types, VEGF-A is a mitogen specific for the vascular endothelium. VEGF-A is a highly
conserved dimeric glycoprotein (34-45kd), constituted of two chains arranged in an antipar‐
allel fashion and bonded via disulfides. The coding region of VEGF-A on chromosome 6
consists of eight exons. Depending on the alternate splicing three different isoforms are
prominently encoded in human cells with polypeptides of 189, 165 and 121 amino acids.
Despite physical differences, the three VEGF-A isoforms apparently have identical biological
activity when in solution.
VEGF-A signals through two major transmembrane tyrosine kinase receptors binding the
factor with high affinity. The first is termed flt-1 or VEGF receptor 1 (VEGFR1) and the second
is flk-1/KDR (VEGF-receptor-2, VEGFR2). Both tyrosin kinase receptors are mainly though not
exclusively expressed on vascular endothelium. Especially endothelial cells of newly formed
blood vessels and the vasculature of tumors expressing VEGF-A have a highly elevated
expression of both receptors [30]. VEGF-A is overexpressed by the vast majority of cancers [31]
and premalignant lesions (e.g. precursor lesions of breast, cervix and colon cancer) and,
furthermore, correlates positively with malignant progression [32, 33].
Previously,  neuropilin-1  (NRP-1,  NP-1)  a  semaphorine  receptor  involved  in  axon  guid‐
ance during brain development [34, 35] has been shown to play a role in angiogenesis-in‐
dependent malignant progression [36] by increasing the affinity of various VEGF ligands
to  the  primary  VEGF-receptors.  Cariboni  et  al.  were  also  able  to  illustrate  a  KDR  and
blood  vessel  independent  way  via  VEGF-NRP-1  interactions  [37].  Its  isoform,  neuropi‐
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lin-2  receptor  probably  modulates  the  affinity  of  VEGF-C  and  -D  to  VEGFR-3  and  is
thought to be important in lymphangiogenesis [38, 39].
Although the specific biological functions mediated by the different receptors are not estab‐
lished precisely, it seems likely that VEGFR-2 is one of the major players in tumor-induced
angiogenesis and carcinogenesis. Inasmuch as VEGFR-2 is responsible for the microvascular
permeability and the subsequent proliferation and migration of endothelial cells, it is holding
a unique position in tumor angiogenesis:
As tumor-derived VEGF-A binds to receptors on the tumor cells themselves, VEGF-A creates
a self-perpetuating loop and induces angiogenesis and carcinogenesis in a paracrine or
autocrine fashion. The possibility of a therapeutic intervention stimulated academic centers as
well as the biotech and pharmaceutical industries to develop VEGF-R-blockers. Inter alia,
Sunitinib, Imatinib or Avastin/Bevacizumab have so far been created and are used as thera‐
peutics in various cancers.
More recently a second family of ligands and receptors specific for vascular endothelial cells
has emerged: the angiopoietin-tie-system as non-redundant regulator of endothelial cell
activation [40, 41]. Curiously, in this case was that the receptors were discovered first
(tie-2/tek and tie-1) and remained orphan receptors until angiopoietin-1 (ang-1) and angio‐
poietin-2 (ang-2) have been found to be ligands of tie-2 by Yancopolous et al. Ang-1 is essen‐
tially expressed by pericytes and smooth muscle cells, whereas ang-2 is stored in the granules
of endothelial cells (Weibel-Palade bodies) and secreted after stimulation. Most interestingly
ang-1 and ang-2 are antagonistic ligands with a high binding affinity to tie-2. While ang-1
functions as agonist to tie-2 promoting angiogenesis, inhibiting vessel leakage and suppressing
inflammatory gene expression [42, 43], ang-2 behaves oppositely, causes endothelial cell
apoptosis and as a result regression of newly formed vessels [44]. The situation changes
completely when ang-2 acts in combination with VEGF-A, for the two work in and promote
angiogenesis [45].
After focusing the first two decades of research on pro-angiogenic growth factor stimulators
and how to intervene in their pathways to exogenously block the process of angiogenesis,
endogenous inhibitors entered the scene and a large, growing family of antiangiogenic
basement membrane proteins, hormone metabolites and apoptosis modulators has been
discovered. Among others thrombospondin-1, interferon α/β, arresten, canstatin, angiostatin,
tissue inhibitors of matrix metalloproteinases (TIMP) and vascular endothelial growth
inhibitor (VEGI) have been proven to be endogenous inhibitors (Table 1).
Today, it is accepted that endogenous inhibitors activate a cellular ‘brake’ mechanism. This
mechanism leads to altered cell-cell-interactions, malignancy associated with induced
angiogenesis and other diseases like ocular disorders or rheumatoid arthritis when turned off.
In case of dominant endogenous inhibitors and deactivated angiogenic switch, launching
angiogenesis is (almost) impossible.
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ance during brain development [34, 35] has been shown to play a role in angiogenesis-in‐
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inhibitor (VEGI) have been proven to be endogenous inhibitors (Table 1).
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Non-matrix derived; stored in Weibel-Palade bodies; inhibits EC proliferation an migration;
antagonist of ang-1; in clinical trial [ 46, 47]
Angiostatin
Non-matrix derived; 38-45kDa, involves either kringle domains 1-3, or smaller kringle 5
fragments [ 48, 49]
Arresten
Matrix derived; 26-kDa; from type IV collagen; selectively inhibits EC tube formation, interferes
with FGF-2 [ 50, 51]
Canstatin
Matrix derived; 24-kDa; from type IV collagen; inhibits EC migration and tube formation dose-
dependently [ 52]
Endorepellin Matrix derived; from perlecan; inhibits several aspects of angiogenesis [ 53, 54]
Endostatin
Matrix derived; 20-kDa; zinc-binding fragment of type XVIII collagen; blocks angiogenesis,
primary tumor growth and metastasis; interferes with FGF-2; Phase II [ 55]
Interferon α/β Non-matrix derived; anti-viral proteins; Phase III (Interferon-β) [ 56]
Interleukins Leukocyte-derived; heterogeneous superfamily [ 57]
2-Methoxyestradiol Estradiol metabolite; Phase II [ 58]
Meth-1/-2 Non-matrix derived; proteins containing metalloprotease and thrombospondin domains [ 59]
Platelet factor-4 Inhibits FGF-2-induced EC proliferation [ 60]
Prolactin fragment
Derived from prolactin; 16-kDa; blocks angiogenesis; inhibits VEGF-induced Ras-activation
[ 61]
Thrombospondin-1/-2 Matrix derived; large extracellular matrix protein; Phase II (Thrombospondin-1) [ 62]
TIMP
Non-matrix derived; suppress MMP activity; pluripotent effect on EC growth, apoptosis and
cell differentiation [ 63]
Troponin I Cartilage-derived; inhibits EC proliferation and angiogenesis [ 64]
Tumstatin Matrix derived; 28-kDa from type IV collagen; apoptosis of EC [ 65, 66]
VEGI 174 amino acid cytokine; TNF-superfamily; autocrine apoptosis in EC [ 67]
Vasostatin
Non-matrix derived; fragment of calreticulin; selectively inhibits EC proliferation and
angiogenesis in response to stimulus; suppresses tumor growth [ 68]
Table 1. Summary chart of various endogenous inhibitors of angiogenesis
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Figure 2. The key steps of angiogenesis. After binding of angiogenic factors to their receptor, endothelial cells start
to proliferate and migrate towards the source of angiogenic activity (upper panel). This induces the sprouting and for‐
mation of a new branch (middle). Newly sprouted vasculature can either undergo maturation or regression (lower
panel). Depending on the biological events of interest different bioassays are available with particular advantages for
gauging.
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3. In vitro assays to study brain tumor angiogenesis
The human brain is made up of various cell types of different lineages (neuroepithelial,
epithelial and mesenchymal traits). Brain cells include astrocytes, oligodendrocytes, neurons,
microglia, ependyma and vessels which interact with each other and form a particular
environment via signaling molecules. Therefore the most important issues for in vitro bioassays
are to reduce such complexity and to make single biological events measurable in a reasonable
way. In vitro assays allow a high level of redundancy and permit the researcher to focus on
single biological events.
Besides perictyes and the vessel-surrounding tissue, endothelial cells lining all blood vessels
of the body are the prominent cells involved in neovascularization. New blood vessel forma‐
tion follows in principle four cardinal steps: First step is that endothelial cells need to adhere,
proliferate and permeabilize the environmental boundaries. Therefore endothelial cells
undergo cell division and start to secret proteases to degrade the matrix and brake through
the basal lamina, which is the second inner layer of the vessel. Second, migration and invasion
towards angiogenic stimuli needs to be facilitated (VEGF, FGF, PDGF, etc.). Endothelial cells
use for instance integrins to travel in tandem. This event is connected with the sprouting of
newly formed vessel barbs. As a source, angiogenic stimuli can be secreted by activated
lymphocytes, tumor cells, microglia and macrophages. Thirdly, endothelial vessel sprouts
form new vessels and recruit cellular components to line up a fully functional vessel. The fourth
key step is the modeling and reorganization process. Newly formed vessels can maturate or
undergo regression. For each of the four key steps several in vitro assays have been developed.
3.1. Tube Formation Assay (TFA)
In the past we considered the vascular endothelium as a passive structure which acts like a
filter between the blood in the vessel lumen and the vessel wall itself. In fact endothelial cells
are active members of the vascular homeostasis playing a vital role in the coagulation and the
fibrinolysis system as well as in adhesion and aggregation of blood platelets via secreted
activators and inhibitors. These processes (among others) can be studied in vitro using human
vascular endothelial cells isolated from umbilical veins.
Human umbilical vein endothelial cells (HUVECs) were isolated from freshly obtained human
umbilical cords the first time by Eric A. Jaffe in 1973 [69]. They were able to identify the cell
morphologically (Weible-Palade bodies) and immunologically (ABH antigens fitting to the
donor’s blood type) as human endothelial cells and demonstrated that it is possible to culture
them for a period of time. Endothelial cells of all origin seem to have the ability to form three-
dimensional structures (tubes, cobblestone pattern), which can be fostered by coating the
plastic culture dishes with either collagen or fibrin clots. The formation of tight junctions
between endothelial cells can be confirmed by electron microscopy.
The tube formation assay is a viable assay, which can be accomplished within a day. Image
analysis is used generally to measure the endothelial cells ability to form tube-like structures.
Further endothelial cell adhesion, migration and invasion have been reported [70]. Though
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very reliable in studying the reorganization, the TFA represents only a small part of angio‐
genesis and allows specific predictions of the nature of different endothelial cell strains rather
than testifying the angiogenic process itself.
3.2. Cell proliferation assays
There is a large variety of assays to measure cell proliferation. Well-established ones are for
example the MTT-assay, in which living cells reduce 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe‐
nyltetrazolium bromide, a yellow tetrazole to purple formazan, and the thymidine incorpo‐
ration assay using BrdU (5-bromo-2'-deoxyuridine), an analogue of thymidine. Both assays
are performed to detect proliferating cells in living tissue, Especially the BrdU incorporation
assay is most frequently used for cell proliferation studies in angiogenesis.
The cells used in proliferation assays are endothelial cells. However, it matters from which
source the endothelial cells are isolated since they differ not only between large-vessel-derived
endothelial cells and ones originated from microvasculature. They also seem to have distinc‐
tive characteristics when obtained from different organs and even when taken from different
sites in one single organ ( 71, 72, 73). Another fact is the total difference between species, which
cannot be ignored: One example are the pig and murine endothelial cells, which bind BSL-1
and BSL-4 (lectin from Bandeira simplifolica) and are therefore a target for hyper-immune
destruction when implanted into patients.
The most common cell types used in this assay are either bovine aortic endothelial cells or
human umbilical vein endothelial cells. During culture in the laboratory these cells are by
nature in a proliferative state, while they are more in a quiescent, non-proliferative state in
vivo. Therefore endothelial cells in vitro depend on the environment in which they are kept
during culturing.
Figure 3. Tube formation assay in time lapse modus. Representative photographs of tubes formed by human um‐
bilical vein endothelial cells (HUVECs). The left picture is taken 2 h after plating and shows beginning tube formation.
The right picture is taken 6 hours after plating and shows the typical ‘cobblestone’ forming. Images are given as x10
magnification.
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3.3. Cell migration assay
Cell migration is the movement of cells from one area to another induced by chemical signals.
Generally cell migration plays a vital role in processes like cell differentiation, tumor metastasis
and wound healing. In angiogenesis studies the focus is mainly laid on migrating endothelial
cells. In terms of angiogenesis one should speak of cell invasion, for endothelial primarily
degrade the basal lamina before migrating toward an angiogenic stimulus.
The assays most frequently performed are the blind-well chemotaxis chamber and the scratch-
wound assay. The blind-well chemotaxis chamber is a modified Boyden chamber as used for
classic neutrophil chemotaxis. Instead, endothelial cells are placed on a cell permeable filter.
When an angiogenic stimulus is added into the medium below the filter, the cells start to
migrate. The system is very useful in concentration-dependent effects.
In the other preferred assay, the scratch-wound assay [74, 75], HUVECs are used to be seeded
into trans-wells. When the cells are 85-95% confluent a wound/scratch is set. The test is used
to measure the time needed under different conditions (drug treatment, etc.) to close the
wound again.
3.4. Aortic Ring Assay (ARA)
The Rat Aortic Ring Assay, originally developed by Nicosia et al. [76] phenocopies all the key
steps in the angiogenesis process: matrix degradation, migration and proliferation of endo‐
thelial cells and structural reorganization. The basis of this assay is the excised aorta (of rats
or mice) from which the connective tissue has been removed. The aortic tube will then be cut
into rings or small pieces (aortic explants) and taken into culture with collagen gel. Several
days after culture initiation the aortic tissue gives rise to a microvascular network of branching
endothelial tubes, a process which is triggered by the dissection procedure and the growth
factors produced by the rings/explants.
Since angiogenesis in vivo not only involves endothelial cells, but also pericytes, the basal
lamina and other surrounding cells, researchers have moved to asses angiogenesis by organ
culture methods. Of these, the rat aortic ring assay has become one of the most widely used
ones. In particular, it has several advantages compared to “normal” in vitro single-cell culture:
As the assay is based on explants, it does not only consist of endothelial cells which have been
selected via cell passaging, but of endothelial cells and multiple other cell types which are in
a non-proliferative state and therefore closer to a real-life environment. It is even possible to
recapitulate all of the key steps of endothelial cell sprouting or angiogenesis: Matrix degrada‐
tion, that is to say breaking through the basal lamina, which is the second layer of mature vessel
enveloping the endothelial cells, migration toward a signal source, proliferation and finally
reorganization or tube-forming can be analyzed. After several days in culture image analysis
is used to measure length and abundance of the sprouting endothelial cells.
Although the situation in the aortic ring assay is closer to the in vivo environment than in
dissociated single cell culture assays, one has to deal with the higher experimental variability
due to animal strains and animal age. The main factors here are the incomplete removal of the
surrounding connective tissue which can affect the sprouting and outgrowth of endothelial
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cells, the tissue from multiple animals itself which can result in an inconstant angiogenic
response and last, the evaluation of the images, for the sprouting is a three-dimensional
process.
The aortic ring assay is a reliable assay to test substances for their potential to positively or
negatively affect angiogenesis and is able to monitor angiogenesis activity.
4. In vivo assays in neuro–oncology
4.1. Chronic window preparations
4.1.1. Rabbit ear chamber
In 1924 Sandison et al. developed the first chronic window preparation. They implanted a
transparent window chamber in the ear of a rabbit [77]. The preparation allows inspection of
an in vivo environment from outside the body, a long-term monitoring of angiogenesis is
possible. Clark et al. made the first steps by studying wound-healing associated angiogenesis
[78, 79]. Ide et al. adopted the method, transplanted tumors and were able to observe strong
tumour growth associated with a newly formed vascular network [80]. Their results led to the
proposal of a 'vessel growth- stimulating substance' produced by the tumor.
4.1.2. Dorsal skinfold chamber
The dorsal skinfold chamber is an adaption of the rabbit ear chamber made by Algire et al. in
the 1940s [81, 82]. A metal chamber with a transparent window is implanted in various animal
species, in rodents it is the most widely used window preparation. The dorsal window can last
30-40 days. To study the effect of tumors on vessel formation, fluorescent tumor cells are
implanted into the chamber and the angiogenic activity, infiltration by immune cells, tumor
cell migration and tumor growth are then monitored by intravital microscopy (IVM) [83, 84].
Figure 4. Aortic ring assay experiments. Phase-contrast images showing endothelial sprouting from aortic rings em‐
bedded in Matrigel and the method of quantification. To make the data comparable, we developed a tangents meas‐
ure methods. Tangents are set in respect to the ring and measurements can be conducted of the sprouting distance
with 90° to the tangent (white bars).
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lamina and other surrounding cells, researchers have moved to asses angiogenesis by organ
culture methods. Of these, the rat aortic ring assay has become one of the most widely used
ones. In particular, it has several advantages compared to “normal” in vitro single-cell culture:
As the assay is based on explants, it does not only consist of endothelial cells which have been
selected via cell passaging, but of endothelial cells and multiple other cell types which are in
a non-proliferative state and therefore closer to a real-life environment. It is even possible to
recapitulate all of the key steps of endothelial cell sprouting or angiogenesis: Matrix degrada‐
tion, that is to say breaking through the basal lamina, which is the second layer of mature vessel
enveloping the endothelial cells, migration toward a signal source, proliferation and finally
reorganization or tube-forming can be analyzed. After several days in culture image analysis
is used to measure length and abundance of the sprouting endothelial cells.
Although the situation in the aortic ring assay is closer to the in vivo environment than in
dissociated single cell culture assays, one has to deal with the higher experimental variability
due to animal strains and animal age. The main factors here are the incomplete removal of the
surrounding connective tissue which can affect the sprouting and outgrowth of endothelial
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cells, the tissue from multiple animals itself which can result in an inconstant angiogenic
response and last, the evaluation of the images, for the sprouting is a three-dimensional
process.
The aortic ring assay is a reliable assay to test substances for their potential to positively or
negatively affect angiogenesis and is able to monitor angiogenesis activity.
4. In vivo assays in neuro–oncology
4.1. Chronic window preparations
4.1.1. Rabbit ear chamber
In 1924 Sandison et al. developed the first chronic window preparation. They implanted a
transparent window chamber in the ear of a rabbit [77]. The preparation allows inspection of
an in vivo environment from outside the body, a long-term monitoring of angiogenesis is
possible. Clark et al. made the first steps by studying wound-healing associated angiogenesis
[78, 79]. Ide et al. adopted the method, transplanted tumors and were able to observe strong
tumour growth associated with a newly formed vascular network [80]. Their results led to the
proposal of a 'vessel growth- stimulating substance' produced by the tumor.
4.1.2. Dorsal skinfold chamber
The dorsal skinfold chamber is an adaption of the rabbit ear chamber made by Algire et al. in
the 1940s [81, 82]. A metal chamber with a transparent window is implanted in various animal
species, in rodents it is the most widely used window preparation. The dorsal window can last
30-40 days. To study the effect of tumors on vessel formation, fluorescent tumor cells are
implanted into the chamber and the angiogenic activity, infiltration by immune cells, tumor
cell migration and tumor growth are then monitored by intravital microscopy (IVM) [83, 84].
Figure 4. Aortic ring assay experiments. Phase-contrast images showing endothelial sprouting from aortic rings em‐
bedded in Matrigel and the method of quantification. To make the data comparable, we developed a tangents meas‐
ure methods. Tangents are set in respect to the ring and measurements can be conducted of the sprouting distance
with 90° to the tangent (white bars).
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The main limitation of this model is the non-organotypical environment of tumors other than
skin cancer.
4.2. Chick embryo chorioallantoic membrane (CAM-) assay
A widely performed assay to test angiogenesis in vivo is the chorioallantoic membrane (CAM-)
assay. Initially, Murphy et al. [85] implanted rat Jensen sarcoma cells into the CAM of chicken
eggs and were able to show signs of tumor-induced angiogenesis. Highly promoted by
Folkman et al., the CAM-assay has been transposed to the developing field of angiogenesis [86].
Since the introduction of the CAM-assay almost a century ago multiple modifications of the
original angiogenic assay were made which allow quantification of the angiogenic process. In
addition chick embryos are immune-incompetent until embryonic day 17. Therefore grafting
of cells of different species (e.g. human tumor cells) is possible so that the CAM-assay became
a useful tool for analysis of the proangiogenic potential of test cells. The HET-CAM developed
by Niels-Peter Lüpke in 1985 [87, 88] and the CAMVA (chorio allantoic membrane vascular
assay) are the two modified CAM-assays mainly used in the field of angiogenesis.
The hen’s egg test on the chorioallantoic membrane (HET-CAM-) assay is an organotypic
model which was initially designed to replace the highly discussed Draize-test to identify
irritative reactions in the eye: haemorrhage, lysis and coagulation. These three reactions of the
CAM are observed on the ninth day of embryonation. Test substances are applied directly onto
the CAM and the membrane is scanned after five minutes for the above named reactions.
Further the test allows analysis for angiogenesis of tumor-models growing on the CAM.
The CAMVA monitors the effects of potential eye irritants, drugs or other chemicals on the
blood vessels of the CAM. It was developed by Leighton et al. [89] in 1985 and adjusted to
industrial laboratory standards by Bagley et al. [90, 91]. The chorioallantoic membrane vascular
assay is considered suitable as an option to replace animal trials to study vascular effects. The
preparation of the test starts with an egg four days after fertilization in which a small window
over the CAM is cut. By sucking out approximately 3 ml of albumen, best conditions are created
for optimal growth of the CAM. Thereafter, the opening is resealed and the eggs incubated for
another six days. In the course of incubation, test substances are applied directly onto the CAM,
followed by an examination for vascular changes in the CAM. Changes observed are hyper‐
aemia, haemorrhaging and the occurrence of ghost vessels.
4.3. Subcutaneous Air Sac model (SAS)
The rat subcutaneous air sac (SAS-) model was promoted by Lichtenberger et al. [92, 93] as a
straightforward method to study anti-angiogenesis in vivo. A sac is produced by introducing
air dorsally to anesthetized rats via subcutaneous injection. So that the wall of the air sac
becomes progressively thicker in time, the air sac is re-inflated every fourth day. After 10-14
days an acceptable lining of cells has been grounded and an almost transparent avascular
membrane has been created. Before treated another 10 days subcutaneously with various test
compounds, a sponge is implanted into the cavity. It is important to choose a good injection
site which eliminates the risk of interfering and irritating the membrane. To study tumor-
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induced angiogenesis, tumor cells are inoculated subcutaneously on the membrane. Funahashi
et al. modified the assay and use a tumor cell-containing chamber to determine the angiogenic
effect. After the 10-day-treatment the animals are being sacrificed, the overlying skin of the air
sac is removed and the transparent membrane is evaluated in situ for angiogenesis.
4.4. Matrigel plug assay
Most angiogenesis in vivo assays are very complex in both, the experimental setup and the
surgical skills one needs. The matrigel plug assay is a simple in vivo angiogenesis assays.
Derived from the engelbroth-holm-swarm (EHS) mouse sarcoma, the matrigel matrix is
comparable to basement membrane proteins. It is “loaded” with either cells (mostly tumor
cells) or angiogenesis-inducing substances (FGF, VEGF, etc.). Cold (and therefore liquid)
matrigel is injected subcutaneously in nude mice. With increasing temperature the gel
solidifies and forms a plug, which allows cell growth and vessel formation [94]. The plug is
removed from the animal after 7-21 days inoculation, fixed with paraffin, stained and exam‐
ined histologically.
The main benefit of the matrigel plug assay is that it is relatively easy and fast to perform, nei‐
ther special experimental setup nor surgical skills are required and the test materials are avail‐
able without difficulty. Nevertheless, the assay is limited to its specific organotypic location, i.e.
subcutaneous. Further, matrigel is a reconstituted matrix, with a particular biochemical com‐
position. In addition, Auerbach et al. reported considerable difficulties to maintain compara‐
ble three-dimensional plugs despite the fact that the gel volume is kept constant [95].
5. New ex vivo model for tumor angiogenesis
5.1. The Organotypic Glioma Invasion Model (OGIM)
The Organotypic Glioma Invasion Model (OGIM) is a recently developed method to study
physiological angiogenesis and tumor-induced angiogenesis and allows researchers to
address systematically molecular pathways of angiogenesis as well as tumor-vessel interac‐
tions [96, 97]. Furthermore, it is possible to monitor neuronal and tumor cell death, tumor
proliferation and migration in time lapse with focus on specific tumor-host interactions and
tumor microenvironment. The method bridges in vitro and in vivo-assays, since all cells of the
brain (astrocytes, oligodendrocytes, neurons, ependymal cells microglia and vessels) are
present in a natural environment.
Hippocampal brain slice cultures are acquired from postnatal rats and enhanced green
fluorescent protein expressing rat glioma cells are implanted into slices in culture. After
implantation cell death can be monitored in different regions of interest: The tumor bulk, the
peritumoral invasion zone and the surrounding tissue. The brain slices can be kept in culture
for several days after tumor implantation. Consecutively, various immunohistochemical
staining for vessels can be performed. Beside the classical vessel marker, the platelet/endo‐
thelialmembrane cell adhesion molecule-1 (PECAM-1 or CD31), staining can also be per‐
Brain Tumor–Induced Angiogenesis: Approaches and Bioassays
http://dx.doi.org/10.5772/53182
137
The main limitation of this model is the non-organotypical environment of tumors other than
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assay. Initially, Murphy et al. [85] implanted rat Jensen sarcoma cells into the CAM of chicken
eggs and were able to show signs of tumor-induced angiogenesis. Highly promoted by
Folkman et al., the CAM-assay has been transposed to the developing field of angiogenesis [86].
Since the introduction of the CAM-assay almost a century ago multiple modifications of the
original angiogenic assay were made which allow quantification of the angiogenic process. In
addition chick embryos are immune-incompetent until embryonic day 17. Therefore grafting
of cells of different species (e.g. human tumor cells) is possible so that the CAM-assay became
a useful tool for analysis of the proangiogenic potential of test cells. The HET-CAM developed
by Niels-Peter Lüpke in 1985 [87, 88] and the CAMVA (chorio allantoic membrane vascular
assay) are the two modified CAM-assays mainly used in the field of angiogenesis.
The hen’s egg test on the chorioallantoic membrane (HET-CAM-) assay is an organotypic
model which was initially designed to replace the highly discussed Draize-test to identify
irritative reactions in the eye: haemorrhage, lysis and coagulation. These three reactions of the
CAM are observed on the ninth day of embryonation. Test substances are applied directly onto
the CAM and the membrane is scanned after five minutes for the above named reactions.
Further the test allows analysis for angiogenesis of tumor-models growing on the CAM.
The CAMVA monitors the effects of potential eye irritants, drugs or other chemicals on the
blood vessels of the CAM. It was developed by Leighton et al. [89] in 1985 and adjusted to
industrial laboratory standards by Bagley et al. [90, 91]. The chorioallantoic membrane vascular
assay is considered suitable as an option to replace animal trials to study vascular effects. The
preparation of the test starts with an egg four days after fertilization in which a small window
over the CAM is cut. By sucking out approximately 3 ml of albumen, best conditions are created
for optimal growth of the CAM. Thereafter, the opening is resealed and the eggs incubated for
another six days. In the course of incubation, test substances are applied directly onto the CAM,
followed by an examination for vascular changes in the CAM. Changes observed are hyper‐
aemia, haemorrhaging and the occurrence of ghost vessels.
4.3. Subcutaneous Air Sac model (SAS)
The rat subcutaneous air sac (SAS-) model was promoted by Lichtenberger et al. [92, 93] as a
straightforward method to study anti-angiogenesis in vivo. A sac is produced by introducing
air dorsally to anesthetized rats via subcutaneous injection. So that the wall of the air sac
becomes progressively thicker in time, the air sac is re-inflated every fourth day. After 10-14
days an acceptable lining of cells has been grounded and an almost transparent avascular
membrane has been created. Before treated another 10 days subcutaneously with various test
compounds, a sponge is implanted into the cavity. It is important to choose a good injection
site which eliminates the risk of interfering and irritating the membrane. To study tumor-
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induced angiogenesis, tumor cells are inoculated subcutaneously on the membrane. Funahashi
et al. modified the assay and use a tumor cell-containing chamber to determine the angiogenic
effect. After the 10-day-treatment the animals are being sacrificed, the overlying skin of the air
sac is removed and the transparent membrane is evaluated in situ for angiogenesis.
4.4. Matrigel plug assay
Most angiogenesis in vivo assays are very complex in both, the experimental setup and the
surgical skills one needs. The matrigel plug assay is a simple in vivo angiogenesis assays.
Derived from the engelbroth-holm-swarm (EHS) mouse sarcoma, the matrigel matrix is
comparable to basement membrane proteins. It is “loaded” with either cells (mostly tumor
cells) or angiogenesis-inducing substances (FGF, VEGF, etc.). Cold (and therefore liquid)
matrigel is injected subcutaneously in nude mice. With increasing temperature the gel
solidifies and forms a plug, which allows cell growth and vessel formation [94]. The plug is
removed from the animal after 7-21 days inoculation, fixed with paraffin, stained and exam‐
ined histologically.
The main benefit of the matrigel plug assay is that it is relatively easy and fast to perform, nei‐
ther special experimental setup nor surgical skills are required and the test materials are avail‐
able without difficulty. Nevertheless, the assay is limited to its specific organotypic location, i.e.
subcutaneous. Further, matrigel is a reconstituted matrix, with a particular biochemical com‐
position. In addition, Auerbach et al. reported considerable difficulties to maintain compara‐
ble three-dimensional plugs despite the fact that the gel volume is kept constant [95].
5. New ex vivo model for tumor angiogenesis
5.1. The Organotypic Glioma Invasion Model (OGIM)
The Organotypic Glioma Invasion Model (OGIM) is a recently developed method to study
physiological angiogenesis and tumor-induced angiogenesis and allows researchers to
address systematically molecular pathways of angiogenesis as well as tumor-vessel interac‐
tions [96, 97]. Furthermore, it is possible to monitor neuronal and tumor cell death, tumor
proliferation and migration in time lapse with focus on specific tumor-host interactions and
tumor microenvironment. The method bridges in vitro and in vivo-assays, since all cells of the
brain (astrocytes, oligodendrocytes, neurons, ependymal cells microglia and vessels) are
present in a natural environment.
Hippocampal brain slice cultures are acquired from postnatal rats and enhanced green
fluorescent protein expressing rat glioma cells are implanted into slices in culture. After
implantation cell death can be monitored in different regions of interest: The tumor bulk, the
peritumoral invasion zone and the surrounding tissue. The brain slices can be kept in culture
for several days after tumor implantation. Consecutively, various immunohistochemical
staining for vessels can be performed. Beside the classical vessel marker, the platelet/endo‐
thelialmembrane cell adhesion molecule-1 (PECAM-1 or CD31), staining can also be per‐
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formed with antibodies against laminin, factorVIII (von Willebrand - factor), and smooth
muscle actin (SMA). Anti-laminin is used to stain the basal membrane, anti-vWF for endothe‐
lial cells and anti-SMA for pericytes.
Figure 5. The Organotypic Glioma Invasion Model (OGIM) for angiogenesis studies. Left, Scheme of the brain
slice and its vessels in the hippocampus and entorhinal cortex. The vessel architecture in the peritumoral invasion zone
differs highly from that of the tumor zone and control area. Right, the fluorescent image shows a typical example of a
GFP-tumor-implanted brain slice after immunohistochemistry performed for vessels. Green: glioma cells, blue: nuclei,
red: laminin staining. The image is given as x4 magnification.
The OGIM measures vessel density (overlaying grid method), branching as well as morpho‐
logical vessel aberrations such as tortuous, disorganized vessels, blind-ends and auto-loops.
It is also possible to monitor and analyze vascular mimicry in a time lapse mode. In our lab
we established glioma vessel features over time. The regular vessel architecture ranging from
big lumen vessels down to arteriols, metarteriols and capillaries is breached and replaced by
a chaotic vessel structure with probable back-and-forth blood flow and non-functional vessels
with blind ends in tumors. Moreover a high-density microvessel network is produced via
tumor-induction. The organotypic brain slice model represents the tumor microenvironment
in vitro in a three-dimensional culture [98], which is biologically more relevant, but technically
more challenging than migration, proliferation and cytotoxic assays being an appropriate
possibility to test and optimize anti-cancer compounds.
6. Conclusion
The current development of the tumor angiogenesis field with newly identified angiogenic fac‐
tors craves for robust, viable and easy to perform assays which are also assessable for analysis.
Although divergent opinions exist on what are the best methods for studying angiogenesis,
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several in vitro bio-assays have been established and are in worldwide use. Here we described
various established in vitro assays commonly used in the phase of expedition and confirma‐
tion. Since at least four key steps in angiogenesis exist, i.e. proliferation, migration and inva‐
sion, sprouting and vessel formation, and vessel modeling and reorganization (maturation,
regression). Thus, in vitro bio-assays cannot reflect all key events in one. In principle, this is also
the case for in vivo assays. For this reason, assays make certain key vascular events assessable in
a short period of time leaving others not detected. So far, established endothelial cell culture as‐
says have a high level of redundancy and utilize endothelial cells from different origin which
have been preselected for their proliferative capacity. In addition, in vitro tissue assays have
been established which also consider the microenvironment and represent higher cellular com‐
plexity. Further, regarding the amount of data in vitro tests can generate, it appears also neces‐
sary to spent efforts on the precise evaluation system to be used. Some in vitro assays such as
the tube formation assay allow not only for one parameter to investigate, i.e. tube formation,
but open the possibility to analyze also the dynamic and morphology of such tubes. In vivo as‐
says are more demanding in terms of material, time and labor. Also, these assays often require
surgical skills. With all the interactions present, evaluation of certain angiogenesis processes
can be hard to perform accurately. On the other hand, in vivo assays reflect the organotypic en‐
vironment and cellular components involved. When developing antiangiogenic drugs, assays
are needed that are easy to perform in a short period of time and that consider certain aspects of
the in vivo situation to prevent artificial phenomena. We describe here a bridge technique, i.e.
the organotypic glioma invasion model (OGIM), which combines the advantages of in vitro assays
with that of the organotypic brain environment as an in vivo situation [98]. The OGIM is a ro‐
bust in vitro assay enabling the investigation of key events of tumor angiogenesis within the
brain. This assay allows to analyze the impact of a therapeutic within the balance of concerted
factors promoting and inhibiting angiogenesis.
Acknowledgements
We thank all members of our neurooncology lab for critical suggestions and valuable com‐
ments during developing new techniques. Our work is supported in part by the German
Research Foundation (DFG grant Ey 94/2-1).
Author details
Stefan W. Hock, Zheng Fan, Michael Buchfelder, Ilker Y. Eyüpoglu and Nic E. Savaskan*
*Address all correspondence to: Savaskan@gmx.net
Department of Neurosurgery, University of Erlangen-Nuremberg, Schwabachanlage, Erlan‐
gen, Germany
The authors declare no competing financial interests.
Brain Tumor–Induced Angiogenesis: Approaches and Bioassays
http://dx.doi.org/10.5772/53182
139
formed with antibodies against laminin, factorVIII (von Willebrand - factor), and smooth
muscle actin (SMA). Anti-laminin is used to stain the basal membrane, anti-vWF for endothe‐
lial cells and anti-SMA for pericytes.
Figure 5. The Organotypic Glioma Invasion Model (OGIM) for angiogenesis studies. Left, Scheme of the brain
slice and its vessels in the hippocampus and entorhinal cortex. The vessel architecture in the peritumoral invasion zone
differs highly from that of the tumor zone and control area. Right, the fluorescent image shows a typical example of a
GFP-tumor-implanted brain slice after immunohistochemistry performed for vessels. Green: glioma cells, blue: nuclei,
red: laminin staining. The image is given as x4 magnification.
The OGIM measures vessel density (overlaying grid method), branching as well as morpho‐
logical vessel aberrations such as tortuous, disorganized vessels, blind-ends and auto-loops.
It is also possible to monitor and analyze vascular mimicry in a time lapse mode. In our lab
we established glioma vessel features over time. The regular vessel architecture ranging from
big lumen vessels down to arteriols, metarteriols and capillaries is breached and replaced by
a chaotic vessel structure with probable back-and-forth blood flow and non-functional vessels
with blind ends in tumors. Moreover a high-density microvessel network is produced via
tumor-induction. The organotypic brain slice model represents the tumor microenvironment
in vitro in a three-dimensional culture [98], which is biologically more relevant, but technically
more challenging than migration, proliferation and cytotoxic assays being an appropriate
possibility to test and optimize anti-cancer compounds.
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The current development of the tumor angiogenesis field with newly identified angiogenic fac‐
tors craves for robust, viable and easy to perform assays which are also assessable for analysis.
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the case for in vivo assays. For this reason, assays make certain key vascular events assessable in
a short period of time leaving others not detected. So far, established endothelial cell culture as‐
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There is a convergence between ontogenesis and carcinogenesis. In theory all antigens
correspond to a specific stage of embryo/fetal development. These antigens – oncodevelop‐
mental proteins - are also present in homologous neoplatic tissues during cancer growth. The
first illustration of this theory is alpha-fetoprotein (AFP), a common tumor marker, which is
present during the normal development of central nervous system of the rat. Immunohisto‐
chemical analysis of the localization of AFP during normal development of the central nervous
system and in pathological homologous nervous tissues of teratocarcinoma, shows a remark‐
able parallelis [1]. A similar demonstration was demonstrated for serum albumin antigen and
blood group H antigen [2]. As AFP was a specific marker for neuronal cells, a search for a
specific marker of glial cells has constituted the next step in the nervous system research to
distinguish glial and neuronal cells, because the known markers were not totally specific. It
was demonstrated that the growth factor IGF-I (Insulin like Grow Factor I) [3-6] is present only
in glial cells, and absent in neuronal cells in normal and neoplastic developmen [7]. IGF-I is,
therefore, a specific marker of glioblastoma. The use of IGF-I for the study of malignant tumors,
including the gliomas, became the best choice as a marker [8-10].
1.2. Anti — Gene strategies
1.2.1. Antisense
For nearly twenty years various treatments of tumors, based on the injection of antibodies
directed against specific antigens and stem cells have been tested. The results were not
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successful because of non-selective affinity for the tumor. Moreover, direct injection of protein
coupled to an isotope such as iodine-125, has also posed the problem of the limited specificity
of the distribution of the protein [11]. After that, the researchers have approached the study in
a radically different way, trying to stop the production of IGF-I, acting directly on the mes‐
senger RNA [7,12].
Since 1978 it is known that antisense messengers are naturally produced and destroyed in the
process of DNA replicatio [13-17]. The authors successfully demonstrated that this phenom‐
enon is possible in twenty different species. Fortunately, the researchers could produce
artificial antisense messengers in a significant number [12,17-19]. Moreover, using antisense
oligonucleotides associated with the photoluminescent amino-terminated poly amido amine
dendrimer, they can be directly analyzed by fluorescence microscopy and flow cytometry [20].
The antisense sequences are capable of blocking the messenger RNA translation conducting
to block of specific protein synthesis.
1.2.2. Triple helix
Since the 90s, another approach in parallel with the strategy of antisense RNA has become
successful in gene therapy and clinical trials: the triple helix strategy [21-23]. The triple helix
technology (HT) is the newest approach, which belongs to the antisense approach and sensu
lato anti gene strategies. TH technology was discovered by PB Derwan and C. Helene [24,25]
and its action was defined as inhibition of gene expression at the level of transcription. In short,
specific oligonucleotide sequences (also called triple helix-forming oligonucleotides, TFOs) are
introduced into cells by transfection using chemical carriers, such as plasmid vectors which
can direct synthesis TFOs. The TFOs are linked to the genomic DNA forming the triple helix
structure with the target gene and inhibiting its transcription. The TFOs usually are directed
against sequences located in the promoter region of genes of interest [24]. Examples of the
inhibitory activity of TFOs on target genes involved in tumorigenesis are currently available.
This approach, based on the triple helix of DNA has been used for the inhibition of IGF-I, which
plays a major role in tumorigenesis [26]. Triplex strategy has also been applied to the inhibition
of Ras oncogenes which are the most frequently activated in human cancer. Transcription was
inhibited by human Hras TFOs targeting sequences recognized by the transcription factor Sp
I [27]. Moreover, synthesis of Human Tumor Necrosis Factor (TNF), which acts as an autocrine
growth factor in various tumor cell lines including neuroblastoma and glioblastoma has been
blocked by treatment with TFOs [28,29].
2. Experimental results
2.1. In vitro and in vivo experiments on glioma tumors
The vector of antisense type was transfected into established glioma C6 cell line. All transfected
cells have changed phenotype. Morphologically these cells had an elongated appearance.
Transfected glial cells have produced a large amount of antisense RNA [7,30].
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Regarding in vivo experiment, subcutaneous injection of C6 glioma cells into DBX rats have
produced a glioma tumor after ten days. When transfected glioma cells were injected (with
vector carrying the cDNA antisense against IGF-I) the tumors did not develop.
The experience was reproducible in 200 rats and the results were confirmatory. It was
demonstrated that if injected initially native C6 glioma cells were followed a week later by
injection into another point of subcutaneously transfected glial cells, the tumor developed, but
disappeared completely after 2 to 3 weeks [12].
The tumor examined histologically shortly before the death of animals, have shown an
important lymphocytes / plasmocytes infiltration. Histological analysis of the tumor during
its disappearance suggests that the essential mechanism is related to the presence of specifically
CD8 + cytotoxic T lymphocytes. Systematic analysis of all tissues showed that these lympho‐
cytes were of splenic origin, and were observed in very large quantities in the spleen of
experimental animals (10 to15%) [12,31,32].
2.2. Mechanism of glioma tumor destruction
The cytotoxic T CD8+ cell can exert its effect, if a bridge between CD8 and the antigen of class
I major histocompatibility complex (MHC) occurs [33-36]. Following transfection of glial cells
with the antisense cDNA of IGF-I, the expression of MHC-I in transfected glioma cells and in
vivo, is greatly enhanced (5 times). This mechanism may play a role in the cytotoxic response,
although not the only one involve [37]. The bearing tumor rats receiving injections of trans‐
fected cells, have revealed a very high rate of CD8 + cells. This anti-tumor immune response
has stopped the tumor development [12,31,38-40].
3. Application in clinical trial
3.1. Ethical committees
Approval for the clinical trial of gene therapy (based on the NIH clinical study No 1602,
Bethesda, Maryland, 24. 11. 1993) [41] was administered by the Commission of Bioethics at
the University of Medicine, Bromberg (No KB / 176/2001, 28. 06. 2002) and registered by
Wiley International Gene Therapy Clinical Trial database No. 635 and 636 (J  Gene Med,
updated 2002), and by NATO Science program 2003/2007 - USA, France, Poland, Germany
(LST 980 517).
3.2. Conditions
The NIH Committee raised a number of conditions. Initially, for all patients, tumor cells must
be isolated from biopsies and cells clones to be used should be only IGF-I and GFAP positive.
NIH also requires that all cells are irradiated with a dose of 5000 cGy before reinjection, to
avoid the possibility of subsequent cell divisions. After irradiation, the cells must be main‐
tained in cell culture for 24 hours.
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The elimination of the plasmid in the cells before injection is ensured by the possibility of a
deletion in vitro of the hygromicine for 2 to 3 weeks. (The safety of the method was guaranteed
by the use of an episomal vector without the risk of integration of the DNA vector).
Gene therapy will be preceded by a lymphocyte transformation test (TTL): in vitro, the
lymphocytes of patients with glioblastoma are brought into contact with their own tumor cells
transfected; the increase in tritiated thymidine incorporation will allow to demonstrate the
stimulation of immune cells.
The first stage is the biopsy, to harvest the cells for transfection in vitro. This step requires 4 to
6 weeks. Then, cells are frozen after verification that all cells are positive for IGF-I and GFA.
In case of cellular heterogeneity after cloning, only IGF-I positive population will be frozen
and preserved. The transfected cells should not produce IGF-I. The cells before injection should
be irradiated. The first authorization was granted in 1994 to 12 patients [30,41].
3.3. Methodology
Primary cultures of glioma cells were etablished from biopsies of human glioblastoma patients
[40]. The human glioma cell lines were transfected with plasmid vector of the "triple helix"
pMT-AG TH type [26]. Clones of transfected cells, no expressing IGF-I but expressing MHC-
I and B7 molecules, were selected one month after transfection. Prior to injection the transfected
cells were irradiated with cGy. The first injection was performed using only cell membranes
[42,43] derived from 100 000 cells, followed by two cell injection of 1 – 2 million cells, with
interval of one month each (subcutaneous injection in the left arm of patients). Blood was
collected before the first “membrane” vaccination, and then 3 weeks after the first and second
injection. The labeling of peripheral blood lymphocytes (PBL) was performed using mouse
monoclonal antibodies directed against cell surface antigens. The samples of monoclonal
antibodies were used for flow cytometric analysis as follows: FITC conjugated - (a) CD45, (b)
of CD4, (c) CD3, (d) CD25, (e) CD45RO, ( f) CD19 (g) CD8, (h) CD8CD11b +, (i) IgG1 control
antibody, and these conjugated with PE - (a) CD14, (b) CD8, (c) CD16 + CD6, (d) CD4 (CD8),
e) CD4 (CD8), (f) CD5, (g) CD8CD11b-, (h) CD8CD28, (i) IgG2 (18,27) [43].
4. Clinical results
The promising results were obtained in six patients at University Hospitals of Cleveland, in
two patients in Bangkok and in four patients at the University Hospital of Bromberg. Admit‐
ting that the group of glioblastoma patients treated with antisense/triple helix cell injection
has given the significant results, comparatively studied two cases of colon cancer and two cases
of prostate cancer patients were treated, after surgery and radiotherapy with this type of
“cellular therapy (Hospital of Bromberg).
Significant changes were observed mainly after the first cell vaccination. Phenotypic changes
in peripheral blood lymphocytes were as follows: an increase in the percentage of CD8 + T cells
accompanied in parallel by an increase of CD8 + CD11b- and CD8CD28 + molecules, after each
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Figure 1. Antisense anti – IGF-I therapy. After in vitro transfection of tumor cells with a vector containing IGF-I cDNA
in antisense orientation, the cells express IGF-I antisense RNA; the cells become negatively labeled with anti IGF-I anti‐
bodies, and positively with anti MHC-I and B7 antibodies. On the other hand, about half of these transfected cells be‐
come apoptotic. Both immune and apoptotic phenomena are related to signal transduction pathway. The injected
transfected cells including apoptotic cells, together with induced in vivo APC cells, activat T lymphocytes (CTLCD8 +
CD28 +). Activated CTL produce an antitumor immune response [40,44,47,61,79,80-83]. Abreviations: TAP 1,2 (trans‐
porter associated with antigen processing antigen); TK (tyrosine kinase); PI3K (phosphatidyinositol 3 kinase); PDK1
(phosphoinositide-dependent kinase 1); AKT (PKB, protein kinase B); Bcl 2 (key molecule of apoptose); GSK3 (glyco‐
gene synthetase kinase 3); GS (glycogene synthetase); MAPK (MAP kinase – mitogen activated protein kinase); PKC
(protein kinaseC C).
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of the three vaccinations. This alteration may reflect the increased activation of T cells cytotoxic
blood (Figure 1.). Additionally, it was observed an increased percentage of lymphocytes
positive for surface receptor of interleukin-2 (CD25). No changes were demonstrated in other
CD molecules [44]. In our ongoing work (new protocol), 4 and 5 injections of IGF-I TH cells
were introduced in patients with glioblastoma. After the fourth injection, the samples of the
blood obtained from treated patients have shown a progressive increase in CD8 and NK cells,
which highlights the effect of treatment on immune response. Also an increase of CD25
molecules was observed after the second and third injection. There was no difference before
or after vaccination in the levels of CD3, CD16 + CD56, CD19, CD5, CD45 and CD14. The only
side effect was a fever of 38°C noted after cell vaccinations. That probably corresponds to a
cellular immune response (T cell induction). These changes may reflect the increased activation
of cytotoxic T cells [36,45-47].
One glioblastoma patient who was treated at University Hospital of Cleveland, had lived 24
months from the time of diagnosis. Among other five glioblastoma patients treated in U.S.A.
(University Hospital of Cleveland), two of the patients have survived 19 months. The treatment
in U.S.A. has shown that the number of cell vaccines (between two and four) was not related
to median survival of the patients. Another group of three patients treated in the U.S.A. have
not responded so positively to therapy. These patients had an advanced disease with cerebral
edema before gene therapy and were also treated with high doses of decadron or related
steroids to reduce the effect of edema in CNS. Of course, this additional treatment has
produced a negative effect on immune response and survival of patients. In two of the four
patients with glioblastoma multiforme treated in Bromberg (NATO Science Program - USA /
France / Poland / Germany), the average survival has ranged from 19 to 24 months, whereas
the two patients in the control group survived 9.5 and 10 months respectively. Histopatho‐
logical examination of removed glioblastoma tumors has shown that subjects had developed
a necrosis around the tumor. Moreover the necrotic tissue surrounding the tumor has shown
an infiltration of CD4 + and CD8 + T lymphocytes [32]. As to colon and prostate cancer patients
the period of 19 months was also chosen as the end of clinical observations in all treated cancer
patients. At 19 months, all these cancer patients were alive and the treatments were well
tolerated. The PBL labelling results were similar to those obtained with glioblastoma patients
(Figure 2. A,B,C) [48].
5. Discussion
The significant clinical findings were published in 2006/2012; it was demonstrated that due to
the use of AS anti - IGF-I therapy following radiotherapy, the median survival of glioblastoma
patients has reached 21 months. In 2010 we have reported that this survival could be explained
by the immune anti-tumor response related to the increase of CD28 molecules in PBL cells
analyzed after every of two "vaccinations". Moreover, this phenomenon was also observed in
other tumors studied (four cases of liver cancer, colon, ovary, uterus and prostate). Phenotypic
changes in peripheral blood lymphocytes (PBL) were clearly observed in all types of cancer
treated with "cell therapy" - after every vaccination, an increase of CD8 + T lymphocytes,





Figure 2. Flow cytometric “FACS” peripheral blood lymphocyte CD marker patterns following comparative therapies
in cancers of neuroectodermal origin - glioblastoma multiforme (A), entodermal origin – colon adenocarcinoma (B),
and mesodermal origin – prostate adenocaarcinoma (C). CD molecules were labelled in peripheral blood lymphocytes
(PBLs) obtained from prevaccinated and “vaccinated” patients. Each of the first column corresponds to data obtained
before vaccinations; each second and third column corresponds to data obtained after one and two successive cellular
vaccinations (IGF-I antisense/triple helix cells). Bar graphs represent the median value of the two cases. Data are ex‐
pressed as percent of positive cells when compared to the isotype control. Difference in percentage of CD8+ CD11b−
and CD8+ CD28+ subpopulations from the relevant patients before and after vaccination was strongly significant with
a range of P from 0.001 to 0.02 according to the Student’s t-test. The P value for CD8+, CD8+28+, and CD8+11b−
(below 0.01) is illustrated in the bar graph for statistical significance.
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tolerated. The PBL labelling results were similar to those obtained with glioblastoma patients
(Figure 2. A,B,C) [48].
5. Discussion
The significant clinical findings were published in 2006/2012; it was demonstrated that due to
the use of AS anti - IGF-I therapy following radiotherapy, the median survival of glioblastoma
patients has reached 21 months. In 2010 we have reported that this survival could be explained
by the immune anti-tumor response related to the increase of CD28 molecules in PBL cells
analyzed after every of two "vaccinations". Moreover, this phenomenon was also observed in
other tumors studied (four cases of liver cancer, colon, ovary, uterus and prostate). Phenotypic
changes in peripheral blood lymphocytes (PBL) were clearly observed in all types of cancer
treated with "cell therapy" - after every vaccination, an increase of CD8 + T lymphocytes,





Figure 2. Flow cytometric “FACS” peripheral blood lymphocyte CD marker patterns following comparative therapies
in cancers of neuroectodermal origin - glioblastoma multiforme (A), entodermal origin – colon adenocarcinoma (B),
and mesodermal origin – prostate adenocaarcinoma (C). CD molecules were labelled in peripheral blood lymphocytes
(PBLs) obtained from prevaccinated and “vaccinated” patients. Each of the first column corresponds to data obtained
before vaccinations; each second and third column corresponds to data obtained after one and two successive cellular
vaccinations (IGF-I antisense/triple helix cells). Bar graphs represent the median value of the two cases. Data are ex‐
pressed as percent of positive cells when compared to the isotype control. Difference in percentage of CD8+ CD11b−
and CD8+ CD28+ subpopulations from the relevant patients before and after vaccination was strongly significant with
a range of P from 0.001 to 0.02 according to the Student’s t-test. The P value for CD8+, CD8+28+, and CD8+11b−
(below 0.01) is illustrated in the bar graph for statistical significance.
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particularly of CD8+11b-, accompanied by a characteristic shift of CD8+11b+ to CD8+11b-
(Figure 2.). This phenomenon was practically not significant in a group of patients treated only
with "membrane" injections (as applied to two patients with glioblastoma) [47,48].
Glioblastoma and other malignancies were recently successfully treated with antisense
therapy focused on TGF beta [49], using either antisense anti TGF beta expressing vector
[50,51] or direct use of antisense oligodeoxynucleotides [52,53]. The use of phosphorothioate
antisense oligonucleotides TGF beta2 (AP-12009, trabedersen) was initiated in patients with
tumors that showed overexpression of TGF beta, such as high-grade gliomas - anaplastic
astrocytoma (AA) or glioblastoma. Treatment was well tolerated. In 2007, the overall survival
time was about 24 months, and in the control group, survival was 20 months. Recently, in three
phase I/II studies and a randomized, active-controlled dose-finding phase IIb study, trabe‐
dersen treatment of high-grade glioma patients with recurrent or refractory tumor disease led
to long-lasting tumor responses and so far promising survival data [52,54,55]. The results of
clinical trials with other tumors that overexpress TGF beta have also been published recently
[52,56]. Recently, the antisense approach, using also antisense oligonucleotides, targeting
tumor neovascular trimer protein, laminin-411, was also proposed for clinical trial [57]. The
innovation concerns a polymeric nanobioconjugate drug based on biodegradable, nontoxic,
and nonimmunogenic polymalic acid as a universal delivery nanoplatform; this platform is
applied for synthesis of nanomedicine drug which passes through the blood brain tumor
barrier and tumor cell membrane. Other approach of antisense treatment, especially using
antisense IGF-I-receptor has been developed [58-60]. It seems that this therapy, could be more
efficient if the "cell vaccines" would be prepared after cell cloning for the expression of MHC-
I. The different examples of antisense strategy in experimental and clinical trials of gliomas
are showed in Table 1.
IGF-I Antisense vector
Clinical trial
Trojan et al. Biomed & Pharmacother 2010; 64(8):
TGF beta








Ding et al. Proc Natl Acad Sci USA 2010; 107(42):18143.
AKT2 Antisense oligonucleotide
Experimental therapy
Zhang et al. Oncol Rep 2010;24(1):65.
EGFR Antisense oligonucleotide
Experimental therapy





Botta et al. Hum Gene Ther 2010; 21(9): 1067.
miR-21 & 5FU Antisense oligonucleotide
Experimental therapy
Ren et al. J Biomater Sci Polym Ed 2010; 21(3): 303.
miR-21 Antisense oligonucleotide Zhou et al. Lab Invest. 2010; 90(2): 144.
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Kang et al. J Biomed Mater Res A 2010; 93(2): 585.
VEGF Antisense (vector)
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Wang et al., Mol Med Report. 2010; 3(6): 935.
c-Met Antisense oligonucleotide
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Katsushima et al., J Biol Chem. 2012 Jun 26. [Epub]
Table 1. Examples of experimental and clinical gene therapies of gliomas using antisense technology (selection of
articles of last two years).
In the strategies of anti TGF-beta and anti IGF-I and anti IGF-IR antisense techniques, the anti-
tumor immune response was designated as a primary mechanism involving growth factors
inhibited by antisense technology and its signaling pathway [37,51]. As PI3K/AKT/GWK3/GS
pathway is considered in antisense mechanism, it was recently demonstrated that also
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articles of last two years).
In the strategies of anti TGF-beta and anti IGF-I and anti IGF-IR antisense techniques, the anti-
tumor immune response was designated as a primary mechanism involving growth factors
inhibited by antisense technology and its signaling pathway [37,51]. As PI3K/AKT/GWK3/GS
pathway is considered in antisense mechanism, it was recently demonstrated that also
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antisense anti-glycogen synthase (GS) cells express MHC-I molecules [44,61,62]. The IGF-I,
through its binding to IGF-IR, activates the PI3K/AKT transduction cascade related to the
pathway of apoptosis (IRS/PI3K/AKT/Bcl or AKT / Ca2 + or GSK3 or caspases). The end result
of IGF-I AS approach involves an inhibition of the pathway elements of TK/PI3K/AKT
inducing an in vivo immune response mediated by CD8 T cells and APC cells (Figure 1.) [44 ].
6. Conclusions
This review draws attention to the recent studies in cancer gene therapy, particularly of
glioblastoma treatment using anti - gene anti IGF-I approach. Although the number of clinical
trials of "antisense" type is much lower than those of pre-clinical experimental therapies, we
wish to emphasize that any experimental therapy is a potential clinical trial (Table 1.). The
current clinical strategies for the treatment of gliomas are usually a combination of chemo‐
therapy and use of different types of inhibitors (imatinib, gefitinib) including antibodies (i.e.
avastin), targeting growth factors and their receptors [63-66]. The new therapies are now
focusing on technology of inhibitors and antigene techniques (antisense or triple helix) used
alone or combined with drug treatment [67-71]. A pharmacological strategy - the use of
temozolomide introduced by R. Stupp, has offered a new hope for treatment of glioblastoma.
However, although median survival has reached almost two years, we are still far from victory
[72,73]. The new strategies proposing to target different growth factors, especially IGF-I, TGF-
beta or VEGF, their receptors and signaling pathway elements, seem to offer a promising
solution [54,73-76]. We would like to underline that the research on IGF-I which has resulted
in diagnostic application – the IGF-I being considered as one of the principal precancerous
markers [10,12], has conducted to experiments on suppression of IGF-I expression in tumors,
following directly by immuno-gene therapy of malignant tumors. Gene therapy, particularly
cellular imuno-gene therapy, and cellular immunotherapy are currently among the most
promising approaches for treatment of cancer diseases [66,68,77,78].
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1. Introduction
Microarray technology developed in the late 1990’s allows one to simultaneously analyze the
entire transcriptome of a given population of cells at a single time. It is essentially a microchip
with each spot containing about a picogram of DNA immobilized at defined locations. This
DNA captures mRNA or cDNA from defined cell populations (tissue, cell line, etc) in a
quantitative manner. This technique allows complex patterns of global gene expressions to be
quickly and easily detected between two specimens. Microarrays were initially used to
describe cell cycle patterns of Saccharomyces cerevisiae [1]. Its powerful potential was quickly
recognized and applied towards cancer. The first successful application of this technology was
to show that diffuse large cell B lymphomas had two different subtypes. One subset of this
cancer was easily treatable with chemotherapy; whereas, the second phenotype required a
more aggressive therapy [2].
Microarray analysis of human GBM quickly revealed that this cancer could be divided into
three different subtypes: neural/pro-neural, mesenchymal and classical GBM [3]. Each subset
has its own unique profile of gene expression along with a unique survival pattern. The
microarray data also represents a composite of the tumor and the surrounding non-cancerous
cells that are involved in the microenvironment including host immune cells. Microarrays have
also recently provided possible mechanisms that GBM have used to avoid the effects of anti-
angiogenic therapies [4]. Thus, this in silico technology offers new strategies to target various
cancers in still many unknown ways.
© 2013 Dang et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
[80] Lebedeva IV, Stein CA. Antisense Down Regulation of the Apoptosis – Related bcl-2
and bcl-xl Proteins: a New Approach to Cancer Therapy. In: Lattime EC, Gerson SL
(ed.) Gene Therapy of Cancer. New York; Academic Press: 2002. p315-330.
[81] Patel S, Doble B, Woodgett JR. Glycogen synthase kinase-3 in insulin and Wnt signal‐
ling: a double-edged sword?. Biochemical Society Transversal 2004; 32: 803-808.
[82] Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J, Pollack IF.
Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and in‐
hibitors of PI3K and gluconeogenesis. Laboratory Investigation 2005; 85: 1457-1470.
[83] Lo HW. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for
malignant gliomas. Current Cancer Drug Targets 2010; 10(8): 840–848.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications166
Chapter 6
Using REMBRANDT to Paint in the Details of Glioma
Biology: Applications for Future Immunotherapy
An Q. Dang, Neil T. Hoa, Lisheng Ge,
Gabriel Arismendi Morillo, Brian Paleo,
Esteban J. Gomez, Dayeon Judy Shon, Erin  Hong,
Ahmed M.  Aref and Martin R. Jadus
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52363
1. Introduction
Microarray technology developed in the late 1990’s allows one to simultaneously analyze the
entire transcriptome of a given population of cells at a single time. It is essentially a microchip
with each spot containing about a picogram of DNA immobilized at defined locations. This
DNA captures mRNA or cDNA from defined cell populations (tissue, cell line, etc) in a
quantitative manner. This technique allows complex patterns of global gene expressions to be
quickly and easily detected between two specimens. Microarrays were initially used to
describe cell cycle patterns of Saccharomyces cerevisiae [1]. Its powerful potential was quickly
recognized and applied towards cancer. The first successful application of this technology was
to show that diffuse large cell B lymphomas had two different subtypes. One subset of this
cancer was easily treatable with chemotherapy; whereas, the second phenotype required a
more aggressive therapy [2].
Microarray analysis of human GBM quickly revealed that this cancer could be divided into
three different subtypes: neural/pro-neural, mesenchymal and classical GBM [3]. Each subset
has its own unique profile of gene expression along with a unique survival pattern. The
microarray data also represents a composite of the tumor and the surrounding non-cancerous
cells that are involved in the microenvironment including host immune cells. Microarrays have
also recently provided possible mechanisms that GBM have used to avoid the effects of anti-
angiogenic therapies [4]. Thus, this in silico technology offers new strategies to target various
cancers in still many unknown ways.
© 2013 Dang et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
In 2005 the National Cancer Institute and the National Institute of Neurological Disorders and
Stroke (NINDS) initiated the REMBRANDT (REpository for Molecular BRAin Neoplasia DaTa
(http://rembrandt.nci.nih.gov/) database. This informatics venture originated from the
leadership of Dr. Subhashree Madhaven (NCI Center for Bioinformatics) and Dr. Howard Fine
(Glioma Molecular Diagnostic Initiative at the Center of Cancer Research). Currently this
research portal molecularly characterizes a large number of primary brain tumors and
correlates this gene expression, copy number data with patient survival. At this time, there are
several active collaborators who are supplying information into this database: Henry Ford
Institute (Detroit), Johns Hopkins University (Baltimore), National Cancer Institute-Neuro-
Oncology Branch, National Institute of Neurological Disorders and Stroke (NINDS), M.D.
Anderson Cancer Center (Houston), Mofitt Cancer Center (Tampa), Thomas Jefferson
(Philadelphia), Univ. of California, Los Angeles, Univ. of California, San Francisco, Univ. of
Pittsburgh Medical Center, and Univ. of Wisconsin Carbone Cancer Center (Madison). At the
time of writing this chapter 568 brain cancer specimens are available for gene expression
analysis, while 552 patients were analyzed (May-Aug 2012) for copy number studies using
REMBRANDT version 1.5.5. Thus, we have a relatively large database for which we can draw
good information to determine the usefulness of targeting any given gene of interest towards
a given brain cancer.
Van der Bruggen, et al., [5] compiled a listing of various tumor antigens that have been found
within various human cancers. Tumor antigens can be defined as either being tumor-specific
or tumor-associated. These tumor-associated antigens are composed of mutations, shared
tumor-specific, differentiation and over-expressed antigens. Tumor specific antigens are
actually quite rare. The epidermal growth factor receptor variant III (EGFRvIII) is an example
of a glioma-specific tumor antigen. Most antigens used for cancer therapy are shared antigens,
in which the cancers over-express these proteins. By this definition most antigens should be
described as cancer-associated antigens, as opposed to cancer-specific antigens. When tumor
antigens are discovered, either by molecular techniques or using immunological techniques,
only a handful of tumor cases are actually evaluated to generate the initial scientific report.
Hence the real scope of the true expression pattern was usually limited due to a small sampling
size of the initial report. Analyzing large databases are perhaps the best way to validate the
universal nature of any tumor antigen.
Traditionally, there are antibody-based or cell-mediated-based antigens. Back in the
1970’s-1980’s, antibody responses were viewed as the best way to treat tumors. These anti‐
bodies need to be specifically designed to bind to cancer-specific cell surface proteins. Anti‐
bodies have been detected coming from glioma patients (PHD finger proteins-3 and -20 were
identified [6, 7]. When these were evaluated by REMBRANDT, there were only 1 and 5 patients
who over-expressed these respective transcripts and there were no statistical significance.
Many antibodies were designed against glioma cells. Antibodies targeting internal antigens
will obviously not be clinically applicable, since these antibodies’ binding regions can’t access
their targeted intracellular epitopes. Antibodies with 150,000 dalton molecular weighs can’t
penetrate deeply into intracellular tumor cells due to their inability to cross cell-adhesion
junctions between adjacent cells. Peripherally located tumor cells usually bind the most
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amount of antibody, leaving the more internally located ones less affected. Single chain
variable antibody fragments (scFv) are being developed out of monoclonal antibody technol‐
ogy can penetrate deeper into tumor beds, since they have lowered molecular weights (about
15-20 kd). ScFv targeting EGFRvIII, MRP3, TRAIL and c-Met have been used in preclinical
models of human gliomas [8-11]. But just like regular antibodies, the scFv will undoubtedly
predominantly bind to peripheral tumor cells. The clinical efficacy of scFv still has not been
firmly established.
In contrast, internal and external antigens can be processed by intracellular proteosome using
a universal ubiquitization pathway. Eventually some of these antigenic peptides are presented
on the cell-surface of major histocompatibility (MHC) molecules, provided they have the right
affinity and the right concentration. So once the correct anti-cancer T cells are activated towards
these peptides, the T cells can respond to multiple tumor cells. The caveat to this approach is
that many tumor cells down-regulate their MHC expression, making themselves “invisible”
to the T cells. The use of dendritic cell (DC)-based vaccines to generate endogenous T cells in
vivo seems to show that T cell-induced therapies are a better way to treat gliomas than humoral
approaches [12]. Prins, et al, [13] showed that DC-based therapy using the autologous tumor
to prime the T cells works better against the mesenchymal type of GBM than the other two
subsets. So the identification of the right tumor antigens that glioma cells possess is the Holy
Grail of tumor immunotherapy.
2. Hallmarks of cancer
In 2012 Hanahan and Weinburg updated their classic “Hallmarks of Cancer” paper where they
described the original six Hallmarks (resisting cell death, sustained proliferation, evading
growth suppression, activating invasion and metastasis, enabling replicative immortality and
inducing angiogenesis) with two more emerging Hallmarks (deregulating energetic and
avoiding immune destruction), along with two enabling characteristics (genomic instability
and mutation and tumor promoting inflammation) [14]. Hanahan and Weinburg pointed out
that various anti-cancer therapies currently being developed actually target one of these
possible ten Hallmarks of Cancer. Each of these drugs is designed to be very specific and only
affect a certain cancer pathway. Hence these drugs should avoid any unwanted side effects.
One obvious down-side to this way is that cancers are very resourceful and can quickly mutate
to avoid the actions of this drug.
They also speculated that if you design a drug that targets two or more of these pathways,
then that drug should then theoretically be more potent than a drug that targets a single
“Hallmark”. We think it is possible to simultaneously target multiple “Hallmarks”. A whole
tumor cell vaccine which targets a wide variety of possible “Hallmarks” is possible.
Figure 1 shows some representative glioma antigens that are known and can induce immune
responses against seven of the “Hallmarks”. So the true power of tumor vaccines using whole
cells as the source of the vaccine might be that it targets multiple proposed Hallmarks of Cancer
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at once. So finding newer antigens that might additionally target different Hallmarks could
also improve immunotherapy.
Figure 1. Whole tumor vaccines can target multiple Hallmarks of Cancer. Listed are some glioma tumor-associated
antigens which can be classified under the various categories of the Hallmarks of cancer.
3. Current glioma associated tumor antigens: How well do our current
tumor antigens fit the survival data of GBM?
REMBRANDT is quite easy to use. One can access the data of all glioma types or limit the
selection of brain cancers to GBM, mixed gliomas, or oligodendroglioma. At the gene expres‐
sion level, one can concentrate on over-expression that is 2.0-fold better than control samples,
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or under expression < 0.5-fold expression, or an intermediate expression pattern. For this
chapter we will be examining the universal nature of all glioma types. If readers want more
specific brain cancer subtypes, they can easily study the various subsets of brain tumors on
their own using REMBRANDT.
Previously,  many tumor antigens  used for  glioma immunotherapy have been described
[15-20].  A good tumor-associated antigen is  one that  is  found in a large number of  hu‐
man  glioma  patients  and  has  many  different  epitopes,  so  that  many  different  T  cell
clones  can  respond to  it,  regardless  of  the  major  histocompatibility  complex  haplotype.
The targeted antigen should also be associated with a poor prognosis. Therefore proper‐
ly targeting this antigen interferes with some key glioma cell  function; i.e.,  cell  division,
growth factor  signaling,  migration and other  processes  of  the Hallmarks of  Cancer.  Im‐
proved patient survival if  a successful therapy was mounted against this tumor antigen,
should  also  eliminate  those  antigen-positive  cells.  By  changing  the  tumor  population
from  an  antigen-positive  one,  to  an  antigen-negative  one,  overall  survival  should  im‐
prove, if that antigen/protein was indeed critical to glioma biology. Even at this time, we
still  don’t precisely know what the best glioma-specific antigens are to use for immuno‐
therapy, except by doing expensive clinical trials. The other theoretical possibility, is that
the antigen must be found on every tumor cell. In which case, every antigen-positive cell
needs  to  be  eliminated.  In  which  case,  every  antigen  is  created  equally.  This  question
will eventually need to be answered, before immunotherapeutic cures can become a real‐
ity. Our own speculation is that not all glioma-associated antigens are equally useful.
When the currently known glioma-associated tumor antigens are subjected to REMBRANDT
analysis, some of these antigens do seem to show a good inverse correlation with survival.
Having more of the antigen does seem to correlate with a poorer survival in a dose-dependent
manner. Figure 2 shows a representative illustration of this effect using the well-known
glioma-associated antigen, IL13Rα2. There were 121 patients (red) who possessed elevated
IL13Rα2 mRNA levels (21% of all glioma patients), while 115 (20% of all gliomas examined)
had down-regulated IL13Rα2 expression (green). The more IL13Rα2 mRNA the patient’s
glioma had, the poorer the prognosis of these patients was. This data can be considered as a
dose response experiment. By the Log-rank test, provided by REMBRANDT, these values were
quite statistically significant from the total 568 glioma patients (blue) that were examined.
Thus, this tumor antigen should be good one to target for a subset of glioma patients, since the
lower the expression of IL13Rα2 lead to better patient survival. Other very good glioma-
associated antigens are: EphA2, FABP7, FosL1, MRP-3, NR2E1 and podoplanin (Table 1).
Some antigens such as survivin/Birc5, CD133, her2 and Sart-2 were considered good antigens
in that either their over-expression lead to poor survival or their under-expression had a better
prognosis. This observation could be that some samples didn’t have sufficient samples to
provide a statistical significant value. WT1 also seems to be a good target. In an early clinical
trial using WT-1 peptide vaccinated patients, there was some survival benefit for the first 100
weeks after the vaccination [21]. Thus, an early test of our hypothesis seems at first glance to
be a viable one.
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IGF2BP3, Sart-2, Survivin, WT-1
Art-1, Art-4, ARF4L/ARL4D, CLIP2, CSPG4,EphB6,
EZH2, Gnt-V, GP100, KIF1C, KIF3C, HNRPL, livin,
Mage-A1, MELK, NES, NLGN4X, NRCAM, PHF-3,
PHF-20, Prame, PTH-rP, PTPRZ1, Sart-1, Sart-3,
SLC01C1, Sox-2, Sox-6, Sox-10, Sox-11, SSX2, TNC,
Tert, Trp-2/DCT, Tyrosinase, Whsc2
Very Good Antigens: both over-expression predicts shorter patient survival and under-expression leads to longer
survival rates. Statistical significance reached by REMBRANDT.
Good Antigens: one value (over-expression or under-expression) achieved statistical significance.
Poor Antigens: Neither over- nor under-expression correlated with patient survival and had any statistical
significance.
Table 1. Currently known Glioma-associated antigens and their predicted usefulness against all gliomas as predicted
by REMBRANDT.
Unfortunately,  most  reported glioma-associated antigens  such as  Sox2,  Sart3,  etc  do not
seem to have any prognostic value.  Their expression profile does not indicate any posi‐
tive or negative effect. From this we would conclude, even though the glioma cells carry
this tumor antigen, and in vitro  experiments suggest that CTLs can kill tumor cells bear‐
ing this specific antigen, this antigen does not appear to have any selective or predictive
advantage.  Therefore even if  a  robust  immune response were mounted in vivo  by some
vaccination  or  therapeutic  process,  chances  are  this  response  will  not  produce  any  de‐
monstrable effect, unless all of those antigen-positive tumor cells were eliminated. There‐
fore, just because CTLs can be generated against tumor cells doesn’t necessarily mean it
will produce any clinical response, unless every tumor cell was eliminated. Killing every
tumor within any cancer is highly doubtful.
In conclusion,  some of  our currently known tumor-associated antigens found in human
glioma are still good ones to target by therapeutic interventions including immunological
ones,  while  others  probably  will  not  be  that  much  in  helping  eliminate  this  cancer.
Searching out new target antigens is  still  a  vital  goal  of  immunotherapy and new strat‐
egies to find more appropriate antigens are required. This may be where REMBRANDT
can come in quite handy in developing intelligent rationales for designing better targets
for future immunotherapy (see below).
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Figure 2. REMBRANDT survival of all gliomas showing differential IL13Rα2 expression. The blue symbols show the sur‐
vival of all glioma patients. The red lines show the survival of IL13Rα2 over-expressing gliomas. While the green sym‐
bols show the patients that survived with a low expression of IL13Rα2. Both populations were statistically significantly
different (asterisks) from the majority of all gliomas (blue).
4. Cells of the immune system involved in glioma
The immune system plays an important role in combating a wide variety of pathogens ranging
from viruses, bacteria, fungi, parasites and others. Cancers can also be considered a type of
pathogen that the body must rid itself of on a routine basis. In the mid-1980’s, CD4+ T cell
clones were classified into various subsets of T helper cells, Th1 cells produced cytokines that
stimulated cell-mediated functions, while Th2 cells produced humoral immune responses [22].
New CD4 T helper subsets are still being discovered. Th9, Th17, Th22, Tfh and Treg are
populations recently described in the last several years. Each subset seems to have its own
niche with regards to certain immunological functions controlling certain pathogens or
antigens. Besides CD4+ T cells, CD8, NK, and γδ T cells all play roles in tumor immunity.
Figure 3 shows these various subsets that are currently known along with some of their
postulated effector cytokines. By REMBRANDT, we tried to analyze these different T cell
subtypes. We examined their respective cytokine(s), possible effector molecules or putative
transcription factors that control the transcription of these cell types.
REMBRANDT surprisingly revealed that CD4 expression had a bad prognosis for glioma
patients. Over-expression of CD4 had a statistically significant poor survival prognosis, while
an under-expression trended towards better survival, but this last condition was not consid‐
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significance.
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egies to find more appropriate antigens are required. This may be where REMBRANDT
can come in quite handy in developing intelligent rationales for designing better targets
for future immunotherapy (see below).
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ered significant (p=0.10). Naïve CD4+ T helper cells can give rise to numerous subtypes of
CD4+ T cells: Th1, Th2, Th9, Th17, Th22, Tfh, and Treg. Thus, the sum total of all these CD4
subsets represents this poor overall survival.
Figure 3. The cells of the Immune system and how they mediate some of their functions. Lymphocyte precursors give
rise to either CD4+ or CD8/NK precursors. As a result of T cell receptor engagement along with the presence of cyto‐
kines shown in the rectangles can give rise to various T helper subsets. After the Th subsets are restimulated they can
then release various cytokines as shown in the polygons. These cytokines can either affect the glioma or the cells in the
local microenvironment. CD8/NK precursors can differentiate into either NK, γδ, or CD8 T cells. These cells can either
kill tumor cells directly or via other undefined pathways.
In has been generally acknowledged that Th1 cells produce cell-mediated immunity that
results in effective anti-tumor immune responses. Th1 cells tend to release cytokines such as
IL2, IFN-γ, TNFα and LT, that either work directly on the tumor or indirectly by stimulating
effector anti-tumoricidal cells, CTLs, NK, macrophages, etc. REMBRANDT suggested the
expression of IL2 portrays a slightly better survival when these cytokines were elevated in
patients but these were not significant. IFN-γ over-expression produced statistically significant
positive outcomes while TNF down regulation lead to a worse survival. Three transcription
factors, t-bet (TBX21), Signal Transducer and Activator of Transcription factor-1 and -4, Stat1
and Stat4, respectively regulate Th1 cell functions. T-bet and Stat-4 failed to show any
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significance. Stat1 showed a poorer survival, but we can’t eliminate the possibility that glioma
cells themselves directly utilize stat1 [23]. Thus, the classic Th1 cells where all Th1 associated
cytokines and transcription factors that are simultaneously made, were not really displayed
within human clinical gliomas.
Th2 cells are classified by their production of the cytokines IL3, IL4, IL5, IL6, IL10, IL13, and
IL25. Interleukins 3, 4, 10 and 13 failed to show any significant relationship with glioma survi‐
vorship. The over-expression of IL6 and IL25 lead to poor patient survival, while over-expres‐
sion of IL5 forecast better survival of glioma patients. Looking at the transcription factors that
control the fate of Th2 (Gata-3, Stat6, Stat5 and MAF) also displayed a mixed effect. Stat6 was
not significant, while Stat5, and MAF correlated with poorer survival. Again the secretion pro‐
files predicted by current dogma within in situ Th2 cells gliomas are not consistent with cur‐
rent experimental conclusions about Th2 cells and their global cytokine expression pattern.
A few not so well known T helper subsets (Th9, Th22 and Tfh cells) are easily studied by
microarray analyses. As a result of exposure to antigen with IL4 and TGF-β, Th9 cells can be
generated. Th9 can release IL9 and IL10. As described above for these cells, IL10 didn’t have
any relationship with glioma survival. IL9 had a mixed expression, both under-expression and
over-expression both had poor prognoses. Hence Th9 cells probably do not play an important
role in glioma immunology. Th22 cells are induced after antigen exposure when IL6 and TNF
are also present. These cells produce IL13 and IL22. Both cytokines appeared to be devoid of
any significance, so the contributions of Th22 are probably minor. Tfh (follicular helper) cells
are stimulated by IL6, IL21 and IL27. Tfh produce IL6, IL10 and IL21. Both IL6 and IL21 lead
towards poor survival. Thus, Tfh cells are suspicious and may contribute to the poor response
of CD4+ cells in glioma patients.
Treg cells are currently in vogue explaining poor anti-tumor immunity in many tumors
including gliomas [24]. TGF-β and IL2 drive the appearance of Treg. IL2 as mentioned earlier,
trends towards a favorable patient survival, however the IL2Rα (CD25) gene didn’t show any
significant relationship contradicting the current dogma that IL2Rα+ Treg are as predominant
in GBM as previously thought [25]. The presence of TGF-β1 and TGF–β2 mRNA showed a
very poor survival, glioma cells do make TGF-β1 and TGF-β2, so the initial source of stimu‐
lation of Treg may come directly from the glioma cells. Upon stimulation with TGF-β, the Treg
can also release this cytokine or express the membrane form of TGF-β and thus amplifies the
glioma’s immunosuppressive nature. Treg use the FoxP3, Smad3 and Stat5 transcription
factors. Stat5 and Smad3 showed a correlation with poor patient survival, but gliomas can also
use smad3 and Stat5 [26,27], so the contribution of these transcription factors from Treg can’t
truly be assessed. FoxP3 is thought to be very specific for Treg, but it’s presence within gliomas
actually failed to show any significant correlation with patient survival. IL10 is released by
Treg in vitro, but REMBRANDT doesn’t show any survival relationship of IL10 production
with gliomas, as described with Th2 and Th9 cells. The various mechanisms by which Treg
can inhibit the immune system will be described in the next section (see Section 5: Immuno‐
supression). Thus, the previously held belief that Treg are solely responsible for poor patient
performance via various immunotherapies, needs a critical reassessment.
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Th17 cells type also uses TGF-β to help drive their initial activation. In addition, these Th17
precursor cells require IL6, IL21, IL1α and IL1β to become polarized into the Th17 phenotype
after the initial T cell receptor engagements. IL6 and IL21 over-expression correlated with poor
patient survival, while the expression of IL1α or IL1β subtypes didn’t. Th17 cells have been
identified in gliomas [28], but their precise role isn’t defined. For melanomas, Th17 cells can
mediate tumor destruction [29], but in colon cancer Th17 helps tumors grow [30]. REM‐
BRANDT analysis of the transcription factors used by Th17: RORC (RORγT), RORA (RORα)
and Stat3 did not show any positive or negative effects. Th17 cells release IL17A, IL17F, IL22,
IL21 and IL26. The first three cytokines fail to correlate with patient survival. IL21 does show
a poor patient survival prognosis, while IL26 shows a better patient survival. So the final
verdict about Th17 cell’s role in glioma is still undecided.
In conclusion, our current understandings of Th helper subsets seem to show multiple
cytokines being expressed by cloned cells in vitro. However these distinct subsets can not be
firmly identified in situ. This complexity is probably due to the complex cytokine/growth
factor/environmental factors being produced within the tumor by the tumor, Treg or immune
cells. One might even have to postulate subsets of these cells; e.g. Th1.1, Th1.2, Th2.1, Th2.2,
Treg1.1, Treg 1.2, etc to explain these empirical observations. As described earlier, activated
dendritic cell vaccines pulsed with autologous GBM tumors do improve GBM survival, so it
will be important to describe what cytokines or subsets are correlating in those patients that
are positively responding to such therapies.
CD8a is a more promiscuous marker, since it can be found on CTLs, NK, DC and other cell
types. CD8b expression is exclusively found on CTLs; there were only 11 patients which over-
expressed CD8b, while 89 patients down-regulated CD8b. The down-regulation of CD8b did
however have a poor survival although not significant. Eosmesdermin (Eomes) is a transcrip‐
tion factor reported to control CTL function [31]. There was trend towards lower Eomes
expression with longer patient survival occurred in 11 patients. Twenty patients over-
expressed this gene, but this profile didn’t alter patient survival when compared to all glioma
patients. Hence, the evidence for a beneficial role of CTLs in situ seems to be weak.
NK cells and γδ type T cells are innate immunity-based lymphocytes. We examined a couple
of NK/ γδ related genes [32]: NKG2D (KLRK1) and NKp30 (NCR3). Both of these genes when
they were down-regulated lead to poor survival. Conversely, when patients presented higher
expression, this produced a better survival. Both findings had statistical significance. Thus,
these innate type immune cells seem to show a dose-dependent in vivo effectiveness. This at
first glance seemed unexpected. Two targets of γδ type T cells are the MICA and MICB
molecules [32]. Both of these molecules when over-expressed in glioma had poor prognoses,
while low expressing gliomas had better outcomes. Hence the use of γδ type T cells to treat
gliomas might be a good clinical approach [33-35]. CTLs, NK and γδ T cells use perforin (PRF1)
and granzymes A and B (GRMA and GRMB) to actively lyse tumor targets in vitro. None of
these gene expression patterns was associated with beneficial or deleterious effects. The exact
mechanism by which NK/ γδ type T cells could have anti-glioma tumor effects is still unknown.
This anti-tumor immunity might not actually be mediated through direct cell-mediated
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cytotoxicity using perforin and granzymes but could be through the release of unknown
cytokines or other unknown effector molecules.
One thing that can be concluded from this REMBRANDT analysis dealing with current tumor
immunity is the in situ process is much more complicated than was previously concluded from
experimental in vitro conditions. Hence new tools need to be developed to explore the anti-
tumor mechanisms that are present within the in situ tumor.
5. Immunosuppression
It has been known for awhile, that advanced cancer patients, including gliomas, have abnormal
and diminished immune responses [36]. This impediment undoubtedly prevents the success‐
ful application of any cellular immunotherapeutic modality and helps explain the complex T
cell immune responses described above. Over the years, it has postulated that a wide range of
cytokines, growth factors and micro-environmental factors (hypoxia, reactive oxygen and
nitrogen) lead to diminished immunological responses [15,37,38]. Figure 4 shows these
potential causes of glioma/immune suppression pathways that have been postulated over the
years. Besides immunosuppressive molecules such as transforming growth factor-β subtypes
1-3 (TGF-β subtypes 1-3), interleukin-10 (IL-10), vascular endothelial cell growth factor (VEGF)
or prostaglandin E (PGE), there are also suppressor cells such as T regulatory cells (Treg) and
myeloid derived suppressor cells (MDSC) that contributes to the overall immunosuppressive
microenvironment.
REMBRANDT data analysis does show that some cytokines/growth factors have good
statistical inverse correlations with patient survival. TGF-β1 and TGF-β2 inversely correlate
with patient survival in a dose-dependent manner (high expression correlated with poor
survival, while low expression prognosticated a better survival). TGF-β3 doesn’t appear to
play much of a significant role within glioma patients. Interleukin-10 previously considered
to play a major role in immunosuppression doesn’t seem to have that much of an effect as seen
above with the Th2 and Th9 phenotypes. VEGF inhibits immune activity via inhibitory actions
upon dendritic cells [39]. Immune responses within the brain are initiated by the local dendritic
cells [40].Both VEGF-A and VEGF-B over-expression significantly correlated with poor patient
survival, while VEGF-C and VEGF-D failed to show any deleterious behavior. Thus, VEGF-A
and VEGF-B besides promoting angiogenesis of brain cancers promotes immune suppression.
Treg and MDSC suppress the immune system through different mechanisms. Treg can release
TGF-β or express cell surface TGF-β (as described above). Treg can release indoleamine-
oxidase-1 (Ido-1) in various tumor models [41]. Ido-1 helps degrade the amino acid, trypto‐
phan. T cells are very sensitive to tryptophan deprivation and become inactivated by this
condition. REMBRANDT shows a significant detrimental effect when IDO-1 is over-expressed,
while in those patients showing reduced expression of IDO-1 a better survival was seen. In
both cases, this data was significant. Human GBM cell lines don’t seem to make Ido-1, so the
contribution of Ido-1 is probably from the Treg. Cytotoxic T lymphocyte antigen-4 (CTLA-4),
Programmed Cell Death-1 (PCD-1), Fas Ligand (FasL), B7-H1, B7-H3 molecules which are
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membrane molecules and can inhibit other effector lymphocytes are possible immunosup‐
pressive pathways of Treg. PCD1 over-expression was not associated with diminished
survival, but under-expression did statistically show improved survival in a cohort of 104
patients. FasL and B7-H1 didn’t show any survival effect, and are probably eliminated in their
role in glioma immunology. B7-H3 was over-expressed in 203 patients and did inversely
correlate with survival in a statistically significant way. There are currently thought to be two
types of Treg, the natural and induced Treg subpopulations. When we examined the cell
surface markers for either induced or natural Treg, nothing was immediately obvious. We
postulate that in situ glioma Tregs are Foxp3-, FasL-, TGF-β+, Ido1+, PCD1+ and B7-H3+ based
upon evaluation by REMBRANDT.
Figure 4. Mechanisms of immunosuppression found within gliomas. As a result of the glioma cell release growth fac‐
tors and cytokines T regulatory (Treg) and myeloid derived suppressor cells (MDSC) are recruited. Glioma cells can ex‐
press membrane proteins Fas Ligand and B7-H3. For sake of simplicity only 1 transmembrane protein is shown.
Likewise Treg can express transmembrane inhibitory molecules FasL, CTLA4, B7-H3 and PCD1. A Red X indicates the
pathways by REMBRANDT analysis are not likely playing a major role pathways. MDSC and gliomas can release Cox 1.
MDSC can either be composed of CD33+ cells or CD14+ cells [42]. These markers can be found
on either the granulocytic or monocytic types of MDSC. MDSC are stimulated by a wide variety
of cytokines and growth factors found in gliomas: GM-CSF, M-CSF, VEGF, IL1, IL4, IL6, IL13
and PGE, most of these cytokines were over-expressed by gliomas as determined by REM‐
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BRANDT. Fifty glioma patients did demonstrate an earlier demise when CD33 was deter‐
mined to be over-expressed. In contrast only 8 patients down-regulated expression of CD33;
this observation was not considered significant. CD14 expression was increased in 186 patients
and possessed significantly shortened lives. Seventeen glioma patients were CD14 down-
regulated and were approaching a significant survival advantage (p=0.058). So both types of
MDSC can reside within human gliomas. MDSC can release TGF-β, arginase or prostaglandin
(PGE) that prevents T cell expansion through different pathways [42]. As described above TGF-
β1 and TGF-β2 are inversely correlated with glioma survival. But TGF-β can come from either
Treg, the glioma itself or from MDSC. Arginase suppresses T cell function in a manner similar
to IDO, in that T cells also require sufficient arginine for proper function. Two isoforms of
arginase are known, Arg-1 and Arg-2. Arg-1 is a cytoplasmic enzyme; Arg-2 is a mitochondria
contained enzyme. Neither form of arginase had any significant effect, eliminating this likely
pathway from occurring in human gliomas. Thus, the way that MDSC mediate their actions
is probably through TGF-β or PGE.
Figure 5. Survival statistics of glioma patients with Cox 1 and Cox 2 differential gene expression using REMBRANDT.
The Left Panel shows the survival statistics of glioma patient analyzed for Cox 1 expression. There were 9 patient un‐
der-expressing Cox 1, which failed to achieve statistical significance. Eighty-four patients over-expressed Cox 1, which
did reach a significant p value. The Right panel shows the REMBRANDT analysis of Cox 2 expression. There were 205
patients that under-expressed Cox 2, while only 27 patients over-expressed the Cox 2 transcripts. Neither phenotypes
were considered significantly different from the total population of gliomas.
PGE2 is synthesized by either the cyclo-oxygenase-1 (Cox-1) or -2 (Cox-2) enzymes [43]. Cox
1 is considered by some to be a house-keeping gene and is constitutively produced and
synthesizes low amounts of PGE2. Figure 5 shows the REMBRANDT data dealing with the
cyclo-oxygenases. Cox-2 is inducible and produces much more PGE2 when cells are properly
activated. Many tumors [43], including glioma cells [44,45] are reported to over-express the
Cox2 enzyme. Cox2 derived epitopes have been described in human esophageal cancers that
CTLs can recognize [46], so this enzyme might be a potential human glioma antigen, too.
Epidemiological studies have shown that a daily dose of aspirin helps reduce PGE2 production
and lowers the incidence of a variety of cancers [47]. When Cox2 was analyzed by REM‐
BRANDT, there was an association showing that gliomas that over-expressed Cox2 (27
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
179
membrane molecules and can inhibit other effector lymphocytes are possible immunosup‐
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Figure 4. Mechanisms of immunosuppression found within gliomas. As a result of the glioma cell release growth fac‐
tors and cytokines T regulatory (Treg) and myeloid derived suppressor cells (MDSC) are recruited. Glioma cells can ex‐
press membrane proteins Fas Ligand and B7-H3. For sake of simplicity only 1 transmembrane protein is shown.
Likewise Treg can express transmembrane inhibitory molecules FasL, CTLA4, B7-H3 and PCD1. A Red X indicates the
pathways by REMBRANDT analysis are not likely playing a major role pathways. MDSC and gliomas can release Cox 1.
MDSC can either be composed of CD33+ cells or CD14+ cells [42]. These markers can be found
on either the granulocytic or monocytic types of MDSC. MDSC are stimulated by a wide variety
of cytokines and growth factors found in gliomas: GM-CSF, M-CSF, VEGF, IL1, IL4, IL6, IL13
and PGE, most of these cytokines were over-expressed by gliomas as determined by REM‐
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Epidemiological studies have shown that a daily dose of aspirin helps reduce PGE2 production
and lowers the incidence of a variety of cancers [47]. When Cox2 was analyzed by REM‐
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patients) showed an unfavorable survival, while the under-expression of Cox 2 in 205 patients
had only slightly improved patient survival. Neither of these expression patterns showed
statistical significance when compared to all gliomas. Cox2 production of PGE might not
therefore be a major source of PGE production as previously thought. When Cox1 expression
was examined as a control, a surprisingly better correlation was found with patient survival.
There were only 5 patients who under-expressed Cox 1, so statistically, this is not considered
significant. Eighty-four glioma patients who over-expressed Cox1 succumbed earlier to their
cancer. This later group of patients did achieve a very good statistical significance (p = 2.8x10-6).
PGE2 is a vasodilator and it is involved in angiogenesis so it may have multiple roles in glioma
biology, besides immune suppression. Only prostaglandin receptors EP2 and EP4 were
elevated within human gliomas using REMBRANDT. Based upon this REMBRANDT
assessment, the role of Cox-1 needs to be investigated further in glioma biology and could be
a target for therapy in some patients.
6. Growth factors, cytokines, chemokine are there targets of
immunotherapy by T cells
PGE2 receptors are coupled to G-proteins that activate adenylate cyclase, leading to an increase
of intracellular cAMP which activates protein kinase A (PKA). This cellular signaling results
in increased production of Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast
Growth Factor (bFGF) that assists new blood vessel formation (angiogenesis) (Figure 6).
Glioma cells also possess growth factor and cytokine receptors, such as the interleukin-13Rα
2 (IL-13Rα2) [48], EphA2 [49], platelet derived growth factor receptor (PDGFR2) [50,51],
epidermal growth factor receptor (EGFR)[52], insulin-like growth factor receptor (IGFR)[53],
c-met (which binds hepatocyte growth factor/ scatter factor (HGF/SF)[54], interleukin-6
receptors (IL-6R) [55], and GM-CSF receptors [56]. Table 2 summarizes this data of growth
factors/cytokines expressed within human gliomas along with their respective receptors. It can
be speculated that some glioma cells use these potential autocrine growth pathways. REM‐
BRANDT does seem to indicate that PDGF-B and PDGFR2 and the IL6/IL6R pathways are
viable models of this autocrine process. The other cytokine/growth factors could be indicative
of paracrine routes. Upon proper binding to their receptors, most growth factors/cytokines
(EGF, IGF, PDGF, FGF, HGF/SF, Ephrin A, IL-6, IL-13 and others) use the PI3 kinase family of
signal transducing docking molecules [57,58].
Upon ligation of the receptor, the Rac, Ras and Raf1 docking proteins are interacting and
activate PI3K. H-ras and N-Ras have a positive correlation with poor glioma survival. Members
of the Ras family, rab4,5,8,11,21,25, have been investigated with multiple aspects of signal
transduction with glioma cells. But REMBRANDT showed that these rabs didn’t have any
significance. PI3 kinase family members do have a strong linkage with poor glioma survival
by our analysis of the current data. Akt1 or Akt2 is also activated and does also show the same
inverse relationship with patient survival. Thus, targeting PI3K/Akt dependent pathways are
still a valid target.
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Figure 6. Generalized mechanism by which growth factor/cytokine interactions can initiate down-stream biochemical
pathways. Upon binding a growth factor or cytokines, Ras/Raf/Rac signal transduction begins. PI3 kinase converts
PIP2 into PIP3. PIP3 stimulates PDK1 which in turn activates Akt. eNOS is turned on by Akt. The asterisks indicate that
protein is over-expressed and leads to poor patient survival by REMBRANDT.
The normal brain contains a variety of neurons, Schwann cells, glial cells, microglia and other
cells. These cells are held in place and are embedded by an extracellular matrix (ECM)[59,60].
Matrix proteins besides providing cell anchorage, can also bind and sequester various soluble
biological modulators. Table 3 also lists the various extracellular matrix proteins found within
the brain that can bind to various glioma-related cytokines/growth factors. Several growth
factors upon binding to their extracellular matrix enhance binding affinity to their receptors.
Since the soluble factor is tethered to a large matrix protein, endocytosis may be slowed and
allowed for increased intracellular signaling to be mediated. A prolonged signal transduction
via PIP3 can also recruits intracellular cytoskeletal elements Wave/WASP-like proteins which
allows actin polymerization to be initiated at this membrane site, this can then help explain
the presence of filopodia, lamellopodia, microvilli and invadopodia of gliomas [61-64]. See
Section 7.2.
7. Mechanisms of invasion of gliomas
7.1. Extracellular mechanisms
It has been concluded that the reason why many human gliomas cannot be cured by con‐
ventional surgical, chemotherapeutic and radiation modalities is these tumors are very in‐
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be speculated that some glioma cells use these potential autocrine growth pathways. REM‐
BRANDT does seem to indicate that PDGF-B and PDGFR2 and the IL6/IL6R pathways are
viable models of this autocrine process. The other cytokine/growth factors could be indicative
of paracrine routes. Upon proper binding to their receptors, most growth factors/cytokines
(EGF, IGF, PDGF, FGF, HGF/SF, Ephrin A, IL-6, IL-13 and others) use the PI3 kinase family of
signal transducing docking molecules [57,58].
Upon ligation of the receptor, the Rac, Ras and Raf1 docking proteins are interacting and
activate PI3K. H-ras and N-Ras have a positive correlation with poor glioma survival. Members
of the Ras family, rab4,5,8,11,21,25, have been investigated with multiple aspects of signal
transduction with glioma cells. But REMBRANDT showed that these rabs didn’t have any
significance. PI3 kinase family members do have a strong linkage with poor glioma survival
by our analysis of the current data. Akt1 or Akt2 is also activated and does also show the same
inverse relationship with patient survival. Thus, targeting PI3K/Akt dependent pathways are
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PIP2 into PIP3. PIP3 stimulates PDK1 which in turn activates Akt. eNOS is turned on by Akt. The asterisks indicate that
protein is over-expressed and leads to poor patient survival by REMBRANDT.
The normal brain contains a variety of neurons, Schwann cells, glial cells, microglia and other
cells. These cells are held in place and are embedded by an extracellular matrix (ECM)[59,60].
Matrix proteins besides providing cell anchorage, can also bind and sequester various soluble
biological modulators. Table 3 also lists the various extracellular matrix proteins found within
the brain that can bind to various glioma-related cytokines/growth factors. Several growth
factors upon binding to their extracellular matrix enhance binding affinity to their receptors.
Since the soluble factor is tethered to a large matrix protein, endocytosis may be slowed and
allowed for increased intracellular signaling to be mediated. A prolonged signal transduction
via PIP3 can also recruits intracellular cytoskeletal elements Wave/WASP-like proteins which
allows actin polymerization to be initiated at this membrane site, this can then help explain
the presence of filopodia, lamellopodia, microvilli and invadopodia of gliomas [61-64]. See
Section 7.2.
7. Mechanisms of invasion of gliomas
7.1. Extracellular mechanisms
It has been concluded that the reason why many human gliomas cannot be cured by con‐
ventional surgical, chemotherapeutic and radiation modalities is these tumors are very in‐
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filtrative. After the neurosurgeons and the radiation oncologists treat their patients, some
remaining cancer  cells  have escaped these  interventions.  Perhaps the  glioma cancer  ini‐
tiating  cells  or  “stem cells”  have  even already migrated into  new areas  of  the  brain  in
searching for  new sources  of  cytokines  or  other  stimuli  (see  Section 6).  There  are  more
components that enable the glioma cells to become more invasive and can become poten‐
tial targets of some therapy.
Glioma  cells  possess  receptors/molecules  than  can  bind  to  environmental  components.
These  receptors  can  be  either  cell-adhesion integrins  or  CD44 [65].  The  most  important
integrins are considered to be the αvβ3, and αvβ5 heterodimers [66]. These integrins act as
receptors to bind vitronectin, fibronectin, osteopontin and cyr61 [67]. The last three ECM
proteins when they were over-expressed also showed a predicted poor survival with glio‐
ma patients. Two other integrins, α6β1 [68] and α5β1 [69], have been reported to also play
roles  in  glioma  tumorigenesis.  The  αvβ3  and  α6β1  integrins  are  functional  receptors  for
several  heparin  binding  growth  factors,  pleiotrophin  and  midkine,  respectively  [70,71].
Midkine has been identified as a potential mediator that promotes chemoresistance with‐
in those midkine-stimulated cells [71].  As described in Table 3 some of these genes that
interacted with the cytokines and growth factors were identified by REMBRANDT as sig‐
nificant  in  predicting  patient  outcome.  REMBRANDT  confirmed  that  CD44,  αv,  α6  and
midkine lead to poorer prognoses.
Cancer cells, including gliomas do release matrix metalloproteineases (MMP) which digest
the surrounding tissue and extracellular matrix allowing the cancer cells to invade sur‐
rounding tissue. By REMBRANDT we identified that MMP1, MMP2, MMP9, MMP11 and
MMP14 all were associated with a bad prognosis. A natural inhibitor of the MMP, called
TIMP3, associated with better patient survival when over-expressed, as current dogma pre‐
dicts. So strategies that counter these MMPs or by increasing TIMP3 activity might have an
important role in preventing the glioma cells from breaking its initial containment.
Gliomas might  also  release  excess  glutamate  and kill  surrounding normal  tissue  via  an
excitotoxic  process  [72].  There  is  speculation  that  gliomas  can  also  down-regulate  their
glutamate receptors [73,74] so that they become impervious to the cytotoxic levels of glu‐
tamate that they release. Glutamate can be synthesized from the enzyme glutamate syn‐
thethese  (GLUL) or  can be  scavenged via  numerous catabolic  pathways.  Glutamate  can
be released via exporters that use K+ and Na+ cation exchangers, or SoLute Carriers (see
Section 7.3 below).  We found that  there was no correlation with GLUL expression with
patient survival or demise. So the most likely source of the released glutamate is coming
via  protein  catabolism.  The  glutamate  receptors  GRIA1,  GRIA2,  GRIA3,  GRIA4,  GRM5
and GRM7 all  correlated with  a  bad prognosis  by  a  REMBRANDT analysis  when they
were down-regulated. The interpretation here is consistent with the initial hypothesis that
this  down-regulation by the glioma cells  can make themselves resistant  to the cytotoxic
levels of glutamate found in the local microenvironment.
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Figure 7. Electron microscopy of human GBM in situ. Panel A shows gliomas with microvilli invading surrounding ex‐
tracellular matrix: magnified 15,000 x times. Panel B shows gliomas with filopodia invading through other cells. Mag‐
nification 5,000 x times.
7.2. Microvilli and filopodia
Cell surface superstructures including microvilli, invadopodia and filopodia have been
described over the years [75-79]. These structures allow tumor cells to probe for weak spots in
surrounding normal cells and then begin to invade that area as described above. Some of the
gliomas found in GBM do have these microvilli structures in situ. Some microvilli actually had
mitochondria within them (Figure 7A), and their apparent function appears linked with the
ROS generation and subsequent activation of several pathways essentials for glioma inva‐
siveness [80]. Thus, microvilli have a built in power supply to immediately supply the energy
into their probing mechanisms via re-organization of microfilaments and microtubules. At
some edges there were long filopodial projections that could extend past two cell- lengths.
Some glioma cells possess these long filopodia and thus have the ability to probe into distant
sites (Figure 7B). Glioma cells like U251 display her2/neu on their microvilli and filopodia [81].
We have also seen the receptors such as: IL13Ra2, EphA2, EGFR, PDGFR, c-Met, IGFR and
IL6R on the microvilli and filopodia of U251 gliomas [unpublished data]. These microvilli also
provide a novel “sea urchin” type defense that prevents various lymphocytes from mediating
cytotoxicity. Thus these microvilli and filopodia can be used for multiple purposes by glioma
cells and assist in their invasiveness.
We searched out the molecules that have been associated with microvilli, lamellipodia and
filopodia with REMBRANT to identify pathways that are most likely being used by human
gliomas. Figure 8 shows a basic schematic of how these superstructures could be composed
of actin-related proteins Microfilaments, actin-binding proteins and microtubules have been
reviewed in [82-84]. Microfilaments are composed of the actin family members. There are
two types of actin. The monomeric, globular (G-form) represents the single unit, whereas,
when these monomers polymerize, they form the filamentous, F-actin type. Actin contains
both pointed and a barbed ends. The barbed end is protruding from the growing end of the
F-actin polymer. Actin plays many roles in cellular processes. Actin anchors many mem‐
brane-bound proteins in place and are associated with glioma cell motility and the cytoske‐
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filtrative. After the neurosurgeons and the radiation oncologists treat their patients, some
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searching for  new sources  of  cytokines  or  other  stimuli  (see  Section 6).  There  are  more
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These  receptors  can  be  either  cell-adhesion integrins  or  CD44 [65].  The  most  important
integrins are considered to be the αvβ3, and αvβ5 heterodimers [66]. These integrins act as
receptors to bind vitronectin, fibronectin, osteopontin and cyr61 [67]. The last three ECM
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roles  in  glioma  tumorigenesis.  The  αvβ3  and  α6β1  integrins  are  functional  receptors  for
several  heparin  binding  growth  factors,  pleiotrophin  and  midkine,  respectively  [70,71].
Midkine has been identified as a potential mediator that promotes chemoresistance with‐
in those midkine-stimulated cells [71].  As described in Table 3 some of these genes that
interacted with the cytokines and growth factors were identified by REMBRANDT as sig‐
nificant  in  predicting  patient  outcome.  REMBRANDT  confirmed  that  CD44,  αv,  α6  and
midkine lead to poorer prognoses.
Cancer cells, including gliomas do release matrix metalloproteineases (MMP) which digest
the surrounding tissue and extracellular matrix allowing the cancer cells to invade sur‐
rounding tissue. By REMBRANDT we identified that MMP1, MMP2, MMP9, MMP11 and
MMP14 all were associated with a bad prognosis. A natural inhibitor of the MMP, called
TIMP3, associated with better patient survival when over-expressed, as current dogma pre‐
dicts. So strategies that counter these MMPs or by increasing TIMP3 activity might have an
important role in preventing the glioma cells from breaking its initial containment.
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Cell surface superstructures including microvilli, invadopodia and filopodia have been
described over the years [75-79]. These structures allow tumor cells to probe for weak spots in
surrounding normal cells and then begin to invade that area as described above. Some of the
gliomas found in GBM do have these microvilli structures in situ. Some microvilli actually had
mitochondria within them (Figure 7A), and their apparent function appears linked with the
ROS generation and subsequent activation of several pathways essentials for glioma inva‐
siveness [80]. Thus, microvilli have a built in power supply to immediately supply the energy
into their probing mechanisms via re-organization of microfilaments and microtubules. At
some edges there were long filopodial projections that could extend past two cell- lengths.
Some glioma cells possess these long filopodia and thus have the ability to probe into distant
sites (Figure 7B). Glioma cells like U251 display her2/neu on their microvilli and filopodia [81].
We have also seen the receptors such as: IL13Ra2, EphA2, EGFR, PDGFR, c-Met, IGFR and
IL6R on the microvilli and filopodia of U251 gliomas [unpublished data]. These microvilli also
provide a novel “sea urchin” type defense that prevents various lymphocytes from mediating
cytotoxicity. Thus these microvilli and filopodia can be used for multiple purposes by glioma
cells and assist in their invasiveness.
We searched out the molecules that have been associated with microvilli, lamellipodia and
filopodia with REMBRANT to identify pathways that are most likely being used by human
gliomas. Figure 8 shows a basic schematic of how these superstructures could be composed
of actin-related proteins Microfilaments, actin-binding proteins and microtubules have been
reviewed in [82-84]. Microfilaments are composed of the actin family members. There are
two types of actin. The monomeric, globular (G-form) represents the single unit, whereas,
when these monomers polymerize, they form the filamentous, F-actin type. Actin contains
both pointed and a barbed ends. The barbed end is protruding from the growing end of the
F-actin polymer. Actin plays many roles in cellular processes. Actin anchors many mem‐
brane-bound proteins in place and are associated with glioma cell motility and the cytoske‐
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leton. Surprisingly, by REMBRANDT, there was no significance of actin expression. So
glioma cells probably just recycle and reuse their actin in a more efficient manner.
Figure 8. Schematic diagram of microvilli/filopodia. The microvilli (left) and a microvilli with a branched filopodia
(right) are shown. Various growth factor/cytokine receptors and cell adhesion molecules are found on these struc‐
tures. Upon binding with their ligands, the transmembrane receptors become activated and allow the nucleation of
various cytoskeletal elements to begin. Hence the activated receptors can now begin a process where cell polarity is
initiated.
There are molecules that crosslink the actin locking proteins together. Some proteins bundle
actin polymers together making these proteins stronger, fascin is a prime example. Actin-
binding proteins like Arp2/3 cause branch points within the polymerized actin strands and
help explain the bending of the filopodia [85]. At least 100 proteins can associate directly or
indirectly with actin some of the more important ones are listed in Table 3. It is therefore not
surprising that actin-binding proteins are associated with the mobility of many cancer cells.
The proteins, fascin, podoplanin, and myosin IIB, have been actively studied with regards to
cancer cell motility [86-90]. These two proteins are also over-expressed in gliomas and in other
cancers. The over-expression of fascin and podoplanin mRNA within gliomas is linked with
a worse prognosis in those patients. Actin and fascin are important for maintaining the
lamellopodia, microvilli and filopodia of various cells (Figure 8). This infiltrative nature of
gliomas is believed to be the prime reason why this tumor remains such a lethal cancer, despite
the best efforts to surgical remove and irradiate the surgical incision sites. So these two
molecules can be considered good targets for possible molecular intervention. Table 3
summarizes as many cytoskeletal elements which have been associated with cell invasion and
migration over the years and correlated them with significance by REMBRANDT.
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Figure 9. Proposed model of ion channel regulation of glioma cell invasion. The main cell body (left) is in normal ionic
homeostasis, where there are high intracellular K+ ion concentrations with relatively low concentrations of Na+ ions.
The invading part of the cell (right) is now swelling as a result of possible activation of several ion channels listed at the
bottom. K+ ions are exported while Na+ and Cl- ions along with water is imported causing the cell swell. As a result of
the swelling at the leading edge the rest of the main cell body can be pulled into the new area. The bottom lines list
the possible ion channels/aquaporins that were identified to be of significance by REMBRANDT.
7.3. A mechanism for glioma cells to squeeze through normal tissue
Harald Sontheimer has pioneered ion channel discovery in brain cancers. His unified hypothe‐
sis is that gliomas can shrink at the leading edge of the glioma cell [91]. In this way, the glioma
cell then behaves like an amoeba and pushes itself through the normal tissue. Figure 9 shows a
simplistic model of the dynamic aspects of ion-driven movements in a slightly different model
19. While at rest and in homeostasis, the glioma cell maintains its normal physiological ionic
composition and has multiple filipodia projections. Some projections find an area which stimu‐
lates proper intracellular interactions and begin an invasive process. Here there is high intracel‐
lular levels of K+, and normal concentrations of Na+, Ca+2, Cl- and water. At the leading edge of
the cell, now a disruption of normal ionic homeostasis occurs. Here K+ channels are activated
and K+ ions are released, while Na+ ions are allowed inside. As Na+ ions enter, so does Cl- anions
and water, hence the cell can expand within this region of the cell. Colman et al., [92] found that
one of the channels that are strongly correlated with poor survival was a CLIC1 chloride chan‐
nel. REMBRANDT confirmed this ion channel expression inversely associated with poor pa‐
tient survival.  This chloride channel, CLIC1, also can share a subunit (BKβ as known as
KCNMB2 or KCNMB3) with the big potassium (BKα, KCNMA1) ion channel channel [93].
REMBRANDT analysis showed the BKβ2 or BKβ3 chains had an inverse correlation with sur‐
vival, like the CLIC1 expression. The KCNMA1/BKα ion channel failed to show any relation‐
ship with glioma patient survival. This last finding prompted us to consider whether other
potassium channels could provide an alternative pathway for exporting of K+ ions instead. The
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leton. Surprisingly, by REMBRANDT, there was no significance of actin expression. So
glioma cells probably just recycle and reuse their actin in a more efficient manner.
Figure 8. Schematic diagram of microvilli/filopodia. The microvilli (left) and a microvilli with a branched filopodia
(right) are shown. Various growth factor/cytokine receptors and cell adhesion molecules are found on these struc‐
tures. Upon binding with their ligands, the transmembrane receptors become activated and allow the nucleation of
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initiated.
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cancers. The over-expression of fascin and podoplanin mRNA within gliomas is linked with
a worse prognosis in those patients. Actin and fascin are important for maintaining the
lamellopodia, microvilli and filopodia of various cells (Figure 8). This infiltrative nature of
gliomas is believed to be the prime reason why this tumor remains such a lethal cancer, despite
the best efforts to surgical remove and irradiate the surgical incision sites. So these two
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potassium channels  are associated with poor glioma survival  are KCNN4, KCNQ1, and
KCNQ4.
For cells to maintain electroneutrality, as K+ ions are eliminated Na+ ions must enter. REM‐
BRANDT analysis reveals that four sodium ion channels are strongly correlated with an ad‐
verse survival rate. These sodium ion channels are TRPM8, TRPM4, TRPV2 and a sodium-
hydrogen exchanger (a.k.a. NHE1, SLC9A1). As sodium ions enter the cell, so does water, so
the aquaporins (water channels) are playing an active role in this dynamic swelling process,
too. The aquaporins, AQP1, AQP5 and AQP9 all show dose-dependent inverse pattern of
survival within glioma patients. Interestingly, AQP7 and AQP10 display an opposite pattern
than the previous three aquaporins. Here over-expression of AQP7 and AQP10 lead to‐
wards better survival, while lowered expression produced a worse prognosis.
Sontheimer’s lab found that a novel spliced version of the BK channel, called the glioma BK
channel is found in human gliomas [94]. We created an antibody directed towards this re‐
gion and confirmed that all human gliomas and many rat and mouse glioma cells lines also
possessed gBK [95]. We also found that two epitopes within these gBK regions can induce
human HLA-A2 restricted CTLs which lyse a variety of human cancer cells including glio‐
ma cells. Thus, ion channels have the potential to be developed into immunotherapeutic tar‐
gets. So the ion channels, CLIC1, KCNMB2, KCNMB3, KCNN4, KCNQ1, KCNQ4, TRPM4,
TRPM8, TRPV2 and SLC9A1 could also theoretically be targeted by immunotherapy. Du‐
troit and colleagues [96] have mapped a HLA-A2 derived peptidome which could stimulate
possible immunotargets for CTL therapy. Some of these identified peptides did include ion
and transporter channels, such as: ATP1A2, ATP2B1, CACNA1A, GRIA2, GRIA3 and
SLC4A4. So immunotherapy might be directed towards these ion channels, aquaporins and
transporters could be playing a role in glioma invasiveness.
7.4. “Death signatures”
Glinsky, et al., [97] analyzed a wide variety of cancers by using microarray technology and
discovered that a series of 11 genes (GBX2, Ki67, CCNB1, BUB1, KNTC2, USP22, HCFC1,
RNF2, ANK3, FGFR2, and CES1) had a unique pattern. When this profile was expressed in
those various cancers it had a high statistical probability that the patient will die of the cancer.
They called this expression pattern, a “Death Signature”. In theory, one would think that if an
immunological intervention could be developed, these gene products might be perfect targets
for immunotherapy, assuming that these genes or their synthesized proteins are actively
playing a role in the cancer’s aggressiveness which leads to the patient’s demise. Since these
genes foretold the patient death, if you could then vaccinate a patient against these antigens
and prevent these genes from manifesting themselves, you should then interfere with their
final outcome, death. When we examined the REMBRANDT survival data with this series of
genes found in the Death Signature, there was actually very little significance; most of the gene
expression patterns, when investigated individually were the opposite of what was predicted
by the Death Signature concept. The only gene that correlated well with poor glioma survival
was a marker for cell proliferation that pathologists regularly use as a sign of cell division,
Ki67. Thus, we feel that this “Death Signature” doesn’t fit too well with gliomas. In fairness to
Glinsky and coworkers, they did use a large variety of cancers and they did do a multigene
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analysis, which REMBRANDT currently does not allow. So any multifactoral effect may have
simply been masked by the complexity of their analysis.
8. Targeting the genes commonly found in human GBM
In 2010, Colman and colleagues reported a series of 31 genes that were associated with poor
GBM survival [92]. When Rembrandt analysis was done using these genes, the vast majority
of these genes correlated extremely well. This evaluation was much better than “Death
Signature profile”. Since the MD Anderson and University of California, San Francisco groups
include many of their patients into REMBRANDT, it would be expected a much better
correlation could be found.
One interesting finding was that a couple of these genes from the Colman, et al. study were
also found in the glioblastoma peptidome derived from HLA-A2 alleles obtained from GBM
surgical specimens [96]. These T cells-derived antigens included: CHI3L1 (YKL-40), IGFBP3
(insulin-like growth factor binding protein-3), PDPN (podoplanin) and TNC (tenascin C). We
further examined these 31 genes from the Colman study and found their protein sequences.
We subjected them to SYPEITHI data analysis program (http://www.syfpeithi.de/) to deter‐
mine the possibility of generating nonomer peptide determinants towards their potential
antigenic peptides. Table 4 summarizes this study. We limited this inquiry to those peptides
that are found restricted to the HLA-0201 allele, since that is the most common HLA allele
found in the US with just a little less than half the Caucasians possessing this phenotype. Some
of the Colman and colleague’s proteins are quite small ranging from 116 amino acids (dynein
light chain) to fibronectin isoform1 that possess 2477 amino acids. For the dynein light chain
there were only 12 predicted peptides that could bind to HLA-A0201 with a binding score of
16 or better. In contrast, the fibronectin isoform-1 had 236 possible peptides. In sum, these
proteins provides 1,802 peptides that could theoretically be used to vaccinate patients against
HLA-0201+ tumor cells. Hence this might provide a particularly rich source of very clinically
relevant antigens to target glioma.
9. New targets
As we have described in Table 1, we only have 17 very good or good tumor antigens by which
we can target brain cancers, thus new antigens are needed. REMBRANDT has validated in
silico that there might be new targets that haven’t been considered before. It will be important
to consider targeting these molecules using a variety of mechanisms since they cause poor
patient survival and their under-expression leads to better survival. This can include immu‐
notherapy, molecular gene silencing or even knock-in strategies to take advantage of those
genes which prolonged patient survival. In Table 2 we show that several growth factors, their
cytokines or their extracellular matrix proteins might be potential good targets. Table 3
illustrated many intracellular cytoskeletal elements that are also good targets for either
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potassium channels  are associated with poor glioma survival  are KCNN4, KCNQ1, and
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possessed gBK [95]. We also found that two epitopes within these gBK regions can induce
human HLA-A2 restricted CTLs which lyse a variety of human cancer cells including glio‐
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TRPM8, TRPV2 and SLC9A1 could also theoretically be targeted by immunotherapy. Du‐
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and transporter channels, such as: ATP1A2, ATP2B1, CACNA1A, GRIA2, GRIA3 and
SLC4A4. So immunotherapy might be directed towards these ion channels, aquaporins and
transporters could be playing a role in glioma invasiveness.
7.4. “Death signatures”
Glinsky, et al., [97] analyzed a wide variety of cancers by using microarray technology and
discovered that a series of 11 genes (GBX2, Ki67, CCNB1, BUB1, KNTC2, USP22, HCFC1,
RNF2, ANK3, FGFR2, and CES1) had a unique pattern. When this profile was expressed in
those various cancers it had a high statistical probability that the patient will die of the cancer.
They called this expression pattern, a “Death Signature”. In theory, one would think that if an
immunological intervention could be developed, these gene products might be perfect targets
for immunotherapy, assuming that these genes or their synthesized proteins are actively
playing a role in the cancer’s aggressiveness which leads to the patient’s demise. Since these
genes foretold the patient death, if you could then vaccinate a patient against these antigens
and prevent these genes from manifesting themselves, you should then interfere with their
final outcome, death. When we examined the REMBRANDT survival data with this series of
genes found in the Death Signature, there was actually very little significance; most of the gene
expression patterns, when investigated individually were the opposite of what was predicted
by the Death Signature concept. The only gene that correlated well with poor glioma survival
was a marker for cell proliferation that pathologists regularly use as a sign of cell division,
Ki67. Thus, we feel that this “Death Signature” doesn’t fit too well with gliomas. In fairness to
Glinsky and coworkers, they did use a large variety of cancers and they did do a multigene
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analysis, which REMBRANDT currently does not allow. So any multifactoral effect may have
simply been masked by the complexity of their analysis.
8. Targeting the genes commonly found in human GBM
In 2010, Colman and colleagues reported a series of 31 genes that were associated with poor
GBM survival [92]. When Rembrandt analysis was done using these genes, the vast majority
of these genes correlated extremely well. This evaluation was much better than “Death
Signature profile”. Since the MD Anderson and University of California, San Francisco groups
include many of their patients into REMBRANDT, it would be expected a much better
correlation could be found.
One interesting finding was that a couple of these genes from the Colman, et al. study were
also found in the glioblastoma peptidome derived from HLA-A2 alleles obtained from GBM
surgical specimens [96]. These T cells-derived antigens included: CHI3L1 (YKL-40), IGFBP3
(insulin-like growth factor binding protein-3), PDPN (podoplanin) and TNC (tenascin C). We
further examined these 31 genes from the Colman study and found their protein sequences.
We subjected them to SYPEITHI data analysis program (http://www.syfpeithi.de/) to deter‐
mine the possibility of generating nonomer peptide determinants towards their potential
antigenic peptides. Table 4 summarizes this study. We limited this inquiry to those peptides
that are found restricted to the HLA-0201 allele, since that is the most common HLA allele
found in the US with just a little less than half the Caucasians possessing this phenotype. Some
of the Colman and colleague’s proteins are quite small ranging from 116 amino acids (dynein
light chain) to fibronectin isoform1 that possess 2477 amino acids. For the dynein light chain
there were only 12 predicted peptides that could bind to HLA-A0201 with a binding score of
16 or better. In contrast, the fibronectin isoform-1 had 236 possible peptides. In sum, these
proteins provides 1,802 peptides that could theoretically be used to vaccinate patients against
HLA-0201+ tumor cells. Hence this might provide a particularly rich source of very clinically
relevant antigens to target glioma.
9. New targets
As we have described in Table 1, we only have 17 very good or good tumor antigens by which
we can target brain cancers, thus new antigens are needed. REMBRANDT has validated in
silico that there might be new targets that haven’t been considered before. It will be important
to consider targeting these molecules using a variety of mechanisms since they cause poor
patient survival and their under-expression leads to better survival. This can include immu‐
notherapy, molecular gene silencing or even knock-in strategies to take advantage of those
genes which prolonged patient survival. In Table 2 we show that several growth factors, their
cytokines or their extracellular matrix proteins might be potential good targets. Table 3
illustrated many intracellular cytoskeletal elements that are also good targets for either
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immunotherapy or potential gene knock-in. Colman’s study [92] (Table 4) provided an
incredible wealth of potential tumor antigens that could conceivably be targeted.






FGFR* neurocan, syndecan-1*,-2*,-3, glypican-1*,-2,-3,
phosphacan, nerve-glial antigen-2 (NG2) also known as
chondroiten sulfate proteoglycan 4, phosphacan (PTPRZ1).





syndecan-1*, decorin**, dermatan sulfate
Insulin-like growth factor-1 IGF1R glypican-3
Hepatocyte growth factor/ c-Met* dermatan sulfate/chondroiten sulfate B









Pleiotrophin* nucleolin, αv*β3 syndecan-3
Α6*β1
Midkine** nucleolin, αv*β3 various heparans
Α6*β1
Neuroregulin-1 erbB3 erbB4 heparan sulfated proteoglycans
Fibroblast growth factor-4 FGFR1 heparan sulfate
SDF-1 (CXCL12) CXCR4* syndecan-4
Epidermal growth factor* EGFR syndecan-2*, laminin A2**, lamininB1**, laminin A5*,
laminin B3*
Interleukin-6* IL6R* not reported yet
Interleukin-8* IL8RA, IL8RB* syndecan-2*
Interleukin-13 IL13Ra1** not reported as yet.
IL13Ra2**
Granulocyte-macrophage CSF2R syndecan-2*
Colony Stimulating Factor c-fms not reported as yet.
Table 2. Growth factors, cytokines and their receptors along with brain derived ECM. Single asterisk indicates either
over-expression leads to poor survival or under-expression leads towards better survival. Double asterisk indicates
both conditions described immediately above were true.
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Thus, targeting some of these genes using DC based vaccines could encompass using whole
tumor cell lysates, recombinant proteins or peptides using this information might be able to
target these key proteins. One can also interfere with these vital functions of glioma invasion
via molecular methods. In support of this concept, Dutroit and colleagues [96] using the
peptidomics approach with HLA-A2 associated peptides has found evidence that some of
these REMBRANDT validated peptides are present and could be possible targets of immuno‐
therapy if one was to use the same starting material that they used.
Signal transduction
Good Potential antigen No relevance Opposite expression
CDC42, grb2, h-ras, n-ras




Actn, Arf6, basigin, caveolin1, 2,
CDC42, CrkII, diaph1, erm/ moesin,
filamin A, C, fascin1, grb2, gelsolin,
IQGAP1, 2, 3, Mrlc2, Myh9, Nck1,
paxilin, Pdpn, Ppir12a, Pfn1, Rhamm,
supervillin, vimentin, Was/nWasp,
Wasf2
Abi2, Actr3, Arp2, Arp3, Bcar1,
caveolin 3, cofilin, c-Src, Cyfip1,
diaph3, dynamin1, 2, ezrin, f-actin,
fascin2, GFAP, Lmk1, Mena/Enah,
MLCK, Myh2, netrin, Pak1, 3, 4,
profilin 2, RhoA, Sh3pxd2a/Tks5,
Ssh1, vinculin, Wasl, Wipf1
Apc, Aref/ARHGEF4, ARHGEF7,
doublecortin, dynamin3, dock1,
Dtnb, FAK, fascin3, Myh10, Ntn4,
Pak7, Stathmin 2,3, 4, Wasf1
Tubulin cytoskeleton
Kif2c, Kif11/eg5
Dnch2, Dynll2, Dync1l11, Dynein




CD44, Itga6, Itgav, Itgb1, Itgb5,
Pdpn,
Itgb3
Table 3. Cytoskeletal proteins associated with cell migration, invasion and structure analyzed by REMBRANDT. (+)
indicates significant values, opposite (+) indicates a significant value, but is opposite to what is actually predicted by
current dogma.
REMBRANDT  was  then  used  to  determine  whether  this  gene  is  either  over-expressed
with a bad prognosis or under-expressed with a better survival was. When either one of
those conditions was met then that antigen was considered a potentially good antigen. If
both  conditions  were  met,  then  it  is  considered  a  potentially  very  good  antigen.  Con‐
versely, if neither condition was met then it was considered not good. Opposite indicates
the  REMBRANDT  analysis  contradicts  the  expected  prediction,  where  over  expression
lead to a better survival and vice versa.
The numbers of amino acids of the translated protein are shown. This protein was then
analyzed by SFYPEITHI analysis looking at possible nonamers that can theoretically bind to
HLA-A*0201, as a metric for how tentatively immunogenic this protein could be. SFYPEITHI
scores better than 16 were then counted. REMBRANDT was then used to determine whether
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immunotherapy or potential gene knock-in. Colman’s study [92] (Table 4) provided an
incredible wealth of potential tumor antigens that could conceivably be targeted.
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peptidomics approach with HLA-A2 associated peptides has found evidence that some of
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therapy if one was to use the same starting material that they used.
Signal transduction
Good Potential antigen No relevance Opposite expression
CDC42, grb2, h-ras, n-ras




Actn, Arf6, basigin, caveolin1, 2,
CDC42, CrkII, diaph1, erm/ moesin,
filamin A, C, fascin1, grb2, gelsolin,
IQGAP1, 2, 3, Mrlc2, Myh9, Nck1,
paxilin, Pdpn, Ppir12a, Pfn1, Rhamm,
supervillin, vimentin, Was/nWasp,
Wasf2
Abi2, Actr3, Arp2, Arp3, Bcar1,
caveolin 3, cofilin, c-Src, Cyfip1,
diaph3, dynamin1, 2, ezrin, f-actin,
fascin2, GFAP, Lmk1, Mena/Enah,
MLCK, Myh2, netrin, Pak1, 3, 4,
profilin 2, RhoA, Sh3pxd2a/Tks5,
Ssh1, vinculin, Wasl, Wipf1
Apc, Aref/ARHGEF4, ARHGEF7,
doublecortin, dynamin3, dock1,
Dtnb, FAK, fascin3, Myh10, Ntn4,
Pak7, Stathmin 2,3, 4, Wasf1
Tubulin cytoskeleton
Kif2c, Kif11/eg5
Dnch2, Dynll2, Dync1l11, Dynein




CD44, Itga6, Itgav, Itgb1, Itgb5,
Pdpn,
Itgb3
Table 3. Cytoskeletal proteins associated with cell migration, invasion and structure analyzed by REMBRANDT. (+)
indicates significant values, opposite (+) indicates a significant value, but is opposite to what is actually predicted by
current dogma.
REMBRANDT  was  then  used  to  determine  whether  this  gene  is  either  over-expressed
with a bad prognosis or under-expressed with a better survival was. When either one of
those conditions was met then that antigen was considered a potentially good antigen. If
both  conditions  were  met,  then  it  is  considered  a  potentially  very  good  antigen.  Con‐
versely, if neither condition was met then it was considered not good. Opposite indicates
the  REMBRANDT  analysis  contradicts  the  expected  prediction,  where  over  expression
lead to a better survival and vice versa.
The numbers of amino acids of the translated protein are shown. This protein was then
analyzed by SFYPEITHI analysis looking at possible nonamers that can theoretically bind to
HLA-A*0201, as a metric for how tentatively immunogenic this protein could be. SFYPEITHI
scores better than 16 were then counted. REMBRANDT was then used to determine whether
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
189
this gene is either over-expressed with a bad prognosis or under-expressed with a better
survival. When either one of those conditions was met then that antigen was considered a
potentially good antigen. If both conditions were met, then it is considered a potentially very
good antigen. Conversely, if neither condition was met then it was considered not good.




α-actinin-1 isoform a 914 122 Very Good
Aquaporin-1, isoform1 269 66 Very Good
Chitinase-3like protein 1 383 40 Very Good
Chloride intracell. channel protein 1 241 39 Good
Collagen α2 1366 95 Very Good
Epithelial membrane protein-3 163 45 Very Good
Fatty acid binding protein-5 135 14 Very Good
Fibronectin isoform 1 2477 236 Good
Transmembrane glycoprotein NMB 572 77 Very Good
Insulin-like growth factor bind. protein-2 328 41 Very Good
Insulin-like growth factor bind. protein-3 297 33 Very Good
Lactate dehydrogenase A 332 62 Very Good
Galectin-1 135 10 Very Good
Galectin-3 250 23 Very Good
Gycoprotein (transmembrane) NMB 572 44 Very Good
Monoamine oxidase B 520 84 Very Good
Nicotinamide N-methyltransferase 264 38 Very Good
Podoplanin a 238 46 Very Good
Proteolipid protein 2 152 34 Very Good
Transmembrane protein-158 (RIS) 300 50 Very Good
Serpine A3 423 80 Very Good
Plasminogen activator inhibitor 1 402 66 Very Good
Plasma protease C1 inhibitor 500 92 Very Good
Protein S100-A10 97 15 Good
Transgelin 201 21 Very Good
Transgelin 2 199 24 Very Good
Dynein light chain (Tctex) 116 12 No Good
Transforming growth factor-β1 390 57 Very Good
Tissue inhib. Metalloprot inhibitor 1 207 31 Very Good
Thymosin β10 (TMSB10) 44 0 Very Good
Tenascin 2201 179 No Good
VEGF-A 412 28 Very Good
Total Potential T cell epitopes: 1,802
Table 4. SYPEITHI predicted binding epitopes for the genes restricted to HLA-A*0201 that were over-expressed in
glioma and correlated with poor survival.
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10. Limitations and improvements for REMBRANDT
REMBRANDT type databases will be the future analyzing other types of cancer. Overall,
this program is quite useful and easy to use. One must have the proper abbreviation of
the  gene,  which  can  usually  be  found at  websites  like  Gene  Cards,  Wiki  Genes  or  the
HUGO Gene  Nomenclature  Committee  HGNC databases.  Occasionally  for  some  of  the
genes  we  searched,  our  analyses  ran  into  some  technical  problems  that  won’t  perform
the computations,  obviously some glitches remain in the system that  will  be  eventually
ironed out. For the next version of REMBRANDT it will be important to allow the glio‐
ma  sub-classes  to  be  assessed:  proneural,  mesenchymal  and  classic  GBM.  This  option
will  be  important,  since  each  GBM  subclass  has  its  own  particular  targets  to  be  used;
such as growth factor requirements proneural/neural GBM use the PDGF pathway, while
classical GBM use more EGF driven pathways. YKL-40 is a marker of the mesenchymal
GBM subtype and it might be a way to identify key interactions. Multivariant gene anal‐
ysis, where one can analyze several genes simultaneously will also allow better analyses.
So REMBRANDT version 2.0 should be enhanced with this kind of analysis.
The data we analyzed was based on gene expression measuring mRNA levels using microar‐
rays. So the danger is that these conclusions does not necessarily mean that the corresponding
proteins were synthesized. Splice variants are also not taken into account. For example gBK
and BKα channels cannot be distinguished as separate isoform resulted from the current
microarray platform. Nevertheless, this type of analysis will provide neuro-oncologists with
some exciting concepts to think about for years to come.
11. Conclusions
After many frustrating years of attempting to use immunotherapy against cancers, tumor
immunologists are starting to see successful results in melanomas, prostate cancer and in some
GBM patients including high grade gliomas. The identification of better glioma-associated
antigens is paramount to continue this investigative process. Many defined antigens have been
discovered by serendipity and this random process has lead to developments such as using a
variety of modalities: immunotoxins, chimeric antigen re-directed T cells, molecular silencing
approaches, DC-based vaccines, etc. But there are undoubtedly many more antigens still to be
discovered. Microarray analysis of tumors has already been proven to be a powerful way of
classifying tumors and provide novel tumor-specific therapies. The REMBRANDT data portal
allows researchers a chance to quickly assess this microarray data and quickly test potential
therapies in silico as we have attempted to do here before doing expensive clinical trials.
REMBRANDT gives one a chance to determine whether a gene has any importance in glioma
biology using a large data base. In this chapter we showed that REMBRANDT offers oncolo‐
gists a chance to analyze various biological pathways to see if predicted molecules seen in
tissue culture cell lines are applicable with the in situ scenario. REMBRANDT offers immu‐
nologists a chance to now make use of the key genes involved in gliomas and then target them
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potentially good antigen. If both conditions were met, then it is considered a potentially very
good antigen. Conversely, if neither condition was met then it was considered not good.
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for immunotherapy. By targeting critical genes by therapy, one hopes to attack cancers at their
strong points. REMBRANDT is pioneering this ability and its ability will undoubtedly will be
copied by other medical oncologists in studying their cancer of interest. So this is the first step
towards using knowledge to specifically target cancer.
Acknowledgements
We would like to thank Trina Formolo in Dr. Yetrib Hathout’s lab in the Department of
Integrative Systems Biology, Biochemistry & Molecular Biology at Children's National Medical
Center, Washington DC, for telling us about REMBRANDT. This little suggestion blossomed
into this book chapter. We also thank Susan Holsclaw of the VAMC-Long Beach for the
majority of the artwork presented here. This work is sponsored by the 2012 Summer Research
Fellowship Program from Southern California Institute for Research and Education, Long
Beach.
Author details
An Q. Dang1, Neil T. Hoa1, Lisheng Ge1, Gabriel Arismendi Morillo2, Brian Paleo1,
Esteban J. Gomez1, Dayeon Judy Shon6, Erin  Hong6, Ahmed M.  Aref1,6,7 and
Martin R. Jadus1,3,4,5*
*Address all correspondence to: martin.jadus@va.gov
1 Research Service Healthcare Group, Veterans Affairs Medical Center, Long Beach, CA,
USA
2  Biological  Research  Institute,  Faculty  of  Medicine,  University  of  Zulia,  Maracaibo,
Venezuela
3 Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long
Beach, CA, USA
4 Neuro-Oncology Program, Chao Comprehensive Cancer Center, University of California,
Irvine. Orange, CA, USA
5 Pathology and Laboratory Medicine, University of California Irvine, CA, USA
6 Southern California Institute for Research and Education, Veterans Affairs Medical Center,
Long Beach, CA, USA
7 Modern Sciences and Arts University (MSA), Biological Science Department, Cairo, Egypt
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications192
References
[1] Spellman, P. T, Sherlock, G, Zhang, M. Q, Iyer, V. R, Anders, K, Eisen, M. B, Brown,
P. O, & Botstein, D. and Bruce Futcher ((1998). Comprehensive identification of cell
cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridi‐
zation. Mol. Biol. Cell. , 9, 3273-3297.
[2] Alizadeh, A. A, Eisen, M. B, Davis, R. E, Ma, C, Lossos, I. S, Rosenwald, A, Boldrick,
J. C, Sabet, H, Tran, T, Yu, X, Powell, J. I, Yang, L, Marti, G. E, & Moore, T. Hudson J
Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger
DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D,
Brown PO, Staud LM ((2000). Distinct types of diffuse large B-cell lymphoma identi‐
fied by gene expression profiling. Nature , 403, 503-511.
[3] Phillips, H. S, Kharbanda, S, Chen, R, Forrest, W. F, Soriano, R. H, Wu, T. D, Misra,
A, Nigro, J. M, Colman, H, Soroceanu, L, Williams, P. M, Modrusan, Z, Feuerstein, B.
G, & Aldape, K. (2006). Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in neurogenesis. Can‐
cer Cell , 9, 157-173.
[4] Delay, M, Jahangiri, A, Carbonell, W. S, Hu, Y. L, Tsao, S, Tom, M. W, Paquette, J, &
Tokuyasu, T. A. (2012). Microarray Analysis Verifies Two Distinct Phenotypes of
Glioblastomas Resistant to Antiangiogenic Therapy. Clinical Cancer Res. , 18,
2930-42.
[5] Van Der Bruggen, P, Stroobant, V, & Vigneron, N. B. Van den Eynde. Peptide Data‐
base Cancer Immunity, http://www.cancerimmunity.org/peptidedatabase/Tcellepi‐
topes.html.
[6] Struss, A. K, Romeike, B. F, Munnia, A, Nastainczyk, W, Steudel, W. I, König, J, Oh‐
gaki, H, Feiden, W, Fischer, U, & Meese, E. (2001). PHF3-specific antibody responses
in over 60% of patients with glioblastoma multiforme. Oncogene , 20, 4107-4114.
[7] Pallasch, C. P, Struss, A. K, Munnia, A, König, J, Steudel, W. I, Fischer, U, & Meese,
E. (2005). Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor-associat‐
ed autoantibodies correlated with prolonged survival. International Journal of Can‐
cer , 117, 456-459.
[8] Kuan, C. T, Wikstrand, C. J, Archer, G, Beers, R, Pastan, I, Zalutsky, M. R, & Bigner,
D. D. (2000). Increased binding affinity enhances targeting of glioma xenografts by
EGFRvIII-specific scFv. International Journal of Cancer , 88, 6962-6969.
[9] Kuan, C. T, Srivastava, N, Mclendon, R. E, Marasco, W. A, Zalutsky, M. R, & Bigner,
D. D. (2010). Recombinant single-chain variable fragment antibodies against extracel‐
lular epitopes of human multidrug resistance protein MRP3 for targeting malignant
gliomas,” International Journal of Cancer. , 127, 598-611.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
193
for immunotherapy. By targeting critical genes by therapy, one hopes to attack cancers at their
strong points. REMBRANDT is pioneering this ability and its ability will undoubtedly will be
copied by other medical oncologists in studying their cancer of interest. So this is the first step
towards using knowledge to specifically target cancer.
Acknowledgements
We would like to thank Trina Formolo in Dr. Yetrib Hathout’s lab in the Department of
Integrative Systems Biology, Biochemistry & Molecular Biology at Children's National Medical
Center, Washington DC, for telling us about REMBRANDT. This little suggestion blossomed
into this book chapter. We also thank Susan Holsclaw of the VAMC-Long Beach for the
majority of the artwork presented here. This work is sponsored by the 2012 Summer Research
Fellowship Program from Southern California Institute for Research and Education, Long
Beach.
Author details
An Q. Dang1, Neil T. Hoa1, Lisheng Ge1, Gabriel Arismendi Morillo2, Brian Paleo1,
Esteban J. Gomez1, Dayeon Judy Shon6, Erin  Hong6, Ahmed M.  Aref1,6,7 and
Martin R. Jadus1,3,4,5*
*Address all correspondence to: martin.jadus@va.gov
1 Research Service Healthcare Group, Veterans Affairs Medical Center, Long Beach, CA,
USA
2  Biological  Research  Institute,  Faculty  of  Medicine,  University  of  Zulia,  Maracaibo,
Venezuela
3 Diagnostic and Molecular Health Care Group, Veterans Affairs Medical Center, Long
Beach, CA, USA
4 Neuro-Oncology Program, Chao Comprehensive Cancer Center, University of California,
Irvine. Orange, CA, USA
5 Pathology and Laboratory Medicine, University of California Irvine, CA, USA
6 Southern California Institute for Research and Education, Veterans Affairs Medical Center,
Long Beach, CA, USA
7 Modern Sciences and Arts University (MSA), Biological Science Department, Cairo, Egypt
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications192
References
[1] Spellman, P. T, Sherlock, G, Zhang, M. Q, Iyer, V. R, Anders, K, Eisen, M. B, Brown,
P. O, & Botstein, D. and Bruce Futcher ((1998). Comprehensive identification of cell
cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridi‐
zation. Mol. Biol. Cell. , 9, 3273-3297.
[2] Alizadeh, A. A, Eisen, M. B, Davis, R. E, Ma, C, Lossos, I. S, Rosenwald, A, Boldrick,
J. C, Sabet, H, Tran, T, Yu, X, Powell, J. I, Yang, L, Marti, G. E, & Moore, T. Hudson J
Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger
DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D,
Brown PO, Staud LM ((2000). Distinct types of diffuse large B-cell lymphoma identi‐
fied by gene expression profiling. Nature , 403, 503-511.
[3] Phillips, H. S, Kharbanda, S, Chen, R, Forrest, W. F, Soriano, R. H, Wu, T. D, Misra,
A, Nigro, J. M, Colman, H, Soroceanu, L, Williams, P. M, Modrusan, Z, Feuerstein, B.
G, & Aldape, K. (2006). Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in neurogenesis. Can‐
cer Cell , 9, 157-173.
[4] Delay, M, Jahangiri, A, Carbonell, W. S, Hu, Y. L, Tsao, S, Tom, M. W, Paquette, J, &
Tokuyasu, T. A. (2012). Microarray Analysis Verifies Two Distinct Phenotypes of
Glioblastomas Resistant to Antiangiogenic Therapy. Clinical Cancer Res. , 18,
2930-42.
[5] Van Der Bruggen, P, Stroobant, V, & Vigneron, N. B. Van den Eynde. Peptide Data‐
base Cancer Immunity, http://www.cancerimmunity.org/peptidedatabase/Tcellepi‐
topes.html.
[6] Struss, A. K, Romeike, B. F, Munnia, A, Nastainczyk, W, Steudel, W. I, König, J, Oh‐
gaki, H, Feiden, W, Fischer, U, & Meese, E. (2001). PHF3-specific antibody responses
in over 60% of patients with glioblastoma multiforme. Oncogene , 20, 4107-4114.
[7] Pallasch, C. P, Struss, A. K, Munnia, A, König, J, Steudel, W. I, Fischer, U, & Meese,
E. (2005). Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor-associat‐
ed autoantibodies correlated with prolonged survival. International Journal of Can‐
cer , 117, 456-459.
[8] Kuan, C. T, Wikstrand, C. J, Archer, G, Beers, R, Pastan, I, Zalutsky, M. R, & Bigner,
D. D. (2000). Increased binding affinity enhances targeting of glioma xenografts by
EGFRvIII-specific scFv. International Journal of Cancer , 88, 6962-6969.
[9] Kuan, C. T, Srivastava, N, Mclendon, R. E, Marasco, W. A, Zalutsky, M. R, & Bigner,
D. D. (2010). Recombinant single-chain variable fragment antibodies against extracel‐
lular epitopes of human multidrug resistance protein MRP3 for targeting malignant
gliomas,” International Journal of Cancer. , 127, 598-611.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
193
[10] Bremer, E, Samplonius, D, Kroesen, B. J, Van Genne, L, De Leij, L, & Helfrich, W.
(2004). Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion
protein with specificity for EGP2 toward target antigen-negative tumor cells. Neopla‐
sia , 6, 636-645.
[11] Solly, S. K, Nguyen, T. H, Weber, A, & Horellou, P. (2005). Targeting of c-Met and
Urokinase Expressing Human Glioma Cell Lines by Retrovirus Vector Displaying
Single-Chain Variable Fragment Antibody Cancer Biology & Therapy , 4, 987-992.
[12] Kim, W, & Liau, L. M. (2010). Dendritic cell vaccines for brain tumors. Neurosurgery
Clinics of North America. , 21, 139-157.
[13] Prins, R. M, Soto, H, Konkankit, V, Odesa, S. K, Eskin, A, Yong, W. H, Nelson, S. F, &
Liau, L. M. (2011). Gene expression profile correlates with T cell infiltration and sur‐
vival in glioblastoma patients vaccinated with dendritic cell immunotherapy,” Clini‐
cal Cancer Research, , 17, 1603-1615.
[14] Hanahan, D, & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation.
Cell , 144, 646-674.
[15] Ge, L, Hoa, N, Bota, D. A, Natividad, J, Howat, A, & Jadus, M. R. (2010). Immuno‐
therapy of brain cancers: the past, the present and future directions. Clinical and De‐
velopmental Immunology (2010:296453, 2010). doi:10.1155/2010/296453.
[16] Chow, K. H, & Gottschalk, S. (2011). Cellular immunotherapy for high-grade glioma
Immunotherapy 3(3), 4 23-434 10.2217/IMT.10.110.
[17] Toda, M. (2012). Glioma Antigen. Advances in Experimental Medicine and Biology ,
746, 77-84.
[18] Ge, L, Cornforth, A. N, Hoa, N. T, Delgado, C, Zhou, Y. H, & Jadus, M. R. (2012). Dif‐
ferential glioma-associated tumor antigen expression profiles of human glioma cells
grown in hypoxia. PLOS One, in press 2012.
[19] Dietrich, P. Y, & Dutoit, V. Thang NNT, Walker PR ((2010). T-cell immunotherapy
for malignant glioma: toward a combined approach. Current Opinion in Oncology ,
22, 604-610.
[20] Zhang, J. G, Eguchi, J, Kruse, C. A, Gomez, G. G, Fakhrai, H, Schroter, S, Ma, W, Hoa,
N, Minev, B, Delgado, C, Wepsic, H. T, Okada, H, & Jadus, M. R. (2007). Antigenic
profiles of glioma cells to generate allogeneic vaccines or DC-based therapeutics.
Clinical Cancer Research, , 13, 566-575.
[21] Skog, J. (2010). Glioma-specific antigens for immune therapy. Expert Review in Vac‐
cines , 5, 793-802.
[22] Izumoto, S, Tsuboi, A, Oka, Y, Suzuki, T, Hashiba, T, Kagawa, N, Hashimoto, N,
Maruno, M, Elisseeva, O. A, Shirakata, T, Kawakami, M, Oji, Y, Nishida, S, Ohno, S,
Kawase, I, Hataza, J, Nakatsuka, S. I, Aozasa, K, Morita, S, Akamoto, S, Sugiyama, J,
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications194
Yoshimine, H, & Phase, T. II clinical trial of Wilms tumor 1 peptide vaccination for
patients with recurrent glioblastoma multiforme. J Neurosurg , 108, 963-971.
[23] Mosmann, T. R, & Coffman, R. L. (1989). Heterogeneity of cytokine secretion patterns
and functions of helper T cells Advances in Immunol, , 46, 111-147.
[24] Schaefer, L. K, Menter, D. G, & Schaefer, T. S. (2000). Activation of Stat3 and Stat1
DNA binding and transcriptional activity in human brain tumour cell lines by gp130
cytokines. Cellular Signalling , 12, 143-151.
[25] Humphries, W, Wei, J, Sampson, J. H, & Heimberger, A. B. (2010). The Role of Tregs
in Glioma-Mediated Immunosuppression: Potential Target for Intervention. Neuro‐
surg Clin N Am. , 21(1), 125-137.
[26] Andaloussi, A. E, & Lesniak, M. S. (2006). An increase in CD4+CD25+FOXP3+ regula‐
tory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.
Neuro. Oncol. , 8, 234-243.
[27] Rich, J. N, Zhang, M, Datto, M. B, Bigner, D. D, & Wang, X. F. (1999). Transforming
growth factor-β-mediated induction and growth inhibition in astrocytes is SMAD3-
dependent and a pathway prominently altered in human glioma cell lines. Journal
Biological Chemistry 274: 35053- 35058., 15INK4B.
[28] Cao, S, Wang, C, Zheng, Q, Qiao, Y, Xu, K, Jiang, T, & Wu, A. (2011). STAT5 regu‐
lates glioma cell invasion by pathways dependent and independent of STAT5 DNA
binding Neuroscience Letters , 487, 228-233.
[29] Wainwright, D. A, Sengupta, S, Han, Y, Ulasov, I. V, & Lesniak, M. S. (2010). The
presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and hu‐
man glioma. PLoS ONE 5(10): e15390. doi:10.1371/journal.pone.0015390.
[30] Muranski, P, Boni, A, Antony, P. A, Cassard, L, Irvine, K. R, Kaiser, A, Paulos, C. M,
Palmer, D. C, Touloukian, C. E, Ptak, K, Gattinoni, L, Wrzesinski, C, Hinrichs, C. S,
Kerstann, K. W, Feigenbaum, L, Chan, C. C, & Restifo, N. P. (2008). Tumor-specific
Th17-polarized cells eradicate large established melanoma. Blood , 112, 362-373.
[31] Wu, S, Rhee, K. J, Albesiano, E, Rabizadeh, S, Wu, X, Yen, H. R, Huso, D. L, Brancati,
F. L, Wick, E, Mcallister, F, Housseau, F, Pardoll, D. M, & Sears, C. L. (2009). A hu‐
man colonic commensal promotes colon tumorigenesis via activation of T helper
type 17 T cell responses. Nature Medicine , 15, 1016-1022.
[32] Cruz-guilloty, F, Pipkin, M. E, Djuretic, I. M, Levanon, D, Lotem, J, Lichtenheld, M.
G, & Groner, Y. Anjana Rao A ((2009). Runx3 and T-box proteins cooperate to estab‐
lish the transcriptional program of eff ector CTLs J. Exp. Med. , 206, 51-59.
[33] Friese, M. A, Platten, M, Lutz, S. Z, Naumann, U, Aulwurm, S, Bischof, F, Bühring,
H. J, Dichgans, J, Rammensee, H. G, Steinle, A, & Weller, M. (2003). MICA/NKG2D-
mediated immunogene therapy of experimental gliomas. Cancer Res. , 63, 8996-9006.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
195
[10] Bremer, E, Samplonius, D, Kroesen, B. J, Van Genne, L, De Leij, L, & Helfrich, W.
(2004). Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion
protein with specificity for EGP2 toward target antigen-negative tumor cells. Neopla‐
sia , 6, 636-645.
[11] Solly, S. K, Nguyen, T. H, Weber, A, & Horellou, P. (2005). Targeting of c-Met and
Urokinase Expressing Human Glioma Cell Lines by Retrovirus Vector Displaying
Single-Chain Variable Fragment Antibody Cancer Biology & Therapy , 4, 987-992.
[12] Kim, W, & Liau, L. M. (2010). Dendritic cell vaccines for brain tumors. Neurosurgery
Clinics of North America. , 21, 139-157.
[13] Prins, R. M, Soto, H, Konkankit, V, Odesa, S. K, Eskin, A, Yong, W. H, Nelson, S. F, &
Liau, L. M. (2011). Gene expression profile correlates with T cell infiltration and sur‐
vival in glioblastoma patients vaccinated with dendritic cell immunotherapy,” Clini‐
cal Cancer Research, , 17, 1603-1615.
[14] Hanahan, D, & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation.
Cell , 144, 646-674.
[15] Ge, L, Hoa, N, Bota, D. A, Natividad, J, Howat, A, & Jadus, M. R. (2010). Immuno‐
therapy of brain cancers: the past, the present and future directions. Clinical and De‐
velopmental Immunology (2010:296453, 2010). doi:10.1155/2010/296453.
[16] Chow, K. H, & Gottschalk, S. (2011). Cellular immunotherapy for high-grade glioma
Immunotherapy 3(3), 4 23-434 10.2217/IMT.10.110.
[17] Toda, M. (2012). Glioma Antigen. Advances in Experimental Medicine and Biology ,
746, 77-84.
[18] Ge, L, Cornforth, A. N, Hoa, N. T, Delgado, C, Zhou, Y. H, & Jadus, M. R. (2012). Dif‐
ferential glioma-associated tumor antigen expression profiles of human glioma cells
grown in hypoxia. PLOS One, in press 2012.
[19] Dietrich, P. Y, & Dutoit, V. Thang NNT, Walker PR ((2010). T-cell immunotherapy
for malignant glioma: toward a combined approach. Current Opinion in Oncology ,
22, 604-610.
[20] Zhang, J. G, Eguchi, J, Kruse, C. A, Gomez, G. G, Fakhrai, H, Schroter, S, Ma, W, Hoa,
N, Minev, B, Delgado, C, Wepsic, H. T, Okada, H, & Jadus, M. R. (2007). Antigenic
profiles of glioma cells to generate allogeneic vaccines or DC-based therapeutics.
Clinical Cancer Research, , 13, 566-575.
[21] Skog, J. (2010). Glioma-specific antigens for immune therapy. Expert Review in Vac‐
cines , 5, 793-802.
[22] Izumoto, S, Tsuboi, A, Oka, Y, Suzuki, T, Hashiba, T, Kagawa, N, Hashimoto, N,
Maruno, M, Elisseeva, O. A, Shirakata, T, Kawakami, M, Oji, Y, Nishida, S, Ohno, S,
Kawase, I, Hataza, J, Nakatsuka, S. I, Aozasa, K, Morita, S, Akamoto, S, Sugiyama, J,
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications194
Yoshimine, H, & Phase, T. II clinical trial of Wilms tumor 1 peptide vaccination for
patients with recurrent glioblastoma multiforme. J Neurosurg , 108, 963-971.
[23] Mosmann, T. R, & Coffman, R. L. (1989). Heterogeneity of cytokine secretion patterns
and functions of helper T cells Advances in Immunol, , 46, 111-147.
[24] Schaefer, L. K, Menter, D. G, & Schaefer, T. S. (2000). Activation of Stat3 and Stat1
DNA binding and transcriptional activity in human brain tumour cell lines by gp130
cytokines. Cellular Signalling , 12, 143-151.
[25] Humphries, W, Wei, J, Sampson, J. H, & Heimberger, A. B. (2010). The Role of Tregs
in Glioma-Mediated Immunosuppression: Potential Target for Intervention. Neuro‐
surg Clin N Am. , 21(1), 125-137.
[26] Andaloussi, A. E, & Lesniak, M. S. (2006). An increase in CD4+CD25+FOXP3+ regula‐
tory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.
Neuro. Oncol. , 8, 234-243.
[27] Rich, J. N, Zhang, M, Datto, M. B, Bigner, D. D, & Wang, X. F. (1999). Transforming
growth factor-β-mediated induction and growth inhibition in astrocytes is SMAD3-
dependent and a pathway prominently altered in human glioma cell lines. Journal
Biological Chemistry 274: 35053- 35058., 15INK4B.
[28] Cao, S, Wang, C, Zheng, Q, Qiao, Y, Xu, K, Jiang, T, & Wu, A. (2011). STAT5 regu‐
lates glioma cell invasion by pathways dependent and independent of STAT5 DNA
binding Neuroscience Letters , 487, 228-233.
[29] Wainwright, D. A, Sengupta, S, Han, Y, Ulasov, I. V, & Lesniak, M. S. (2010). The
presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and hu‐
man glioma. PLoS ONE 5(10): e15390. doi:10.1371/journal.pone.0015390.
[30] Muranski, P, Boni, A, Antony, P. A, Cassard, L, Irvine, K. R, Kaiser, A, Paulos, C. M,
Palmer, D. C, Touloukian, C. E, Ptak, K, Gattinoni, L, Wrzesinski, C, Hinrichs, C. S,
Kerstann, K. W, Feigenbaum, L, Chan, C. C, & Restifo, N. P. (2008). Tumor-specific
Th17-polarized cells eradicate large established melanoma. Blood , 112, 362-373.
[31] Wu, S, Rhee, K. J, Albesiano, E, Rabizadeh, S, Wu, X, Yen, H. R, Huso, D. L, Brancati,
F. L, Wick, E, Mcallister, F, Housseau, F, Pardoll, D. M, & Sears, C. L. (2009). A hu‐
man colonic commensal promotes colon tumorigenesis via activation of T helper
type 17 T cell responses. Nature Medicine , 15, 1016-1022.
[32] Cruz-guilloty, F, Pipkin, M. E, Djuretic, I. M, Levanon, D, Lotem, J, Lichtenheld, M.
G, & Groner, Y. Anjana Rao A ((2009). Runx3 and T-box proteins cooperate to estab‐
lish the transcriptional program of eff ector CTLs J. Exp. Med. , 206, 51-59.
[33] Friese, M. A, Platten, M, Lutz, S. Z, Naumann, U, Aulwurm, S, Bischof, F, Bühring,
H. J, Dichgans, J, Rammensee, H. G, Steinle, A, & Weller, M. (2003). MICA/NKG2D-
mediated immunogene therapy of experimental gliomas. Cancer Res. , 63, 8996-9006.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
195
[34] Bryant, N. L, Suarez-cuervo, C, Gillespie, G. Y, Markert, J. M, Nabors, L. B, Meleth, S,
& Lopez, R. D. Lamb LS Jr. (2009). Characterization and immunotherapeutic poten‐
tial of γδT-cells in patients with glioblastoma. Neuro. Oncol. , 11, 357-367.
[35] Lamb, L. S. (2009). T-cells as immune effectors against high-grade gliomas, Immuno‐
logic Research, , 45, 85-95.
[36] Bryant, N. L, Gillespie, G. Y, Lopez, R. D, Markert, J. M, Cloud, G. A, Langford, C. P,
Arnouk, H, Su, Y, Haines, H. L, & Suarez-cuervo, C. (2011). Preclinical evaluation of
ex vivo expanded/activated γδ T-cells for immunotherapy of glioblastoma multi‐
forme, Journal of Neuro-Oncology, , 2010, 101-179.
[37] Whiteside, T. L. (2006). Immune suppression in cancer: Effects on immune cells,
mechanisms and future therapeutic intervention. Seminars in Cancer , 16, 3-15.
[38] Gomez, G. G, & Kruse, C. A. (2006). Mechanisms of malignant glioma immune resist‐
ance and sources of immunosuppression, Gene Therapy & Molecular Biology,
10(A): , 133-146.
[39] Jadus, M. R, Driggers, L, & Hoa, N. Pham JTH, Natividad J, Delgado C, Jeffes EWB,
Limoli C, Giedzinski E, Ge L. Mechanisms of immune evasion exhibited by different
rat glioma cell lines. Chapter 4 in Neuro-Oncology and Cancer Targeted Therapy, ed‐
itor: L.M. Gutierrez. Nova Science Publishers, (2010). 978-1-61668-708-3, 109-139.
[40] Gabrilovich, D. I, Chen, H. L, Girgis, K. R, Cunningham, H. T, Meny, G. M, Nadaf, S,
Kavanaugh, D, & Carbone, D. P. (1996). Production of vascular endothelial growth
factor by human tumors inhibits the functional maturation of dendritic cells. Nat.
Med. , 2, 1096-103.
[41] Karman, J, Ling, C, Sandor, M, & Fabry, Z. (2004). Initiation of immune responses in
brain is promoted by local dendritic cells. J. Immunol, , 173, 2353-2361.
[42] Munn, D. H, & Mellor, A. L. (2004). IDO and tolerance to tumors. Trends in Molecu‐
lar Medicine , 10, 15-18.
[43] Gabrilovich, D. I, & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regula‐
tors of the immune system Nature Reviews Immunology , 9, 162-174.
[44] Cao, Y, & Prescott, S. M. (2002). Many actions of cyclooxygenase-2 in cellular dynam‐
ics and in cancer, Journal of Cellular Physiology, , 190, 279-286.
[45] Prayson, R. A, Castilla, E. A, Vogelbaum, M. A, & Barnett, G. H. (2002). Cyclooxyge‐
nase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.
Annals Diag Path 6:148-53 (2002).
[46] Akasaki, Y, Liu, G, Chung, H. C, Ehtesham, M, Black, K. L, & Yu, J. S. (2004). Induc‐
tion of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing
glioma. J.Immunol. , 173, 4352-9.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications196
[47] Gao, Y. F, Sun, Z. Q, Qi, F, Qi, Y. M, Zhai, M. X, Lou, H. P, Chen, L. X, Li, Y. X, &
Wang, X. Y. (2009). Identification of a new broad-spectrum CD8+ T cell epitope from
over-expressed antigen COX-2 in esophageal carcinoma. Cancer Letters , 284, 55-61.
[48] Schreinemachers, D. M, & Everson, R. B. (1994). Aspirin use and lung, colon, and
breast cancer incidence in a prospective study,” Epidemiology, , 5, 138-146.
[49] Debinski, W, Gibo, D. M, Slagle, B, Powers, S. K, & Gillespie, G. Y. (1999). Receptor
for interleukin 13 is abundantly and specifically over-expressed in patients with glio‐
blastoma multiforme. Int J Oncol. , 15, 481-6.
[50] Wykosky, J, Gibo, DM, Stanton, C, Debinski, W, & Eph, . 2 as a novel molecular
marker and target in glioblastoma multiforme. Mol Cancer Res 3:541-551.
[51] Lokker, N. A, Sullivan, C. M, Hollenbach, S. J, Israel, M. A, & Neill, A. (2002). Plate‐
let-derived growth factor (PDGF) autocrine signaling regulates survival and mito‐
genic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D
ligands may play a role in the development of Brain Tumors. Cancer Res , 62,
3729-3735.
[52] Fleming, T. P, Saxena, A, Clark, W. C, Robertson, J. T, Oldfield, E. H, Aaronson, S. A,
& Ali, I. U. (1992). Amplification and/or overexpression of platelet-derived growth
factor receptors and epidermal growth factor receptor in human glial tumors. Cancer
Res. , 52, 4550-4553.
[53] Hatanpaa, K. J, Burma, S, Zhao, D, & Habib, A. A. (2010). Epidermal growth factor
receptor in glioma: signal transduction, neuropathology, imaging, and radioresist‐
ance. Neoplasia , 12, 675-684.
[54] Gammeltoft, S, Ballotti, R, Kowalski, A, Westermark, B, & Van Obberghen, E. (1988).
Expression of two types of receptor for insulin-like growth factors in human malig‐
nant glioma. Cancer Res. , 48, 1233-1237.
[55] Lamszus, K, Laterra, J, Westphal, M, & Rosen, E. M. (1999). Scatter factor/hepatocyte
growth factor (SF/HGF) content and function in human gliomas,” International Jour‐
nal of Developmental Neuroscience , 17, 517-530.
[56] Weissenberger, J, Loeffler, S, Kappeler, A, Kopf, M, Lukes, A, Afanasieva, T. A,
Aguzzi, A, & Weis, J. (2004). IL-6 is required for glioma development in a mouse
model. Oncogene , 23, 3308-3316.
[57] Mueller, M. M, Herold-mende, C. C, Riede, D, Lange, M, Steiner, H, & Fusenig, N. E.
(1999). Autocrine growth regulation by granulocyte colony stimulating factor and
granulocyte-macrophage colony stimulating factor in human gliomas with tumor
progression, American Journal of Pathology, , 155, 1557-1567.
[58] Joy, A. M, Beaudry, C. E, Tran, N. L, Ponce, F. A, Holz, D. R, Demuth, T, & Berens,
M. E. (2003). Migrating glioma cells activate the PI3-K pathway and display de‐
creased susceptibility to apoptosis. Journal of Cell Science , 116, 4409-4417.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
197
[34] Bryant, N. L, Suarez-cuervo, C, Gillespie, G. Y, Markert, J. M, Nabors, L. B, Meleth, S,
& Lopez, R. D. Lamb LS Jr. (2009). Characterization and immunotherapeutic poten‐
tial of γδT-cells in patients with glioblastoma. Neuro. Oncol. , 11, 357-367.
[35] Lamb, L. S. (2009). T-cells as immune effectors against high-grade gliomas, Immuno‐
logic Research, , 45, 85-95.
[36] Bryant, N. L, Gillespie, G. Y, Lopez, R. D, Markert, J. M, Cloud, G. A, Langford, C. P,
Arnouk, H, Su, Y, Haines, H. L, & Suarez-cuervo, C. (2011). Preclinical evaluation of
ex vivo expanded/activated γδ T-cells for immunotherapy of glioblastoma multi‐
forme, Journal of Neuro-Oncology, , 2010, 101-179.
[37] Whiteside, T. L. (2006). Immune suppression in cancer: Effects on immune cells,
mechanisms and future therapeutic intervention. Seminars in Cancer , 16, 3-15.
[38] Gomez, G. G, & Kruse, C. A. (2006). Mechanisms of malignant glioma immune resist‐
ance and sources of immunosuppression, Gene Therapy & Molecular Biology,
10(A): , 133-146.
[39] Jadus, M. R, Driggers, L, & Hoa, N. Pham JTH, Natividad J, Delgado C, Jeffes EWB,
Limoli C, Giedzinski E, Ge L. Mechanisms of immune evasion exhibited by different
rat glioma cell lines. Chapter 4 in Neuro-Oncology and Cancer Targeted Therapy, ed‐
itor: L.M. Gutierrez. Nova Science Publishers, (2010). 978-1-61668-708-3, 109-139.
[40] Gabrilovich, D. I, Chen, H. L, Girgis, K. R, Cunningham, H. T, Meny, G. M, Nadaf, S,
Kavanaugh, D, & Carbone, D. P. (1996). Production of vascular endothelial growth
factor by human tumors inhibits the functional maturation of dendritic cells. Nat.
Med. , 2, 1096-103.
[41] Karman, J, Ling, C, Sandor, M, & Fabry, Z. (2004). Initiation of immune responses in
brain is promoted by local dendritic cells. J. Immunol, , 173, 2353-2361.
[42] Munn, D. H, & Mellor, A. L. (2004). IDO and tolerance to tumors. Trends in Molecu‐
lar Medicine , 10, 15-18.
[43] Gabrilovich, D. I, & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regula‐
tors of the immune system Nature Reviews Immunology , 9, 162-174.
[44] Cao, Y, & Prescott, S. M. (2002). Many actions of cyclooxygenase-2 in cellular dynam‐
ics and in cancer, Journal of Cellular Physiology, , 190, 279-286.
[45] Prayson, R. A, Castilla, E. A, Vogelbaum, M. A, & Barnett, G. H. (2002). Cyclooxyge‐
nase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme.
Annals Diag Path 6:148-53 (2002).
[46] Akasaki, Y, Liu, G, Chung, H. C, Ehtesham, M, Black, K. L, & Yu, J. S. (2004). Induc‐
tion of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing
glioma. J.Immunol. , 173, 4352-9.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications196
[47] Gao, Y. F, Sun, Z. Q, Qi, F, Qi, Y. M, Zhai, M. X, Lou, H. P, Chen, L. X, Li, Y. X, &
Wang, X. Y. (2009). Identification of a new broad-spectrum CD8+ T cell epitope from
over-expressed antigen COX-2 in esophageal carcinoma. Cancer Letters , 284, 55-61.
[48] Schreinemachers, D. M, & Everson, R. B. (1994). Aspirin use and lung, colon, and
breast cancer incidence in a prospective study,” Epidemiology, , 5, 138-146.
[49] Debinski, W, Gibo, D. M, Slagle, B, Powers, S. K, & Gillespie, G. Y. (1999). Receptor
for interleukin 13 is abundantly and specifically over-expressed in patients with glio‐
blastoma multiforme. Int J Oncol. , 15, 481-6.
[50] Wykosky, J, Gibo, DM, Stanton, C, Debinski, W, & Eph, . 2 as a novel molecular
marker and target in glioblastoma multiforme. Mol Cancer Res 3:541-551.
[51] Lokker, N. A, Sullivan, C. M, Hollenbach, S. J, Israel, M. A, & Neill, A. (2002). Plate‐
let-derived growth factor (PDGF) autocrine signaling regulates survival and mito‐
genic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D
ligands may play a role in the development of Brain Tumors. Cancer Res , 62,
3729-3735.
[52] Fleming, T. P, Saxena, A, Clark, W. C, Robertson, J. T, Oldfield, E. H, Aaronson, S. A,
& Ali, I. U. (1992). Amplification and/or overexpression of platelet-derived growth
factor receptors and epidermal growth factor receptor in human glial tumors. Cancer
Res. , 52, 4550-4553.
[53] Hatanpaa, K. J, Burma, S, Zhao, D, & Habib, A. A. (2010). Epidermal growth factor
receptor in glioma: signal transduction, neuropathology, imaging, and radioresist‐
ance. Neoplasia , 12, 675-684.
[54] Gammeltoft, S, Ballotti, R, Kowalski, A, Westermark, B, & Van Obberghen, E. (1988).
Expression of two types of receptor for insulin-like growth factors in human malig‐
nant glioma. Cancer Res. , 48, 1233-1237.
[55] Lamszus, K, Laterra, J, Westphal, M, & Rosen, E. M. (1999). Scatter factor/hepatocyte
growth factor (SF/HGF) content and function in human gliomas,” International Jour‐
nal of Developmental Neuroscience , 17, 517-530.
[56] Weissenberger, J, Loeffler, S, Kappeler, A, Kopf, M, Lukes, A, Afanasieva, T. A,
Aguzzi, A, & Weis, J. (2004). IL-6 is required for glioma development in a mouse
model. Oncogene , 23, 3308-3316.
[57] Mueller, M. M, Herold-mende, C. C, Riede, D, Lange, M, Steiner, H, & Fusenig, N. E.
(1999). Autocrine growth regulation by granulocyte colony stimulating factor and
granulocyte-macrophage colony stimulating factor in human gliomas with tumor
progression, American Journal of Pathology, , 155, 1557-1567.
[58] Joy, A. M, Beaudry, C. E, Tran, N. L, Ponce, F. A, Holz, D. R, Demuth, T, & Berens,
M. E. (2003). Migrating glioma cells activate the PI3-K pathway and display de‐
creased susceptibility to apoptosis. Journal of Cell Science , 116, 4409-4417.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
197
[59] Cantley, L. C. (2002). The Phosphoinositide 3-Kinase Pathway Science , 296,
1655-1657.
[60] Ruoslahti, E. (1996). Brain extracellular matrix. Glycobiology , 6, 489-492.
[61] Ulrich, T. A. de Juan Pardo EM, Kumar S ((2009). The mechanical rigidity of the ex‐
tracellular matrix regulates the structure, motility, and proliferation of glioma cells.
Cancer Research 69: 4167.
[62] Le Clainche C Carlier MF ((2008). Regulation of actin assembly associated with pro‐
trusion and adhesion in cell migrationPhysiol Rev , 88, 489-513.
[63] Nemethova, M, Auinger, S, & Small, J. V. (2008). Building the actin cytoskeleton: filo‐
podia contribute to the construction of contractile bundles in the lamella. Journal Cell
Biol , 180, 1233-1244.
[64] Kurisu, S, & Takenawa, T. (2010). WASP and WAVE family proteins: Friends or foes
in cancer invasion? Cancer Science , 101, 2093-2104.
[65] Yamazaki, D, Kurisu, S, & Takenawa, T. (2005). Regulation of cancer cell motility
through actin reorganization. Cancer Science. , 96, 379-386.
[66] Isacke, C. M, & Yarwood, H. (2002). The hyaluronan receptor, CD44. International
Journal of Biochemistry & Cell Biology , 34, 718-721.
[67] Abaco, D, Kaye, G. M, & Integrins, A. H. Molecular determinants of glioma invasion.
Journal of Clinical Neuroscience , 11, 1041-1048.
[68] Delamarre E, Taboubi S, Mathieu S, Bérenguer C, Rigot V, Lissitzky JC, Figarella-
Branger D, Ouafik LH, Luis J (2009) Expression of integrin 6β1 enhances tumorigene‐
sis in glioma cells. American Journal of Pathology 175:844-855.
[69] Färber, K, Synowitz, M, Zahn, G, Vossmeyer, D, Stragies, R, Van Rooijen, N, & Ket‐
tenmann, H. integrin inhibitor attenuates glioma growth. Molecular and Cellular
Neuroscience , 39, 579-585.
[70] Mikelis, C, Sfaelou, E, Koutsioumpa, M, & Kieffer, N. E. is a pleiotrophin receptor re‐
quired for pleiotrophin-induced endothelial cell migration through receptor protein
tyrosine phosphatase β/ζ. FASEB Journal , 23, 1459-1469.
[71] Kadomatsu, K, & Muramatsu, T. (2004). Midkine and pleiotrophin in neural develop‐
ment and cancer. Cancer Letters , 204, 127-143.
[72] Mirkin, B. L, Clark, S, Zheng, X, Chu, F, White, B. D, Greene, M, & Rebbaa, A. (2005).
Identification of midkine as a mediator for intercellular transfer of drug resistance.
Oncogene 24, 4965-4974.Sontheimer, H (2003) Malignant gliomas: perverting gluta‐
mate and ion homeostasis for selective advantage. Trends in Neurosciences, , 26,
543-549.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications198
[73] Maas, S, Patt, S, Schrey, M, & Rich, A. (2001). Underediting of glutamate receptor
GluR-B mRNA in malignant gliomas. Underediting of glutamate receptor GluR-B
mRNA in malignant gliomas. Proc Natl Acad Sci (USA) , 98, 14687-14692.
[74] Teh, J, & Chen, S. (2012). Metabotropic glutamate receptors and cancerous growth.
WIREs Membr Transp Signal , 1, 211-220.
[75] Collins, V. P, Brunk, U. T, Freddriksson, B. A, & Westermark, B. (1979). The fine
structure of growing human glia and glioma cells. Acta Path. Microbiol. Scand Sec‐
tion , 1, 87-29.
[76] Collins, V. P, Forsby, N, Brunk, U. T, & Westermark, B. (1977). The surface morphol‐
ogy of cultured human glia and glioma cells. A SEM and time-lapse study at differ‐
ent cell densities. Cytobiologie , 16, 52-62.
[77] Spence, A. M, & Coates, P. W. (1978). Scanning electron microscopy of clones astro‐
cytic lines derived from ethyl nitrosurea-induce rat gliomas. Virchows Arch. B Cell
Path. , 28, 27-35.
[78] Höglund, A. S. (1985). The arrangement of microfilaments and microtubules in the
periphery of spreading fibroblasts and glial cells. Tissue and Cell , 17, 649-666.
[79] Arismendi-morillo, G. J, & Castellano-ramirez, A. V. (2008). Ultrastructural mito‐
chondrial pathology in human astrocytic tumors: potentials implications pro-thera‐
peutics strategies. J. Electron Microscopy , 57, 33-39.
[80] Arismendi-morillo, G, Hoa, N. T, Ge, L, & Jadus, M. (2012). Mitochondrial network
in glioma´s invadopodia displays an activated state both in situ and in vitro: Poten‐
tial functional implications. Ultrastructural Pathology in press.
[81] Hoa, N, Ge, L, Kuznetsov, Y, Mcpherson, A, & Cornforth, A. N. Pham JTH, Myers
MP, Ahmed N, Salsman VS, Lamb, LS Jr, Bowersock JE, Hu Y, Zhou YH, Jadus MR
((2010). Glioma cells display complex cell surface topographies that resist the actions
of cytolytic effector lymphocytes. Journal of Immunology , 185, 4793-4803.
[82] Bretscher, A. (1991). Microfilament Structure and Function in the Cortical Cytoskele‐
ton. Annual Review of Cell Biology , 7, 337-374.
[83] Dos Remedios CGChhabra D, Kekic M, Dedova IV, Tsubakihara M, Berry DA
((2003). Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol
Rev , 83, 433-473.
[84] Cardelli, J, & Skalli, O. (2010). Divide and Conquer: the dynamic cytoskeleton of glio‐
ma. In: Glioblastoma: molecular mechanisms of pathogenesis and current therapeu‐
tic strategies S.K. Ray (ed).
[85] Winder, S. J, & Ayscough, K. R. (2004). Actin-binding proteins. J. Cell Sci , 118,
651-654.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
199
[59] Cantley, L. C. (2002). The Phosphoinositide 3-Kinase Pathway Science , 296,
1655-1657.
[60] Ruoslahti, E. (1996). Brain extracellular matrix. Glycobiology , 6, 489-492.
[61] Ulrich, T. A. de Juan Pardo EM, Kumar S ((2009). The mechanical rigidity of the ex‐
tracellular matrix regulates the structure, motility, and proliferation of glioma cells.
Cancer Research 69: 4167.
[62] Le Clainche C Carlier MF ((2008). Regulation of actin assembly associated with pro‐
trusion and adhesion in cell migrationPhysiol Rev , 88, 489-513.
[63] Nemethova, M, Auinger, S, & Small, J. V. (2008). Building the actin cytoskeleton: filo‐
podia contribute to the construction of contractile bundles in the lamella. Journal Cell
Biol , 180, 1233-1244.
[64] Kurisu, S, & Takenawa, T. (2010). WASP and WAVE family proteins: Friends or foes
in cancer invasion? Cancer Science , 101, 2093-2104.
[65] Yamazaki, D, Kurisu, S, & Takenawa, T. (2005). Regulation of cancer cell motility
through actin reorganization. Cancer Science. , 96, 379-386.
[66] Isacke, C. M, & Yarwood, H. (2002). The hyaluronan receptor, CD44. International
Journal of Biochemistry & Cell Biology , 34, 718-721.
[67] Abaco, D, Kaye, G. M, & Integrins, A. H. Molecular determinants of glioma invasion.
Journal of Clinical Neuroscience , 11, 1041-1048.
[68] Delamarre E, Taboubi S, Mathieu S, Bérenguer C, Rigot V, Lissitzky JC, Figarella-
Branger D, Ouafik LH, Luis J (2009) Expression of integrin 6β1 enhances tumorigene‐
sis in glioma cells. American Journal of Pathology 175:844-855.
[69] Färber, K, Synowitz, M, Zahn, G, Vossmeyer, D, Stragies, R, Van Rooijen, N, & Ket‐
tenmann, H. integrin inhibitor attenuates glioma growth. Molecular and Cellular
Neuroscience , 39, 579-585.
[70] Mikelis, C, Sfaelou, E, Koutsioumpa, M, & Kieffer, N. E. is a pleiotrophin receptor re‐
quired for pleiotrophin-induced endothelial cell migration through receptor protein
tyrosine phosphatase β/ζ. FASEB Journal , 23, 1459-1469.
[71] Kadomatsu, K, & Muramatsu, T. (2004). Midkine and pleiotrophin in neural develop‐
ment and cancer. Cancer Letters , 204, 127-143.
[72] Mirkin, B. L, Clark, S, Zheng, X, Chu, F, White, B. D, Greene, M, & Rebbaa, A. (2005).
Identification of midkine as a mediator for intercellular transfer of drug resistance.
Oncogene 24, 4965-4974.Sontheimer, H (2003) Malignant gliomas: perverting gluta‐
mate and ion homeostasis for selective advantage. Trends in Neurosciences, , 26,
543-549.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications198
[73] Maas, S, Patt, S, Schrey, M, & Rich, A. (2001). Underediting of glutamate receptor
GluR-B mRNA in malignant gliomas. Underediting of glutamate receptor GluR-B
mRNA in malignant gliomas. Proc Natl Acad Sci (USA) , 98, 14687-14692.
[74] Teh, J, & Chen, S. (2012). Metabotropic glutamate receptors and cancerous growth.
WIREs Membr Transp Signal , 1, 211-220.
[75] Collins, V. P, Brunk, U. T, Freddriksson, B. A, & Westermark, B. (1979). The fine
structure of growing human glia and glioma cells. Acta Path. Microbiol. Scand Sec‐
tion , 1, 87-29.
[76] Collins, V. P, Forsby, N, Brunk, U. T, & Westermark, B. (1977). The surface morphol‐
ogy of cultured human glia and glioma cells. A SEM and time-lapse study at differ‐
ent cell densities. Cytobiologie , 16, 52-62.
[77] Spence, A. M, & Coates, P. W. (1978). Scanning electron microscopy of clones astro‐
cytic lines derived from ethyl nitrosurea-induce rat gliomas. Virchows Arch. B Cell
Path. , 28, 27-35.
[78] Höglund, A. S. (1985). The arrangement of microfilaments and microtubules in the
periphery of spreading fibroblasts and glial cells. Tissue and Cell , 17, 649-666.
[79] Arismendi-morillo, G. J, & Castellano-ramirez, A. V. (2008). Ultrastructural mito‐
chondrial pathology in human astrocytic tumors: potentials implications pro-thera‐
peutics strategies. J. Electron Microscopy , 57, 33-39.
[80] Arismendi-morillo, G, Hoa, N. T, Ge, L, & Jadus, M. (2012). Mitochondrial network
in glioma´s invadopodia displays an activated state both in situ and in vitro: Poten‐
tial functional implications. Ultrastructural Pathology in press.
[81] Hoa, N, Ge, L, Kuznetsov, Y, Mcpherson, A, & Cornforth, A. N. Pham JTH, Myers
MP, Ahmed N, Salsman VS, Lamb, LS Jr, Bowersock JE, Hu Y, Zhou YH, Jadus MR
((2010). Glioma cells display complex cell surface topographies that resist the actions
of cytolytic effector lymphocytes. Journal of Immunology , 185, 4793-4803.
[82] Bretscher, A. (1991). Microfilament Structure and Function in the Cortical Cytoskele‐
ton. Annual Review of Cell Biology , 7, 337-374.
[83] Dos Remedios CGChhabra D, Kekic M, Dedova IV, Tsubakihara M, Berry DA
((2003). Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol
Rev , 83, 433-473.
[84] Cardelli, J, & Skalli, O. (2010). Divide and Conquer: the dynamic cytoskeleton of glio‐
ma. In: Glioblastoma: molecular mechanisms of pathogenesis and current therapeu‐
tic strategies S.K. Ray (ed).
[85] Winder, S. J, & Ayscough, K. R. (2004). Actin-binding proteins. J. Cell Sci , 118,
651-654.
Using REMBRANDT to Paint in the Details of Glioma Biology: Applications for Future Immunotherapy
http://dx.doi.org/10.5772/52363
199
[86] Machesky, L. M, & Li, A. (2010). Fascin: Invasive filopodia promoting metastasis.
Commun Integr Biol. , 3, 263-270.
[87] Li, A, Dawson, J. C, Forero-vargas, M, Spence, H. J, Yu, X, König, I, Anderson, K, &
Machesky, L. M. (2010). The actin-bundling protein fascin stabilizes actin in invado‐
podia and potentiates protrusive invasion. Cell Biology , 23, 339-345.
[88] Beadle, C, Assanah, M. C, Monzo, P, Vallee, R, Rosenfeld, S. S, & Canoll, P. (2008).
The role of myosin II in glioma invasion of the brain. Molecular Biology of the Cell ,
19, 3357-3368.
[89] Gillespie, G. Y, & Soroceanu, L. Manning TJ Jr., Gladson CL ((1999). Glioma migra‐
tion can be blocked by nontoxic inhibitors of myosin II. Cancer Research 59:2076.
[90] Mishima, K, Kato, Y, Kaneko, M. K, Nishikawa, R, Hirose, T, & Matsutani, M. (2006).
Increased expression of podoplanin in malignant astrocytic tumors as a novel molec‐
ular marker of malignant progression. Acta Neuropathologica , 111(5), 483-488.
[91] Sontheimer, H. (2008). An unexpected role for ion channels in brain tumor metasta‐
sis. Experimental. Biology and Medicine. , 233, 779-791.
[92] Colman, H, Zhang, L, Sulman, E. P, Mcdonald, J. M, Shooshtari, N. L, Rivera, A, Pop‐
off, S, Nutt, C. L, Louis, D. N, Cairncross, J. G, Gilbert, M. R, Phillips, H. S, Mehta, M.
P, Chakravarti, A, Pelloski, C. E, Bhat, K, Feuerstein, B. G, & Jenkins, R. B. (2010). A
multigene predictor of outcome in glioblastoma. Neuro- Oncology. , 12, 49-57.
[93] Greenwood, I. A, Miller, L. J, Ohya, S, & Horowitz, B. (2002). The large conductance
potassium channel-subunit can interact with and modulate the functional properties
of a calcium-activated chloride channel, CLCA1. J. Biol. Chem. , 277, 22119-22122.
[94] Liu, X, Chang, Y, Reinhart, P. H, Sontheimer, H, & Chang, Y. (2002). Cloning and
characterization of glioma BK, a novel BK channel isoform highly expressed in rat
glioma cells. J. Neuroscience. , 22, 1840-937.
[95] Ge, L, Cornforth, A. N, Hoa, N. T, Bota, D. A, Mai, A, Kim, D. I, Chiou, S. K, & Jadus,
M. R. (2012). Glioma BK channel expression in human gliomas and possible glioma
specific epitopes for the immunotherapy of gliomas. J Immunol. In press.
[96] Dutoit, V, Herold-mende, C, Hilf, N, Schoor, O, Beckhove, P, Bucher, J, Dorsch, K,
Flohr, S, Fritsche, J, Lewandrowski, P, Lohr, J, Rammensee, H. G, Stevanovic, S,
Trautwein, C, Vass, V, Walter, S, Walker, P. R, Weinschenk, T, Singh-jasuja, H, &
Dietrich, P. Y. (2012). Exploiting the glioblastoma peptidome to discover novel tu‐
mour-associated antigens for immunotherapy. Brain , 135, 1042-1054.
[97] Glinsky, G. V, Berezovska, O, & Glinskii, A. B. (2005). Microarray analysis identifies
a death-from-cancer signature predicting therapy failure in patients with multiple
types of cancer. Journal of Clinical Investigation , 115, 1503-1521.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications200
Section 3
Molecular Biology of Brain Tumors and
Associated Therapeutic Implications
[86] Machesky, L. M, & Li, A. (2010). Fascin: Invasive filopodia promoting metastasis.
Commun Integr Biol. , 3, 263-270.
[87] Li, A, Dawson, J. C, Forero-vargas, M, Spence, H. J, Yu, X, König, I, Anderson, K, &
Machesky, L. M. (2010). The actin-bundling protein fascin stabilizes actin in invado‐
podia and potentiates protrusive invasion. Cell Biology , 23, 339-345.
[88] Beadle, C, Assanah, M. C, Monzo, P, Vallee, R, Rosenfeld, S. S, & Canoll, P. (2008).
The role of myosin II in glioma invasion of the brain. Molecular Biology of the Cell ,
19, 3357-3368.
[89] Gillespie, G. Y, & Soroceanu, L. Manning TJ Jr., Gladson CL ((1999). Glioma migra‐
tion can be blocked by nontoxic inhibitors of myosin II. Cancer Research 59:2076.
[90] Mishima, K, Kato, Y, Kaneko, M. K, Nishikawa, R, Hirose, T, & Matsutani, M. (2006).
Increased expression of podoplanin in malignant astrocytic tumors as a novel molec‐
ular marker of malignant progression. Acta Neuropathologica , 111(5), 483-488.
[91] Sontheimer, H. (2008). An unexpected role for ion channels in brain tumor metasta‐
sis. Experimental. Biology and Medicine. , 233, 779-791.
[92] Colman, H, Zhang, L, Sulman, E. P, Mcdonald, J. M, Shooshtari, N. L, Rivera, A, Pop‐
off, S, Nutt, C. L, Louis, D. N, Cairncross, J. G, Gilbert, M. R, Phillips, H. S, Mehta, M.
P, Chakravarti, A, Pelloski, C. E, Bhat, K, Feuerstein, B. G, & Jenkins, R. B. (2010). A
multigene predictor of outcome in glioblastoma. Neuro- Oncology. , 12, 49-57.
[93] Greenwood, I. A, Miller, L. J, Ohya, S, & Horowitz, B. (2002). The large conductance
potassium channel-subunit can interact with and modulate the functional properties
of a calcium-activated chloride channel, CLCA1. J. Biol. Chem. , 277, 22119-22122.
[94] Liu, X, Chang, Y, Reinhart, P. H, Sontheimer, H, & Chang, Y. (2002). Cloning and
characterization of glioma BK, a novel BK channel isoform highly expressed in rat
glioma cells. J. Neuroscience. , 22, 1840-937.
[95] Ge, L, Cornforth, A. N, Hoa, N. T, Bota, D. A, Mai, A, Kim, D. I, Chiou, S. K, & Jadus,
M. R. (2012). Glioma BK channel expression in human gliomas and possible glioma
specific epitopes for the immunotherapy of gliomas. J Immunol. In press.
[96] Dutoit, V, Herold-mende, C, Hilf, N, Schoor, O, Beckhove, P, Bucher, J, Dorsch, K,
Flohr, S, Fritsche, J, Lewandrowski, P, Lohr, J, Rammensee, H. G, Stevanovic, S,
Trautwein, C, Vass, V, Walter, S, Walker, P. R, Weinschenk, T, Singh-jasuja, H, &
Dietrich, P. Y. (2012). Exploiting the glioblastoma peptidome to discover novel tu‐
mour-associated antigens for immunotherapy. Brain , 135, 1042-1054.
[97] Glinsky, G. V, Berezovska, O, & Glinskii, A. B. (2005). Microarray analysis identifies
a death-from-cancer signature predicting therapy failure in patients with multiple
types of cancer. Journal of Clinical Investigation , 115, 1503-1521.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications200
Section 3
Molecular Biology of Brain Tumors and
Associated Therapeutic Implications
Chapter 7
From Gliomagenesis to Multimodal Therapeutic
Approaches into High-Grade Glioma Treatment
Giuseppe Raudino, Maria Caffo, Gerardo Caruso, Concetta Alafaci,
Federica Raudino, Valentina Marventano, Alberto Romano,
Francesco Montemagno, Massimo Belvedere, Francesco Maria Salpietro,
Francesco Tomasello and Anna Schillaci
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52782
1. Introduction
While primary malignant brain tumors account for only 2% of all adult cancers, these neo‐
plasms cause a disproportionate rate of cancer-related disability and death. The five-year
survival rates for brain tumors are the third lowest among all types of cancer, after pancreas
and lung ones, respectively.
High-grade gliomas (glioblastoma multiforme [GBM] and anaplastic astrocytoma [AA])
comprise the most common types of primary central nervous system (CNS) tumors and have
a combined incidence of 5-8/100,000 population. The median survival of patients with
malignant gliomas treated conservatively is 14 weeks; by surgical resection alone, 20 weeks;
by surgery and radiation, 36 weeks; by the addition of chemotherapy, 40-50 weeks [1].
The oncogenesis of gliomas, in particular high-grade gliomas (HGGs), the most frequent
primary malignant brain tumors in adults, is driven by several biological processes and genetic
alterations, involved in the transformation of a normal cell into a neoplastic one [2, 3].
Classically this step-by-step evolution from normal cells to early-stage tumors, to aggressive
cancer is found in cases of “secondary” multiforme glioblastoma (GBM), derived from a lower-
grade glioma, whereas some glioblastomas occur directly without previous evidence of a
lower-grade tumor. This last subset of tumors are classified as “primary” or “de novo” GBM
[4]. A relatively novel feature of GBM, so as of many other types of malignant tumors, is the
presence inside the gross of tumors of a particular kind of tumor cells, GBM stem cells. These
cells could represent the trigger and the maintenance of gliomagenesis.
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The majority of GBM cases (>90%) are primary GBM, involving mainly the elderly and
genetically characterized by loss of eterozygosity (LOH) 10q [70% of cases), EGFR amplifica‐
tion [36%), p16INK4a deletion [31%) and PTEN mutations [25%). Secondary GBMs [5% of all
cases of sporadic GBM) manifest in younger patients and are characterized often by TP53
mutations, the most frequent and detectable genetic alteration, already present at stage of low-
grade astrocytomas, in 60% of cases. LOH 10q [10q25-qter) is the most frequent [70%) genetic
alteration in both primary and secondary GBMs [5].
Gliomagenesis is driven by several biological processes and genetic alterations, involved in
the transformation of a normal cell into a neoplastic one [2, 3].
One of the most fashinating and futurible therapeutic strategy against gliomas is represented
by antisense therapy to block selectively glioma cells, trying to revert gliomagenetic molecular
pathways towards the wild-type status. This aim could be reached through antisense mole‐
cules, delivered inside the brain and in particular inside tumoral cells, able to penetrate into
glioma cells nucleus and to integrate with their genome to silence some specific genic functions.
Among antisense molecules there are antisense oligonucleotides, ribozymes and RNA
interference (iRNA). The specificity of hybridization makes antisense method an interesting
strategy to selectively modulate the expression of genes involved in tumorigenesis. Glial
tumors seem to be able to create a favorable environment for the invasion of glioma cells in
cerebral parenchyma when they combine with the extracellular matrix via cell surface
receptors. In this review we will focus on the different antisense approaches and on the
mechanisms of action of each kind of antisense molecule and relative strategy in human
gliomas therapy.
Among dysregulated molecular pathways, into brain tumor cells, there are activated growth
factors signaling pathways, marked angiogenesis, downregulation of apoptotic genes and
upregulation of antiapoptotic genes.
Gliomagenesis is driven by several biological events, such as activated growth factor receptor
signaling pathways, downregulation of many apoptotic mechanisms and unbalance among
proangiogenic and antiangiogenic factors. This last aspect is very crucial in glioma progression,
because of prominent angiogenesis is a cardinal feature of malignant gliomas [2]. Several
growth factor receptors, such epidermal growth factor receptor (EGFR), platelet-derived
growth factor receptor (PDRGF), C-Kit, vascular endhotelial growth factor receptor (VEGFR)
and other growth factors receptors, are overexpressed, amplified and/or mutaded in gliomas.
Features of glioma cells are the loss of tumor suppressor genes, which are critical for cell
growth, differentiation and function. These genes are TP53, the retinoblastoma (Rb) gene, the
inhibitor of cyclin-dependent kinase 4a (INK4a) gene and the phosphatase and tensin homolog
(PTEN) gene [6].
On the basis of this high importance of gene expression disregulation inside cancer cell
genome, the modulation of gene expression at more levels, such as DNA, mRNA, proteins and
transduction signal pathways, may be the most effective modality to downregulate or silence
some specific genic functions pathologically upregulated or introduce genes, downregulated
or deleted selectively into neoplastic cells. Therapeutic genes (Transgenes) can lead to
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generation of anticancer drugs within the tumor (pro-drug activation), increase of selective
intratumoral drug levels without increasing systemic toxicity, protection of hematopoietic cells
from drug damage by inducing drug resistance and delivery of secreted fusion proteins which
combine a targeting ligand and a toxin/enzyme, sensitization of tumors to radiations, that in
turn can be used to induce expression of transgenes via radiation-activated promoters [7].
(Ohgaki and Kleihues. AJP May 2007, Vol. 170, No. 5)
Figure 1. De novo vs Secondary GBM genetic pathways
Progression from low-grade to high-grade astrocytomas involve inactivating mutations of
tumor-suppressor gene TP53 and elevated expression of platelet-derived growth factor
(PDGF) ligands and receptors, accumulation of genetic alteration of retinoblastoma-associated
cell-cycle regulatory pathways, including deletion or mutations of cyclin-dependent kinase
inhibitor p16INK4A/(CDKN2A) or the retinoblastoma susceptibility locus 1 (pRB1), as well as
amplification or over-expression of cyclin-dependent kinase 4 (CDK4) and human double
minute 2 (HDM2). Evolution to secondary GBM is associated with deletion of chromosome
10, which includes tumor-suppressor phosphatase and tensin homolog (PTEN). The hyper‐
methilatyion in the promoter region and successive mutation of p16 is evident in HGGs
progression. Additionally BcI2-like 12 increased expression (BcI2L12) inhibits apoptosis [8].
The astrocyte elevated gene-1 (AEG-1) is over-expressed in the majority of HGGs and stimu‐
lates cellular transformation and invasion together with the Ha-ras family of retrovirus-
associated DNA sequences (RAS). Furthermore, oncogenic Ha-ras induces AEG-1 expression
by modulating the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway and contrib‐
utes to the growth of HGGs. Mitogenetic signals activate a molecular cascade known as ras-
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mitogen activated protein kinase (Ras/MAPK). MAPK inhibits the Rb gene, activates the
transcriptional factor E2F and cells enter the S phase. The INK4a gene influences the Rb
pathway by activating three cyclin kinase inhibitors: p15, p16, and p19.The final result is the
blockage of cyclin-dependent kinase 2, 4 and 6, triggering cell-cycle progression by inhibiting
pRb. Through the new technique of genome-wide sequencing and survey of gene copy
number, have been discovered novel amplicons linked to glioma progression. Table 1
summarizes the main genes involved in gliomagenesis (Tab. 1).
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EGFR (c-erb-2) Cr7p11-p12 Amplification/overexpression Cell transformation and
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MDM2 Cr12q14.3-q15 Overexpression Cell cycle control loss and
proliferation
De novo GBM
Table 1. Main genetic alteration in human gliomas
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Gliomagenesis can develop through two different ways, resulting in evolution of a cluster
genic alteration directly from normal astrocyte to GBM or of a step by step different kinds of
mutations of various genes passing gradually from normal astrocyte to low-grade glioma, to
high-grade glioma, to GBM.
Primary GBM shows amplification of the epidermal growth factor receptor (EGFR), deletion or
mutation of homozygous cyclin-dependent kinase (CDK) inhibitor p16INK4A /(CDKN2A), alter‐
ations in tumor suppressor PTEN on chromosome 10, and deletion in the INK4a gene with loss
of p14 and p16 [6, 9]. In table 2 we, also, report the principal familial genetic syndromes associat‐
ed with HGGs (Tab. 2). In the total amount of GBM, the total prevalence rate concern for the 95%
cases of sporadic GBM, and only for the 5% (not more) cases of syndromic familiar cancer.
Syndrome Involved gene Chromosomal
location
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Table 2. Principal familial genetic syndromes associated with human gliomas
2. Glioma invasion
Glioma cells invasion consist of an active translocation of glioma cells through host cellular
and extracellular matrix barriers [10].
Three steps are fundamental in the phenomenon of glioma invasion: a) adhesion of glioma
cells to proteins of the surrounding extracellular matrix (ECM) mediated by cell adhesion
receptors; b) degradation of ECM components by proteases secretion by glioma cells; c)
migration of glioma cells into the newly created space through the ECM.
ECM is composed of proteoglycans, glycoproteins, collagens and also contains fibronectin,
laminin, tenascin, hyaluronic acid, vitronectin. In recent years the glioma invasion has also
been interpreted by numerous authors in terms of interaction between neoplastic cells and
ECM [11].
Critical factors include the synthesis and deposition of ECM components by glioma and
mesenchymal cells, the release of ECM-degrading activities for remodeling interstitial spaces,
the presence of adhesion molecules (matrix receptors on glioma cell surfaces that specifically
recognize and adhere to ECM components) and the effects of cell-matrix interactions on the
behavior of glioma cells. ECM modification aids the loss of contact inhibition allowing tumor
cells to freely migrate and invade the surrounding tissues. Changes in these ECM components
are felt to modulate brain tumor growth, proliferation and invasion, although specific
interactions and exact mechanisms are unknown.
Integrins, a class of adhesion molecules, play a major role in glioma cell-matrix adhesion. Integ‐
rins regulate many aspects of the cell behavior including survival, proliferation, migration and
differentiation. They act with a physical trans-membrane link between the ECM and the cytos‐
keleton and with a bi-directional signal across the cell membrane. Integrins of the β1 and αν
classes are expressed on different cell types, including neurons, glial cells, meningeal and endo‐
thelial cells. β2 integrins are specifically expressed by leukocytes and they are found on micro‐
glia and on infiltrating leukocytes within the CNS. Down-regulation of β1 expression in
intracerebrally transplanted glioma cells in vivo by placing β1 antisense sequences under an in‐
ducible, tetracycline-responsive promoter markedly inhibited diffuse brain invasion [13-17].
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Down-regulated β1 integrin protein levels in vivo probably affect interactions of glioma cells
with ECM components, leading to reduced migration along vascular basement membranes.
Figure 2.
The proteolytic degradation of the basement membrane (BM) is mediated by proteases, such as
the matrix metalloproteases (MMPs), secreted by tumor and stromal cells [11, 12]. MMPs are se‐
creted as proenzymes and are activated by proteolytic cleavage of their amino-terminal domain.
MMPs play an important role in human brain tumor invasion, probably due to an imbalance be‐
tween the production of MMPs and tissue inhibitor of metalloproteases-1 (TIMP-1) by the tumor
cells. Among these molecules, MMP-1 is the crucial enzyme able to initiate breakdown of the in‐
terstitial collagens, collagen type 1, collagen type 2 and collagen type 3; in this way it activates the
other MMPs which allow the glioma cells to infiltrate normal brain tissue.
3. Angiogenesis
The formation of new blood vessels from existing microvessels is angiogenesis, an histological
indicator of the degree of malignancy and prognosis of patients. Of all solid tumors, malignant
brain tumors show the highest degree of vascular proliferation. The WHO classification
distinguishes low grade from high grade diffuse astrocytomas by the presence of microvas‐
cular proliferation as a diagnostic criterion and an independent prognostic parameter [18].
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HGGs are characterized by extensive microvascular proliferation and a higher degree of
vasculature. The presence of marked endothelial glomeruloid-like proliferations demonstrates
active tumor invasiveness through vascular angiogenesis, disruption of pre-existing anatom‐
ical structures and neoplastic cellular migration along neoangiogenic vascular channel and
through the BM, with evidence of proliferation of new fine capillaries [8, 19]. These mecha‐
nisms demonstrate a very strong and bidirectional correlation between glioma angiogenesis
and invasiveness into glioma progression. The new vessel growth is stimulated through the
tumor cells secretion of pro-angiogenic growth factors; these factors bind to receptors on
endothelial cells thereby activating them [20].
Vascular endothelial growth factor-A (VEGF-A) is regulated in HGGs and it is secreted by
tumor cells as well as by stromal and inflammatory cells. VEGF-A can be linked in the ECM
through the interaction with proteoglycans or glycosaminoglycans. The expression of the
receptors VEGFR1 and VEGFR2 is regulated on the endothelial cells in HGGs. The ligands for
VEGF3 (VEGF-C&D) are expressed by multiple cell types that surround the angiogenic vessels,
suggesting the existence of a novel pro-angiogenic paracrine signaling pathways in these
neoplasms [10, 21]. Basic fibroblast growth factor (bFGF) is expressed by vascular cells and,
focally, by the tumor cells too. The receptors for bFGF include FGFR1, expressed by both the
tumor cells and the tumor endothelial cells; FGFR2 is expressed only by the tumor cells whereas
FGFR4 is not detected in HGGs [22]. The binding of VEGF on endothelial cells activates the
phosphatidylinositol-3-hydroxyl kinase (PI3K)/protein kinase B (Akt) pathway, whereas the
bFGF receptors are predominantly shown through the protein kinase Cα (PKCα) pathway.
The activation of endothelial cells results in increased expression of cell adhesion receptors,
such as integrins ανβ3 and α5β1, and in increased cell survival, proliferation and migration
responses. Other pro-angiogenic growth factors, including interleukin-8, hepatocyte growth
factor, urokinase can promote or amplify angiogenesis.
Cancer angiogenesis is similar to angiogenesis seen during development except that it is less
controlled and precise [23]. These blood vessels have many marked features including blind
ends, erratic size and connections, and most significantly, large gaps in the endothelial lining.
This last feature is important because it signifies that larger molecules can enter the tumor
effectively bypassing the blood brain barrier. In fact, tumor vasculature can have intercellular
gaps as large as 2 µm which is large enough for passive accumulation of 100-200nm particles
into the tumor interstitium [24]. Neovascularization in brain tumors correlates directly with
their biological aggressiveness, degree of malignancy and clinical recurrence and inversely
with the post-operative survival of patients with gliomas. Diffuse astrocytomas tend to
progress from grade II to grade III tumors with a time interval of several years, whereas,
progression of grade III to grade IV is more rapid, typically 2 years. GBMs that arise from a
low-grade glioma lesion are called “secondary glioblastoma”.
However, in most cases, GBMs appear “de novo” and are thus termed “primary glioblastoma”.
Regardless of their mode of progression, primary and secondary GBMs are morphologically
indistinguishable and show their histologic hallmarks, such as “glomeruloid” microvascular
tufts and necrosis [25, 26].
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The discovery of hypoxia inducible factor-1 (HIF-1) and the observation that hypoxia-induced
HIF-1α expression in pseudopalisading cells, into intratumoral necrotic areas, was concomi‐
tant with the expression of one of its target genes, VEGF, established a biological link between
hypoxia and angiogenesis [27]. The formation of new blood vessels occurs physiologically
during embryogenesis. In adult life it is observed in the female reproductive system and during
wound healing and in a wide range of pathologic settings, such as ischemic diseases, chronic
inflammatory reactions, and neoplasia. During embryonic development, blood vessels are
newly formed from endothelial precursors and hematopoietic stem cells, a process known as
vasculogenesis [28]. In contrast, angiogenesis, the sprouting of new blood vessels from pre-
existing ones results from an altered balance of proangiogenic factors and antiangiogenic
factors [29, 10].
The sequence of events leading to the formation of new blood vessels is well characterized and
involves an initial VEGF-mediated increase of vascular permeability leading to extravasation
of plasma proteins associated with dilatation of native vessels and reduction in their pericyte
coverage. Subsequently, endothelial cells migrate and proliferate. For this cascade to occur,
deposition of a proangiogenic matrix for the newly sprouting vessel is essential. This involves
breakdown of the vascular basement membrane and extracellular matrix (ECM) through the
action of cathepsin B, matrix metalloproteases (MMPs) and other enzymes as well as the
expression of matrix proteins such as fibronectin, laminin, tenascin-C and vitronectin. Finally,
the angiogenic process culminates in the assembly of endothelial cells to form a vascular lumen
followed by the elaboration of a new basement membrane and the recruitment of pericytes. In
contrast to the accepted dogma that tumor development occurs in 2 phases (avascular and
vascular), we observed that tumor growth in the brain follows 2 vascular phases. In the first
vascular phase, the vessels are native cerebral vessels, which are coopted by tumor cells, while
in the second phase, there is true neovascularization arising from existing vessels. During the
transition period between these two phases, hypoxia driven HIF-1 expression occurs which
results in VEGF secretion and induction of neovascularization. In Stage IV, angiogenesis
adjacent to the necrotic area is triggered in response to increased expression of HIF-1α and
VEGF, a process that rescues the remaining tumor cells. Thus, it is possible to suggests four
sequential steps in glioma progression: i) perivascular organization, ii) proliferation, iii)
vascular regression followed by necrosis, and iv) angiogenesis.
Glioma vasculature is structurally and functionally abnormal and it correlates and leads to
vasogenic edema, increased interstitial pressure, and eterogeneous delivery of oxygen and
drugs [23].
VEGF expression is stimulated by hypoxia and acidosis, and probably correlates with many
other growth factors and their specific receptors (EGFR, HGFR, PDGFR, C-Kit, IGFR), and
downstream signaling pathways (PI3K-Akt, Ras-MAPK) upregulation and activation in
gliomas.
Many other proangiogenic factors are upregulated in gliomas and this aspect might explain
the failure of many actual antiangiogenic therapeutic strategies in gliomas management.
Among these other angiogenic factors a very important role has absolved by bFGF, IL-1beta,
IL-6, IL-8, TNF-alpha and stromal-cell-derived factor (SDF)-1 alpha [2].
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Another group of endothelial growth factors is represented by angiopoietins. Their signal
transduction pathway passes via the Tie2 receptor tyrosine kinase expressed on endothe‐
lial cells. In particular, Ang-1 and -2, have been implicated in glioma angiogenesis. Ang-1
mediated activation of  Tie2  is  required for  stabilization,  remodelling and maturation of
blood  vessels,  promotes  angiogenesis  and  tumor  growth  and  is  associated  with  an  in‐
creased number of highly branched vessels covered by pericytes. While VEGF and Ang-1
may act in concert (proliferation and maturation), Ang-2 has been implicated in further re‐
modeling of the initial microvasculature [30, 31]. Increased expression of Ang-2 on GBM
microvasculature appears early during glioma angiogenesis.  However,  binding of Ang-2
to the Tie2 receptor on endothelial cells antagonizes this receptor’s phosphorylation, there‐
by disrupting contacts  between endothelial  and periendothelial  support  cells  and disen‐
gaging  pericytes  from  the  tumor  vessels  during  initiation  of  vessel  sprouting  or
regression.  Examination  of  the  expression  patterns  of  angiopoietins  and  their  receptors
suggests a role in GBM vasculature and malignant transformation. For example, increased
Tie2  expression  has  been  observed  with  increasing  human  astrocytoma  grading.  Ang-2
and Tie2 expression are absent in the normal brain vasculature but are induced in tumor
endothelium of coopted tumor vessels prior to their regression. Of particular importance,
treatment of glioma cell derived mouse xenografts with a dominant negative form of Tie2
results in a significant decrease in tumor growth [32].
A new more complex understatement of angiogenic pathways in glioma progression gives a
crucial role to the Ca2+ permeable transient receptor potential (TRPC) channels in tumor
angiogenesis, and in particular in endothelial permeability up-regulation, focal adhesion
assembly, cell orientation and directional migration and involvement in hypoxia-induced
angiogenesis and vascular remodeling. According this complex molecular pathological
network, tumor angiogenesis should be not only the result of physiological adaptation to
hypoxia in response to an increasing tumor mass but it should be also the result of critical
genetic mutations that activate a transcriptional program for angiogenesis. Calcium (Ca2+) is
an important second messenger and its entry through plasma membrane affects angiogenesis.
Several reports indicate that Ca2+ permeable transient receptor potential (TRP) channels
belonging to the TRPC, TRPV and TRPM represent target genes, down-stream to Notch1,
PTEN, NFAT and Hif-1 transcriptional factors are activated during tumor angiogenesis.
Several studies indicate that angiogenic growth factors such as vascular endothelial growth
factor (VEGF) and basic firoblast growth factor (bFGF) may activate TRP channels at tran‐
scriptional and post-transcriptional levels, causing a subsequent rise in endothelial [Ca2+]i,
which modulates signal transduction pathways regulating the angiogenesis. Conversely, Ca2+
influx through TRP channel activation may stimulate endothelial cells to trigger transcription,
production and release of angiogenic growth factors such as VEGF and platelet-derived
growth factor (PDGF) that stimulate angiogenesis.
In the field of new targeted-based molecular therapeutic approaches, TRP channels, and not
only VEGF/VEGFR and HIF-1alpha, might be a promising target for new therapeutic agents
to anti-angiogenic therapy [33].
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4. Current treatment of glioblastoma
The efficacy of current anti-cancer multimodal therapeutic strategies in gliomas is limited by
the lack of specific therapies against malignant cells, and the prognosis in patients affected by
primary brain tumors is still very unfavorable. Glial tumors seem to be able to create a favorable
environment for the invasion of neoplastic cells when they combine with the extracellular
matrix via cell surface receptors, through the upregulation of crucial pathways such as
angiogenesis and invasion. The major problem in brain drug delivery is the presence of the
blood brain barrier which limits the delivery of many chemotherapeutic agents and other kinds
of therapeutic molecules. This event often contributes to the failure of treatment. Current
treatment of glioblastoma (GBM) is difficult and a great mysterious challenge, and, results in
high recurrence rates. Upon display of symptoms of a brain tumor (seizure, chronic headache,
loss of consciousness, loss of motor/sensory function) a patient will undergo MRI for detection
of the tumor. This is followed by a host of treatments to remove the bulk of the tumor if possible,
starting always when possible from gross total removal of tumor [34]. Patients are then
monitored for recurrence. This is standard protocol for treatment of glioma regardless of grade
[35]. This line of treatment can often lead to decreased quality of life. Last, if tumor recurs,
there are last line treatments given after which there is no ability to treat further. The treatment
of glioma is varied depending on grade, but this discussion will focus on the treatment of the
most aggressive form: glioblastoma (GBM). The common treatment after detection has several
components including: 1. Surgical resection of tumor from the primary site, 2. Lining of the
primary site with carmustine wafers designed to kill cells in the close proximity, after gross
total removal and histological confirmation of high-grade gliomas 3. Metronomic oral
temozolmide chemotherapy and 4. Radiotherapy to the brain. As mentioned previously, in
the case of recurrence, this treatment is coupled with anti-angiogenic therapy to prolong
patients’ life.
5. Surgical resection
Represents the microneurosurgical removal of the tumor from the primary site. The general
procedure involves craniotomy followed by suction and gross total removal of tumor from the
site. Though there are experimental imaging agents, such as optically visible fluorescent dyes
coupled with intravital magnetic resonance imaging of the brain for guidance and assessment
of accuracy and completion, this is not an exact science [35-37].
6. Local, intracavitary, chemotherapy
It is applied in the resection site after removal of the tumor gross in the form of Poly (lactic-
co-glycolic acid)-BCNU wafers that slowly degrade and release the chemotherapeutic BCNU
(Carmustine - gliadel®) into the resection site, after extemporaneous histological intra-
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operatory examination and confirmation of high-grade gliomas [38]. This local chemothera‐
peutic approach has been reported to yield a slight increase in survival times, as opposed to
leaving the tumor site empty, however, it still does not allow adequate decrease in recurrence.
Use of gliadel® has become less common place due to both cost-benefit analysis and preference
of use by surgeons [39, 40].
7. Radiotherapy and stereotactic radiosurgery
It involves the use of gamma-irradiation in order to induce cell death through DNA damage,
often inside a post-operatory adjuvant therapy. The technologic support to apply this thera‐
peutic step does see the use of Gamma-knife, cyber-knife or conformational collimation
system-based linear accelerator. This therapy is used in over 50% of all cancer patients at some
point during treatment and has been in use in cancer for almost a century. In brain tumors,
this treatment works by sending gamma rays through to the site of the tumor to directly
damage DNA, but in longer-lasting effects, creates free radicals which can go on to cause
further damage [41, 42]. Radiation therapy involves not just radiation of the tumor, as would
be desirable, but irradiation of an area which can include both tumor tissue and healthy brain
tissue. Radiotherapy does usually results in death of large amounts of the tumor, however,
recent discoveries suggest that radiation may actually be causing side effects which can aid in
recurrence. Glioma cells exposed to radiation in vitro show increased invasion post treatment,
indicating progression and enhanced malignancy of disease [43]. Further, radiation leads to
many side effects associated with cancer malignancy and disease progression, including the
creation of free radical species, degradation of the extracellular matrix, inflammation and
immune cells recruitment, and increased blood flow to the tumor area [44, 45].
Radiotherapy improved several clinical end points in brain tumors. Standard radiation therapy
of gliomas involves the provision of 59.4 / 60 Gy, in 30/33 from 1.8 to 2 Gy daily fractions, and
each should begin within 4-6 weeks after surgery. Treatment is generally given to the area of
the tumor and a surrounding margin (“limited-field” method). Postoperative radiotherapy
significantly prolongs median survival to approximately 12 months for glioblastoma multi‐
forme and to 36 months for anaplastic astrocytoma [46]. A slight improvement of the results
obtained with conventional radiotherapy has been achieved through the hyperfractionation
daily, the use of radiosensitizers or hyperoxygenation by hyperbaric treatment [47].
Stereotactic radiotherapy is helpful for the treatment of high grade gliomas and involves the
local system of radioactive sources (interstitial brachytherapy) or external targeted radiother‐
apy. In case of tumors of a limited volume boost stereotactic radiotherapy, administered by
linear accelerator or Gamma-Knife or Cyber-knife and performed after limited-field radio‐
therapy, achieved a slight increase in survival in some studies [48].
The metabolic radioimmunotherapy, using radiolabeled antibodies injected systemically or
intramuscularly, is still experimental because there are no phase III trials that showed a
survival advantage [49].
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4. Current treatment of glioblastoma
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matrix via cell surface receptors, through the upregulation of crucial pathways such as
angiogenesis and invasion. The major problem in brain drug delivery is the presence of the
blood brain barrier which limits the delivery of many chemotherapeutic agents and other kinds
of therapeutic molecules. This event often contributes to the failure of treatment. Current
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most aggressive form: glioblastoma (GBM). The common treatment after detection has several
components including: 1. Surgical resection of tumor from the primary site, 2. Lining of the
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operatory examination and confirmation of high-grade gliomas [38]. This local chemothera‐
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of use by surgeons [39, 40].
7. Radiotherapy and stereotactic radiosurgery
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apy. In case of tumors of a limited volume boost stereotactic radiotherapy, administered by
linear accelerator or Gamma-Knife or Cyber-knife and performed after limited-field radio‐
therapy, achieved a slight increase in survival in some studies [48].
The metabolic radioimmunotherapy, using radiolabeled antibodies injected systemically or
intramuscularly, is still experimental because there are no phase III trials that showed a
survival advantage [49].




At present there is not a standard treatment of anaplastic oligoastrocytoma and oligodendro‐
glioma but the common practice, based on recommendations of the National Comprehensive
Cancer Network (NCCN), consists in surgery followed by radiation therapy. Adjuvant
chemotherapy can also be administered and consists in PCV or TMZ.
Loss of heterozygosity (LOH) of chromosome 1p/19q (present in approximately 40-60% of
oligodendroglial tumors) has been showed to be related to the sensitivity to the treatment with
alkylating agents (especially TMZ and poli-chemotherapy scheme PVC) and to a more
favorable prognosis. For a most appropriate therapy would therefore be necessary to look for
the loss of heterozygosity 1p and 19q in all tumors with oligodendroglial component [50].
Two clinical trials are evaluating the role of chemotherapy in the treatment of anaplastic glioma
correlating it to the co-deletion 1p/19q. The first, EORTC 26053-22054 is a Phase III trial on
concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic
glioma. The second is EORTC 26081-22086 a Phase III intergroup study of radiotherapy versus
temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for
patients with 1p/19q codeleted anaplastic glioma.
Oligodendrogliomas and oligoastrocytomas, especially in anaplastic forms, are highly
sensitive to adjuvant chemotherapy with PCV after radiation therapy, with a significant
increase in progression-free survival (23 months vs. 13 months) compared to radiotherapy
alone. An increase of the progression-free survival is also reflected by administering the PCV
before radiotherapy. None prolongation of the median overall survival time is noted [51].
Nevertheless, there is the common practice of proposing chemotherapy as the initial therapy
for pure oligodendroglioma. Further, in the case of small tumors RT remains the best thera‐
peutic choice. Although there is no phase III clinical studies comparing PCV and TMZ in
clinical practice TMZ is preferred as first line treatment for the lower toxicity and comparable
efficacy to PCV. Second line chemotherapy with TMZ in recurrent oligodendroglial tumors
after PCV-chemotherapy gave excellent results, and similar responses to PCV but with less
toxicity [52].
Standard therapy of anaplastic astrocytoma, according to Stupp protocol, is radiotherapy
with adjuvant TMZ, administered for the duration of radiotherapy ( 75 mg/m2 daily) and
after in six cycles (150-200 mg/m2 for five days every 28 days). There are no randomized
studies with adequate statistical power in patients with anaplastic astrocytoma that demon‐
strated a benefit of adjuvant or concomitant chemotherapy with nitrosoureas. In a EORTC
study, comparing adjuvant dibromodulcitol and BCNU chemotherapy with radiotherapy
alone in patients with anaplastic astrocytoma, no statistically significant improvement in
survival was observed after BCNU/DBD adjuvant chemotherapy [53].  Temozolomide, an
imidazotetrazinone acting through the formation of a reactive methyldiazonium cation and
methylation of O6-guanine in DNA, induce its clinical effects through the activity of O6-al‐
kylguanine-DNA alkyltransferase (AGT), a DNA repair protein that removes O6-alkylgua‐
nine adducts in DNA, result of translation from gene MGMT, whose grade of promoter
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methylation is  recognized important  epigenetic  predictive factor  to  temozolomide thera‐
peutic response. The therapeutic advantage is showed for patients with MGMT (methyl‐
guanine methyltransferase) methylated tumors. The enzyme remove alkyl groups from the
O6 position of guanine, one of the targets of alkylating agents. Epigenetic silencing of the
MGMT gene in tumor tissue occurs through the methylation of the CpG islands in the pro‐
moter region. Patients whose tumors have MGMT promoter methylation are likely to bene‐
fit from the addition of TMZ chemotherapy [54]. TMZ is characterized from an excellent
oral bioavailability and good penetration of the blood-brain barrier (BBB). The activity of
temozolomide is highly dependent on dosing schedule, with multiple administrations be‐
ing more effective than a single dose (as normally codified in Stupp protocol). Peak plasma
concentration is achieved within 30-60 min of oral administration and the compound has
an elimination half-life of one to two hours. Myelosuppression, which is dose limiting at
1,200 mg/m2, and nausea and vomiting are the most frequent adverse events [55].
A new promising agent, recently evaluated for the treatment of anaplastic astrocytoma, is
Trabedersen, a phosphorothioate antisense oligonucleotide that act as an inhibitor of TGF- β2
(Transforming growth factor-beta 2) biosintesys. TGF- β2 levels seems to be higher in high
grade gliomas. TGF-β2 is an attractive target because it regulates key mechanisms of carcino‐
genesis, in particular immunosuppression and metastasis. The compound was tested in phase
I/II studies, in which it was administered at two doses (10 µM or 80 µM) comparing response
rate, survival, and safety respect to standard chemotherapy (TMZ or PCV). Trabedersen 10
µmol/L was superior to trabedersen 80 µmol/L in both efficacy and safety for high-grade
gliomas, especially in anaplastic astrocytoma. In patients with anaplastic astrocytoma, the
trabedersen 10 µmol/L group had a higher overall survival rate at 24 months than the trabe‐
dersen 80 µmol/L group and the control group (83.3%, 53.3% and 41.7%, respectively). The
median overall survival for patients with anaplastic astrocytoma was higher in both trabe‐
dersen groups than in the chemotherapy control group, with a survival benefit for 10 µmol/L
trabedersen over chemotherapy (17.4 months). Based on the promising results of these studies,
presented at the 101st annual meeting of American Association of Cancer Research, in 2010
started the pivotal Phase III study SAPPHIRE (Efficacy and Safety of AP 12009 in Adult Patients
With Recurrent or Refractory Anaplastic Astrocytoma [WHO Grade 3) as Compared to
Standard Treatment with Temozolomide or BCNU: A Randomized, Actively Controlled, Open
label Clinical Phase 3 Study). Unfortunately, the study has been stopped prematurely in
January 2012, due to slow patient recruitment [56].
Historically, the standard of care for older adult with GBM was surgical resection or biopsy,
followed by involved-field radiotherapy. The new therapeutic standard is based on the results
of several studies that demonstrated a significant survival benefit in GBM patients with the
addition of concurrent and adjuvant TMZ to radiation. Patients treated with TMZ/RT had a
median survival time of 15 months, compared with 12 months for the patients initially treated
with RT alone. Further, the first group showed a 2-year survival rate of 26% compared with
only 10% for the RT group. Now the standard treatment consist in surgery followed by RT
with adjuvant TMZ, administered for the duration of radiotherapy and after in six cycles
(Stupp protocol) [57].




At present there is not a standard treatment of anaplastic oligoastrocytoma and oligodendro‐
glioma but the common practice, based on recommendations of the National Comprehensive
Cancer Network (NCCN), consists in surgery followed by radiation therapy. Adjuvant
chemotherapy can also be administered and consists in PCV or TMZ.
Loss of heterozygosity (LOH) of chromosome 1p/19q (present in approximately 40-60% of
oligodendroglial tumors) has been showed to be related to the sensitivity to the treatment with
alkylating agents (especially TMZ and poli-chemotherapy scheme PVC) and to a more
favorable prognosis. For a most appropriate therapy would therefore be necessary to look for
the loss of heterozygosity 1p and 19q in all tumors with oligodendroglial component [50].
Two clinical trials are evaluating the role of chemotherapy in the treatment of anaplastic glioma
correlating it to the co-deletion 1p/19q. The first, EORTC 26053-22054 is a Phase III trial on
concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic
glioma. The second is EORTC 26081-22086 a Phase III intergroup study of radiotherapy versus
temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for
patients with 1p/19q codeleted anaplastic glioma.
Oligodendrogliomas and oligoastrocytomas, especially in anaplastic forms, are highly
sensitive to adjuvant chemotherapy with PCV after radiation therapy, with a significant
increase in progression-free survival (23 months vs. 13 months) compared to radiotherapy
alone. An increase of the progression-free survival is also reflected by administering the PCV
before radiotherapy. None prolongation of the median overall survival time is noted [51].
Nevertheless, there is the common practice of proposing chemotherapy as the initial therapy
for pure oligodendroglioma. Further, in the case of small tumors RT remains the best thera‐
peutic choice. Although there is no phase III clinical studies comparing PCV and TMZ in
clinical practice TMZ is preferred as first line treatment for the lower toxicity and comparable
efficacy to PCV. Second line chemotherapy with TMZ in recurrent oligodendroglial tumors
after PCV-chemotherapy gave excellent results, and similar responses to PCV but with less
toxicity [52].
Standard therapy of anaplastic astrocytoma, according to Stupp protocol, is radiotherapy
with adjuvant TMZ, administered for the duration of radiotherapy ( 75 mg/m2 daily) and
after in six cycles (150-200 mg/m2 for five days every 28 days). There are no randomized
studies with adequate statistical power in patients with anaplastic astrocytoma that demon‐
strated a benefit of adjuvant or concomitant chemotherapy with nitrosoureas. In a EORTC
study, comparing adjuvant dibromodulcitol and BCNU chemotherapy with radiotherapy
alone in patients with anaplastic astrocytoma, no statistically significant improvement in
survival was observed after BCNU/DBD adjuvant chemotherapy [53].  Temozolomide, an
imidazotetrazinone acting through the formation of a reactive methyldiazonium cation and
methylation of O6-guanine in DNA, induce its clinical effects through the activity of O6-al‐
kylguanine-DNA alkyltransferase (AGT), a DNA repair protein that removes O6-alkylgua‐
nine adducts in DNA, result of translation from gene MGMT, whose grade of promoter
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications216
methylation is  recognized important  epigenetic  predictive factor  to  temozolomide thera‐
peutic response. The therapeutic advantage is showed for patients with MGMT (methyl‐
guanine methyltransferase) methylated tumors. The enzyme remove alkyl groups from the
O6 position of guanine, one of the targets of alkylating agents. Epigenetic silencing of the
MGMT gene in tumor tissue occurs through the methylation of the CpG islands in the pro‐
moter region. Patients whose tumors have MGMT promoter methylation are likely to bene‐
fit from the addition of TMZ chemotherapy [54]. TMZ is characterized from an excellent
oral bioavailability and good penetration of the blood-brain barrier (BBB). The activity of
temozolomide is highly dependent on dosing schedule, with multiple administrations be‐
ing more effective than a single dose (as normally codified in Stupp protocol). Peak plasma
concentration is achieved within 30-60 min of oral administration and the compound has
an elimination half-life of one to two hours. Myelosuppression, which is dose limiting at
1,200 mg/m2, and nausea and vomiting are the most frequent adverse events [55].
A new promising agent, recently evaluated for the treatment of anaplastic astrocytoma, is
Trabedersen, a phosphorothioate antisense oligonucleotide that act as an inhibitor of TGF- β2
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presented at the 101st annual meeting of American Association of Cancer Research, in 2010
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January 2012, due to slow patient recruitment [56].
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median survival time of 15 months, compared with 12 months for the patients initially treated
with RT alone. Further, the first group showed a 2-year survival rate of 26% compared with
only 10% for the RT group. Now the standard treatment consist in surgery followed by RT
with adjuvant TMZ, administered for the duration of radiotherapy and after in six cycles
(Stupp protocol) [57].
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A therapeutic alternative or adjunctive treatment is BCNU wafer (Gliadel®), positioned at sur‐
gery and followed by radiation therapy. Gliadel® is a biodegradable polymer wafer impregnat‐
ed with BCNU. At the time of resection, up to eight wafers are implanted into the surgical cavity.
Water in the interstitial fluid causes the polymer slowly to degrade. The BCNU is thus released
in a controlled manner over several days to weeks and diffuses into the brain parenchyma at a
high dose density. It causes a statistically significant increase in survival compared to patients
treated only with surgery and radiotherapy. The SIGMA (Stupp including Gliadel for glioma) is
a multi-center, spontaneous observational trial to evaluate the efficacy of Gliadel® wafers plus
concomitant TMZ in patients with newly-diagnosed high grade glioma. This study is conduct‐
ed at the Foundation of the Carlo Besta Neurological Institute, IRCCS, in Milan and is based on
several examples in literature on this association. Samaggi et al. of the IRCCS published a study
on the research and comparison of data in literature about efficacy and toxicity in patients with
newly diagnosed GBM treated with the combination of Gliadel® and the Stupp protocol. Anal‐
ysis of data revealed that this combination is well tolerated and it significantly improved sur‐
vival without a substantial increase in toxicity [58].
Recently was demonstrated that for elderly patients with newly diagnosed glioblastoma,
therapy with TMZ alone is an alternative to radiotherapy. In the study, published in the July
issue of the Lancet Oncology, were recruited 412 older patients. 195 were randomly assigned
to TMZ and 178 to radiotherapy. The results showed that single-agent TMZ and radiotherapy
alone seem equally effective. Both treatments were well tolerated. Major side effects observed
were neutropenia, (16 in the TMZ group and 2 in the RT group), lymphocytopenia (46 vs. 1),
thrombocytopenia (14 vs. 4), hepatic enzyme increased (30 vs. 16), infections (35 vs. 23) and
thromboembolic events (24 vs. 8). Even in older patients the MGMT methylation status of
tumor is a predictive marker for the success of therapy with alkylating agents as mentioned
above. So testing of tumor MGMT methylation status in elderly patients with newly diagnosed
glioblastoma should be a priority to decide the best treatment [59].
9. Antiangiogenic therapy
Angiogenesis inhibition represents a new target for therapeutic intervention in malignant
gliomas because GBMs are highly vascularized brain tumors and their growth seems to be
angiogenesis dependent.
The inhibition of angiogenesis is achieved through the use of inhibitors of VEGF receptor (such
as bevacizumab or aflibercept) or kinase or integrin inhibitors (cilengitide or erlotinib) which
have been tested in several clinical trials.
The antiangiogenic effect is achieved through different mechanisms assumed on the basis of re‐
sults from several studies. According to the first hypothesis (starvation hypothesis), the reduc‐
tion of new blood vessels formation decreases the amount of metabolites that may reach the
tumor, causing tumor cell death. According to a new hypothesis (normalization hypothesis), in
the early stages (1 month) of the antiangiogenic therapy there is a normalization of the blood
vessels, followed by their damage due to hypoxia, and then by the reduction of tumor growth.
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These hypothesis have been confirmed by recent studies in which was highlighted the increase
of metabolites associated with anaerobic glycolysis in the long-term therapy with anti-VEGF.
This would explain the failures obtained in the treatment of solid tumors with anti-VEGF
monotherapy but also the excellent results of several trials with the association anti-angiogenic
agent and chemotherapy, even compared to chemotherapy alone [60].
The need to associate an antiangiogenic agent to traditional therapy is useful not only to
improve the vehiculation of the anticancer drug but also to control recurrences. According to
clinical experience, after surgical resection, radiotherapy and adjuvant chemotherapy with
TMZ, there is a recurrence or progression within six months. This recurrence is localized in
most cases where there was the resection of the primary tumor, in which are localized tumor
cells infiltrated. This phenomenon has been explained assuming that the primary tumor
secretes not only pro-angiogenic agents but also anti-angiogenic agents that inhibit neovas‐
cularization at the level of infiltrating tumor cells, which are located at a certain distance from
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the primary tumor. For this reason the use of anti-angiogenic agents is recommended not only
in newly diagnosed gliomas but also in recurrences [61].
10. Anti VEGFR — Bevacizumab
Bevacizumab (Avastin®;Genentech, CA, USA) is a recombinant humanized monoclonal
antibody that binds with high affinity to human VEGF preventing it from binding to its
receptors VEGFR1 and VEGFR2, on the surface of endothelial cells and thereby determining
the block of the cascade of events following its receptors activation. Will be therefore inhibited
proliferation and increased permeability due to receptor VEGFR2 and tumor growth due to
receptor VEGFR1 through the production of matrix metalloproteinases. Bevacizumab inhibits
the growth of new blood vessels and reduces the blood flow to the tumor. Like other antian‐
giogenic agents it shows, in the initial phase of the treatment, a normalizing effect on blood
vessels. This normalizing effect is important because tumor vasculature is often incomplete
and tends to leak. The abnormal permeability may prevent the administration of cancer
treatment such as chemotherapy. Bevacizumab can normalize the chaotic vascularization of
the tumor, in order to maximize the effectiveness of the overall therapeutic strategy.
In the U.S., Avastin® is the first anti-angiogenesis therapy approved by Food and Drug
Administration (FDA) to treat patients with glioblastoma multiforme (GBM) when this form
of brain cancer continues to progress following standard therapy. The drug is also approved
for the treatment of advanced stages of other 3 types of cancer: breast, colorectal, and non small
cell lung cancer (NSCLC). Even before FDA approval, bevacizumab was widely used for this
indication in the United States and in some European countries [62].
Many clinical trials evaluated efficacy of bevacizumab and irinotecan versus bevacizumab
alone (and the addition of irinotecan at progression) with several results but also with many
questions unanswered about the end points used, the increase in survival, the best dose and
timing. Teri N. Kreisl et al. conducted a trial to evaluate single-agent activity of bevacizumab
in patients with recurrent glioblastoma. The dose of bevacizumab was 10 mg/kg every 2 weeks.
At tumor progression bevacizumab was associated in combination with irinotecan 340
mg/m2 or 12 mg/m2 every two weeks. The study found that single-agent bevacizumab has a
significant antitumor effect in recurrent glioblastoma and show less overall toxicity but also a
lower response rates (29% vs. 46%) compared with combination therapy. The study shows that
it is not always strictly necessary the addition of irinotecan after tumor progression during the
treatment with bevacizumab. It is not possible, however, exclude the contribution of irinotecan
if the two agents are used together in the initial treatment. Will be necessary to conduct further
studies to understand whether the addition of this drug is so useful to offset the toxic effects
associated with its use [63].
Results from this trial are consistent with data presented by Vrendenburgh et al. emerged from
a phase II trial testing bevacizumab plus irinotecan in recurrent GBM. They reported a response
rate of 57% and a 6-month progression-free survival of 46% with this combination. The
rationale of combining the two drug is based on the normalization effect of antiangiogenic
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agents that reduce the intratumoral pressure and increase drug delivery to tumor. But there
could be also another unwanted effect, the reduction of drug penetration to the brain due to
the restoring of the blood-brain barrier [64].
Avastin® is approved in Europe for the treatment of advanced stages of four types of cancer:
colorectal cancer, breast cancer, lung cancer and kidney cancer. Together, these four types of
cancer cause nearly 3 million deaths every year. The use of the drug in Italy for malignant
gliomas is possible through the enrollment in clinical trials or the compassionate use. Com‐
passionate use programs are intended to facilitate the availability to patients of new treatment
options under development. National compassionate use programs, making medicinal
products available either on a named patient basis or to cohorts of patients, are governed by
individual Member States legislation. In Italy the global compassionate use is ruled by the
Ministerial Decree dated 8th May 2003. Drugs under experimentation may be used outside the
experimentation if there isn’t a valid therapeutic alternative [65].
The neuro-oncology department of Besta Institute is conducting a study on the therapeutic use
of bevacizumab and irinotecan in patients with recurrent grade III and IV glioma in the absence
of therapeutic alternative since is emerged by various studies the effectiveness of this associ‐
ation [66]. However, not all patients respond to bevacizumab-irinotecan combination. This is
probably due to the different pathways involved in tumor angiogenesis, in which VEGF is
only one factor, even though prevalent. The lack of response in some patients may be related
to any of the alternative routes [67].
Despite their contribution in the treatment of vascularized GBM, these agents have some
serious side effects including hypertension. For this reason, this therapy is a problem for
patients with underlying hypertension. In such cases is possible to associate calcium channel
blockers or ACE inhibitors to cancer therapy. ACE inhibitors are often preferred because in
hypertension caused by VEGF inhibitors the way of NO is involved, and it can be blocked by
these antihypertensive agents. Another side effect caused by the antiangiogenic therapy is
proteinuria, which can be prevented by these agents. The bevacizumab-irinotecan combination
is responsible for serious side effects such as renal failure and gastric perforation, which in
some cases lead to discontinuation of treatment. It is recommended that bevacizumab not be
initiated for at least 28 days after surgery and until any surgical wound is fully healed and that
bevacizumab be discontinued at least 28 days prior to elective surgery [62].
11. Integrin inhibitors — CILENGITIDE
Integrins are a family of transmembrane receptors whose natural ligands are represented
by vibronectin, fibronectin, laminin. Their ligands are recognized by the common portion
arg-gly-asp (RGD); upon binding occurs a conformational change, the formation of clusters
of integrins and the activation of intracellular kinases, from which depend many intracellu‐
lar signal cascades. These cascades result in the processes of proliferation, differentiation,
motility, survival and cell adhesion. Some integrins are ubiquitous, others are specific for
various tissues and are also expressed on the surface of different types of tumors. In such
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the primary tumor. For this reason the use of anti-angiogenic agents is recommended not only
in newly diagnosed gliomas but also in recurrences [61].
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is responsible for serious side effects such as renal failure and gastric perforation, which in
some cases lead to discontinuation of treatment. It is recommended that bevacizumab not be
initiated for at least 28 days after surgery and until any surgical wound is fully healed and that
bevacizumab be discontinued at least 28 days prior to elective surgery [62].
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Integrins are a family of transmembrane receptors whose natural ligands are represented
by vibronectin, fibronectin, laminin. Their ligands are recognized by the common portion
arg-gly-asp (RGD); upon binding occurs a conformational change, the formation of clusters
of integrins and the activation of intracellular kinases, from which depend many intracellu‐
lar signal cascades. These cascades result in the processes of proliferation, differentiation,
motility, survival and cell adhesion. Some integrins are ubiquitous, others are specific for
various tissues and are also expressed on the surface of different types of tumors. In such
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cases there will be an increase in the levels of both integrins in tumor cells than in endothe‐
lial cells in the proliferation phase during angiogenesis. Integrins most expressed are αvβ3
and αvβ5. Using these integrins as targets, will be therefore possible to obtain an antiangio‐
genic and anticancer effect.
There are several types of integrine inhibitors that have been evaluated in preclinical and in
clinical trials: peptidomimetics (Cilengitide), antibodies (Intetumumab, Natalizumab), small
organic molecules (E7820- MK0429]). The advantage of small organic molecules compared to
previous compounds lies in greater stability and in oral administration instead of intravenous.
Cilengitide (developed by Merck KGaA) is a new anti-angiogenic agent for the treatment of
recurrent gliomas that act as an inhibitor of integrin receptors αvβ3 and αvβ5, expressed on
activated endothelial cells during angiogenesis. Integrins are proteins that facilitate the
formation of new blood vessels within the tumor; blocking the receptor binding leads to the
inability to invade the brain by the glioblastoma cells. This antitumoral and antiangiogenic
effect of Cilengitide was demonstrated by several preclinical studies [68]. The molecule, in a
phase II study presented at the American Society of Clinical Oncology (ASCO) in Chicago, was
tested at two different doses (2 g or 500 mg twice a week) and provided very promising results
in the group treated with the higher dose. Surprisingly, more than one third of patients in this
group was still alive after one year and 22% after 2 years. 10% were still alive after 4 years [69].
Stupp et al. conducted a Phase I/IIa study of cilengitide and TMZ with concomitant radio‐
therapy followed by cilengitide and TMZ maintenance therapy in patients with newly
diagnosed glioblastoma. Cilengitide at 500mg was administered as a 1-hour intravenous
infusion twice weekly. The study highlighted how treatment with cilengitide, combined with
the standard treatment, showed benefits in patients with MGMT promoter methylation.
MGMT gene promoter methylation status was determined by methylation-specific polymer‐
ase chain reaction (PCR). The combination of cilengitide with TMZ and radiotherapy was well
tolerated, without other side effects [70].
Merck is currently conducting two trials; the CORE study (cilengitide at a dose of 2 g twice
weekly in combination with TMZ and radiotherapy) is a Phase II randomized, multicenter,
open-label controlled trial investigating two regimens of intravenous cilengitide in combi‐
nation with standard therapy (radiotherapy with concurrent  and adjuvant  TMZ) versus
standard therapy alone, and is currently in progress in GBM patients with an unmethylat‐
ed MGMT promoter.
The CENTRIC study is a multicenter, open-label, controlled phase III study, testing Cilengitide
(at a dose of 2 g twice weekly) in combination with standard treatment (with TMZ and
radiotherapy ) versus standard treatment alone, in subjects with newly diagnosed glioblasto‐
ma multiforme and methylated MGMT gene promoter. Promising results in these trials
probably will lead to a higher interest in integrins as targets for glioma therapy and to a bigger
development of new anti-integrin agents. The results of clinical studies will be useful to explore
the knowledge on the best dose of cilengitide used to obtain the desired therapeutic effect with
lower side effects.
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Recently the research of biomarkers predictive of patient response to anti-integrin agents has
been directed toward the quantification of their expression through imaging, using radiola‐
beled galacto-RGD positron emission tomography, a new diagnostic technique [68].
12. Antisense approaches and mi-RNA inhibitors as anti-angiogenic agents
New antiangiogenic agents have been developed and tested in several preclinical studies with
many results that encourage further research in this field. These are unconventional com‐
pounds such as siRNA and angiomirs which differently act through gene silencing. This
silencing mechanism has been used to interfere with the process of angiogenesis [61].
Other treatments to halt invasion involve genetic interventions using DNA, siRNA, and
microRNA delivery via a host of transfection methods [71]. These therapies are all in animal
phases at the moment, largely due to the invasive nature of the interventions and the difficul‐
ties in the past twenty years with gene therapy in clinical trials. The advantage of these
interventions is the ability to directly target specific genes necessary for glioma invasion
without need for design of a novel drug and determination of a particular target. However,
like all compounds, there are delivery issues associated with these treatments as well as
possible unforeseen side effects. Another kind of new possible antisense approach is repre‐
sented by long non coding RNA, different RNA-based molecules than miRNA, probably
transcripted not from intronic DNA sequences. All of these antisense approaches should be
reach to knockout or down-regulate pathways pathologically involved in glioma progression
and invasion, trying to reverse towards normality glioma cell genome or selectively kill only
glioma cells. Into this fashionable therapeutic field, our study group is improving the study of
possible involvement of IL-8 and HIF-1 alpha into high-grade glioma patients to hypothesize
an antisense block of both these molecules at the same time with a single approach.
13. Other potential molecular targets
Recent discoveries in molecular biology have shown further potential signaling pathways
involved in the pathogenesis of malignant gliomas. Were therefore assumed new targets
for novel  therapeutic  approaches like grow factor ligands,  receptors,  intracellular down‐
stream effectors. Several studies highlighted an over-expression of EGFR in malignant glio‐
mas, which is related with survival and proliferation of cancer cells. EGFR tyrosine kinase
inhibitors  (TKIs)  Gefitinib  (Iressa®)  and Erlotinib  (Tarceva®),  used in  combination with
ionizing radiation, can increase the antitumoral effect of this therapy. The results of several
phase I/II studies using Gefitinib and Erlotinib with conventional therapy in the treatment
of GBM are controversial [72]. For this matter were investigated other molecular markers
(besides the over-expression of EGFR) more predictive of EGFR TKIs activity. Among these
there  are:  EGFR  variant  III  (EGFRvIII  co-expressed  when  there  is  an  amplification  of
EGFR),  phosphatase  and  tensin  homolog  (PTEN)  expression,  and  phospho-Akt  (P-Akt).
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group was still alive after one year and 22% after 2 years. 10% were still alive after 4 years [69].
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infusion twice weekly. The study highlighted how treatment with cilengitide, combined with
the standard treatment, showed benefits in patients with MGMT promoter methylation.
MGMT gene promoter methylation status was determined by methylation-specific polymer‐
ase chain reaction (PCR). The combination of cilengitide with TMZ and radiotherapy was well
tolerated, without other side effects [70].
Merck is currently conducting two trials; the CORE study (cilengitide at a dose of 2 g twice
weekly in combination with TMZ and radiotherapy) is a Phase II randomized, multicenter,
open-label controlled trial investigating two regimens of intravenous cilengitide in combi‐
nation with standard therapy (radiotherapy with concurrent  and adjuvant  TMZ) versus
standard therapy alone, and is currently in progress in GBM patients with an unmethylat‐
ed MGMT promoter.
The CENTRIC study is a multicenter, open-label, controlled phase III study, testing Cilengitide
(at a dose of 2 g twice weekly) in combination with standard treatment (with TMZ and
radiotherapy ) versus standard treatment alone, in subjects with newly diagnosed glioblasto‐
ma multiforme and methylated MGMT gene promoter. Promising results in these trials
probably will lead to a higher interest in integrins as targets for glioma therapy and to a bigger
development of new anti-integrin agents. The results of clinical studies will be useful to explore
the knowledge on the best dose of cilengitide used to obtain the desired therapeutic effect with
lower side effects.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications222
Recently the research of biomarkers predictive of patient response to anti-integrin agents has
been directed toward the quantification of their expression through imaging, using radiola‐
beled galacto-RGD positron emission tomography, a new diagnostic technique [68].
12. Antisense approaches and mi-RNA inhibitors as anti-angiogenic agents
New antiangiogenic agents have been developed and tested in several preclinical studies with
many results that encourage further research in this field. These are unconventional com‐
pounds such as siRNA and angiomirs which differently act through gene silencing. This
silencing mechanism has been used to interfere with the process of angiogenesis [61].
Other treatments to halt invasion involve genetic interventions using DNA, siRNA, and
microRNA delivery via a host of transfection methods [71]. These therapies are all in animal
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stream effectors. Several studies highlighted an over-expression of EGFR in malignant glio‐
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ionizing radiation, can increase the antitumoral effect of this therapy. The results of several
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(besides the over-expression of EGFR) more predictive of EGFR TKIs activity. Among these
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Specifically, co-expression of EGFRvIII and the tumor-suppressor protein PTEN seems to
be associated with a significant clinical response to EGFR TKIs but also these results are
controversial. Further studies are needed to clarify the efficacy of these agents and to select
patients who may benefit from EGFR inhibitor therapy. Imatinib (Glivec®), an antagonist
of PDGFR (who may be overexpressed in high grade gliomas), showed in vitro on GBM
cells cytostatic or cytotoxic activity in relation to its concentration [73]. This led to clinical
trials  in  patient  with  recurrent  glioma.  A randomized,  multicenter,  open-label  Phase  III
study of imatinib in combination with hydroxyurea versus hydoxyurea alone as oral thera‐
py in patients with progressive pretreated GBM resistant to standard dose TMZ failed to
show clinically significant differences between the two treatment arms [74].
Most experimental and more traditional anti-invasive therapeutic platforms have focused on
the ability of compounds to inhibit matrix metalloproteinases (MMPs) and the other extracel‐
lular matrix (ECM) components and thus limiting invasive progress of cancer cells [75].
One such compound, Marimastat, an MMP-2 inhibitor, was developed and showed promise
in some clinical trials, demonstrating a possible synergic effect when used with TMZ in
anaplastic astrocytoma and recurrent GBM. Despite it, actually, it isn’t sure a long term
therapeutic effect better than TMZ alone [76, 77]. More recently, there has been a shift in the
development of novel drugs to that of more personalized therapy. In these cases, specific
receptors and signaling molecules are targeted for inhibition in order to kill cancer cells. The
main goal to reach the selectivity and efficacy of antitumor treatment consist on targeted
therapeutic molecular-based approaches. These therapies in the field of brain tumor and in
particular in case of intra-assial brain tumor, such as high-grade gliomas, represent the most
fascinating challenge to achieve the killing of glioma cells into the brain and, with an adequate
engineering of targeted drugs and nanoparticles systems, the population of glioma and GBM
stem cells. Treatment can be modified to the individual cancer type and patient which is
advantageous in reducing side effects. They work often by relying on receptor addiction of the
cancer cells meaning if the receptor becomes useless through blocking, the cancer cell will
almost go through withdrawal and can die [78, 79]. However, this is not known to occur with
all potential targets and it is always possible that pathways will be rerouted to compensate.
This type of treatment often has a side effect of halting invasion of cancer cells though more
commonly treatment leads to cell death. A recent review highlights many of these compounds
and their potential anti-invasive effects based on the target molecule for which they were
developed. However, the exact anti-invasive effects are unknown for most of these compounds
based on lack of in depth studies of invasion opting instead for survival and tumor growth
measures. Most of the targets of this type of therapy are receptor tyrosine kinases (RTKs)
which, upon activation by a ligand, will change conformation and phosphorylate intracellular
signaling proteins leading to downstream events. In cancer, these receptors are often mutated
to be constituitively active and thus require no growth factors to function. A cancer cell can
actually become “addicted” to this activation and so by turning it off, the cell will die. Inhibitors
of RTKs are most often antibodies due to the high specificity. The more notable RTK inhibitors
are Herceptin® (against EGFR), Avastin® (against VEGF), and Tarceva® (against PDGFR).
These are all used clinically for different types of cancers and have been thought to have
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possible anti-invasive effects due to their signaling pathways involving targets for invasion
[80]. However, there is insufficient evidence to tie their effects to halting glioma invasion and
as aforementioned, in vivo, Avastin causes glioma invasion. EGFR inhibition is particularly
exciting due to the overexpression or mutation of EGFR in >60% of glioblastomas (de novo
GBM) and alteration of glioblastoma to express EGFRvIII causes a more invasive phenotype
of cells in vitro [81, 82]. However, these compounds are expensive and difficult to work with.
Further, their actual role in invasion prevention is yet to be seen due to the far-reaching effects
of the involved pathways.
Inhibitors of downstream proteins such as Src-kinase have shown promise in inhibiting tumor
growth and progression. Based on the ability of Src to increase the invasive phenotype
including cytoskeletal remodeling, MMP secretion, and adhesion disassembly, it was tested
for anti-invasive activity. This treatment inhibited invasion in brain, prostate and breast
cancers while also inhibiting growth, angiogenesis and proliferation [83].
Another new agent tested in clinical trials is Talampanel, a noncompetitive antagonist of the
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. The receptor levels
may be related with the GBM growth. This compound was tested in a multicenter Phase II
study in association with standard therapy with RT and TMZ for newly diagnosed GBM.
Patients showed a median survival of 20.3 months and 2 year overall survival of 41.7%. Only
29% of patients had MGMT promoter methylated [72].
14. Conclusions and future perspectives
Based on the results obtained from both the old and the most innovative therapies seems clear
that a better understanding of the pathological and physiological mechanisms of brain cells
can result in a more targeted therapeutic approach by designing personalized therapies. This
would overcome the current limitations in the treatment and lead to a better prognosis for
patients with brain tumors.
Nowday, the treatment of gliomas represents one of the most challenging areas in neurosur‐
gery and oncology. Malignant gliomas involves multiple aberrant signaling pathways and the
BBB restricts the delivery of many chemotherapeutic agents. The efficectiveness of the actual
chemotherapeutic approach, multimodal targeted therapies, differently than the other
malignant extracerebral tumors, remains very modest in gliomas. Considering the multitude
of molecular entities and signaling pathways regulating the proliferation and cellular survival/
cell death, the inhibition of a singular target gene or transcriptional factor could not be
sufficient to suppress neoplastic progression. In this intricate and complex field it seems to be
very important to improve specific selective drug delivery systems to lead to diffusion of
drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibod‐
ies and other therapeutic molecules into CNS overcoming BBB.
Considering the multitude of actually used chemotherapeutic approaches, starting from Stupp
protocol (TMZ plus radiotherapy) and the results in term of recurrences and survival, the field
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almost go through withdrawal and can die [78, 79]. However, this is not known to occur with
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signaling proteins leading to downstream events. In cancer, these receptors are often mutated
to be constituitively active and thus require no growth factors to function. A cancer cell can
actually become “addicted” to this activation and so by turning it off, the cell will die. Inhibitors
of RTKs are most often antibodies due to the high specificity. The more notable RTK inhibitors
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including cytoskeletal remodeling, MMP secretion, and adhesion disassembly, it was tested
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cancers while also inhibiting growth, angiogenesis and proliferation [83].
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may be related with the GBM growth. This compound was tested in a multicenter Phase II
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Patients showed a median survival of 20.3 months and 2 year overall survival of 41.7%. Only
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can result in a more targeted therapeutic approach by designing personalized therapies. This
would overcome the current limitations in the treatment and lead to a better prognosis for
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Nowday, the treatment of gliomas represents one of the most challenging areas in neurosur‐
gery and oncology. Malignant gliomas involves multiple aberrant signaling pathways and the
BBB restricts the delivery of many chemotherapeutic agents. The efficectiveness of the actual
chemotherapeutic approach, multimodal targeted therapies, differently than the other
malignant extracerebral tumors, remains very modest in gliomas. Considering the multitude
of molecular entities and signaling pathways regulating the proliferation and cellular survival/
cell death, the inhibition of a singular target gene or transcriptional factor could not be
sufficient to suppress neoplastic progression. In this intricate and complex field it seems to be
very important to improve specific selective drug delivery systems to lead to diffusion of
drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibod‐
ies and other therapeutic molecules into CNS overcoming BBB.
Considering the multitude of actually used chemotherapeutic approaches, starting from Stupp
protocol (TMZ plus radiotherapy) and the results in term of recurrences and survival, the field
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of glioma therapy is again subject to high rate of investigation and development with the hope
to postulate new possible molecular targets and therapeutic schemes to attack glioma cells.
Understanding the genetic bases of gliomas and of the invasive behaviour, in particular the
differentiated gene expression in distinct areas of the same tumor during glioma progression,
may suggest new molecular targets to overcome the mechanisms of multi-drug-resistance of
the actual therapeutic approaches to gliomas and to attack at the same time different crucial
biological events of gliomagenesis.
Glioma gene expression and its development during gliomagenesis will may help to better
understand the role of important molecules involved in tumor-safe brain parenchyma
relationships. These molecules, such as ECM proteases, cell adhesion molecules and their
related signaling pathways show an important role in glioma cell migration and invasion and
could be selectively downregulated to inhibit the glioma invasive rim. It is clear that the
complexity and cross-talk between signal transduction pathways limits the potential efficacy
of targeting a single receptor or molecule.
We are now investigating the role of HIF (Hypoxic inducing factor) isoforms and IL-8
(Interleukine-8) in glioma progression and the possibility to block their pathways through a
only antisense molecule loaded into a nonaparticle-base system, and directed against both
these molecular targets. HIF-1α actively regulates downstream processes and it is also
influenced by the tumor microenviroment in many different ways. Antisense inhibition of HIF
may be a strong target for anti-angiogenic therapy. In fact, HIF is the crucial molecule and
transcriptional factor produced in response to hypoxic conditions within HIF-1α/VEGF-
regulation expression-dependent angiogenic pathway. In this molecular cascade HIF-1α up-
regulated levels finally induce up-regulation of VEGF expression, and, at the same time, may
stimulate gene expression of other genes involved in gliomagenesis.
Our group has recently demonstrated high expression levels of PGES-1 (Prostaglandine E 1
Sinthase) and IL-8 in HGG cells and microglial cells, strongly correlated with grading tumor.
During malignancy progression, leukocyte infiltration and necrosis are two biological
phenomena associated with the development of neovascularization. IL-8 expression is first
observed in low grade astrocytoma in perivascular tumor areas expressing inflammatory
cytokines. In HGGs, IL-8 further localizes in oxygen-deprived cells surrounding necrosis.
Macrophages are known to produce high levels of IL-8, which has a tumorigenic activity, by
inducing tumor growth and angiogenesis; IL-8 is an inflammatory chemoattractant respond‐
ing to the tumor microenvironment. Tumor pseudopalisading cells secrete hypoxic inducing
factor (HIF) which induces IL-8 secretion. On the base of our preliminary results, we hypothese
an important role of IL-8 as crucial angiogenesis mediator within HIF-1α pathway and
crosstalk between hypoxia-induced high levels of HIF-1α and VEGF expression. A simulta‐
neous selective antisense strategy against two molecular targets involved at different levels in
the same pathological pathway could be an attractive therapeutic mechanism aimed at
enhancing an anti-angiogenic and anti-tumoral effect.
A very interesting new field of research and therapeutic application in glioma treatment is
represented by studying and knowledge of differential phenotypic transcriptional profiles
expressed into gliomas, and GBM in particular. Hoelzinger et al. in their study have showed
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two different gene expression profiles into two distinct subpopulations of glioma cells,
respectively the glioma cells located inside the stationary and proliferative tumor core and the
glioma cells, located inside the motile and invading tumor rim. The authors report two
different pattern of gene expression, characterized respectively by high levels of IGFBP2 and
vimentin into tumor core glioma cells and upregulated expression of genes involved in
adhesion, extracellular signal transduction, cytoskeletal rearrangement, intracellular signal
transduction and apoptosis. In particular genes upregulated in invasive cells are autotoxin
(ATX), the autocrin motility factor, protein tyrosine kinase 2 beta (PYK2), ephrin B3, antia‐
poptotic factor B-cell lymphoma-w (BCLW) and death-associated protein 3 (DAP3). The
existence of two different gene expression profiles into distinct areas of the same tumor
suggests the possibility to attack different molecular pathways and steps of glioma progression
at the same time, targeting selectively different subsets of glioma cells. This introduces the
possibility of multiagent treatment modalities, specifically targeting invasive cells, through
new molecular therapeutic approaches in conjuction with classic treatments [84].
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1. Introduction
Malignant gliomas rank among the most aggressive human tumors. The hallmarks of these
tumors include a highly infiltrative behavior, aberrant cell proliferation and apoptosis, in‐
creased angiogenesis and intratumoral as well as systemic immunosuppression [1, 2]. Pro‐
teases localized on the cell-surface or released extracellularly may significantly contribute to
these characteristics by mediating the breakdown of the components of the extracellular ma‐
trix (ECM), liberating growth factors sequestered by binding to the ECM, regulating the ac‐
tivity of paracrine mediators and shedding of cell-surface proteins [3]. There is substantial
evidence for the role of matrix metalloproteinases (MMP), the serine protease urokinase-
type plasminogen activator (uPA) and the cysteine protease cathepsin B in glioma invasion
[4], angiogenesis [5] and proliferation. In addition, expression of proteases such as cathepsin
D, uPA or MMP-9 in the clinical material may predict patient prognosis [6-8]. Nevertheless,
the role of several proteases including the canonical dipeptidyl peptidase-IV (DPP-IV) and
related proteases in glioma progression remains largely unknown with only few studies us‐
ing synthetic inhibitors or genetic manipulation to determine their function. In this chapter,
we review the basic characteristics of DPP-IV and related proteases, focus on their function‐
al role in the transformed as well as stromal cells, and discuss the implications for the biolo‐
gy of human gliomas.
1.1. "Dipeptidyl peptidase-IV activity and/or structure homologous" (DASH) molecules
Historically, dipeptidyl peptidase-IV (DPP-IV, EC 3.4.14.5, identical with the lymphocyte
differentiation antigen CD26) was described by Hopsu-Havu and Glenner [9] in liver homo‐
genates on the basis of its unique hydrolytic activity cleaving N-terminal dipeptides from
synthetic chromogenic substrates with the proline residue in the penultimate position. The
© 2013 Busek and Sedo; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Chapter 8
Dipeptidyl Peptidase-IV and Related
Proteases in Brain Tumors
Petr Busek and Aleksi Sedo
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/53888
1. Introduction
Malignant gliomas rank among the most aggressive human tumors. The hallmarks of these
tumors include a highly infiltrative behavior, aberrant cell proliferation and apoptosis, in‐
creased angiogenesis and intratumoral as well as systemic immunosuppression [1, 2]. Pro‐
teases localized on the cell-surface or released extracellularly may significantly contribute to
these characteristics by mediating the breakdown of the components of the extracellular ma‐
trix (ECM), liberating growth factors sequestered by binding to the ECM, regulating the ac‐
tivity of paracrine mediators and shedding of cell-surface proteins [3]. There is substantial
evidence for the role of matrix metalloproteinases (MMP), the serine protease urokinase-
type plasminogen activator (uPA) and the cysteine protease cathepsin B in glioma invasion
[4], angiogenesis [5] and proliferation. In addition, expression of proteases such as cathepsin
D, uPA or MMP-9 in the clinical material may predict patient prognosis [6-8]. Nevertheless,
the role of several proteases including the canonical dipeptidyl peptidase-IV (DPP-IV) and
related proteases in glioma progression remains largely unknown with only few studies us‐
ing synthetic inhibitors or genetic manipulation to determine their function. In this chapter,
we review the basic characteristics of DPP-IV and related proteases, focus on their function‐
al role in the transformed as well as stromal cells, and discuss the implications for the biolo‐
gy of human gliomas.
1.1. "Dipeptidyl peptidase-IV activity and/or structure homologous" (DASH) molecules
Historically, dipeptidyl peptidase-IV (DPP-IV, EC 3.4.14.5, identical with the lymphocyte
differentiation antigen CD26) was described by Hopsu-Havu and Glenner [9] in liver homo‐
genates on the basis of its unique hydrolytic activity cleaving N-terminal dipeptides from
synthetic chromogenic substrates with the proline residue in the penultimate position. The
© 2013 Busek and Sedo; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
presence of similar enzymatic activity was observed in body fluids soon after that [10, 11].
At that time, DPP-IV was hypothesized to participate on the turnover of the regulatory as
well as structural proteins bearing the consensus cleavage sequence. However, the specula‐
tions about its particular biological roles awaited experimental confirmation. Subsequently,
multiple authors noted substantial heterogeneity of molecular forms that possessed striking‐
ly similar enzymatic activity but differed in molecular weight, isoelectric point and subcellu‐
lar localization [12]. It took several years to identify and characterize other "DPP-IV-like"
molecules, individual gene products, exhibiting various degree of structural homology with
the canonical DPP-IV. These comprise the intracellularly localized DPP8 and DPP9 (both
still assigned under the same EC 3.4.14.5) [13, 14], the plasma membrane fibroblast activa‐
tion protein-alpha/seprase (FAP, EC 3.4.21.B28) [15] as well as the DPP-IV sequentially dis‐
similar intracellular DPP-II (quiescent cell proline dipeptidase, DPP7, EC 3.4.14.2)[16].
Besides, highly structurally similar but hydrolytically inactive DPP6 and DPP10 were dis‐
covered later [17]. Recently, all these molecular species are by some authors referred to as
the "Dipeptidyl peptidase-IV activity/and or structure homologous" (DASH) molecules
[18-24]. Formerly, Glutamate carboxypeptidase II (GCPII, N-acetyl-L-aspartyl-L-glutamate
peptidase I, NAALADase I, prostate specific membrane antigen, EC 3.4.17.21) and Attractin
were proposed to belong to this group on the basis of the presumed DPP-IV-like enzymatic
activity [24]. However, further research did not confirm the hydrolytic potential of these
molecules [25, 26]. Since both of them also lack any significant structural homology with
DPP-IV, they are no more included in the DASH group.
1.1.1. Dipeptidyl peptidase-IV
In humans, the canonical DPP-IV is almost ubiquitously expressed as a single-pass type II
integral transmembrane glycoprotein in a variety of cell types, tissues and organs (reviewed
in [11, 27]). Its soluble counterpart is detectable in body fluids, being either a product of pro‐
teolytic shedding from the cell surface or a putative specific secretory form [28]. Upregula‐
tion of the plasma membrane DPP-IV is associated with cell differentiation in e.g. T cells [29,
30], hepatocytes [31] and intestinal epithelium [32]. The expression and function of DPP-IV/
CD26, a marker of a subset of activated T-cells, was intensively studied in the immune sys‐
tem [33]. Its crosslinking in T cells affects the synthesis and secretion of a number of cyto‐
kines and interleukins [34, 35]. DPP-IV is also identical with the adenosine daeminase
binding protein and participates on the immunoregulations by influencing the pericellular
concentration of free adenosine [36, 37]. The physiological relevance of the interaction of
DPP-IV with plasminogen 2 [38] and several proteins of the ECM [39, 40] is still more specu‐
lated than proven.
1.1.2. Fibroblast activation protein
Possessing about 52% amino acid sequence identity with DPP-IV, FAP represents its closest
homologue within the DASH group. Its gene is located on chromosome 2q23 and is believed
to be a product of DPP-IV gene duplication (reviewed in [15]). FAP is typically expressed as
a type II transmembrane protein and its soluble counterpart is present in blood plasma and
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is also known as α2-antiplasmin cleaving enzyme [41, 42]. In contrast to DPP-IV, FAP ex‐
pression is substantially restricted and the majority of normal adult cells are FAP negative
[27]. FAP expression is significantly induced in non-malignant states associated with tissue
remodeling such as wound healing, embryogenesis, osteoarthritis as well as rheumatoid ar‐
thritis [43, 44], in liver cirhosis [45], and in cancer stroma [46]. In addition to the DPP-IV-like
exopeptidase activity, FAP also possesses gelatinolytic endopeptidase activity [47, 48], and
was thus suggested to participate in the degradation of structural proteins of the extracellu‐
lar matrix during tissue remodeling and cancer cell invasion (reviewed in [15]). Matrix met‐
alloproteinases (MMP), in particular MMP 2 [49], seem to be important functional partners
of FAP in the modification of extracellular matrix [15]. Interestingly, heteromeric DPP-IV/
FAP complexes, possessing both the DPP-IV-like exopeptidase and proline-specific endo‐
peptidase enzymatic activity, are suspected to influence the migratory and invasive poten‐
tial of fibroblasts and endothelial cells [49, 50].
1.1.3. Dipeptidyl peptidase 8 and 9
DPP8 and 9  are  cytosolic  dimeric  proteins  that  are  expressed in  the  majority  of  tissues
including the human brain [13, 14, 51, 52], for review see [53]. The enzymatic activity of
DPP 9 is thought to be important for the degradation of intracellular proline containing
proteins with presentation of the peptide fragments on MHC-I molecules [54].  Some re‐
ports also suggest the involvement of  both DPP8 and 9 in the processes of  cell  growth,
migration and adhesion,  probably via  an indirect,  enzymatic  activity  independent  effect
on the cell-extracellular matrix interactions [55]. DPP 9 may also influence the intracellu‐
lar signaling cascades: DPP9 overexpression reduces the EGF mediated Akt activation by
an enzyme activity dependent mechanism, and in addition DPP9 interacts with Ras [56].
Both proteases  are  expressed in  the immune system [52,  57]  and some of  the effects  of
non-selective DPP inhibitors on immune cells may be in fact caused by the inhibition of
DPP8 and 9 [53].
1.1.4. Dipeptidyl peptidase-II
DPP-II (DPP7, QPP, EC 3.4.14.2) possesses the unique DPP-IV-like enzymatic activity, but is
structurally different from the canonical DPP-IV. It is a widely expressed intracellular en‐
zyme that is typically localized in lysosomes and extralysosomal vesicles [16]. It is the only
enzyme from the DASH group that has an acidic pH optimum [16]. Although the physiolog‐
ical function of DPP-II remains largely unknown, it is speculated to participate on the intra‐
lysosomal turnover of short peptides [58, 59]. In addition, several reports from the Huber
lab argue for its role in the maintenance of quiescence in lymphocytes and fibroblasts [60,
61] and possibly also in glucose homeostasis [62]. DPP-II knockout is embryonic lethal in
mice [62, 63], inhibition of DPP-II triggers apoptosis in noncycling G0 lymphocytes [64, 65]
probably through deregulation of the cell cycle entry, and its absence in T cells leads to fast‐
er proliferation and differentiation into Th17 cells [63].
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remodeling such as wound healing, embryogenesis, osteoarthritis as well as rheumatoid ar‐
thritis [43, 44], in liver cirhosis [45], and in cancer stroma [46]. In addition to the DPP-IV-like
exopeptidase activity, FAP also possesses gelatinolytic endopeptidase activity [47, 48], and
was thus suggested to participate in the degradation of structural proteins of the extracellu‐
lar matrix during tissue remodeling and cancer cell invasion (reviewed in [15]). Matrix met‐
alloproteinases (MMP), in particular MMP 2 [49], seem to be important functional partners
of FAP in the modification of extracellular matrix [15]. Interestingly, heteromeric DPP-IV/
FAP complexes, possessing both the DPP-IV-like exopeptidase and proline-specific endo‐
peptidase enzymatic activity, are suspected to influence the migratory and invasive poten‐
tial of fibroblasts and endothelial cells [49, 50].
1.1.3. Dipeptidyl peptidase 8 and 9
DPP8 and 9  are  cytosolic  dimeric  proteins  that  are  expressed in  the  majority  of  tissues
including the human brain [13, 14, 51, 52], for review see [53]. The enzymatic activity of
DPP 9 is thought to be important for the degradation of intracellular proline containing
proteins with presentation of the peptide fragments on MHC-I molecules [54].  Some re‐
ports also suggest the involvement of  both DPP8 and 9 in the processes of  cell  growth,
migration and adhesion,  probably via  an indirect,  enzymatic  activity  independent  effect
on the cell-extracellular matrix interactions [55]. DPP 9 may also influence the intracellu‐
lar signaling cascades: DPP9 overexpression reduces the EGF mediated Akt activation by
an enzyme activity dependent mechanism, and in addition DPP9 interacts with Ras [56].
Both proteases  are  expressed in  the immune system [52,  57]  and some of  the effects  of
non-selective DPP inhibitors on immune cells may be in fact caused by the inhibition of
DPP8 and 9 [53].
1.1.4. Dipeptidyl peptidase-II
DPP-II (DPP7, QPP, EC 3.4.14.2) possesses the unique DPP-IV-like enzymatic activity, but is
structurally different from the canonical DPP-IV. It is a widely expressed intracellular en‐
zyme that is typically localized in lysosomes and extralysosomal vesicles [16]. It is the only
enzyme from the DASH group that has an acidic pH optimum [16]. Although the physiolog‐
ical function of DPP-II remains largely unknown, it is speculated to participate on the intra‐
lysosomal turnover of short peptides [58, 59]. In addition, several reports from the Huber
lab argue for its role in the maintenance of quiescence in lymphocytes and fibroblasts [60,
61] and possibly also in glucose homeostasis [62]. DPP-II knockout is embryonic lethal in
mice [62, 63], inhibition of DPP-II triggers apoptosis in noncycling G0 lymphocytes [64, 65]
probably through deregulation of the cell cycle entry, and its absence in T cells leads to fast‐
er proliferation and differentiation into Th17 cells [63].
Dipeptidyl Peptidase-IV and Related Proteases in Brain Tumors
http://dx.doi.org/10.5772/53888
237
1.1.5. Dipeptidyl peptidase 6 and 10
DPP6 (dipeptidyl peptidase-IV like protein 1, DPPX) [66] and DPP10 (dipeptidyl peptidase-
IV like protein 2)[67] are the enzymatically inactive, DPP-IV structurally related members of
the DASH group [17]. Both proteins participate on the regulation of the voltage gated potas‐
sium channels [68] and may play a role in the development of the central nervous system
and neurodegenerative diseases [69, 70]. There are currently no data on their role in glioma‐
genesis and only two studies suggested an association of mutations in DPP6 with pancreatic
cancer [71, 72].
A substantial leap of interest in the DASH molecules was induced i) by the introduction of
DPP-IV inhibitors in the treatment of type II diabetes [19, 244] and ii) observations of
marked alterations of their expression and activity in the course of several diseases especial‐
ly involving the immune system, and in cancer, where a direct pathogenetic role for DPP-IV
and FAP seems to be highly probable. A significant proportion of the biologically active,
mostly pro-proliferative peptides, systemic as well as local hormones, chemokines, neuro‐
peptides, incretins and growth factors (Figure 1) contains a penultimate N-terminal proline
residue as an evolutionary conserved proteolytic regulatory “check-point” [245]. Thus, the
DPP-IV enzymatic activity is believed to be a functional regulator of their biological action.
Limited proteolysis of these peptides by DPP-IV may lead both to quantitative and, due to
the diversification of receptor subset preference, also to qualitative changes of their signal‐
ing potential [73-75].
While the systematic description of individual DASH molecules is available, including the
cloning and structure resolution, the interpretations of biological studies are often equivocal
because of their “moonlighting” character [76]. First, the overlap of enzymatic activities
among the DASH molecules implies their sharing of similar sets of substrates (Figure 1) and
thus, to some extent, DASH molecules may substitute each other. Second, DASH molecules
execute more biological functions, depending on the given cell population and actual con‐
text of the biologically active substrates and the relevant receptors within the immediate en‐
vironment. Third, the functional potential of DASH molecules is broadened by interactions
with non-hydrolytic molecular partners (Ramirez-Montagut et al. 2004; Wang et al. 2005).
2. Expression and function of dipeptidyl peptidase-IV and related
proteases in the microenvironment of human malignancies
2.1. Expression in transformed cells- tumor type specific and context dependent functions
Altered expression of DPP-IV and FAP is associated with several malignancies including
brain tumors [87].  Both molecules may be expressed by the transformed as well as stro‐
mal  cells  and  are  associated  with  tumor  promotion  or  suppression  depending  on  the
cancer type (for review see [88, 89, 27]). The mechanisms by which these molecules con‐
tribute to cancer pathogenesis  and progression remain largely unknown, but  several  re‐
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ports indicate that DASH molecules may serve as diagnostic and prognostic markers as
well as therapeutic targets.
Figure 1. Potential overlaps of DPP-IV and related proteases in the processing of biologically active peptides. The
pathophysiological importance of the cleavage is established e.g. for GLP-1, GIP, CXCL12 and NP Y, some of the in
vitro cleaved substrates are unlikely to be of significance in vivo (e.g. Heat shock protein 1 for DPP-IV, SPRY2 for FAP).
Not all identified DPP-IV substrates were tested with DPP8, 9 and FAP, the cleavage by these proteases is usually slow‐
er compared to DPP-IV. * cleavage has only been established for DPP-IV and DPP8; ** substrates of the endopeptidase
activity of FAP; *** only tested for DPP8 and DPP9; VIP= Vasoactive intestinal peptide, PACAP= Pituitary adenylate cy‐
clase-activating peptide, GRP= Gastrin-releasing peptide, GIP= Gastric inhibitory polypeptide/ glucose-dependent in‐
sulinotropic peptide, PHM= Peptide Histidine-Methionine, GHRH= Growth hormone releasing hormone, BNP= Brain
natriuretic peptide, SP= Substance P, GLP-1, 2= Glucagon-like peptide-1, 2, PYY= Peptide YY, NP Y= Neuropeptide Y,
SPRY2= sprouty (Drosophila) homolog 2, RU1(34-42)= antigenic peptide VPYGSFKHV. Compiled based on [15, 54, 73,
77-86].
DPP-IV expression is typical for a subset of aggressive T cell malignancies, which may be
related to its function in T cell activation [90, 91]. The presence of DPP-IV is also associated
with a more malignant behavior in B-cell chronic lymphocytic leukaemia [92], thyroid can‐
cer [93], gastrointestinal stromal tumors [94], and was recently linked to a subpopulation of
cancer stem cells responsible for the metastatic spread of colorectal cancer [95].
Recent studies aimed at examining the functional role of DPP-IV in malignant cells. In meso‐
thelioma, DPP-IV is expressed in tumors in situ and in mesothelioma cell lines [96]. By bind‐
ing fibronectin and collagen I, DPP-IV likely contributes to the interaction of these cells with
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DPP-IV expression is typical for a subset of aggressive T cell malignancies, which may be
related to its function in T cell activation [90, 91]. The presence of DPP-IV is also associated
with a more malignant behavior in B-cell chronic lymphocytic leukaemia [92], thyroid can‐
cer [93], gastrointestinal stromal tumors [94], and was recently linked to a subpopulation of
cancer stem cells responsible for the metastatic spread of colorectal cancer [95].
Recent studies aimed at examining the functional role of DPP-IV in malignant cells. In meso‐
thelioma, DPP-IV is expressed in tumors in situ and in mesothelioma cell lines [96]. By bind‐
ing fibronectin and collagen I, DPP-IV likely contributes to the interaction of these cells with
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the ECM [97]. A different mechanism may operate in Ewing sarcoma: DPP-IV (and likely al‐
so the intracellular proteases DPP8 and 9) proteolytically cleaves NP Y1-36 to NP Y3-36 and
thus abolishes its cell death inducing activity in the cancer cells and switches it to an angio‐
genesis promoting mediator [98].
Contrary to the above cited reports, some malignancies exhibit decreased DPP-IV expres‐
sion. This is typical for melanoma and melanoma derived cell lines [99-102], cancer cell lines
derived from neuroblastoma [103] and prostate [104] as well as non-small-cell lung cancer
[105]. It should be however noted that on the tissue level, the data on DPP-IV expression are
equivocal at least for prostate and lung cancer [106-109]. DPP-IV was shown to act as a tu‐
mor suppressor in melanoma [99, 102], neuroblastoma [103], prostate [104] and non-small-
lung cancer [105] cells: its reexpression in the transformed cells led do decreased growth,
increased apoptosis and sensitivity to growth factor withdrawal, decreased invasiveness
and slower xenotransplant growth in immunodeficient animals.
The mechanisms that account for these diverse effects of DPP-IV on tumor cells are rather
poorly understood. The currently best characterized physiological function of DPP-IV is
proteolytic inactivation of incretins and possibly other biologically active peptides [73, 110].
The biological relevance of this phenomenon is confirmed by the clinically exploited DPP-IV
inhibitors resulting in systemic elevation of DPP-IV substrates such as GLP-1 [111]. In addi‐
tion, a variety of growth factors, chemokines and neuropeptides implicated in the progres‐
sion of human tumors are potential DPP-IV substrates (reviewed in [74]) and DPP-IV may
therefore act as a “gate-keeper” regulating their biological function on the systemic and/or
local level. The decreased clearance of biologically active substrates due to the absence of
DPP-IV may lead to sustained pro-proliferative signaling and promote tumor growth and
metastasis. Masur et al. [112] showed that the growth promoting and promigratory activity
of GLP-2 in colon cancer cells in vitro is increased in the presence of a DPP-IV inhibitor. Sim‐
ilarly, the inhibition of the DPP-IV enzymatic activity facilitated metastatic spread of pros‐
tate cancer cells by preventing the cleavage of the chemokine CXCL12 (SDF-1, stromal cell
derived factor -1) [113].
On the other hand, DPP-IV also triggers changes in signaling cascades and expression of
molecules mediating interaction with the ECM that are harder to reconcile with the cleavage
of biologically active substrates in the pericellular space. In ovarian carcinoma, DPP-IV ex‐
pression led to suppression of MAPK signaling, enhanced E-cadherin expression and the
downregulation of MMP-2 and MT-MMP-1, which was associated with decreased invasive‐
ness, tumor progression and enhanced chemosensitivity [114-116]. In prostate cancer cells,
re-expression of DPP-IV interfered with the signaling of a non-DPP-IV substrate bFGF and
inhibited their malignant phenotype in the study by Wesley et al. [104]. Yet, Goznalez-Gro‐
now et al. [117] identified DPP-IV as a receptor for plasminogen 2 epsilon that promoted the
invasiveness of the prostate cancer cell line 1-LN.
To test the relevance of the hypothesized non-proteolytic functions of DPP-IV, several
groups including ours engineered an enzymatically inactive form of DPP-IV with a single
amino acid substitution in the active site (Ser630→Ala630). Reintroduction of this mutant form
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of DPP-IV frequently results in similar tumor suppressing effects as observed with the enzy‐
matically active DPP-IV [99, 102, 105, 118].
The proteolytic and non-proteolytic mechanisms may also combine and thus extend the
portfolio of the biological functions of DPP-IV. Arscott et al. [103] showed that DPP-IV reex‐
pression in neuroblastoma cells induced differentiation, increased their sensitivity to serum
withdrawal and reduced their migration, invasion and pro-angiogenic capacity in vitro as
well as in vivo. This was most likely caused by the downmodulation of the CXCL12-CXCR4
axis and possibly also other chemokine systems. Although not specifically demonstrated by
the authors, DPP-IV most likely inactivated CXCL12 proteolytically, resulting in the down‐
regulation of its downstream effectors, but in addition it downregulated the mRNAs of
CXCL12 and CXCR4 and several other chemokines including non-DPP-IV substrates [103].
FAP was originally described to be typically expressed in the stromal compartment of tu‐
mors (see section 2.2), but several reports, including ours, also show its expression in the
transformed elements. A prototypical example is the LOX melanoma cell line, where FAP
co-localizes with the urokinase plasminogen activator receptor (uPAR) on the invadopodia
and likely contributes to the pericellular proteolysis and invasiveness of these cells [119, 120,
47, 121, 122]. Somewhat surprisingly, Ramirez-Montagut et al. [123] were able to show that
in mouse melanoma cells FAP may actually act as a tumor suppressor with the main effects
on cell growth and survival independently of its enzymatic activity. These results are in
agreement with Rettig et al., who observed loss of FAP during Ras mediated transformation
of melanocytes [124] and with the fact that FAP is upregulated upon reintroduction of DPP-
IV into melanoma cells with the resulting tumor suppressing effects [99]. Similarly, FAP
negative subclones in osteosarcoma were tumorigenic and grew to high densities in contrast
to non-tumorigenic FAP positive subclones [124].
Breast cancer cells also express FAP in vivo [15, 125]. FAP is associated with their decreased
dependence on growth factors in vitro and formation of more rapidly growing and more
vascularized tumors in a xenotransplantation model [125-127]. Interestingly and somewhat
in contrast to the previously published data in other cancer types, the tumor promoting ac‐
tivities in breast cancer cells may be independent of the intrinsic enzymatic activity of FAP
[128]. FAP is also expressed in the tumor cells of mesenchymal origin in malignant and be‐
nign tumors, but is probably rather linked to their myofibroblastic differentiation than to
their malignant potential [129]. Epithelial cancer cells e.g. in gastric [130], esophageal [131],
colorectal [132] and cervical cancer [133] were also demonstrated to be FAP positive. The
function of FAP in these cells is unclear but in analogy to other cancers it is presumed to be
linked to their invasiveness.
There is limited data on the expression and in particular the function of DPP8, DPP9 and
DPP-II in cancer cells. Yu et al. described increased DPP9 mRNA in testicular cancers on a
small patient sample [52], both DPP8 and DPP9 are expressed in human breast, ovarian and
hepatic cancer cells as well as in lymphoma cells lines [52, 134] and chronic B cell leukemia
cells [135]. Interestingly, transgenic DPP9 was shown to induce apoptosis in hepatoma cells
and decrease the EGF mediated activation of Akt [56]. These effects were dependent on the
enzymatic activity of DPP9, but in addition to that, both DPP9 and DPP8 were demonstrat‐
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therefore act as a “gate-keeper” regulating their biological function on the systemic and/or
local level. The decreased clearance of biologically active substrates due to the absence of
DPP-IV may lead to sustained pro-proliferative signaling and promote tumor growth and
metastasis. Masur et al. [112] showed that the growth promoting and promigratory activity
of GLP-2 in colon cancer cells in vitro is increased in the presence of a DPP-IV inhibitor. Sim‐
ilarly, the inhibition of the DPP-IV enzymatic activity facilitated metastatic spread of pros‐
tate cancer cells by preventing the cleavage of the chemokine CXCL12 (SDF-1, stromal cell
derived factor -1) [113].
On the other hand, DPP-IV also triggers changes in signaling cascades and expression of
molecules mediating interaction with the ECM that are harder to reconcile with the cleavage
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pression led to suppression of MAPK signaling, enhanced E-cadherin expression and the
downregulation of MMP-2 and MT-MMP-1, which was associated with decreased invasive‐
ness, tumor progression and enhanced chemosensitivity [114-116]. In prostate cancer cells,
re-expression of DPP-IV interfered with the signaling of a non-DPP-IV substrate bFGF and
inhibited their malignant phenotype in the study by Wesley et al. [104]. Yet, Goznalez-Gro‐
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To test the relevance of the hypothesized non-proteolytic functions of DPP-IV, several
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of DPP-IV frequently results in similar tumor suppressing effects as observed with the enzy‐
matically active DPP-IV [99, 102, 105, 118].
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pression in neuroblastoma cells induced differentiation, increased their sensitivity to serum
withdrawal and reduced their migration, invasion and pro-angiogenic capacity in vitro as
well as in vivo. This was most likely caused by the downmodulation of the CXCL12-CXCR4
axis and possibly also other chemokine systems. Although not specifically demonstrated by
the authors, DPP-IV most likely inactivated CXCL12 proteolytically, resulting in the down‐
regulation of its downstream effectors, but in addition it downregulated the mRNAs of
CXCL12 and CXCR4 and several other chemokines including non-DPP-IV substrates [103].
FAP was originally described to be typically expressed in the stromal compartment of tu‐
mors (see section 2.2), but several reports, including ours, also show its expression in the
transformed elements. A prototypical example is the LOX melanoma cell line, where FAP
co-localizes with the urokinase plasminogen activator receptor (uPAR) on the invadopodia
and likely contributes to the pericellular proteolysis and invasiveness of these cells [119, 120,
47, 121, 122]. Somewhat surprisingly, Ramirez-Montagut et al. [123] were able to show that
in mouse melanoma cells FAP may actually act as a tumor suppressor with the main effects
on cell growth and survival independently of its enzymatic activity. These results are in
agreement with Rettig et al., who observed loss of FAP during Ras mediated transformation
of melanocytes [124] and with the fact that FAP is upregulated upon reintroduction of DPP-
IV into melanoma cells with the resulting tumor suppressing effects [99]. Similarly, FAP
negative subclones in osteosarcoma were tumorigenic and grew to high densities in contrast
to non-tumorigenic FAP positive subclones [124].
Breast cancer cells also express FAP in vivo [15, 125]. FAP is associated with their decreased
dependence on growth factors in vitro and formation of more rapidly growing and more
vascularized tumors in a xenotransplantation model [125-127]. Interestingly and somewhat
in contrast to the previously published data in other cancer types, the tumor promoting ac‐
tivities in breast cancer cells may be independent of the intrinsic enzymatic activity of FAP
[128]. FAP is also expressed in the tumor cells of mesenchymal origin in malignant and be‐
nign tumors, but is probably rather linked to their myofibroblastic differentiation than to
their malignant potential [129]. Epithelial cancer cells e.g. in gastric [130], esophageal [131],
colorectal [132] and cervical cancer [133] were also demonstrated to be FAP positive. The
function of FAP in these cells is unclear but in analogy to other cancers it is presumed to be
linked to their invasiveness.
There is limited data on the expression and in particular the function of DPP8, DPP9 and
DPP-II in cancer cells. Yu et al. described increased DPP9 mRNA in testicular cancers on a
small patient sample [52], both DPP8 and DPP9 are expressed in human breast, ovarian and
hepatic cancer cells as well as in lymphoma cells lines [52, 134] and chronic B cell leukemia
cells [135]. Interestingly, transgenic DPP9 was shown to induce apoptosis in hepatoma cells
and decrease the EGF mediated activation of Akt [56]. These effects were dependent on the
enzymatic activity of DPP9, but in addition to that, both DPP9 and DPP8 were demonstrat‐
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ed to interact with Ras [56]. In Ewing sarcoma cells, DPP8 and DPP9 seem to exert similar
effects as DPP-IV (see above) due to their similar enzymatic activity [98] and efficient cleav‐
age of NP Y [77](Figure 1.). Whether DPP8 and DPP9 regulate the adhesion and migration
[55] of malignant cells remains to be established. Lower DPP-II catalytic histochemistry
staining was suggested as a favorable prognostic marker in chronic lymphocytic leukemia
(CLL) [136]. In addition, DPP-II inhibition leads to induction of apoptosis in CLL cells in ap‐
proximately 60% of patients, which is associated with the presence of other established posi‐
tive prognostic markers and a clinically more benign disease course [137]. Whether DPP-II is
functionally involved in the pathogenesis in CLL and/or other cancers is currently not
known.
2.2. Expression and role of dipeptidyl peptidase-IV and related proteases in the stromal
compartment of tumors
Tumor stroma is composed of an extracellular matrix and a diverse set of cell types that sig‐
nificantly contribute to tumor progression [138]. Among others, the stroma is an important
source of tumor associated proteases including the DASH molecules.
Vascular and lymphatic endothelial cells express DPP-IV in cell culture as well as in situ [139,
140], but the expression is variable and several reports show no DPP-IV staining of cell vessels
[141]. Similarly ambiguous are the data regarding the function of DPP-IV in endothelial cells: it
is speculated to contribute to their interaction with the extracellular matrix proteins, convert NP
Y to its pro-angiogenic form and promote their migration and invasion [50, 142-144]. Contrari‐
ly, a recent report showed that DPP-IV ablation using either genetic or pharmacologic ap‐
proaches  may  increase  endothelial  cell  proliferation  and  migration  induced  by  the
inflammatory cytokines TNF-α or IL-1β [139]. These somewhat conflicting results may be due
to regional differences in the proteolytic makeup of endothelial cells as well as differing func‐
tions of DPP-IV depending on the presence of its “molecular partners” and microenvironmen‐
tal  stimuli.  FAP  mRNA  was  also  detected  in  endothelial  cells  cultured  in  vitro  [145].
Interestingly, Ghilardi et al. [146] observed higher FAP expression in endothelial cells derived
from ovarian and renal carcinoma compared to cells derived from normal tissues. The functions
of FAP in endothelial cells are mostly speculative but it may (probably together with DPP-IV)
contribute to the degradation of extracellular matrix [50]. FAP may be also expressed by peri‐
cytes [138], although in some cancer models its expression was restricted to isolated infiltrating
stromal cells rather than pericytes [147].
Expression of DPP-IV in the normal and cancer associated fibroblasts is rather variable
[148-151], but cultured fibroblasts and myofibroblasts in the majority of epithelial cancers
strongly express FAP [15, 152, 153]. Stimuli leading to the upregulation of FAP may involve
inflammatory mediators such as TGF beta, Il1 and oncostatin M [43, 154], factors secreted by
tumor cells (i.e. PDGF-BB, TGF-beta1 and Wnt5a in melanoma cells [155]) and the transcrip‐
tion factor EGR1 [156]. Pathophysiologically, FAP likely participates in the turnover and
modification of the extracellular matrix [157]. Lee et al. [158] found that fibroblasts engi‐
neered to express FAP seeded on gelatin produced matrices with changed composition and
structure, which promoted the migratory behavior of pancreatic carcinoma cells. These
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changes were mediated by the enzymatic activity of FAP as demonstrated by using a FAP
inhibitor naphthalenecarboxy-Gly-boroPro [158]. FAP inhibition was also shown to block
the growth of lung and colon cancer in a mouse model by increased accumulation of colla‐
gen, decreased myofibroblast content and vessel density [159] suggesting its crucial role for
the effective establishment of tumor stroma. Other mechanisms may also contribute to the
important role of FAP in tumor microenvironment. By selectively depleting the FAP posi‐
tive stromal cells, Kraman et al. demonstrated that they are crucial for the suppression of
antitumor immune response [160]. Whether FAP is just an “innocent by-stander” marker of
these cells, or plays a direct role in this process remains to be established. In multiple myelo‐
ma, the stromal FAP expression is important in promoting the survival of myeloma cells [18,
161], but the mechanisms are unknown. The expression of FAP in tumors is in general asso‐
ciated with a more aggressive disease course and shorter patient survival [153, 162, 163].
Surprisingly, one study in breast cancer [164] described longer overall survival and the dis‐
ease free interval in patients with higher stromal FAP expression.
Immune cells are another important constituent of the tumor microenvironment that may
express DPP-IV, DPP8 and DPP9, but do not express FAP [135, 165, 166]. In cancer patients,
changes in the DPP-IV levels are frequently seen in serum and in lymphocytes [80] and cyto‐
kines such as TGF-β may contribute to these changes in peripheral blood lymphocytes as
documented in patients with oral cancer [167]. Despite the well established role of DPP-IV in
human lymphocyte proliferation and activation [33], its function, as well as the possible sig‐
nificance of DPP8 and DPP9 in mediating or suppressing effective antitumor responses is
unknown. Talabostat (PT-100), an inhibitor of DPP-IV and FAP, was demonstrated to stimu‐
late the immune response to several experimental tumors, but the mechanisms were not de‐
pendent on the inhibition of DPP-IV [168].
In conclusion, the expression of DPP-IV and related proteases is frequently deregulated in the
parenchymal and/or stromal compartment in human malignancies. The molecules may pro‐
mote or suppress tumor progression depending on the tumor type and the presence of their
substrates and/or interactors in the microenvironment, which are characteristic for individual
tumors. This highly context dependent role is the likely explanation for the conflicting data re‐
ported on their role in cancer [27, 74, 169]. The mechanisms seem to involve proteolytic process‐
ing as well as non-proteolytic protein-protein interactions and modification of intracellular
signaling pathways. Similar mechanisms likely operate for the intracellular proteases DPP8
and DPP9, but the evidence for their role in human cancers is currently limited.
3. Dipeptidyl peptidase-IV and related proteases in the pathogenesis of
brain tumors
3.1. Expression of DPP-IV and related proteases in glioma cell lines
In astrocytoma cells, DPP-IV was first detected using immunohistochemistry by Medeiros
[170]. Subsequent work in our laboratory revealed the presence of DPP-IV-like enzymatic
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ed to interact with Ras [56]. In Ewing sarcoma cells, DPP8 and DPP9 seem to exert similar
effects as DPP-IV (see above) due to their similar enzymatic activity [98] and efficient cleav‐
age of NP Y [77](Figure 1.). Whether DPP8 and DPP9 regulate the adhesion and migration
[55] of malignant cells remains to be established. Lower DPP-II catalytic histochemistry
staining was suggested as a favorable prognostic marker in chronic lymphocytic leukemia
(CLL) [136]. In addition, DPP-II inhibition leads to induction of apoptosis in CLL cells in ap‐
proximately 60% of patients, which is associated with the presence of other established posi‐
tive prognostic markers and a clinically more benign disease course [137]. Whether DPP-II is
functionally involved in the pathogenesis in CLL and/or other cancers is currently not
known.
2.2. Expression and role of dipeptidyl peptidase-IV and related proteases in the stromal
compartment of tumors
Tumor stroma is composed of an extracellular matrix and a diverse set of cell types that sig‐
nificantly contribute to tumor progression [138]. Among others, the stroma is an important
source of tumor associated proteases including the DASH molecules.
Vascular and lymphatic endothelial cells express DPP-IV in cell culture as well as in situ [139,
140], but the expression is variable and several reports show no DPP-IV staining of cell vessels
[141]. Similarly ambiguous are the data regarding the function of DPP-IV in endothelial cells: it
is speculated to contribute to their interaction with the extracellular matrix proteins, convert NP
Y to its pro-angiogenic form and promote their migration and invasion [50, 142-144]. Contrari‐
ly, a recent report showed that DPP-IV ablation using either genetic or pharmacologic ap‐
proaches  may  increase  endothelial  cell  proliferation  and  migration  induced  by  the
inflammatory cytokines TNF-α or IL-1β [139]. These somewhat conflicting results may be due
to regional differences in the proteolytic makeup of endothelial cells as well as differing func‐
tions of DPP-IV depending on the presence of its “molecular partners” and microenvironmen‐
tal  stimuli.  FAP  mRNA  was  also  detected  in  endothelial  cells  cultured  in  vitro  [145].
Interestingly, Ghilardi et al. [146] observed higher FAP expression in endothelial cells derived
from ovarian and renal carcinoma compared to cells derived from normal tissues. The functions
of FAP in endothelial cells are mostly speculative but it may (probably together with DPP-IV)
contribute to the degradation of extracellular matrix [50]. FAP may be also expressed by peri‐
cytes [138], although in some cancer models its expression was restricted to isolated infiltrating
stromal cells rather than pericytes [147].
Expression of DPP-IV in the normal and cancer associated fibroblasts is rather variable
[148-151], but cultured fibroblasts and myofibroblasts in the majority of epithelial cancers
strongly express FAP [15, 152, 153]. Stimuli leading to the upregulation of FAP may involve
inflammatory mediators such as TGF beta, Il1 and oncostatin M [43, 154], factors secreted by
tumor cells (i.e. PDGF-BB, TGF-beta1 and Wnt5a in melanoma cells [155]) and the transcrip‐
tion factor EGR1 [156]. Pathophysiologically, FAP likely participates in the turnover and
modification of the extracellular matrix [157]. Lee et al. [158] found that fibroblasts engi‐
neered to express FAP seeded on gelatin produced matrices with changed composition and
structure, which promoted the migratory behavior of pancreatic carcinoma cells. These
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changes were mediated by the enzymatic activity of FAP as demonstrated by using a FAP
inhibitor naphthalenecarboxy-Gly-boroPro [158]. FAP inhibition was also shown to block
the growth of lung and colon cancer in a mouse model by increased accumulation of colla‐
gen, decreased myofibroblast content and vessel density [159] suggesting its crucial role for
the effective establishment of tumor stroma. Other mechanisms may also contribute to the
important role of FAP in tumor microenvironment. By selectively depleting the FAP posi‐
tive stromal cells, Kraman et al. demonstrated that they are crucial for the suppression of
antitumor immune response [160]. Whether FAP is just an “innocent by-stander” marker of
these cells, or plays a direct role in this process remains to be established. In multiple myelo‐
ma, the stromal FAP expression is important in promoting the survival of myeloma cells [18,
161], but the mechanisms are unknown. The expression of FAP in tumors is in general asso‐
ciated with a more aggressive disease course and shorter patient survival [153, 162, 163].
Surprisingly, one study in breast cancer [164] described longer overall survival and the dis‐
ease free interval in patients with higher stromal FAP expression.
Immune cells are another important constituent of the tumor microenvironment that may
express DPP-IV, DPP8 and DPP9, but do not express FAP [135, 165, 166]. In cancer patients,
changes in the DPP-IV levels are frequently seen in serum and in lymphocytes [80] and cyto‐
kines such as TGF-β may contribute to these changes in peripheral blood lymphocytes as
documented in patients with oral cancer [167]. Despite the well established role of DPP-IV in
human lymphocyte proliferation and activation [33], its function, as well as the possible sig‐
nificance of DPP8 and DPP9 in mediating or suppressing effective antitumor responses is
unknown. Talabostat (PT-100), an inhibitor of DPP-IV and FAP, was demonstrated to stimu‐
late the immune response to several experimental tumors, but the mechanisms were not de‐
pendent on the inhibition of DPP-IV [168].
In conclusion, the expression of DPP-IV and related proteases is frequently deregulated in the
parenchymal and/or stromal compartment in human malignancies. The molecules may pro‐
mote or suppress tumor progression depending on the tumor type and the presence of their
substrates and/or interactors in the microenvironment, which are characteristic for individual
tumors. This highly context dependent role is the likely explanation for the conflicting data re‐
ported on their role in cancer [27, 74, 169]. The mechanisms seem to involve proteolytic process‐
ing as well as non-proteolytic protein-protein interactions and modification of intracellular
signaling pathways. Similar mechanisms likely operate for the intracellular proteases DPP8
and DPP9, but the evidence for their role in human cancers is currently limited.
3. Dipeptidyl peptidase-IV and related proteases in the pathogenesis of
brain tumors
3.1. Expression of DPP-IV and related proteases in glioma cell lines
In astrocytoma cells, DPP-IV was first detected using immunohistochemistry by Medeiros
[170]. Subsequent work in our laboratory revealed the presence of DPP-IV-like enzymatic
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activity together with the expression of mRNA for DPP-IV, FAP and DPP-8 and 9 in perma‐
nent glioma cell lines C6, U373, T98G, U251, U87, U138, U118 and in human glioma primary
cell cultures as well as in glioma stem-like cells ([118, 171-175] and unpublished data). The
DPP-IV-like enzymatic activity in the permanent glioma cell lines is only partially inhibited
by a highly specific DPP-IV inhibitor sitagliptin. In U87, U138 and U118 lines 30, 60 and 85%
respectively of the total enzymatic activity is inhibited and can therefore be attributed to the
canonical DPP-IV. In contrast, only 12-15% of the DPP-IV-like enzymatic activity in U373,
T98G, U251 cells is inhibited by sitagliptin (Busek et al. unpublished data). These results cor‐
respond well with the relatively high DPP-IV mRNA expression in the U87, U138 and U118
cell lines [175, 176].
FAP is also expressed in glioma cells. The early work by Rettig et al. [177] detected FAP in
19 out of 22 of astrocytoma cell lines by immunohistochemistry using the F19 monoclonal
antibody. Similarly Mentlein et al. [176] showed high FAP mRNA expression in 6 out of 7
glioma cell lines. According to our data, the expression of FAP may be more variable [118]
with substantial variation in individual primary cell cultures as well as permanent cell lines.
In the panel of glioma cell lines examined in our studies, FAP expression mirrored the ex‐
pression of DPP-IV and was substantially higher in U87, U138 and U118 cell lines than in
U373, T98G, U251 lines [175]. Therefore, although FAP is significantly less efficient in cleav‐
ing the H-Gly-Pro-AMC substrate compared to DPP-IV [48], it may partly contribute to the
sitagliptin resistant DPP-IV-like enzymatic activity in some of the glioma cells lines. Interest‐
ingly, we have consistently observed a positive correlation between the mRNA expression
of the two transmembrane proteases DPP-IV and FAP in glioma cell lines as well as in glio‐
ma primary cell cultures [178]. Moreover, the expression of both DPP-IV and FAP increased
concomitantly in glioma cells cultured in serum free media and decreased after the addition
of serum to the starved cells [178] suggesting that similar pathways regulate their expression
in this model, most likely on the transcription and/or mRNA stability levels [178]. The
mRNAs for the ubiquitous intracellular enzymes DPP8 and DPP9 are expressed in similar
quantities in the glioma cell lines tested in our laboratory and probably make the largest
contribution to the residual DPP-IV-like enzymatic activity after inhibition with sitagliptin
(Busek et al. unpublished data).
It is currently unclear to what extent the in vitro cell culture conditions and the standard
process of glioma cell line establishment may influence the observed expression of DPP-IV
and especially FAP, a known phenotypic marker of mesenchymal cells such as activated fi‐
broblasts [15]. The typical media supplemented with 10% fetal calf serum are known to pro‐
mote the mesenchymal phenotype in cultured cells (“mesenchymal drift”; [179]) which
could lead to the upregulation of FAP. Xenotransplants generated by orthotopic implanta‐
tion of the glioma cells into immunodeficient mice exhibited higher DPP-IV-like enzymatic
activity compared to the contralateral hemisphere (Figure 2) and the enzymatic activity was
in part sensitive to a specific DPP-IV inhibitor. DPP-IV as well as FAP could be detected on
the mRNA level as well as by immunohistochemistry in the xenotransplants from the U87
and U138 cells (data not shown), which suggests that their expression in glioma cells is re‐
tained under the conditions closely mimicking the microenvironment of human gliomas.
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Similarly, Li et al. [180] were able to demonstrate the enzymatic activity of FAP in a U87 tu‐
mor model, although the subcutaneous implantation used in their study exposed the glioma
cells to somewhat unnatural microenvironment. Orthotopic xenotransplantation of freshly
isolated glioma cells or expanded glioma stem-like cells are necessary to determine whether
the expression of FAP in particular is maintained in glioma cells in situ. Such experimental
approach would be suitable for the preclinical tests of therapies targeting this protease.
Figure 2. DPP-IV-like enzymatic activity detected by catalytic histochemistry in orthotopic glioma xenotransplants (A-
C). 106 cells of the indicated cell lines were used for intracerebral implantation into immunodeficient mice [118]. DPP-
IV-like enzymatic activity (red precipitate) was detected by incubating 10μm frozen sections with 7-(glycyl-l-
prolylamido)-4-methoxy-β-naphthylamide hydrochloride as a substrate and Fast Blue B in PBS (pH 7.4) at 4°C
overnight [181]. 1μM sitagliptin was used to inhibit the enzymatic activity of canonical DPP-IV (CD26), nuclei were
counterstained with haematoxylin. Only small areas of DPP-IV-like enzymatic activity (arrows) can be detected in U373
tumors (A). In (B), the dashed line marks the interface between the diffusely stained tumor tissue and surrounding
normal brain (asterisk). (D) DPP-IV-like enzymatic activity in homogenates from the xenotransplants compared to the
contralateral hemisphere. H-Gly-Pro-7-amino-4-methylcoumarin was used as a substrate at pH 7.5 and 37°C [118].
3.2. Expression of DPP-IV and related proteases in normal brain and human astrocytic
tumors
The data on the expression of DPP-IV, DPP-II, FAP and DPP8 and 9 in the human brain is
limited. Using immunohistochemistry, Bernstein et al. detected abundant expression of
DPP-IV in the immature central nervous system with much lower expression in adults [246].
In rats, mice and ginea-pigs, the expression of DPP-IV was studied in more detail and DPP-
IV was detected in the capillaries, meninges as well as certain neuronal structures (see [175]
and references therein). By means of its enzymatic activity, DPP-IV is speculated to partici‐
pate on nociception and behavior regulation most likely by inactivating biologically active
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activity together with the expression of mRNA for DPP-IV, FAP and DPP-8 and 9 in perma‐
nent glioma cell lines C6, U373, T98G, U251, U87, U138, U118 and in human glioma primary
cell cultures as well as in glioma stem-like cells ([118, 171-175] and unpublished data). The
DPP-IV-like enzymatic activity in the permanent glioma cell lines is only partially inhibited
by a highly specific DPP-IV inhibitor sitagliptin. In U87, U138 and U118 lines 30, 60 and 85%
respectively of the total enzymatic activity is inhibited and can therefore be attributed to the
canonical DPP-IV. In contrast, only 12-15% of the DPP-IV-like enzymatic activity in U373,
T98G, U251 cells is inhibited by sitagliptin (Busek et al. unpublished data). These results cor‐
respond well with the relatively high DPP-IV mRNA expression in the U87, U138 and U118
cell lines [175, 176].
FAP is also expressed in glioma cells. The early work by Rettig et al. [177] detected FAP in
19 out of 22 of astrocytoma cell lines by immunohistochemistry using the F19 monoclonal
antibody. Similarly Mentlein et al. [176] showed high FAP mRNA expression in 6 out of 7
glioma cell lines. According to our data, the expression of FAP may be more variable [118]
with substantial variation in individual primary cell cultures as well as permanent cell lines.
In the panel of glioma cell lines examined in our studies, FAP expression mirrored the ex‐
pression of DPP-IV and was substantially higher in U87, U138 and U118 cell lines than in
U373, T98G, U251 lines [175]. Therefore, although FAP is significantly less efficient in cleav‐
ing the H-Gly-Pro-AMC substrate compared to DPP-IV [48], it may partly contribute to the
sitagliptin resistant DPP-IV-like enzymatic activity in some of the glioma cells lines. Interest‐
ingly, we have consistently observed a positive correlation between the mRNA expression
of the two transmembrane proteases DPP-IV and FAP in glioma cell lines as well as in glio‐
ma primary cell cultures [178]. Moreover, the expression of both DPP-IV and FAP increased
concomitantly in glioma cells cultured in serum free media and decreased after the addition
of serum to the starved cells [178] suggesting that similar pathways regulate their expression
in this model, most likely on the transcription and/or mRNA stability levels [178]. The
mRNAs for the ubiquitous intracellular enzymes DPP8 and DPP9 are expressed in similar
quantities in the glioma cell lines tested in our laboratory and probably make the largest
contribution to the residual DPP-IV-like enzymatic activity after inhibition with sitagliptin
(Busek et al. unpublished data).
It is currently unclear to what extent the in vitro cell culture conditions and the standard
process of glioma cell line establishment may influence the observed expression of DPP-IV
and especially FAP, a known phenotypic marker of mesenchymal cells such as activated fi‐
broblasts [15]. The typical media supplemented with 10% fetal calf serum are known to pro‐
mote the mesenchymal phenotype in cultured cells (“mesenchymal drift”; [179]) which
could lead to the upregulation of FAP. Xenotransplants generated by orthotopic implanta‐
tion of the glioma cells into immunodeficient mice exhibited higher DPP-IV-like enzymatic
activity compared to the contralateral hemisphere (Figure 2) and the enzymatic activity was
in part sensitive to a specific DPP-IV inhibitor. DPP-IV as well as FAP could be detected on
the mRNA level as well as by immunohistochemistry in the xenotransplants from the U87
and U138 cells (data not shown), which suggests that their expression in glioma cells is re‐
tained under the conditions closely mimicking the microenvironment of human gliomas.
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Similarly, Li et al. [180] were able to demonstrate the enzymatic activity of FAP in a U87 tu‐
mor model, although the subcutaneous implantation used in their study exposed the glioma
cells to somewhat unnatural microenvironment. Orthotopic xenotransplantation of freshly
isolated glioma cells or expanded glioma stem-like cells are necessary to determine whether
the expression of FAP in particular is maintained in glioma cells in situ. Such experimental
approach would be suitable for the preclinical tests of therapies targeting this protease.
Figure 2. DPP-IV-like enzymatic activity detected by catalytic histochemistry in orthotopic glioma xenotransplants (A-
C). 106 cells of the indicated cell lines were used for intracerebral implantation into immunodeficient mice [118]. DPP-
IV-like enzymatic activity (red precipitate) was detected by incubating 10μm frozen sections with 7-(glycyl-l-
prolylamido)-4-methoxy-β-naphthylamide hydrochloride as a substrate and Fast Blue B in PBS (pH 7.4) at 4°C
overnight [181]. 1μM sitagliptin was used to inhibit the enzymatic activity of canonical DPP-IV (CD26), nuclei were
counterstained with haematoxylin. Only small areas of DPP-IV-like enzymatic activity (arrows) can be detected in U373
tumors (A). In (B), the dashed line marks the interface between the diffusely stained tumor tissue and surrounding
normal brain (asterisk). (D) DPP-IV-like enzymatic activity in homogenates from the xenotransplants compared to the
contralateral hemisphere. H-Gly-Pro-7-amino-4-methylcoumarin was used as a substrate at pH 7.5 and 37°C [118].
3.2. Expression of DPP-IV and related proteases in normal brain and human astrocytic
tumors
The data on the expression of DPP-IV, DPP-II, FAP and DPP8 and 9 in the human brain is
limited. Using immunohistochemistry, Bernstein et al. detected abundant expression of
DPP-IV in the immature central nervous system with much lower expression in adults [246].
In rats, mice and ginea-pigs, the expression of DPP-IV was studied in more detail and DPP-
IV was detected in the capillaries, meninges as well as certain neuronal structures (see [175]
and references therein). By means of its enzymatic activity, DPP-IV is speculated to partici‐
pate on nociception and behavior regulation most likely by inactivating biologically active
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peptides such as SP, endomorphin-2 and NP Y [182-184]. DPP-IV may also be involved in
the pathogenesis of ischemia-reperfusion injury. Roehnert et al. [185] described the appear‐
ance of DPP-IV immunoreactivity in rat microglia, astrocytes and neurons following unilat‐
eral transient occlusion of the medial carotid artery. Interestingly, intracranial
administration of a specific DPP-IV inhibitor sitagliptin led to a 21.1±5.8% decrease in infarct
size suggesting neuroprotection in this model [185].
Enzymatic activity attributed to DP-II was detected in brain homogenates [186, 187] and his‐
tochemically in specific neuronal populations in rat brain by Gorenstein et al. [188]. Later
studies demonstrated its presence in glial cells [189] and speculated its association with as‐
trocyte differentiation [190].
DPP8 and 9 are also expressed in the brain tissue [13, 52] and are probably responsible for a
significant part of the DPP-IV-like enzymatic activity detected in human brain tissue homo‐
genates [87]. In rats, DPP8 was detected in neurons, but not astroglial cells and microglia by
immunohistochemistry [185].
On the contrary, FAP protein is most likely absent in non-tumorous human brain: Rettig et
al. [177] failed to detect its expression in human autopsy material using the F19 antibody;
similarly, samples obtained from patients with pharmacoresistant epilepsy show no staining
using several anti FAP antibodies ([87] and unpublished data). Although FAP mRNA can be
detected by sensitive RT-qPCR assays [87, 176], it is probably not being translated or the
protein levels are bellow the detection limit of the methods used.
In gliomas the DPP-IV-like enzymatic activity is substantially higher compared to the non-
tumorous brain [87, 191] and DPP8 and 9 represent the major part in both cases [87]. In con‐
trast to DPP8 and 9, the expression of DPP-IV and FAP is significantly increased in gliomas
compared to the non-tumorous brain. According to The Cancer Genome Atlas ([192], http://
cancergenome.nih.gov/) DPP-IV and FAP mRNA are upregulated more than two times
compared to controls in 200 of 424 (47%) and in 162 of 424 (38%) glioblastoma patients re‐
spectively. In our patient cohort ([87] and unpublished data) DPP-IV and FAP mRNA were
upregulated 9.9 and 4.6 fold respectively in newly diagnosed glioblastoma (N=28) compared
to controls (pharmacoresistant epilepsy, N=15). Using RT-qPCR, Mentlein et al. also ob‐
served upregulation of DPP-IV and FAP in a small cohort of glioblastoma patients com‐
pared to the autopsy material [176]. Similarly, increased FAP expression in grade IV tumors
and especially in gliosarcomas was observed by Mikheeva et al. [193].
Using catalytic histochemistry, Mares et al. could show that the DPP-IV-like enzymatic ac‐
tivity in grade II astrocytomas was mainly localized perivascularly and in mononuclear-like
cells in the parenchyma [191]. In grade IV tumors (glioblastomas), the proportion of these
stained cells was markedly increased and in addition, the DPP-IV-like enzymatic activity
was present in spindle shaped, smooth muscle- or pericyte-like cells around hyperplastic
vessels, and in tumor parenchyma [191]. Interestingly, the overall DPP-IV-like enzymatic ac‐
tivity determined by catalytic histochemistry correlated negatively (r= -0.30, p= 0.04) with
the proliferation marker Ki67 [191]. Immunohistochemistry staining with DPP-IV and FAP
specific antibodies revealed minimal positivity in non-tumorous brain with frequent fiber-
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like positivity in glioblastomas, occasionally close to the capillaries [191]. Mentlein et al.
showed that at least part of the FAP expressing cells also coexpressed GFAP and Ki67 [176].
Collectively, these data demonstrate that the expression of DPP-IV and FAP as well as the
DPP-IV-like enzymatic activity is increased in a substantial part of glioblastomas. Both the
transformed as well as stromal cells such as reactive astrocytes, cells in the vessel wall and
infiltrating immune cells may contribute to this increased expression.
3.3. Possible functions of DPP-IV and FAP in the glioma microenvironment
Glioblastomas are highly heterogenous both histologically and on the molecular level [194,
195]. The transformed cells themselves represent a mixture of cell types that may originate
from the stochastic clonal expansion or from a more hierarchical organization of gliomas as
postulated by the cancer stem cell hypothesis [196, 197]. In addition to the transformed cells,
a variety of host cells contributes to the glioma microenvironment. This stromal compart‐
ment is an important contributor to the malignant phenotype of glioma cells and comprises
of microglia/macrophages, lymphocytes, neural precursor cells, neurons, pericytes/vascular
smooth muscle cells, reactive astrocytes and endothelial cells [198].
Given the marked increase of the expression of DPP-IV and FAP mRNA in glioblastoma tis‐
sue homogenates and the increase of the DPP-IV-like enzymatic activity in the microvascu‐
lature and parenchyma, the proteases seem to be functionally important for the transformed
as well as nontransformed cells.
3.3.1. DPP-IV as a possible regulator of glioma cell growth
The DPP-IV-like enzymatic activity may influence signaling of various soluble mediators in‐
volved in the pathogenesis of gliomas (Table 1).
DPP-IV substrate Role in gliomagenesis
CCL3L1 (LD78beta) Enhances glioma cell proliferation[199].
CCL5
Possible role in the recruitment of microglia/macrophages [200], promotion of
glioma invasion and angiogenesis [201].
CCL22 Recruitment of immunosuppressive Treg cells [202, 203].
CXCL9 Increased expression in glioblastoma [204], promotes glioma cell growth [205].
CXCL10 Pro-proliferative signaling through ERK1/2 in glioma cells [205, 206].
CXCL11
A ligand for CXCR7, which mediates prosurvival signaling in glioma cells [207,
208].
CXCL12 Promotion of glioma invasion, growth and angiogenesis (for review see [209])
SP Promotion of glioma growth and secretion of cytokines (reviewed in [210, 211]).
PACAP, VIP Stimulation of glioma cell growth [212, 213].
Table 1. DPP-IV substrates implicated in the pathogenesis of gliomas
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peptides such as SP, endomorphin-2 and NP Y [182-184]. DPP-IV may also be involved in
the pathogenesis of ischemia-reperfusion injury. Roehnert et al. [185] described the appear‐
ance of DPP-IV immunoreactivity in rat microglia, astrocytes and neurons following unilat‐
eral transient occlusion of the medial carotid artery. Interestingly, intracranial
administration of a specific DPP-IV inhibitor sitagliptin led to a 21.1±5.8% decrease in infarct
size suggesting neuroprotection in this model [185].
Enzymatic activity attributed to DP-II was detected in brain homogenates [186, 187] and his‐
tochemically in specific neuronal populations in rat brain by Gorenstein et al. [188]. Later
studies demonstrated its presence in glial cells [189] and speculated its association with as‐
trocyte differentiation [190].
DPP8 and 9 are also expressed in the brain tissue [13, 52] and are probably responsible for a
significant part of the DPP-IV-like enzymatic activity detected in human brain tissue homo‐
genates [87]. In rats, DPP8 was detected in neurons, but not astroglial cells and microglia by
immunohistochemistry [185].
On the contrary, FAP protein is most likely absent in non-tumorous human brain: Rettig et
al. [177] failed to detect its expression in human autopsy material using the F19 antibody;
similarly, samples obtained from patients with pharmacoresistant epilepsy show no staining
using several anti FAP antibodies ([87] and unpublished data). Although FAP mRNA can be
detected by sensitive RT-qPCR assays [87, 176], it is probably not being translated or the
protein levels are bellow the detection limit of the methods used.
In gliomas the DPP-IV-like enzymatic activity is substantially higher compared to the non-
tumorous brain [87, 191] and DPP8 and 9 represent the major part in both cases [87]. In con‐
trast to DPP8 and 9, the expression of DPP-IV and FAP is significantly increased in gliomas
compared to the non-tumorous brain. According to The Cancer Genome Atlas ([192], http://
cancergenome.nih.gov/) DPP-IV and FAP mRNA are upregulated more than two times
compared to controls in 200 of 424 (47%) and in 162 of 424 (38%) glioblastoma patients re‐
spectively. In our patient cohort ([87] and unpublished data) DPP-IV and FAP mRNA were
upregulated 9.9 and 4.6 fold respectively in newly diagnosed glioblastoma (N=28) compared
to controls (pharmacoresistant epilepsy, N=15). Using RT-qPCR, Mentlein et al. also ob‐
served upregulation of DPP-IV and FAP in a small cohort of glioblastoma patients com‐
pared to the autopsy material [176]. Similarly, increased FAP expression in grade IV tumors
and especially in gliosarcomas was observed by Mikheeva et al. [193].
Using catalytic histochemistry, Mares et al. could show that the DPP-IV-like enzymatic ac‐
tivity in grade II astrocytomas was mainly localized perivascularly and in mononuclear-like
cells in the parenchyma [191]. In grade IV tumors (glioblastomas), the proportion of these
stained cells was markedly increased and in addition, the DPP-IV-like enzymatic activity
was present in spindle shaped, smooth muscle- or pericyte-like cells around hyperplastic
vessels, and in tumor parenchyma [191]. Interestingly, the overall DPP-IV-like enzymatic ac‐
tivity determined by catalytic histochemistry correlated negatively (r= -0.30, p= 0.04) with
the proliferation marker Ki67 [191]. Immunohistochemistry staining with DPP-IV and FAP
specific antibodies revealed minimal positivity in non-tumorous brain with frequent fiber-
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like positivity in glioblastomas, occasionally close to the capillaries [191]. Mentlein et al.
showed that at least part of the FAP expressing cells also coexpressed GFAP and Ki67 [176].
Collectively, these data demonstrate that the expression of DPP-IV and FAP as well as the
DPP-IV-like enzymatic activity is increased in a substantial part of glioblastomas. Both the
transformed as well as stromal cells such as reactive astrocytes, cells in the vessel wall and
infiltrating immune cells may contribute to this increased expression.
3.3. Possible functions of DPP-IV and FAP in the glioma microenvironment
Glioblastomas are highly heterogenous both histologically and on the molecular level [194,
195]. The transformed cells themselves represent a mixture of cell types that may originate
from the stochastic clonal expansion or from a more hierarchical organization of gliomas as
postulated by the cancer stem cell hypothesis [196, 197]. In addition to the transformed cells,
a variety of host cells contributes to the glioma microenvironment. This stromal compart‐
ment is an important contributor to the malignant phenotype of glioma cells and comprises
of microglia/macrophages, lymphocytes, neural precursor cells, neurons, pericytes/vascular
smooth muscle cells, reactive astrocytes and endothelial cells [198].
Given the marked increase of the expression of DPP-IV and FAP mRNA in glioblastoma tis‐
sue homogenates and the increase of the DPP-IV-like enzymatic activity in the microvascu‐
lature and parenchyma, the proteases seem to be functionally important for the transformed
as well as nontransformed cells.
3.3.1. DPP-IV as a possible regulator of glioma cell growth
The DPP-IV-like enzymatic activity may influence signaling of various soluble mediators in‐
volved in the pathogenesis of gliomas (Table 1).
DPP-IV substrate Role in gliomagenesis
CCL3L1 (LD78beta) Enhances glioma cell proliferation[199].
CCL5
Possible role in the recruitment of microglia/macrophages [200], promotion of
glioma invasion and angiogenesis [201].
CCL22 Recruitment of immunosuppressive Treg cells [202, 203].
CXCL9 Increased expression in glioblastoma [204], promotes glioma cell growth [205].
CXCL10 Pro-proliferative signaling through ERK1/2 in glioma cells [205, 206].
CXCL11
A ligand for CXCR7, which mediates prosurvival signaling in glioma cells [207,
208].
CXCL12 Promotion of glioma invasion, growth and angiogenesis (for review see [209])
SP Promotion of glioma growth and secretion of cytokines (reviewed in [210, 211]).
PACAP, VIP Stimulation of glioma cell growth [212, 213].
Table 1. DPP-IV substrates implicated in the pathogenesis of gliomas
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Although DPP-IV and FAP exhibit similar dipeptidyl peptidase activity on small fluorogen‐
ic substrates, a recent study found substantial differences in their ability to cleave peptide
substrates [79]. All peptides (with the exception of VIP) listed in Table 1 are cleaved rapidly
by recombinant DPP-IV; in contrast FAP can only cleave SP effectively and does not cleave
chemokines, PACAP or VIP [79](Figure 1). Given that, DPP-IV is the main candidate for in‐
fluencing the functions of these mediators in gliomas.
By removing the N-terminal dipeptide from the biologically active peptides, DPP-IV in gen‐
eral diminishes their activity and/or increases their susceptibility to cleavage by other pro‐
teases [73]. Given that the majority of the substrates listed in Table 1 are thought to promote
the malignant phenotype of glioma cells, DPP-IV would be somewhat paradoxically expect‐
ed to suppress it. Indeed, we have previously shown the ability of DPP-IV to abrogate the
calcium mediated signaling of SP in glioma cells [214]. We also observed that higher DPP-
IV-like enzymatic activity in primary glioma cell cultures correlated with their slower
growth [118]. In addition, overexpression of the transgenic DPP-IV in several glioma cell
lines decreased their proliferation, led to a cell cycle block and a 50% decrease of the size of
xenotransplanted tumors in immunodeficient mice [118]. Interestingly, our microarray data
suggested that expression of several molecules linked to glioma pathogenesis was perturbed
in glioma cells with forced expression of DPP-IV [118]. This included e.g. downregulated ex‐
pression of transcripts encoding membrane growth factor receptors (PDGFRA, CALCRL,
GRPR) and adhesion molecules (CD97, COL8A1, COL13A1, NLGN1, NLGN4X, PCDH20,
SCARF2, NrCAM) as well as molecules typically overexpressed in gliomas (e.g. CALCRL,
COL8A1, HAS2, NES, RRM2 [192], http://cancergenome.nih.gov). On the contrary, several
tumor suppressors e.g. BEX2, RAP1GAP, DUSP26, SYT13, TSPYL2 were upregulated ([118]
and references therein). In order to determine whether the observed in vitro and in vivo
growth inhibitory effects were mediated by the enzymatic activity, the experiments were
done in parallel with cells transfected with an enzymatically inactive mutant DPP-IV due to
a single amino acid (Ser630→Ala630) substitution in the active site [118]. These studies re‐
vealed similarly decreased growth of glioma cells overexpressing the enzymatically inactive
DPP-IV providing evidence that these effects were independent of the enzymatic activity
[118]. In summary, our studies demonstrate that DPP-IV may modify the function of its sub‐
strates through proteolysis, but likely has also an enzymatic activity independent growth in‐
hibitory effect in glioma cells. The detailed molecular mechanism(s) for these effects
however remain to be identified.
These data strongly argue that DPP-IV in glioma cells in vivo is unlikely to directly promote
the malignant potential of the expressing cells. However, DPP-IV did not suppress the ma‐
lignant phenotype of glioma cells completely in our studies – albeit the tumors were smaller
with lower percentage of Ki67 positive nuclei, they exhibited an infiltrative growth pattern
similar to controls [118]. We also observed a highly infiltrative growth of the xenotrans‐
planted glioma stem-like cells expressing DPP-IV (Busek et al. unpublished). Several possi‐
bilities exist to explain these seeming contradictions: i) DPP-IV expression / enzymatic
activity may reflect a mechanism striving to prevent the inappropriate proliferation of ma‐
lignant cells. In support of this possibility, Mares et al. [191] observed an inverse correlation
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between the DPP-IV-like enzymatic activity and Ki67 in glioblastoma tissues. On the other
hand, these less proliferative cells may be more resistant to conventional adjuvant therapies
and therefore contribute to tumor recurrence. ii) Glioblastomas are highly heterogeneous
and likely composed of several interacting subpopulations establishing a complex “ecosys‐
tem” [197]. DPP-IV may contribute to the interaction with other tumor clones and/or stromal
compartment by local proteolytic processing of biologically active peptides with an overall
increased tumor growth despite its growth inhibitory effects in the expressing subpopula‐
tion. Such a role of DPP-IV could not have been identified using conventional cell-line based
xenotransplantation models in immunodeficient animals utilized in our studies. iii) DPP-IV
expression may also be linked to the microenvironment typical of glioblastomas. The grade
IV tumors characteristically contain necrotic areas and exhibit enormous stimulation of an‐
giogenesis caused by hypoxia. Hypoxia also promotes the aggressiveness of glioma cells
through the transcription factor HIF-1α (hypoxia inducible factor-1α) [215]. DPP-IV was
demonstrated to be regulated by hypoxia in several systems although with variable out‐
comes. In extravillous trophoblast cells, the hypoxia induced increase of DPP-IV was associ‐
ated with their decreased invasiveness [216]. In colon and gastric cancer cell lines, DPP-IV
was increased in a HIF-1α dependent manner in response to hypoxia in vitro and in xeno‐
transplants depleted of VEGF [217]. The purpose of this induction of DPP-IV in the response
to hypoxia is not clear. The data from other experimental systems nevertheless suggest that
by promoting the expression of DPP-IV together with the angiogenic receptor Y2, ischemia
may enhance the angiogenic response to NPY [218, 219].
In addition to the transformed glioma cells, DPP-IV is also increased in the microvasculature
[191]. Here, DPP-IV may contribute to neoangiogenesis by promoting the proliferation and
invasiveness of endothelial cells.
In summary, higher expression of DPP-IV is typical for glioblastomas. Although the func‐
tion of the protease cannot be currently ascribed with certainty, it may negatively affect glio‐
ma cell proliferation even independent of its enzymatic activity [118] and participate on the
pericellular proteolysis with possible paracrine effects on other tumor subpopulations in‐
cluding stromal cells. The functional significance of DPP-IV upregulation in the glioma stro‐
mal compartment remains to be established.
3.3.2. Implications of FAP for glioma migration, ECM remodeling and angiogenesis
Several reports suggest a possible role of FAP in glioma cell migration not only because of
its role in the extracranial malignancies (section 2.1). Lal et al. [220] studied the phenotypic
and molecular changes caused by the introduction of the activating mutant form of EGFR
(EGFRvIII) into glioma cells with low EGFR expression. They observed increased invasive‐
ness of the EGFRvIII transduced cells, which was accompanied by upregulation of several
transcripts encoding proteins of the extracellular matrix and proteases, including FAP [220].
A similarly designed study tested the effects of the introduction of IGFBP2, a molecule with
pleiotrophic roles in glioblastoma [221], into the SNB19 glioma cell line. Here, increased in‐
vasion was also observed and FAP was among the 28 significantly induced genes with a 4.5
to 16 fold increase in different clones according to the microarray data [222]. Likewise, intro‐
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Although DPP-IV and FAP exhibit similar dipeptidyl peptidase activity on small fluorogen‐
ic substrates, a recent study found substantial differences in their ability to cleave peptide
substrates [79]. All peptides (with the exception of VIP) listed in Table 1 are cleaved rapidly
by recombinant DPP-IV; in contrast FAP can only cleave SP effectively and does not cleave
chemokines, PACAP or VIP [79](Figure 1). Given that, DPP-IV is the main candidate for in‐
fluencing the functions of these mediators in gliomas.
By removing the N-terminal dipeptide from the biologically active peptides, DPP-IV in gen‐
eral diminishes their activity and/or increases their susceptibility to cleavage by other pro‐
teases [73]. Given that the majority of the substrates listed in Table 1 are thought to promote
the malignant phenotype of glioma cells, DPP-IV would be somewhat paradoxically expect‐
ed to suppress it. Indeed, we have previously shown the ability of DPP-IV to abrogate the
calcium mediated signaling of SP in glioma cells [214]. We also observed that higher DPP-
IV-like enzymatic activity in primary glioma cell cultures correlated with their slower
growth [118]. In addition, overexpression of the transgenic DPP-IV in several glioma cell
lines decreased their proliferation, led to a cell cycle block and a 50% decrease of the size of
xenotransplanted tumors in immunodeficient mice [118]. Interestingly, our microarray data
suggested that expression of several molecules linked to glioma pathogenesis was perturbed
in glioma cells with forced expression of DPP-IV [118]. This included e.g. downregulated ex‐
pression of transcripts encoding membrane growth factor receptors (PDGFRA, CALCRL,
GRPR) and adhesion molecules (CD97, COL8A1, COL13A1, NLGN1, NLGN4X, PCDH20,
SCARF2, NrCAM) as well as molecules typically overexpressed in gliomas (e.g. CALCRL,
COL8A1, HAS2, NES, RRM2 [192], http://cancergenome.nih.gov). On the contrary, several
tumor suppressors e.g. BEX2, RAP1GAP, DUSP26, SYT13, TSPYL2 were upregulated ([118]
and references therein). In order to determine whether the observed in vitro and in vivo
growth inhibitory effects were mediated by the enzymatic activity, the experiments were
done in parallel with cells transfected with an enzymatically inactive mutant DPP-IV due to
a single amino acid (Ser630→Ala630) substitution in the active site [118]. These studies re‐
vealed similarly decreased growth of glioma cells overexpressing the enzymatically inactive
DPP-IV providing evidence that these effects were independent of the enzymatic activity
[118]. In summary, our studies demonstrate that DPP-IV may modify the function of its sub‐
strates through proteolysis, but likely has also an enzymatic activity independent growth in‐
hibitory effect in glioma cells. The detailed molecular mechanism(s) for these effects
however remain to be identified.
These data strongly argue that DPP-IV in glioma cells in vivo is unlikely to directly promote
the malignant potential of the expressing cells. However, DPP-IV did not suppress the ma‐
lignant phenotype of glioma cells completely in our studies – albeit the tumors were smaller
with lower percentage of Ki67 positive nuclei, they exhibited an infiltrative growth pattern
similar to controls [118]. We also observed a highly infiltrative growth of the xenotrans‐
planted glioma stem-like cells expressing DPP-IV (Busek et al. unpublished). Several possi‐
bilities exist to explain these seeming contradictions: i) DPP-IV expression / enzymatic
activity may reflect a mechanism striving to prevent the inappropriate proliferation of ma‐
lignant cells. In support of this possibility, Mares et al. [191] observed an inverse correlation
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between the DPP-IV-like enzymatic activity and Ki67 in glioblastoma tissues. On the other
hand, these less proliferative cells may be more resistant to conventional adjuvant therapies
and therefore contribute to tumor recurrence. ii) Glioblastomas are highly heterogeneous
and likely composed of several interacting subpopulations establishing a complex “ecosys‐
tem” [197]. DPP-IV may contribute to the interaction with other tumor clones and/or stromal
compartment by local proteolytic processing of biologically active peptides with an overall
increased tumor growth despite its growth inhibitory effects in the expressing subpopula‐
tion. Such a role of DPP-IV could not have been identified using conventional cell-line based
xenotransplantation models in immunodeficient animals utilized in our studies. iii) DPP-IV
expression may also be linked to the microenvironment typical of glioblastomas. The grade
IV tumors characteristically contain necrotic areas and exhibit enormous stimulation of an‐
giogenesis caused by hypoxia. Hypoxia also promotes the aggressiveness of glioma cells
through the transcription factor HIF-1α (hypoxia inducible factor-1α) [215]. DPP-IV was
demonstrated to be regulated by hypoxia in several systems although with variable out‐
comes. In extravillous trophoblast cells, the hypoxia induced increase of DPP-IV was associ‐
ated with their decreased invasiveness [216]. In colon and gastric cancer cell lines, DPP-IV
was increased in a HIF-1α dependent manner in response to hypoxia in vitro and in xeno‐
transplants depleted of VEGF [217]. The purpose of this induction of DPP-IV in the response
to hypoxia is not clear. The data from other experimental systems nevertheless suggest that
by promoting the expression of DPP-IV together with the angiogenic receptor Y2, ischemia
may enhance the angiogenic response to NPY [218, 219].
In addition to the transformed glioma cells, DPP-IV is also increased in the microvasculature
[191]. Here, DPP-IV may contribute to neoangiogenesis by promoting the proliferation and
invasiveness of endothelial cells.
In summary, higher expression of DPP-IV is typical for glioblastomas. Although the func‐
tion of the protease cannot be currently ascribed with certainty, it may negatively affect glio‐
ma cell proliferation even independent of its enzymatic activity [118] and participate on the
pericellular proteolysis with possible paracrine effects on other tumor subpopulations in‐
cluding stromal cells. The functional significance of DPP-IV upregulation in the glioma stro‐
mal compartment remains to be established.
3.3.2. Implications of FAP for glioma migration, ECM remodeling and angiogenesis
Several reports suggest a possible role of FAP in glioma cell migration not only because of
its role in the extracranial malignancies (section 2.1). Lal et al. [220] studied the phenotypic
and molecular changes caused by the introduction of the activating mutant form of EGFR
(EGFRvIII) into glioma cells with low EGFR expression. They observed increased invasive‐
ness of the EGFRvIII transduced cells, which was accompanied by upregulation of several
transcripts encoding proteins of the extracellular matrix and proteases, including FAP [220].
A similarly designed study tested the effects of the introduction of IGFBP2, a molecule with
pleiotrophic roles in glioblastoma [221], into the SNB19 glioma cell line. Here, increased in‐
vasion was also observed and FAP was among the 28 significantly induced genes with a 4.5
to 16 fold increase in different clones according to the microarray data [222]. Likewise, intro‐
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duction of TWIST1, a basic helix-loop-helix domain-containing transcription factor implicat‐
ed in EMT (epithelial mesenchymal transition) and cancer metastasis [223], into glioma cells
promoted their invasion and among other genes activated the expression of FAP [193]. Ta‐
tenhorst et al. [247] took a different approach and compared the expression profile in two
subpopulations isolated from the U373 glioma cell line based on their differing migratory
rates on Matrigel. FAP was the top upregulated gene (11.7 fold) in the clone with high mi‐
gration in vitro. Although these studies do not provide direct evidence that FAP contributes
to the high migration and invasiveness characteristic for glioma cells, they strongly suggest
an association of FAP expression with the glioma migratory phenotype and its activation in
response to molecular abnormalities frequently occurring in glioblastomas. Mentlein et al.
[176] addressed the role of FAP in glioma migration directly by siRNA mediated downregu‐
lation in the A746 glioma cell line. No effect on cell migration was noted in the transwell
assay when uncoated or Matrigel coated inserts were used [176]. However, the cells invaded
slightly less efficiently through the gelatin coated inserts and their invasion through brevi‐
can, a chondroitin sulfate proteoglycan abundantly present in the adult human brain, was
reduced by almost 50% [176]. The underlying mechanisms remain to be established. The ex‐
tracellular matrix of gliomas is substantially different from the extracranial malignancies:
the fibrillary proteins (e.g. collagens, fibronectin, laminin) are much less abundant and most‐
ly present in the perivascular space. Instead, hyaluronic acid and associated proteins such as
versican and brevican prevail [224, 225]. Although Mentlein et al. [176] demonstrated that
FAP cleaved brevican, the cleavage by the recombinant protease was inefficient and re‐
quired prolonged incubations. Thus, the siRNA mediated downregulation of FAP in glioma
cells could instead have effects on other ECM degrading systems. FAP is known to be part
of multiprotein complexes in invadopodia [153, 226] and it was demonstrated to physically
interact with uPAR in a β1-integrin dependent manner [121]. Interestingly, simultaneous
downregulation of uPAR and cathepsin B was shown to downregulate FAP in glioma cells
[227]. FAP therefore seems to act in cooperation with other proteolytic systems and its pres‐
ence may influence the remodeling of glioma ECM not only by its intrinsic gelatinolytic ac‐
tivity but also by its possible role in the formation and/or stabilization of invadopodia.
Another interesting but unexplored aspect is the possible role of FAP in the promotion of
angiogenesis of glioblastomas. The expression of FAP in endothelial cells [145, 146], higher
microvessel densities in breast cancer xenotransplants engineered to express FAP [127] and
the decreased microvessel density in response to FAP ablation in a lung cancer model con‐
sistently imply its role in angiogenesis. This may be –similarly to DPP-IV– via the processing
of NP Y 1-36 to an angiogenic NP Y 3-36 [228]. In addition, FAP expressing fibroblasts are
able to modify collagen type I matrices in a way that promotes the invasion of tumor cells
(see section 2.2, [158]). Possibly, FAP may participate on the transformation of the glioma
extracellular matrix into an environment that would be more supportive for the migration of
endothelial cells [15].
Glioblastomas typically contain necrotic areas surrounded by pseudopalisades. A model for
the pathogenesis of this typical morphological feature of glioblastoma has been proposed
[229, 230] and postulates that thrombotic occlusion of the central vessel results in hypoxia,
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which than drives the migration of the surrounding glioma cells and robustly stimulates an‐
giogenesis. Several mechanisms likely contribute to the vaso-occlusive process including the
leakage of plasma clotting factors through the damaged vessels and their contact with a pro‐
coagulant tumor environment (see [231] for review). FAP was previously demonstrated to
be identical with α2-antiplasmin cleaving enzyme [42]. Upon conversion by FAP, α2-anti‐
plasmin is more effectively incorporated into fibrin and protects the fibrin clot from plasmin
degradation [232]. By this mechanism, FAP may contribute to the prothrombogenic state in
glioblastoma with resulting development of necrosis and stimulation of angiogenesis. The
speculated mechanisms listed above are mediated by the DPP-IV-like or prolyl- endopepti‐
dase enzymatic activities of FAP. In addition, FAP has probably other, enzymatic activity in‐
dependent pro-angiogenic effects as recently demonstrated in breast cancer using
catalytically inactive mutant FAP [15, 128].
4. DPP-IV and FAP as possible markers and treatment targets in gliomas?
Glioblastomas have dismal prognosis and despite the multimodality treatment the majority
of patients die within 10-14 months [248, 249]. Regardless of ongoing efforts, the pathogene‐
sis of glioblastoma remains unknown and therefore specific targeted therapies are currently
not available. Despite their rather peculiar role in cancer pathogenesis, both DPP-IV and
FAP were suggested as diagnostic and prognostic markers and therapeutic targets for tu‐
mors outside of the central nervous system (reviewed in [15, 88]). DPP-IV staining was sug‐
gested as a useful adjunct marker for the differentiation of malignant melanomas from deep
penetrating nevi [101] and benign and malignant diseases of the thyroid gland [93, 233]. To
the best of our knowledge, there is only one study suggesting a possible prognostic rele‐
vance of DASH molecules in the brain tumors. Shaw et al. [234] studied the expression sig‐
nature that was related to the chemosensitivity of oligodendroglial tumors and observed
that FAP was downregulated several fold in tumors that were chemosensitive and/or exhib‐
ited the prognostically favorable 1p/19q loss [234].
Preclinical studies with DPP-IV targeting antibodies suggest that DPP-IV may be a new
therapeutic target in malignant mesothelioma [96, 97], renal carcinoma [235] and some hem‐
atologic malignancies [236]. The highly selective expression of FAP in the tumor microenvir‐
onment and its expected direct pathogenetic participation on tumor progression has also
raised interest in its possible therapeutic exploitation with a simultaneous impact not only
on the transformed cells, but also on the stromal elements („stroma targeted therapies“)
[138]. Experimentally, FAP specific antibodies were utilized for the targeting of TNF alpha
carrying nanoparticles [237] or in the form of a chimeric protein with the extracellular do‐
main of the ligand of the TNF receptor 4-1BB to enhance the local T cell-mediated antitumor
responses [238]. Further, induction of immune response against FAP leads to a decreased tu‐
mor growth and an enhanced effect of cytostatic therapy in several experimental models
[239-242]. FAP activated cytotoxic prodrugs have also been designed [243] and the inhibi‐
tion of FAP enzymatic activity by specific low molecular weight inhibitors was tested in ex‐
perimental myeloma treatment [18].
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duction of TWIST1, a basic helix-loop-helix domain-containing transcription factor implicat‐
ed in EMT (epithelial mesenchymal transition) and cancer metastasis [223], into glioma cells
promoted their invasion and among other genes activated the expression of FAP [193]. Ta‐
tenhorst et al. [247] took a different approach and compared the expression profile in two
subpopulations isolated from the U373 glioma cell line based on their differing migratory
rates on Matrigel. FAP was the top upregulated gene (11.7 fold) in the clone with high mi‐
gration in vitro. Although these studies do not provide direct evidence that FAP contributes
to the high migration and invasiveness characteristic for glioma cells, they strongly suggest
an association of FAP expression with the glioma migratory phenotype and its activation in
response to molecular abnormalities frequently occurring in glioblastomas. Mentlein et al.
[176] addressed the role of FAP in glioma migration directly by siRNA mediated downregu‐
lation in the A746 glioma cell line. No effect on cell migration was noted in the transwell
assay when uncoated or Matrigel coated inserts were used [176]. However, the cells invaded
slightly less efficiently through the gelatin coated inserts and their invasion through brevi‐
can, a chondroitin sulfate proteoglycan abundantly present in the adult human brain, was
reduced by almost 50% [176]. The underlying mechanisms remain to be established. The ex‐
tracellular matrix of gliomas is substantially different from the extracranial malignancies:
the fibrillary proteins (e.g. collagens, fibronectin, laminin) are much less abundant and most‐
ly present in the perivascular space. Instead, hyaluronic acid and associated proteins such as
versican and brevican prevail [224, 225]. Although Mentlein et al. [176] demonstrated that
FAP cleaved brevican, the cleavage by the recombinant protease was inefficient and re‐
quired prolonged incubations. Thus, the siRNA mediated downregulation of FAP in glioma
cells could instead have effects on other ECM degrading systems. FAP is known to be part
of multiprotein complexes in invadopodia [153, 226] and it was demonstrated to physically
interact with uPAR in a β1-integrin dependent manner [121]. Interestingly, simultaneous
downregulation of uPAR and cathepsin B was shown to downregulate FAP in glioma cells
[227]. FAP therefore seems to act in cooperation with other proteolytic systems and its pres‐
ence may influence the remodeling of glioma ECM not only by its intrinsic gelatinolytic ac‐
tivity but also by its possible role in the formation and/or stabilization of invadopodia.
Another interesting but unexplored aspect is the possible role of FAP in the promotion of
angiogenesis of glioblastomas. The expression of FAP in endothelial cells [145, 146], higher
microvessel densities in breast cancer xenotransplants engineered to express FAP [127] and
the decreased microvessel density in response to FAP ablation in a lung cancer model con‐
sistently imply its role in angiogenesis. This may be –similarly to DPP-IV– via the processing
of NP Y 1-36 to an angiogenic NP Y 3-36 [228]. In addition, FAP expressing fibroblasts are
able to modify collagen type I matrices in a way that promotes the invasion of tumor cells
(see section 2.2, [158]). Possibly, FAP may participate on the transformation of the glioma
extracellular matrix into an environment that would be more supportive for the migration of
endothelial cells [15].
Glioblastomas typically contain necrotic areas surrounded by pseudopalisades. A model for
the pathogenesis of this typical morphological feature of glioblastoma has been proposed
[229, 230] and postulates that thrombotic occlusion of the central vessel results in hypoxia,
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which than drives the migration of the surrounding glioma cells and robustly stimulates an‐
giogenesis. Several mechanisms likely contribute to the vaso-occlusive process including the
leakage of plasma clotting factors through the damaged vessels and their contact with a pro‐
coagulant tumor environment (see [231] for review). FAP was previously demonstrated to
be identical with α2-antiplasmin cleaving enzyme [42]. Upon conversion by FAP, α2-anti‐
plasmin is more effectively incorporated into fibrin and protects the fibrin clot from plasmin
degradation [232]. By this mechanism, FAP may contribute to the prothrombogenic state in
glioblastoma with resulting development of necrosis and stimulation of angiogenesis. The
speculated mechanisms listed above are mediated by the DPP-IV-like or prolyl- endopepti‐
dase enzymatic activities of FAP. In addition, FAP has probably other, enzymatic activity in‐
dependent pro-angiogenic effects as recently demonstrated in breast cancer using
catalytically inactive mutant FAP [15, 128].
4. DPP-IV and FAP as possible markers and treatment targets in gliomas?
Glioblastomas have dismal prognosis and despite the multimodality treatment the majority
of patients die within 10-14 months [248, 249]. Regardless of ongoing efforts, the pathogene‐
sis of glioblastoma remains unknown and therefore specific targeted therapies are currently
not available. Despite their rather peculiar role in cancer pathogenesis, both DPP-IV and
FAP were suggested as diagnostic and prognostic markers and therapeutic targets for tu‐
mors outside of the central nervous system (reviewed in [15, 88]). DPP-IV staining was sug‐
gested as a useful adjunct marker for the differentiation of malignant melanomas from deep
penetrating nevi [101] and benign and malignant diseases of the thyroid gland [93, 233]. To
the best of our knowledge, there is only one study suggesting a possible prognostic rele‐
vance of DASH molecules in the brain tumors. Shaw et al. [234] studied the expression sig‐
nature that was related to the chemosensitivity of oligodendroglial tumors and observed
that FAP was downregulated several fold in tumors that were chemosensitive and/or exhib‐
ited the prognostically favorable 1p/19q loss [234].
Preclinical studies with DPP-IV targeting antibodies suggest that DPP-IV may be a new
therapeutic target in malignant mesothelioma [96, 97], renal carcinoma [235] and some hem‐
atologic malignancies [236]. The highly selective expression of FAP in the tumor microenvir‐
onment and its expected direct pathogenetic participation on tumor progression has also
raised interest in its possible therapeutic exploitation with a simultaneous impact not only
on the transformed cells, but also on the stromal elements („stroma targeted therapies“)
[138]. Experimentally, FAP specific antibodies were utilized for the targeting of TNF alpha
carrying nanoparticles [237] or in the form of a chimeric protein with the extracellular do‐
main of the ligand of the TNF receptor 4-1BB to enhance the local T cell-mediated antitumor
responses [238]. Further, induction of immune response against FAP leads to a decreased tu‐
mor growth and an enhanced effect of cytostatic therapy in several experimental models
[239-242]. FAP activated cytotoxic prodrugs have also been designed [243] and the inhibi‐
tion of FAP enzymatic activity by specific low molecular weight inhibitors was tested in ex‐
perimental myeloma treatment [18].
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Several important issues arise when designing treatment modalities targeting the DASH
molecules by enzyme inhibitors or antibodies. In the case of DPP-IV, its almost ubiquitous
presence, combined with multiple tissue specific biological roles, increases the risk of on-tar‐
get side effects. In this respect, the restricted expression of FAP seems to be a substantial ad‐
vantage. Further, the similar enzymatic properties of DASH proteases represent a possible
source of off-target side effects [19]. Such a problem may be avoided by using highly specific
inhibitors as documented by the successful introduction of DPP-IV inhibitors into clinical
practice for the treatment of diabetes mellitus [244]. On the other hand, the moonlighting na‐
ture of the DASH molecules (combination of enzymatic and non-enzymatic functions),
might hypothetically represent an advantage for their targeting as the non-enzymatic func‐
tions would remain untouched when using low molecular weight inhibitors to block the en‐
zymatic functions.
In conclusion, given the emerging role of DPP-IV and FAP in the processes of gliomagenesis
and the precedent evidence for their possible therapeutic exploitation in extracranial malig‐
nancies, they seem to be promising candidates for the targeting of gliomas.
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Several important issues arise when designing treatment modalities targeting the DASH
molecules by enzyme inhibitors or antibodies. In the case of DPP-IV, its almost ubiquitous
presence, combined with multiple tissue specific biological roles, increases the risk of on-tar‐
get side effects. In this respect, the restricted expression of FAP seems to be a substantial ad‐
vantage. Further, the similar enzymatic properties of DASH proteases represent a possible
source of off-target side effects [19]. Such a problem may be avoided by using highly specific
inhibitors as documented by the successful introduction of DPP-IV inhibitors into clinical
practice for the treatment of diabetes mellitus [244]. On the other hand, the moonlighting na‐
ture of the DASH molecules (combination of enzymatic and non-enzymatic functions),
might hypothetically represent an advantage for their targeting as the non-enzymatic func‐
tions would remain untouched when using low molecular weight inhibitors to block the en‐
zymatic functions.
In conclusion, given the emerging role of DPP-IV and FAP in the processes of gliomagenesis
and the precedent evidence for their possible therapeutic exploitation in extracranial malig‐
nancies, they seem to be promising candidates for the targeting of gliomas.
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1. Introduction
A cancer of the brain that arises from supporting tissue (glial cells) is referred to as a glioma.
Glioblastomas are fast growing gliomas and can be referred to as a Grade IV astrocytomas or
glioblastoma multiformes (GBMs). GBMs that affect the brain do not readily spread to parts
of the body outside of the brain, but they are highly invasive and invade surrounding tissue
in the brain. The persistent invasiveness, which is extremely difficult to reverse, is what makes
GBMs so deadly. Therapeutic regimens for GBM and other high grade gliomas have fallen
short of providing effective treatment. Clinical studies comparing chemotherapeutic agents
have indicated increased tumor shrinkage and a very slight increase in median survival times,
but no evidence for an increase in survival rates [1, 2]. More recent clinical studies employing
surgery with the use of chemotherapeutic regimens in combination with radiation therapy or
by receptor mediated growth hormone deprivation are slightly more effective in increasing
median survival times, but again have had limited success in increasing the overall survival
rate in patients being treated for primary or recurrent GBM [3-7]. Clinicians and neurosurgeons
are diligently pursuing new treatments and provide hope for patients and their families [8, 9].
However, the difficulties of complete resection, the resistance to radiation and other therapies
and particularly the intractable malignant invasiveness still remains at the root of the very
poor survival prognosis for patients with GBM and other high grade gliomas. Despite
extensive studies regarding the clinical aspects of GBM very little is known about the behavior
of GBM during apoptosis. The ideas pursued in this paper are relevant to apoptotic cells within
a glioma enhancing the invasiveness of the apoptotic resistant cells and thus contributing to
the tumor’s malignant properties.
Apoptosis is a type of cell death in which there is a multipath sequence of programmed events
within the cell. These events require energy and lead to a suicidal self-destruction of the cell
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without releasing intracellular components to the surrounding area. The apoptotic process is
accompanied by numerous biochemical changes within the cell that are manifested by
morphological changes which include blebbing, cell shrinkage, chromatin condensation and
DNA fragmentation. The etymological origins of the word apoptosis is a Greek term meaning
“falling off” and first appeared in a publication in 1972 by Kerr and his colleagues [10]. Over
the past four decades apoptosis has been extensively studied [11]. Apoptosis is considered an
essential physiological process in eukaryotes which impacts embryonic development, tissue
homeostasis, wound healing, elimination of cells by the immune response and is an important
process in the elimination of malignant or potentially malignant cells. For a tumor mass to
arise, the cells within the cancerous tumor in some way had to escape apoptosis. The cancerous
cell type that emerges requires clinical treatment by surgical, radiological and chemothera‐
peutic techniques. It is well known that all radiological and pharmacological treatments of
cancerous cells are treatments that induce cell death by apoptosis. In fact, other than surgery,
malignant cell types require a clinical treatment that induces cell death by apoptosis because
the cellular debris and inflammation produced by massive necrosis of an extensive tumor
would be systemically injurious to the patient. Thus, capable investigations of some of the
mechanisms associated with apoptotic cell death in Glioblastomas can of themselves be
significant. Beyond that however, the fact that Glioblastomas are usually highly invasive, but
in general do not metastasize is what renders studies about invasiveness particularly relevant
to clinical treatments of Glioblastomas [12]. In light of this, any contribution to furthering the
understanding about the invasiveness of Glioblastomas would be significant and is likely to
be well received.
Metalloproteinases are a group of enzymes that can break down proteins such as collagen and
other extracellular matrix proteins. Because these enzymes need zinc or calcium to work
properly, they are called metalloproteinases. It has been known for some time that metallo‐
proteinases play an important role in the degradation of the extracellular matrix (ECM) [13,
14]. However, the basic action of metalloproteinases, which is the cleavage of proteins, has
proven sufficiently sophisticated to orchestrate various functions in addition to degradation
of the ECM [15, 16]. The metalloproteinase family includes: matrix metalloproteinases (MMPs)
[17, 18], membrane type matrix metalloproteinases (MT-MMPs) [19, 20], a disintegrin and
metalloproteinases (ADAMs) [21] and a disintegrin and metalloproteinases with thrombo‐
spondin type 1 motif (ADAMTs) [22]. The MMPs and the ADAMTs are secreted while the
activated ADAMs and MT-MMPs remain anchored to the cell. All four of the metalloproteinase
families have the ability to act on ECM proteins and growth factor receptors as substrates. The
metalloproteinases have the capacity to regulate tumorigenesis [23], angiogenesis [24, 25],
tumor growth [26], and invasiveness [16]. Metalloproteinases are naturally inhibited by
specific tissue inhibitors of metalloproteinases (TIMPs) [27]. Thus, over the last two decades,
it has become clear that metalloproteinases do more than degrade structural ECM proteins.
Metalloproteinases are produced in an inactive zymogen form. One of the aims of this present
report is to focus on the role of apoptosis with regard to the secretion and activation of
metalloproteinases. Although metalloproteinases have been extensively studied, the total
relevance of secreted MMPs or MT-MMPs with regard to invasiveness and malignancy of
Glioblastomas is not completely resolved at present. It might be anticipated that metallopro‐
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications272
teinases have important and yet to be discovered roles with regard to the invasiveness of
Glioblastomas.
Anoikis is a form of cell death induced by inadequate or inappropriate cell–matrix interactions
whereupon there is a loss of cell adhesion signals [28]. In the case of noncancerous cells, as
they lose contact with the extracellular matrix an anoikic cell death response is initiated.
Anoikic cell death proceeds via apoptotic programs and can be considered a natural protection
against cells being detached and subsequently migrating from their primary site and becoming
established outside of their normal environment. With regard to cancerous cells many of them
are anoikic resistant. Anoikis is regulated by a variety of signaling pathways depending on
the cell type [29]. The circumventing of anoikic cell death by cancer cells enables the cancer
cells to migrate from their primary site and enter new environments and survive [30, 31].
Despite the fact that in general Glioblastomas do not metastasize, there is motivation to know
more about the secretion and activity of metalloproteinases in anoikic resistant glioma cells.
A focus of this present report is to address the question of whether apoptotic and anoikic
resistant LN18 cells are an important factor with regard to metalloproteinase secretion and
activation of the zymogen form. The question is significant given the nonhomogeneous state
of a tumor which most likely consists of a mixture of apoptotic and non-apoptotic cells. As
cells within a tumor become apoptotic micro cavities will be formed and not all of the cells will
receive a full complement of cell adhesion signals. Thus, whether treated by radiation,
chemotherapeutics or natural defenses, a tumor is most likely to exist as a milieu of dying
apoptotic cells, anoikic resistant cells, and non-apoptotic cells that are resistant to treatment.
The question of whether MMPs are activated or secreted from apoptotic or anoikic resistant
cells is relevant to the possibility that loosely attached cells or therapeutically induced
apoptotic cells can interact with apoptotic resistant cells and thus contribute to angiogenesis,
tumor growth and the invasiveness of Glioblastomas. Experiments within this report have
been done with the view that anoikis and the escape from anoikis are worthy of investigation
in the context of MMP secretion; particularly in the context of the effects of activated MMPs
upon GBM invasiveness.
2. Overall purpose
This report will first provide evidence that the apoptotic state of LN18 glioblastoma cells can
be readily delineated and as such provides a convenient in vitro model to study effects of
apoptotic cells upon the malignant properties of gliomas. In the context of metalloproteinase
activation, an objective is to point out that in late apoptosis LN18 cells manifest a degradation
of surface determinants including: growth factor receptors EGFR and IGF1-R, histocompati‐
bility markers such as HLA-ABC, and a variety of cluster determinants including alpha and
beta integrins. The degradation of surface determinants like integrins and growth factor
receptors could be viewed as a full commitment to apoptosis through a decrease in survival
signals. However, the perspective presented here is that Glioblastomas that lose growth factor
signals and cell adhesion signals, even if dying, still have the capacity to affect the malignancy
of those GBM cells within the tumor that are in a non-apoptotic state. In addition, it has been
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teinases have important and yet to be discovered roles with regard to the invasiveness of
Glioblastomas.
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presumed that GBM cells going into apoptosis is a condition that is totally beneficial to the
patient. However, an aim of this report is to point out that there may be a down side to
apoptosis that is worthy of consideration. In addition, anoikic resistance is thought of mostly
in terms of cells traveling through the circulatory system and surviving to be the root cause of
metastases [32]. Yet, anoikic resistant cells that lose their adhesion signals in situ may be
supportive of the deadly invasive characteristics of the malignant non-apoptotic cells within
the GBM tumor. More specifically the explorations of this report are intended to:
• present evidence for the presence and increased activation of metalloproteinases in LN18
glioblastoma cells as they proceed through apoptosis,
• address the possibility that MMP secretion increases in LN18 cells that are devoid of cell
adhesion signals and,
• call attention to the idea that within the milieu of a glioblastoma, apoptosis may have a role
in enhancing the invasiveness of the non-apoptotic cells.
3. Methods
3.1. Cell culture conditions
The LN18 cell line (ATTC CRL-2610) was established in 1976 from a patient with a high grade
right temporal lobe glioma. The cells are poorly differentiated, are adherent, and grow well in
culture [33]. For cell maintenance, the cells were incubated at 37◦C in an atmosphere of 5%
CO2, 95% air, and 100% humidity. Cells were maintained in 75 cm2 flasks in Dulbecco’s
Modified Eagle Medium free of phenol red and supplemented with the dipeptide L-alanyl-L-
glutamine (2mM), non-essential amino acids, pyruvate (100µg/ml), penicillin (100 units/ml),
streptomycin (100µg/ml), amphotericin B (0.25µg/ml), HEPES (25mM), and fetal bovine serum
(10%). Media and all tissue culture reagents were purchased from Invitrogen. Cells were plated
from a trypsin digest (0.25% trypsin, EDTA). All plastic ware used for tissue culture and other
experimentation including flasks, 96, 24 and 6 well plates were purchased from Fisher (Costar).
Numerical data represent 3 to 4 replicates per sample. When establishing significant differen‐
ces between samples (α=0.05) the data were analyzed by One Way Anova/Tukey Tests.
3.2. Apoptotic inducing agents
The apoptotic inducing agents used in the report are MK886 and staurosporine. MK886 is a
molecule reported to inhibit both five lipoxygenase activating protein (FLAP) [39] and
peroxisome proliferator activated receptor-α (PPAR-α) [34]. Staurosporine has been reported
to inhibit protein kinase c [35]. Both MK886 and staurosporine are proven apoptotic inducing
agents [36-40]. MK886 and staurosporine were purchased from Sigma. Apoptosis was induced
by micro molar levels of inducing agent solubilized in DMSO and diluted to the appropriate
concentration in the Dulbecco's reaction medium
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3.3. Antibodies and reagents
Mouse  monoclonal  primary  antibodies  used  for  flow  cytometry  included:  mouse  anti-
KLH  (Biolegend),  mouse  anti-β  actin,  mouse  anti-integrins  and  mouse  anti-HLA-ABC
(Upstate,  Chemicon,  Linco)  and goat  anti-mouse-IgG conjugated to  phycoerythrin (Jack‐
son Laboratories).
4. Assays for apoptosis for LN18 cells in a monolayer
Classical apoptotic morphology was used as a manifestation of apoptosis. Early apoptosis was
determined by phosphatidylserine (PS) translocation to the outer membrane as measured by
flow cytometry manifested by annexin binding in the absence of propidium iodide uptake
(Roche, Annexin-V-FLOUS kit) or annexin binding in the absence of uptake of 7-aminoactio‐
mycin D (Molecular Probes).
Apoptosis was also detected by measuring the degradation and loss of activity of Poly(ADP-
ribose) polymerase (PARP). The functional activity of PARP was determined using a PARP
Activity Assay kit (R&D Systems). PARP activity extracted from cells and activated was
measured by determining the level of incorporation of biotin labeled NAD into histones that
are coated onto a microtiter plate. The color development was measured with a computer-
assisted MR4000 Dynatech Microplate Reader at 450nm.
Late apoptosis was measured by the release of nucleosome histone complexes from the nucleus
into the cytosol. The Cell Death ELISA kit (Roche) was used. The method includes a microtiter
plate which has its wells streptavidin coated. The primary immunoreagent is a biotin labeled
anti-histone antibody which binds to the streptavidin coated plate and histones within the
experimental sample. The secondary antibody is a peroxidase conjugated anti-DNA that was
added after sample addition. The assay detects soluble cytoplasmic DNA-histone complexes
resulting from apoptotic nucleosomes that are tightly bound with core histones that appear in
the cytosol before the plasma membrane disintegrates. The ELISA color development was
measured with a computer-assisted MR4000 Dynatech Microplate Reader at 405nm.
Late apoptosis was also measured by the electrophoretic manifestation of DNA degradation.
DNA extraction for electrophoresis was done according to the procedure described by Gong
et al. [41]. Essentially, the cells were prefixed in 70% ethanol and the DNA was extracted with
0.2 M phosphate-citrate buffer at pH 7.8. The extract was sequentially treated with RNase A
and proteinase K and then subjected to electrophoresis. After 12 hours of treatment with
MK886 the DNA was extracted from 3x106 LN18 cells and loaded in a 20µL volume into a 4%
agarose gel. The gel was run at 85volts for 1h. The gels where subsequently stained with 0.4µg/
ml of ethidium bromide and photographed under UV exposure in an Alpha Innotech Fluo‐
rchem 8800 photo imager.
Measuring the degree of nuclear condensation and fragmentation by staining with the DNA
binding fluorescent dye 4',6-diamidino-2-phenylindole (DAPI) was another indicator of
apoptosis that was used.
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4.1. Flow cytometry to detect surface proteins and apoptosis
The surface proteins of apoptotic cells were compared to the surface proteins of non-apoptotic
cells. Following treatment the apoptotic and non-apoptotic cells were suspended, centrifuged
and washed. The cells were then suspended in the appropriate buffer and reacted with the
primary antibodies (mouse @ ITGA2, mouse @ ITGB2 or mouse @ HLA-ABC). Following
incubation with the primary antibody the cells were rewashed and incubated with goat @
mouse IgG conjugated to phycoerythrin. The cells were then washed and assayed by flow
cytometry. To measure apoptosis the dyes annexinV conjugated to fluorescein isothiocyanate
(annexin –FITC) and 7-Amino-actinomycinD (7-AAD) were used. Dyes were added in the
appropriate buffer. Following labeling, cells were analyzed with Becton-Dickinson FACSCa‐
libur (San Jose, CA) using CellQuest Pro software.
4.2. Real time RT-PCR
The  RNA  was  isolated  from  cells  using  TRIZOL  Reagent  (Life  Technologies).  Reverse
transcriptase  generated  c-DNAs  were  obtained  using  random  hexamers  with  the  high
capacity  archive kit  from Applied Biosystems.  C-DNAs were allowed to  form for  2h at
37°C.  Negative  controls  were  generated  by  omitting  the  reverse  transcriptase  in  the
cDNA generating  step.  For  the  PCR step,  the  primers  and Taq-Man fluorescent  probes
were  purchased  from  Applied  Biosystems.  The  primers  were  designed  to  span  an  in‐
tron  to  avoid  amplification  of  any  contaminating  DNA.  Real  time  PCR was  performed
using the Applied Biosystems Gene Amp 5700 system with the Taq-Man Universal PCR
Master  Mix.  Relative  mRNA  levels  were  measured  using  the  threshold  cycle  (Ct).  The
threshold  cycle  was  defined  as  the  cycle  number  that  first  gives  detection  of  the  PCR
amplicon above a  fixed threshold baseline  set  within  the  log phase  of  the  plot  of  fluo‐
rescence versus cycle number. The amplicons were generated over 40 cycles where each
cycle  consisted of  a  15  sec  dissociation step at  92°C and a  polymerization step at  60°C
for  1  min.  The  ΔCt  was  calculated  by  subtracting  the  Ct  value  for  the  housekeeping
gene  β-actin  (ACTB)  from  the  Ct  value  for  the  gene  of  interest  for  the  same  c-DNA
sample.  The ΔCt of  the vehicle  (DMSO) control  cells  was then compared to  the ΔCt of
the MK886 treated cells.
4.3. ELISA assay of matrix metalloproteinase proteins released from LN18 cells
The level of each MMP protein released into the supernatant from non-adherent anoikic LN18
cells incubated in polyhema coated flasks was measured by a sandwich ELISA (R&D Systems).
Monoclonal antibodies specific for the human MMP were immobilized onto the surface of the
wells of a plastic 96 well microtiter plate. 100µl of undiluted samples were added and following
incubation (2h @ RT), the unbound material was washed away (4X) and a biotinylated goat
anti-human MMP conjugated to horseradish peroxidase (HRP) was added and incubated for
2h @ RT. The cells were then washed 4X. The substrate tetra-methyl-benzidine (TMB) was
added and allowed to develop for 30min. Sulfuric acid was added as a stopping solution. A
BMG Labtech FLUOstar OPTIMA plate reader at 450nm was used to quantify the absorbance
that resulted from the developed color of the substrate.
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4.4. Fluorometric assay of metalloproteinase activity
The enzymatic activity of released MMPs from suspended LN18 cells was tested using the
Fluorescence Resonance Energy Transfer (FRET) peptide QXL520 -Arg-Pro-Leu-Ala-Leu-Trp-
Arg-Lys(5-FAM)-NH2 (ANASPEC). The hydrolysis of the FRET peptide by the pure recombi‐
nant MMP3 was used as a control. The fluorescence was monitored in microtiter plates using
a FLUOStar OPTIMA Fluorometer at an Ex/Em=490nm/520nm. The complete activation of the
released MMPs was insured by the use of 1mM of 4-aminophenylmercuric acetate (APMA).
4.5. Matrigel measure of LN18 cell invasiveness
The invasiveness was measured in vitro using a BD Falcon matrigel matrix system. This system
consists of a 24-multiwell plate where each well has an insert consisting of an 8.0µ pore size
polyethylene terephthalate (PET) membrane that has been uniformly coated with a layer of
matrigel which serves as a reconstituted matrix in vitro. The coating process occludes the pores
of the PET membrane and thereby blocks the non-invasive cells from migrating through the
membrane. In contrast, invasive cells are able to degrade the matrigel coating of the membrane
and migrate through the 8.0µ pores of the PET membrane. The invasive non-apoptotic LN18
cells were stained with the lipophilic fluorescent dye DiI (Molecular Probes). Since the PET
membrane effectively blocks the passage of light from 490-700nm at >99% efficiency only those
stained cells that pass through the PET membrane are detected. Fluorescently-labeled cells that
have not passed through the matrigel and the PET membrane are not detected by the bottom
reading fluorescent plate reader. The chemoattractant in the lower chambers of the 24 well
plate (below the matrigel insert) was DMEM medium that is 0.5% fetal bovine serum (FBS).
Invasiveness was monitored using a FLUOStar OPTIMA plate reading fluorometer at an Ex/
Em=549nm/565nm for 2h at 37°C.
5. Results
5.1. Characterization of apoptosis induced by MK886 in a monolayer of LN18 cells
DNA fragmentation is a classic indicator of apoptosis. Figure1 is a photographed UV ex‐
posure  of  DNA  agarose  gels.  The  DNA  was  extracted  from  control  LN18  cells  and
MK886 treated LN18 cells while in a monolayer. Following electrophoresis of the extract‐
ed DNA the gels were stained with ethidium bromide. Column A is the electrophoretic
pattern of  a  100bp standard.  The following columns are the electrophoretic  patterns for
the  medium control  (column B),  10µM of  MK886 for  12h (column C),  25µM of  MK886
for  12h  (column D)  and 50µM of  MK886  for  12h  (column E).  DNA fragmentation  is  a
very late event in the apoptotic process. Not all cell types respond the same in the frag‐
mentation of DNA. Some cell types give a very clear laddering and others produce more
of a smearing of DNA similar to that found in states of necrosis. For apoptotic processes
the  nuclear  DNA  would  have  been  previously  condensed  during  the  earlier  stages  of
apoptosis distinguishing it  from necrosis.  The asynchrony and slowness of apoptotic en‐
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try can also contribute to the formation of wider smeared bands of degraded DNA. We
have  found that the more compact a monolayer of LN18 cells is the slower is the apop‐
totic  entry as  indicated by the slower development of  morphological  changes of  round‐
ing up and blebbing of the cells. The electrophoretic patterns of Figure 1 show that there
is more degradation of DNA when LN18 cells are treated with increasing concentrations
of MK886.
Figure 1. Electrophoretic patterns of DNA fragmentation of apoptotic LN18 cells. Column A: 100 bp standard. Column
B: non-apoptotic control. Columns C-E: increasing concentrations of apoptotic MK886 inducing agent of 10, 25 & 50
µM respectively for 12h.
Another classical indicator of apoptosis is the degradation and loss of enzymatic activity of
Poly(ADP-ribose) polymerase (PARP). PARP is a family of multifunctional enzymes the most
dominant of which are PARP-1 and PARP-2. One of the major roles of PARP-1 is the post‐
translational modification of nuclear proteins induced by DNA strand-breaks that contributes
to the survival of injured proliferating cells [42]. The catalytic activity of PARP is immediately
stimulated by DNA strand-breaks [43]. As delineated in the Methods, activated PARP-1
cleaves NAD into nicotinamide and ADP-ribose and catalyzes the transfer of ADP-ribose units
from NAD+ to target nuclear proteins. Apoptosis initiates a caspases degradation of PARP
which is manifested by a decrease in PARP’s enzymatic activity [44]. The data of Table 1 show
the activity of PARP for control cells held in medium and MK886 treated cells at 10, 25 and
50µM of MK886. The decrease in activity of PARP is indicated by the decrease in color
development as demonstrated by the decrease in absorbance at 450nm. In addition to the
measures of apoptosis shown here, MK886 induced apoptosis in monolayer LN18 cells has
been shown to be caspases dependent and is exhibited by the release of nucleosomes, annexinV
binding to phosphatidylserine in the presence and absence of nuclear staining, changes in
morphology and changes in the fluorescent intensity of mitotracker deep red indicating
changes in mitochondrial oxidative function [45]. The alteration of the mitochondrial function
implies that apoptosis is induced in the LN18 cells via a mitochondrial pathway.
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Treatment A450 nm
Medium 0.756 +/- 0.136
Medium W/O bio-NAD 0.155 +/- 0.058
10 μM MK886 0.481 +/- 0.173
25 μM MK886 0.308 +/- 0.079
50 μM MK886 0.296 +/- 0.094
1LN18 cells were treated for 10h at indicated MK886 concentrations while in a monolayer
Table 1. MK886 Treatment of LN18 Cells Inhibits PARP Activity1
5.2. Degradation of surface determinants of monolayered LN18 cells in late apoptosis
The data presented here and the previous assessments of the time course and characteristics
of apoptosis in monolayered LN18 cells render the system useful for further studies about the
role of apoptosis and anoikis in enhancing GBN malignancy. LN18 cells losing contact with
the extracellular matrix as they proceed through apoptosis is of interest. Integrins are a class
of molecules relevant to cell adhesion to extracellular matrix proteins. Integrins exist as
heterodimers consisting of linked alpha and beta chains forming a family of 24 distinct
integrins. Integrins were first recognized as a family of receptors in a seminal paper put forth
by Hynes in 1987 [46]. Since that time, it has become established that integrins have roles in
addition to being receptors for cell adhesion proteins [47, 48]. Integrins act as membrane
transduction receptors with the ability to promote a variety of signals to the cytoskeleton which
activate many intracellular signaling pathways. An important property in the resistance to
apoptosis is the ability of the beta1 integrin subunit (designated ITGB1 or Integrin β1) to bind
extracellular domains and promote the formation of the Focal adhesion kinase-1 (FAK)
complex. The FAK complex in turn results in activating the PI 3-kinase/Akt signaling pathway
which promotes survival and delivers anti-apoptotic signals [49]. This raises the possibility
that in the normal process of apoptosis there is a commitment by the apoptotic LN18 cells to
degrade those surface determinants that promote survival signals and resistance to apoptosis.
Figure 2 and Figure 3 are both composites of flow cytometry histograms (Curves A, B and C)
showing phycoerythrin fluorescence intensity vs. cell counts. The curves were obtained by
using mouse primary IgG antibodies specific for the integrin in question followed by goat anti-
mouse-IgG conjugated to phycoerythrin. The intent of Figure 2 is to illustrate the density of
the integrin subunit IGA2 (α2) on the surface of the LN18 cell as the cell progresses through
apoptosis. The subunit α2 in combination with the subunit ITGB1 (β1) forms the dimer receptor
that binds collagen which is a ubiquitous extracellular matrix protein [50, 51].
Similarly to Figure 2, Figure 3 illustrates the density of the integrin subunit ITGB5 (β) on the
surface of the LN18 cell vs. cell count as the cell progresses through apoptosis. The integrin
subunit β5 in combination with αV recognizes the short motif Arg-Gly-Asp (RGD motif) which
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try can also contribute to the formation of wider smeared bands of degraded DNA. We
have  found that the more compact a monolayer of LN18 cells is the slower is the apop‐
totic  entry as  indicated by the slower development of  morphological  changes of  round‐
ing up and blebbing of the cells. The electrophoretic patterns of Figure 1 show that there
is more degradation of DNA when LN18 cells are treated with increasing concentrations
of MK886.
Figure 1. Electrophoretic patterns of DNA fragmentation of apoptotic LN18 cells. Column A: 100 bp standard. Column
B: non-apoptotic control. Columns C-E: increasing concentrations of apoptotic MK886 inducing agent of 10, 25 & 50
µM respectively for 12h.
Another classical indicator of apoptosis is the degradation and loss of enzymatic activity of
Poly(ADP-ribose) polymerase (PARP). PARP is a family of multifunctional enzymes the most
dominant of which are PARP-1 and PARP-2. One of the major roles of PARP-1 is the post‐
translational modification of nuclear proteins induced by DNA strand-breaks that contributes
to the survival of injured proliferating cells [42]. The catalytic activity of PARP is immediately
stimulated by DNA strand-breaks [43]. As delineated in the Methods, activated PARP-1
cleaves NAD into nicotinamide and ADP-ribose and catalyzes the transfer of ADP-ribose units
from NAD+ to target nuclear proteins. Apoptosis initiates a caspases degradation of PARP
which is manifested by a decrease in PARP’s enzymatic activity [44]. The data of Table 1 show
the activity of PARP for control cells held in medium and MK886 treated cells at 10, 25 and
50µM of MK886. The decrease in activity of PARP is indicated by the decrease in color
development as demonstrated by the decrease in absorbance at 450nm. In addition to the
measures of apoptosis shown here, MK886 induced apoptosis in monolayer LN18 cells has
been shown to be caspases dependent and is exhibited by the release of nucleosomes, annexinV
binding to phosphatidylserine in the presence and absence of nuclear staining, changes in
morphology and changes in the fluorescent intensity of mitotracker deep red indicating
changes in mitochondrial oxidative function [45]. The alteration of the mitochondrial function
implies that apoptosis is induced in the LN18 cells via a mitochondrial pathway.
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can be found in many proteins of the extracellular matrix [52]. Curves labeled A (green) of
Figures 2 and 3 show the non-specific labeling that was obtained by using mouse anti-KLH as
a primary antibody. Curves labeled B (purple) of Figures 2 and 3 indicate the fluorescence
obtained by the mouse antibodies specific for each growth factor receptor for LN18 cells in
mid apoptosis. For curves B, the cells were treated for 10h while in a monolayer with 50µM of
MK886. The bimodal curve indicates that the population consists of cells that have high and
low density of integrin determinants on the surface of the cells. Curves labeled C (red) indicate
the fluorescence obtained by the mouse antibodies specific for each growth factor receptor for
LN18 cells treated with MK886 for 15h. A clear down shift in the intensity of the growth factor
histograms can be seen for the 15h MK886 treated cells (red) as compared to the cells treated
for 10 h (purple). The down shift in integrin fluorescence intensities of the 15h MK886 treated
cells fall almost completely into the region of non-specific binding indicating a high degree of
degradation of the integrin determinants.
Figure 2. Flow cytometry histograms showing the density of integrin-α 5 on the surface of LN18 cells in mid and late
apoptosis. Curve A: @KLH non-binding control. Curve B: bimodal histogram of LN18 cells in mid apoptosis. Curve C:
LN18 cells in late apoptosis.
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Figure 3. Flow cytometry histograms showing the density of integrin-β 5 on the surface of LN18 cells in mid and late
apoptosis. Curve A: @KLH non-binding control. Curve B: bimodal histogram of LN18 cells in mid apoptosis. Curve C:
LN18 cells in late apoptosis.
5.3. RT–PCR of integrins
It is possible that the observed decrease in the density of the integrins on the surface of the
LN18 cells is due to a decrease in expression rather than a degradation of the integrin deter‐
minants. To answer this we measured the expression of a number of integrins in control LN18
cells as compared to apoptotic LN18 cells. Table 2 shows the results obtained by real time
reverse transcriptase polymerase chain reaction (real time RT-PCR) as a measure of message
for specific integrins. The data were obtained from an amplification plot of the fluorescence
signal versus cycle number. The numbers in the columns of Table 2 show the cycles to threshold
(Ct values) for β-actin and the specific integrin subunits listed in column 1. The β-actin was
used as a housekeeping control. The data of Table 2 show the Ct value for non-treated LN18
cells (2nd column) and cells exposed to 50µM MK886 for 10h (3rd column). The changes in Ct
values (ΔCt) for each mRNA were obtained by subtracting the Ct value of the DMSO control
cells from the Ct value for the MK886 treated cells at 10h and 15h. The Ct values for β-actin
and the integrin subunits increased by about a cycle indicating a slight decrease of message as
the LN18 cells proceeded through apoptosis. This slight increase in cycle number to threshold
could not account for the large decreases in surface integrins shown in Figures 2 and 3. A
normed (ΔΔCt) was calculated for each sample by subtracting the ΔCt value of β-actin from
the ΔCt value for the gene of interest. The Ct values for the calculation of the 10h ΔΔCt values
(4th column) are shown above, but the Ct values at 15h for the calculation of the 15h ΔΔCt
values (5th column) are not shown.
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β- ACTIN (ACTB) 17 18 NA NA
INTEGRIN-α 5 (ITGA5) 19 20 0 1
INTEGRIN-α V (ITGAV) 19 20 0 -1
INTEGRIN-β 1 (ITGB1) 19 20 0 0
INTEGRIN- β 3 (ITGB3) 23 24 0 0
INTEGRIN- β 5 (ITGB5) 20 21 0 1
Table 2. Effect of MK886 on the level of specific mRNAs in LN18 cells
5.4. Degradation of LN18 cell surface determinants is mediated by metalloproteinases
There is the question of whether the degradation of surface determinants due to apopto‐
sis is  specific  or whether there is  a gross loss of  surface determinants as the cells  prog‐
ress  through  apoptosis.  An  additional  question  is,  are  there  specific  proteases  that  are
activated that degrade the surface determinants of LN18 cells as they go into apoptosis?
Human  leukocyte  antigens  ABC  (HLA-ABC)  are  within  the  major  histocompatibility
complex class1 and are virtually ubiquitous in tissues. Thus, the HLA-ABC complex was
chosen to  determine if  they also are  degraded in apoptotic  cells  and if  the degradation
can be reversed by various protease inhibitors.
The flow cytometry output of Table 3 was obtained by using mouse primary IgG antibodies
specific for HLA-ABC determinants followed by goat @mouse IgG conjugated to phycoery‐
thrin. The first column of Table 3 is a list of protease inhibitors. The numerical values within
the columns of Table 3 represent the integrated fluorescence intensity of the phycoerythrin
dye where a decrease in integrated intensity indicates a decrease in the density of HLA-ABC
determinants on the surface of the LN18 cell. The data of Table 3 show that as LN18 cells
progress through apoptosis, induced by 50µM of MK886, there is a decrease in the surface
determinants of HLA-ABC as compared to vehicle control cells (2nd column vs. 3rd column).
For the non-apoptotic controls (2nd column) the proteolytic inhibitors were added at 7h after
the initiation of the incubation. For the apoptotic MK886 treated cells (3rd column) no proteo‐
lytic inhibitors were added. For the cells that had both MK886 and proteolytic inhibitor added,
the proteolytic inhibitor was added 7h after the MK886 was added (4th column). The cells were
allowed to incubate for an additional 6h after the addition of the protease inhibitors. It can be
seen from the third column of Table 3 as compared to the second column that treatment with
the matrix metalloproteinase inhibitors GM6001 and MM-2 MM-9 demonstrated a significant
inhibition of the apoptotic loss of HLA-ABC determinants. Some of the proteasome inhibitors
severely exacerbated the LN18 cell’s loss of determinants while the calpain inhibitors had little
to no effect. Similar effects were obtained for the cell surface receptors EGFR, INGF1-R and
INGF2-R (not shown). Serine protease inhibitors such as aprotinin and soybean trypsin
inhibitor partially reversed surface determinant degradation induced by apoptosis indicating
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that degradation of surface determinants is the result of a combination or interplay of serine
proteases and metalloproteinases (not shown). The reversal of the degradation of cluster
determinants by metalloproteinase inhibitors is relevant to the studies showing matrix
metalloproteinase secretion from LN18 glioblastoma cells in suspension.






ZVAD-FMK (50μM) 3299 2001 2335
CALPAIN III (50μM) 3449 2465 2350
CALPEPTIN (50μM) 2690 1647 1425
MG-132 (50μM) 2858 1791 TOO LOW
PSI (50μM) 2880 2089 1003
GM6001 (10μM) 2907 1914 2854
MM-2 MM-9 (50μM) 3069 1722 2759
PD 150606 (50μM) 3822 2153 742
ALLN,MG101 (50μM) 3534 1795 211
ZVAD-FMK (50μM) Broad caspases inhibitor
CALPAIN III (50μM) Inhibits calpain 1&2
CALPEPTIN (50μM) Inhibits calpain 1&2 and papain
MG-132 (50μM) Proteasome inhibitor that also inhibits NF-κB
PSI (50μM) Proteasome inhibitor that also inhibits NF-κB and chymotrypsin
GM6001 (10μM) Broad matrix metalloproteinase inhibitor
MM-2 MM-9 (50μM) Broad matrix metalloproteinase inhibitor
PD 150606 (50μM) Calpain 1 inhibitor: directed against the calcium binding site
ALLN,MG101 (50μM) Inhibits Calpain 1&2 , cysteine proteases, proteasomes, IκB-α, IκB-β, ubiquitin-proteasome
complexes, arrests cell cycle at G1/S
Table 3. Effect of Proteolytic Inhibitors upon Apoptotic Decrease of the HLA-ABC Determinants on the Surface of
LN18 Cells















β- ACTIN (ACTB) 17 18 NA NA
INTEGRIN-α 5 (ITGA5) 19 20 0 1
INTEGRIN-α V (ITGAV) 19 20 0 -1
INTEGRIN-β 1 (ITGB1) 19 20 0 0
INTEGRIN- β 3 (ITGB3) 23 24 0 0
INTEGRIN- β 5 (ITGB5) 20 21 0 1
Table 2. Effect of MK886 on the level of specific mRNAs in LN18 cells
5.4. Degradation of LN18 cell surface determinants is mediated by metalloproteinases
There is the question of whether the degradation of surface determinants due to apopto‐
sis is  specific  or whether there is  a gross loss of  surface determinants as the cells  prog‐
ress  through  apoptosis.  An  additional  question  is,  are  there  specific  proteases  that  are
activated that degrade the surface determinants of LN18 cells as they go into apoptosis?
Human  leukocyte  antigens  ABC  (HLA-ABC)  are  within  the  major  histocompatibility
complex class1 and are virtually ubiquitous in tissues. Thus, the HLA-ABC complex was
chosen to  determine if  they also are  degraded in apoptotic  cells  and if  the degradation
can be reversed by various protease inhibitors.
The flow cytometry output of Table 3 was obtained by using mouse primary IgG antibodies
specific for HLA-ABC determinants followed by goat @mouse IgG conjugated to phycoery‐
thrin. The first column of Table 3 is a list of protease inhibitors. The numerical values within
the columns of Table 3 represent the integrated fluorescence intensity of the phycoerythrin
dye where a decrease in integrated intensity indicates a decrease in the density of HLA-ABC
determinants on the surface of the LN18 cell. The data of Table 3 show that as LN18 cells
progress through apoptosis, induced by 50µM of MK886, there is a decrease in the surface
determinants of HLA-ABC as compared to vehicle control cells (2nd column vs. 3rd column).
For the non-apoptotic controls (2nd column) the proteolytic inhibitors were added at 7h after
the initiation of the incubation. For the apoptotic MK886 treated cells (3rd column) no proteo‐
lytic inhibitors were added. For the cells that had both MK886 and proteolytic inhibitor added,
the proteolytic inhibitor was added 7h after the MK886 was added (4th column). The cells were
allowed to incubate for an additional 6h after the addition of the protease inhibitors. It can be
seen from the third column of Table 3 as compared to the second column that treatment with
the matrix metalloproteinase inhibitors GM6001 and MM-2 MM-9 demonstrated a significant
inhibition of the apoptotic loss of HLA-ABC determinants. Some of the proteasome inhibitors
severely exacerbated the LN18 cell’s loss of determinants while the calpain inhibitors had little
to no effect. Similar effects were obtained for the cell surface receptors EGFR, INGF1-R and
INGF2-R (not shown). Serine protease inhibitors such as aprotinin and soybean trypsin
inhibitor partially reversed surface determinant degradation induced by apoptosis indicating
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications282
that degradation of surface determinants is the result of a combination or interplay of serine
proteases and metalloproteinases (not shown). The reversal of the degradation of cluster
determinants by metalloproteinase inhibitors is relevant to the studies showing matrix
metalloproteinase secretion from LN18 glioblastoma cells in suspension.






ZVAD-FMK (50μM) 3299 2001 2335
CALPAIN III (50μM) 3449 2465 2350
CALPEPTIN (50μM) 2690 1647 1425
MG-132 (50μM) 2858 1791 TOO LOW
PSI (50μM) 2880 2089 1003
GM6001 (10μM) 2907 1914 2854
MM-2 MM-9 (50μM) 3069 1722 2759
PD 150606 (50μM) 3822 2153 742
ALLN,MG101 (50μM) 3534 1795 211
ZVAD-FMK (50μM) Broad caspases inhibitor
CALPAIN III (50μM) Inhibits calpain 1&2
CALPEPTIN (50μM) Inhibits calpain 1&2 and papain
MG-132 (50μM) Proteasome inhibitor that also inhibits NF-κB
PSI (50μM) Proteasome inhibitor that also inhibits NF-κB and chymotrypsin
GM6001 (10μM) Broad matrix metalloproteinase inhibitor
MM-2 MM-9 (50μM) Broad matrix metalloproteinase inhibitor
PD 150606 (50μM) Calpain 1 inhibitor: directed against the calcium binding site
ALLN,MG101 (50μM) Inhibits Calpain 1&2 , cysteine proteases, proteasomes, IκB-α, IκB-β, ubiquitin-proteasome
complexes, arrests cell cycle at G1/S
Table 3. Effect of Proteolytic Inhibitors upon Apoptotic Decrease of the HLA-ABC Determinants on the Surface of
LN18 Cells
Apoptotic Events in Glioma Activate Metalloproteinases and Enhance Invasiveness
http://dx.doi.org/10.5772/52359
283
5.5. Apoptosis induced by MK886 and staurosporine in LN18 cells held in suspension and
devoid of integrin signaling
The panels of Figure 4 are flow cytometry outputs and are plots of annexin conjugated to
fluorescein isothiocyanate (annexinV-FITC) versus 7-amino-actinomycinD (7AAD) staining of
the LN18 cells. The flow cytometry data of annexinV-FITC versus 7AAD is a classical test for
apoptosis. The data of Figure 4 are a measure of the degree of apoptosis in LN18 glioblastoma
cells while suspended in polyhema coated flasks. Panel A of Figure 4 illustrates vehicle control
cells which were iced while in suspension and then immediately stained. Pharmacologically
induced apoptosis of the suspended cells was brought about by treating the cells with 50µM
of MK886 for 8h (panel B) and for 10h (panel C). Numbers denoted in quadrants of each panel
represent the percentage of cells in each quadrant. Viable cells that are not positive for
annexinV-FITC or 7AAD are neither apoptotic nor necrotic and are represented in the lower
left quadrant. Necrotic cells devoid of apoptosis that stained positive for 7AAD, but not for
annexinV-FITC, are represented in the upper left quadrant. Apoptotic cells devoid of necrosis
that stained for annexinV-FITC, but not 7AAD, are in the lower right quadrant and late
apoptotic/necrotic cells that stained for both annexinV-FITC and 7AAD are represented in the
upper right quadrant. Panel A of Figure 4 shows that 90% of control cells are devoid of
annexinV-FITC or 7AAD staining indicating no initial necrosis or apoptosis. LN18 cells in
suspension devoid of extracellular signaling rapidly go into apoptosis. It can be seen that 67%
of the cells are stained positive for annexinV-FITC by 6h (sum of the 2 right quadrants of panel
B) due to treatment with MK886. When the LN18 cells are in suspension devoid of integrin
signaling, they proceed into apoptosis much more rapidly than when in a monolayer. After
8h of stimulation with MK886, 77% of the cells stain positive with annexinV-FITC (sum of the
2 right quadrants of panel C). The data of Figure 4 are relevant to those experiments which
show that LN18 cells rendered apoptotic while in suspension enhance the invasiveness of non-
apoptotic LN18 cells.
Nucleosomes are essentially DNA-histone complexes which in non-apoptotic cells are
confined to the nucleus. An additional well established test for apoptosis is the release of
nucleosomes from the nucleus into the cytosol. To further demonstrate apoptosis for cells that
lack integrin stimulation, LN18 cells were treated with a variety of concentrations of stauro‐
sporine while in suspension in polyhema coated flasks. The data of Table 4 show the results
of assaying for the release of DNA-histone complexes from the nucleus into the cytosol for
LN18 cells in polyhema coated flasks. The LN18 cells were treated with staurosporine at the
concentrations indicated for 8h. The cells were then centrifuged and washed and then treated
with lysis buffer. The supernatants of the lysed cells were then transferred to a streptavidin
coated 96 well microtiter plates and tested for DNA-histone complexes by ELISA using anti-
histone-biotin-antibody followed by peroxidase conjugated to anti-DNA. The development of
peroxidase substrate was measured by reading a Dynatech Microplate Reader at 405nm. It can
be seen that 1µM of staurosporine can induce the release of a significant amount of histone-
associated DNA-fragments into the cytosol by 8h. Furthermore, the release of DNA fragments
was inhibited by the broad caspases inhibitor ZVAD-FMK, indicating that staurosporine-
induced degradation of DNA in LN18 cells is caspases dependent.
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Figure 4. Flow cytometry data showing nuclear staining vs. translocated phosphatidylserine ( PS) staining as LN18 cells
proceed through MK886 induced apoptosis while in suspension and devoid of integrin stimulation.
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Staurosporine Concentration A405 nm SD
Medium Control 0.145 +/-0.051
0.5 μM 0.297 +/-0.081
1.0 μM 0.643 +/-0.073
2.0 μM 0.862 +/-0.136
2.0 μM + 50μM ZVAD-FMK 0.197 +/-0.026
1LN18 cells were treated for 8h at indicated staurosporine concentrations.
Table 4. Apoptotic Release of Nucleosome from LN18 Cells Treated with Staurosporine while Suspended in Polyhema
Coated Flasks1
The LN18 cells shown in the micrograph labeled Figure 5 were incubated in suspension with
1uM staurosporine for 6h. After the incubation the cells were harvested by centrifugation and
then fixed in 70% ethanol. The cells were then centrifuged and washed and suspended in 2ml
of phosphate buffered saline. For the assay 10ul of stock (0.1mg/ml) 4,6-diamidino-2-phenyl‐
indole (DAPI) was added to the 2ml PBS. After completion of the staining with DAPI, the cells
were observed on a slide with an inverted microscope set for DAPI. The arrows of the
micrograph labeled Figure 5 show nuclear condensation within LN18 cells. Nuclear conden‐
sation is another established indicator of apoptosis. The condensation correlates with the
nucleosome release and is clear indication that both staurosporine and MK886 induce late
apoptotic effects in LN18 cells that are not integrin stimulated as early as 8-10h.
Figure 5. The arrows within the micrograph show nuclear condensation within LN18 cells in suspension upon the in‐
duction of apoptosis by treating the cells with 1µM Staurosporine for 6h.
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5.6. LN18 cells that are devoid of integrin stimulation release matrix metalloproteinases
Cells held in suspension in polyhema coated flasks are devoid of those extracellular matrix
transduction signals that are derived from cells bring stimulated by extracellular matrix
proteins. The data of Figures 6 and 7 were accumulated by an ELISA technique as presented
in the Methods. The data show the release of MMP13 (Figure 6) and the lack of release of MMP8
(Figure 7). The MMPs were released in the absence of pharmacological stimulation (MK886 or
staurosporine) by LN18 glioblastoma cells when there is merely a loss of cell adhesion signals
brought about by incubating the cells in suspension in polyhema coated flasks. The samples
for the Figures 6 and 7 are as follows: Bar A is the medium control; Bar B is the supernatant of
the ice control where the cells were suspended, but not allowed to progress at 37⁰C; Bars C
through G illustrate dose responses for pure MMP13 (Figure 6) and pure MMP8 (Figure 7)
which are 0.5ng/ml (Bar C), 1.0ng/ml (Bar D), 2.0ng/ml (Bar E), 4.0ng/ml (Bar F), and 6.0ng/ml
(Bar G). Bars H through J are the supernatants of LN18 cells suspended in polyhema coated
flasks at 1.5 x 106 cells/ml in Dulbecco’s medium with 2% FBS for 2hrs (Bar H), 4hrs (Bar I),
6hrs (Bar J) at 37⁰C. Bar K is the response from LN18 cells held for 6hrs in suspension, but in
the presence of 1.78 x 10-4 M cycloheximide. Other metalloproteinases released from LN18 cells
while being held in suspension include MMP1, MMP2 and MMP3 (not shown).
Figure 6. ELISA measurement of released MMP13 from LN18 cells in suspension. Bars A&B are controls. Bars C &D are
the dose responses for pure MMP13. Bars H-J are measures of the MMP13 released from cells held in suspension for 2,
4 & 6h respectively. Bar K is the cycloheximide control at 6h.
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Staurosporine Concentration A405 nm SD
Medium Control 0.145 +/-0.051
0.5 μM 0.297 +/-0.081
1.0 μM 0.643 +/-0.073
2.0 μM 0.862 +/-0.136
2.0 μM + 50μM ZVAD-FMK 0.197 +/-0.026
1LN18 cells were treated for 8h at indicated staurosporine concentrations.
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Coated Flasks1
The LN18 cells shown in the micrograph labeled Figure 5 were incubated in suspension with
1uM staurosporine for 6h. After the incubation the cells were harvested by centrifugation and
then fixed in 70% ethanol. The cells were then centrifuged and washed and suspended in 2ml
of phosphate buffered saline. For the assay 10ul of stock (0.1mg/ml) 4,6-diamidino-2-phenyl‐
indole (DAPI) was added to the 2ml PBS. After completion of the staining with DAPI, the cells
were observed on a slide with an inverted microscope set for DAPI. The arrows of the
micrograph labeled Figure 5 show nuclear condensation within LN18 cells. Nuclear conden‐
sation is another established indicator of apoptosis. The condensation correlates with the
nucleosome release and is clear indication that both staurosporine and MK886 induce late
apoptotic effects in LN18 cells that are not integrin stimulated as early as 8-10h.
Figure 5. The arrows within the micrograph show nuclear condensation within LN18 cells in suspension upon the in‐
duction of apoptosis by treating the cells with 1µM Staurosporine for 6h.
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5.6. LN18 cells that are devoid of integrin stimulation release matrix metalloproteinases
Cells held in suspension in polyhema coated flasks are devoid of those extracellular matrix
transduction signals that are derived from cells bring stimulated by extracellular matrix
proteins. The data of Figures 6 and 7 were accumulated by an ELISA technique as presented
in the Methods. The data show the release of MMP13 (Figure 6) and the lack of release of MMP8
(Figure 7). The MMPs were released in the absence of pharmacological stimulation (MK886 or
staurosporine) by LN18 glioblastoma cells when there is merely a loss of cell adhesion signals
brought about by incubating the cells in suspension in polyhema coated flasks. The samples
for the Figures 6 and 7 are as follows: Bar A is the medium control; Bar B is the supernatant of
the ice control where the cells were suspended, but not allowed to progress at 37⁰C; Bars C
through G illustrate dose responses for pure MMP13 (Figure 6) and pure MMP8 (Figure 7)
which are 0.5ng/ml (Bar C), 1.0ng/ml (Bar D), 2.0ng/ml (Bar E), 4.0ng/ml (Bar F), and 6.0ng/ml
(Bar G). Bars H through J are the supernatants of LN18 cells suspended in polyhema coated
flasks at 1.5 x 106 cells/ml in Dulbecco’s medium with 2% FBS for 2hrs (Bar H), 4hrs (Bar I),
6hrs (Bar J) at 37⁰C. Bar K is the response from LN18 cells held for 6hrs in suspension, but in
the presence of 1.78 x 10-4 M cycloheximide. Other metalloproteinases released from LN18 cells
while being held in suspension include MMP1, MMP2 and MMP3 (not shown).
Figure 6. ELISA measurement of released MMP13 from LN18 cells in suspension. Bars A&B are controls. Bars C &D are
the dose responses for pure MMP13. Bars H-J are measures of the MMP13 released from cells held in suspension for 2,
4 & 6h respectively. Bar K is the cycloheximide control at 6h.
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Figure 7. ELISA measurement of released MMP8 from LN18 cells in suspension. Bars A&B are controls. Bars C&D are
the dose responses for pure MMP8. Bars H-J are measures of the MMP8 released from cells held in suspension for 2, 4
& 6h respectively. Bar K is the cycloheximide control at 6h.
As determined by RT-PCR there was a slight increase in message (one to two cycles) for the
metalloproteinases shown in Figures 6 and 7 when the cells were held in suspension for 6h at
37⁰C (not shown). Examining Bars H-J of Figure 6 as compared to cells not allowed to progress
at 37⁰C in suspension (ice control Bar B) it can be seen that there is a significant amount of
MMP13 release from the LN18 cells held in suspension. Whether the zymogen form of the
MMPs is stored in the cytosol was not determined but it appears from Bar K that, even if much
of the metalloproteinase are stored in the cytosol prior to secretion, translation is essential
indicating that the production of some type of protein is required for secretion to proceed.
Figure 7 shows a lack of secretion of MMP8. In addition to MMP8, MMP7 and MMP9 were
not secreted in amounts that were detectable (not shown).
5.7. Metalloproteinase inhibitors block the MMP activity released from LN18 cells held in
suspension
The data of Figure 8 illustrate the inhibition of the total metalloproteinase activity released into
the supernatant from LN18 cells held in suspension. The cells were incubated in polyhema
coated flasks in the presence of DMEM supplemented with 1% FBS and growth hormones for
6hrs. As described in the Methods, the MMP activity in the supernatant of the suspended cells
was measured fluorometrically using the broad MMP substrate QXL520 -Arg-Pro-Leu-Ala-
Leu-Trp-Arg-Lys(5-FAM)-NH2. The total secreted metalloproteinase activity included a
variety of MMPs secreted from the LN18 cells including that of MMP-1, -2, -3 (not shown) in
addition to MMP13 (shown in Figure 6). Bar A is the metalloproteinase activity of the super‐
natant of cells left on ice (control blank). Bar B is supernatant of the 6hr incubation positive
control showing the secreted enzymatic activity tested in the absence of inhibitors. For the
remaining samples, the supernatant of the 6hr suspended cells containing the secreted
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metalloproteinases was tested for enzymatic activity in the presence of the following inhibitors:
10mM EDTA (Bar C); 5mM EDTA (Bar D); 5mM of the zinc chelator 1,10 phenanthroline (Bar
E); 2.5mM of 1,10 phenanthroline (Bar F); 50µM of the broad metalloproteinase inhibitor
GM6001 (Bar G); and, 25µM of GM6001 (Bar H). Bar I shows the effect of the solvent isopropyl
alcohol (12.5%), which was used to dissolve the 1,10 phenanthroline. Bar J shows the effect of
the solvent DMSO (12.5%), which was used to dissolve the GM6001. The data indicate that
metalloproteinases secreted from the suspended LN18 cells have enzymatic activity that was
inhibited by a variety of known MMP inhibitors.
Figure 8. Inhibition of metalloproteinase activity secreted from LN18 cells. Bar A is the non-releasing ice control. Bar B
is the non-inhibited sample. Bars C-H show reduced activity by a variety of known metalloproteinase inhibitors. Bars I
& J are solvent controls.
5.8. Effect of apoptotic LN18 cells upon the invasiveness of non–apoptotic LN18 cells
The invasiveness was measured in vitro using a BD Falcon matrigel matrix system. This system
consists of a 24-multiwell plate where each well has an insert consisting of an 8.0µ pore size
polyethylene terephthalate (PET) membrane that has been uniformly coated with a layer of
matrigel which serves as a reconstituted matrix in vitro. The coating procedure occludes the
pores of the PET membrane. Those cells capable of degrading the matrigel coating of the PET
membrane will migrate through the 8.0µ pores of the PET membrane. For clarification, a
diagram of one well of the 24 well plate matrigel system is shown in Figure 9.
The system requires a chemoattractant in the lower chamber. Constituents within fetal bovine
serum (FBS) are known to act as chemoattractants, which enables the cells to migrate from the
serum free upper chamber toward the lower chamber. Various concentrations of FBS were
tested and it was determined that 0.5% FBS in Dulbecco’s medium was an effective concen‐
tration (not shown). The invasive cells are stained with the lipophilic fluorescent dye DiI
(Molecular Probes). Since the PET membrane effectively blocks the passage of light from
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Figure 7. ELISA measurement of released MMP8 from LN18 cells in suspension. Bars A&B are controls. Bars C&D are
the dose responses for pure MMP8. Bars H-J are measures of the MMP8 released from cells held in suspension for 2, 4
& 6h respectively. Bar K is the cycloheximide control at 6h.
As determined by RT-PCR there was a slight increase in message (one to two cycles) for the
metalloproteinases shown in Figures 6 and 7 when the cells were held in suspension for 6h at
37⁰C (not shown). Examining Bars H-J of Figure 6 as compared to cells not allowed to progress
at 37⁰C in suspension (ice control Bar B) it can be seen that there is a significant amount of
MMP13 release from the LN18 cells held in suspension. Whether the zymogen form of the
MMPs is stored in the cytosol was not determined but it appears from Bar K that, even if much
of the metalloproteinase are stored in the cytosol prior to secretion, translation is essential
indicating that the production of some type of protein is required for secretion to proceed.
Figure 7 shows a lack of secretion of MMP8. In addition to MMP8, MMP7 and MMP9 were
not secreted in amounts that were detectable (not shown).
5.7. Metalloproteinase inhibitors block the MMP activity released from LN18 cells held in
suspension
The data of Figure 8 illustrate the inhibition of the total metalloproteinase activity released into
the supernatant from LN18 cells held in suspension. The cells were incubated in polyhema
coated flasks in the presence of DMEM supplemented with 1% FBS and growth hormones for
6hrs. As described in the Methods, the MMP activity in the supernatant of the suspended cells
was measured fluorometrically using the broad MMP substrate QXL520 -Arg-Pro-Leu-Ala-
Leu-Trp-Arg-Lys(5-FAM)-NH2. The total secreted metalloproteinase activity included a
variety of MMPs secreted from the LN18 cells including that of MMP-1, -2, -3 (not shown) in
addition to MMP13 (shown in Figure 6). Bar A is the metalloproteinase activity of the super‐
natant of cells left on ice (control blank). Bar B is supernatant of the 6hr incubation positive
control showing the secreted enzymatic activity tested in the absence of inhibitors. For the
remaining samples, the supernatant of the 6hr suspended cells containing the secreted
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metalloproteinases was tested for enzymatic activity in the presence of the following inhibitors:
10mM EDTA (Bar C); 5mM EDTA (Bar D); 5mM of the zinc chelator 1,10 phenanthroline (Bar
E); 2.5mM of 1,10 phenanthroline (Bar F); 50µM of the broad metalloproteinase inhibitor
GM6001 (Bar G); and, 25µM of GM6001 (Bar H). Bar I shows the effect of the solvent isopropyl
alcohol (12.5%), which was used to dissolve the 1,10 phenanthroline. Bar J shows the effect of
the solvent DMSO (12.5%), which was used to dissolve the GM6001. The data indicate that
metalloproteinases secreted from the suspended LN18 cells have enzymatic activity that was
inhibited by a variety of known MMP inhibitors.
Figure 8. Inhibition of metalloproteinase activity secreted from LN18 cells. Bar A is the non-releasing ice control. Bar B
is the non-inhibited sample. Bars C-H show reduced activity by a variety of known metalloproteinase inhibitors. Bars I
& J are solvent controls.
5.8. Effect of apoptotic LN18 cells upon the invasiveness of non–apoptotic LN18 cells
The invasiveness was measured in vitro using a BD Falcon matrigel matrix system. This system
consists of a 24-multiwell plate where each well has an insert consisting of an 8.0µ pore size
polyethylene terephthalate (PET) membrane that has been uniformly coated with a layer of
matrigel which serves as a reconstituted matrix in vitro. The coating procedure occludes the
pores of the PET membrane. Those cells capable of degrading the matrigel coating of the PET
membrane will migrate through the 8.0µ pores of the PET membrane. For clarification, a
diagram of one well of the 24 well plate matrigel system is shown in Figure 9.
The system requires a chemoattractant in the lower chamber. Constituents within fetal bovine
serum (FBS) are known to act as chemoattractants, which enables the cells to migrate from the
serum free upper chamber toward the lower chamber. Various concentrations of FBS were
tested and it was determined that 0.5% FBS in Dulbecco’s medium was an effective concen‐
tration (not shown). The invasive cells are stained with the lipophilic fluorescent dye DiI
(Molecular Probes). Since the PET membrane effectively blocks the passage of light from
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490-700nm at >99% efficiency, only those stained cells that pass through the PET membrane
were detected. Fluorescently-labeled cells that have not passed through the matrigel and the
PET membrane were not detected by the bottom reading fluorescent plate reader. Invasiveness
was monitored using a FLUOStar OPTIMA plate reading fluorometer at an Ex/Em=549nm/
565nm for 2h at 37°C. It was determined that 2x105 stained LN18 cells in the upper chamber
that were capable of migrating into the lower chamber gave a strong fluorometric signal.
Figure 9. Diagram of one well of the 24 well plate matrigel system.
The intent of using the matrigel invasive system was to measure the effect various numbers of
apoptotic LN18 cells have upon the invasiveness of a fixed number of stained non-apoptotic
LN18 cells. Figure 10 shows the effect of combining in the upper chamber a variety of apoptotic
LN18 cells upon 2x105 of the invasive, non-apoptotic, Dil stained LN18 cells. Before mixing the
two cell populations apoptosis was induced separately from the non-apoptotic cell population.
The apoptotic population was obtained by stimulating the LN18 cells with 1µM of staurospor‐
ine for 8h. The apoptotic LN18 cells were then washed but not stained. The non-apoptotic cells
were stained with DiI and the mixtures of the non-apoptotic and apoptotic cells were aliquoted
into the upper chambers in Dulbecco’s medium supplemented with growth factors and 0.5%
bovine serum albumin (BSA) but devoid of FBS. Dulbecco’s medium supplemented with 0.5%
FBS was the chemoattractant within the lower chamber. Samples A through D represent the fol‐
lowing cell mixtures where in each case only the 2x105 non-apoptotic cell populations were
stained with DiI. Sample A is 1.7x105 unstained apoptotic LN18 cells + 2x105 non-apoptotic dil
stained LN18 cells with no FBS in the lower chamber (no chemoattractant control). Sample B is
1.7x105 unstained non-apoptotic LN18 cells + 2x105 non-apoptotic Dil stained LN18 cells (non-
apoptotic equal cell count control). Sample C is 2.7x105 unstained apoptotic LN18 cells + 2x105
non-apoptotic Dil stained LN18 cells. Sample D is 4.7x105 unstained apoptotic LN18 cells + 2x105
non-apoptotic Dil stained LN18 cells. Only sample A was devoid of FBS in the lower chamber. It
can be seen from samples C and D of Figure 10 that increasing populations of apoptotic LN18
cells enhance the invasiveness of the of the non-apoptotic LN18 cells.
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Figure 10. Enhanced invasiveness of non-apoptotic LN18 cells by the presences of apoptotic LN18 cells. Bar A no che‐
moattractant control. Bar B invasiveness of non-apoptotic cells in the absence of apoptotic cells. Bars C&D increased
invasiveness of the non-apoptotic cells by increasing populations of apoptotic cells.
6. Conclusions
The main focus of this report was examining the effects of apoptotic glioblastoma cells upon
the non-apoptotic glioblastoma cell population. Overall, the data show that the effects are in
large part mediated by metalloproteinases.
A summary of the findings of this study are as follows:
• Apoptosis induced in LN18 cells, that are in a monolayer and integrin stimulated, is
accompanied by an enhanced activation of metalloproteinases on the surface of the LN18
cells.
• Matrix metalloproteinases are secreted from LN18 cells that are in suspension and devoid
of integrin signals, even in the absence of the pharmacological stimulation of apoptosis.
• The matrix metalloproteinase released from LN18 cells can be made to exhibit enzymatic
activity which is reversed by metalloproteinase inhibitors.
• As LN18 glioblastoma cells progress through apoptosis, there is a degradation of surface
determinants including, growth factor receptors, histocompatibility markers such as HLA-
ABC, and a variety of cluster determinant including alpha and beta integrins. The degra‐
dation takes place in mid to late apoptosis. Metalloproteinase inhibitors blocked the
degradation of surface determinants even when added after the cells where fully committed
to apoptosis.
Apoptotic Events in Glioma Activate Metalloproteinases and Enhance Invasiveness
http://dx.doi.org/10.5772/52359
291
490-700nm at >99% efficiency, only those stained cells that pass through the PET membrane
were detected. Fluorescently-labeled cells that have not passed through the matrigel and the
PET membrane were not detected by the bottom reading fluorescent plate reader. Invasiveness
was monitored using a FLUOStar OPTIMA plate reading fluorometer at an Ex/Em=549nm/
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were stained with DiI and the mixtures of the non-apoptotic and apoptotic cells were aliquoted
into the upper chambers in Dulbecco’s medium supplemented with growth factors and 0.5%
bovine serum albumin (BSA) but devoid of FBS. Dulbecco’s medium supplemented with 0.5%
FBS was the chemoattractant within the lower chamber. Samples A through D represent the fol‐
lowing cell mixtures where in each case only the 2x105 non-apoptotic cell populations were
stained with DiI. Sample A is 1.7x105 unstained apoptotic LN18 cells + 2x105 non-apoptotic dil
stained LN18 cells with no FBS in the lower chamber (no chemoattractant control). Sample B is
1.7x105 unstained non-apoptotic LN18 cells + 2x105 non-apoptotic Dil stained LN18 cells (non-
apoptotic equal cell count control). Sample C is 2.7x105 unstained apoptotic LN18 cells + 2x105
non-apoptotic Dil stained LN18 cells. Sample D is 4.7x105 unstained apoptotic LN18 cells + 2x105
non-apoptotic Dil stained LN18 cells. Only sample A was devoid of FBS in the lower chamber. It
can be seen from samples C and D of Figure 10 that increasing populations of apoptotic LN18
cells enhance the invasiveness of the of the non-apoptotic LN18 cells.
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Figure 10. Enhanced invasiveness of non-apoptotic LN18 cells by the presences of apoptotic LN18 cells. Bar A no che‐
moattractant control. Bar B invasiveness of non-apoptotic cells in the absence of apoptotic cells. Bars C&D increased
invasiveness of the non-apoptotic cells by increasing populations of apoptotic cells.
6. Conclusions
The main focus of this report was examining the effects of apoptotic glioblastoma cells upon
the non-apoptotic glioblastoma cell population. Overall, the data show that the effects are in
large part mediated by metalloproteinases.
A summary of the findings of this study are as follows:
• Apoptosis induced in LN18 cells, that are in a monolayer and integrin stimulated, is
accompanied by an enhanced activation of metalloproteinases on the surface of the LN18
cells.
• Matrix metalloproteinases are secreted from LN18 cells that are in suspension and devoid
of integrin signals, even in the absence of the pharmacological stimulation of apoptosis.
• The matrix metalloproteinase released from LN18 cells can be made to exhibit enzymatic
activity which is reversed by metalloproteinase inhibitors.
• As LN18 glioblastoma cells progress through apoptosis, there is a degradation of surface
determinants including, growth factor receptors, histocompatibility markers such as HLA-
ABC, and a variety of cluster determinant including alpha and beta integrins. The degra‐
dation takes place in mid to late apoptosis. Metalloproteinase inhibitors blocked the
degradation of surface determinants even when added after the cells where fully committed
to apoptosis.
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• By the use of Real-Time RT-PCR, it was determined that, overall, the down-regulation of
surface proteins that takes place in late apoptosis is not mediated by an interruption of
transcription mechanisms.
• Apoptotic LN18 glioblastoma cells when mixed with non-apoptotic LN18 cells enhance the
invasiveness of the non-apoptotic LN18 cells
As aforementioned, when a malignancy is diagnosed and is subjected to primary treatment
some of the cells will be more resistant to apoptosis than others which will inherently result
in a mixture of apoptotic and viable non-apoptotic tumor cells. The existence of a mixture of
apoptotic and non-apoptotic tumor cells is particularly true during recurrence and the required
therapy that inevitably induces apoptosis which leads to a population of apoptotic cells within
the tumor. As treatment progresses beyond the primary stage, mutated cells and resistant cells
that escape apoptosis will proliferate. Thus, the sustained cell population of a tumor will
consist of non-apoptotic cells capable of invading surrounding tissue while coexisting with a
dying population of apoptotic cells. This view that recurrent GBM tumors consist of cells that
are refractory to treatment while being highly invasive, and exist as a mixed population of
apoptotic and non-apoptotic cells, was the stimulus for this study.
There have been elegant studies comparing non-cancerous glial cells to gliomas and demon‐
strating elevated membrane-type metalloproteinases in gliomas [53]. There are also studies
demonstrating membrane-type metalloproteinases expression and function during glioma
invasion [54, 55]. These studies have provided a footing and direction for this present study.
The important idea here is that there are metalloproteinase activating processes that are taking
place in apoptotic and anoikic cells. What is different about the approach proposed here is that
we are not comparing glioma cells to normal glial cells, but rather investigating the presence
of, and activity of, metalloproteinases in glioma cells as they progress through apoptosis.
It can be concluded from the data of this report that the membrane bound metalloproteinases in
LN18 glioblastoma cells are surprisingly active during the late phases of pharmacologically in‐
duced apoptosis. In addition, matrix metalloproteinases are secreted from LN18 glioblastoma
cells in early anoikis. One of the hallmarks for the induction of anoikis is the absence of cell adhe‐
sion signals. It can be assumed that the secreted matrix metalloproteinases, when activated, have
effects on the pericellular matrix and adjacent cells. Even if the anoikic cells are apoptotic resist‐
ant, because metalloproteinases are secreted in early anoikis, apoptotic resistant cells devoid of
adhesion signals could have the capacity to affect the surrounding matrix and nearby cells.
Most metalloproteinases are synthesized and secreted in a latent zymogen form. Furin-like
proteases are known to act as sheddases acting on membrane type metalloproteinases [56].
Also there are type II transmembrane serine proteases (TTSPs), and possibly other proteases,
present on the surface of glioma cells [57-59]. From the data presented here, it is reasonable to
suspect that during the process of apoptosis there are secreted furins and possibly membrane-
bound TTSPs that are capable of converting latent membrane bound or secreted metallopro‐
teinases to their active form.
To reiterate, the conventional assumption is that ongoing apoptosis within a malignant tumor
is desirable with no effects that may be harmful to the patient. What has been presented here
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raises the possibility that within the mixed cell population of LN18 glioma cells and non-
apoptotic LN18 cells, the apoptotic dying cells are capable of enhancing the invasiveness of
the LN18 cells that are not apoptotic. As far as we know, investigating the invasive synergy
between a mixture of apoptotic and non-apoptotic cells is somewhat neglected as an approach.
The data of this study can be distinctive and be complementary to other studies directed
toward the long standing problem of the malignant invasiveness of high grade gliomas.
7. Future studies
We look to identify which membrane type metalloproteinases (MT-MMPs and ADAMs) are
on the surface of the LN18 glioblastoma cells and whether there is an increase in synthesis and
their presence during apoptosis. One would surmise that inhibition of metalloproteinase
activity would be an effective clinical treatment. There have been a good number of clinical
trials for a variety of cancers determining the effectiveness of metalloproteinase inhibition
upon patient improvement and survival rates [60-65] Unfortunately such studies have been
disappointing particularly those clinical trials that have focused on glioblastomas [66,67]. The
role of metalloproteinases with regard to invasiveness of GBM appears to be more complex
than the ability of metalloproteinases to degrade the extracellular matrix (ECM). The experi‐
ments presented here raise questions about the role of furins, serine proteases, anoikis and
apoptosis and their interrelationship to metalloproteinases and invasiveness. To expand upon
the ideas presented here there is a need to determine whether the synthesis, secretion and
presence of furins and TTSPs increase with apoptosis and whether these proteases are
responsible for the activation of the latent zymogen form of metalloproteinases. Investigating
the interplay between furins, TTSPs and the increased presence and activation of metallopro‐
teinases during apoptosis in the context of the ability of apoptotic glioblastoma cells to enhance
the invasiveness and motility of glioblastoma cells is a natural extension of what was presented
here. Of particular interest is whether the apoptotic cells are acting on the extracellular matrix
or there are direct effects upon the invading non-apoptotic cells. Findings utilizing the LN18
glioblastoma cell line will need to be tested in a variety of available glioma cell lines.
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some of the cells will be more resistant to apoptosis than others which will inherently result
in a mixture of apoptotic and viable non-apoptotic tumor cells. The existence of a mixture of
apoptotic and non-apoptotic tumor cells is particularly true during recurrence and the required
therapy that inevitably induces apoptosis which leads to a population of apoptotic cells within
the tumor. As treatment progresses beyond the primary stage, mutated cells and resistant cells
that escape apoptosis will proliferate. Thus, the sustained cell population of a tumor will
consist of non-apoptotic cells capable of invading surrounding tissue while coexisting with a
dying population of apoptotic cells. This view that recurrent GBM tumors consist of cells that
are refractory to treatment while being highly invasive, and exist as a mixed population of
apoptotic and non-apoptotic cells, was the stimulus for this study.
There have been elegant studies comparing non-cancerous glial cells to gliomas and demon‐
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demonstrating membrane-type metalloproteinases expression and function during glioma
invasion [54, 55]. These studies have provided a footing and direction for this present study.
The important idea here is that there are metalloproteinase activating processes that are taking
place in apoptotic and anoikic cells. What is different about the approach proposed here is that
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of, and activity of, metalloproteinases in glioma cells as they progress through apoptosis.
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cells in early anoikis. One of the hallmarks for the induction of anoikis is the absence of cell adhe‐
sion signals. It can be assumed that the secreted matrix metalloproteinases, when activated, have
effects on the pericellular matrix and adjacent cells. Even if the anoikic cells are apoptotic resist‐
ant, because metalloproteinases are secreted in early anoikis, apoptotic resistant cells devoid of
adhesion signals could have the capacity to affect the surrounding matrix and nearby cells.
Most metalloproteinases are synthesized and secreted in a latent zymogen form. Furin-like
proteases are known to act as sheddases acting on membrane type metalloproteinases [56].
Also there are type II transmembrane serine proteases (TTSPs), and possibly other proteases,
present on the surface of glioma cells [57-59]. From the data presented here, it is reasonable to
suspect that during the process of apoptosis there are secreted furins and possibly membrane-
bound TTSPs that are capable of converting latent membrane bound or secreted metallopro‐
teinases to their active form.
To reiterate, the conventional assumption is that ongoing apoptosis within a malignant tumor
is desirable with no effects that may be harmful to the patient. What has been presented here
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raises the possibility that within the mixed cell population of LN18 glioma cells and non-
apoptotic LN18 cells, the apoptotic dying cells are capable of enhancing the invasiveness of
the LN18 cells that are not apoptotic. As far as we know, investigating the invasive synergy
between a mixture of apoptotic and non-apoptotic cells is somewhat neglected as an approach.
The data of this study can be distinctive and be complementary to other studies directed
toward the long standing problem of the malignant invasiveness of high grade gliomas.
7. Future studies
We look to identify which membrane type metalloproteinases (MT-MMPs and ADAMs) are
on the surface of the LN18 glioblastoma cells and whether there is an increase in synthesis and
their presence during apoptosis. One would surmise that inhibition of metalloproteinase
activity would be an effective clinical treatment. There have been a good number of clinical
trials for a variety of cancers determining the effectiveness of metalloproteinase inhibition
upon patient improvement and survival rates [60-65] Unfortunately such studies have been
disappointing particularly those clinical trials that have focused on glioblastomas [66,67]. The
role of metalloproteinases with regard to invasiveness of GBM appears to be more complex
than the ability of metalloproteinases to degrade the extracellular matrix (ECM). The experi‐
ments presented here raise questions about the role of furins, serine proteases, anoikis and
apoptosis and their interrelationship to metalloproteinases and invasiveness. To expand upon
the ideas presented here there is a need to determine whether the synthesis, secretion and
presence of furins and TTSPs increase with apoptosis and whether these proteases are
responsible for the activation of the latent zymogen form of metalloproteinases. Investigating
the interplay between furins, TTSPs and the increased presence and activation of metallopro‐
teinases during apoptosis in the context of the ability of apoptotic glioblastoma cells to enhance
the invasiveness and motility of glioblastoma cells is a natural extension of what was presented
here. Of particular interest is whether the apoptotic cells are acting on the extracellular matrix
or there are direct effects upon the invading non-apoptotic cells. Findings utilizing the LN18
glioblastoma cell line will need to be tested in a variety of available glioma cell lines.
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1. Introduction
The discovery of somatic isocitrate dehydrogenase (IDH) mutations in gliomas is an example
of the powerful impact of the next-generation sequencing on the comprehension of both tumor
biology and human diseases.
IDHs catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate with production
of NADH/NADPH. Thus, they are key enzymes in the Krebs cycle. For this family of metabolic
genes, no previous role in human cancer has been described. However, in a recent genome-
wide study, recurrent somatic mutations in the IDH1 gene have been identified in patients
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NADH or NADPH, depending on the isoform that catalyzes the reaction. A scheme of this
reaction is shown in Figure 1. In mammalian tissues, three different isoforms have been
described: cytosolic NADP(+)-specific IDH (IDH1), mitochondrial NADP(+)-specific IDH
(IDH2), and mitochondrial NAD(+)-specific IDH (IDH3).
The IDH1 and IDH2 isoforms are structurally related with 70% of sequence identity [2]. Both
function as homodimers, are NADP+ dependent [3] and show a moderate expression in a
variety of tissues, including brain [4]. IDH1 is active in cytosol and peroxisomes [5] while IDH2
has a mitochondrial localization [6].
The IDH3 isoform is NAD+ dependent, functions as heterodimer and is structurally unrelated
to IDH1 and IDH2 [7,8]. It is composed of three subunits (α, β and γ) organized in a multi-
tetrameric structure (2α, 1β and 1γ). α-subunit has a catalytic function whereas β- and γ-
subunits have a regulatory function [9,10]. IDH3 is localized in the mitocondria [11].
Figure 1. Enzymatic activity of wild-type and mutant IDH isoforms.
The activity of IDH1 and IDH2 in normal cells is regulated by the availability of substrate and
cofactors. A key feature of this kinetic regulatory mechanism is the directionality of the
enzymatic activity. Reactions catalyzed by IDH1 and IDH2 are reversible but not the similar
reaction catalyzed by IDH3.
The crystal structure of mammalian IDH1 and IDH2 enzymes is well-known [2,12]. The
structure of the wild-type IDH1 homodimer is reported in Figure 2.
In the IDH1 homodimer, each homolog comprises a large domain, a clasp domain and a small
domain. Each homodimer contains two asymmetric and identical active sites, each composed
of a cleft formed by the large and small domain of the other IDH1 homolog. The active sites
are exposed to solvent and are accessible to the substrate and cofactors. The clasp holds the
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two subunits together to form the active site. IDH1 shifts between an inactive open, a transi‐
tional semi-open and a catalytically active closed conformation. It dimerizes with two active
sites in the inactive open conformation, which is maintained by intramolecular interactions
between Ser94 and Asp279 residues, blocking access to the active site. Asp279 resides in the
position where the isocitrate normally forms hydrogen bonds with Ser94. During the two-step
catalysis of the oxidative decarboxylation of isocitrate to α-KG, IDH1 adopts the active closed
conformation where the steric hindrance by Asp279 to magnesium (Mg2+)-isocitrate complex
binding is relieved and the latter binds between the large and small domains of the enzyme
[2]. The reaction proceeds with production of α-KG and NADPH, followed by either the
reoccupation of the active site by another Mg2+-isocitrate complex or by restoring Ser94-Asp279
interactions in the inactive open conformation.
Figure 2. Structure of the wild-type IDH1 homodimer.
2.2. Function of isocitrate dehydrogenases in cellular metabolism
IDHs play prominent but distinctive roles in a variety of cellular metabolic functions [13]. The
main functions of IDH1 are the lipid synthesis and the cellular glucose sensing [14] while IDH2
participates in the control of both the mitochondrial redox balance and cellular oxidative
damage [15]. IDH3 plays an integral role in cellular energy metabolism.
In addition, IDHs contribute to the cellular protection generating the reducing equivalent
NAPDH and, on the other hand, they regulate the function of a variety of α-KG-dependent
processes [16-18]. Several cellular enzymes use α-KG, partially produced by IDH reactions
with isocitrate, as co-substrate. α-KG is required for the optimal function of 5-methylcytosine
(5mC) hydroxylases and histone methyltransferases that are crucial in the regulation of
epigenetic processes [18-22].
Likewise, α-KG plays an important role in the degradation of hypoxia-inducible factor-1 alpha
(HIF-1α), through a prolyl hydroxylase domain-containing protein (PHD)-mediated pathway
[23], and in the glia-specific glutamine and glutamate metabolism [24].
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2.2. Function of isocitrate dehydrogenases in cellular metabolism
IDHs play prominent but distinctive roles in a variety of cellular metabolic functions [13]. The
main functions of IDH1 are the lipid synthesis and the cellular glucose sensing [14] while IDH2
participates in the control of both the mitochondrial redox balance and cellular oxidative
damage [15]. IDH3 plays an integral role in cellular energy metabolism.
In addition, IDHs contribute to the cellular protection generating the reducing equivalent
NAPDH and, on the other hand, they regulate the function of a variety of α-KG-dependent
processes [16-18]. Several cellular enzymes use α-KG, partially produced by IDH reactions
with isocitrate, as co-substrate. α-KG is required for the optimal function of 5-methylcytosine
(5mC) hydroxylases and histone methyltransferases that are crucial in the regulation of
epigenetic processes [18-22].
Likewise, α-KG plays an important role in the degradation of hypoxia-inducible factor-1 alpha
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2.3. Function of isocitrate dehydrogenases in response to oxidative stress
In mammalian cells, the activity of IDHs increases in response to a variety of oxidative insults,
with concomitant decrease of IDH3, α-KG dehydrogenase and succinate dehydrogenase
functions [13]. NADPH plays a major role in the cellular protection against oxidative damage
due to free oxygen radicals, and from both gamma and ultraviolet radiations [16,17,25,26]. It
is also essential for the regeneration of glutathione (GSH) that neutralizes free radicals and
reactive oxygen species (ROS), and for the activity of the thioredoxin system. Although the
pentose phosphate pathway is the main source of NADPH, IDH1 and IDH2 enzymes are as
much important.
Further evidences do exist for their role in cell protection from different insults. IDH1 and
IDH2 deficiency leads to increased lipid peroxidation, oxidative DNA damage, intracellular
peroxide generation and decreased survival of a fibroblast cell line after exposure to oxidative
agents [16].
3. Epidemiology of IDH mutations in human malignancies and genetic
disorders
3.1. IDH mutations in GBMs
Mutations in the IDH1 gene were identified in a recent genome-wide analysis where 20661
protein coding genes were systematically sequenced on 22 patients affected by WHO (World
Health Organization) grade IV GBM. Among the several candidate genes not previously
associated with GBM, the IDH1 gene on chromosome 2q33.3 was the most interesting one [1].
Somatic and recurrent IDH1 mutations affecting the highly conserved arginine (R) residue at
codon 132 in the enzyme’s active site were found with a frequency of 12%. They occurred in
a large fraction of younger patients and, especially, in secondary GBMs. They were also
associated with a significant increase in patient overall survival (OS).
In agreement with the current WHO classification of the central nervous system (CNS) tumors
[27], GBMs are considered to be secondary (sGBMs) or primary (pGBM) tumors according to
the histologically verified presence or not of a previous low-grade glioma.
In a small group of GBM patients without IDH1 mutations, somatic recurrent mutations were
identified in the IDH2 gene, even though at lower frequency. They affected codon R172,
homologous to R132 of the IDH1 gene [28].
In contrast to sGBMs, IDH1 or IDH2 mutations were only found in a minority of pGBMs
(<5-10%) [1,28,29]. The recurrence of IDH1 and IDH2 mutations among GBM patients was
confirmed by following studies on larger series in Caucasian patients [30-44] as well as in
Japanese, Indian, Korean, Brazilian and Chinese patients [45-49].
In pediatric GBMs, somatic IDH mutations were only rarely identified (approximately 16%)
[28,29,50-52]. Pediatric malignant gliomas in patients ≥14 years showed a higher frequency
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(about 35%) of IDH mutations in comparison with children malignant gliomas [52]. This
finding suggests that the biology of histologically similar high-grade gliomas in younger
pediatric patients differs from adults.
Stabilized GBM cell lines (both neurospheres and adherent cells) did not show IDH1 or IDH2
mutations [53]. This finding is not surprising considering that the majority of GBM cell lines
that develop in in vitro culture originate from pGBMs.
The frequency of IDH mutations in high-grade gliomas is summarized in Table 1.







Pilocytic astrocytoma (I) 221 5 2.3 (0-5.9) 28*,30,32-34,39,42,43,59
Diffuse astrocytoma (II) 608 455 75 (30.7-100)
28*,
30,32-34,36,38-43,45,46,56
Anaplastic astrocytoma (III) 566 330 58 (44.4-87.5) 28*,30,32-36,38-42,45,46
Oligodendroglioma (II) 597 366 61 (42.9-100) 28*,30,32-34,36,38-42,46
Anaplastic oligodendroglioma (III) 561 346 62 (46-100) 28*,30,32-36,38-42,45,46,57
Oligoastrocytoma (II) 207 149 72 (49-100) 28*,30,32,33,36,38,41,42,46
Anaplastic oligoastrocytoma (III) 297 202 66 (63-100) 28*,30,32,33,36,38,42,45,46
Primary glioblastoma (IV) 2362 170 7.2 (1.8-19.4) 28*,31-37,38-43,45-49
Secondary glioblastoma (IV) 335 250 75 (15.4-84.6) 28*,31-36,38-42,45,46,48
Giant cell glioblastoma (IV) 18 4 22 (20-25) 28*
Pediatric glioblastoma (IV) 69 2 3 (0-7.6) 30,50-52
Gliomatosis cerebri 15 5 33 58
* Combined results from Balss and Hartmann studies due to duplication of some cases. Abbreviations: WHO, World Health
Organization; IDH, isocitrate dehydrogenase.
Table 1. Table 1. Frequency of IDH1 and IDH2 mutations in high- and low-grade gliomas.
3.2. IDH mutations in low-grade gliomas
After the discovery of IDH mutations in sGBMs, a great interest arose in verifying whether
these mutations were also present among low-grade gliomas. As expected, IDH1 or IDH2
mutations recur in >65-80% of WHO grade II and III astrocytomas
[28,30,32-36,38-43,45,46,54-56], and even more (approximately 70-85%) in WHO grade II and
III oligoastrocytomas and oligodendrogliomas [28-30,32-36,38-43,45,46,5-59].
Mutations in the IDH1 gene have also been found in some cases of gliomatosis cerebri [58].
In contrast to diffuse gliomas, IDH mutations are very rare or absent in a variety of WHO grade
I and II CNS tumors, such as pilocytic astrocytomas, subependymal giant cell tumors,
gangliogliomas, ependymomas and pleiomorphic xanthoastrocytomas
The Distribution and Significance of IDH Mutations in Gliomas
http://dx.doi.org/10.5772/52357
303
2.3. Function of isocitrate dehydrogenases in response to oxidative stress
In mammalian cells, the activity of IDHs increases in response to a variety of oxidative insults,
with concomitant decrease of IDH3, α-KG dehydrogenase and succinate dehydrogenase
functions [13]. NADPH plays a major role in the cellular protection against oxidative damage
due to free oxygen radicals, and from both gamma and ultraviolet radiations [16,17,25,26]. It
is also essential for the regeneration of glutathione (GSH) that neutralizes free radicals and
reactive oxygen species (ROS), and for the activity of the thioredoxin system. Although the
pentose phosphate pathway is the main source of NADPH, IDH1 and IDH2 enzymes are as
much important.
Further evidences do exist for their role in cell protection from different insults. IDH1 and
IDH2 deficiency leads to increased lipid peroxidation, oxidative DNA damage, intracellular
peroxide generation and decreased survival of a fibroblast cell line after exposure to oxidative
agents [16].
3. Epidemiology of IDH mutations in human malignancies and genetic
disorders
3.1. IDH mutations in GBMs
Mutations in the IDH1 gene were identified in a recent genome-wide analysis where 20661
protein coding genes were systematically sequenced on 22 patients affected by WHO (World
Health Organization) grade IV GBM. Among the several candidate genes not previously
associated with GBM, the IDH1 gene on chromosome 2q33.3 was the most interesting one [1].
Somatic and recurrent IDH1 mutations affecting the highly conserved arginine (R) residue at
codon 132 in the enzyme’s active site were found with a frequency of 12%. They occurred in
a large fraction of younger patients and, especially, in secondary GBMs. They were also
associated with a significant increase in patient overall survival (OS).
In agreement with the current WHO classification of the central nervous system (CNS) tumors
[27], GBMs are considered to be secondary (sGBMs) or primary (pGBM) tumors according to
the histologically verified presence or not of a previous low-grade glioma.
In a small group of GBM patients without IDH1 mutations, somatic recurrent mutations were
identified in the IDH2 gene, even though at lower frequency. They affected codon R172,
homologous to R132 of the IDH1 gene [28].
In contrast to sGBMs, IDH1 or IDH2 mutations were only found in a minority of pGBMs
(<5-10%) [1,28,29]. The recurrence of IDH1 and IDH2 mutations among GBM patients was
confirmed by following studies on larger series in Caucasian patients [30-44] as well as in
Japanese, Indian, Korean, Brazilian and Chinese patients [45-49].
In pediatric GBMs, somatic IDH mutations were only rarely identified (approximately 16%)
[28,29,50-52]. Pediatric malignant gliomas in patients ≥14 years showed a higher frequency
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications302
(about 35%) of IDH mutations in comparison with children malignant gliomas [52]. This
finding suggests that the biology of histologically similar high-grade gliomas in younger
pediatric patients differs from adults.
Stabilized GBM cell lines (both neurospheres and adherent cells) did not show IDH1 or IDH2
mutations [53]. This finding is not surprising considering that the majority of GBM cell lines
that develop in in vitro culture originate from pGBMs.
The frequency of IDH mutations in high-grade gliomas is summarized in Table 1.







Pilocytic astrocytoma (I) 221 5 2.3 (0-5.9) 28*,30,32-34,39,42,43,59
Diffuse astrocytoma (II) 608 455 75 (30.7-100)
28*,
30,32-34,36,38-43,45,46,56
Anaplastic astrocytoma (III) 566 330 58 (44.4-87.5) 28*,30,32-36,38-42,45,46
Oligodendroglioma (II) 597 366 61 (42.9-100) 28*,30,32-34,36,38-42,46
Anaplastic oligodendroglioma (III) 561 346 62 (46-100) 28*,30,32-36,38-42,45,46,57
Oligoastrocytoma (II) 207 149 72 (49-100) 28*,30,32,33,36,38,41,42,46
Anaplastic oligoastrocytoma (III) 297 202 66 (63-100) 28*,30,32,33,36,38,42,45,46
Primary glioblastoma (IV) 2362 170 7.2 (1.8-19.4) 28*,31-37,38-43,45-49
Secondary glioblastoma (IV) 335 250 75 (15.4-84.6) 28*,31-36,38-42,45,46,48
Giant cell glioblastoma (IV) 18 4 22 (20-25) 28*
Pediatric glioblastoma (IV) 69 2 3 (0-7.6) 30,50-52
Gliomatosis cerebri 15 5 33 58
* Combined results from Balss and Hartmann studies due to duplication of some cases. Abbreviations: WHO, World Health
Organization; IDH, isocitrate dehydrogenase.
Table 1. Table 1. Frequency of IDH1 and IDH2 mutations in high- and low-grade gliomas.
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After the discovery of IDH mutations in sGBMs, a great interest arose in verifying whether
these mutations were also present among low-grade gliomas. As expected, IDH1 or IDH2
mutations recur in >65-80% of WHO grade II and III astrocytomas
[28,30,32-36,38-43,45,46,54-56], and even more (approximately 70-85%) in WHO grade II and
III oligoastrocytomas and oligodendrogliomas [28-30,32-36,38-43,45,46,5-59].
Mutations in the IDH1 gene have also been found in some cases of gliomatosis cerebri [58].
In contrast to diffuse gliomas, IDH mutations are very rare or absent in a variety of WHO grade
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[28-30,32-34,39,42,43,59-62]. The frequency of IDH1 and IDH2 mutations in low-grade gliomas
is reported in Table 1.
Relatively rare neuronal and glioneuronal tumors as central neurocytomas, dysembryoplastic
neuroepithelial tumors and rosette-forming glioneuronal tumors, as well as embryonal tumors
as medulloblastomas, do not show IDH mutations [28,32,33,42,59-64].
Mutations in the IDH genes were not detected among non-glial brain tumors, with the
exception of adult (but not children) primitive neuroectodermal tumors (sPNETs)
[29,42,65,66], and maybe two cases of atypical meningiomas [67,68].
3.3. IDH mutations in other malignancies
IDH1 and IDH2 mutations are relatively glioma specific. However, they have been reported
at lower frequency in some other mesenchymal tumors, especially haematopoietic malignan‐
cies and chondroid neoplasms [69-74]. IDH mutations were identified in approximately 8% of
patients with acute myeloid leukemia (AML), in some myelodysplastic syndromes and
myeloproliferative neoplasms [70-72]. Among AML patients, they were mainly found in
tumors without cytogenetic abnormalities, and typically affect the IDH2 gene, at codons R140
or R172 [70-74]. Unlike gliomas, rare instances of AML patients with mutations in both IDH1
and IDH2 genes have been reported [75].
IDH1 mutations have also been described as a frequent event (56%) in endochondromas, as
well as in central or differentiated chondrosarcomas [69], but not in peripheral chondrosarco‐
mas or osteochondromas [76]. The majority of IDH mutations in chondroid neoplasms are
represented by the p.R132C substitution [69].
Mutations in the IDH1 and IDH2 genes are extremely rare in most of other human malignances
[35,47]. Rare IDH1 mutations, mostly characterized by the p.R132C substitution, have been
described in prostatic adenocarcinomas, thyroid carcinomas, melanomas and B-acute lym‐
phoblastic leukemia [45,77-79]. No IDH mutations were detected in brain metastases of
colorectal cancers [80].
3.4. IDH mutations in hereditary diseases
L-2- and D-2-hydroxyglutaric aciduria (L-2-HGA and D-2-HGA, respectively) are rare
neurometabolic disorders with mendelian inheritance caused by mutations in the L-2-
hydroxyglutarate dehydrogenase (L2HGDH) or D-2-hydroxyglutarate dehydrogenase (type
I D2HGDH) genes. Both are characterized by elevated levels of 2-hydroxyglutarate (2-HG) in
body fluids including urine, plasma and cerebrospinal fluid [81,82]. L-2-HGA is the most
common and severe of the two, and mainly affects the CNS. In contrast, symptoms associated
to D-2-HG may be mild to nearly absent. Interestingly, heterozygous mutations at codon R140
of the IDH2 gene were found in a subset of D2HGDH (type II D2HGDH) patients with normal
D2HGDH enzymatic activity, no D2HGDH gene mutations but with increased D2HGDH
levels in body fluids [83,84].
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Although IDH mutations result in D-2-HG accumulation, L-2-HGA but not D-2-HGA patients
have unexpectedly been reported to have a higher risk of malignant brain tumors [85-87].
Somatic mosaic IDH1 and IDH2 mutations have also been found associated in humans to
multiple endochondromatosis, Ollier disease and Maffucci symdrome [88,89]. Patients with
Ollier disease/Maffucci syndrome develop multiple central cartilaginous tumors with an
uncertain inheritance (possibly dominant inheritance with reduced penetrance); interestingly,
some of them develop gliomas and AML. A model in which IDH1 and IDH2 mutations are
early post-zygotic events in individuals affected by these syndromes has been proposed,
suggesting their implication in tumorigenesis [88].
4. Molecular genetics of IDH mutations in gliomas
4.1. Spectrum of IDH mutations
Five genes encoding human isocitrate dehydrogenases have been identified. IDH1 on 2q33.3
encodes for the IDH1 isoform [90], IDH2 on 15q26.1 for the IDH2 isoform [91], IDH3A on
15q25.1 for the α-subunit of the IDH3 isoform [92], IDH3B on 20p13 for the β-subunit [93] and
IDH3G on Xq28 for the γ-subunit [94].
All the identified mutations in gliomas affect either the IDH1 or the IDH2 gene. IDH3A, IDH3B
and IDH3G genes have not been implicated to date in gliomas [95].
All IDH1 and IDH2 mutations are somatic, heterozygous and missense changes. They typically
affect codon R132 in the IDH1 gene and its homologous R172 in the IDH2 gene, both within
the enzyme’s substrate binding site. In contrast to ALM, in gliomas mutations in the IDH1 and
IDH2 genes are always mutually exclusive.
Over 90% of the reported mutations affect the IDH1 gene and, among them, different types of
mutations have been described. The p.R132H substitution accounts for about 92.4%, followed
by p.R132C for 3.2%, p.R132G for 2.1%, p.R132G for 1.6% and p.R132L for <1%
[28,30-39,41-48,56,57,59]. The rare p.R132V nucleotide substitution, originally proposed as
somatic mutation, was later labeled as single nucleotide polymorphism (SNP) [29,78].
Interestingly, >90% of IDH1 mutations at codon R132 leads to a histidine change, suggesting
a significant selective advantage in favor of this particular point mutation.
A single report has recently identified a predicted new mutation at codon R100 (p.R100Q),
located in the enzyme’s active site, in two WHO grade III oligodendrogliomas and in one WHO
grade II astrocytoma [54]. Two other very rare IDH1 mutations (p.R49C and p.G97D) have
only been described in a single pediatric GBM patient [50].
Mutations in the IDH2 gene are less common in gliomas, accounting for 3-5% or less of all the
identified mutations [30,31,34,39,42-45,56,57,59]. The p.R172K mutation accounts for about
60%, followed by p.R172M for 26.7%, p.R172W for 11.1%, p.R172S for 2.2% [30,31,34,39,42-45,
56,57,59]. Rare nonsense IDH2 mutations have been described in a single study, with uncertain
significance [39].
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[28-30,32-34,39,42,43,59-62]. The frequency of IDH1 and IDH2 mutations in low-grade gliomas
is reported in Table 1.
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Although IDH mutations result in D-2-HG accumulation, L-2-HGA but not D-2-HGA patients
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and IDH3G genes have not been implicated to date in gliomas [95].
All IDH1 and IDH2 mutations are somatic, heterozygous and missense changes. They typically
affect codon R132 in the IDH1 gene and its homologous R172 in the IDH2 gene, both within
the enzyme’s substrate binding site. In contrast to ALM, in gliomas mutations in the IDH1 and
IDH2 genes are always mutually exclusive.
Over 90% of the reported mutations affect the IDH1 gene and, among them, different types of
mutations have been described. The p.R132H substitution accounts for about 92.4%, followed
by p.R132C for 3.2%, p.R132G for 2.1%, p.R132G for 1.6% and p.R132L for <1%
[28,30-39,41-48,56,57,59]. The rare p.R132V nucleotide substitution, originally proposed as
somatic mutation, was later labeled as single nucleotide polymorphism (SNP) [29,78].
Interestingly, >90% of IDH1 mutations at codon R132 leads to a histidine change, suggesting
a significant selective advantage in favor of this particular point mutation.
A single report has recently identified a predicted new mutation at codon R100 (p.R100Q),
located in the enzyme’s active site, in two WHO grade III oligodendrogliomas and in one WHO
grade II astrocytoma [54]. Two other very rare IDH1 mutations (p.R49C and p.G97D) have
only been described in a single pediatric GBM patient [50].
Mutations in the IDH2 gene are less common in gliomas, accounting for 3-5% or less of all the
identified mutations [30,31,34,39,42-45,56,57,59]. The p.R172K mutation accounts for about
60%, followed by p.R172M for 26.7%, p.R172W for 11.1%, p.R172S for 2.2% [30,31,34,39,42-45,
56,57,59]. Rare nonsense IDH2 mutations have been described in a single study, with uncertain
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The type and frequency of the identified mutations at codons IDH1 R132 and IDH2 R172 are











c.G395A p.R132H 1655 92.4 28,30-39,41-48,56,59
c.C394T p.R132C 58 3.2 28,30-39,41-48,56,59
c.C394G p.R132G 38 2.1 28,30-39,41-48,56,59
c.C394A p.R132S 29 1.6 28,30-39,41-48,56,59
c.G395T p.R132L 11 0.6 28,30-39,41-48,56,59
IDH2 45
c.G515A p.R172K 27 60 30,31,34,39,42-45,56,57,59
c.G515T p.R172M 12 26.7 30,31,34,39,42-45, 56,57,59
c.A514T p.R172W 5 11.1 30,31,34,39,42-45,56,57,59
c.G516T p.R172S 1 2.2 30,31,34,39,42-45,56,57,59
The reported nucleotide and amino acid numbering for the IDH1 and IDH2 genes is relative to the transcription start site
(+1) corresponding to the A of the ATG on the respective GenBank reference sequences NM_005896 and NM_002168.
Abbreviations: IDH, isocitrate dehydrogenase.
Table 2. Type and frequency of IDH1 R132 and IDH2 R172 mutations in gliomas.
4.2. Association with clinical and histological features
The occurrence of IDH mutations correlates with some clinical and histopathological features
of gliomas. The strongest significant association is between IDH mutations and patient’s age
at diagnosis in most glioma tumor subtypes [28,30,31,36,42,46,49]. Generally, the mean age of
patients with IDH mutations is significantly lower in comparison with patients without IDH
mutations. In contrast, in pediatric high-grade gliomas, patients with IDH1 mutations are older
than children with wild-type tumors [28].
In GBMs, the average time from the first clinical symptom to the histological diagnosis is
significantly longer in patients with IDH mutations than in wild-type patients, consistently
with a slower growth and less aggressive tumor [31].
In adult patients, IDH mutations are significantly and inversely associated with the histological
malignancy grade [28,36]. Interestingly, they show a non-random distribution within the
glioma subtypes [30]. The p.R132C mutation in the IDH1 gene is strongly associated with the
astrocytic phenotype while IDH2 mutations mainly affect oligodendroglial tumors [30,41].
When astrocytomas develop in patients affected by Li-Fraumeni syndrome, they always show
the p.R132C mutation [55], suggesting that precursor cells, which for definition already carry
a germline tumor protein p53 (TP53) mutation, specifically acquire this relatively uncommon
IDH1 mutation.
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In GBMs, the occurrence of an oligodendroglial component is significantly more frequent in
tumors with IDH mutations, as well as large ischemic and pseudopalisading necroses are
typical hallmarks of wild-type tumors [31].
Finally, a preferential distribution of IDH mutations within different regions of the brain has
been reported in two recent large-scale studies. WHO grade II-III gliomas and pGBMs with
IDH1 mutations are mainly located in the frontal lobe (73.5%) rather than in the temporal lobe
(41.7%) [49,96]. This distribution, similar to that of 1p/19q co-deletion, provides further
evidence for the distinctiveness of gliomas from different brain lobes. The absence of IDH
mutations also identify, among WHO grade II gliomas, a novel tumor subtype characterized
by a predominant insular location, greater tumor size, infiltrative aspects on magnetic
resonance imaging (MRI) and dismal prognosis [56].
4.3. Association with genetic and epigenetic alterations
IDH mutations show significant associations with some of the typical genetic and epigenetic
changes of gliomas. IDH mutations are tightly associated with the 1p/19q co-deletion and the
methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation status
[33,36,37,42,57,97,98].
Interestingly, they are inversely correlated with the specific genetic alterations of pGBMs, such
as the epidermal growth factor receptor (EGFR) amplification, the cyclin-dependent kinase
inhibitor 2A or 2B (CDKN2A/CDKN2B) deletion and the phosphatase and tensin homolog
(PTEN) mutations [28,32]. The mutual exclusion with EGFR amplification coincides with the
rarity of IDH mutations in pGBMs [33,36,37,42,57,98].
Furthermore, astrocytic tumors and GBMs with IDH mutations typically show a higher rate
of TP53 mutations in comparison with wild-type tumors [28,32,33,46,98].
The strong association between IDH mutations and the 1p/19q co-deletion in oligodendro‐
gliomas corresponds to approximately 100% concordance in the occurrence of both genetic
alterations, as confirmed by three independent large-scale studies [28,98,99]. In oligodendro‐
cytic tumors, IDH mutations also correlate with somatic mutations in the homolog of the
Drosophila capicua (CIC) gene on chromosome 19q13.2, suggesting a putative role of the latter
in the pathogenesis of this tumor subtype [100,101]. Interestingly, a significant association was
also found with the epithelial membrane protein 3 (EMP3) promoter hypermethylation status
[personnal data].
IDH mutations and the KIAA1549- v-raf murine sarcoma viral oncogene homolog B1 (BRAF)
fusion gene are considered two mutually exclusive genetic events in diffuse and pilocytic
astrocytomas, respectively. However, in a series of 185 adult diffuse gliomas, IDH mutations
coexist with the KIAA1549-BRAF fusion gene, mainly in oligodendroglial tumors [102].
4.4. Timing and relationships with gliomagenesis
The majority of tumors with IDH mutations also harbor either TP53 mutations or 1p/19q co-
deletion [28,29,32]. The concurrence of IDH and TP53 mutations is typically observed in WHO
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grade II and III astrocytic tumors, as well as in sGBMs. The concomitance of IDH mutations
with 1p/19q co-deletion is mainly found in WHO grade II and III oligodendrogliomas. WHO
grade II and III oligoastrocytic tumors mostly show IDH mutations in association with TP53
mutations and 1p/19q co-deletion.
The temporal sequence of the genetic and epigenetic events during gliomagenesis has recently
been determined [33]. A series of paired initial and recurrent tumors from 51 patients was
screened for the occurrence of both IDH1 and TP53 mutations, and 1p/19q co-deletion. In this
study, diffuse astrocytomas and oligodendrogliomas with IDH1 mutations at first surgery
developed, respectively, either TP53 mutations or 1p/19q co-deletion, at recurrence. In this
series, no tumor developed IDH1 mutations after the acquisition of either TP53 mutations or
1p/19q co-deletion [33]. This finding validates the chronological order proposed for the genetic
events during gliomagenesis with IDH1 mutations as the earliest genetic event, interesting the
common glial precursor cell population, even before EGFR amplification [36,57]. The succes‐
sive acquisition of TP53 mutations or 1p/19q co-deletion may lead, respectively, to the
astrocytic or oligodendroglial differentiation. This hypothesis is further supported by the
significant association of IDH mutations with 1p/19q co-deletion in oligodendrogliomas and
with TP53 mutations in astrocytomas [57,99].
In contrast, pilocytic astrocytomas showing the KIAA1549-BRAF fusion gene should derive
from different progenitors.
Interestingly, IDH mutations do occur in sGBMs, but not in pGBMs. This difference must be
referred to the different origin of the two tumor subtypes. sGBM develops from a previous
astrocytoma, whereas pGBM is a de novo tumor. They differ for the genetic configuration, age,
and growth speed [103], but not for location and phenotype; at the most, they can differ for the
spreading modalities [104]. It is not known how de novo tumors arise, whereas it is believed that
secondary ones originate through anaplasia, i.e. through dedifferentiation of tumor cells which
follows mutation accumulation [27]. Generally, it is known that GBMs originate either from
Neural Stem Cells (NSCs) or from astrocytes [105] and this could correspond to the distinction
between pGBMs and sGBMs. Obviously, it is likely that the two GBM subtypes must originate
ab initio from the same Cancer Stem Cells (CSCs). The development of GBM in the emisphere,
far away from the sub-ventricular zone (SVZ), could be in contrast with its origin from NSCs of
the same region, but this can be got over if we refer to the concept of both asymmetric division
and migration of progenitors [106]. A path has been traced from mitotically active precursors to
the developed tumors [107], which recognizes in transiently dividing progenitors and in somatic
stem cells, the elements where mutations accumulate; they also express EGFR, present in normal
progenitors of the SVZ [108]. These cells are the possible source of pGBMs, whereas for sGBMs
it is mandatory to refer to a previous astrocytoma [109,110].
A genetic model for the origin and progression of the different glioma subtypes is shown in
Figure 3.
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4.5. Association with the Proneuronal glioma subtype
Gene expression profiling studies of high-grade gliomas have permitted a subclassification of
tumors according to a molecular signature [112]. In a recent study on 115 WHO grade II and
III astrocytomas, three distinct subgroups termed Proneuronal, Proliferative and Mesenchy‐
mal have been identified, in agreement with similarities in expression profiling of survival-
related genes [112]. The Proneuronal group is characterized by a better prognosis and by
expression of genes associated with normal brain and neurogenesis. The Proliferative group
has a markedly better prognosis and shows expression of genes associated with both prolif‐
eration and angiogenesis, whereas the Mesenchymal group has a poorer prognosis and
expresses genes associated to mesenchymal origin. Most WHO grade III gliomas, as well as
Abbreviations: IDH, isocitrate dehydrogenase; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CDKN2A/B, cy‐
clin-dependent kinase inhibitors 2A and 2B; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin
homolog; TP53, tumor protein p53; HD, homozygous deletion; GBM, glioblastoma multiforme; WHO, World Health
Organization.
Figure 3. Model for the development of astrocytic and oligodendrocytic tumors. Two different pathways have been
proposed, according to the IDH mutation status [111]. In the IDH-dependent pathway, WHO grade II astrocytomas
and oligodendrogliomas arise by first acquisition of IDH mutations and successive development of either TP53 muta‐
tions or 1p/19q co-deletion. They further progress to WHO grade III astrocytomas or oligodendrogliomas and, ulti‐
mately, become secondary GBMs. WHO grade II and III oligoastrocytomas show genetic changes common to both
astrocytomas or oligodendrogliomas. In the IDH-independent pathway, primary GBMs de novo develop irrespective of
IDH mutations, by acquisition of the following genetic alterations: EGFR amplification, PTEN mutations and CDKN2A/
CDKN2B homozygous deletion. Pilocytic astrocytomas arise by acquisition of the KIAA1549-BRAF fusion gene (modi‐
fied from Ref.111).
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75% of low-grade gliomas, were classified as Proneuronal. Interestingly, IDH mutations were
significantly associated to the latter subgroup.
Recently, the Cancer Genome Atlas (TCGA) Research Network has been hired to generate the
comprehensive catalogue of genomic abnormalities occurring during tumorigenesis in the
majority of human cancers [113]. Among them, GBM was chosen as the pilot disease for this
project. Based on gene expression profiling of 206 GBMs, the following four clinically relevant
subtypes were identified: Classical, Proneuronal, Neuronal and Mesenchymal. Aberrations
and gene expression of EGFR, neurofibromatosis type I (NF1) and platelet-derived growth
factor receptor A (PDGFRA)/IDH1 each defines the Classical, Mesenchymal and Proneuronal
subtype [113]. Notably, most sGBMs were classified as Proneuronal. The successive up-dated
TGCA report confirmed the association with this favorable GBM subtype [114].
An independent study by array-based comparative genomic hybridization (CGH) analy‐
sis identified distinct genomic and expression profiles between pGBMs and sGBMs [44].
Few pGBMs with IDH1 mutations have similar expression profiles as sGBMs with IDH1
mutations [44].
Similar findings were described in low-grade gliomas [115]. In a series of 101 diffuse astrocytic
gliomas, IDH mutation status discriminated molecularly and clinically distinct low-grade
glioma subsets, where tumors with IDH mutations show TP53 mutations, PDGFRA overexpres‐
sion, and better survival. In contrast, tumors without IDH mutations show EGFR amplifica‐
tion, PTEN loss, and unfavorable disease outcome. Furthermore, global expression profiling
revealed three robust molecular subclasses within lower grade diffuse astrocytic gliomas, two
of which mainly characterized by IDH mutations and TP53 mutations and one prevailingly wild-
type. The former can be distinguished from each other on the basis of TP53 mutations, DNA
copy number abnormalities, and links to distinct stages of neurogenesis in the SVZ [115].
4.6. Association with the G-CIMP hypermethylated phenotype
In a genome-wide DNA methylation analysis in human gliomas distinct methylation profiles
have been associated with gene expression subtypes [114]. Interestingly, a specific glioma CpG
island methylator phenotype (G-CIMP) was found, able to define a distinct molecular subclass
of tumors. G-CIMP is analogous to the CpG island methylator phenotype (CIMP) previously
described in a number of human malignances, including AML and colorectal carcinoma [116].
Similarly to these, G-CIMP is characterized by a high number of hypermethylated loci. The G-
CIMP prevails among low-grade gliomas, shows distinct copy number alterations and
correlates with better survival and younger age [114].
Notably, it is strongly associated with IDH mutations and the Proneuronal subtype
[114,117,118]. The significant association between IDH mutations and MGMT promoter
hypermethylation found by us [42,97] and by others [33,36,37,57] in low-grade gliomas is in
line with this finding.
Remarkably, IDH mutations alone are sufficient to establish the G-CIMP, by remodelling the
methylome and the transcriptome. Introduction of mutant IDH1 into primary human astro‐
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cytes alters specific histone marks, induces extensive DNA hypermethylation and reshapes
the methylome [119].
As for gliomas, IDH mutations have also been found associated with peculiar DNA hyper‐
methylation pattern in AML [116]. In the latter, hypermethylation may be alternatively caused
by inhibition of the oncogene family member 2 (TET2). TET2 encodes an α-KG-dependent
dioxygenase that catalyzes the formation of 5-hydroxymethylcytosine (5hmC), with subse‐
quent DNA demethylation [120,121].
5. Molecular pathogenesis of IDH mutations
5.1. Biochemistry of mutant isocitrate dehydrogenases
All the identified IDH mutations in gliomas are amino acid substitutions at codon R132 in the
IDH1 and codon R172 in the IDH2 gene. Both residues are highly conserved and involved in
the formation of the active site of the two enzymes.
During the two-step catalysis of the oxidative decarboxylation of isocitrate to α-KG, IDH
adopts an active closed conformation where the Mg2+-isocitrate substrate complex binds
between large and small domains of the enzyme [2]. The active site is composed of two groups
of key residues. The first consists of two essential catalytic residues in IDH1, tyrosine (Y) 140
and lysine (K) 212, that participate in the acid-base catalysis during decarboxylation of
isocitrate and are evolutionarily highly conserved [122]. The second consists of a triad of
arginines (R100, R109 and R132 in IDH1 and R140, R149 and R172 in IDH2) in the Mg2+-
isocitrate complex recognition site that forms a salt-bridge with the substrate [77].
Modelling studies on human cytosolic IDH1 structure suggest that substitutions at R132 would
impair interactions of the enzyme with the substrate [23]. Among all the amino acid residues
involved in the binding with isocitrate, R132 only forms three hydrogen bonds with the α- and
β-carboxyl of isocitrate, while all the others no more than one or two. Therefore, substitutions
at R132 may weaken the hydrogen bond of IDH1 to substrate. Since R132 contacts Asp297 in
the transitional semi-open conformation of IDH1, it may be important in the transition from
open to closed conformation [19]. In this regard, R172, as well as R140 in IDH2, is equivalent
to R132. These chemical factors may explain why mutations in the IDH1 and IDH2 genes
exclusively affect these amino acids.The position, rather than the nature of the amino acid
substitution, seems to affect the IDH activity, by conferring a selective advantage to tumor
cells with IDH mutations [77].
To date, all the identified mutations have been tested, and all of them impair the normal IDH
enzymatic activity [23,32]. The enzymatic activity of IDH mutant proteins is significantly
reduced, irrespective of the nature of the amino acid substitution [35,111]. Any amino acid
substitutions in one of the two homologue arginines R100 or R132 in IDH1 and R140 and R172
in IDH2 lead to the same gain of function in both proteins. Interestingly, the third conserved
arginine (R109 in IDH1 and R149 in IDH2) of the triad has never been reported to be mutated [54].
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the formation of the active site of the two enzymes.
During the two-step catalysis of the oxidative decarboxylation of isocitrate to α-KG, IDH
adopts an active closed conformation where the Mg2+-isocitrate substrate complex binds
between large and small domains of the enzyme [2]. The active site is composed of two groups
of key residues. The first consists of two essential catalytic residues in IDH1, tyrosine (Y) 140
and lysine (K) 212, that participate in the acid-base catalysis during decarboxylation of
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isocitrate complex recognition site that forms a salt-bridge with the substrate [77].
Modelling studies on human cytosolic IDH1 structure suggest that substitutions at R132 would
impair interactions of the enzyme with the substrate [23]. Among all the amino acid residues
involved in the binding with isocitrate, R132 only forms three hydrogen bonds with the α- and
β-carboxyl of isocitrate, while all the others no more than one or two. Therefore, substitutions
at R132 may weaken the hydrogen bond of IDH1 to substrate. Since R132 contacts Asp297 in
the transitional semi-open conformation of IDH1, it may be important in the transition from
open to closed conformation [19]. In this regard, R172, as well as R140 in IDH2, is equivalent
to R132. These chemical factors may explain why mutations in the IDH1 and IDH2 genes
exclusively affect these amino acids.The position, rather than the nature of the amino acid
substitution, seems to affect the IDH activity, by conferring a selective advantage to tumor
cells with IDH mutations [77].
To date, all the identified mutations have been tested, and all of them impair the normal IDH
enzymatic activity [23,32]. The enzymatic activity of IDH mutant proteins is significantly
reduced, irrespective of the nature of the amino acid substitution [35,111]. Any amino acid
substitutions in one of the two homologue arginines R100 or R132 in IDH1 and R140 and R172
in IDH2 lead to the same gain of function in both proteins. Interestingly, the third conserved
arginine (R109 in IDH1 and R149 in IDH2) of the triad has never been reported to be mutated [54].
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Recently, IDH1 mutations at codons R100 (in adult glioma) and G97 (in pediatric GBM and
colon cancer cell lines), as well as at the predicted Y139, have been found to be associated with
D-2-HG production [124]. In contrast, IDH1 SNPs V71I and V178I, as well as several single
report non-synonymous substitutions, have no effect on cellular D-2-HG levels and retain the
wild-type ability for isocitrate-dependent NADPH production [123].
5.2. Dominant negative enzymatic activity
The mechanism by which IDH1 and IDH2 mutations mediate oncogenesis in gliomas is not
completely clarified [20,24,124]. However, two hypotheses have been proposed (Figure 4)
[125-128]. Both IDH1 and IDH2 mutant enzymes show a loss of function in the forward reaction
leading to a reduced production of α-KG and NAPDH [23] and a gain of function in the reverse
reaction leading to an increased production of D-2-HG [19]. Both loss- and gain-of function
reactions may have significant implications for cellular metabolism in glioma tumor cells.
In agreement with the loss of function hypothesis, IDH mutations may dominantly inhibit the
wild-type copy of the homodimer. By in vitro studies, it was found that the IDH1 wild-type/
mutant heterodimer exhibits only 4% of the enzymatic activity of the IDH1 wild-type homo‐
dimer, with a reduced production of α-KG and NADPH [23]. Neverthless, this dominant
negative inhibition by the mutant proteins may not be observed for all the known IDH mutant
types [129]. Definite evidence that dominant negative activity occurs in vivo is lacking [73, 128].
Figure 4. Functions of normal (A) and mutant (B) isocitrate dehydrogenase (IDH) enzymes (modified from Ref.126).
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5.3. Neomorphic enzymatic activity
The only consequence universally recognized for all types of IDH mutations is the acquisition
of a neomorphic enzymatic activity to reduce α-KG to the new metabolite D-2-HG [19]. This
finding is in favor of the oncogenetic function of the IDH mutant proteins. Furthermore, the
mutation pattern with hot-spot missense nucleotide substitutions in a heterozygous status is
typical of activated oncogenes, for example v-ki-ras2 kirsten rat sarcoma viral oncogene
homolog (KRAS) and BRAF [128]. Thus, IDH1 and IDH2 genes may function as oncogenes
rather than tumor suppressor genes, and IDH1 and IDH2 mutations as oncogenic driver rather
than passenger mutations [77]. Moreover, the 2q34 region, in which IDH1 maps, is one of the
most stable chromosomal regions in gliomas, with rare deletions described.
The specific orientation by which the hydride transfer takes place in the IDH1 active site results
in the production of the R(-) enantiomer of 2-HG, that is equivalent to the D-isomer [77].
Interestingly, the IDH mutant proteins only produce D-2-HG but not its enantiomer L-2-HG
[19]. This unique feature may be useful to understand the mechanism by which IDH mutations
contribute to gliomagenesis [127].
The occurrence of IDH mutations results in an increased (approximately 100-fold) amount of
D-2-HG [19,73]. D-2-HG is structurally similar to α-KG and then it functions as a competitive
inhibitor of multiple α-KG-dependent enzymes with important roles in cancer. They are
mainly dioxygenases, which use α-KG as co-substrate to catalyze a variety of reactions,
including the repair of alkylated DNA, the response to hypoxia and the biosynthesis of
collagene or L-carnitine [130]. Three relevant classes of dioxygenases are PHDs, histone
demethylases and the TET family of 5mC hydroxylases [131].
5.4. Hypoxia signaling pathway
PHD promotes the degradation of the HIF-1α. The latter is a transcription factor of crucial
importance in the cellular response to hypoxia. It activates the transcription of genes involved
in apoptosis, cell survival, and angiogenesis, most notably vascular endothelial growth factor
(VEGF) [23]. A variety of human cancers show up-regulation of HIF-1α, probably associated
with the VEGF-mediated angiogenesis. D-2-HG produced by the IDH mutant enzymes may
compete with α-KG and inhibit the PHD-mediated degradation of HIF-1α. Increased HIF-1α
levels may induce VEGF expression and consequently promote angiogenesis and enhance‐
ment of tumor growth [23]. In favor of this hypothesis, induction of R132H mutant IDH1 up-
regulates HIF-1α inducible genes including VEGF in U87MG glioma cells [23]. However, the
up-regulation of HIF-1α in glioma tissues with IDH1 mutations has not been replicated by
others [132]. Moreover, WHO grade II and III gliomas are not so vascularized and do not show
angiogenesis, as it would expect for tumors that activate this hypoxia signaling pathway.
5.5. Genome-wide epigenetic deregulation
IDH mutations may promote tumorigenesis by genome-wide epigenetic deregulation through
the inhibition of demethylation of 5mC and histones. A member of the α-KG-dependent
dioxygenases is the TET family of 5mC hydroxylases [18,131]. TET2 is a putative tumor
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suppressor gene at chromosome 4q24 that plays an important role in the regulation of DNA
methylation by conversion of 5mC into 5hmC. The great majority of DNA methylation sites
are 5mC at CpG dinucleotides and 5hmC is regarded as an intermediate product of DNA
demethylation. D-2-HG produced by the IDH mutant proteins may inhibit TET2-mediated
demethylation, leading to a global hypermethylation [131].
Interestingly, a subset of AML patients with TET mutations, which are mutually exclusive with
IDH mutations, show the same hypermethylation phenotype of patients with IDH mutations,
suggesting that IDH-mutant tumors may be mediated by TET2 inhibition [120]. This finding
also suggests that IDH and TET2 mutations may be functionally redundant.
The tight association between the occurrence of IDH mutations and the before mentioned G-
CIMP in gliomas, as well as with the CIMP in AML, is a strong evidence in favour of this
hypothesis. Not least is the direct evidence that IDH mutations alone establish G-CIMP, as
recently reported [119]. Moreover, overexpression of R132H mutant IDH1 or R172K mutant
IDH2 in 293T cells leads to increased D-2-HG and to a significant up-regulation of global 5mC
levels [120].
An alternative epigenetic mechanism involved in the regulation of gene expression is repre‐
sented by histone lysine methyltransferases that mediate the methylation of histone proteins
[131]. Increased D-2-HG levels may result in alterations of the methylation status of lysine
residues in histones, such as H3K9, H3K27 and H3K79 [132]. D-2-HG-producing IDH mutants
can prevent the histone demethylation required for lineage-specific progenitor cells to
differentiate into completely differentiated cells [133]. The introduction of either mutant IDH
or cell-permeable 2-HG is associated with repression of the inducible expression of lineage-
specific differentiation genes and with a block in cell differentation. Notably, the aberrant
histone methylation may precede and occur independently of DNA methylation [133].
Overall, by these two mechanisms IDH mutations may induce DNA hypermethylation at a
number of target genes and globally deregulate gene expression.
5.6. Response to oxidative insults
An alternative hypothesis is related to the IDH function in the cellular protection by generation
of the reducing equivalent NADPH. The latter plays an important role in the protection of cell
from oxidative damage and radiation-induced stress by contributing to GSH reductase and
thioredoxin systems.
Human brain is highly susceptible to oxidative stress because of high oxygen consumption,
relative lack of antioxidant enzymes and large amount of iron, a well-known pro-oxidant [134].
The main source of DNA damage in brain is represented by ROS produced during normal
cellular metabolism [135]. GSH is the most important antioxidant against the oxidative stress
caused by ROS. NAPDH is required for the reduction of glutathione disulfide (GSSG) to GSH
by glutathione reductase and for the maintenance of the antioxidant status of GSH in the cell.
The cytosolic IDH1 contributes to the NADPH pool in the cell, even though two other cytosolic
enzymes, glucose 6-phosphate dehydrogenase (G6PD) and the malic enzyme, also generate
NADPH [16].
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Under oxidative stress conditions, the activity of NAD+-dependent IDHs increases. IDH
mutations reduce the ability of IDH to produce NADPH from NADP+ [19,23,32,111], but also
deplete NADPH by consuming it as cofactor to convert α-KG in D-2-HG with NADP+
production [19]. Cells with reduced NADP-dependent IDH activity have increased oxidative
DNA damage, higher GSSG to total GSH ratio and reduced survival on exposure to oxidative
stress [16].
Oxidative DNA damage may promote the occurrence of other genetic changes, for example
TP53 mutations or t(1;19) translocation favoring, respectively, the differentiation of the
astrocytic or oligodendrocytic lineage. Furthermore, DNA damage may lead to DNA double-
strand breaks [136] and ROS accumulation has been shown to induce unbalanced translocation
in leukemia cells [137]. This finding may explain the high prevalence of t(1;19) translocation
(corresponding to the total 1p/19q co-deletion) in oligodendrogliomas with IDH mutations.
This hypothetical model may also explain why D-2-HGA patients do not develop gliomas,
because mutations in the D2HGDH gene in these patients would not affect the redox system
via GSH [127].
5.7. Aberrant glucose sensing
A possible selective advantage for tumor cells could derive from the role of IDH1 in the glucose
sensing. IDH1 participates in a glucose-sensing pathway in pancreatic islets [138] by signaling
the presence of high glucose to downstream members of this pathway by raising the NADPH
levels. IDH1 and IDH2 mutant proteins consume NADPH to convert α-KG to D-2-HG
decreasing the cytosolic NADPH level. This may be wrongly considered as signal of a low
nutrient status in the glucose-sensing pathway. Cells may compensate this status by increasing
cellular nutrient consumption or by blocking cellular differentiation. The former is known as
a typical tumor hallmark and it may give tumor cells a selective growth advantage. Indeed,
both glioma and AML tumor cells are relative undifferentiated [73]. The block of differentia‐
tion, finally, may benefit tumor cells by self-renewal.
6. Assessment of IDH mutation status
Currently, different methods are available to determine the IDH mutation status. They analyze
either the nucleotide sequence of the gene or the altered structure of the protein.
6.1. Gene sequencing
Practical guidelines are available for a reliable detection of IDH mutations with molecular
genetics techniques. In this regard, crucial aspects are the availability of tumor tissue, the tumor
cell content and the quality of the respective genomic DNA (gDNA). The amount of tumor
tissue available for the genetic analysis is often limited, especially for stereotactic biopsies. It
also depends on the modality of tissue dissection, by manual macrodissection or laser capture
microdissection (LCM).
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(corresponding to the total 1p/19q co-deletion) in oligodendrogliomas with IDH mutations.
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6. Assessment of IDH mutation status
Currently, different methods are available to determine the IDH mutation status. They analyze
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Practical guidelines are available for a reliable detection of IDH mutations with molecular
genetics techniques. In this regard, crucial aspects are the availability of tumor tissue, the tumor
cell content and the quality of the respective genomic DNA (gDNA). The amount of tumor
tissue available for the genetic analysis is often limited, especially for stereotactic biopsies. It
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microdissection (LCM).
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The content in tumor cells is a critical point because contaminating cells from adjacent normal
brain tissue, lymphocyte infiltrates, microglial and endothelial cells may dilute the mutant
allele below the detection threshold level leading to false negative results. Consequently, each
tumor sample should be as pure as possible and should reflect the highest percentage of tumor
cells. This can be particularly problematic in tumor biopsy specimens. Prior to gDNA extrac‐
tion, the identification and selection of tumor areas as proliferating, by haematoxylin and eosin
(H&E) staining and microscopic examination, is therefore mandatory.
Among DNA-based methods, conventional Sanger sequencing is the most frequently used. It
is a relatively inexpensive method for laboratories with access to an automated sequencer and
it represents to date the “gold standard” for the detection of IDH mutations. It allows to identify
all the possible sequence variations in the amplified region with a sensitivity of approximately
20% of the mutant allele in a wild-type background. Typically, Sanger sequencing is carried
out on formalin or RCL2 fixed paraffin embedded tumor tissue, rather than on fresh frozen
tissue, because the latter is frequently unavailable. The effects on gDNA quality of the different
variables affecting tissue fixation are not to be neglected.
Bi-directional Sanger sequencing on at least two replicates is strongly recommended [139].
Representative electropherograms of IDH1 and IDH2 mutations detected in our previous
study [42] are shown in Figures 5,6.
Figure 5. Electropherograms of representative mutations in the IDH1 gene. A – IDH1 wild-type; B – c.G395A
(p.R132H); C – c.C394G (p.R132G); D – c.G395T (p.R132L); E – c.C394T (p.R132C); F – c.C394A (p.R132S).
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Figure 6. Electropherograms of representative mutations in the IDH2 gene. A – IDH2 wild-type; B – c.G515T
(p.R172M); C – c.G516T (p.R172S).
Alternatively to Sanger sequencing, several studies have successively applied pyrosequencing
technique [40,140]. The tightly clustered nature of the IDH mutations makes them ideal
candidates for pyrosequencing. This technique allows a quantitative analysis and high
throughput, with a sensitivity of 5-7% of the mutant allele in a wild-type background.
6.2. Alternative molecular techniques
Alternative methods to assess the IDH mutation status exist. They include derived cleaved
amplified polymorphic sequence (dCAPS) [141], PCR-based restriction length polymorphism
assays [142], cold PCR high resolution melting (HRM) [143], post-PCR fluorescence melting
curve analysis (FMCA) [39] and SNaPshot assays [144]. The two latter methods are character‐
ized by a sensitivity of approximately 2 and 5%, respectively.
Among the above mentioned techniques, melting curve analysis is currently approved for
clinical use in the detection of BRAF and KRAS point mutations [62].
Anyway, the choice of the detection method both depends on the researcher’s expertise and
the laboratory facilities.
6.3. Immunohistochemistry
Two monoclonal antibodies (Mab), H09 (referred in some papers as anti-mIDH1R132H) and
IMab-1, have been developed to recognize the mutant-specific epitope of the IDH1 R132H
mutant protein [145,146]. These antibodies can be used for both immunohistochemical
analyses of tumor tissue and Western blotting analyses of tumor cell lysates. However, the
latter procedure is not used in the clinical practice. Currently, the clone H09 antibody is the
only commercially available (Dianova, Hamburg, Germany), with satisfactory results in the
routine immunohistochemistry of formalin or RCL2 fixed paraffin embedded tissues
[29,34,38,42,43].
The sensitivity and specificity of the clone H09 to detect positive tumor cells has been widely
demonstrated in several studies and approaches 100% [38,42,145]. In comparison with IMab-1,
clone H09 shows superior staining results [139].
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latter procedure is not used in the clinical practice. Currently, the clone H09 antibody is the
only commercially available (Dianova, Hamburg, Germany), with satisfactory results in the
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Recently, a new Mab (SMab-1) directed to the p.R132S mutation of the IDH1 gene has been
developed [148]. SMab-1 seems to show a specificity similar to that of clone H09 in both
immunohistochemistry and immunocytochemistry; further studies are required to validate its
use. The monoclonal antibody SMab-1 should be soon commercially available.
While the current clone H09 is highly specific for the IDH1 p.R132H mutation, it does not detect
the other rare substitutions in the IDH1 or IDH2 genes [38]. For this reason, Sanger sequencing
of the relevant exons of the IDH1 and IDH2 genes is always recommended to exclude the
occurrence of other types of mutations in immunonegative cases [42,59,62,56,148].
The  immunohistochemical  analysis  of  the  IDH1  p.R132H  mutation  can  be  manually
performed or by automated immunostaining instruments. The Euro-CNS research commit‐
tee has recently proposed practical guidelines to standardize the diagnostic IDH test with
clone H09 by both procedures [139]. The “Vienna protocol”, established at the Institute of
Neurology, Medical University of Vienna (Austria), is recommended for manual immunos‐
taining. In contrast, the “Heidelberg protocol”, established at the Department of Neuropa‐
thology,  Institute  of  Pathology,  Ruprecht-Karls-Universität  Heidelberg  (Germany),  is
recommended  for  automatic  immunostaining  on  Ventana  BenchMark  immunostainers
(Ventana Medical Systems, Tucson, AZ, USA) [139].
6.4. Immunoreactivity of the IDH1 R132H mutant protein
In our experience, as well as in the experience of others, the anti-mIDH1R132H immunoreactivity
is cytoplasmic and perinuclear. In a variable percentage of cases, the staining is diffuse in the
glia-fibrillary network. In some instances, an additional slightly weaker nuclear staining can
be observed, although IDH1 is physiologically located in cytoplasm and peroxisomes. Normal
cells, endothelial cells and lymphocytes are immunonegative.
In positive diffuse astrocytomas, all the cells show immunoreactivity (Figure 7A). The
gemistocytic cells of astrocytomas are weakly positive with a reduced reaction in the center of
the cells (Figure 7B). In this case, the doubt that it is not a specific reaction cannot be excluded.
In oligodendrogliomas, the staining is intense and perinuclear (Figure 7C). The minigemisto‐
cytes show a more compact staining of the cytoplasm. In oligodendroglial tumors with a sharp
boundary with the normal tissue, the protein expression abruptly ceases at the tumor border;
only isolated and rare positive cells are scattered in the normal tissue. In infiltrating tumors,
a gradient of positive cells at the border with normal tissue is clearly visible (Figure 7D). In
these tumors, tumor cells positive for the clone H09 are mixed with and distinguishable from
normal oligodendrocytes (Figure 8E). The latter can be identified for their Cyclin D1 positive
expression, being the two stainings complementary. In gliomas, only cycling cells such as
tumor oligodendrocytes and reactive and tumor astrocytes express Cyclin D1 while all the
other cells are immunonegative. In contrast, normal oligodendrocytes of the cortex and white
matter, and microglial cells exhibit a Cyclin D1 positive nuclear staining [149,150]. Applied to
oligoastrocytomas, the analysis of Cyclin D1 could prevent the identification of tumor cells as
normal oligodendrocytes. In tumors with high cell density, oligodendrocytes appear com‐
pacted with a round cytoplasm, whereas in infiltrated areas they acquire an elongated form
with polar processes, similar to that observed by silver impregnation (Figure 8B).
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The majority of perivascular oligodendrocytes (Figure 8A) and perineuronal satellites are
positive with elegant images (Figure 8C), with some exceptions (Figure 8D). Some of them are
immunonegative for clone H09 but immunopositive for Cyclin D1.
Figure 7. Anti-mIDH1R132H immunohistochemistry. A – Diffuse astrocytoma, immunoreactive cells; B – Gemistocytic as‐
trocytoma, immunoreactive cells; C – Oligodendroglioma, diffuse immunoreactivity of the cells; D – Oligodendroglio‐
ma, gradient of immunoreactivity toward the cortex; E – sGBM, sharp border; F – sGBM, immunoreactive cells. All DAB,
x200.
In GBMs, positive cells may be polymorphous and the tumor borders could be either sharp or
with a gradient of positive cells (Figures 7E,F). Cells crowded around vessels are strongly
positive. Giant cells could be either positive or negative.
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Pilocytic astrocytomas rarely show immunoreactivity. Reactive astrocytes could be easily
recognized for their H09-negative and GFAP-positive immunostaining (Figure 8F).
Figure 8. Anti-mIDH1R132H immunohistochemistry. A – Oligodendroglioma, pericapillary cell crowding. DAB, x200; B –
Oligodendroglioma, various cell forms in the tumor periphery. DAB, x400; C – Oligodendroglioma, positive perineuro‐
nal satellites. DAB, x400; D – Oligodendroglioma, positive and negative perineuronal satellites. DAB, x400; E – Oligo‐
dendroglioma, positive and negative cells in an infiltrated area. DAB, x200; F – Double immunohistochemistry
showing mIDH1R132H-positive tumor oligodendrocytes and GFAP-positive reactive astrocytes. DAB and Alkaline Phos‐
phatase Red, respectively, x400.
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7. Diagnostic, prognostic, predictive and therapeutic considerations
7.1. Diagnostic relevance of IDH mutation assessment
The anti-mIDH1R132H immunohistochemical evaluation is of great utility in the diagnosis of
human brain tumors. As already reported, it allows differential diagnosis between gliomas
and non-neoplastic CNS lesions (astrocytosis or therapy-induced changes) [151,152], between
gliomas and non-glial CNS tumors, and within glioma subtypes [88,90,153].
In our experience, it is useful in the further following diagnostic situations.
1. In small stereotactic biopsies with hypercellular white matter, to recognize tumor
infiltration, because single tumor cells can be detected among normal cells in the infil‐
trating nervous tissue. This is especially relevant in oligodendrogliomas, where it allows
to identify the pattern of the tumor infiltration. A clear-cut distinction can be made
between tumors with a sharp border with the normal tissue and the infiltrating tumors,
where a gradient of tumor cells can be observed toward the normal tissue. Perineuronal
and pericapillary satellitoses are immunopositive for the clone H09, with the exception of
some cells that may remain unstained. The latter should represent normal perineuronal
satellites joined by tumor cells. However, this finding leaves unresolved the question
whether the increased number of satellites corresponds to infiltrating cells or whether
they derive by transformation of normal satellites. In infiltrating oligodendrogliomas,
Cyclin D1 positive normal oligodendrocytes are recognizable by H09-positive tumor
oligodendrocytes. This finding may be useful when an oligoastrocytoma must be distin‐
guished from an astrocytoma infiltrating the white matter, contributing to the resolution
of the diagnostic ambiguity of these tumors.
2. To discriminate between tumor astrocytes and reactive astrocytes. The latter point is
sometimes of paramount importance, especially when the diagnosis must be carried out
on small samples, for example in stereotactic biopsies where infiltrative cells must be
recognized among normal cells. Immunoreactivity for the clone H09 is a strong evidence
for the tumor nature of positive cells among normal or reactive cells. However, the absence
of immunoreactivity does not exclude the occurrence of a glioma.
3. In the differential diagnosis between diffuse astrocytomas, frequently immunopositive,
and pilocytic or pleomorphic astrocytomas, both typically immunonegative.
4. Among GBMs, to differentiate primary from secondary tumors (see 4.4). Interesting is the
diagnostic utility of the IDH status, together with the assessment of TP53 mutation status,
in the recognizing of secondary gliosarcoma [154].
5. To discriminate gemystocytes that show variable immunopositivity with usually a less
stained center, from minigemistocytes of oligodendrogliomas, in contrast, uniformly and
intensely stained [38,145].
6. In the diagnostic ambiguity of oligoastrocytomas or of a tumor with astrocytes, where it
is important to identify the normal or tumor nature of oligodendrocytes and the tumor or
normal reactive nature of astrocytes [155].
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7.2. Prognostic significance of IDH mutations
The occurrence of IDH mutations predicts significantly longer survival for patients affected
by GBMs and by WHO grade III astrocytomas and oligodendrogliomas. This was reported in
the original discovery of IDH mutations in GBMs [1] and successively confirmed in a large
study on WHO grade II and III astrocytomas, oligodendrogliomas and GBMs [28]. Later, the
association of IDH mutations with a better patient overall survival (OS) and progression-free
survival (PFS) has been confirmed by several reports [36,37,42,57,156-160].
In a recent and partially retrospective study, including the NOA-04 trial cohort of anaplastic
astrocytomas and GBMs, IDH mutations are the most powerful single prognostic factor for
improved OS, followed by age, tumor type and MGMT promoter hypermethylation [161]. The
most favorable outcome is observed in anaplastic astrocytomas with IDH1 mutations, followed
by GBMs with IDH1 mutations, anaplastic astrocytomas without IDH1 mutations and GBMs
without IDH1 mutations [162].
Likewise, IDH mutations also confer an independent favorable prognosis in WHO grade III
oligodendrogliomas, as reported by the European Organization for Research and Treatment
(EORTC) trial 2951 [57].
In GBMs, a significant association of IDH1 mutations with OS and PFS was found in primary
tumors [37,49] with limited independent prognostic effect [45,159].
In low-grade gliomas, however, the prognostic role of IDH mutations is still controversial,
although patients with IDH mutations tend to show a longer survival [36,98,163]. In inde‐
pendent studies on WHO grade II and III gliomas, IDH mutations are prognostic on OS
[30,36,56] and PFS [56]. However, in the largest series of low-grade gliomas so far analyzed,
no prognostic role of IDH mutations was found in diffuse astrocytomas and oligodendroglio‐
mas [164], in agreement with two recent reports on low-grade astrocytomas [165,166].
Furthermore, patients with low-grade gliomas without IDH1 mutations have a dismal
prognosis [56].
In Japanese glioma patients, IDH mutations were significantly associated with increased OS
and PFS in WHO grade III tumors but not in WHO grade II [68,98] or in GBMs [98].
In two recent reports on gliomatosis cerebri IDH mutations are strongly correlated to better
OS [167,168].
Anyway, the prognostic significance of IDH mutations may be secondary to their prevalence
among younger patients, and age is a well-known prognostic factor in gliomas [27]. An
explanation for the better prognosis may potentially be related to the biological effect of the
IDH mutations. Indeed, IDH1 R132H mutant enzyme seems to impede both migration and
growth of stabilized transfected glioma cell lines [169].
In conclusion, the consistent finding of a more favorable outcome in malignant glioma patients
with IDH mutations suggests the evaluation of IDH mutation status for prognostic consider‐
ations in the clinical setting [139].
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7.3. Predictive significance of IDH mutations
Generally, IDH mutations do not show correlations with response to antineoplastic therapy
in GBMs [37], anaplastic gliomas [159,161], anaplastic oligodendrogliomas [57] or progressive
low-grade gliomas [156]. However, IDH mutations correlate with a higher rate of responses
to up-front Temozolomide (TMZ) in a series of 84 low-grade glioma patients, independently
from the 1p/19q co-deletion [157]. They also show evidence for differential responsiveness to
genotoxic therapy of low-grade glioma patients [163]. The occurrence of IDH mutations is
associated with favorable PFS and OS in a cohort of WHO grade II gliomas who received
radiotherapy or chemotherapy at diagnosis but not in a cohort of low-grade diffuse gliomas
initially treated with surgery alone. In a single report, IDH mutations predict response to TMZ
in sGBMs [170].
Interestingly, patients with IDH mutations treated for recurrent gliomas have a longer OS from
the time of recurrence when treated with the VEGF (receptor) (VEGF(R))-targeted agents
sunitinib malate and bevacizumab, rather than with the EGFR-targeted blocking monoclonal
antibody cetuximab. This finding supports the hypothesis that IDH1 mutation may benefit
from VEGF(R)- versus EGFR-targeted therapy at the time of recurrence [158].
7.4. Therapeutic significance of IDH mutations
As before mentioned, the impact of IDH mutations on both radio- and chemotherapy responses
in gliomas has not yet been clarified. Anyway, a higher therapeutic sensitivity is expected for
IDH mutant rather than wild-type tumor cells.
No therapy that specifically targets IDH mutations is currently available. However, mutant
IDH enzymes are attractive candidate for a target therapy in gliomas and there is increasing
interest in the development of IDH-related therapies. The standard goal should be the block
of the D-2-HG oncometabolite by inhibition of IDH mutant enzymes. Restoring normal IDH
function, replacing depleted α-KG and/or depleting D-2-HG should be beneficial for glioma
patients.
Importantly, in the design of inhibitor molecules for IDH mutant proteins in gliomas, com‐
pound selection criteria should include consideration for blood-brain barrier penetration. To
date, only few reports of inhibitors against dehydrogenases are available. Among them,
inositol monophosphate dehydrogenase (IMPDH) inhibitors only have been introduced into
clinical development [171].
A recent intriguing possibility is the opportunity to in vivo measure D-2-HG levels on glioma
patients. Different methods are available, including direct liquid-chromatography-mass
spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) and non invasive
imaging techniques as proton magnetic resonance spectroscopy (MRS). Preliminary data in
the use of D-2-HG as pharmacodynamic biomarker seem to be promising. Interestingly, D-2-
HG levels detected by MRS in glioma patients correlates with the occurrence of IDH mutations
[172-175]. However, in a small series of gliomas, D-2-HG levels in serum do not correlate with
IDH mutations [176], in contrast to previous findings in AML [177].
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7.2. Prognostic significance of IDH mutations
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survival (PFS) has been confirmed by several reports [36,37,42,57,156-160].
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astrocytomas and GBMs, IDH mutations are the most powerful single prognostic factor for
improved OS, followed by age, tumor type and MGMT promoter hypermethylation [161]. The
most favorable outcome is observed in anaplastic astrocytomas with IDH1 mutations, followed
by GBMs with IDH1 mutations, anaplastic astrocytomas without IDH1 mutations and GBMs
without IDH1 mutations [162].
Likewise, IDH mutations also confer an independent favorable prognosis in WHO grade III
oligodendrogliomas, as reported by the European Organization for Research and Treatment
(EORTC) trial 2951 [57].
In GBMs, a significant association of IDH1 mutations with OS and PFS was found in primary
tumors [37,49] with limited independent prognostic effect [45,159].
In low-grade gliomas, however, the prognostic role of IDH mutations is still controversial,
although patients with IDH mutations tend to show a longer survival [36,98,163]. In inde‐
pendent studies on WHO grade II and III gliomas, IDH mutations are prognostic on OS
[30,36,56] and PFS [56]. However, in the largest series of low-grade gliomas so far analyzed,
no prognostic role of IDH mutations was found in diffuse astrocytomas and oligodendroglio‐
mas [164], in agreement with two recent reports on low-grade astrocytomas [165,166].
Furthermore, patients with low-grade gliomas without IDH1 mutations have a dismal
prognosis [56].
In Japanese glioma patients, IDH mutations were significantly associated with increased OS
and PFS in WHO grade III tumors but not in WHO grade II [68,98] or in GBMs [98].
In two recent reports on gliomatosis cerebri IDH mutations are strongly correlated to better
OS [167,168].
Anyway, the prognostic significance of IDH mutations may be secondary to their prevalence
among younger patients, and age is a well-known prognostic factor in gliomas [27]. An
explanation for the better prognosis may potentially be related to the biological effect of the
IDH mutations. Indeed, IDH1 R132H mutant enzyme seems to impede both migration and
growth of stabilized transfected glioma cell lines [169].
In conclusion, the consistent finding of a more favorable outcome in malignant glioma patients
with IDH mutations suggests the evaluation of IDH mutation status for prognostic consider‐
ations in the clinical setting [139].
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7.3. Predictive significance of IDH mutations
Generally, IDH mutations do not show correlations with response to antineoplastic therapy
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to up-front Temozolomide (TMZ) in a series of 84 low-grade glioma patients, independently
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genotoxic therapy of low-grade glioma patients [163]. The occurrence of IDH mutations is
associated with favorable PFS and OS in a cohort of WHO grade II gliomas who received
radiotherapy or chemotherapy at diagnosis but not in a cohort of low-grade diffuse gliomas
initially treated with surgery alone. In a single report, IDH mutations predict response to TMZ
in sGBMs [170].
Interestingly, patients with IDH mutations treated for recurrent gliomas have a longer OS from
the time of recurrence when treated with the VEGF (receptor) (VEGF(R))-targeted agents
sunitinib malate and bevacizumab, rather than with the EGFR-targeted blocking monoclonal
antibody cetuximab. This finding supports the hypothesis that IDH1 mutation may benefit
from VEGF(R)- versus EGFR-targeted therapy at the time of recurrence [158].
7.4. Therapeutic significance of IDH mutations
As before mentioned, the impact of IDH mutations on both radio- and chemotherapy responses
in gliomas has not yet been clarified. Anyway, a higher therapeutic sensitivity is expected for
IDH mutant rather than wild-type tumor cells.
No therapy that specifically targets IDH mutations is currently available. However, mutant
IDH enzymes are attractive candidate for a target therapy in gliomas and there is increasing
interest in the development of IDH-related therapies. The standard goal should be the block
of the D-2-HG oncometabolite by inhibition of IDH mutant enzymes. Restoring normal IDH
function, replacing depleted α-KG and/or depleting D-2-HG should be beneficial for glioma
patients.
Importantly, in the design of inhibitor molecules for IDH mutant proteins in gliomas, com‐
pound selection criteria should include consideration for blood-brain barrier penetration. To
date, only few reports of inhibitors against dehydrogenases are available. Among them,
inositol monophosphate dehydrogenase (IMPDH) inhibitors only have been introduced into
clinical development [171].
A recent intriguing possibility is the opportunity to in vivo measure D-2-HG levels on glioma
patients. Different methods are available, including direct liquid-chromatography-mass
spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) and non invasive
imaging techniques as proton magnetic resonance spectroscopy (MRS). Preliminary data in
the use of D-2-HG as pharmacodynamic biomarker seem to be promising. Interestingly, D-2-
HG levels detected by MRS in glioma patients correlates with the occurrence of IDH mutations
[172-175]. However, in a small series of gliomas, D-2-HG levels in serum do not correlate with
IDH mutations [176], in contrast to previous findings in AML [177].
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In conclusion, IDH mutations identify in gliomas a biologically distinct tumor identity [109].
Suggestions are in favor of the hypothesis that rare pGBMs with IDH mutations might be
sGBMs progressed by clinically undetected preceding gliomas of lower malignancy grade.
Likewise, sGBMs without IDH mutations might be pGBMs, unrecognized because of inap‐
propriate histological sampling [111]. Anyway, GBMs with IDH mutations seems to be a
distinct entity [111] and stratification of GBMs patients according the IDH mutation status
should be mandatory.
8. Conclusions
The discovery of recurrent somatic IDH mutations in gliomas is the most significant advance
in the field of neuro-oncology in the recent years. This finding emphasizes the putative role of
the IDH1 and IDH2 metabolic genes in the molecular pathogenesis of gliomas and, more
importantly, the translational relevance of the IDH mutations.
Currently, they are considered a strong prognostic marker for glioma patients, independently
from the other well-known prognostic factors. For this reason, the knowledge of the IDH
mutation status has a great importance for the diagnosis and prognosis of patients, especially
when affected by WHO grade III gliomas and GBMs.
This finding suggests revisions of the current WHO classification of human brain tumors with
the addition of the IDH mutation status, as well as the KIAA1549/BRAF fusion gene for
pilocytic astrocytomas and the total 1p/19q co-deletion for oligodendrogliomas. Common
opinion is in favor of a molecular stratification over the conventional WHO grading for
prognostic and therapeutic considerations in both low- and high-grade glioma patients. This
may also contribute to solve the ambiguity in the histophatological diagnosis of oligoastrocy‐
toma [155,164].
One of the major question remains the molecular pathogenesis of WHO grade II and III gliomas
without IDH mutations, which often do not show alterations in genes typically involved in
gliomas, as TP53 mutations or CDKN2A homozygous deletion. Whole-genome or exome
sequencing by the next generation sequencing technology may be useful in future to identify
the molecular basis of these tumors and to a better comprehension of the molecular patho‐
genesis of gliomas.
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1. Introduction
Gliomas  are  the  most  common  central  nervous  system  neoplasms  that  arise  from  the
transformation of  astrocytes or their  precursor cells.  Glial  tumors develop as a result  of
stepwise accumulation of genetic alterations, which disrupt the cell cycle arrest pathways
or  activate  various  signal  transduction  pathways.  Despite  recent  advances  in  treatment
modalities  such  as  surgical  techniques,  radiation  therapy,  chemotherapy  and  targeted
gene therapy,  their  prognosis  remains poor.  Gliomas are graded from I  to IV according
to the 2007 World Health Organization (WHO) malignancy scale. Grade I lesions are be‐
nign  and  quite  constrained  with  a  slow propagation  rate  and  they  constitute  the  most
common glioma of children, pilocytic astrocytoma. Grade II tumors, called diffuse astro‐
cytoma have a slow growth rate and a high degree of cellular differentiation, with their
ability  to  diffuse  into  normal  brain  parenchyma  and  progress  toward  more  malignant
form.  Grade  III  tumors  include  anaplastic  astrocytoma,  which  are  characterized  by  a
higher cellular density and the plentiful persistence of atypia and mitotic cells. Grade IV
tumors are the most frequent malignant gliomas and they are characterized as glioblasto‐
ma with high recurrence rate. GBMs include two subtypes, primary GBMs arise `de novo'
and secondary GBMs develop due to accumulation of mutations in lower grade gliomas.
EGFR amplification, LoH 10q, p16Ink4A deletion and PTEN mutations are the common ge‐
netic alterations associated with primary GBMs whereas p53 mutations and PDGFR am‐
plifications  are  frequent  in  secondary  GBMs  (Ohgaki  and  Kleihues.,  2007;  Holland.,
2001). These genetic alterations disrupt the cell cycle arrest pathways or activate various
signal transduction pathways. Mutation of the p53, retinoblastoma (RB) and PTEN, dele‐
tion of p16Ink4A, activation of the Ras and Akt pathways, and amplification of CDK4 and
EGFR contribute to the development of gliomas (Cavenee., 1992; Hayashi et al., 1997).
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Cell polarity is an essential phenomenon in several biological processes that contribute to
normal tissue integrity and maturity. Several studies in different genetic models has identified
and revealed different roles of polarity complexes in maintenances of stem cell population and
their asymmetric division (Knoblich., 2010), T-cell function like migration in response to
chemokines and antigens (Krummel and Macara., 2006), neuronal cell axon and dendritic
specification (Arimura and Kaibuchi., 2007) and cell polarity is crucial for epithelial cell and
tissue polarization for maintenance of multicellular structures and perform normal physio‐
logical functions like secretion, absorption and distribution of cytoplasmic and membrane
proteins in appropriate positions within the cell in order to conduct proper signals.
2. Cell polarity regulators and their deregulation in cancer
Proficient research work in organisms like Caenorhabditis elegans and Drosophila melanogaster
has led to discovery of three different polarity complexes which are asymmetrically distributed
within the cell. They are Partitioning defective (Par) complex consists of Par3, Par6 and an
atypical protein kinase C, Crumbs complex consists of Crumbs, Pals1 (Protein associated with
Lin seven 1) and Pals1-associated tight junction protein (PATJ) and Scribble complex consists
of Scribble, Discs large (Dlg) and Lethal giant larvae (Lgl). Crumbs polarity complex and the
Partitioning defective (Par) polarity complex are localized to the apical cortex, whereas
members of the Scribble polarity complex are localized at the basolateral regions of the cell
(Bilder and Perrimon., 2000; Humbert et al., 2006).
Figure 1. Localization of cell polarity complexes in epithelial cell. Par complex consisting of Par3, Par6, aPKC and
Crumbs complex consisting of Crb, Palsl, PAT J are localized apically in the region of tight junctions (T Js). Scribble com‐
plex consisting of Scrib, Dlg and Lgl is localized basolaterally in the region of adherens Junction. ( this illustrationis re‐
produced fiom I)Djiane laboratory)
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2.1. PAR polarity complex
Par complex was initially identified in C.elegans and it consists of two scaffold proteins, PAR6
and PAR3 and an atypical protein kinase C, aPKC. In mammals Par6 protein is encoded by
three different genes PAR6A/C, PAR6B and PAR6D/G, Par3 is encoded by PAR3A and PAR3B
genes and two aPKC genes, aPKCλ/ι and aPKCζ encode two different proteins. Par3 and Par6
interact with each other via their PDZ domains and the interaction between Par 3 protein to
aPKC/Par6 is dynamic and aPKC-dependent phosphorylation can expel Par3 from the aPKC/
Par6 unit (Horikoshi et al., 2009). PAR complex is essential for defining the appropriate apico-
lateral axis and assembly of tight junction proteins at their respective position.
2.2. Crumb polarity complex
Crumbs polarity complex was identified in Drosophila and in mammals it consists of trans‐
membrane protein CRB encoded by CRB1, 2, and 3 genes along with two cytoplasmic scaf‐
folding proteins PALS1 and PATJ. CRB1 connect to PDZ domains of Pals1 and PATJ through
C-terminal ERLI motif. Pals1 is a member of the membrane-associated guanylate kinase
(MAGUK) family, which has a PDZ domain, two L27 domains, a SH3 domain and a guanylate
kinase domain. PATJ has 10 PDZ domains and one L27N domain (Tepass and Knust., 1993).
CRB complex is involved in formation of tight junctions and differentiation of the apical
membrane.
2.3. SCRIB polarity complex:
Scribble, Dlg and Lgl were identified in Drosophila as tumor suppressors, in mammals SCRIB
is also called VARTUL. Scribble is a member of LAP family with leucine-rich repeats and PDZ
domains, while Dlg in mammals exists in five isoforms and it is a member of the MAGUK
family containing PDZ domains. Lgl which exists as Lgl1 and Lgl2 in mammals does not
contain PDZ domains but has WD40 domains, which is thought to mediate interactions with
phosphorylated serine and tyrosine (Dow et al. 2007).
Interaction among these three complexes dictates them to localize in their respective po‐
sitions, for example Lgl1 and 2 can compete with Par3 for binding to a module of Par6
and aPKC and aPKC phosphorylate Lgl releasing it  from the Par6/aPKC dimer, ensuing
its localization to the basolateral region of cells (Betschinger et al. 2003). These complexes
induce  their  function  by  regulating  cytoskeleton  architecture  and  there  is  a  substantial
data  showing  direct  link  with  small  GTPases  of  the  Rho  family  and  Cdc42,  Rac1  and
RhoA,  control  the  cytoskeletal  changes  in  cells  by  switching  between  an  active  GTP-
bound state and an inactive GDP-bound state. For example Par3 can bind the Rac-activa‐
tor Tiam1 during tight junction formation and Par6/Par3 regulates Cdc42-mediated Rac1
activation through Tiam1 in neuronal cells (Nishimura et al. 2005). These multifaceted in‐
teractions between polarity proteins and with small GTPases is essential for maintenance
of polarity and carrying out normal physiological functions of the cell  and any aberrant
regulation in any of these proteins is related to tumor genesis.
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Cell polarity proteins regulate cancer cell properties like proliferation, apoptosis, and epithe‐
lial-mesenchymal transition. Studies have shown that Par6 induces growth factor independent
proliferation of human mammary epithelial cells by activating MAPK signaling through aPKC
and Cdc42/Rac (Muthuswamy et al. 2008). aPKC can regulate cell proliferation through ERK
and SRC-3 dependent manner (Castoria et al. 2004 and Yi et al. 2008) and knock down of aPKC
in MCF-7 breast cancer cell line inhibited cell proliferation. Down regulation of Scribble
induces JNK-dependent cell death (Brumby and Richardson. 2003) and in similar manner
inhibition of aPKC increases apoptosis of MDCK cell by activating GSK3β (Kim et al., 2007).
Acquisition of mesenchymal property by cancer cells during metastasis is due to change in the
cell architecture which is regulated by cell polarity proteins. Research in genetic model
Drosophila led to discovery that Scribble, DLg, Lgl, Par and Cdc42 cooperate with Rasv12
during invasion (Pagliarini and Xu. 2003). TGFβ signaling has been shown to phosphorylate
Par6 protein which leads to RhoA degradation through Smurf1 (Wang et al., 2003). ZEB1 which
is a transcriptional regulator of EMT represses the expression of polarity proteins like Crumbs,
Lgl2 and PATJ ultimately leading to mesenchymal transition (Aigner et al., 2007).
Cancer is a multistep process whereby cells first acquire benign over proliferation due to
genetic assaults, followed by inhibition of apoptosis and increased cell proliferation. The
conversion of benign to malignant form is accompanied by loss in cell-cell to contact and apical-
basal polarity which ultimately leads to EMT associated with invasion into different parts from
the site of cancer. During cancer progression steps these different polarity complexes are either
aberrantly expressed or mislocalised from their respective locations. Genetic studies in model
organisms and in vitro cell culture has shown that these polarity complexes append to take
apart in diverse hierarchy of human cancer. aPKC is over expressed in various human cancers
like non-small cell lung cancer, ovarian cancer and its expression level correlates with over
expression of Cyclin E and with their poor prognosis (Regala et al., 2005 and Eder et al.,
2005). In human esophageal squamous cell carcinoma Par3 gene is homozygously lost with
reduced protein expression (Zen et al., 2009). Par6 is regarded as a tumor promoter as it is over
expressed in human breast cancer and its interaction with TGFβ receptor implicates its role in
EMT (Ozdamar et al., 2005).
However contribution of Crumb complex for tumor progression is not completely elucidated.
Few studies have shown that Crb-3 expression negatively correlates with metastatic behavior
of cells as its decreased expression is associated with increased expression of vimentin and
reduced expression of E-cadherin (Bhat et al., 1999). Assembly of Crumb complex leads to
phosphorylation of transcription effector molecule of Hippo signaling pathway TAZ/YAP
which in turn leads to inhibition of TGF-β-SMAD signaling essential for vimentin expression
(Varels et al., 2010). ZEB1 and SNAIL represses the Crumb complex activity. PATJ and Pals1
are required for tight junction (TJ) assembly. PATJ is targeted for degradation by human
papiloma virus (HPV) oncoprotein during development of cervical cancer (Javier. 2008). Till
date there is no evidence for role of Pals1 in cancer, however few studies in mice model have
shown that Pals1 is essential for survival since its loss results in embryonic lethality.
Scribble complex, regarded as fly tumor suppressor genes and basolateral polarity complex
are regulated at different levels in human cancers. Dlg and Lgl proteins are down regulated
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and mislocalised in tumors of breast, prostate, lung, ovary, cervical and liver.scribble and Dlg
are targeted for degradation by viral oncoproteins from HPV(Thomas et al., 2005), Human T-
cell leukemia (HTLV) (Okajima et al., 2008) and their expression levels are correlated with loss
of tissue architecture. Scribble is miss localized in cervical, colon, endometrial and prostate
cancer (Nakagawa et al., 2004, Gardiol et al., 2006, Ouyang et al., 2010 and Pearson et al.,
2011). In Drosophila genetic study, it has been exposed that loss of Scribble function alone is
not sufficient to induce tumor, instead Scrib mutant cells expressing oncogenic Raf, Ras or
Notch results in loss of apical-basal polarity, neoplastic overgrowth and metastasis.
3. Cell polarity in glial cell
Glial cells include myelinating oligodendrocytes, Schwann cells and astrocytes and they
execute diverse functions that are vital for the development, functioning and regeneration of
neurons. Unlike epithelial cells which require cell polarity for polarization of cellular compo‐
nents and neurons for axon and dendrite specification, glial cells require cell polarity for
migration and myelination.
Oligodendrocytes and Schwann cells are responsible for myelination of neurons, it requires
proper sorting of proteins and lipids and polarized membrane trafficking to organize myelin
domains and maintain this highly polarized phenotype (DeBruin and Harauz. 2007). Astro‐
cytes are the cells which carry out major functions in brain including interactions with neurons
and blood vessels (Schipke and Kettenmann., 2004), migration towards inflammation called
astrogliosis (Ridet et al. 1997) which requires polarization of astrocytes into front-rear axis.
Astrocytes polarize and migrate by interacting with extra cellular matrix components. Upon
interaction of ECM with integrin receptors on astorcytes, activates intracellular signaling
through small G proteins like Rac and Cdc42 for controlled polarization and orientation
(Heasman and Ridley. 2008). Guanine exchange factors are in charge for the GDP–GTP
exchange and therefore are the major regulators of small G proteins activity. It has been shown
that cell polarity protein Scrib plays a crucial role in astrocyte migration by binding with Rac
and Cdc42-specific exchange factor βPIX and controlling the localization of Cdc42 at leading
edge of migratory processes (Osmani et al. 2006). Besides Scrib other evolutionary conserved
polarity proteins like Par protein complex is implicated in astrocyte migration. Par6-aPKC
complex controls and regulates the microtubule organization during astrocyte migration. The
GTP-bound form of Cdc4 binds to Par6 and activates aPKC kinase at leading edge of astrocyte
(Etienne-Manneville et al., 2005).
4. Loss of cell polarity during gliomagenesis
Previously loss of cell polarity was regarded as post effect of cancer, but recent research work
led to discovery that cell polarity is lost and responsible for tumorigenesis and its progression.
Loss of cell polarity in brain tumors is not well documented and very few works like Klezovitch
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inhibition of aPKC increases apoptosis of MDCK cell by activating GSK3β (Kim et al., 2007).
Acquisition of mesenchymal property by cancer cells during metastasis is due to change in the
cell architecture which is regulated by cell polarity proteins. Research in genetic model
Drosophila led to discovery that Scribble, DLg, Lgl, Par and Cdc42 cooperate with Rasv12
during invasion (Pagliarini and Xu. 2003). TGFβ signaling has been shown to phosphorylate
Par6 protein which leads to RhoA degradation through Smurf1 (Wang et al., 2003). ZEB1 which
is a transcriptional regulator of EMT represses the expression of polarity proteins like Crumbs,
Lgl2 and PATJ ultimately leading to mesenchymal transition (Aigner et al., 2007).
Cancer is a multistep process whereby cells first acquire benign over proliferation due to
genetic assaults, followed by inhibition of apoptosis and increased cell proliferation. The
conversion of benign to malignant form is accompanied by loss in cell-cell to contact and apical-
basal polarity which ultimately leads to EMT associated with invasion into different parts from
the site of cancer. During cancer progression steps these different polarity complexes are either
aberrantly expressed or mislocalised from their respective locations. Genetic studies in model
organisms and in vitro cell culture has shown that these polarity complexes append to take
apart in diverse hierarchy of human cancer. aPKC is over expressed in various human cancers
like non-small cell lung cancer, ovarian cancer and its expression level correlates with over
expression of Cyclin E and with their poor prognosis (Regala et al., 2005 and Eder et al.,
2005). In human esophageal squamous cell carcinoma Par3 gene is homozygously lost with
reduced protein expression (Zen et al., 2009). Par6 is regarded as a tumor promoter as it is over
expressed in human breast cancer and its interaction with TGFβ receptor implicates its role in
EMT (Ozdamar et al., 2005).
However contribution of Crumb complex for tumor progression is not completely elucidated.
Few studies have shown that Crb-3 expression negatively correlates with metastatic behavior
of cells as its decreased expression is associated with increased expression of vimentin and
reduced expression of E-cadherin (Bhat et al., 1999). Assembly of Crumb complex leads to
phosphorylation of transcription effector molecule of Hippo signaling pathway TAZ/YAP
which in turn leads to inhibition of TGF-β-SMAD signaling essential for vimentin expression
(Varels et al., 2010). ZEB1 and SNAIL represses the Crumb complex activity. PATJ and Pals1
are required for tight junction (TJ) assembly. PATJ is targeted for degradation by human
papiloma virus (HPV) oncoprotein during development of cervical cancer (Javier. 2008). Till
date there is no evidence for role of Pals1 in cancer, however few studies in mice model have
shown that Pals1 is essential for survival since its loss results in embryonic lethality.
Scribble complex, regarded as fly tumor suppressor genes and basolateral polarity complex
are regulated at different levels in human cancers. Dlg and Lgl proteins are down regulated
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and mislocalised in tumors of breast, prostate, lung, ovary, cervical and liver.scribble and Dlg
are targeted for degradation by viral oncoproteins from HPV(Thomas et al., 2005), Human T-
cell leukemia (HTLV) (Okajima et al., 2008) and their expression levels are correlated with loss
of tissue architecture. Scribble is miss localized in cervical, colon, endometrial and prostate
cancer (Nakagawa et al., 2004, Gardiol et al., 2006, Ouyang et al., 2010 and Pearson et al.,
2011). In Drosophila genetic study, it has been exposed that loss of Scribble function alone is
not sufficient to induce tumor, instead Scrib mutant cells expressing oncogenic Raf, Ras or
Notch results in loss of apical-basal polarity, neoplastic overgrowth and metastasis.
3. Cell polarity in glial cell
Glial cells include myelinating oligodendrocytes, Schwann cells and astrocytes and they
execute diverse functions that are vital for the development, functioning and regeneration of
neurons. Unlike epithelial cells which require cell polarity for polarization of cellular compo‐
nents and neurons for axon and dendrite specification, glial cells require cell polarity for
migration and myelination.
Oligodendrocytes and Schwann cells are responsible for myelination of neurons, it requires
proper sorting of proteins and lipids and polarized membrane trafficking to organize myelin
domains and maintain this highly polarized phenotype (DeBruin and Harauz. 2007). Astro‐
cytes are the cells which carry out major functions in brain including interactions with neurons
and blood vessels (Schipke and Kettenmann., 2004), migration towards inflammation called
astrogliosis (Ridet et al. 1997) which requires polarization of astrocytes into front-rear axis.
Astrocytes polarize and migrate by interacting with extra cellular matrix components. Upon
interaction of ECM with integrin receptors on astorcytes, activates intracellular signaling
through small G proteins like Rac and Cdc42 for controlled polarization and orientation
(Heasman and Ridley. 2008). Guanine exchange factors are in charge for the GDP–GTP
exchange and therefore are the major regulators of small G proteins activity. It has been shown
that cell polarity protein Scrib plays a crucial role in astrocyte migration by binding with Rac
and Cdc42-specific exchange factor βPIX and controlling the localization of Cdc42 at leading
edge of migratory processes (Osmani et al. 2006). Besides Scrib other evolutionary conserved
polarity proteins like Par protein complex is implicated in astrocyte migration. Par6-aPKC
complex controls and regulates the microtubule organization during astrocyte migration. The
GTP-bound form of Cdc4 binds to Par6 and activates aPKC kinase at leading edge of astrocyte
(Etienne-Manneville et al., 2005).
4. Loss of cell polarity during gliomagenesis
Previously loss of cell polarity was regarded as post effect of cancer, but recent research work
led to discovery that cell polarity is lost and responsible for tumorigenesis and its progression.
Loss of cell polarity in brain tumors is not well documented and very few works like Klezovitch
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et al. have show that loss of cell polarity causes severe brain dysplasia using Lgl1 knockout
mice. We analyzed total of 50 astrocytic tumor samples from Krishna Institute of Medical
Sciences (Hyderabad, India), they were classified histopathologically according to the WHO
classification: 16 pilocytic astrocytoma (PILO; grade I), 8 diffuse astrocytomas (DA; grade II),
7 anaplastic astrocytomas (AA; grade III), and 19 glioblastoma multiforme (GBM; grade IV)
and one normal brain sample was obtained during autopsy for the expression of Scribble
polarity complex in astocytic tumors. All samples were obtained from patients after taking the
informed consent form patients or their guardians. Using western blotting and immuno
histochemical examination we found that protein levels of Scrib was negatively associated
with increase in the tumor grade and in few GBM samples Scrib was completely absent.
Immuno fluorescence staining as shown in Fig. 2, 3, 4 revealed that in control brain astrocytes,
Scrib was localized at the end of astrocyte processes and it was mislocalised in low grade
tumors with complete absence in GBM (Khamushavalli et al., unpublished data).
Figure 2. Localization of hSrib in control astrocytes: Paraffin-embedded control brain section was prepared from au‐
topsy brain specimen. Secations were incubated with anti-rabbit-hScrib and anti-mouse-GFAP specific primary anti‐
bodies (1:100 dilution) overnight at 4oC and anti-rabbit-TRITC and anti-mouse-FITC secondary antibodies were used
for 1 h at room temperature. DAPI was used for the detection of nuclei and fluorescence was captured under Leica
confocal microscope. Representative figure showed the localization of hScrib in GFAP positive astrocyte processes.
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Figure 3. Localization of hScrib in grade II astrocytoma: Paraffin-embedded grade II astrocytoma section was pre‐
pared and incubated with anti-rabbit-hScrib and anti-mouseGFAP specific primary antibodies (1:100 delution) over‐
night at 4oC and anti-rabbit-TRITC and anti-mouse-FITC secondary antibodies were used for 1 h at room temperature.
DAPI was used for the detection of nuclei and fluorescence was captured under Leica confocal microscope. Represen‐
tative figure showed the diffuse localization and low level expression of hScrib in GFAP positive astrocytes.
Figure 4. Localization of hScrib in grade IV astrocytoma: Paraffin-embedded grade II astrocytoma section was pre‐
pared and incubated with anti-rabbit-hScrib and anti-mouseGFAP specific primary antibodies (1:100 delution) over‐
night at 4oC and anti-rabbit-TRITC and anti-mouse-FITC secondary antibodies were used for 1 h at room temperature.
DAPI was used for the detection of nuclei and fluorescence was captured under Leica confocal microscope. Represen‐
tative figure showed the loss of hScrib in GFAP positive astrocytes
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Figure 3. Localization of hScrib in grade II astrocytoma: Paraffin-embedded grade II astrocytoma section was pre‐
pared and incubated with anti-rabbit-hScrib and anti-mouseGFAP specific primary antibodies (1:100 delution) over‐
night at 4oC and anti-rabbit-TRITC and anti-mouse-FITC secondary antibodies were used for 1 h at room temperature.
DAPI was used for the detection of nuclei and fluorescence was captured under Leica confocal microscope. Represen‐
tative figure showed the diffuse localization and low level expression of hScrib in GFAP positive astrocytes.
Figure 4. Localization of hScrib in grade IV astrocytoma: Paraffin-embedded grade II astrocytoma section was pre‐
pared and incubated with anti-rabbit-hScrib and anti-mouseGFAP specific primary antibodies (1:100 delution) over‐
night at 4oC and anti-rabbit-TRITC and anti-mouse-FITC secondary antibodies were used for 1 h at room temperature.
DAPI was used for the detection of nuclei and fluorescence was captured under Leica confocal microscope. Represen‐
tative figure showed the loss of hScrib in GFAP positive astrocytes




Loss of cell architecture and cell-cell contacts is the hall mark of metastasis, and these process
are regulated by cell polarity proteins. Recent work in different cancers has revealed the
expressional loss and mislocalisation of cell polarity proteins and their potential role as tumor
suppressors. Till date there is no report explaining the role of these polarity proteins in glioma
and the above results indicate that cell polarity proteins do have role in glioamgenesis and
further research is necessary to elucidate how these proteins are deregulated during glioma
prosression.
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Glioblastoma (GBM) with their invasive and aggressive nature, are the most common pri‐
mary brain tumours. GBM accounts for about 60% of all gliomas and 12–15% of all brain
tumors, and it is per se the most frequent primary brain tumor [1,2]. Although advances
in therapies, clinicians and researchers fail to arrive at overcoming poor prognosis with a
median  survival  of  only  one  year  from  the  time  of  diagnosis.  In  Europe  and  North
America, the incidence is three new cases per 100.000 inhabitants per year [3]. Although
GBM can manifest  itself  at  any age,  it  preferentially occurs in adults,  with a wide peak
age of incidence between 45 and 70 years [4].
GBMs arised from glial cells which are the building-block cells of the connective and suppor‐
tive, tissues in the central nervous system. Diffuse gliomas defined as astrocytomas, oligo‐
dendrogliomas, and oligoastrocytomas are the common gliomas which infiltrate throughout
the brain parenchyma. They are graded on a World Health Organization (WHO) classification
system scale of I to IV according to their degree of malignancy based on different histological
features and genetic alterations. Grade I tumors are pilocytic astrocytomas and they are benign
and can be cured if they can be surgically resected; grade II tumors are low grade astrocytomas
(LGAs) which are incurable with surgery because of their early diffuse infiltration of the
surrounding brain, and long treatment regimens are needed to treat this disease completely;
grade III tumors are anaplastic astrocytomas and they have increased anaplasia and proliferate
over grade IV tumors and are more rapidly fatal; grade IV tumors are GBMs which possess
advanced features of malignancy, and are resistant to radio/chemotherapy [5].
Important  characteristics  of  GBMs are  aberrant  cellular  proliferation,  diffuse  infiltration,
prospensity for  necrosis,  robust  angiogenesis,  high resistance to  apoptosis,  and genomic
instability.  The  intratumoral  heterogenity  combined  with  a  putative  cancer  stem  cell
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(CSC)  subpopulation and incomplete  atlas  of  epigenetic  lesions  are  the  reasons  of  poor
prognosis/high  tumoral  resistance  against  chemotherapeutics  and  recurrence  [1,2,5-8].
Studies showing crosstalks between genetics  and epigenetics  in GBM are highlighted to
solve mystery [5-7]. There are two types of GBM: Type 1 GBM typically shows inactiva‐
tion of the TP53 tumor suppressor gene but no amplification of the EGFR oncogene. Mu‐
tations  of  p53,  mostly  associated  with  loss  of  heterozygosity  (LOH)  in  the  17p
chromosome region,  can be observed in GBM originating from a less  malignant  glioma
precursor. TP53 inactivation does not occur together with amplification of the EGFR on‐
cogene, which is only identified in GBM without TP53 mutation More than 70% of ma‐
lignant  gliomas  show  a  deregulated  TP53  pathway  not  only  by  mutation  of  TP53  but
also amplification of MDM2, homozygous deletion/mutation, or promoter hypermethyla‐
tion-mediated silencing of CDKN2A. Type 2 GBM shows overexpression or amplification
of the EGFR without mutations of TP53, and it appears de novo, that is, in patients with‐
out a less malignant precursor neoplasm such as grade II or III astrocytoma [6,7].
Two independent GBM pathways were also identified [9]. Moreover, epidermal growth factor
receptor (EGFR) amplification is almost always consistent with LOH in chromosome region
10q [16]. The tumor suppressor gene Phosphatase and tensin homolog (PTEN), mapping the
10q23 region, is mutated in approximately 30% of type 2 GBM [6,10]. Mutations in this gene
have been described only in malignant gliomas and are rarely associated with p53 mutations.
Other frequent mutations in type 2 GBM affect the cyclin dependent kinase (CDK) cell-cycle-
regulator genes. Amplification of CDK4 and CDK6 was observed in 15% of type 2 GBMs [6,7].
Mutations of the cell-cycle-regulator genes CDKN2A/CDKN2B have been observed in 40% of
all GBM. Moreover, a functional loss of expression of the CDKN2A gene by promoter hyper‐
methylation was found in 15% of GBM [6,7]. Mutations of the Isocitrate dehydrogenase 1
(IDH1) gene have been frequently observed in those GBM progressing from a less malignant
precursor lesion, that is in type 1 GBM, mostly of them affecting young patients. Interestingly,
these IDH1 mutations were associated with a better outcome [6]. In addition to type 1 and type
2 GBMs, there are other forms, whose molecular profiles do not identify them as belonging to
either of the two classic pathways [6,7].
The methylation signature of gliomas is also rather associated with tumor lineage and
malignancy grade. Thus, astrocytomas grades WHO II and III and GBM grade IV show
different methylation status of several genes. Even though, primary and secondary GBMs were
found to differ concerning methylation of genes which was associated with decreased mRNA
levels. In this context, methylation of methyl guanine methyl transferase (MGMT) is more
frequently observed in 75% of secondary GBM than in primary GBMs (36%). Moreover, MGMT
methylation has been observed to be associated with TP53 mutations in secondary GBMs.
Cellular pathways deregulated in gliomas and associated epigenetic events through promoter
hypermethylation, CpGs hypomethylation, and histone alterations leading to modified
chromatin states are Ras signaling (RASSF1A, RRP22, DIRAS3), Cell migration and adherence
(NECL1, E-cadherin, SLIT2, EMP3, TIMP3), Wnt signaling (WIF1, FZD9, IGFBP-3, SFRP
family, PEG3), Tyrosine kinase pathways (KIT, SYK, c-ROS),Transcription factors (SOX2,
KLF4, GATA 6, ATOH1), Homeobox genes (HOXA 9, HOXA10, HOXA11), Sonic hedgehog
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signaling (PTCH1, Cyclin D2, Plakoglobin, PAX6, NKX2.2), Notch signaling (NEURL1, HES1,
HEY1), bone morphogenic protein (BMP) developmental pathway (BMPR1B), Hypermutator
pathways (hMLH1, hPMS2, MGMT,WRN), Apoptosis (TMS1, DAPK1, CASP8, DR4, DR5),
TP53/cell cycle (HIC-1, CDKN2A, RB1, p16INK4a), MicroRNAs (miR-124a, miR-21, miR-7,
miR-137, miR12) [6,7,11].
MGMT can be given for instance for these pathways MGMT, which has been observed to be
hypermethylated in low-grade gliomas (grade II) further evolving to gliomas grade III and
GBM [6,7]. Furthermore, this biomarker allows neurooncologists to predict patient’s response
to current chemotherapy with temozolomide [12]. Second instance can be microsatellite
instability (MSI) which was observed to be more frequent in those GBMs evolving from less
malignant gliomas grade II or III, which typically display TP53 mutations without EGFR
amplification, as well as in relapse GBM [5,6]. Third instance can be given as epigenetic
inactivation ofone of the apoptosis-related genes (TMS1/ASC and DAPK1, WIF-1, SFRP1 and
CASP8 ) as proapoptotic gene CASP8 which is an epigenetic silenced during progression of
primary-to-recurrent GBM. GBM can change its epigenetic profile quickly, therefore its
adaptation (heterogenity) to novel therapies is big obstacle [6,7,11].
Because of incomplete atlas of genetic and epigenetic pathways, gene therapies and chemo‐
therapies have limited efficacy and they are under investigation [6,7,13,14]. Researchers and
clinicians are trying to fight this monster following products of these genes [15-17]. Many
"Trojan horse" approaches, based on potential applications in the pharmacological therapy of
GBMs which blood-brain barrier (BBB) represents an obstacle are being proposed day by day
[18,19]. The passage of drugs across the BBB limits the efficacy of chemotherapy in brain tumors
[18-21]. Many anti-neoplastic drugs evaluated as “magic bullets” that is effective against
glioblastoma in vitro, has poor efficacy in vivo or has both efficacy in vitro and in vivo, has
poor efficacy in clinic because it is extruded by P-glycoprotein (Pgp/ABCB1), multidrug
resistance-related proteins (MRPs) and breast cancer resistance protein (BCRP/ABCG2) of BBB
cells [20,21]. Although these proteins are commonly studied in order to overcome drug
resistance for several decades, GBM attack with other weapons in order to win this war and
it continues to surprise researchers and clinicians [20,21]. Other weapons of GBM can be
defined as aquaporins (AQPs) [22,23].
2. AQPs
AQPs, water channels, have been proposed as novel targets in cancer and oedema and are
associated with a surprising array of important processes in the brain and body, such as
angiogenesis, cell migration, development and neuropathological diseases. In both cancer and
brain oedema, current therapies are limited and new pharmacological approaches focused on
AQPs offer exciting potential for clinical advances [23]. The expression of six isoforms of AQP
protein (AQP1, 3, 4, 5, 8, 9) has been reported in the glial cells [in astrocytes (AQP1, 3, 4, 5, 8,
9), oligodendrocytes (AQP8), tanycytes (AQP9) and ependymal cells (AQP1, 4, 9) [24]. As
astrocytes are the most numerous glial cell type and account for one third of brain mass [25]
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and they are involved in the maintenance of the blood–brain barrier (BBB), and as the GBM is
the most malignant form astrocytic brain tumor [1,2], we focused on the AQPs on the astrocytes
related to GBM. Previous reports showed that AQPs 1, 4, and 9 have significant roles in the
pathogenesis of malignant brain tumours [24].
3. AQP1
AQP1 plays an important role in water transport in expressed in various organs and cells
(microvascular endothelial cells, kidney, central nervous system, eye, lacrimal and salivary
glands, respiratory apparatus, gastrointestinal tract, hepatobiliary compartments, female and
male reproductive system, inner ear, skin) [26]. Previous reports sowed that brain astrocytes
express AQP1 under pathologic conditions as the early stage of Alzheimer disease, subarach‐
noid hemorrhage, cerebral infarction [27-29]. Monzani and coworkers showed a role for AQPs
in facilitating cell migration at the first time for AQP1 in human endothelial and melanoma
cell lines in vivo [30].
Hypoxia stimulates astrocytic migration it is possible that hypoxic conditions after spinal cord
injury (SCI) trigger AQP1 synthesis in astrocytes, as an attempt of injured spinal cords to
facilitate astrocytic migration to the lesion site [31,32]. Hypoxic conditions may contribute to
chronic accumulation of water within neurons and cytotoxic edema in chronically injured
spinal cords [33]. AQP1 expression in spinal cord may have a role in axonal remodeling and
plasticity, necessary for normal sensory processing [34]. Abreu-Rodríguez and coworkers
showed that HIF-1α participates in the hypoxic induction of AQP1 in 9L glioma cells. They
also demonstrated that the activation of AQP1 promoter by hypoxia is complex and multifac‐
torial and suggested that in addition to HIF-1α other transcription factors might contribute to
this regulatory process [35].
GBMs express increased aquaporin AQP1. AQPs may contribute to edema, cell  motility,
and shuttling of H2O and H+ from intracellular to extracellular space [36]. In comparison
to  normal  brain,  GBMs have  different  vascular  structures  and metabolic  changes.  GBM
cells make higher aerobic glycolysis under hypoxia than under normoxia leading to inva‐
sion of cancer cell [37,38].
4. AQP4
AQP4, the most important water channel in the brain, is found in supporting cells as astrocytes
(astrocyte endfeet abutting microvessels), ependyma and its also found in retina [39, 40]. AQP4
expression is polarized in astrocytes and AQP4 redistributes throughout the astrocyte cell
membrane, suggesting that endothelial cells signal astrocytes to polarize AQP4 expression in
the cell membrane [41]. Previous study showed that AQP4 is involved in the formation and
resolution of brain and spinal cord edemas. In the absence of AQP4, brain edema is decreased
and neurologic improvement following ischemic brain injury is increased [42].
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AQP4 expression is commonly up-regulated in astrocytes associated with brain edema [42]. It
was showed that an up-regulation and redistribution of AQP4 accompanied by a loss of its
polarized expression pattern and so the evidence for a role of it in vasogenic edema formation
in GBM [43, 44]. Altered expression levels of AQP4 and redistribution of the protein through‐
out the membranes of cells are found in GBM and this leads to development of the oedema
often found surrounding the tumour mass. AQP4 also facilitates the elimination of excess brain
water. Excess water is eliminated primarily through the glia limiting membranes into the CSF
that vasogenic edema fluid is eliminated by an AQP4-dependent route. AQP4 pumps out
excess fluid assembled in the brain parenchyma after BBB disruption [43,44]. Wang and
coworkers suggested that HIF-1α plays a role in brain edema formation and BBB disruption
via a molecular signaling pathway involving AQP4 and matrix metalloproteinase 9 (MMP-9)
[45]. HIF-1α binds the promoter of AQP4 resulting in the increase in its’ expression [46].
It was shown that in human immunodeficiency virus (HIV) infected patients, AQP4 expression
was increased indicating the role of AQP4 in a protective and/or maladaptive response to CNS
inflammation [47,48].
Recent study have found changes in astroglia Kir and AQP4 water channels in temporal lobe
epilepsy specimens [49]. Dysregulation of AQP4 also occurs in hippocampal sclerosis and
cortical dysplasia in patients with refractory partial epilepsy [50]. These are clue for both AQP4
and Kir4.1 participate in clearance of K+ following neural activity. Othe report suggested that
AQP4 and Kir4.1 may also act in concert in K+ and H2O regulation [51]. K+ re-uptake into glial
cells might be AQP4-dependent, as water influx coupled to K+ influx is thought to underlie
activity-induced glial cell swelling [52]. Further studies are required to clarify the expression
and functional interaction of AQP4 and Kir4.1 in the hippocampus and their changes during
epileptogenesis.
Recent reports have also suggested a role of AQP4 for neuroglial activation in autism and more
studies are also needed as epileptogenesis to confirm its spesific role in autism [53].
AQP4 is highly expressed in the basolateral membrane of the ependyma and glia limitans. This
meaning of this distribution feature can be evaluated that AQP4 provides a highly efficient
pathway to transport the redundant water from parenchyma to ventricle system and subar‐
achnoid space [42]. The highly polarized expression of AQP4 may be involved in the structural
and functional integrity of the ependyma maintance [42,54,55]. AQP4 is highly related with
the gap junction protein connexin43 (Cx43), which is the main gap-junction protein in
astrocytes as well as ependymal cells [53,55].
Previous report showed that reactive microglial cells expresses AQP4 mRNA and protein in
in vivo [56]. All cells which are expressing AQP4 in microglial cells may represent a molecular
adaptation to maintain ion water homeostasis in the injured brain. Activated microglia is
important in the clearance of K+ and restoration of osmotic equilibrium in absence of astro‐
cytes. It is well known that glial cells play an important role in regulating the homeostasis to
ensure an appropriate neuronal environment [24,56,57]. AQP4 seems to play an essential role
because of the possible role of astrocytes in pomping out excess K+ around active neuron
[24,56,57].
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and they are involved in the maintenance of the blood–brain barrier (BBB), and as the GBM is
the most malignant form astrocytic brain tumor [1,2], we focused on the AQPs on the astrocytes
related to GBM. Previous reports showed that AQPs 1, 4, and 9 have significant roles in the
pathogenesis of malignant brain tumours [24].
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spinal cords [33]. AQP1 expression in spinal cord may have a role in axonal remodeling and
plasticity, necessary for normal sensory processing [34]. Abreu-Rodríguez and coworkers
showed that HIF-1α participates in the hypoxic induction of AQP1 in 9L glioma cells. They
also demonstrated that the activation of AQP1 promoter by hypoxia is complex and multifac‐
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to  normal  brain,  GBMs have  different  vascular  structures  and metabolic  changes.  GBM
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and neurologic improvement following ischemic brain injury is increased [42].
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AQP4 expression is commonly up-regulated in astrocytes associated with brain edema [42]. It
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excess fluid assembled in the brain parenchyma after BBB disruption [43,44]. Wang and
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astrocytes as well as ependymal cells [53,55].
Previous report showed that reactive microglial cells expresses AQP4 mRNA and protein in
in vivo [56]. All cells which are expressing AQP4 in microglial cells may represent a molecular
adaptation to maintain ion water homeostasis in the injured brain. Activated microglia is
important in the clearance of K+ and restoration of osmotic equilibrium in absence of astro‐
cytes. It is well known that glial cells play an important role in regulating the homeostasis to
ensure an appropriate neuronal environment [24,56,57]. AQP4 seems to play an essential role
because of the possible role of astrocytes in pomping out excess K+ around active neuron
[24,56,57].




AQP9 transports glycerol, mannitol and urea. It was firstly found in human leukocytes, and
it is also expressed in liver, testis, and brain [58,59]. In the brain, AQP9 is expressed in tanycytes
(they possess no cilia). The tanycytes are found in circumventricular organs of the third
ventricle lacking a BBB [60, 61]. More studies are needed to confirm AQP9 expression in the
subset of ciliated ependymal cells [60]. AQP9 is also expressed in astrocytes and spinal cord
of the glia limitans and white matter tracts. Its expression is throughout the astrocyte cell bodies
and processes in the brain [62]. AQP9 may play a role in extracellular water homeostasis/
oedema and it also helps glycerol and monocarboxylate diffusion [63].
In addition, it is proposed that AQP9 plays a role in clearing lactate from the extracellular space
in pathological ischemic conditions. Most glioma cells throughout the tumour revealed a
strong AQP9 expression across the whole surface of the cells in human GBM. AQP9 expression
is increased in all grades of human astrocytic tumours and this expression is increased from
low-grade tumours to high-grade tumours [64]. The increase of AQP9 expression is essential
for the clearance of glycerol and lactate from the extracellular space at the glioma-associated
lactic acidosis [65]. AQP9 expression may account for GBM resistance to hypoxic and ischemic
situations, by facilitating clearance of lactate and glycerol resulting from hypoxia and cellular
damage, respectively [66-69]. HIF-1α binds AQP4 promoter, consequently it increases the
expression of AQP4 [70].
It might, therefore, play a role in both the energy metabolism of normal brain tissue and
provide increased tolerance for hypoxia under pathological conditions. AQP9 may play an
important role in the malignant progression of brain tumours and it can be used as a biomarker
for molecular diagnosis and as a new target for gene therapy.
6. AQPs 1,4,9 in stem cells
In the study of Fussdal and coworkers at biopsies from GBMs, they analyzed the expression
of AQPs 1, 4, and 9 in isolated tumour stem cells grown in a tumoursphere assay and analyzed
the progenitor and differentiated cells from these cultures. They compared these expressions
to the situation in normal rat brain, its stem cells, and differentiated cells. They concluded that
AQP 9 is markedly more highly expressed in the tumour progenitor population, whilst AQP4
is downregulated in tumour-derived differentiated cells. They proposed that AQP 9 may have
a central role in the tumorigenesis of GBM [71].
7. Midkine
Midkine (MK) with the molecular weight of MK is 13 kDA is a heparin-binding growth factor/
an angiogenic factor with cytokine actions. MK binds to oversulfated structures in heparan
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sulfate and chondroitin sulfate. MK and pleiotrophin (known as PTN and HB-GAM) are
belonging to same family [72]. MK is 50% homologous to PTN at the amino acid level and
shares with PTN the genomic organization and predicted protein structure [72-73].
MK is mainly composed of two domains which are linked by disulfide bonds [74]. The C-
domain has basic heparin-binding activity and this is responsible for the mechanism of action
[75]. Each domain of MK has also homology to the thrombospondin Type I repeat [76]. Two
domains are composed of three anti-parallel β-sheets [77]. The C-domain has two clusters of
basic amino acids named as Cluster-1 and -2. These clusters are required for heparin-binding
activity [78]. MK forms dimers via spontaneous association and transglutaminase stabilize
dimers through crosslinking process. MK is seemed to require dimerization for its activity [79].
After dimerization, Cluster-2 forms a fused strong binding site [77].
MK was originally reported to be the product of a retinoic acid-responsive gene during
embryogenesis [80]. its expression was high during embryogenesis, but interestingly, MK is
not detectable in healthy adults and only re-appears in the body as a part of the pathogenesis
of diseases [81]. MK promotes proliferation, migration, anti-apoptotic manner, mitogenesis,
transforming, and angiogenesis various cells [82-87]. It has significant roles in reproduction,
repair and in epidemiology of many diseases as rheumatoid arthritis, multiple sclerosis,
hypertension and renal disease and cancer [88-90]. It’s very important data that the expression
of MK is increased in advanced tumors with high frequency [84, 91]. Previous reports showed
that the blood MK level is frequently elevated with advance of human carcinomas, decreased
after surgical removal of the tumors [91,92].
Human MK recognizes glycosaminoglycans through its C-domain as heparan sulfate trisul‐
fated unit and chondroitin sulfate E unit is important in its mechanism of action. The compo‐
nent of the MK receptor is a chondroitin sulfate proteoglycan protein tyrosine phosphatase-z
(PTPz). Low density lipoprotein receptor-related protein (LRP), α4β1-integrin and α6β1-
integrin are also MK receptors [93,94].These proteins and PTPz form a receptor complex of
MK. After the complex formation with PTPz and integrins, MK starts downstream signaling
systems as Src family kinases and tyrosine phosphorylation,respectively. Increased tyrosine
phosphorylation of paxillin leads to migration at osteoblast like cells and followed by sup‐
pression of caspases, activation of PI3 kinase and MAP kinase takes part in survival [83, 93,
95]. The previous report showed that when MK binds to a6b1-integrin and tetraspanin, and
induces tyrosine phosphorylation of focal adhesion kinase (FAK) followed by activation of
paxillin and signal transducer and activator of transcription (STAT) 1 alpha pathway, it
increases migration and invasion at human head and neck squamous cell carcinoma cells in
vitro [96]. Due to phosphorylation of STAT3 by MK, the proliferation of postconfluent 3T3-L1
cells are stimulated and this leads to adipogenesis [97]. Notch2 reserves an another receptor
for MK and acting through the janus kinase 2 (Jak2)/STAT3 signalling pathway, MK leads to
epithelial-mesenchymal transition (EMT) in immortalized keratinocytes. Both MK and PTN
plays important role in EMT and neurogenesis during organogenesis process in embryonal
development [96]. Previous reports proposed that anaplastic lymphoma kinase (ALK) can be
included in the receptor group of MK [98]. Muramatsu and coworkers suggested that, ALK
also involves in the MK complex with LRP and integrins that it is recruited to the receptor
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important role in the malignant progression of brain tumours and it can be used as a biomarker
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sulfate and chondroitin sulfate. MK and pleiotrophin (known as PTN and HB-GAM) are
belonging to same family [72]. MK is 50% homologous to PTN at the amino acid level and
shares with PTN the genomic organization and predicted protein structure [72-73].
MK is mainly composed of two domains which are linked by disulfide bonds [74]. The C-
domain has basic heparin-binding activity and this is responsible for the mechanism of action
[75]. Each domain of MK has also homology to the thrombospondin Type I repeat [76]. Two
domains are composed of three anti-parallel β-sheets [77]. The C-domain has two clusters of
basic amino acids named as Cluster-1 and -2. These clusters are required for heparin-binding
activity [78]. MK forms dimers via spontaneous association and transglutaminase stabilize
dimers through crosslinking process. MK is seemed to require dimerization for its activity [79].
After dimerization, Cluster-2 forms a fused strong binding site [77].
MK was originally reported to be the product of a retinoic acid-responsive gene during
embryogenesis [80]. its expression was high during embryogenesis, but interestingly, MK is
not detectable in healthy adults and only re-appears in the body as a part of the pathogenesis
of diseases [81]. MK promotes proliferation, migration, anti-apoptotic manner, mitogenesis,
transforming, and angiogenesis various cells [82-87]. It has significant roles in reproduction,
repair and in epidemiology of many diseases as rheumatoid arthritis, multiple sclerosis,
hypertension and renal disease and cancer [88-90]. It’s very important data that the expression
of MK is increased in advanced tumors with high frequency [84, 91]. Previous reports showed
that the blood MK level is frequently elevated with advance of human carcinomas, decreased
after surgical removal of the tumors [91,92].
Human MK recognizes glycosaminoglycans through its C-domain as heparan sulfate trisul‐
fated unit and chondroitin sulfate E unit is important in its mechanism of action. The compo‐
nent of the MK receptor is a chondroitin sulfate proteoglycan protein tyrosine phosphatase-z
(PTPz). Low density lipoprotein receptor-related protein (LRP), α4β1-integrin and α6β1-
integrin are also MK receptors [93,94].These proteins and PTPz form a receptor complex of
MK. After the complex formation with PTPz and integrins, MK starts downstream signaling
systems as Src family kinases and tyrosine phosphorylation,respectively. Increased tyrosine
phosphorylation of paxillin leads to migration at osteoblast like cells and followed by sup‐
pression of caspases, activation of PI3 kinase and MAP kinase takes part in survival [83, 93,
95]. The previous report showed that when MK binds to a6b1-integrin and tetraspanin, and
induces tyrosine phosphorylation of focal adhesion kinase (FAK) followed by activation of
paxillin and signal transducer and activator of transcription (STAT) 1 alpha pathway, it
increases migration and invasion at human head and neck squamous cell carcinoma cells in
vitro [96]. Due to phosphorylation of STAT3 by MK, the proliferation of postconfluent 3T3-L1
cells are stimulated and this leads to adipogenesis [97]. Notch2 reserves an another receptor
for MK and acting through the janus kinase 2 (Jak2)/STAT3 signalling pathway, MK leads to
epithelial-mesenchymal transition (EMT) in immortalized keratinocytes. Both MK and PTN
plays important role in EMT and neurogenesis during organogenesis process in embryonal
development [96]. Previous reports proposed that anaplastic lymphoma kinase (ALK) can be
included in the receptor group of MK [98]. Muramatsu and coworkers suggested that, ALK
also involves in the MK complex with LRP and integrins that it is recruited to the receptor
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complex and plays roles in MK signaling [99]. After activation by MK, ALK phosphorylates
insulin receptor substrate-1, activates MAP kinase and PI3 kinase leading to transcriptional
activation of Nuclear Factor-KappaB (NF-κB) [98].
MK binds to nucleolin, a nuclear protein which is also located at the cell surface and functions
as a shuttle to the nucleus [85]. A component of the MK receptor LRP has major function as
endocytose and delivering its ligands to lysosomes for degradation or catabolism [100]. LRP
takes part in internalization of MK [101]. MK is not internalized in LRP-deficient cells, whereas
transfection of a LRP expression vector can restore MK internalization and subsequent nuclear
translocation, suggesting that LRP binds to MK and mediates nuclear targeting by MK. After
this internalization, nucleolin transfer cytoplasmic MK to the nucleus [101]. With respect to
nuclear targeting by MK, laminin-binding protein precursor (LBP) binds to MK and is
cotranslocated with MK into nuclei [102]. MK may use both nucleolin and LBP precursor as
shuttle proteins, revealing a novel role of LRP in intracellular signaling by its ligand, and the
importance of nucleolin and LBP in the process of nuclear target of MK. MK transferred to the
nucleolus is involved in the synthesis of ribosomal RNA [85]. Muramatsu and coworkers
observed, however didn’t publish that translation initiation factor (eIF3) can be an MK-binding
protein in the embryonic brain [31].
8. MK and GBM
In the central nervous system, MK is expressed by astrocytes in the fetal brain and its ex‐
pression is  developmentally regulated,  decreasing progressively to an undetectable level
as the fetus matures [103,104].  Previous reports showed that  increased levels of  MK ex‐
pression correlate with the progression of human astrocytomas, MK mRNA and protein
expression levels were higher in high-grade astrocytomas as anaplastic astrocytomas and
GBMs  than  in  low-grade  astrocytomas  (oligodendroglioma,  ependioma,  schwannoma,
meningioma  and  pituitary  adenoma)  [105].  These  reports  conclude  that  MK  correlates
with the poor prognosis of GBM.
One of the report showed that MK activates PI3-kinase and MAP kinase signal transduc‐
tion in U87MG human glioblastoma cells which express ALK protein [98]. In this report
it was shown that MK is also unable to stimulate Akt phosphorylation upon reduction of
ALK. In their report they revealed that in contrast with the diminished PTN and MK sig‐
nals  after  reduction of  ALK, Akt phosphorylation in the same cells  via a different tyro‐
sine  kinase  receptor,  the  platelet-derived  growth  factor  receptor  (PDGF-R),  was  not
altered by the reduction of ALK levels [107]. Interestingly, in the U87MG cells MAPK is
activated  constitutively  and  remains  unaffected  by  the  ALK reduction  or  by  MK addi‐
tion. In contrast to other report showed that no mRNA levels of ALK and RPTP β/ς lev‐
els, but high mRNA levels of MK and PTN were determined in another human GBM cell
lines named T98G [98, 107]. This condition is also same for human glioblastoma cell lines
named G55T2. U118 GBM cells possess high mRNA levels of ALK, low mRNA levels of
MK and RPTP β/ς but no mRNA levels of PTN are detected. All cell lines derived from
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications362
human GBMs are different. Autophagy can both lead to cell death (autophagic cell death
or  apoptotic  cell  death)  and  cell  survival  (survival/recurrence/resistance).  This  means  it
becomes sometimes foe sometimes friend. Lorente and coworkers showed that activation
of the tyrosine kinase receptor ALK by its ligand MK interferes with the signaling mech‐
anism by which Δ9-tetrahydrocannabinol  (THC) which is  the main active component of
marijuana, promotes cancer cell death via autophagy stimulation [108].
GBM has a complex tumor structure consisting of accumulating tumors cells, abnormal vessel
and necrotic debris. The increasing tumor mass leads to increased capillary and venous
collapse [109]. The new formed vessels are structurally and functionally abnormal, and leaky,
leading to edema, and low oxygen tension [110]. High O2 tension degrades HIF-1α and
consequently promotes differentiation or apoptosis, HIF-1α maintains at lower O2 tension this
augments signal transduction pathways leading to promote self-renewal [111]. Hypoxia
induces MK expression through the binding of to a hypoxia responsive element in the MK
promoter.
Notch2 has been suggested to lead embryonic brain tumor growth, however Notch3 has been
implicated in choroid plexus tumors [112]. The frequency and the intensity of Notch2 expres‐
sion is higher than that of Notch1 in GBM and in medulloblastoma [113]. As a consequence of
local genomic amplifications at the Notch2 locus in both brain tumor types, this may also be
linked to the later persistence of Notch2 expression in postnatal mouse brain [114]. Previous
report showed that Notch1 regulates transcription of the epidermal growth factor receptor
gene EGFR, known to be overexpressed or amplified in GBM, through TP53 [115]. Reports
showed that there is a direct correlation between p53 and MK levels. Consistently, transcription
of Notch signaling mediator genes are significantly overexpressed in the molecular subset of
GBM with EGFR amplification [116]. Notch signaling pathway activates the major GBM
signalling pathway. Glioma subsets with impaired Notch signaling have slower progression.
The most frequent genetic alteration occurring in GBM is genomic amplification of EGFR [117].
Consistently, EGF is the major proliferation pathway in GBM, mediated by activation of the
RAS-RAF-MEK-ERK and the PI3K-AKT-mTOR cascades [58]. Interestingly, mTOR has
recently been shown to activate Notch signaling in lung and kidney tumor cells through
induction of the STAT3/p63/Jagged signaling cascade [118]. Lino and coworkers proposed this
cross-talk for GBM that this suggests potential creation of a positive feedback loop between
Notch and EGF signalling [119]. The most frequent GBM subset consists of the association of
EGFR amplification, homozygous deletions at the cyclin dependent kinase 2A (CDKN2A)
locus, and TP53 mutations [120]. Notch activates expression of EGFR via TP53 thus Notch is
expected to stimulate the main GBM proliferation pathway [116]. In addition, Notch also
transactivates the gene for the EGFR-related ERBB2 in a DTX1-dependent manner [121].
Notch-2 serves another receptor for MK and so cross-talk between MK and Notch-2 has been
also shown to be a mediator of chemotherapy resistance to neighboring cells in GBM [122].
When a subset of cells overexpress drug transport proteins, possess receptor changes for the
commitment of drug bounding and lack of ability to commit apoptosis, this situation leads to
tumors resistance during chemotherapy. Mirkin and coworkers investigate the cytoprotective
relationship between resistant and nonresistant cells in tumors which both accomplish to
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els, but high mRNA levels of MK and PTN were determined in another human GBM cell
lines named T98G [98, 107]. This condition is also same for human glioblastoma cell lines
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augments signal transduction pathways leading to promote self-renewal [111]. Hypoxia
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report showed that Notch1 regulates transcription of the epidermal growth factor receptor
gene EGFR, known to be overexpressed or amplified in GBM, through TP53 [115]. Reports
showed that there is a direct correlation between p53 and MK levels. Consistently, transcription
of Notch signaling mediator genes are significantly overexpressed in the molecular subset of
GBM with EGFR amplification [116]. Notch signaling pathway activates the major GBM
signalling pathway. Glioma subsets with impaired Notch signaling have slower progression.
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Consistently, EGF is the major proliferation pathway in GBM, mediated by activation of the
RAS-RAF-MEK-ERK and the PI3K-AKT-mTOR cascades [58]. Interestingly, mTOR has
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Notch and EGF signalling [119]. The most frequent GBM subset consists of the association of
EGFR amplification, homozygous deletions at the cyclin dependent kinase 2A (CDKN2A)
locus, and TP53 mutations [120]. Notch activates expression of EGFR via TP53 thus Notch is
expected to stimulate the main GBM proliferation pathway [116]. In addition, Notch also
transactivates the gene for the EGFR-related ERBB2 in a DTX1-dependent manner [121].
Notch-2 serves another receptor for MK and so cross-talk between MK and Notch-2 has been
also shown to be a mediator of chemotherapy resistance to neighboring cells in GBM [122].
When a subset of cells overexpress drug transport proteins, possess receptor changes for the
commitment of drug bounding and lack of ability to commit apoptosis, this situation leads to
tumors resistance during chemotherapy. Mirkin and coworkers investigate the cytoprotective
relationship between resistant and nonresistant cells in tumors which both accomplish to
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survive against drug cytotoxicity in human neuroblastoma and osteosarcoma [123]. They
hypothized that drug-resistant cells may secrete in their culture medium factors able to protect
sensitive cells from cytotoxicity of drug. They showed that expression of MK was only detected
in drug resistant cells and MK-enriched fractions exert a significant cytoprotective effect
against doxorubicin (DXR) in the wild-type drug-sensitive cells. In addition, they transfected
these cells with MK gene resulting in decreased response to DXR due to activation of AKT
pathway and supression of caspase pathway. They concluded that the existence of intercellular
cytoprotective signals such as the one mediated by MK, originating from cells with acquired
drug resistance to protect neighboring drug-sensitive cells and thus contribute to development
of resistance to chemotherapy. They didn’t show anything aout direct effect of MK on drug
efflux transporters.
Report by Hu and coworkers showed that the possible effects of MK gene on the chemother‐
apeutic drugs efflux. They concluded that there was powerful drug efflux ability in lympho‐
blastic leukemia cells with high MK gene expression [124]. They proposed that MK gene
expression regulates drug efflux upstream of the p-gp and the other transporter proteins in
this cell line. Previous reports showed that the expression of MRP-1 is higher than expression
of p-gp in T98G [125]. In our study, we investigated whether the combination of an antineo‐
plastic imatinib mesylate (IM) and an antitussive noscapine (Nos) with new identified
chemotherapeutic effects, can be an effective GBM treatment and the role of MK in this
treatment by using T98G cells [126]. The lowest MRP-1 levels, but highest MK levels were
detected in the combination group. The lowest MK levels were detected in IM group especially
at the 72nd hr (p<0.05) but IM takes second place at MRP-1 inhibition. The highest and the lowest
p-170 levels were detected at IM group (p<0.05) and Nos group (p<0.05), respectively. Thus,
we can conclude that drug efflux ability was not correlated with MK levels in this experiment.
Suppression of PTN and ALK expression has already been employed as means to treat GBM,
and promising results have been obtained in animal experiments [107].
9. MK and GBM stem cells
Previous publication showed that MK is expressed in mouse embryonic stem cells (mESCs),
human embryonic stem cells (hESCs) and mouse embryonic fibroblasts (MEFs) [127]. In their
study, MK promotes proliferation and self-renewal of both mESCs and hESCs. Another study
showed that the promoted growth of mESCs by MK is occured through inhibiting apoptosis
while accelerating the progression toward the S phase, and MK leads to enhancement of mESC
self-renewal through PI3K/Akt signaling pathway. They concluded that MK plays profound
roles in ESCs and MK/PTPzeta signaling pathway is a novel pathway in the signal network
maintaining pluripotency of ESCs. Their results gives more detailed information about the
pluripotency control of ESCs and the relationship between ESCs and cancers. Huang and
coworkers showed that a highly tumorigenic subpopulation of cancer cells named GBM stem
cells (GSCs) promotes therapeutic resistance [127]. In their study, they showed that GSCs
stimulate tumor angiogenesis by expressing elevated levels of VEGF and contribute to tumor
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growth. In addition, cancer stem cells have been shown to promote metastasis. MK was found
to be expressed in neural precursor cells, which consist of neural stem cells and the progenitor
cells which has been translated into a useful therapeutic strategy in the treatment of recurrent
or progressive GBMs [128].
10. MK and AQPs
Hypoxia is the intersection point for AQP and MK. Hypoxia increases all these protein levels
as I mentioned above: their levels are all increased under hypoxic conditions. HIF-1α binds
promoter of MK and AQP, then it increases its expression. In addition, HIF-1α serves as an
upstream regulator of cerebral glycerol concentrations and brain edema via a molecular
pathway involving AQP4 and AQP9 [70].
In our previous study published in Oncology Letter, we investigated the combination of
imatinib (IM) and roscovitine (ROSC) to overcome resistance and whether or not MK had an
effect on this combination in the treatment of GBM with other anti-apoptotic factors such as
AQP4 in T98G human GBM cells. These cells are expressing high MK and AQP4 levels. In this
study, all applications decreased the cell proliferation index and increased the apoptotic index,
but ROSC was the most efficient drug and the second most efficient drug was IM to decrease
cell proliferation and induce cell death. Combination therapy showed antagonist manner.
Notably, ROSC increased AQP-4 levels, however it decreased MK levels. The combination
group induced highest decrease in p170 levels (p<0.05), the second one was determined as the
IM group (p<0.05). All drug applications decreased MRP-1 levels (p<0.05), but the highest
decrease was determined in the combination group and the latter was IM (p<0.05). IM
decreased AQP-4 levels, however the combination group and ROSC increased AQP4 levels in
T98G GBM cells. This increase was higher in the combination group.
In our other study, we combined IM with lithium chloride (LiCl) in T98G cells [unpublished
data]. This shows combination also showed antagonist effect. MRP-1 levels were decreased by
LiCl, the combination group and IM, respectively. Firstly the combination group and secondly
IM decreased p170 levels efficiently, but LiCl didn’t make any change on these levels. Firstly
LiCl and secondly the combination group induced highest decrease in AQP4 levels for 72 h.
For MK levels, the decrease rate from highest to lowest were IM, LiCl and the combination
group [unpublished data].
In this studies, you can see that we only searched for correlation between MK and AQP4 and
there were no hypoxic conditions or no three dimensional cell culture model which hypoxic
center is formed without hypoxic conditions. This means that we might have different results
if 1) we used this model, 2) investigated other types of AQPs as AQP9, 3) use different GBM
cell lines for these novel combinations.
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1. Introduction
The molecule 5-aminolevulinic acid (5-ALA) is a substrate for a heme synthesized in cells us‐
ing succinyl CoA and glycine. Initially, 5-ALA is converted to porphobilinogen (PBG), and the
metabolism progresses by the action of PBG deaminase, and its product is incorporated into
the mitochondria via uroporphyrinogen and coproporphyrinogen by an enzymatic reaction
and transformed into protoporphyrin IX (PPIX). This PPIX is then converted to a heme by the
action of ferrochelatase. These metabolic reactions are conducted in the liver and erythroblasts
of normal human subjects [16]. It is thought that a larger amount of 5-ALA is incorporated by
rapidly proliferating tumor cells as compared to normal cells, due to the active synthesis of
heme [5, 20]. In the metabolic pathway of 5-ALA, it is reported that the rate limiting enzyme in
normal cells is different from that in tumor cells [16]. PBG deaminase is the rate limiting en‐
zyme in normal cells [3]. Large amounts of uroporphyrinogen, coproporphyrinogen, and PPIX
are produced in tumor cells compared to normal cells because metabolism after the PBG is pro‐
moted by high PBG deaminase activity and low ferrochelatase activity [15]. The PPIX accumu‐
lates in tumor cells and produces a red fluorescent response to ultraviolet light. Intraoperative
photodynamic diagnosis using this method is used for patients with glioma [21, 24, 26]. There
are numerous reports concerning the PPIX concentration in the tumor tissue; however, re‐
ports concerning plasma titers and urinary excretion of uroporphyrinogen and copropor‐
phyrinogen after 5-ALA administration are rare [25]. In this study, 5-ALA was administered to
healthy adult volunteers, and changes in serum and urinary porphyrins were measured. Uri‐
nary excretion of porphyrins in volunteers and patients with brain tumors after the 5-ALA ad‐
ministration were compared and examined.
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1. Introduction
The molecule 5-aminolevulinic acid (5-ALA) is a substrate for a heme synthesized in cells us‐
ing succinyl CoA and glycine. Initially, 5-ALA is converted to porphobilinogen (PBG), and the
metabolism progresses by the action of PBG deaminase, and its product is incorporated into
the mitochondria via uroporphyrinogen and coproporphyrinogen by an enzymatic reaction
and transformed into protoporphyrin IX (PPIX). This PPIX is then converted to a heme by the
action of ferrochelatase. These metabolic reactions are conducted in the liver and erythroblasts
of normal human subjects [16]. It is thought that a larger amount of 5-ALA is incorporated by
rapidly proliferating tumor cells as compared to normal cells, due to the active synthesis of
heme [5, 20]. In the metabolic pathway of 5-ALA, it is reported that the rate limiting enzyme in
normal cells is different from that in tumor cells [16]. PBG deaminase is the rate limiting en‐
zyme in normal cells [3]. Large amounts of uroporphyrinogen, coproporphyrinogen, and PPIX
are produced in tumor cells compared to normal cells because metabolism after the PBG is pro‐
moted by high PBG deaminase activity and low ferrochelatase activity [15]. The PPIX accumu‐
lates in tumor cells and produces a red fluorescent response to ultraviolet light. Intraoperative
photodynamic diagnosis using this method is used for patients with glioma [21, 24, 26]. There
are numerous reports concerning the PPIX concentration in the tumor tissue; however, re‐
ports concerning plasma titers and urinary excretion of uroporphyrinogen and copropor‐
phyrinogen after 5-ALA administration are rare [25]. In this study, 5-ALA was administered to
healthy adult volunteers, and changes in serum and urinary porphyrins were measured. Uri‐
nary excretion of porphyrins in volunteers and patients with brain tumors after the 5-ALA ad‐
ministration were compared and examined.
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2. Materials and Methods
Healthy adult volunteers (n = 8) and 58 patients with glioma (12 benign gliomas (WHO
grade II) and 46 glioblastomas) who were resected by intraoperative fluorescence diagnosis
using 5-ALA were enrolled in the study. Eight adult volunteers were given 1 gram of 5-ALA
orally, and blood sampling was done before administration, 2 hours, 4 hours, and 6 hours
later. Blood samples were analyzed for plasma titers of 5-ALA, PPIX, coproporphyrin I
(CPI), coproporphyrin III (CPIII), uroporphyrin I (UPI), and uroporphyrin III (UPIII). Urine
collection was done before and 4 hours after 5-ALA administration, and the urinary excre‐
tion of 5-ALA, CPI, CPIII, UPI, and UPIII were measured. Fifty-eight patients with glioma
were given 1 gram of 5-ALA orally 2 hours before anesthesia, and blood and urine samples
were collected from these patients 4 hours later for analyses of plasma titers and urinary ex‐
cretion of 5-ALA, PPIX, CPI, CPIII, UPI, and UPIII. Intraoperative fluorescence diagnosis for
58 patients with glioma was performed using a semiconductor laser device (VLD-V1 version
2: M & M Co., Ltd., Tokyo, Japan). The brain tumor was exposed to a laser light that had a
peak wavelength of 405 nm and a light output of 120 mW by placing the optical fiber as
close as possible. The spectra of the response light from tumors were analyzed by a personal
computer for a fluorescent identification of PPIX and the measurement of the fluorescent ob‐
jective strength. When fluorescence from PPIX was observed, a waveform with a peak at 636
nm was observed. When the intensity of the peak at 636 nm was ≥3000, the tumor was de‐
fined as a strong fluorescence tumor. In contrast, when the intensity of the peak at 636 nm
was < 3000, the tumor was defined as a weak fluorescence tumor. Two groups distributed
based on these spectra were examined for macroscopic findings; i.e., fluorescence for the
strong PPIX group was observed macroscopically in all of the strong fluorescence tumors.
When there was not a waveform peak at 636 nm, and the fluorescence of PPIX was not ob‐
served for a tumor, the tumor was considered to be a non-fluorescence tumor. The total uri‐
nary excretion products were adjusted for creatinine value. Testing for significant
differences was done using analysis of variance (analysis of variance; ANOVA) or the PLSD
(protected least significant difference) method of Fisher as a post-hoc test.
3. Results
The plasma 5-ALA concentration in volunteers reached a peak 2 hours after 5-ALA adminis‐
tration (Figure 1). The plasma titer peaks of protoporphyrin IX, CPI, and CPIII in volunteers
were reached 2 hours after administration of 5-ALA. The plasma titer peaks of UPI and UP‐
III in volunteers were reached 4 hours after 5-ALA administration (Figure 2). The plasma tit‐
er and urinary excretion of CPI, CPIII, UPI, UPIII, and 5-ALA were not significantly
different in volunteers and glioma patients prior to 5-ALA administration (data not shown).
Urinary excretion CPI and CPIII 4 hours after 5-ALA administration were significantly high‐
er in patients with glioma than in volunteers (Figures 3, 4) (p <0.0001). Urinary excretion of
UPI and UPIII 4 hours after 5-ALA administration in volunteers and glioma patients were
not significantly different (Figures 5，6). Urinary excretion of CPI, CPIII, UPI, UPIII, and 5-
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ALA 4 hours after 5-ALA administration in patients with benign glioma was not significant‐
ly different compared to patients with glioblastoma. All of the glioblastomas were strong
fluorescence tumors. Benign gliomas were comprised of 3 strong fluorescence tumors, 5
weak fluorescence tumors, and 4 non-fluorescence tumors. Urinary excretion of CPI, CPIII,
UPI, UPIII, and 5-ALA 4 hours after 5-ALA administration was not significantly different
when comparing strong fluorescence tumors, weak fluorescence tumors, and non-fluores‐
cence tumors in benign glioma patients (data not shown).
Figure 1. Graph shows the plasma titer of 5-ALA when 5-ALA was administered to volunteers. The peak concentration
is reached 2 hours after administration of 5-ALA, and the concentration is ≤ 50% of the peak level 4 hours later. The
concentration is ≤ 10% of the peak level 6 hours later.
Figure 2. Graph shows various plasma titers of porphyrins when 5-ALA was administered to volunteers. The plasma
titers of protoporphyrin IX, CPI, and CPIII reached maximal levels 2 hours following 5-ALA administration. The plasma
titers of UPI and UPIII peaked at 4 hours after administration of 5-ALA.
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Figure 3. Graph shows urinary excretion of CPI 4 hours following administration of 5-ALA to normal volunteers, and
patients with benign gliomas and glioblastomas. Urinary excretion of CPI in patients with benign gliomas and glioblas‐
tomas was significantly higher than in normal volunteers.
Figure 4. Graph shows urinary excretion of CPIII 4 hours after 5-ALA was administered to normal volunteers, and pa‐
tients with benign gliomas and glioblastomas. Urinary excretion of CPIII in patients with benign gliomas and glioblas‐
tomas was significantly higher than in normal volunteers.
4. Discussion
It was reported that plasma titers and urinary excretion of porphyrins were increased when
tumor-bearing mice were administered 5-ALA [8]. Also, it was reported that the plasma tit‐
ers and urinary excretion of these porphyrins were increased when 5-ALA was adminis‐
tered to adult mice without malignant tumors [14]. The reason why these porphyrins
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increase in healthy volunteers after 5-ALA administration might be that those porphyrins
leak as the intermediate product after being metabolized by the erythroblasts and liver [14].
When healthy volunteers were administered 5-ALA in our study, the plasma titers of 5-
ALA, CPI, CPIII, UPI, UPIII, and PPIX reached maximum levels at 2-4 hours following 5-
ALA administration. Therefore, it was thought that most of these porphyrins were done
being excreted in the urine 4 hours after 5-ALA administration.
Figure 5. Graph shows urinary excretion of UPI 4 hours after 5-ALA was administered to normal volunteers, and pa‐
tients with benign gliomas and glioblastomas. The urinary excretion of UPI showed no significant differences among
subjects who were normal volunteers, and patients with benign gliomas and glioblastomas.
Figure 6. Graph shows urinary excretion of UPIII 4 hours after 5-ALA was administered to normal volunteers and pa‐
tients with benign gliomas and the glioblastomas. The urinary excretion of UPIII showed no significant differences
among subjects who were normal volunteers, and patients with benign gliomas and glioblastomas
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If 5-ALA were not administered, there would be no difference in the metabolism of these
porphyrins in volunteers and glioma patients, because plasma titers and urinary excretion
of CPI, CPIII, UPI, UPIII, and 5-ALA were not significantly different in volunteers and glio‐
ma patients prior to 5-ALA administration. Also, there would not be the specific metabolic
process in tumor cells for converting 5-ALA to uroporphyrin, because urinary excretion of
UPI and UPIII was not different when comparing volunteers, patients with benign glioma,
and patients with glioblastoma. However, the urinary excretion of CPI and CPIII 4 hours af‐
ter 5-ALA administration significantly increased in patients with glioma as compared to vol‐
unteers. Therefore, it was thought that high levels of CPI and CPIII were being produced in
tumor cells as compared to normal cells. Heme is rapidly synthesized in cells with accelerat‐
ed metabolism, such as tumor cells, and 5-ALA is incorporated into tumor cells and metabo‐
lized. Consequently, large quantities of CPI and CPIII are produced as the metabolites, and
it was thought that urinary excretion increased [11]. In the healthy adults without a tumor,
PBG deaminase becomes the rate limiting enzyme even if 5-ALA is incorporated into cells,
and extensive metabolism occurs prior to production of PBG. Therefore, CPI and CPIII,
which are down-stream metabolites, will not be produced in large quantities [3].
It is known that ATP-binding cassette (ABC) transporters, such as ABCG2 and ABCB6, are
associated with trafficking of these porphyrins. ABCG2 is expressed mainly in the cell mem‐
brane and serves as the active transporter for anticancer drugs present outside of cells [6].
ABCG2 drains excessive levels of porphyrin outside of cells while performing this function
[13]. ABCB6 transports coproporphyrinogen from the cytoplasm into the mitochondria, and
both. ABCG2 and ABCB6 are overexpressed in cancer cells [6, 12, 23]. ABCG2 is overex‐
pressed in brain tumors [1, 9], and its presence is more common in malignant tumors [9].
CPI and CPIII that are produced in the cytoplasm of tumor cells are actively transported by
ABCG2 overexpressed in brain tumor cells. This was considered the cause of higher urinary
excretion of CPI and CPIII in patients with a brain tumor compared to normal volunteers.
Similarly, it is reported that urinary excretion of porphyrins increases even in cancers other
than brain tumors [7]. Therefore, these porphyrins may be used as a nonspecific marker in
screening for tumors [25]. In other words, presence of hypermetabolic tumor cells may be
suggested if urinary excretion measures of CPI and CPIII are elevated in a person orally ad‐
ministered orally 5-ALA. In such a case, it may be useful to investigate the whole body for
the presence of a tumor.
The urinary excretion of CPI and CPIII were not different in benign glioma and glioblastoma
patients, and the metabolism of 5-ALA to produce CPI and CPIII should not differ between be‐
nign gliomas and glioblastomas. Many of the benign gliomas were weak fluorescence or non-
fluorescence tumors, whereas all glioblastomas were strong fluorescence tumors. In other
words, high levels of PPIX had accumulated in the glioblastomas, while only low levels of
PPIX accumulated in benign gliomas. Metabolic processes involved in the pathway leading
from CPI and CP III to PPIX will be different in benign gliomas and glioblastomas. These dif‐
ferences will be due differences in the activity of ABCB6 which transports CPI and CPIII in mi‐
tochondria,  or  coproporphyrinogen  oxidase,  which  converts  CPI  and  CPIII  into  PPIX.
Concerning these ABC transporters, it is reported in accordance with genetic polymorphism
that the functions and levels of expression are different [23]. Therefore, the intracellular PPIX
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications382
concentration will be higher for a tumor having higher levels of ABCB6 [12]. Also, the glioblas‐
tomas will have much higher levels of PPIX than benign gliomas, because the presence of cop‐
roporphyrinogen oxidase is common in a malignant tumor [22].
However, differences in PPIX accumulation (fluorescent strength) are not necessarily pro‐
portional to urinary excretion of these porphyrins after 5-ALA administration. The volume
of a tumor (the total amount of PPIX) is one factor affecting results. The factors related to
differences in accumulation of protoporphyrin IX have been investigated in various ways,
and various factors such as ALA uptake by cells [2, 19], mitochondrial properties [18], mole‐
cules involved in PpIX metabolism including porphobilinogen deaminase [4], ferrochelatase
[15], iron content [10], transferring receptor [17], and mRNA levels of the coproporphyrino‐
gen oxidase (CPOX) gene [13] are thought to be associated with protoporphyrin IX accumu‐
lation. Due to the involvement of these multiple factors, differences in the accumulation of
PPIX will occur [24].
5. Conclusion
Following administration of 5-ALA, patients with a brain tumor showed higher urinary ex‐
cretion of CPI and CPIII than did healthy volunteers. This was due to the active production
of porphyrins in metabolically active tumor cells. The urinary excretion of CPI and CPIII fol‐
lowing administration of 5-ALAcould possibly be used as a screening assay for the presence
or absence of a tumor. Differences in the presence of the ABC transporter may contribute to
metabolic differences of the porphyrins in benign gliomas and glioblastomas.
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Glioblastoma (GBM) is the most prevalent and most malignant (WHO grade IV) type of brain
tumor in adults [1, 2]. In the United States, there are ~10,000 new cases diagnosed annually,
and >50,000 patients living with the disease [2, 3]. The clinical responses of patients are
particularly poor and vary greatly among individuals [4], and ~32% of all diagnosed cases
survive less than a year [3]. This highly aggressive tumor develops either de novo (primary
GBM), or as the result of the malignant progression from a lower-grade glioma (secondary
GBM). In both cases, prognosis is very poor, and the median survival when radiotherapy and
chemotherapy are combined is approximately 15 months [5]. Importantly, GBM is also
characterized by extensive heterogeneity at the cellular and molecular levels. These tumors
are highly diffuse, with extensive dissemination of tumor cells within the brain, which hinders
complete surgical resection. These aggressive characteristics are associated with a remarkable
resistance to therapies available today [6], which unfortunately are mostly palliative. In the
context of their highest incidence of all malignant brain tumors in adults, their highly aggres‐
sive behavior and therapy-insensitive nature, which together account for a very poor prognosis
of GBM patients, this chapter will focus specifically on GBM. In particular, it will review the
different hypotheses of glioma/GBM-initiating cells, the major alterations at the levels of gene
expression and signaling pathways found in GBM, as well as putative biomarkers of GBM
prognosis, and current therapies currently available or under investigation for dealing with
these tumors.
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Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Figure 1. Schematic representation of the differentiation process of neural stem cells into different cell lineages of the CNS
and putative cells of origin of gliomas. Protein markers for neural stem cells, progenitors cells, and differentiated cells are
indicated in boxes. The normal differentiation process (green arrows) originates three main types of cells in the mature CNS,
including neurons and glial cells (particularly oligodendrocytes and astrocytes; ependymal cells are not represented). The
most classical hypothesis on the origin of glioma cells is represented by orange arrows (differentiated glial cells are malignant‐
ly transformed through a dedifferentiation process). The most recent hypothesis postulating that gliomas originate from the
direct transformation of neural stem cells or glial progenitor cells is represented by grey arrows.
1.2. Glioma/GBM-Initiating cells
The true cellular origin of gliomas, including GBM, is still a debatable question. It is generally
accepted that identifying such tumor-initiating cells may allow a better understanding of
tumor biology, and ultimately help in designing improved therapies for GBM. All human
tumors arise from a series of molecular alterations that occur in a small number, or even single,
founder cells. These tumor cells present a clonal nature due to the sequential accumulation of
multiple rare genetic and epigenetic events. The critical importance of the tumor microenvir‐
onment in influencing tumor cells behavior and evolution has been recently recognized [7].
Indeed, the tumor microenvironment has been associated with the generation and mainte‐
nance of tumor heterogeneity; thus, understanding not only the surrounding microenviron‐
ment but also tumor heterogeneity, as well as their relationships, may be crucial in
understanding the biology of these tumors. In the case of the brain tissue, a highly complex
microenvironment with extreme phenotypic and functional diversity, the multiplicity of
putative brain tumor cells of origin, and the variety of niches in which the malignant cells may
evolve, is even more challenging. Thus, understanding this complexity is crucial to provide
firm evidence for the cellular origin of gliomas [8-10]. Two different hypotheses for the origin
of glioma cells, or tumor cells in general, have been proposed (Figure 1), as detailed below.
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One classical hypothesis postulates that cancer cells arise from the accumulation of alterations
that occur in differentiated mature cells (glial cells in the case of glioma tumors, including
GBM), which would result in a dedifferentiation of these cells along the carcinogenic process.
This concept is supported, for instance, by the histological similarities between functional and
differentiated glial cells and tumor cells from gliomas. In addition, before the experimental
identification of the adult neural stem cells (NSCs), glial cells were the only known replication-
competent population of cells in the adult brain, which further supported the idea that highly-
proliferative glioma cells could derive from accumulated alterations in differentiated and
proliferative glial cells. A landmark study supporting this theory showed that differentiated
cells could be transformed into a pluripotent embryonic stem cell phenotype by using a cocktail
of transcription factors [11]. However, this hypothesis has never been adequately tested, as
there have been experimental limitations that preclude its validation, including: (i) the absence
of good mature “astrocyte” markers in in vivo experiments [12], as it is now well known that
the commonly used astrocyte marker GFAP is also expressed by adult NSCs; (ii) in vitro, the
culture of mature astrocytes is particularly difficult; (iii) culturing astrocytes from neonatal
mouse cortex has been described to contain also immature progenitor cells [13].
The second and most recent hypothesis assumes that cancer cells arise from the accumulation
of alterations that occur directly in stem cells, or progenitor (multipotent) undifferentiated
cells, that are present in different tissues throughout the entire lifetime (neural stem cells or
glial progenitor cells in the case of brain gliomas). According to this rationale, the tumorigenic
process would not be accompanied by a dedifferentiation mechanism, as the molecular
alterations would accumulate directly in undifferentiated cells [7-9, 14]. In support of this
hypothesis is the concept of cancer stem cells (CSCs), which is a subpopulation of cells in the
tumor that displays self-renewal capacity, and which can give rise to heterogeneous cancer
cells that constitute the tumor. However, it should be noted that the concepts of CSCs and
tumor-initiating cells have been frequently confused. The term ‘‘tumor-initiating cells’’ refers
to the cells of origin of the tumor, whose alterations support tumor establishment and
progression; in contrast, CSCs would more accurately be referred to as tumor-propagating
cells, with stem cell-like properties, which are not necessarily the cells of origin [8, 14, 15]. A
study by Chen and colleagues (2010) may help to distinguish these different cell populations
and their role on tumor development, particularly in GBM [16]. They demonstrated a hier‐
archical organization of brain tumor-initiating cells by identifying subpopulations of clonal
and long-term proliferating cells in GBM specimens. These subpopulations were shown to be
hierarchically organized and to give rise to tumors with different molecular and histopatho‐
logical features [16]. There are specific and very well delimited regions in the brain where
neural stem cells and progenitor cells exist, particularly the subventricular zone (SVZ) of the
fore brain lateral ventricles, and the subgranular zone (SGZ) in the dentate gyrus of the
hippocampus [8-10]. It has been hypothesized that these are favorable regions where the
process of gliomagenesis may originate, as these regions present an attractive microenviron‐
ment that has been described as propitious for the growth of stem cells, namely in the SVZ
[8-10]. There is increasing experimental evidence that the SVZ is one of the most important
regions of origin for malignant gliomas [10] as it may present ideal conditions for gliomagen‐
esis, like the exposure to a transcription factor cocktail ideal for their growth. When compared
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tumor that displays self-renewal capacity, and which can give rise to heterogeneous cancer
cells that constitute the tumor. However, it should be noted that the concepts of CSCs and
tumor-initiating cells have been frequently confused. The term ‘‘tumor-initiating cells’’ refers
to the cells of origin of the tumor, whose alterations support tumor establishment and
progression; in contrast, CSCs would more accurately be referred to as tumor-propagating
cells, with stem cell-like properties, which are not necessarily the cells of origin [8, 14, 15]. A
study by Chen and colleagues (2010) may help to distinguish these different cell populations
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and long-term proliferating cells in GBM specimens. These subpopulations were shown to be
hierarchically organized and to give rise to tumors with different molecular and histopatho‐
logical features [16]. There are specific and very well delimited regions in the brain where
neural stem cells and progenitor cells exist, particularly the subventricular zone (SVZ) of the
fore brain lateral ventricles, and the subgranular zone (SGZ) in the dentate gyrus of the
hippocampus [8-10]. It has been hypothesized that these are favorable regions where the
process of gliomagenesis may originate, as these regions present an attractive microenviron‐
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[8-10]. There is increasing experimental evidence that the SVZ is one of the most important
regions of origin for malignant gliomas [10] as it may present ideal conditions for gliomagen‐
esis, like the exposure to a transcription factor cocktail ideal for their growth. When compared
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to any other brain regions, stem cell-containing compartments have been shown to be more
susceptible to tumor transformation [10], which additionally may argue in favor of this
hypothesis of tumors arising from changes in stem/progenitor cells. Additionally, while it may
be coincidence, there is a great similarity between the SVZ stem/progenitor cells and glioma
cells. For instance, malignant astrocytic tumors in the brain typically appear close to the lateral
ventricles [9, 10].
In the recent years, the notable therapy resistance of gliomas, namely GBM, has been associated
with the presence of glioma stem cells (GSCs). These cells present characteristics of stem cells,
including: (i) self-renewal; (ii) multipotency, i.e., the capacity to differentiate into other cell
lineages; and (iii) high replicative potential. GSCs are predicted to be difficult to target by anti-
cancer therapeutics because they have a slow cell cycle, present high levels of proteins involved
in drug efflux, and do not express or are dependent on particular oncoproteins for which
targeted therapies are currently available [17]. GSCs were one of the first types of cancer stem
cells isolated from solid tumors [18]. It was shown that as few as 100 GSCs could give rise to
tumors that recapitulated the parental tumor when implanted in xenografted immunodeficient
mice, whereas as many as 1,000,000 non-GSCs could not [18]. This suggests that neoplastic
clones are maintained exclusively by a little fraction of cells with stem cell properties [18]. Of
note, studies involving the use of GSCs face many difficulties, particularly in isolating such
cells directly from biopsies, partly because of the high cellular heterogeneity composition of
the specimen. On the other hand, currently there are no standardized methods available for
cell sorting and assessment of “stemness” [8]. Indeed, there is a relevant discussion regarding
the best methodology for culturing GSCs isolated from human GBM specimens. It has been
argued by several authors that adherent monolayer cultures of glioma cells allow a more
homogeneous exposure to the culture conditions (e.g., nutrients and oxygen levels) than
nonadherent cultures, thus increasing the homogeneity of the cell population, reviewed in [8].
In contrast, the sphere-forming assay has been widely used for this purpose. The fidelity and
benefits of these assays are still under debate. Thus, there is an exigency to standardize
methods for identifying and isolating GSCs with unequivocal markers. It is believed that the
use of NSCs markers is a good principle for identifying GSCs, as NSCs are now known to exist
in very restricted areas of the brain, and can be unambiguously identified with specific markers
[8]. Indeed, in the last decade, putative markers of GSCs have been identified, including Nestin,
CD133, L1CAM, CD15, CD44, Id1, and integrin-α6 [8, 10, 14, 19-21]. Nonetheless, none of these
markers is sufficient to, independently, identify specifically GSCs, implicating that a functional
identification of GSCs (including their ability to (i) be tumorigenic in in vivo models, (ii) form
neurospheres in culture; (iii) be multipotent) is still mandatory.
2. Gene expression and signaling in GBM
GBM, like other cancers, is a disease that presents several alterations, including DNA muta‐
tions, copy number aberrations, and chromosomal rearrangements, but also DNA and histones
epigenetic modifications, ultimately resulting in alterations in the gene expression profiles [22].
Molecular studies from the last decades have identified critical genetic alterations that affect
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many key pathways involved in the regulation of typical cancer hallmarks, such as alterations
in cell cycle, migration, proliferation, survival, angiogenesis, invasion and apoptosis [22].
While several alterations in signaling pathways occur in GBM, such as Wnt, Notch and Shh
pathways (particularly relevant due to their associations with cancer stem-cells and resistance
to radiochemotherapy) [23, 24], the most frequent aberrations in GBM occur in three critical
signaling pathways: (i) retinoblastoma (RB), (ii) p53, and (iii) RTK/RAS/PI3K pathways [22,
25, 26], as detailed in Figure 2 and below.
2.1. Retinoblastoma (RB) pathway
Mutations in genes implicated in cell cycle regulation that allow cells to proliferate uncontrol‐
lably have been frequently identified in GBM, as in other human tumors [26-28]. The RB
pathway, which is important in the G1/S transition, is aberrantly inactivated in GBM through
the alteration of several genes and proteins [28].
In a normal condition, the RB protein (encoded by RB1 gene, the first tumor suppressor gene
described), a negative regulator of the cell cycle, is recruited to specific promoters through its
interactions with E2F transcription factors. RB inhibits the transcription of genes by directly
suppressing the transactivating function of E2F, and by recruiting factors that mediate
transcriptional repression [27, 28]. E2F regulates the promoters’ activity of several genes
related to (i) cell cycle, such as Cyclin E (CCNE) and A (CCNA), (ii) DNA replication, such as
minichromosome maintenance complex component 7 (MCM7) and cell division cycle 6
(CDC6), (iii) nucleotide byosynthesis, such as ribonucleotide reductase (RRM), (iv) mitotic
progression, such as Cyclin B1 (CCNB1) and cyclin-dependent kinase 1 (CDK1), and (v)
apoptosis activation, such as apoptotic peptidase activating factor 1 (APAF-1) and caspases,
such as caspase 3 (CASP3) [27, 28]. The interaction between RB and E2F can be disrupted due
to the phosphorylation of the RB protein by Cdk4/6 kinases [27, 28]. To be active, these kinases
are dependent of Cyclin proteins, namely CCND2 that competes for the binding site with Ink4
proteins [27]. Thus, the function of Ink4 is to prevent the formation of the active kinase complex
(CCND2/Cdk4/6) [27]. This process is ultimately regulated by external signals, such as growth
factors, which induce the cell to progress to the S phase [27].
In GBM, the RB1 gene is frequently mutated [26]. However, the loss of function of RB is also
reported to be a consequence of the amplification of CDK4 and CDK6, as well as by the
inactivation of the INK4A/B (isoforms of CDKN2A/B) and INK4C (encoded by CDKN2C),
which are inhibitors of Cdk4/6 [26]. Ultimately, these alterations lead to E2F accumulation and
the consequent progression to S phase mediated by E2F-target genes [26, 27].
2.2. p53 Pathway
The TP53 gene encodes a protein (p53) that also controls the cell cycle by regulating target
genes involved in cell cycle arrest, apoptosis and senescence [27]. Moreover, p53 has been
named as the “guardian of the genome” because it leads to the arrest of cells with DNA damage
in G1 phase, in order to promote DNA repair processes [29]. On the other hand, if irreparable
genetic injuries occur, p53 induces cell death by activating the apoptotic machinery [29]. In
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in drug efflux, and do not express or are dependent on particular oncoproteins for which
targeted therapies are currently available [17]. GSCs were one of the first types of cancer stem
cells isolated from solid tumors [18]. It was shown that as few as 100 GSCs could give rise to
tumors that recapitulated the parental tumor when implanted in xenografted immunodeficient
mice, whereas as many as 1,000,000 non-GSCs could not [18]. This suggests that neoplastic
clones are maintained exclusively by a little fraction of cells with stem cell properties [18]. Of
note, studies involving the use of GSCs face many difficulties, particularly in isolating such
cells directly from biopsies, partly because of the high cellular heterogeneity composition of
the specimen. On the other hand, currently there are no standardized methods available for
cell sorting and assessment of “stemness” [8]. Indeed, there is a relevant discussion regarding
the best methodology for culturing GSCs isolated from human GBM specimens. It has been
argued by several authors that adherent monolayer cultures of glioma cells allow a more
homogeneous exposure to the culture conditions (e.g., nutrients and oxygen levels) than
nonadherent cultures, thus increasing the homogeneity of the cell population, reviewed in [8].
In contrast, the sphere-forming assay has been widely used for this purpose. The fidelity and
benefits of these assays are still under debate. Thus, there is an exigency to standardize
methods for identifying and isolating GSCs with unequivocal markers. It is believed that the
use of NSCs markers is a good principle for identifying GSCs, as NSCs are now known to exist
in very restricted areas of the brain, and can be unambiguously identified with specific markers
[8]. Indeed, in the last decade, putative markers of GSCs have been identified, including Nestin,
CD133, L1CAM, CD15, CD44, Id1, and integrin-α6 [8, 10, 14, 19-21]. Nonetheless, none of these
markers is sufficient to, independently, identify specifically GSCs, implicating that a functional
identification of GSCs (including their ability to (i) be tumorigenic in in vivo models, (ii) form
neurospheres in culture; (iii) be multipotent) is still mandatory.
2. Gene expression and signaling in GBM
GBM, like other cancers, is a disease that presents several alterations, including DNA muta‐
tions, copy number aberrations, and chromosomal rearrangements, but also DNA and histones
epigenetic modifications, ultimately resulting in alterations in the gene expression profiles [22].
Molecular studies from the last decades have identified critical genetic alterations that affect
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many key pathways involved in the regulation of typical cancer hallmarks, such as alterations
in cell cycle, migration, proliferation, survival, angiogenesis, invasion and apoptosis [22].
While several alterations in signaling pathways occur in GBM, such as Wnt, Notch and Shh
pathways (particularly relevant due to their associations with cancer stem-cells and resistance
to radiochemotherapy) [23, 24], the most frequent aberrations in GBM occur in three critical
signaling pathways: (i) retinoblastoma (RB), (ii) p53, and (iii) RTK/RAS/PI3K pathways [22,
25, 26], as detailed in Figure 2 and below.
2.1. Retinoblastoma (RB) pathway
Mutations in genes implicated in cell cycle regulation that allow cells to proliferate uncontrol‐
lably have been frequently identified in GBM, as in other human tumors [26-28]. The RB
pathway, which is important in the G1/S transition, is aberrantly inactivated in GBM through
the alteration of several genes and proteins [28].
In a normal condition, the RB protein (encoded by RB1 gene, the first tumor suppressor gene
described), a negative regulator of the cell cycle, is recruited to specific promoters through its
interactions with E2F transcription factors. RB inhibits the transcription of genes by directly
suppressing the transactivating function of E2F, and by recruiting factors that mediate
transcriptional repression [27, 28]. E2F regulates the promoters’ activity of several genes
related to (i) cell cycle, such as Cyclin E (CCNE) and A (CCNA), (ii) DNA replication, such as
minichromosome maintenance complex component 7 (MCM7) and cell division cycle 6
(CDC6), (iii) nucleotide byosynthesis, such as ribonucleotide reductase (RRM), (iv) mitotic
progression, such as Cyclin B1 (CCNB1) and cyclin-dependent kinase 1 (CDK1), and (v)
apoptosis activation, such as apoptotic peptidase activating factor 1 (APAF-1) and caspases,
such as caspase 3 (CASP3) [27, 28]. The interaction between RB and E2F can be disrupted due
to the phosphorylation of the RB protein by Cdk4/6 kinases [27, 28]. To be active, these kinases
are dependent of Cyclin proteins, namely CCND2 that competes for the binding site with Ink4
proteins [27]. Thus, the function of Ink4 is to prevent the formation of the active kinase complex
(CCND2/Cdk4/6) [27]. This process is ultimately regulated by external signals, such as growth
factors, which induce the cell to progress to the S phase [27].
In GBM, the RB1 gene is frequently mutated [26]. However, the loss of function of RB is also
reported to be a consequence of the amplification of CDK4 and CDK6, as well as by the
inactivation of the INK4A/B (isoforms of CDKN2A/B) and INK4C (encoded by CDKN2C),
which are inhibitors of Cdk4/6 [26]. Ultimately, these alterations lead to E2F accumulation and
the consequent progression to S phase mediated by E2F-target genes [26, 27].
2.2. p53 Pathway
The TP53 gene encodes a protein (p53) that also controls the cell cycle by regulating target
genes involved in cell cycle arrest, apoptosis and senescence [27]. Moreover, p53 has been
named as the “guardian of the genome” because it leads to the arrest of cells with DNA damage
in G1 phase, in order to promote DNA repair processes [29]. On the other hand, if irreparable
genetic injuries occur, p53 induces cell death by activating the apoptotic machinery [29]. In
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normal unstressed cycling cells, some proteins, such as the ubiquitin ligase Mdm2, bind to p53
to promote its degradation via the ubiquitin/proteasome pathway [29-31]. The p53-mediated
upregulation of MDM2 gene leads to a negative feedback that will maintain the levels of p53
very low in these cells [30, 31]. In this context, p53 loss of function may lead, for example, to
uncontrolled growth and increased genetic instability. Its loss of function may be due to several
reasons, including: (i) inactivating mutation [26], (ii) amplification of MDM2 and MDM4 [26,
31], and (iii) loss of function of ARF product encoded by CDKN2A, which interacts with and
sequesters Mdm2 [26, 31, 32]. Unlike Mdm2, which degrades p53, Mdm4 inhibits p53 by
binding to its transcriptional activation domain [31]. Moreover, Mdm4 also inhibits the
degradation of Mdm2 [31].
Figure 2 Common genetic alterations in GBM affect the RB, p53 and RTKs pathways. The aberrant deregulation
of these pathways in GBM leads to alterations in cell cycle, migration, proliferation, angiogenesis, and apoptosis.
Known proto-oncogenes or growth-promoting genes (shown in green), such as EGFR, PIK3CA (p110α) and AKT, are
activated by mutations, overexpression and amplification, while tumor suppressor genes (show in red), such as PTEN,
Arf and p53, are lost or inactivated by mutations, deletions, loss of heterozigosity, and epigenetic changes.
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2.3. Receptor Tyrosine Kinase (RTK) pathways
GBM cells also commonly present a constitutive activation of cell growth signaling pathways
by the overexpression of several mitogens and their specific membrane receptors [22, 24, 26,
33]. Glioma cells can also acquire mutations in the membrane receptors becoming independent
of exogenous growth stimulation, increasing survival and motility [22, 24, 26, 33, 34]. In GBM,
the deregulation of growth factor signaling occurs frequently by the amplification and/or
activating mutations of RTKs [22, 26]. These play critical roles in several cellular processes,
including cell growth, motility, survival and proliferation, and are tightly controlled by various
physiological mechanisms (e.g., autocrine loops in which RTK ligands are produced in result
of receptor activation) [26]. One of the most described RTK alteration in GBM is the deletion
of exons 2-7 of epidermal growth factor receptor (EGFR) gene that results in the loss of the
extracellular domain (EGFR-vIII mutant) [26]. Notwithstanding, other genetic alterations
affecting EGFR, such as amplifications, activating point mutations that affect the extracellular
domain, and other deletions in the region coding for the cytoplasmic domain, have also been
described [26]. Moreover, alterations of other RTKs also occurs frequently in GBM, including:
(i) overexpression of platelet-derived growth factor receptor (PDGFR) and its ligands PDGFA
and PDGFB, suggesting an autocrine or paracrine loop activation, (ii) activating mutations in
ERBB2 (member of the EGFR family), and (iii) activating mutations in hepatocyte growth factor
receptor (MET) [22, 26, 33, 34]. RTKs mediate its functions by downstream effectors, namely
phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and signal transducer
and activator of transcription (STAT) signaling cascades [34]. Although genetic alterations in
RTKs may potentially activate these pathways, they can also be specifically activated due to
other aberrations. Among them, the PI3K pathway is the most described in GBM and is
involved in cell growth, proliferation, differentiation, motility and survival [26, 34]. The most
frequent alterations involve inactivating mutations and homozygous deletions of PTEN [26].
This gene encodes the enzyme phosphatidylinositol (3,4,5)-trisphosphate 3-phosphatase,
which removes a phosphate from phosphatidylinositol-(3,4,5)-triphosphate (PIP3), converting
it to phosphatidylinositol-(4,5)-bisphosphate (PIP2) [22]. Thus, PTEN counteracts the action of
the PI3K, which catalyzes the addition of a phosphate to PIP2 at the 3 position, converting it
to PIP3 [22]. The accumulation of PIP3 recruits Akt to the plasma membrane. Here, Akt is
activated by phosphorylation, promoting cell survival and proliferation [22]. The PI3K
enzymatic complex is formed by 2 subunits, one regulatory protein (p85α), encoded by
PIK3R1, and one catalytic protein (p110α), encoded by PIK3CA [22]. Note that other variants
of this complex exist, but the referred subunits are the most expressed in GBM and the most
widely-studied. Activating missense mutations and in-frame deletions have been detected in
the PIK3CA [26]. One deletion was identified in the adaptor binding domain, raising the
hypothesis that it may disrupt the normal interaction between p110α and its regulatory
subunit, p85α [26]. Interestingly, in a few percentage of samples without activating mutations
in the catalytic subunit, inactivating mutations were detected in the regulatory subunit [26].
This suggests a functional redundancy of these mutations as they individually activate PI3K.
Again, the amplification of AKT3 gene, which encodes one of the Akt proteins, was described
recently in a small fraction of GBM samples [26]. Other known mutation that ultimately leads
to activation of PI3K and MAPK is the activating mutation of RAS [26]. RAS is indirectly
Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights
http://dx.doi.org/10.5772/52361
393
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Arf and p53, are lost or inactivated by mutations, deletions, loss of heterozigosity, and epigenetic changes.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications392
2.3. Receptor Tyrosine Kinase (RTK) pathways
GBM cells also commonly present a constitutive activation of cell growth signaling pathways
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of exogenous growth stimulation, increasing survival and motility [22, 24, 26, 33, 34]. In GBM,
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domain, and other deletions in the region coding for the cytoplasmic domain, have also been
described [26]. Moreover, alterations of other RTKs also occurs frequently in GBM, including:
(i) overexpression of platelet-derived growth factor receptor (PDGFR) and its ligands PDGFA
and PDGFB, suggesting an autocrine or paracrine loop activation, (ii) activating mutations in
ERBB2 (member of the EGFR family), and (iii) activating mutations in hepatocyte growth factor
receptor (MET) [22, 26, 33, 34]. RTKs mediate its functions by downstream effectors, namely
phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and signal transducer
and activator of transcription (STAT) signaling cascades [34]. Although genetic alterations in
RTKs may potentially activate these pathways, they can also be specifically activated due to
other aberrations. Among them, the PI3K pathway is the most described in GBM and is
involved in cell growth, proliferation, differentiation, motility and survival [26, 34]. The most
frequent alterations involve inactivating mutations and homozygous deletions of PTEN [26].
This gene encodes the enzyme phosphatidylinositol (3,4,5)-trisphosphate 3-phosphatase,
which removes a phosphate from phosphatidylinositol-(3,4,5)-triphosphate (PIP3), converting
it to phosphatidylinositol-(4,5)-bisphosphate (PIP2) [22]. Thus, PTEN counteracts the action of
the PI3K, which catalyzes the addition of a phosphate to PIP2 at the 3 position, converting it
to PIP3 [22]. The accumulation of PIP3 recruits Akt to the plasma membrane. Here, Akt is
activated by phosphorylation, promoting cell survival and proliferation [22]. The PI3K
enzymatic complex is formed by 2 subunits, one regulatory protein (p85α), encoded by
PIK3R1, and one catalytic protein (p110α), encoded by PIK3CA [22]. Note that other variants
of this complex exist, but the referred subunits are the most expressed in GBM and the most
widely-studied. Activating missense mutations and in-frame deletions have been detected in
the PIK3CA [26]. One deletion was identified in the adaptor binding domain, raising the
hypothesis that it may disrupt the normal interaction between p110α and its regulatory
subunit, p85α [26]. Interestingly, in a few percentage of samples without activating mutations
in the catalytic subunit, inactivating mutations were detected in the regulatory subunit [26].
This suggests a functional redundancy of these mutations as they individually activate PI3K.
Again, the amplification of AKT3 gene, which encodes one of the Akt proteins, was described
recently in a small fraction of GBM samples [26]. Other known mutation that ultimately leads
to activation of PI3K and MAPK is the activating mutation of RAS [26]. RAS is indirectly
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activated by RTKs through the dissociation of a GDP molecule and association to a GTP.
However, in a normal condition, this activation is quickly reverted from RAS-GTP to RAS-
GDP. This RAS mutation impedes the dissociation of GTP, remaining RAS constitutively
active. Neurofibromin 1 (NF1), which negatively regulates RAS signaling, is also downregu‐
lated in GBM by NF1 mutations or deletions, resulting in increased RAS signaling. Moreover,
loss of expression of NF1 without evidence of genomic alteration was also observed [26]. In
addition to its critical effects in cell growth, motility, and survival, the PI3K pathway seems to
be also important in the activation of HOX genes, which were recently described to be
important for the malignant phenotype of GBMs [35-37] (see section 3.3 for details).
2.4. Crosstalk between RB, p53, and RTK pathways in GBM
The development of new platforms of genome-scale screenings has allowed a more robust
identification of  the  accumulation of  genetic  and epigenetic  alterations.  The  Cancer  Ge‐
nome Atlas (TCGA) project, for example, was established with the aim of using genome-
wide  analysis  technologies,  which  include  DNA  copy  number,  gene  expression,  DNA
methylation, and nucleotide sequencing, to understand the molecular basis of cancer [26].
With this multiplatform profiling and using an integrative analysis, they identified a high‐
ly  interconnected  network  of  aberrations  in  GBM  that  include  the  pathways  described
above  (RB,  p53,  RTKs  and  PI3K  pathways)  [26].  Interestingly,  this  integrative  analysis
showed a statistical tendency to mutual exclusivity for the specific alterations of compo‐
nents within each pathway. Nonetheless a great percentage of samples harbored aberra‐
tions in all signaling pathways [26], which is in agreement with the hypothesis that these
pathways are a core prerequisite for GBM disease.
2.5. Other key alterations in GBM
In addition to the most common genetic alterations found in GBM, several other aberrations
have been described. For example, mutations in IDH1 and IDH2 genes, which encode the
metabolic enzymes isocitrate dehydrogenases were described. These reports suggest that these
mutations lead to a new pro-oncogenic activity of IDH1/2 with the production of R(-)-2-
hydroxyglutarate, an onco-metabolite [38, 39] (see section 3.2 for details). Other classes of
proteins extremely important in GBM are DNA repair proteins, as they increase the probability
of mutations. In fact, at least one of the MMR genes (MLH1, MSH2, MSH6 or PMS2) is mutated
in hypermutated GBM samples [26], decreasing DNA repair competencies in these cells.
2.6. Molecular subclasses of GBM
Using an unsupervised hierarchical clustering analysis, Verhaak et al. [40] used TCGA data to
successfully classify GBM into four subtypes - classical, mesenchymal, proneural and neural
- improving and validating previous classifications of GBM [37, 41-47].
The identity of the classical subtype was defined by displaying the most common genomic
aberrations of GBM, with 93% of samples presenting amplifications in chromosome 7 paired
with loss of chromosome 10, 95% showing high levels of EGFR amplification and/or expres‐
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sion, and EGFR-vIII activating point mutations. These amplifications of EGFR co-occurred with
focal homozygous deletions targeting CDKN2A, which in turn was almost mutually exclusive
with other alterations in RB pathway components, such as RB1, CDK4 and CCDN2. However,
this subtype does not present TP53 mutations. Additionally, the Notch (NOTCH3, JAG1,
LFNG) and Sonic hedgehog (SMO, GAS1, GLI2) signaling pathways, as well as the neural
precursor and stem cell marker NES, were highly expressed in this subtype [40].
The mesenchymal subtype presents a focal hemizygous deletions of 17q11.2 region that
contains the NF1 gene. In fact, this deletion was associated with lower expression of NF1 in
most cases. However, NF1 was also found to be mutated predominantly in this subtype, and
sometimes this mutation co-occurred with PTEN inactivating mutations. Moreover, TRADD,
RELB and TNFRSF1A genes, belonging to the tumor necrosis factor (TNF) superfamily, and
genes encoding proteins from the NF-ĸB pathways, are highly expressed. Additionally,
mesenchymal markers, such as CHI3L1 and MET, were expressed [40].
The most relevant features of the proneural subtype were high levels of PDGFRA gene
expression in combination with its focal amplification, and point mutations in IDH1. Impor‐
tantly, these aberrations seem to be mutually exclusive. Loss of heterozygosity and inactivating
mutations of TP53 were frequent in this subtype. While less frequent than in classical GBM
samples, half of proneural samples also manifested amplification in chromosome 7, paired
with loss of chromosome 10. PIK3CA and PIK3R1 activating and inactivating mutations,
respectively, were observed mostly in samples without PDGFRA aberrations. Oligodendro‐
cytic development genes, such as PDGFRA, NKX2-2 and OLIG2, were highly expressed. Lower
expression of CDKN1A was observed, probably due to OLIG2 overexpression, which was
described to be able to downregulate CDKN1A. Additionally, this subtype also presents the
expression of proneural developmental genes, such as SOX genes, as well as DCX, DLL3,
ASCL1 and TCF4 [40].
In what concerns the neural subtype, few characteristics were reported, and it was almost
merely classified based on neuron markers expression, including neurofilament light chain
polypeptide (NEFL), gamma-aminobutyric acid A receptor (GABRA1), synaptotagmin I
(STY1), and solute carrier family 12 (SLC12A5) [40].
3. Molecular prognostic factors of GBM
It is widely recognized that the molecular stratification of GBM patients may prove crucial in
rationalizing treatment decisions, for which a set of molecular markers predictive of tumor
response to specific therapies and/or patient outcome are required. The most well established
prognostic factors in GBM patients include age, general performance status, tumor histological
features and the extent of tumor resection [48]. Recently, several studies have identified
biological and molecular features of GBMs that present prognostic value [37, 46, 49-58] and
may help in therapeutic decisions. The work performed so far presents reasons for both
optimism and caution regarding the improvements in the diagnosis and treatment of patients,
but also demand validation in prospectively followed and in uniformly treated patients.
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activated by RTKs through the dissociation of a GDP molecule and association to a GTP.
However, in a normal condition, this activation is quickly reverted from RAS-GTP to RAS-
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sion, and EGFR-vIII activating point mutations. These amplifications of EGFR co-occurred with
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(STY1), and solute carrier family 12 (SLC12A5) [40].
3. Molecular prognostic factors of GBM
It is widely recognized that the molecular stratification of GBM patients may prove crucial in
rationalizing treatment decisions, for which a set of molecular markers predictive of tumor
response to specific therapies and/or patient outcome are required. The most well established
prognostic factors in GBM patients include age, general performance status, tumor histological
features and the extent of tumor resection [48]. Recently, several studies have identified
biological and molecular features of GBMs that present prognostic value [37, 46, 49-58] and
may help in therapeutic decisions. The work performed so far presents reasons for both
optimism and caution regarding the improvements in the diagnosis and treatment of patients,
but also demand validation in prospectively followed and in uniformly treated patients.
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Therefore, the focus remains in the identification of biomarkers that truly foster patient
distinction in ways that may improve therapeutic decisions. The current most relevant
prognostic biomarkers for GBM are summarized in Table 1, of which the most promising are
briefly discussed below.
Molecular Prognostic Marker References
MGMT promoter methylation [52]
IDH1 and IDH2 mutations [57]
Loss of chromosome 10 [56]
Activation of the PI3K/AKT pathway [50, 58]
HOX genes signature [36, 37]
HOXA9 overexpression [35, 36]
CHI3L1 (YKL40) expression [53, 56]
miRNA expression signatures [59]
EGFR expression [37]
EGFR mutation (EGFR-vIII) [51, 55]
PTEN expression (wild-type) [55]
Molecular signatures [40, 46]
High expression of angiogenic genes [46]
Stem-cell like gene expression signatures [37, 49, 54]
Activation of MAPK members [58]
PTEN and DLL3 expression [46]
Table 1. Selected molecular prognostic markers for glioblastoma.
3.1. MGMT promoter methylation
Many studies have shown that the methylation status of MGMT (O6-methylguanine-DNA
methyltransferase) gene is currently one of the most promising biomarkers of prognosis in
GBM patients, although it has not yet reached broad clinical applicability [52, 60]. MGMT
encodes a DNA-repair protein that removes alkyl groups from the O6 position of guanine, an
important site for DNA alkylation. When DNA is left unrepaired, the lesions induced by
chemotherapy trigger apoptosis and cytotoxicity [61]. Hegi and co-workers [52] showed that
the epigenetic silencing of MGMT by promoter methylation leads to the loss of MGMT
expression and reduced DNA-repair activity, resulting in increased sensitivity of the tumor
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cells to temozolomide (TMZ) treatment. In fact, they reported that this increased sensitivity is
translated into differences in patient survival, as the methylation of the MGMT promoter is
associated with longer overall survival (OS) in patients with GBM. Indeed, patients whose
MGMT promoter is methylated and are treated with TMZ have an increased OS (median of
21.7 months), as well as a higher 2-year survival rate (46%), in comparison to patients treated
with TMZ but with unmethylated MGMT promoter (median survival of 12.7 months and 2-
year survival of 13.8%), suggesting that GBM patients whose tumors present MGMT expres‐
sion do not benefit from TMZ treatment [52]. These results suggest MGMT promoter
methylation as an independent and favorable predictive factor to patients’ response to TMZ
therapy [52]. Despite these remarkable findings suggesting MGMT as a prognostic biomarker
and as a specific predictor of response to TMZ-based chemotherapy, there is still a significant
body of controversy surrounding them. Such controversy is mainly due to the heterogeneity
of the patients enrolled in the study groups, as they present different glioma histologies, grades
and treatment regimens, as well as the fact that different studies analyzed MGMT at different
levels, including mRNA expression, methylation status and protein levels (as summarized in
[62]). In an attempt to replicate Hegi’s findings, Costa and co-workers [62] analyzed a set of
90 GBM patients treated with postoperative TMZ-based chemoradiation regarding MGMT
methylation. Despite a trend for longer overall and progression-free survival in GBM patients
with MGMT promoter methylation, the differences did not reach statistical significance [62].
Moreover, sample classification as methylated or unmethylated for a certain gene is still
controversial, as the relationship between the overall CpG island methylation, CpG methyla‐
tion at individual sites, and their effects on gene silencing, is highly dependent on the location
within the gene [63]. In this sense, Bady and co-workers [64] evaluated the relationship
between the specific location of CpG methylation, MGMT expression and the outcome of
patient in a population homogenously treated with alkylating agents. They reported two
regions of methylated CpG’s that present strong association with patient longer survival,
which negatively correlate with MGMT gene expression [64]. This is consistent with MGMT
expression silencing via CpG methylation, resulting in sensitization to alkylating agents [64].
Similarly, Shah and colleagues also identified three regions of methylated CpGs on MGMT,
associated with favorable patient progression-free survival, within a population of 44 GBM
patients treated with radiotherapy and concomitant and adjuvant TMZ [65]. Nonetheless, the
value of MGMT methylation status is also supported by a recent clinical trial that compares
radiotherapy and TMZ treatment in elder patients, and reported an association between
MGMT methylation and good outcome in the TMZ cohort, but not in the radiotherapy cohort
[66]. Similarly, a meta-analysis performed by Olson and co-workers [67] that included 2018
patients from 20 different studies, showed that the silencing of MGMT was highly associated
with improved OS in patients receiving chemotherapy as a part of the adjuvant treatment, a
mild association in patients that received adjuvant radiotherapy, and no benefit in those
submitted to surgery alone.
3.2. IDH1 and IDH2 mutations
Other important prognostic factors for GBM have been revealed by recent genomic stud‐
ies  and  concern  the  presence  of  mutations  in  isocitrate  dehydrogenase  1  and  2  genes
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(IDH1 and IDH2; IDH when referring to both) [26, 57, 68]. These are NADP-dependent en‐
zymes that catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate, with the
simultaneous  production  of  NADPH [69].  The  high-throughput  sequencing  of  GBM re‐
vealed that IDH1  mutations occur in 12% of GBM, are somatic and heterozygous, and a
consequence of the change of a guanine to an adenine at position 395 of the IDH1  gene
(G395A), leading to the replacement of an arginine with a histidine at amino acid residue
132 of the protein (R132H) [57]. Similarly, sequence evaluation of IDH2  exons revealed a
mutation in a histidine at amino acid residue 172 (R172), which is the exact analogue of
the R132 residue in IDH1  [68]. Overexpression of IDH1  R132H  reduces the formation of α-
ketoglutarate and increases the levels of HIF-1α [70]. As stated above, a recent study sug‐
gested  that  mutant  IDH1  reduces  α-ketoglutarate  to  R(-)-2-hydroxyglutarate,  while
converting NADPH to NADP+ [38, 39]. Even though the mechanism is yet to be clarified,
it seems probable that the increased capacity to produce 2-hydroxyglutarate of cells pre‐
senting IDH1  R132H  mutation contributes to tumorigenesis [38].  IDH  mutations are highly
frequent in secondary GBM (up to 80%), but are rare in primary GBM (less than 10%) [68,
71]. IDH mutations are correlated with younger age at diagnosis, and with GBM patients’
longer survival when compared to patients with IDH wt genes [68, 72]. Mutations in IDH1
and IDH2 are mutually exclusive, which indicates that they might independently confer a
growth  advantage  to  mutated  cells  [73].  Moreover,  IDH  mutations  generally  associate
with specific genetic and clinical characteristics when compared to gliomas that have IDH
wt. In particular, it was shown that IDH mutations and amplification of EGFR in GBM are
mutually exclusive events [74], and that the methylation of the MGMT  gene promoter is
often associated with IDH mutations [74, 75]. However, this association is yet to be clari‐
fied as it may represent a direct consequence of the activity of the mutant IDH, or an al‐
ternative marker for epigenetic changes in tumors presenting IDH mutations (reviewed in
[76]). So, the deep understanding of the link between IDH mutations and common genetic
events in GBM might furnish insights into their roles on gliomagenesis [40, 68]. Further‐
more,  a  recent  study evaluated  the  response  of  a  series  of  86  secondary  GBM to  TMZ
treatment, and correlated several markers of GBM (including IDH mutations, 1p19q co-de‐
letion,  MGMT  promoter  methylation status,  and TP53  expression)  with  progression-free
survival and OS [77]. This study showed that IDH mutations were present in 73.4% of the
analyzed patients, and that these mutations were associated with higher progression-free
survival [77].  The authors also evaluated the response of patients presenting IDH  muta‐
tions and MGMT promoter methylation, and found that patients presenting this combina‐
tion had the best response to TMZ treatment, reporting also that IDH mutations seems to
be a significant marker for positive chemosensitivity in secondary GBM [77].
3.3. Molecular subclasses and prognostic value
Strikingly, as stated above, mutations in IDH1 have been included in a GBM signature that
allowed the division of GBMs into subtypes according to their recurrent genomic alterations
[40] (see section 2.6 for details). The importance in the division of GBM into subtypes lies on
the possible application of different therapeutic approaches, as treatments efficacy differs per
subtype [40]. Aggressive therapy significantly delayed mortality in classical and mesenchymal
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subtypes, and a tendency to longer outcome was observed for the neural subtype, yet patients
whose GBM present proneural features, associated with younger age, do not seem to benefit
from highly aggressive therapies although presenting longer survival [40]. In this sense, some
of the genetic events underlying the different GBM subtypes could become part of the clinical
routine to rationalize therapeutic decisions, and ultimately lead to more personalized therapies
for groups of patients with GBM.
3.4. HOX genes signature
Recent evidences have been revealing a remarkable resemblance between tumorigenic and
developmental processes, indicating the relevance of molecular regulatory mechanisms crucial
on normal development and on the tumorigenic process. Homeobox (HB) genes encode
transcription factors that primarily play a crucial role during normal development, and are
divided into two classes: class I comprises clustered homeobox (HOX) genes, and class II
includes non-HOX genes, which are dispersed through the genome, and mainly serve as
cofactors for HOX proteins [78]. During embryonic development, HOX genes are sequentially
expressed from 3’ to 5’ along the anterior-posterior axis contributing to the temporospatial
development of limbs and organs [79]. The mechanisms underlying HOX genes control in
normal development occur according to three main principles: spatial collinearity, posterior
prevalence, and temporal collinearity [80]. These were found to be altered in cancer as a
consequence of three major mechanisms proposed by Abate-Shen [81]: temporospatial
deregulation, gene dominance and epigenetic regulation. Different groups have been report‐
ing the deregulation of these mechanisms in different HOX genes, and in different tumors
(reviewed in [80]).
The aberrant expression of HOX genes have been reported as crucial in several hallmarks of
cancer, including increased proliferation, angiogenesis and invasion, and apoptosis resistance
in leukemia and in several solid tumors [80, 82-85]. Interestingly, in recent years, HOX genes
aberrant expression has been implicated in gliomagenesis. Abdel-Fattah and co-workers [86]
evaluated the expression of all HOX genes in primary astrocytomas and in non-tumor brain
specimens, reporting that some HOX genes are abnormally expressed in malignant astrocy‐
tomas. A subsequent report by Murat et al. [37] identified a HOX-dominated gene cluster,
suggestive of a signature that displays srm cell-like self-renewal properties. These authors
argue show that the expression of HOXA10 gene in GBM neurospheres is consistent with a
role of HOX genes in glioma stem-like cell compartments [37]. Interestingly, the HOX-
dominated gene signature arises along malignant progression to GBM, and is an independent
predictive factor of chemo-radiotherapy resistance in patients [37]. Later, Costa and co-
workers [35] showed that HOXA genes are predominantly activated in GBM, as compared to
lower-grade gliomas and normal brain tissue, suggesting they may be a useful component of
a molecular classification of gliomas. By analyzing expression microarrays data from 100
GBMs, they identified tumors with abnormal chromosomal domains of transcriptional
activation, which comprise the HOXA cluster, and is reversibly regulated by the PI3K pathway
[35]. Of all HOXA genes, HOXA9 expression was predictive of worse GBM patient outcome,
and associated with pro-proliferative and anti-apoptotic functions, which may explain the
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unfavorable prognosis of GBM patients with HOXA9 reactivation [35]. More recently, Gaspar
et al. [36], showed pediatric GBM cell lines that are resistant to TMZ present the coordinated
expression of several HOX genes, of which HOXA9 and HOXA10 were highlighted as crucial
effectors in this resistance [36]. In line with Costa et al. [35] report, Gaspar suggested that the
HOX-enriched signature is regulated by the PI3K pathway, and interestingly, is associated
with resistance to TMZ in pediatric GBM cell lines [36]. Moreover, pediatric patients with high-
grade gliomas that express HOXA9 and HOXA10 presented shorter survival [36].
3.5. CHI3L1 (YKL40) expression
The molecular prognostic biomarkers currently available require the evaluation of tumor
tissue in order to assess gene expression and promoter methylation levels. Moreover, tumor
progression and treatment responses are monitored using imaging techniques, which do not
distinguish the effects of treatment and tumor regrowth. In fact, patients who are submitted
to magnetic resonance imaging (MRI) shortly after radiotherapy show increased volume of
the tumor, which in up to 50% of the cases, is a consequence of the increased blood vessel
permeability due to radiotherapy, an effect called pseudoprogession [87]. As it is difficult to
distinguish between the therapeutic effects and real growth of the tumor [88], in addition to
the impossibility of multiple tumor sampling during the course of the malignancy [89, 90],
demand the establishment of less invasive prognostic and predictive markers. Serum markers
that correlate with tumor biological properties might prove crucial in providing prognostic
information and response to treatment, therefore allowing the proper adjustment of thera‐
peutics, and improve care of patients with GBM. A study conducted by Tanwar [91] analyzed
gene expression microarray data of tumor tissue from glioma patients, and showed that
chitinase 3-like 1 (CHI3L1 or YKL40) was the most highly expressed among 10000 genes, when
comparing to normal brain tissue [91]. The function of YKL-40 in gliomas and other tumors is
yet to be fully clarified; however, it is thought to be involved in increased cell proliferation,
differentiation, angiogenesis, decreased apoptosis, and extracellular matrix remodeling
[92-94]. Interestingly, YKL-40 is secreted both by tumor cells and by tumor-associated macro‐
phages in the bloodstream, therefore allowing its quantification in the blood. YKL-40 was
found to be increased in the serum of patients with several solid tumor types, as breast,
colorectal, ovary, small cell lung cancer and GBM (reviewed in [93]). Particularly in GBM,
YKL-40 serum concentrations seem to be a strong predictor of an aggressive phenotype [53,
91], as the increased expression of YKL-40 appears to be associated with glioma grade,
resistance to radiotherapy, shorter time to progression, and worse patient OS [53, 95-97].
However, to establish YKL-40 serum levels as a prognostic marker, there is still the need to
perform further prospective studies that concern repeated determinations of YKL-40 levels
before and after surgery. As YKL-40 can be reproducibly measured in the serum, and this
biomarker is already well established for routine use, its inclusion in the clinical practice should
be relatively straightforward, and might provide crucial information on tumor progression.
In conclusion, the identification of molecular biomarkers that truly aid in the distinction of
patients and therapeutic decisions still requires much effort. The integration of clinical and
molecular data is becoming more frequent, and easier to perform and analyze, which will
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probably lead to more targeted and effective treatments. Moreover, it seems probable that sets
of molecular biomarkers for GBM will be established in the next few years, and will become
part of the clinical routine, leading to tailored therapies for subgroups of GBM patients.
Importantly, the timely identification of patients who are not likely to respond to a certain
therapy would allow their integration in clinical trials with novel therapies, but also to avoid
the possible adverse side effects of a therapy that may not prove beneficial. Equally interesting,
the establishment of molecular biomarkers of tumor therapy resistance may lead to a more
guided and rational design of novel therapeutic agents and clinical trials for GBM patients. In
the search for GBM patient individualized therapy, the discovery of particular tumor molec‐
ular features, as the status of MGMT promoter methylation status, the mutation status of IDH1
and IDH2, the expression of HOXA genes, and the serum levels of YKL-40, may prove crucial
as initial building blocks of a panel of molecular biomarkers that may have real clinical
implications. The challenge ahead is to discover further molecular markers of GBM, but also
to integrate all the knowledge in an interdisciplinary way, considering different GBM sub‐
types, which altogether might allow a more rational and efficient fight against GBM.
4. New molecular targets and treatments
As described throughout this chapter, the molecular and cellular heterogeneity of GBM
represents a major therapeutic challenge, but also offers a large number of opportunities to
specific targeting of tumor cells’ alterations. Furthermore, the unsatisfactory prognosis of GBM
patients, independently of the used treatment approaches, and the absence of a cure or
significant advances in the treatment of GBM, are the major drivers of GBM therapeutics
research.
4.1. Classic therapeutics
The current standard therapy for the treatment of GBM includes maximal surgical resec‐
tion, followed by radiotherapy (RT) with concomitant and adjuvant administration of al‐
kylating agents [98].  Administration of RT is usually given after the surgical removal of
the tumor in order to eliminate residual tumor cells [99]. Alkylating agents act by intro‐
ducing methyl groups in different positions in the DNA, resulting in DNA damage and
specific cytotoxicity,  that ultimately leads to apoptosis and cell  death [100].  Before 1999,
only  nitrosourea-based  chemotherapeutics  were  approved  for  the  treatment  of  GBM,
which  includes  oral  lomustine  (CCNU)  and  intravenous  carmustine  (BCNU)  [101].  In
1999,  FDA approved Gliadel® that  consists  in  a  polymeric  biodegradable  wafer  that  is
able to release carmustine during 2-3 weeks after implantation in the gap where the tu‐
mor was removed during surgery [101-103]. Furthermore, in this same year, FDA granted
accelerated approval to the imidazole derivative of the second-generation class of alkylat‐
ing agents, TMZ, mainly because of its efficient absorption after oral administration and
its ability to easily cross the blood-brain barrier [101, 104].
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the tumor, which in up to 50% of the cases, is a consequence of the increased blood vessel
permeability due to radiotherapy, an effect called pseudoprogession [87]. As it is difficult to
distinguish between the therapeutic effects and real growth of the tumor [88], in addition to
the impossibility of multiple tumor sampling during the course of the malignancy [89, 90],
demand the establishment of less invasive prognostic and predictive markers. Serum markers
that correlate with tumor biological properties might prove crucial in providing prognostic
information and response to treatment, therefore allowing the proper adjustment of thera‐
peutics, and improve care of patients with GBM. A study conducted by Tanwar [91] analyzed
gene expression microarray data of tumor tissue from glioma patients, and showed that
chitinase 3-like 1 (CHI3L1 or YKL40) was the most highly expressed among 10000 genes, when
comparing to normal brain tissue [91]. The function of YKL-40 in gliomas and other tumors is
yet to be fully clarified; however, it is thought to be involved in increased cell proliferation,
differentiation, angiogenesis, decreased apoptosis, and extracellular matrix remodeling
[92-94]. Interestingly, YKL-40 is secreted both by tumor cells and by tumor-associated macro‐
phages in the bloodstream, therefore allowing its quantification in the blood. YKL-40 was
found to be increased in the serum of patients with several solid tumor types, as breast,
colorectal, ovary, small cell lung cancer and GBM (reviewed in [93]). Particularly in GBM,
YKL-40 serum concentrations seem to be a strong predictor of an aggressive phenotype [53,
91], as the increased expression of YKL-40 appears to be associated with glioma grade,
resistance to radiotherapy, shorter time to progression, and worse patient OS [53, 95-97].
However, to establish YKL-40 serum levels as a prognostic marker, there is still the need to
perform further prospective studies that concern repeated determinations of YKL-40 levels
before and after surgery. As YKL-40 can be reproducibly measured in the serum, and this
biomarker is already well established for routine use, its inclusion in the clinical practice should
be relatively straightforward, and might provide crucial information on tumor progression.
In conclusion, the identification of molecular biomarkers that truly aid in the distinction of
patients and therapeutic decisions still requires much effort. The integration of clinical and
molecular data is becoming more frequent, and easier to perform and analyze, which will
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probably lead to more targeted and effective treatments. Moreover, it seems probable that sets
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part of the clinical routine, leading to tailored therapies for subgroups of GBM patients.
Importantly, the timely identification of patients who are not likely to respond to a certain
therapy would allow their integration in clinical trials with novel therapies, but also to avoid
the possible adverse side effects of a therapy that may not prove beneficial. Equally interesting,
the establishment of molecular biomarkers of tumor therapy resistance may lead to a more
guided and rational design of novel therapeutic agents and clinical trials for GBM patients. In
the search for GBM patient individualized therapy, the discovery of particular tumor molec‐
ular features, as the status of MGMT promoter methylation status, the mutation status of IDH1
and IDH2, the expression of HOXA genes, and the serum levels of YKL-40, may prove crucial
as initial building blocks of a panel of molecular biomarkers that may have real clinical
implications. The challenge ahead is to discover further molecular markers of GBM, but also
to integrate all the knowledge in an interdisciplinary way, considering different GBM sub‐
types, which altogether might allow a more rational and efficient fight against GBM.
4. New molecular targets and treatments
As described throughout this chapter, the molecular and cellular heterogeneity of GBM
represents a major therapeutic challenge, but also offers a large number of opportunities to
specific targeting of tumor cells’ alterations. Furthermore, the unsatisfactory prognosis of GBM
patients, independently of the used treatment approaches, and the absence of a cure or
significant advances in the treatment of GBM, are the major drivers of GBM therapeutics
research.
4.1. Classic therapeutics
The current standard therapy for the treatment of GBM includes maximal surgical resec‐
tion, followed by radiotherapy (RT) with concomitant and adjuvant administration of al‐
kylating agents [98].  Administration of RT is usually given after the surgical removal of
the tumor in order to eliminate residual tumor cells [99]. Alkylating agents act by intro‐
ducing methyl groups in different positions in the DNA, resulting in DNA damage and
specific cytotoxicity,  that ultimately leads to apoptosis and cell  death [100].  Before 1999,
only  nitrosourea-based  chemotherapeutics  were  approved  for  the  treatment  of  GBM,
which  includes  oral  lomustine  (CCNU)  and  intravenous  carmustine  (BCNU)  [101].  In
1999,  FDA approved Gliadel® that  consists  in  a  polymeric  biodegradable  wafer  that  is
able to release carmustine during 2-3 weeks after implantation in the gap where the tu‐
mor was removed during surgery [101-103]. Furthermore, in this same year, FDA granted
accelerated approval to the imidazole derivative of the second-generation class of alkylat‐
ing agents, TMZ, mainly because of its efficient absorption after oral administration and
its ability to easily cross the blood-brain barrier [101, 104].
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TMZ was regularly approved by the FDA in 2005, and became the standard chemotherapeutic
agent for the treatment of GBM [5]. The approval of TMZ was mainly due to the improvement
in the OS of patients observed in a landmark study by Stupp et al. [5]. This clinical trial involving
573 patients with newly diagnosed GBM showed an increase in OS from 12.1 months to 14.6
months when patients were treated with RT plus TMZ comparing with RT alone [5]. In 2009,
the 5-years retrospective analysis from this phase III clinical trial reported that, in addition to
the improvement in OS, the 5-year survival rate was also higher in the group of patients treated
with RT and TMZ, showing again the benefits of this treatment [105]. Nevertheless, some
molecular mechanisms of resistance to this agent were identified, like the methylation status
of the MGMT gene, which encodes a protein that repairs the damage induced by TMZ, and
alkylating agents in general, resulting in chemoresistance [106].
Besides TMZ, bevacizumab (BVZ, also known as Avastin®) was also conceded accelerated
approval by the FDA in 2009 as monotherapy for patients with progressive GBM that did not
respond to standard care (TMZ + RT) [101, 107]. This drug is a monoclonal antibody that targets
VEGF, which is involved in the formation of new blood vessels [99]. Since GBM are highly
vascularized tumors, this drug presented an attractive way to target tumor-associated
increased angiogenesis [108]. When BVZ was combined with TMZ + RT for the treatment of
newly diagnosed GBM patients in a phase II clinical trial, an improvement in OS (19.6 vs. 14.6
months) and progression-free survival (PFS, 13.6 vs. 6.9 months) was reported, when com‐
pared to the control cohort of the European Organization for Research and Treatment of
Cancer-National Cancer Institute of Canada (EORTC/NCIC), in which patients were treated
only with RT and TMZ [109]. BVZ also showed good radiographic responses in patients with
recurrent GBM (71% and 35%, according to Levin and Macdonald criteria, respectively) when
used first as a single agent, and later combined with irinotecan (topoisomerase I inhibitor) in
a phase II clinical trial [110]. Although some exciting clinical results were described, several
in vitro and in vivo studies have been unmasking unpredictable consequences of BVZ treat‐
ment. The treatment of intracranial xenograft mouse models of GBM with this VEGF inhibitor
showed a decrease in the vascular network and contrast enhancement in MRI, but also a 68%
increase in the infiltration of tumor cells trough the brain parenchyma [111, 112]. Furthermore,
BVZ treatment increased the hypoxic microenvironment which is also implicated in increased
invasion ability of tumor cells [24, 112].
4.2. Novel molecular targeted therapeutics
Conceptually, the development of targeted therapies for the treatment of GBM represents a
significant advance in the search for a cure for this devastating disease. First, the specificity of
these therapies has the potential to reduce toxic side effects. Second, the direct blockade of
altered oncogenic signaling cascades may allow the reduction of tumor cell proliferation [113].
This next part will review some of the most promising therapeutic molecular and targeting
strategies, including membrane proteins and growth factor receptors (e.g. RTK), and intracel‐
lular signaling pathways.
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4.2.1. Therapeutic targeting of membrane protein/growth factor receptors
RTKs represent attractive targets for this therapeutic approach, since they are associated with
GBM oncogenesis, and the binding of growth factors to these receptors activate signaling
pathways that drive GBM cells survival and proliferation [113, 114] (see section 2.3 for
information). There are two kinds of inhibitors for RTKs: (i) inhibitors targeting the intracel‐
lular tyrosine kinase domain (TKD), and (ii) monoclonal antibodies that can block RTK
activation or target the RTK-expressing cells [115].
a. EGFR
As stated above, EGFR amplification, overexpression and mutation are frequent events in GBM
cells and increased EGFR signaling is known to increase tumor proliferation, invasion ability,
angiogenesis and blocking apoptosis [22, 116]. Several small molecule inhibitors targeting
EGFR have been developed and approved for the treatment of particular cancers, as erlotinib
and gefitinib in the treatment of advanced metastatic non-small cell lung cancer [24, 117]. This
RTK can be targeted with a large number of inhibitors, like lapatinib (EGFR2, ErbB2), vande‐
tanib (EGFR, VEGFR-2), PF-00299804 (EGFR, ERBB2 and ERBB4), BIBW2992 (EGFR, ERBB2,
ERBB4), AEE 788 (EGFR, ERBB2, VEGFR), and monoclonal antibodies, as cetuximab (EGFR)
and nimotuzumab (EGFR) [98, 116]; however, this section focus on the most reviewed and
clinically tested drugs for the treatment of GBM (erlotinib, gefitinib and cetuximab). Erlotinib
and gefitinib although, extensively tested in clinical trials for GBM patients (either already
completed or currently ongoing), have not shown a significant benefit, and thus failed to reach
clinical applicability (Table 2) [118]. The chimerical monoclonal antibody cetuximab (Erbitux)
can also inhibit EGFR, and was shown to inhibit the mutant EGFR-vIII in glioma cells [119,
120]. Furthermore, preclinical studies using GBM xenograft models suggest that cetuximab
could be effective for the treatment of invasive GBM [121]. The clinical evaluation of the
administration of cetuximab in phase II trials for recurrent GBM patients has shown mixed
results. The combination of cetuximab with BVZ and irinotecan resulted in 5% complete
responses (CR), 21% partial responses (PR) and 40% of the patients with stable disease (SD),
with only 9% of the GBM patients presenting signs of progressive disease (PD); the 6 months
progression-free survival (6-PFS) of 33% obtained in this trial was also surprising [108]. In
another phase II clinical trial for recurrent GBM patients, treatment with cetuximab showed
worse outcomes, with a median time-to-progression (TTP) of only 1.9 months, and only 7.3%
of the patients being progression free at 6 months after treatment [122].
Most of the EGFR amplified GBMs also present expression of the mutant EGFR-vIII [116]. Since
this mutated form of EGFR is absent in normal tissues, an immunotherapy-based approach to
target EGFR-vIII was developed and is now under clinical trials (phase I, II and III) [118, 123].
This vaccine, called rindopepimut (CDX-110, PEPvIII) consists in a 14 aminoacids peptide that
specifically recognizes EGFR-vIII, combined with an immunoadjuvant (keyhole limpet
hemocyanin), that will potentiate an immune response against EGFR-vIII-positive tumor cells
[124]. The clinical applicability of this vaccine was already tested in different clinical trials
showing the benefits of this strategy (Table 2). Newly diagnosed GBM EGFR-vIII positive had
a significant improvement in OS from 15.2 months (treated with TMZ + RT) to 23.2 months
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TMZ was regularly approved by the FDA in 2005, and became the standard chemotherapeutic
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573 patients with newly diagnosed GBM showed an increase in OS from 12.1 months to 14.6
months when patients were treated with RT plus TMZ comparing with RT alone [5]. In 2009,
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the improvement in OS, the 5-year survival rate was also higher in the group of patients treated
with RT and TMZ, showing again the benefits of this treatment [105]. Nevertheless, some
molecular mechanisms of resistance to this agent were identified, like the methylation status
of the MGMT gene, which encodes a protein that repairs the damage induced by TMZ, and
alkylating agents in general, resulting in chemoresistance [106].
Besides TMZ, bevacizumab (BVZ, also known as Avastin®) was also conceded accelerated
approval by the FDA in 2009 as monotherapy for patients with progressive GBM that did not
respond to standard care (TMZ + RT) [101, 107]. This drug is a monoclonal antibody that targets
VEGF, which is involved in the formation of new blood vessels [99]. Since GBM are highly
vascularized tumors, this drug presented an attractive way to target tumor-associated
increased angiogenesis [108]. When BVZ was combined with TMZ + RT for the treatment of
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months) and progression-free survival (PFS, 13.6 vs. 6.9 months) was reported, when com‐
pared to the control cohort of the European Organization for Research and Treatment of
Cancer-National Cancer Institute of Canada (EORTC/NCIC), in which patients were treated
only with RT and TMZ [109]. BVZ also showed good radiographic responses in patients with
recurrent GBM (71% and 35%, according to Levin and Macdonald criteria, respectively) when
used first as a single agent, and later combined with irinotecan (topoisomerase I inhibitor) in
a phase II clinical trial [110]. Although some exciting clinical results were described, several
in vitro and in vivo studies have been unmasking unpredictable consequences of BVZ treat‐
ment. The treatment of intracranial xenograft mouse models of GBM with this VEGF inhibitor
showed a decrease in the vascular network and contrast enhancement in MRI, but also a 68%
increase in the infiltration of tumor cells trough the brain parenchyma [111, 112]. Furthermore,
BVZ treatment increased the hypoxic microenvironment which is also implicated in increased
invasion ability of tumor cells [24, 112].
4.2. Novel molecular targeted therapeutics
Conceptually, the development of targeted therapies for the treatment of GBM represents a
significant advance in the search for a cure for this devastating disease. First, the specificity of
these therapies has the potential to reduce toxic side effects. Second, the direct blockade of
altered oncogenic signaling cascades may allow the reduction of tumor cell proliferation [113].
This next part will review some of the most promising therapeutic molecular and targeting
strategies, including membrane proteins and growth factor receptors (e.g. RTK), and intracel‐
lular signaling pathways.
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4.2.1. Therapeutic targeting of membrane protein/growth factor receptors
RTKs represent attractive targets for this therapeutic approach, since they are associated with
GBM oncogenesis, and the binding of growth factors to these receptors activate signaling
pathways that drive GBM cells survival and proliferation [113, 114] (see section 2.3 for
information). There are two kinds of inhibitors for RTKs: (i) inhibitors targeting the intracel‐
lular tyrosine kinase domain (TKD), and (ii) monoclonal antibodies that can block RTK
activation or target the RTK-expressing cells [115].
a. EGFR
As stated above, EGFR amplification, overexpression and mutation are frequent events in GBM
cells and increased EGFR signaling is known to increase tumor proliferation, invasion ability,
angiogenesis and blocking apoptosis [22, 116]. Several small molecule inhibitors targeting
EGFR have been developed and approved for the treatment of particular cancers, as erlotinib
and gefitinib in the treatment of advanced metastatic non-small cell lung cancer [24, 117]. This
RTK can be targeted with a large number of inhibitors, like lapatinib (EGFR2, ErbB2), vande‐
tanib (EGFR, VEGFR-2), PF-00299804 (EGFR, ERBB2 and ERBB4), BIBW2992 (EGFR, ERBB2,
ERBB4), AEE 788 (EGFR, ERBB2, VEGFR), and monoclonal antibodies, as cetuximab (EGFR)
and nimotuzumab (EGFR) [98, 116]; however, this section focus on the most reviewed and
clinically tested drugs for the treatment of GBM (erlotinib, gefitinib and cetuximab). Erlotinib
and gefitinib although, extensively tested in clinical trials for GBM patients (either already
completed or currently ongoing), have not shown a significant benefit, and thus failed to reach
clinical applicability (Table 2) [118]. The chimerical monoclonal antibody cetuximab (Erbitux)
can also inhibit EGFR, and was shown to inhibit the mutant EGFR-vIII in glioma cells [119,
120]. Furthermore, preclinical studies using GBM xenograft models suggest that cetuximab
could be effective for the treatment of invasive GBM [121]. The clinical evaluation of the
administration of cetuximab in phase II trials for recurrent GBM patients has shown mixed
results. The combination of cetuximab with BVZ and irinotecan resulted in 5% complete
responses (CR), 21% partial responses (PR) and 40% of the patients with stable disease (SD),
with only 9% of the GBM patients presenting signs of progressive disease (PD); the 6 months
progression-free survival (6-PFS) of 33% obtained in this trial was also surprising [108]. In
another phase II clinical trial for recurrent GBM patients, treatment with cetuximab showed
worse outcomes, with a median time-to-progression (TTP) of only 1.9 months, and only 7.3%
of the patients being progression free at 6 months after treatment [122].
Most of the EGFR amplified GBMs also present expression of the mutant EGFR-vIII [116]. Since
this mutated form of EGFR is absent in normal tissues, an immunotherapy-based approach to
target EGFR-vIII was developed and is now under clinical trials (phase I, II and III) [118, 123].
This vaccine, called rindopepimut (CDX-110, PEPvIII) consists in a 14 aminoacids peptide that
specifically recognizes EGFR-vIII, combined with an immunoadjuvant (keyhole limpet
hemocyanin), that will potentiate an immune response against EGFR-vIII-positive tumor cells
[124]. The clinical applicability of this vaccine was already tested in different clinical trials
showing the benefits of this strategy (Table 2). Newly diagnosed GBM EGFR-vIII positive had
a significant improvement in OS from 15.2 months (treated with TMZ + RT) to 23.2 months
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(CDX-110 + granulocyte macrophage-colony stimulating factor, GM-CSF, and TMZ, after RT),
consistent with the benefit of this vaccine alone in other studies (OS 26 months vs. 15 months)
[124, 125].
b. PDGFR
As referred previously, PDGFR is also frequently overexpressed in GBM [114]. As described
for other RTK, PDGFR can also be blocked with different pharmacological inhibitors, such as
imatinib mesylate (PDGFR, c-KIT, BCR-ABL), sunitinib (PDGFR, VEGFR, c-KIT), sorafenib
(PDGFR, VEGFR, RAF), tandutinib (PDGFR, FLT3, c-KIT), vatalanib (PDGFR, VEGFR, c-KIT),
IMC3G3 (PDGRFα), pazopanib (PDGFR, c-KIT, EGFR) or dasatinib (PDGFRβ, Src, BCR/Abl,
c-KIT, ephrin A2) [98, 116]. However, this part will focus on the best characterized PDGFR
inhibitor, imatinib mesylate (Gleevec or Livec), already evaluated in phase I/II clinical trials
with GBM patients, which was originally FDA approved for the treatment of acute myeloid
leukemia [106, 126]. In vitro treatments of GBM cells with imatinib have already shown
inhibitory effects on cell proliferation, as a result of cell cycle arrest, increase apoptotic
population and decreased clonogenic ability [127]. Its administration in mice models of GBM
also showed an improvement in survival [128]. In clinical studies, imatinib mesylate was
usually combined with hydroxyurea (HU), a ribonucleotide reductase inhibitor that blocks
DNA synthesis [126, 129]. Treatment of recurrent GBM in phase II clinical trials was mostly
disappointing, with 6-months PFS (6-PFS) of only 3% and 16% [130, 131]. Combination with
HU, although showing a mild increase in OS and 6-PFS rates, again showed a lack of efficacy
as compared to RT + TMZ [126]. The best result using imatinib was achieved in a phase I clinical
trial for recurrent malignant glioma (MG), where imatinib was combined with HU and
vatalanib (VEGFR inhibitor), with 24% of GBM patients revealing a radiographic partial
response, 49% showing signals of stable disease, however 27% of the patients had progressive
disease [132] (Table 2).
c. VEGFR
The therapeutic targeting of GBM-associated angiogenesis is already an approved strategy
through VEGF inhibition with BVZ, but can also be achieved through inhibition of VEGF
receptors using specific inhibitors, like cediranib, sorafenib, sunitinib, pazopanib, vandetanib,
CT-332 (all VEGFR), XL-184 (VEGFR2, Met, RET, c-KIT, Flt3, Tie-2), semaxanib or AEE 788 [98,
116, 133]. For instance, cediranib (AZD2171) inhibits all VEGFR subtypes and was explored in
phase I, II and III clinical trials [116]. The outcomes of cediranib (AZD2171) treatment in GBM
patients are described as similar to the ones observed for BVZ, although only one of the
completed trials has published results (Table 2) [116]. As reported for BVZ, also cediranib was
associated with infiltrative cells not visible with contrast-enhanced MRI [112, 134]. In ortho‐
topic mouse models of GBM, this VEGFR inhibitor induced alterations in the permeability and
diameter of blood vessels, alleviating edema and increasing the survival of the mice [135].
d. Met
Met is an RTK for hepatocyte growth factor (HGF) that activates a series of signaling pathways,
as referred above in section 2.3, similar to what is observed for EGFR or PDGFR activation,
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which ultimately leads to proliferative and invasive behaviors of cancer cells [106, 136]. In a
series of 62 GBM patient samples, Met was found to be overexpressed and associated with
poor prognosis, and with an invasive phenotype, supported by invasive multifoci lesions and
expression of metalloproteinases 2 and 9 [137]. Inhibitors targeting Met include tivantinib, and
cabozantinib (XL184) a potent inhibitor of several kinases, cabozantinib (XL184), which hase
shown significant inhibitory effect on GBM tumor growth [138]. Furthermore, three phase I
and II clinical trials for the evaluation of cabozantinib on the treatment of newly diagnosed
GBM (monotherapy or combined with RT + TMZ) and recurrent GBM (monotherapy)
(NCT00960492, NCT00704288 and NCT01068782) are now ongoing [118]. Another therapeutic
approach to target HGF/Met axis is the use of the monoclonal antibody against HGF, rilotu‐
mumab (AMG-102), which was already tested during a phase II [116] clinical trial for recurrent
GBM (Table 2); a second phase II trial to test the combination of rilotumumab with Avastin in
patients with recurrent MG is now recruiting patients (NCT01113398) [118].
e. Integrins
Therapeutic targeting of the cell adhesion receptors integrins, which are transmembrane
glycoproteins that attach cells to extracellular matrix proteins of the basement membrane or
to ligands on other cells, have also proved to be a valuable therapeutic strategy for the
treatment of GBM, with several recent clinical trials testing the success of the integrin inhibitor
cilengetide (EMD 121974) as a monotherapy or in combination with RT + TMZ (Table 2) [139].
Cilengitide is an RGD (Asp-Gly-Asp) synthetic peptide that inhibits integrins αVβ3 and αVβ5
by receptor binding competition [139]. In vitro studies have shown an anti-angiogenic effect
of this inhibitor by inhibiting proliferation and differentiation of endothelial progenitor cells,
without affecting apoptosis [140]. In GBM cells, cilengitide exerted only a moderate loss of
viability and was unable to sensitize GBM cells to radiotherapy and TMZ treatment [141].
Clinical studies with this drug have shown limited toxicity, but also reduced beneficial effect,
when administered in newly diagnosed patients of GBM with RT+ TMZ (Table 2).
4.2.2. Therapeutic targeting of intracellular signaling pathways
a. PI3K/AKT/mTOR pathway
As already mentioned the PI3K/Akt/mTOR pathway represents one of the most altered
pathways in cancer, including GBM [113, 116]. Several inhibitors targeting different elements
of this pathway are available and being tested both pre-clinically and at the clinical level.
Enzastaurin is a specific inhibitor of protein kinase C (PKC) proteins, thus indirectly inhibiting
Akt [104, 113, 142]. In preclinical studies, this inhibitor was able to suppress proliferation of
GBM cells and tumor growth in GBM xenograft mice models [143]. In clinical studies,
especially for recurrent GBM patients this drug failed to improve patient outcome, with PFS,
OS and 6-PFS inferior to that of patients treated with lomustine in phase III clinical trials (Table
2) [144]. Inhibition of Akt can also be achieved using perifosine (KRX-0401), which affects the
interaction of PIP3 with the PH domain of Akt [24]. When this drug was compared to mTOR
inhibition in in vivo models with differential expression of PTEN, the treatment with perifosine
did not alter tumor volume; on the other hand, treatment with mTOR inhibitor resulted in
decrease tumor volume [145]. Furthermore, only a clinical trial phase II for patients with
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(CDX-110 + granulocyte macrophage-colony stimulating factor, GM-CSF, and TMZ, after RT),
consistent with the benefit of this vaccine alone in other studies (OS 26 months vs. 15 months)
[124, 125].
b. PDGFR
As referred previously, PDGFR is also frequently overexpressed in GBM [114]. As described
for other RTK, PDGFR can also be blocked with different pharmacological inhibitors, such as
imatinib mesylate (PDGFR, c-KIT, BCR-ABL), sunitinib (PDGFR, VEGFR, c-KIT), sorafenib
(PDGFR, VEGFR, RAF), tandutinib (PDGFR, FLT3, c-KIT), vatalanib (PDGFR, VEGFR, c-KIT),
IMC3G3 (PDGRFα), pazopanib (PDGFR, c-KIT, EGFR) or dasatinib (PDGFRβ, Src, BCR/Abl,
c-KIT, ephrin A2) [98, 116]. However, this part will focus on the best characterized PDGFR
inhibitor, imatinib mesylate (Gleevec or Livec), already evaluated in phase I/II clinical trials
with GBM patients, which was originally FDA approved for the treatment of acute myeloid
leukemia [106, 126]. In vitro treatments of GBM cells with imatinib have already shown
inhibitory effects on cell proliferation, as a result of cell cycle arrest, increase apoptotic
population and decreased clonogenic ability [127]. Its administration in mice models of GBM
also showed an improvement in survival [128]. In clinical studies, imatinib mesylate was
usually combined with hydroxyurea (HU), a ribonucleotide reductase inhibitor that blocks
DNA synthesis [126, 129]. Treatment of recurrent GBM in phase II clinical trials was mostly
disappointing, with 6-months PFS (6-PFS) of only 3% and 16% [130, 131]. Combination with
HU, although showing a mild increase in OS and 6-PFS rates, again showed a lack of efficacy
as compared to RT + TMZ [126]. The best result using imatinib was achieved in a phase I clinical
trial for recurrent malignant glioma (MG), where imatinib was combined with HU and
vatalanib (VEGFR inhibitor), with 24% of GBM patients revealing a radiographic partial
response, 49% showing signals of stable disease, however 27% of the patients had progressive
disease [132] (Table 2).
c. VEGFR
The therapeutic targeting of GBM-associated angiogenesis is already an approved strategy
through VEGF inhibition with BVZ, but can also be achieved through inhibition of VEGF
receptors using specific inhibitors, like cediranib, sorafenib, sunitinib, pazopanib, vandetanib,
CT-332 (all VEGFR), XL-184 (VEGFR2, Met, RET, c-KIT, Flt3, Tie-2), semaxanib or AEE 788 [98,
116, 133]. For instance, cediranib (AZD2171) inhibits all VEGFR subtypes and was explored in
phase I, II and III clinical trials [116]. The outcomes of cediranib (AZD2171) treatment in GBM
patients are described as similar to the ones observed for BVZ, although only one of the
completed trials has published results (Table 2) [116]. As reported for BVZ, also cediranib was
associated with infiltrative cells not visible with contrast-enhanced MRI [112, 134]. In ortho‐
topic mouse models of GBM, this VEGFR inhibitor induced alterations in the permeability and
diameter of blood vessels, alleviating edema and increasing the survival of the mice [135].
d. Met
Met is an RTK for hepatocyte growth factor (HGF) that activates a series of signaling pathways,
as referred above in section 2.3, similar to what is observed for EGFR or PDGFR activation,
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which ultimately leads to proliferative and invasive behaviors of cancer cells [106, 136]. In a
series of 62 GBM patient samples, Met was found to be overexpressed and associated with
poor prognosis, and with an invasive phenotype, supported by invasive multifoci lesions and
expression of metalloproteinases 2 and 9 [137]. Inhibitors targeting Met include tivantinib, and
cabozantinib (XL184) a potent inhibitor of several kinases, cabozantinib (XL184), which hase
shown significant inhibitory effect on GBM tumor growth [138]. Furthermore, three phase I
and II clinical trials for the evaluation of cabozantinib on the treatment of newly diagnosed
GBM (monotherapy or combined with RT + TMZ) and recurrent GBM (monotherapy)
(NCT00960492, NCT00704288 and NCT01068782) are now ongoing [118]. Another therapeutic
approach to target HGF/Met axis is the use of the monoclonal antibody against HGF, rilotu‐
mumab (AMG-102), which was already tested during a phase II [116] clinical trial for recurrent
GBM (Table 2); a second phase II trial to test the combination of rilotumumab with Avastin in
patients with recurrent MG is now recruiting patients (NCT01113398) [118].
e. Integrins
Therapeutic targeting of the cell adhesion receptors integrins, which are transmembrane
glycoproteins that attach cells to extracellular matrix proteins of the basement membrane or
to ligands on other cells, have also proved to be a valuable therapeutic strategy for the
treatment of GBM, with several recent clinical trials testing the success of the integrin inhibitor
cilengetide (EMD 121974) as a monotherapy or in combination with RT + TMZ (Table 2) [139].
Cilengitide is an RGD (Asp-Gly-Asp) synthetic peptide that inhibits integrins αVβ3 and αVβ5
by receptor binding competition [139]. In vitro studies have shown an anti-angiogenic effect
of this inhibitor by inhibiting proliferation and differentiation of endothelial progenitor cells,
without affecting apoptosis [140]. In GBM cells, cilengitide exerted only a moderate loss of
viability and was unable to sensitize GBM cells to radiotherapy and TMZ treatment [141].
Clinical studies with this drug have shown limited toxicity, but also reduced beneficial effect,
when administered in newly diagnosed patients of GBM with RT+ TMZ (Table 2).
4.2.2. Therapeutic targeting of intracellular signaling pathways
a. PI3K/AKT/mTOR pathway
As already mentioned the PI3K/Akt/mTOR pathway represents one of the most altered
pathways in cancer, including GBM [113, 116]. Several inhibitors targeting different elements
of this pathway are available and being tested both pre-clinically and at the clinical level.
Enzastaurin is a specific inhibitor of protein kinase C (PKC) proteins, thus indirectly inhibiting
Akt [104, 113, 142]. In preclinical studies, this inhibitor was able to suppress proliferation of
GBM cells and tumor growth in GBM xenograft mice models [143]. In clinical studies,
especially for recurrent GBM patients this drug failed to improve patient outcome, with PFS,
OS and 6-PFS inferior to that of patients treated with lomustine in phase III clinical trials (Table
2) [144]. Inhibition of Akt can also be achieved using perifosine (KRX-0401), which affects the
interaction of PIP3 with the PH domain of Akt [24]. When this drug was compared to mTOR
inhibition in in vivo models with differential expression of PTEN, the treatment with perifosine
did not alter tumor volume; on the other hand, treatment with mTOR inhibitor resulted in
decrease tumor volume [145]. Furthermore, only a clinical trial phase II for patients with
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recurrent MG is under evaluation and no results are available until now (NCT00590954) [118].
A HIV type I (HIV-1) protease inhibitor called nelfinavir with applications in HIV infections
is also able to downregulate Akt, and was proposed as an Akt inhibitor [146, 147]. Preclinical
studies showed that treating GBM cells and xenograft mouse models with nelfinavir is able to
sensitize tumor cells to RT and TMZ treatment [148]. Furthermore, this protease inhibitor
decreases VEGF levels and angiogenesis, as well as HIF-1 expression levels and can cause
endoplasmic reticulum stress and autophagy [146, 149]. Three phase I clinical trials to assess
the toxicity of this treatment combined with RT + TMZ in newly diagnosed GBM are currently
recruiting patients or active and ongoing (NCT01020292, NCT00694837, NCT00915694) [118].
Several inhibitors of PI3K are also available, but the clinical evaluation of their efficacy is
still very preliminary [150]. The class of pan-PI3K inhibitors (inhibit the catalytic p110 sub‐
unit)  include  LY294002,  ZSTK474,  and wortmannin.  Derivatives  of  LY294002  and wort‐
mannin,  include  SF1126  (LY294002  conjugated  with  an  RGD  peptide),  PWT-458  and
PX-866 (the first is a PEGylated derivate of wortmannin and the second is a wortmannin
analog)  [150].  From this  group of  specific  PI3K inhibitors,  only  evaluation  of  PX-866  is
proposed in a phase II  clinical  trial  for the treatment of  recurrent GBM patients,  and is
currently recruiting patients (NCT01259869) (Table 2) [118]. XL147 and GDC-0941 are also
class  I  PI3K inhibitors,  and IC877114  (targets  p110δ)  and TG100-115  (targets  p110δ  and
p110γ) are PI3K isoform-specific inhibitors [150]. In turn, LY294002 was able to potentiate
the  citotoxicity  of  TMZ in  glioma cells  [151,  152].  Besides  these  agents  that  only  target
PI3K  there  are  several  dual  PI3K/mTOR  inhibitors,  as  PI-103,  PI-540,  PI-620,  XL765,
BEZ235 and BGT226 [150]. XL765 and XL147 were already tested in a phase I clinical trial
with recurrent GBM patients (Table 2). Some preclinical studies support the theory of tar‐
geting these pathways in GBM therapeutics. Combination of LY294002 with the mTOR in‐
hibitor rapamycin (or sirolimus) was able to diminish the self-renewal capacity of  GBM
cells  and induce differentiation of  cancer stem cell  like cells  (CSC);  the same effect  was
achieved  using  a  dual  PI3K/mTOR  inhibitor,  NVP-BEZ235,  which  additionally  reduced
the ability of GBM CSLC to form tumors in vivo [153].
For  specific  targeting of  mTOR,  several  inhibitors  were  developed and tested clinically,
like  sirolimus (rapamycin),  everolimus (RAD001)  and temsirolimus (CCI-779)  [106,  133].
All  of  these agents  were already evaluated for  the treatment  of  GBM in phase I  and II
clinical  trials,  but  no  significant  improvements  were  seen (Table  2).  A preclinical  study
showed that  the outcome of  mTOR inhibitory treatments could be efficiently monitored
by Positron Emission Tomography (PET)  based only in  glucose  and thymidine metabo‐
lism, through the uptake of [18F]FDG and [18F]FLT [154].  Furthermore,  combination with
other kinase inhibitors like AEE788 (inhibits both EGFR and VEGFR2) also showed some
preclinical promising results, since its combination with everolimus (RAD001) resulted in
increased effect on cell cycle arrest, proliferation and apoptosis, and impact tumor growth
and survival in vivo [155]. This combination was tested in a phase I/II trial in 2006 for the
treatment of recurrent GBM (NCT00107237) [118].  One liability of these therapies is that
they only target mTORC1, and although this is the best characterized mTOR isoform, it is
also known that full activation of PI3K/AKT pathway also requires mTORC2 [156]. Conse‐
quently, it  is argued that dual inhibition of mTOR complexes 1 and 2 will  be more effi‐
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cient  [156].  Preclinical  studies  have  shown a  significant  decrease  in  tumor  volume and
growth in xenograft mouse models of GBM treated with PI3K/mTOR inhibitor AZD8055
[157].  Furthermore,  there  are  three  phase  I  clinical  trials  recruiting  patients  with  MG
(drug/trial  reference:  AZD8055/NCT01316809;  CC-223/NCT01177397;  OSI-027/
NCT00698243) to test this possibility [118].
b. RAS/RAF/MEK/ERK/MAPK pathway
Another important pathway contributing to the neoplastic process is the one mediated by
RAS/RAF/MEK/MAPK  [106].  Inhibitors  targeting  members  of  this  pathway  include  the
farnesil transferase inhibitors of RAS, such as tipifarnib (Zanestra or R115777) and lonafar‐
nib  (Sarasar  or  SCH 66336)  or  multiple  kinases  inhibitors  that  target  this  pathway,  like
sorafenib [98, 116]. Some of the more significant clinical results of tipifarnib are summar‐
ized in  Table  2.  A phase  I  clinical  trial  to  test  the  effectiveness  of  combining tipifarnib
with  TMZ  and  RT  for  newly  diagnosed  GBM  or  gliosarcoma  is  now  ongoing
(NCT00049387)  [118].  Sorafenib is  described as  an inhibitor  of  EGFR,  PDGFR and RAF,
that  can block MEK activation and,  in preclinical  studies,  was able to induce apoptosis,
and decreased proliferation of GBM cells [98, 158]. At the clinical level, it has been exten‐
sively studied in 12 clinical trials with completed, ongoing or recruiting status [118]; how‐
ever,  the  results  have  still  been  somewhat  different,  with  good  results  for  newly
diagnosed GBM and recurrent GBM, but when combined with BVZ for the treatment of
recurrent GBM, it failed to improve survival, showing a high percentage of patients with
progressive disease (Table 2) [118].
c. Histone deacetylases (HDACs)
Epigenetic  events  are  crucial  during  the  carcinogenic  process,  in  which  the  chromatin
state and remodeling are important mediators. Histone deacetylases (HDAC) are respon‐
sible for chromatin condensation and repression of transcription [159, 160]. Mechanistical‐
ly they catalyze the elimination of acetyl groups from lysine residues in N-terminal tails
of histone proteins [161].  The use of specific HDAC inhibitors has been described as an
attractive opportunity to alter cancer-related epigenetic modifications [159]. These inhibi‐
tors are also reported as being able to block angiogenesis and invasion, promote cell cy‐
cle arrest  and apoptosis,  and to act  as immunomodulators [116,  159,  160].  Valproic acid
(VPA) is a short chain fatty acid, class I and IIa HDAC inhibitor, used as an anticonvul‐
sant drug and frequently administered to treat glioma-associated seizures [159, 162, 163].
So, when the results of  the EORTC/NCIC TMZ trial  were analyzed taking in considera‐
tion  the  anti-epileptic  drugs  used,  an  interesting  result  showing  a  benefit  in  OS  of  the
patients treated with TMZ + RT that were under VPA treatment was observed, suggest‐
ing that this drug could enhance the effects of TMZ + RT treatment [162]. VPA in combi‐
nation  with  TMZ  in  vitro  showed  an  increase  in  TMZ  cytotoxicity,  even  for  TMZ
resistant cell lines, through downregulation of MGMT [164-166]; in vivo, this combination
had also a benefit in tumor growth inhibition [164]; and increased the effects of γ-radia‐
tion in glioma cells [165].  Clinically,  the evaluation of VPA for the treatment of GBM is
proposed in two clinical trials:  a phase II  trial  to evaluate the efficacy of VPA + RT fol‐
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recurrent MG is under evaluation and no results are available until now (NCT00590954) [118].
A HIV type I (HIV-1) protease inhibitor called nelfinavir with applications in HIV infections
is also able to downregulate Akt, and was proposed as an Akt inhibitor [146, 147]. Preclinical
studies showed that treating GBM cells and xenograft mouse models with nelfinavir is able to
sensitize tumor cells to RT and TMZ treatment [148]. Furthermore, this protease inhibitor
decreases VEGF levels and angiogenesis, as well as HIF-1 expression levels and can cause
endoplasmic reticulum stress and autophagy [146, 149]. Three phase I clinical trials to assess
the toxicity of this treatment combined with RT + TMZ in newly diagnosed GBM are currently
recruiting patients or active and ongoing (NCT01020292, NCT00694837, NCT00915694) [118].
Several inhibitors of PI3K are also available, but the clinical evaluation of their efficacy is
still very preliminary [150]. The class of pan-PI3K inhibitors (inhibit the catalytic p110 sub‐
unit)  include  LY294002,  ZSTK474,  and wortmannin.  Derivatives  of  LY294002  and wort‐
mannin,  include  SF1126  (LY294002  conjugated  with  an  RGD  peptide),  PWT-458  and
PX-866 (the first is a PEGylated derivate of wortmannin and the second is a wortmannin
analog)  [150].  From this  group of  specific  PI3K inhibitors,  only  evaluation  of  PX-866  is
proposed in a phase II  clinical  trial  for the treatment of  recurrent GBM patients,  and is
currently recruiting patients (NCT01259869) (Table 2) [118]. XL147 and GDC-0941 are also
class  I  PI3K inhibitors,  and IC877114  (targets  p110δ)  and TG100-115  (targets  p110δ  and
p110γ) are PI3K isoform-specific inhibitors [150]. In turn, LY294002 was able to potentiate
the  citotoxicity  of  TMZ in  glioma cells  [151,  152].  Besides  these  agents  that  only  target
PI3K  there  are  several  dual  PI3K/mTOR  inhibitors,  as  PI-103,  PI-540,  PI-620,  XL765,
BEZ235 and BGT226 [150]. XL765 and XL147 were already tested in a phase I clinical trial
with recurrent GBM patients (Table 2). Some preclinical studies support the theory of tar‐
geting these pathways in GBM therapeutics. Combination of LY294002 with the mTOR in‐
hibitor rapamycin (or sirolimus) was able to diminish the self-renewal capacity of  GBM
cells  and induce differentiation of  cancer stem cell  like cells  (CSC);  the same effect  was
achieved  using  a  dual  PI3K/mTOR  inhibitor,  NVP-BEZ235,  which  additionally  reduced
the ability of GBM CSLC to form tumors in vivo [153].
For  specific  targeting of  mTOR,  several  inhibitors  were  developed and tested clinically,
like  sirolimus (rapamycin),  everolimus (RAD001)  and temsirolimus (CCI-779)  [106,  133].
All  of  these agents  were already evaluated for  the treatment  of  GBM in phase I  and II
clinical  trials,  but  no  significant  improvements  were  seen (Table  2).  A preclinical  study
showed that  the outcome of  mTOR inhibitory treatments could be efficiently monitored
by Positron Emission Tomography (PET)  based only in  glucose  and thymidine metabo‐
lism, through the uptake of [18F]FDG and [18F]FLT [154].  Furthermore,  combination with
other kinase inhibitors like AEE788 (inhibits both EGFR and VEGFR2) also showed some
preclinical promising results, since its combination with everolimus (RAD001) resulted in
increased effect on cell cycle arrest, proliferation and apoptosis, and impact tumor growth
and survival in vivo [155]. This combination was tested in a phase I/II trial in 2006 for the
treatment of recurrent GBM (NCT00107237) [118].  One liability of these therapies is that
they only target mTORC1, and although this is the best characterized mTOR isoform, it is
also known that full activation of PI3K/AKT pathway also requires mTORC2 [156]. Conse‐
quently, it  is argued that dual inhibition of mTOR complexes 1 and 2 will  be more effi‐
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cient  [156].  Preclinical  studies  have  shown a  significant  decrease  in  tumor  volume and
growth in xenograft mouse models of GBM treated with PI3K/mTOR inhibitor AZD8055
[157].  Furthermore,  there  are  three  phase  I  clinical  trials  recruiting  patients  with  MG
(drug/trial  reference:  AZD8055/NCT01316809;  CC-223/NCT01177397;  OSI-027/
NCT00698243) to test this possibility [118].
b. RAS/RAF/MEK/ERK/MAPK pathway
Another important pathway contributing to the neoplastic process is the one mediated by
RAS/RAF/MEK/MAPK  [106].  Inhibitors  targeting  members  of  this  pathway  include  the
farnesil transferase inhibitors of RAS, such as tipifarnib (Zanestra or R115777) and lonafar‐
nib  (Sarasar  or  SCH 66336)  or  multiple  kinases  inhibitors  that  target  this  pathway,  like
sorafenib [98, 116]. Some of the more significant clinical results of tipifarnib are summar‐
ized in  Table  2.  A phase  I  clinical  trial  to  test  the  effectiveness  of  combining tipifarnib
with  TMZ  and  RT  for  newly  diagnosed  GBM  or  gliosarcoma  is  now  ongoing
(NCT00049387)  [118].  Sorafenib is  described as  an inhibitor  of  EGFR,  PDGFR and RAF,
that  can block MEK activation and,  in preclinical  studies,  was able to induce apoptosis,
and decreased proliferation of GBM cells [98, 158]. At the clinical level, it has been exten‐
sively studied in 12 clinical trials with completed, ongoing or recruiting status [118]; how‐
ever,  the  results  have  still  been  somewhat  different,  with  good  results  for  newly
diagnosed GBM and recurrent GBM, but when combined with BVZ for the treatment of
recurrent GBM, it failed to improve survival, showing a high percentage of patients with
progressive disease (Table 2) [118].
c. Histone deacetylases (HDACs)
Epigenetic  events  are  crucial  during  the  carcinogenic  process,  in  which  the  chromatin
state and remodeling are important mediators. Histone deacetylases (HDAC) are respon‐
sible for chromatin condensation and repression of transcription [159, 160]. Mechanistical‐
ly they catalyze the elimination of acetyl groups from lysine residues in N-terminal tails
of histone proteins [161].  The use of specific HDAC inhibitors has been described as an
attractive opportunity to alter cancer-related epigenetic modifications [159]. These inhibi‐
tors are also reported as being able to block angiogenesis and invasion, promote cell cy‐
cle arrest  and apoptosis,  and to act  as immunomodulators [116,  159,  160].  Valproic acid
(VPA) is a short chain fatty acid, class I and IIa HDAC inhibitor, used as an anticonvul‐
sant drug and frequently administered to treat glioma-associated seizures [159, 162, 163].
So, when the results of  the EORTC/NCIC TMZ trial  were analyzed taking in considera‐
tion  the  anti-epileptic  drugs  used,  an  interesting  result  showing  a  benefit  in  OS  of  the
patients treated with TMZ + RT that were under VPA treatment was observed, suggest‐
ing that this drug could enhance the effects of TMZ + RT treatment [162]. VPA in combi‐
nation  with  TMZ  in  vitro  showed  an  increase  in  TMZ  cytotoxicity,  even  for  TMZ
resistant cell lines, through downregulation of MGMT [164-166]; in vivo, this combination
had also a benefit in tumor growth inhibition [164]; and increased the effects of γ-radia‐
tion in glioma cells [165].  Clinically,  the evaluation of VPA for the treatment of GBM is
proposed in two clinical trials:  a phase II  trial  to evaluate the efficacy of VPA + RT fol‐
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lowed by combination of VPA + BVZ for the treatment of children with high-grade glio‐
mas  (HGG)  (NCT00879437)  and  a  phase  II  trial  to  test  the  combination  of  VPA  with
TMZ and RT in adult HGG (NCT00302159) [118]. Vorinostat is also an inhibitor of class I
and  II  HDACs,  tested  in  several  clinical  trials  now  recruiting  patients  (NCT01378481,
NCT01266031,  NCT00731731,  NCT01110876,  NCT00555399)  [118,  163].  The  results  of
some of  the  already completed clinical  trials  for  HDAC inhibitors  as  GBM therapeutics
are in some way disappointing, with no radiographic responses observed when recurrent
GBM  patients  treated  with  romidepsin  and  vorinostat  failing  to  improve  survival  out‐







Phase I, and II clinical trials
Acceptable toxicity and tolerable treatment with daily administrations of 150-200 mg/day
dose
Newly diagnosed GBM: combined with TMZ showed a PFS of 7.2 months and OS of 15.3
months; worse outcome for patients older than 70 years old; combined with standard care
(RT + TMZ), the OS was 19.3 months, and correlated with MGMT promoter methylation and
PTEN expression; combinations with other drugs are also under clinical trials (BVZ,
administration after TMZ + RT, RT and erlotinib in younger patients) (NCT00124657,
NCT00720356).
Recurrent GBM: erlotinib as a single agent was not able to improve PFS compared to standard
treatment (TMZ or carmustine + RT); combined with mTOR inhibitor sirolimus, treatment was
well tolerated and OS was 33.8 weeks; combination with carboplatin showed a 30 weeks OS;
Recurrent MG: combination with BVZ resulted in partial or total radiographic response for
48% of GBM patients and association with PFS; GBM tumors showing high levels of HIF-2α
and VEGFR2 expression presented a worst prognosis.
Recruiting or ongoing clinical trials combining erlotinib with isotretinoin, sirolimus and
vorinostat, and also single agent administration for patients harboring the EGFR-vIII mutation
(NCT01110876, NCT01103375, NCT01257594, NCT00509431).
Nonprogressive GBM: as single agent, 1-year PFS was only 9% and less than 53% of 2 months,






Phase I, and II clinical trials
Recurrent GBM: as single agent, the treatment was well tolerated and resulted in OS of 39.4
weeks and PFS of 8.1 weeks. In a phase II study, OS did not overcome 8.8 months.
Newly diagnosed GBM: 1-year OS (54.2%) and 1-year PFS (16.7%) were not significantly






Phase I, II, and III clinical trials
EGFR-vIII-positive newly diagnosed GBM: given with GM-CSF, TTP of 14.2 months (vs. 6.3
months of historical controls) and OS of 26 months (vs. 15 months of historical controls);
administration with TMZ also improved TTP (15.2 months vs. 6.4 months) and OS (23.2
[118, 124]




months vs. 15.2 months); phase III trial (recruiting status) is projected to test the efficacy of
rindopepimut with TMZ (NCT01480479).
Newly diagnosed GBM: TTP was 10.2 months and OS was 22.8 months (vaccine given with
DC);
Phase II clinical trial is recruiting patients with relapsed GBM EGFR-vIII positive to test the






Phase I, II, and III clinical trials
Newly diagnosed GBM: a phase II study with 20 patients showed a OS of 6.2 months.
Recurrent GBM or MG: as single agent was well tolerated until doses of 800-1200 g/day, but
very poor outcome with 6-PFS of 3%, only 2/34 patients with PR, and 6/34 with SD; when
combined with HU, 6-PFS (27%) improved, but still very poor; combination with HU and
vatalanib was well tolerated and resulted in OS of 48 weeks, PFS of 12 weeks and 6-PFS of
25%. In another phase II study the outcome of patients treated with imatinib as single agent
was also (in newly diagnosed GBM) very poor (6-PFS: 16%); when combined with HU,
imatinib also lacked efficacy.
A phase III clinical trial showed no differences in TMZ resistant GBM patients treated with
imatinbib + HU or HU alone (NCT00154375); phase II clinical trials combining imatinib with







Phase I, II, and III clinical trials
Recurrent GBM: as a single agent showed a PFS was 117 days and OS was 227 days (phase II);
phase I trials to test cediranib + lomustine to treat GBM is already completed but without
published results (NCT00503204); a phase III trial with the same combinatory approach for
the treatment of recurrent GBM in currently ongoing (NCT00777153); recruiting trials include
combination with gefitinib (NCT01310855) and with cilengitide (NCT00979862).
Newly diagnosed GBM: all clinical trials are currently ongoing or recruiting – phase I and
phase I/II cediranib + RT + TMZ (NCT01062425 and NCT00662506); phase I combination with






Phase II clinical trial
Recurrent GBM: when combined with prior BVZ treatment, did not affect PFS (4-4.1 weeks vs.




Phase I, and II clinical trials
Completed a phase I clinical study in patients with solid tumors (NCT00726583); Recruiting




Phase I clinical trial
Recurrent GBM: combination with a PI3K inhibitor XL147 already completed phase I trial
(NCT0124460).
Recruiting for a phase I trial for combination with TMZ to treat MG (NCT00704080).
[118]
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NCT01266031,  NCT00731731,  NCT01110876,  NCT00555399)  [118,  163].  The  results  of
some of  the  already completed clinical  trials  for  HDAC inhibitors  as  GBM therapeutics
are in some way disappointing, with no radiographic responses observed when recurrent
GBM  patients  treated  with  romidepsin  and  vorinostat  failing  to  improve  survival  out‐
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dose
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months; worse outcome for patients older than 70 years old; combined with standard care
(RT + TMZ), the OS was 19.3 months, and correlated with MGMT promoter methylation and
PTEN expression; combinations with other drugs are also under clinical trials (BVZ,
administration after TMZ + RT, RT and erlotinib in younger patients) (NCT00124657,
NCT00720356).
Recurrent GBM: erlotinib as a single agent was not able to improve PFS compared to standard
treatment (TMZ or carmustine + RT); combined with mTOR inhibitor sirolimus, treatment was
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Phase I, and II clinical trials
Phase I clinical trials showed that everolimus was well tolerated even when combined with RT
+ TMZ, BVZ or erlotinib. Changes in metabolism detected with FDG positron emission
tomography days after administration of everolimus.
Newly diagnosed GBM: combination with TMZ + RT + BVZ followed by BVZ + everolimus in a
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Phase I trial showed that temsirolimus combined with TMZ and RT increased the risk of
infectious diseases (3/25 fatal infections).
Recurrent GBM: it was well tolerated as a single agent, and 36% radiographic responses were
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Recurrent GBM: treatment well tolerated, but 6-PFS (11.9%) and PFS (8 weeks) very poor,
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combination with BVZ was also tested (NCT00621686).
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treatment of newly diagnosed GBM), NCT00884416 (phase I single agent HGG),




Phase I, II, and III clinical trials
Well tolerated until doses of 2400 mg/m2
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Recurrent GBM: as a single agent no complete responses were observed, but median OS was




Phase I, and II clinical trials
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Phase II clinical trial
Recurrent MG: no radiographic responses, 72% PD and 28% SD; 6-PFS of 3%, PFS of 8 weeks,
and OS of 34 weeks; 83% of the patients stopped treatment due to tumor progression, and
11% due to treatment toxicity.
[203]
PFS (median Progression-Free Survival); OS (median Overall Survival); TTP (median Time-to-Progression); PR (Partial Response); SD
(Stable Disease); PD (Progressive Disease); 6-PFS (6 month PFS); BVZ (Bevacizumab); RT (Radiotherapy); TMZ (Temozolomide); GM-GSF
(granulocyte macrophage-colony stimulating factor); DC (Dendritic Cells); HU (Hydroxyurea); MG (Malignant Glioma); HGG (High
Grade Glioma).
Table 2. Examples of clinical trials with molecularly targeted therapies directed to the most commonly altered
signalling pathways in GBM.
4.3. Novel therapeutic approaches
As stated above,  a  small  population of  cells  within  the  tumor,  called  cancer  stem-cells,
presents self-renewal capacity,  ability to differentiate and initiate tumorigenesis,  and ex‐
press  several  markers  of  neural  stem cells  [24,  33,  116].  Furthermore,  these  cells  are  in‐
creasingly  recognized  as  a  niche  of  radiochemotherapy-resistant  cells,  making  then
attractive targets for new therapies [24, 49, 204]. There are several signaling pathways al‐
tered in cancer stem cells and that represent possible targets, such as PI3K, OLIG2, Shh,
Wnt and Notch signaling pathways [24, 116].
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Another novel therapeutic strategy to treat  cancer-related diseases is  gene therapy (GT).
GT was proposed for a long time as a molecular strategy that may help circumvent the
non-specific cytotoxicity of the current pharmacological inhibitors, through specific deliv‐
ery of suicide, pro-apoptotic, TP53, and other genes to tumor cells that, ultimately, lead to
cancer regression or cure [106, 205]. GT can be performed delivering conditional or toxic
transgenes using viral  or  non-viral  delivery systems,  including exosomes and stem cells
[205, 206]. In GBM, the delivery of the thymidine kinase (TK) gene, produced by the her‐
pes simplex virus type 1 (HSV1), in combination with the prodrug ganciclovir (GCV), us‐
ing both retrovirus and adenovirus, was already tested at clinical level. The advantage of
using retroviruses to deliver viral vectors is the specificity, since they target only highly
proliferating cells. On the other hand, adenoviruses infect both quiescent cells and rapidly
dividing  cells  [207].  A  retroviralmediated  delivery  was  already  applied  to  newly  diag‐
nosed GBM patients  until  phase  III  clinical  trial,  but  it  was rejected after  failing to  im‐
prove  survival  compared  to  RT  +  TMZ  [208].  Another  promising  strategy  is  the
combination of viral vectors with factors that stimulate the immune system, as, for exam‐
ple, the delivery of the suicide gene HSV1 TK gene, with the cytokine IL-2. This strategy
was already tested in 12 patients with recurrent GBM, where it was proved to be safe and
well tolerable [209]. However, in terms of outcome, there were no patients with complete
response and the PFS and OS were only 4.5 and 7.5 months, respectively [209].
The induction of an immune response against tumor cells, called immunotherapy, is also a
novel approach for the treatment of cancer, including GBM [210]. Immunotherapy can be
performed with two different approaches: increasing the immune response to the tumor (active
immunotherapy) with long term immunization, or delivering immune effectors to an imme‐
diate immune response (passive immunotherapy) [106]. Potent anti-tumor immunity is
achieved through antigen-presenting cells, of which dendritic cells (DC) are the most prom‐
ising [210, 211]. In a phase I clinical trial with 12 GBM patients (7 newly diagnosed GBM and
5 recurrent GBM) the administration of autologous DC vaccines showed that this treatment
was well tolerated and minimally toxic. Additionally, it revealed promising outcome results,
such as 2 long term-survivors (≥4 years) and OS of 23.4 months; however, the benefit in clinical
outcomes were mainly observed in patients with stable disease and low levels of TGF-β2, who
also had a higher number of infiltrating cytotoxic T-cells in the tumor bulk, suggesting that
this treatment may favor particularly these patients [212]. In another phase I/II clinical trial
with patients with recurrent GBM, it was found more beneficial the treatment with mature DC
vs. non-mature DC, as well as intradermal and intratumoral administration of the DC pulsed
with autologous tumor lysate, compared to intradermal approach alone [213]. The transfer of
ex vivo maturated immune cells like effector T cells or lymphokine activated killer cells (LAK)
is also under clinical evaluation for GBM immunotherapy [214].
4.4. Current challenges and future trends
As illustrated  by  the  vast  panoply  of  drugs  and therapeutic  strategies  under  investiga‐
tion for the treatment of GBM, there is a major effort to develop more effective therapies
to treat this highly malignant and therapy-insensitive disease. Unfortunately, the success
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of these new therapies has mostly been somewhat disappointing. Nevertheless, the effica‐
cy  of  some  of  these  approaches  has  yet  to  be  determined.  Of  note,  in  addition  to  the
strategies reviewed here, therapies targeting apoptotic elements (like Bcl-2,  and inhibitor
of apoptosis proteins), the mechanisms of resistance to TMZ (such as PARP and MGMT),
or  gene therapy to TP53,  are  also some examples of  the search for  an effective therapy
for  GBM [33].  Additionally,  several  developments  were  also  made  in  helping  surgeons
with fluorescence-guided resection of the tumor and in radiotherapy [116]. In conclusion,
the  relevance of  the  effort  to  find a  cure  for  GBM is  unquestionable.  However,  despite
the hard working search for a therapeutic strategy to reverse the poor outcomes of these
patients, the standard treatment with TMZ and RT remains presently the best option. Fu‐
ture therapeutic trends for the treatment of GBM will have to: (i) include the new molec‐
ular  classification  of  GBM;  (ii)  incorporate  more  efficient  drug  delivery  systems  to
overcome blood-brain barrier restraints;  and (iii)  redirect  the therapeutic choices to each
patient, considering the specific molecular alterations of each tumor.
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1. Introduction
Glioblastoma multiforme (GBM) is the most prevalent and lethal type of primary central
nervous system tumors with a medium survival of 10-12 months, even with aggressive sur‐
gery, radiation and advanced chemotherapy [1]. Poor prognosis of patients with GBM has
recently been connected with elevated expressions of a sphingosine kinase [2].
Although, GBM is an extremely lethal cancer, metastatic cancers to the brain from other or‐
gans are the most common intracranial tumors, out numbering GBM and other primary
brain tumors by at least 10-fold [3]. Lung, breast and melanoma are the 1, 2, 3 most common
cancers that metastasize to the brain [4]. The prognosis for these patients is worse than for
primary CNS malignancies – 3.7 vs.10-12 months for GBM [5].
Intracranial tumors, primary as well as metastatic, are increasing at an alarming rate since
many patients with excellent quality of life who appear to have ‘beaten the odds’ develop
metastatic disease to the brain after years of remission from breast and other cancers [3-6].
The development of CNS metastasis results in progressive physical and cognitive impair‐
ment and culminates in death within a few months of diagnosis.
In the US alone, the incidence of brain metastasis is expected to exceed 200,000 cases in 2012
– more than 20 times the incidence of primary high grade brain tumors. The median surviv‐
al time for metastatic cancer to the brain is 2-3 months and with aggressive therapy – maybe
4-12 months [6]!
Over the past 25 years, approximately 4-25 MM cancer patients have died with brain meta‐
stasis! These staggering facts strengthen a plea for developing new treatments for both pri‐
mary and secondary cancers of the brain.
There are many reasons so few drugs are available to treat CNS cancers. Classically pa‐
tients with brain metastasis have been excluded from clinical trials because of their poor
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prognosis; the FDA has always had concerns regarding patient safety during Phase I trials
with unknown drugs that may cause CNS toxicity and finally once a new drug is identi‐
fied to have activity in non-CNS cancer involvement, few sponsors want to risk the poten‐
tial  hazards of  toxicity that could result  from treating patients with CNS involvement –
primary or metastatic.  Thus,  there have been limited attempts to develop drugs for  pa‐
tients with brain metastasis, as well as primary brain tumors. The problem has been com‐
pounded  by  the  lack  of  attention  to  CNS  drug  distribution  and  penetration  of  brain
tumors, with reduction in toxicities.
Thus, there is a major need for the development of unique anticancer molecules that are able
to cross the blood brain barrier (BBB), initiate anticancer activity in the CNS tumors and are
non-neurotoxicity.
2. Landscape analysis of drugs available for brain tumors
• Temodar (temozolamide, TMZ (Schering-Plough,) is currently approved and marketed
by Schering-Plough for the treatment of high-grade glioblastoma multiforme and refrac‐
tory anaplastic astrocytoma in both in combination with radiation.
• Gliadel (BCNU wafer, Eisai) is an implantable wafer also used for the treatment of pri‐
mary brain tumors.
• Avastin (bevacizumab, Genentech/Roche) is an anti-angiogenic inhibitor that is being
combined with other agents that can penetrate the BBB. Combinations such as Avastin
plus Camptosar (irinotecan/CPT-11) +/- Temodar are in trials.
• Tarceva (erlotinib, OSI Pharmaceuticals), was granted FDA orphan drug designation in
August 2003 for patients with malignant gliomas, a recent study of Tarceva found 16% of
patients with malignant gliomas who were given Tarciva alone or in combination with
Temodar showed tumor shrinkage. The main side effect was an acne-like rash.
• Iressa (gefitinib, AstraZeneca) and has been approved for relapsing non-small cell lung
cancer. A recent phase II trial of Iressa in patients with relapsed glioblastoma resulted in
one of 52 patients achieving a partial response and 22 patients achieving stable disease.
Side effects were limited to rash and diarrhea.
• Zarnestra  (tipifarnib,  Johnson  &  Johnson  Pharmaceutical)  is  in  early  phase  trials  for
brain tumors.  The drug is also being studied in patients with leukemia and breast or
lung cancers.
• 81C6 is a tenascin radioactive monoclonal antibody that is injected into a cavity created
by the neurosurgeon after removal of the tumor. The antibodies deliver radiation to kill
the tumor cells with less radiation to normal brain tissue than conventional radiotherapy.
The product is under development at Duke Comprehensive Cancer Center.
• BMS-247550 (Bristol Myers Squibb) is in Phase II/III @ Memorial Sloan-Kettering.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications436
• Ipilimumab (yervoy, Bristol Myers Squibb) a monoclonal antibody to CTLA-4 has activi‐
ty in melanoma with improved PFS.
• Vemurafenib (zelboraf, Genentech) is a BRAF inhibitor approved to treat melanoma,
however, CNS mets were excluded in the trials, so the drug is being checked formally
now.
• Cisplatin + etoposide, capecitabine (Xeloda), etc. – TTP/PFS - 3 mos max
• Dabrafenib and trametinib have delayed melanoma progression (GlaxoSmithKline)
• And others ……………… [7-9]
3. A new approach to new novel agents for – 1o and 2o brain tumors
The current trend to develop ‘personalized therapy’ based on the presence of specific pheno‐
typic or genotypic pathways is an improved approach over the structure activity relation‐
ships (SAR) of the 20th century medicinal chemists [10]. However, the management of
unresectable brain tumors has not improved. There is still a deficit in drugs that cross the
blood brain barrier (BBB), are not recycled out of the brain, are effective anticancer agents in
the CNS and do not require hepatic activation. Most of the 21st century ‘personalized medicine’
drugs are large molecules that are given with other drugs and are ionizable chemicals that
cannot penetrate the BBB and/or recycled out of the brain.
A suggested platform for new novel agents – that might be effective therapies for brain tu‐
mors comes from the earlier 20th century literature that focused on – ‘the energy of cancer cells
vs. normal cells’ [11-13].
Brain tumor biochemistry began in 1930 with Warburg's publication - The Metabolism of Tu‐
mors [12]. The fundamental finding of this publication was that embryonic and tumor tissues
have in common a high glycolytic metabolism even under aerobic conditions; in contrast to
most normal tissue where oxidative metabolism predominates. The oxidative metabolism in
cells is generally 16 x more economical in respect to energy than the glycolytic pathway. The
Embden-Meyerhof glycolytic pathway is phylogenetically the more primitive form [12]. In
rapidly growing de-differentiated tissue, this pathway prevails over oxidative metabolism.
These concepts are of interest because the energy for a healthy cell is generated from glucose
where 36 ATP molecules are produced from 1 glucose molecule. Hydrolysis of ATP results
in a free energy change of ~ -16,000 cal/ATP molecule, depending on the conditions.
Classically cancer cells generate 2 ATP/1 glucose molecule vs. 36 ATP/1 glucose molecule
(for healthy normal cells) – with the end product of pyruvate, rather than CO2 and water
as occurs in healthy cells [12]. Otto Warburg explained the latter as a result of the cancer
cell’s energy-transfer conversion to aerobic glycolysis, a major shift in energy available for
cellular work [12].
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Albert Szent-Gyorgyi referred to the energy differences of cancer cells vs. normal cells as –
the alpha (α) state with ↑∆S and ↓∆F vs. the beta state (β), with ↓∆S and ↑∆F), resp. [13].
The α state is the ground state of life! The most stable state of any system is with minimum
∆F and maximum ∆S. If the cellular organization becomes unstable, cells will return to an α
state and remain there. The more complete the return – the harder it will be to reverse.
The β state is where there is a high degree of differentiation and potential for release of F if
the cells react and initiate differentiation. Here the energy present allow cellular regulation
and multicellular organisms replication; not a mass of undifferentiated cells – cancer.
[Where, S = entropy or potential (stored capacity) for a reaction to occur and F (free energy),
a state of function depending only on the initial and final states of a system [14].
The importance of ΔF is that the value immediately provides quantitative information about
the potential ability of a substance to undergo a chemical or physical transformation. A reac‐
tion may proceed spontaneously without external energy only if the ΔF is negative (energy
dissipated) [14]. Chemical thermodynamics tells us that “F needs to be a released in order for the
cell to be productive and do work, not just replicate with a low productive reactivity” [13].
We should view entropy as an index of a condition or character. It is an index of the capacity
for spontaneous changes. By historical accident, the index was actually defined so that it
increased as the capacity of an isolated system for spontaneous change decreased.
Hence, entropy is an index of exhaustion. The more a system has lost its capacity for spontane‐
ous change, the greater is the entropy [14].
Yes, cancer cells represent a primitive, high random energy, low functional state with unbri‐
dled proliferation [13]. Cancer cells are not sick or weak, their vitality, as a wild type, may
be even higher than that of a normal cell.
The cancer cell is unable to rebuild its beta state after it has completed its division and has to
persist in the proliferative alpha state until death. In itself, the proliferative state would not
be pathological – it is only its timing and irreversibility, which makes it so. It is not pathologi‐
cal to be an infant, but it is pathological to be one and remain so x 50 years!
Is cancer an outward manifestation resulting from depletion in cellular free energy within
cells and increased entropy?
Although oxygen is considered essential for life, sulfur (S) and phosphorus (P) are the most
common biological selections for energy transfer. The latter two elements are members of
the Third Period of the Periodic Table and are capable of accepting an additional pair of
electrons into unoccupied 3d orbitals. This phenomenon is characteristic of the elements of
the Third Period, which possess d, in addition to s and p orbitals, and thus have a place to
hold electrons beyond the normal outer-shell octet. Molecules that possess P or S can store
electrons (energy) and then release the energy during the transfer of shared electrons to oth‐
er electron deficient molecules [15].
ATP (Fig. 1) is a unique example of how a 3rd Period element - ‘P’ participates in a key natu‐
ral energy-rich compound, which upon hydrolysis generates ~ 8 kcal/mole upon hydrolysis
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with a +ΔF. When hydrolyzed in the presence of suitable transformers (transducing sys‐
tems), the energy liberated may be used for cellular or tissue processes – cellular metabo‐
lism, nerve conduction, cell membrane transport, etc.
Figure 1. Adenosine triphosphate (ATP)
Energy rich phosphates usually possess either a second phosphoryl group or a resonating
organic radical capable of entering into conjugation with the mobile electrons. This type of
molecule usually contains a chain of at least three adjacent atoms, all bearing a net positive
charge (deficient in π electrons), the chain sometimes extends over a five or even six atoms
[Fig. 2], [16].
Figure 2. Examples of 3-atom high-energy moieties
Many of the small molecules used as anti-CNS cancer agents also possess 3-atom high ener‐
gy moieties (in red) [3]
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with a +ΔF. When hydrolyzed in the presence of suitable transformers (transducing sys‐
tems), the energy liberated may be used for cellular or tissue processes – cellular metabo‐
lism, nerve conduction, cell membrane transport, etc.
Figure 1. Adenosine triphosphate (ATP)
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Figure 2. Examples of 3-atom high-energy moieties
Many of the small molecules used as anti-CNS cancer agents also possess 3-atom high ener‐
gy moieties (in red) [3]
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Figure 3. Small Molecules that are used to treat CNS cancer
Where: DM-PEN carbonate, 1 is a carbonate analog of 4-demethyl penclomedine; PRZ, 2 is
dacarbazine; Temodar®, 3 is temozolamide (TMZ); BCNU, 4 is bis-(chloroethyl)nitrosourea;
HOOI, 5 is 4-hydroperoxyifosfamide; Clomesone, 6 is a chloroethylating agent similar to
BCNU – alkylates guanine-O6 [17].
Compounds can be classified as “energy-rich” or “energy-poor” based on their ΔF. Energy
poor compounds do not possess more than two adjacent atoms bearing a positive charge
and poorly absorbed by the CNS.
Thus, the design of “high-energy molecules” that are lipophilic, energetic and absorbed into
a low free energy (ΔF) and high entropy (ΔS) cancer environment are timely. The latter is a
unique therapeutic target – the result of inefficient energy of cancer cells [14].
Life is controlled by the transfer of energy. All living systems obey the 1st law of thermo‐
dynamics – which states that the sum of all  energies in an isolated system remains con‐
stant. Energy may be converted into another form but the quantity can be neither created
nor destroyed [18].
A question to be answered – are high energy compounds really attracted to low energy
highly utilized regions in the body?
4. Polyhalogenated pyridyl carbonates [16, 19-21]
The polyhalogenated pyridyl carbonates are neutral molecules that when coupled with lip‐
ids via high energy linkers – carbonates, phosphates, etc., fulfill the above requirements for
novel high energy anticancer agents that could be attracted to and accumulate in CNS can‐
cer tissue [16, 19-21]. The carbonate moiety like phosphate has the properties (resonance) of
the high energy 3-atom moieties described in Fig. 3.
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DEKK-TEC has designed a series of polychlorinated pyridyl carbonates (with 1 as a tem‐
plate, Fig. 3) that are linked with lipids and lipophilic moieties to promote CNS penetration
[19]. DM-CHOC-PEN (4-demethyl-4-cholesteryloxycarbonylpenclomedine) is the most ac‐
tive and stable member of a large series of carbonates with improved activity vs. intracrani‐
ally (IC) implanted human xenograft models – U251 and D54 glioblastoma and MX-1 breast
cancer [Table 1] [19].
DM-CHOC-PEN is a unique molecule with several functional moieties that enable it to in‐
hibit cancer replication. The structure contains the following moieties of interest:
Figure 4. Lipophilic cholesterol link - blue. Carbonate linker that contains the properties seen in the elements of 2nd
and 3rd period elements with higher energz storage potential - green. A pyridinium ring system that can transfer elec‐
trons via resonance into intermediary metabolism, ATP synthesis and substrate for the ABC cassette transport / red
The importance of the carbonate moiety is its internal energy and ability to transfer electrons
through multiple structures (resonance) (see Fig. 5):
Figure 5. Mesomeric forms of the carbonate; where R = pyridyl group & R'=cholesterol
The additional oxygen in the carbonates [Fig. 5, lower structures] stabilizes the moiety and
allows for distribution of charge through resonance (Fig. 5). This chemical property exists in
the phosphates and other oxides of the 3rd period elements [see below] [15].
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In contrast, esters lack the degree of resonance/electron distribution [Fig. 5, upper structures].
As indicated in Fig. 5, a carbonate is not isosteric with an acyl or ester group nor is it a direct
extension of an ester group. The carbonate group is unique and when combined with cho‐
lesterol its CNS penetration properties are enhanced [Table 1] [16].
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Table 1. Activity of DM-CHOC-PEN vs. Intracerebrally Implanted Xenograft Tumors in Mice
Implant: 106 cells IC; Treatment Route: Intraperitoneal (- 5 days post IC implant); Schedule:
*IV q1d x 5d; +IV q1d x 3d; #po 1d x 5d; Species: Athymic NCr/nu mice – female, Charles
River; Dose: mg/kg; %ILS = % increased life span; %LTS = long term survival; all studies
were terminated at 54 days
Based on the preclinical antitumor activities in Table 1, DM-CHOC-PEN produced a moder‐
ate increase in life span (% ILS); however it was comparable to that seen with BCNU and
TMZ. DM-CHOC-PEN did yield long-term survivors that were healthy with no weight loss.
Even the highly resistant IC implanted D54 glioma was sensitive to DM-CHOC-PEN. The
drug has minimal toxicity and has encouraging potential [16, 19, 21].
An in  vivo  activation  mechanism scheme is  shown in  Fig.  6,  where  DM-CHOC-PEN is
proposed to  be  acting  as  a  non-classical  alkylating  agent.  The  scheme describes  a  dual
carbonium ion - DNA cross-linking mechanism (in a G-X-C sequence) with tumor DNA
in  the  major  groove  via  N7-  guanine  [20].  A  bi-molecular  coupled  product  (via  the  tri‐
chloromethylene group) has been identified as the major microsomal metabolite of  PEN
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[20].  The  trichloromethylene  group  is  required,  since  the  dichloromethylene  analog  of
PEN is  not active [does not react  with 4-(p-nitrobenzyl)  pyridine (NBP] (Struck,  person‐
nel communication).
Figure 6. Proposed mechanism of action of 4 - demethyl - 4 - cholesterolyl - penclomedine (DM - CHOC - PEN)
Mice with IC growing U251 gliomas were treated with DM-CHOC-PEN, 135 mg/kg daily x
5-days and after 3-days the animals were sacrificed and the brains with tumors removed.
The tumors were easily separated from the normal brain tissue. Each was homogenized in
phosphate buffer, extracted with dichloromethane, and evaporated to dryness. The residues
were assayed by HPLC and DM-CHOC-PEN, a guanine-N7-CCl2-adduct with DM-CHOC-
PEN involving the –CCl3 moiety and the DM-CHCO-PEN dimer-Cl2C-CCl2- were identified
in the glioma tissue [16]. Neither DM-CHOC-PEN nor metabolites could be identified in the
normal brain tissue.
Thus, DM-CHOC-PEN alkylates DNA with adducts at guanine-N7 that could be quantitated
in tumor tissue. The above MOA is in contrast to TMZ, BCNU and others, which alkylate
guanine-O6 [22].
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The polyhalogenated pyridyl carbonates are unique structures that cross the BBB, accumu‐
late in CNS tumor tissue, not normal brain tissue and are not recycled out of the CNS are
cytotoxic vs. intracranially (IC) implanted human tumor xenografts in mouse models; fulfill‐
ing all of the criteria of the preceding paragraphs [23].
The combinations of responses in mouse xenograft tumor models, and a lack of neurotoxici‐
ty in rat and dog biopsychology studies, have allowed a Phase I trial to be conducted with
DM- CHOC-PEN in patients with advanced cancer, including CNS involvement - IND
68,876 [24].
DEKK-TEC and its clinical investigators have satisfied the FDA that they are capable of
treating patients with Phase I drugs and diagnosing physical and mental/cognitive altera‐
tions that may be associated with CNS tumor growth vs. toxicity secondary to drugs.
5. Phase I clinical trial with a high energy drug – DM-CHOC-PEN
Weiner, Ware, Friedlander, et al. reported preliminary data from a Phase I trial involving 18-
patients treated with DM-CHOC-PEN in single IV doses of 39-87.5 mg/m2 once every 21-
days [25]. Six [6] patients had either CNS or spinal nervous system (SNS) involvement. Most
patients had multiple treatments. The longest survivor (a sarcoma w/ SNS involvement) is
19+ months with NED [who also received doxorubicin at a later time] [25].
Support for DM-CHOC-PEN crossing the blood brain barrier in humans is provided from
the above trial with reported observations for – GBM, CNS melanoma and breast cancer
(BC) having PFS 4-13 mos., objective reductions in tumor sizes and no CNS toxicity.
One patient with pelvic sarcoma spread to the spinal cord required debulking surgery 21-
days post treatment with DM-CHOC-PEN (39 mg/m2). Tumor tissue was removed, assayed
and DM-CHOC-PEN was quantitated in the spinal sarcoma tissue – 92 ng/g of tumor [25].
The only SLTs noted to date are hyperbilirubinemia in 2-patients with liver metastasis; pa‐
tients with no liver pathology have not demonstrated SLTs. CNS toxicity has not been noted
in any of the patients. Overall, the drug was reported as being tolerated very well [25].
6. CNS melanoma
Melanoma is the third most frequent cancer to metastasize to the brain. It is anticipated that
there will be ~ 20,000 new cases of CNS stage melanoma diagnosed in 2012 [9]. Enrollment
of these patients with CNS melanoma would be critical to appreciating the activity of the
demethylpenclomedine carbonates in this stage of disease [9, 26]. Two of the patients enrol‐
led and treated in the DM-CHOC-PEN Phase I trial had CNS melanoma; one patient had
significant shrinkage of CNS lesions, the other stable (NC) disease [25].
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To test the potential sensitivity of DM-CHOC-PEN as therapy for melanoma, the B-16
mouse melanoma was selected as a screening model and treated with DM-CHOC-PEN in
vitro and in vivo [28].
7. Experimental methods
In Vitro – B-16 mouse melanoma cells [obtained from ATCC, Menassas, VA] were assayed
in culture wells (104/mL) using a complete RPMI media containing 10% FBS with pen/strep
and maintaining cells @ 36o C in a CO2 incubator. Drugs (in 1 mL volumes; in conc. - 0.1-5
µg/mL) were added to the cells in a growth phase and removed after 8-12 h; cultures were
washed with fresh medium. For florescent studies - cells in growth phase were incubated
with dichlorofluorescein diacetate (DCFDA, 3 µg/mL RPMI) x 1-hr, washed and DM-
CHOC-PEN added (1-5 µg/mL); incubation continued for an additional 5-hour. Cells were
washed with fresh complete media and monitored with fluorescent microscopy. For the lat‐
ter – RPMI without phenol red was used.
In Vivo – B-16 mouse melanoma cells (106) were implanted SC into the flank of adult female
C57BL mice (age – 7-9 weeks, Harlan Labs.) and treatments with DM-CHOC-PEN, HOOI,
and other drugs began were initiated when lesions were palpable - 3-5 days post implant.
Drugs – were dissolved in saline or in a soybean oil/egg yolk lecithin emulsion (2 mg/mL)
and administer by IP injection. HOOI was administered as the L-lysine salt [27].
Results – B-16 cells were incubated with DM-CHOC-PEN and after ~ 6-8 hours became
heavily melanotic, lost adherence and floated to the top of the wells. Isolation of the floating
heavily pigmented melanotic cells that formed (Fig. 7b), followed by washing, extraction
with dichloromethane, and HPLC assays revealed that the cells contained DM-CHOC-PEN
in concentrations of 0.003-0.09 µg/mL of packed B-16 cells. Attached amelanotic cells con‐







Figure 7. a) B-16 melanoma cells – untreated; b) After treatment with DM-CHOC-PEN
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In comparison with other agents – DM-CHOC-PEN had an IC50 of 0.4 µg/mL and TMZ,
BCNU, DOX and actinomycin D (Act D), HOOI – 0.5-0.9 µg/mL; cis-platinum (cis-platin)
–  1.5  µg/mL resulted in  IC50  cell  death @ 36 hour post-intial  exposure.  With the excep‐
tion  of  DM-CHOC-PEN,  all  treated  cells  died  with  ghosts  remaining;  excesive  melanin
formation only occurred with DM-CHOC-PEN; the terminal pathways were quite differ‐
ent for the other drugs.
Drug IC50 (µg/mL)
DM-CHOC-PEN 0.4 +/- 0.01
Actinomycin D 0.5 +/- 0.02
BCNU 0.9 +/- 0.1
cis-Platin 1.5 +/- 0.1
DOX 0.7 +/- 0.1
TMZ "/>3.0
HOOI 0.8 +/- 0.2
Table 2. Drugs Responses vs. B-16 Melanoma (IC50)
Figure 8. a)B-16 cells + DCF-DA; b)B-26 cells plus DM-CHOC-PEN + DCF-DA
Viewed with florescent microscopy – green florescent cells are generating ROS and the DCF
is florescent.
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Melanoma cell  death due to DM-CHOC-PEN could be a result of increased intracellular
melanin, as well as DNA alkylation. Addition of DCF-DA (dichlorofluorescein diacetate)
to the culture medium (10 µg/mL) documented the formation of  radical  oxygen species
(ROS) in the DM- CHOC-PEN treated cultures; green labeled cells (Fig. 8b). ROS release
was documented with DCF, which is due to the hydrolysis and oxidized of DCF-DA by
ROS with the release of fluorescent DCF. The generation of ROS was not observed with
B-16 melanoma cells treated with cis-platin or actinomycin D and cultured under similar
conditions.  There  is  some back ground florescence and secondary to  melanin-associated
ROS formation [16].
In Vivo Studies – Adult female C57BL mice in groups of 5-6 mice with palpable SC nodules
were dosed IP daily (175 or 200 mg/kg) for 5-days with DM-CHOC-PEN and monitored dai‐
ly until death (Fig. 9a).
Mice treated with DM-CHOC-PEN (200 mg/kg/d x 5 days, IP) alone demonstrated an ILS of
142% (Fig. 9a). No drug related toxicity was noted – weight gain occurred until tumor
growth was obvious.
Figure 9. a)DM-CHOC-PEN treated; b)Cis-platin treated
Cis-platin was used as a drug control and administered (IP) once weekly x 3 (Fig. 9b); ani‐
mals did not tolerate 3- or 5-day dosing schedules [28, 29]. Although active in vitro, cis-platin
does not improve in vivo survival – as seen in Fig. 9b, although it is used in many melanoma
clinical protocols [3].
Tumor histology of the DM-CHOC-PEN treated B-16 melanomas are reviewed in Fig. 10. On
the left (a) is the saline control and right (b) the DM-CHOC-PEN treated – 200 mg/kg IP dai‐
ly x 5 days. Note - the melanin deposits in the cells with vacuoles, similar to what was seen
in culture [29].
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Figure 11. a)Histology of saline controls; b)Histology of DM-CHOC-PEN treated
Tumor tissue from the above DM-CHOC-PEN treated mice were assayed per cytoflorimetry









Figure 12. a) Mice bearing SC nodules – control animals. b) Mice bearing SC nodules dosed - 200 mg/kg; days 1-5 and
sacrificed 3-days after the last treatment.
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There were less viable cells available in the treated animals. DM-CHOC-PEN reduced the
cellular concentration of the tumors and the cells accumulated in G1 phase, with an inhibi‐
tion in S-phase concentration of cells (Fig. 11b). Thus, more support for DM-CHOCPEN’s
potential use in melanoma. Unfortunately, there was a significant amount of debris present.
Discussion – Mice bearing B-16 melanoma, tolerated DM-CHOC-PEN well when adminis‐
tered IP daily x 5 days or days 1 & 5 with improved overall survival (OAS) for both sched‐
ules; the former was the superior.
Histological examinations of the melanoma tissue from animals that had been treated with
DM-CHOC-PEN revealed tumor cells encompassed in extracellular melanin, very similar to
what was seen in tissue culture (Fig. 7b). DM-CHOC-PEN was extracted in up to 92 ng/g
tissue quantities from the melanoma tissue removed in Fig. 11b [16].
DM-CHOC-PEN is a pseudo-alkylator that binds to DNA’s guanine-N7 via the trichloro‐
methyl moiety → dichloromethylene carbonium ion and can form DNA-guanine adducts
and cell death [Fig. 6] [9]. However, the current observations in a melanoma model support
DM-CHOC-PEN’s additional ability to disrupt cellular metabolism with death via autooxi‐
dation of DOPA to melanin and superoxide formation – an additional MOA for considera‐
tion – Fig. 12 [28, 29].
Electronic modeling studies support DM-CHOC-PEN’s ability to act as a pyridinium co-fac‐
tor oxidized by the pyridine nucleotides (NAD, etc.) with red-ox transfer of electrons from
3,4-dihydroxyphenylalanine (DOPA) to the mitochondria and cytochrome C/cytochrome ox‐
idase transport system (Fig. 13). This result is the formation of 5, 6-indolequinone and mela‐
nin with a trail of electrons that can enter the mitochondrion intermediary pool resulting in
all the same type of lethal changes seen with electron beam therapy for cancer [30, 31].
The ‘melanin balls’ that were seen in vitro are spheres of extracellular melanin polymer en‐
capsulating colonies of melanoma cells that could induce a hostile microenvironment
through ROS formation with death via oxidative stress and apoptosis (Figs. 10) [30]. Clus‐
ters of melanin laden cells contained significantly elevated concentrations of DM-CHOC-
PEN, as compared to the amelanotic variant; a possible storage site for the drug [31]. The
initial DOPA → DOPA quinone transformation is catalyzed by tyrosinase (DOPA oxidase)
intracellular [32-35]. However, the red-ox potential for DM-CHOC-PEN is sufficient to cata‐
lyze the conversion with excess melanin formation per the Rapier Scheme below [32].
Both malignant and benign melanocytes generate melanin pigment via the sequence of
chemical reactions as depicted in the classical Rapier Scheme in Fig.12 [32].
Melanin is far from being an end-product of oxidation [34-37]. At a glance the existence of
energy bands are obvious from the highly conjugated heterocyclic indole quinone structure
for melanin (Fig. 12). The hypothesis has been proposed that non-localized empty molecular
orbitals are associated with the copolymer chain of the indole quinoid units and that the
melanin polymer acts as a one-dimensional semi-conductor/trap with bound protons pro‐
ducing electron traps in the system [36].
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Thus, melanin is a polymer of indole-5, 6-quinone which is highly electrophilic due to its
conjugated structure and capable of attracting, storing and/or transferring electrons as elec‐
trical energy [30, 31, 34]. DM-CHOC-PEN treatment induced ROS formation via the melanin
system resulting in cancer cell death – an end point.
Figure 13. Interaction of DM-CHOC-PEN with Rapier melanin cell cycle and mitochondrion [32]
Melanin is potentially a storage deposit of electrons and/or for electron-rich molecules (re‐
ported by our group years ago) [31]. Due to the high redox potential between DOPA and
DOPA quinone, +0.37v, a possible yield of -19.8 kcal/mole occurs upon the oxidation of 1
mole DOPA. A total of 12 e- are generated per mole of DOPA oxidized to indole quinone
which polymerize to melanin [Fig. 13 [31]. A field of melanin encompassing a colony of can‐
cer cells could generate a hostile electrical microenvironment and inhibit cellular metabo‐
lism and replication [33].
Melanoma cells are a classical representation of cancer cells with a resting low free energy
(ΔF) and high entropy (ΔS) – the alpha state [14]. The interactions of DM-CHOC-PEN and
DOPA induced the formation of melanin and ROS which resulted in an increased envi‐
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications450
ronmental ΔF and a decrease in ΔS; a new resting high energy state – the beta state.  The
cells that are contained in the melanin balls are in a beta state - undergo apoptosis and die
[28, 30, 31].
Thus, DM-CHOC-PEN is a new drug entity that crosses the BBB and couples two new tar‐
gets – the melanin cycle and superoxide formation with apoptosis plus DNA guanine – N7
adducts. DM-CHOC-PEN is a potential triple treat for CNS melanoma, the 3rd most common
cancer that spreads to the CNS.
8. A 2nd High energy drug
Another high energy drug, 4-hydroperoxyifosfamide (HOOI) [Fig. 3, 14] and is a pre-activat‐
ed form of ifosfamide (IFOS) which possesses the criteria for discussion [Fig. 14]. HOOI also
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Figure 14. Ifosfamide and analogs
IFOS is a well-known anticancer agent that requires hepatic activation to 4-HO-IFOS which
spontaneously undergoes hydrolysis with ring opening resulting in isophosphoramide mus‐
tard (IPM) [Fig. 14], the latter is the active cytotoxic form of IFOS [37-39]. As part of the IFOS
activation process, hepatic metabolic dechloroethylation releases chloroacetaldehyde, which
has been proposed to be the major cause of IFOS associated neurotoxicity [40]. Acrolein is
also released and has been implicated in dose limiting toxicities - hemorrhagic cystitis and 2o
tumor promotion [41-45].
In contrast, HOOI does not require hepatic microsomal activation, crosses the BBB and is
readily absorbed by cancer cells where it releases IPM in situ [46, 47]. The former does not
generate chloroacetaldehyde (neurotoxic) during its conversion to IPM, as does IFOS. Nei‐
ther hemorrhagic cystitis nor renal toxicity has been observed with HOOI in animal toxicol‐
ogy models. Pulmonary damage that could occur with peroxides – pulmonary air emboli
was not observed in the dog HOOI study [46]. Hematological toxicity (bone marrow deple‐
tion) was the dose limiting toxicity in the dog study [47].
The potential therapeutic usefulness of HOOI is supported by in vivo activity in human tu‐
mor xenografts and cyclophosphamide (CPA)-resistant murine tumor models plus reduced
toxicities.
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In vivo in comparison to CPA and IFOS in rodent and dog species [Table 3] [47], a potential‐
ly improved safety profile is anticipated – with reduced systemic formation of acrolein and
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5 NA NA +54 (1/5 CR) NA
Dose – qd x 5d (IP) – except TMZ – PO Q4D x 3; *human breast cancer – SC implanted, **human glioblastoma – IC
implanted; ***CPA (cyclophosphamide) – resistant murine leukemia. For MX-1 – T-C (days) = difference in median
times post implant for tumors of treated groups to attain an evaluation size compared to median of control group; +6-
log cell kill; ++>40 mg/kg was too toxic; ***% ILS (increased length of survival – study terminated @ 54 days.
Table 3. Human Xenografts and Murine Tumors Growing in Mouse Models
HOOI possesses two [2] 3-high energy atom chains, thus the drug more than fits the criteria
proposed earlier in this chapter (3). In addition, HOOI does not require activation by the liv‐
er and spontaneously undergoes conversion to IPM and cross-links with nuclear DNA via
major groove alkylation – N7-guanine, forming G-X-C adducts [39].
Of significance is that HOOI was curative (54% LTS, with 20% CR) vs. the human U251 glio‐
blastoma implanted IC as well as the MX-1 breast cancer IC model (Table 3) [47]. It should
also be noted that BCNU – the gold standard for years in the treatment of gliomas produced
no CRs and TMZ the current standard produced identical responses to HOOI.
Like DM-CHOC-PEN, HOOI accumulates in U-251 glioma tissue in 50 ng/g tissue content
when the drug is administered IP to animals bearing IC implanted tumors [47]. No CNS/
behavioral alterations or toxicity have been noted for HOOI [48].
Unlike ifosfamide (IFOS), HOOI is more lipophilic, activated in situ, with less extracellular
acrolein, no chloroacetaldehyde released and no IFOS associated CNS or GU toxicity [48]. In
dogs the principal toxicity with HOOI was bone marrow suppression that reversed with
time [47, 48].
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An early study reported that SK-MEL-31 human melanoma cells were sensitive to HOOI,
which prompted the comparison of the drug with DM-CHOC-PEN in the B-16 melanoma
model [47].
In 2012, the incidence of new cases of melanoma in the US alone is estimated at 76,250, an
increase of ~ 20% during the past 10 years [9]. Of these cases, ~ 25% will metastasize to the
CNS; thus our interest in the drug [26].
Fig. 15 describes the impact on survival of B-16 mouse melanoma when HOOI is adminis‐
tered alone and with DM-CHOC-PEN [49].
DM-CHOC-PEN (200 mg/kg/d) was injected IP daily x 5-days followed by HOOI (90 mg/m2)
IP daily x 3 days (Day 6-8). The latter is a more classical mustard type agent with activity in
the G1 phase, as compared to DM-CHOC-PEN, which inhibited cell replication at the S
phase – Fig. 12b [49].
The %LTS for the 2-drug combination was 173% vs. HOOI alone - 78%; for DM-CHOC-PEN
alone - 142% (see Fig. 14).
No drug related toxicity was noted – weight gain continued until tumor growth was a burden
and animals sacrificed. The use of 5-day dosing for HOOI was toxic and not considered [48].
Combination of the two -‘high energy’ agents selected for discussion as binary therapy has po‐
tential. It will be a while before these 2-drugs are administered together; however, other binary
selections that incorporate DM-CHOC-PEN are in the planning stage for Phase II trials.
Figure 15. DM-CHOC-PEN plus HOOI in the Treatment of B-16 Mouse Melanoma
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Melanoma cells, as seen in Fig. 7a represent classical cancer cells with a resting low free en‐
ergy (ΔF) and high entropy (ΔS) – the alpha state [14]. The interaction of DM-CHOC-PEN
and DOPA induced the formation of melanin – a high energy component/storage that re‐
sulted in an increase in environmental ΔF and a decrease in ΔS; a new resting high energy
state – the beta state [14]. Cells that are encompassed in the ‘melanin balls’ (Fig. 7b) were con‐
verted to a well differentiated state and die. The addition of HOOI to DM-CHOC-PEN in‐
hibited those cells that reversed to the alpha state – survive and continue to replicate. Thus,
the binary combination improved %LTS vs. either drug alone; supporting the in vitro obser‐
vations.
Although, only two patients with CNS melanoma have been treated with DM-CHOC-PEN
in the Phase I trial, the report that one patient did demonstrate an interval response and one
patent had a no change response, both with no neurotoxicity is encouragement for the po‐
tential use of the drug in the treatment of CNS melanoma [25]. HOOI has not been used in
clinical trials as yet.
There are many novel drugs that fall in to the ‘high-energy’ category that should be evaluat‐
ed or re-visited. In particular – clomesone [Fig. 3], a drug developed at Southern Research
Institute, US had potential in animal studies, but produced hematological toxicity in Phase I
trials and discontinued from studies [17, 50]. The drug has novel chloroethylating properties
and like BCNU forms adducts with DNA guanine-O6 [50]. In addition, the drug contains
two - S - atoms which are a 3rd Period element and able to expand its 3d orbital – a real
‘high-energy’ molecule. However, only one of the latter groups has the ability to resonant
with energy storage.
With the two sets of 3-atom chain as a point of interest (Fig. 3, 6), clomesone should be revis‐
ited with dose modifications; it has potential [52].
In summary, three ‘high energy’ drugs have been reviewed as support that a novel ap‐
proach to the treatment of CNS malignancies could be through the inefficient energy system
of brain tumors [11, 12]. Anticancer agents that have the appropriate structure, can penetrate
the CNS, not be recycled out and inhibit cancer growth.
Over all, DM-CHOC-PEN has been well tolerated in Phase I studies with advanced –breast
cancer, sarcoma, glioblastoma multiforme, melanoma, pancreas, esophageal, non-small cell
lung cancer colorectal cancer and cervical cancer and will obviously enter Phase II trials
alone or as binary therapy [25].
Furthermore, HOOI is being readied for Phase I clinical trials and the results should be
equally interesting.
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1. Introduction
Glioblastoma multiforme is one of the deadliest forms of brain tumor with a median survival
of <12 months with a high rate of recurrence. Glioblastoma cells respond poorly to radiother‐
apy and chemotherapy due to elevated DNA repair efficiency coupled with anti-apoptotic
mechanisms [1, 2]. Therefore, development of new therapeutic strategies is absolutely critical
either to control or cure the disease. Since glioblastoma cells have inherently elevated levels
of DNA damage response (DDR) and DNA repair efficiency, we sought to determine whether
or not suppression of key DNA repair factor(s) might be effective in sensitizing the brain tumor
cells to chemotherapy. To test our objective, a pair of isogenic glioblastoma cell lines that differ
in the functional status of DNA dependent protein kinase (DNA-PK) has been chosen. DNA
dependent protein kinase (DNA-PK) belongs to a super family of phosphatidylinositol-3
kinase like kinases (PIKK) which also includes the gene products of ataxia telangiectasia
mutated (ATM) and ATM and Rad 3 related (ATR) kinases [3, 4]. DNA-PK is the main
component of mammalian NHEJ (non-homologous end joining), and also plays a role as a
sensor of DNA damage by phosphorylating several downstream targets [5]. Further, DNA-
PK has been demonstrated to be an important component of nucleotide excision repair (NER)
pathway, which is chiefly responsible for the repair of bulky and helix distorting lesions
induced by ultraviolet radiation (UV) and chemotherapeutic drugs such as cisplatin. To
determine whether or not DNA-PK is a potential molecular therapeutic target for glioblastoma,
two agents with different modes of action have been chosen for our study: (1) Zebularine and
(2) Cisplatin.
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1. Introduction
Glioblastoma multiforme is one of the deadliest forms of brain tumor with a median survival
of <12 months with a high rate of recurrence. Glioblastoma cells respond poorly to radiother‐
apy and chemotherapy due to elevated DNA repair efficiency coupled with anti-apoptotic
mechanisms [1, 2]. Therefore, development of new therapeutic strategies is absolutely critical
either to control or cure the disease. Since glioblastoma cells have inherently elevated levels
of DNA damage response (DDR) and DNA repair efficiency, we sought to determine whether
or not suppression of key DNA repair factor(s) might be effective in sensitizing the brain tumor
cells to chemotherapy. To test our objective, a pair of isogenic glioblastoma cell lines that differ
in the functional status of DNA dependent protein kinase (DNA-PK) has been chosen. DNA
dependent protein kinase (DNA-PK) belongs to a super family of phosphatidylinositol-3
kinase like kinases (PIKK) which also includes the gene products of ataxia telangiectasia
mutated (ATM) and ATM and Rad 3 related (ATR) kinases [3, 4]. DNA-PK is the main
component of mammalian NHEJ (non-homologous end joining), and also plays a role as a
sensor of DNA damage by phosphorylating several downstream targets [5]. Further, DNA-
PK has been demonstrated to be an important component of nucleotide excision repair (NER)
pathway, which is chiefly responsible for the repair of bulky and helix distorting lesions
induced by ultraviolet radiation (UV) and chemotherapeutic drugs such as cisplatin. To
determine whether or not DNA-PK is a potential molecular therapeutic target for glioblastoma,
two agents with different modes of action have been chosen for our study: (1) Zebularine and
(2) Cisplatin.
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Many tumor cells have characteristic epigenetic alterations involving genome wide DNA
hypo-methylation and gene specific hyper-methylation at CpG dinucleotide sequences
leading to aberrant silencing of critical genes involved in DNA damage response, cell cycle
and DNA metabolic processes. Recent studies [6-8] have demonstrated the usefulness of
epigenetic targeting in treating many cancer cell types through inhibition of histone deacety‐
lases (HDAC) or DNA methyl transferases (DNMTs). Zebularine is a potent inhibitor of
DNMTs and is superior to 5-AzaCR in terms of lower cytotoxicity and increased stability in
aqueous solutions [9]. While Zebularine is a DNA-demethylating agent, cisplatin is a DNA
cross-linking agent that induces the formation of DNA inter- and intra-strand cross-links.
These cross-links are removed preferentially by NER pathway and NER deficient tumor cells
are often sensitized to cisplatin treatment. Since DNA-PK plays a critical role in genome
surveillance and DNA repair mechanisms, we wished to evaluate the potential of DNA-PK as
a molecular therapeutic target for glioblastoma.
2. DNA-PK deficient cells are sensitive to zebularine and cisplatin
treatments
2.1. Zebularine sensitizes DNA–PK deficient glioblastoma cells
DNA-PK deficient (MO59J) and proficient (MO59K) glioblastoma cells were purchased from
American Type Culture Collection (Rockville, MD, USA). Cells were routinely cultured in
OPTI-MEM supplemented with 5% fetal bovine serum, vitamins and antibiotics. Zebularine
[1-beta-D-ribofuranosyl)-1, 2-dihydropyrimidin-2-one] was purchased from EMD Biosciences
(San Diego, CA, USA). Zebularine was dissolved in dimethyl sulfoxide (DMSO) at a stock
concentration of 100 mM and stored at 4ºC. Clonogenic survival and proliferations assays were
carried to determine the sensitivity of human gliomas (MO59J and MO59K) to different
Zebularine concentrations (0-300 µM). The LC50 value for Zebularine was found to be 245 µM
for DNA-PK deficient MO59J cells and at this concentration the survival of MO59K cells was
reduced only by 20% [10]. This finding indicates that lack of DNA-PK potentiates the sensiti‐
zation of gliomas to Zebularine. In contrast to MO59K cells, DNA-PK deficient cells (MO59J)
showed a reduction in survival (20%) even at the lowest Zebularine concentration (10 µM).
Further, an elevated frequency of polyploid cells observed specifically in MO59J cells after
Zebularine treatment pointed out a mitotic checkpoint deficiency. Although depletion of
DNMT1 by Zebularine occurred at similar levels in both glioblastoma cell lines, DNA-PK
deficient MO59J cells displayed elevated DNA hypo-methylation detected both at genome
overall and gene promoter levels. Consistent with increased sensitivity, deoxy-Zebularine
adduct level, measured for the first time by us in the genomic DNA, was 3-6 fold higher in
DNA-PK deficient MO59J cells relative MO59K cells. Elevated micronuclei frequency was also
observed in MO59J cells indicating the impairment of DNA damage response and repair.
Collectively, our study suggests that DNA-PK is a potentially useful molecular therapeutic
target for gliomas.
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2.2. DNA–PK deficient cells are sensitive to cisplatin treatment
The relationship between DNA-PK/Ku activity and cisplatin sensitivity has been observed
earlier in gliomas. Gliomas with high expression level of DNA-PK are resistant to cisplatin [11].
In an earlier review, we suggested that DNA-PK inhibition may be a promising strategy for
treating glioblastomas [for review see 12]. To determine the role of DNA-PK in conferring
cisplatin resistance, MO59J and MO59K cells were treated with cisplatin (5-75 µM; Sigma
Aldrich, USA) for 72 h and assayed for proliferation using a fluorescence based CyQuant assay
(Invitrogen, USA). MO59J showed a greater sensitivity to cisplatin compared to MO59K, and
displayed a dose dependent decrease in cell proliferation, being reduced to 20% relative to the
vehicle (DMSO) treated control cells for the highest drug concentration (75 µM). In contrast,
MO59K was sensitive to cisplatin only at high doses (>50 µM). These results clearly indicate
that DNA-PK is a critical factor for cellular protection against cisplatin (Figure 1).
Figure 1. Cell proliferation assay using CyQuant (Invitrogen, USA) in MO59K and MO59J cells treated with cisplatin (5,
10, 25, 50, and 75 µM) for 72 h.
Cell cycle analysis was next performed to verify whether the enhanced cisplatin cytotoxicity
of MO59J cells was due to defective cell cycle checkpoints. MO59K and MO59J cells in
exponential growth phase were exposed to different concentrations (5 to 25 µM) of cisplatin
and the cell cycle profile was analyzed by flow cytometry (24, 48 and 72 h after treatment).
While DNA-PK proficient MO59K cells displayed an efficient accumulation of S-phase cells at
all the concentrations of cisplatin exposure up to 72 h (Figure 2A), DNA-PK mutant MO59J
cells exhibited only a modest S-phase accumulation after 24 h of drug treatment (25 µM
cisplatin) (Figure 2B), which was alleviated at later time points (48 and 72 h).
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Many tumor cells have characteristic epigenetic alterations involving genome wide DNA
hypo-methylation and gene specific hyper-methylation at CpG dinucleotide sequences
leading to aberrant silencing of critical genes involved in DNA damage response, cell cycle
and DNA metabolic processes. Recent studies [6-8] have demonstrated the usefulness of
epigenetic targeting in treating many cancer cell types through inhibition of histone deacety‐
lases (HDAC) or DNA methyl transferases (DNMTs). Zebularine is a potent inhibitor of
DNMTs and is superior to 5-AzaCR in terms of lower cytotoxicity and increased stability in
aqueous solutions [9]. While Zebularine is a DNA-demethylating agent, cisplatin is a DNA
cross-linking agent that induces the formation of DNA inter- and intra-strand cross-links.
These cross-links are removed preferentially by NER pathway and NER deficient tumor cells
are often sensitized to cisplatin treatment. Since DNA-PK plays a critical role in genome
surveillance and DNA repair mechanisms, we wished to evaluate the potential of DNA-PK as
a molecular therapeutic target for glioblastoma.
2. DNA-PK deficient cells are sensitive to zebularine and cisplatin
treatments
2.1. Zebularine sensitizes DNA–PK deficient glioblastoma cells
DNA-PK deficient (MO59J) and proficient (MO59K) glioblastoma cells were purchased from
American Type Culture Collection (Rockville, MD, USA). Cells were routinely cultured in
OPTI-MEM supplemented with 5% fetal bovine serum, vitamins and antibiotics. Zebularine
[1-beta-D-ribofuranosyl)-1, 2-dihydropyrimidin-2-one] was purchased from EMD Biosciences
(San Diego, CA, USA). Zebularine was dissolved in dimethyl sulfoxide (DMSO) at a stock
concentration of 100 mM and stored at 4ºC. Clonogenic survival and proliferations assays were
carried to determine the sensitivity of human gliomas (MO59J and MO59K) to different
Zebularine concentrations (0-300 µM). The LC50 value for Zebularine was found to be 245 µM
for DNA-PK deficient MO59J cells and at this concentration the survival of MO59K cells was
reduced only by 20% [10]. This finding indicates that lack of DNA-PK potentiates the sensiti‐
zation of gliomas to Zebularine. In contrast to MO59K cells, DNA-PK deficient cells (MO59J)
showed a reduction in survival (20%) even at the lowest Zebularine concentration (10 µM).
Further, an elevated frequency of polyploid cells observed specifically in MO59J cells after
Zebularine treatment pointed out a mitotic checkpoint deficiency. Although depletion of
DNMT1 by Zebularine occurred at similar levels in both glioblastoma cell lines, DNA-PK
deficient MO59J cells displayed elevated DNA hypo-methylation detected both at genome
overall and gene promoter levels. Consistent with increased sensitivity, deoxy-Zebularine
adduct level, measured for the first time by us in the genomic DNA, was 3-6 fold higher in
DNA-PK deficient MO59J cells relative MO59K cells. Elevated micronuclei frequency was also
observed in MO59J cells indicating the impairment of DNA damage response and repair.
Collectively, our study suggests that DNA-PK is a potentially useful molecular therapeutic
target for gliomas.
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2.2. DNA–PK deficient cells are sensitive to cisplatin treatment
The relationship between DNA-PK/Ku activity and cisplatin sensitivity has been observed
earlier in gliomas. Gliomas with high expression level of DNA-PK are resistant to cisplatin [11].
In an earlier review, we suggested that DNA-PK inhibition may be a promising strategy for
treating glioblastomas [for review see 12]. To determine the role of DNA-PK in conferring
cisplatin resistance, MO59J and MO59K cells were treated with cisplatin (5-75 µM; Sigma
Aldrich, USA) for 72 h and assayed for proliferation using a fluorescence based CyQuant assay
(Invitrogen, USA). MO59J showed a greater sensitivity to cisplatin compared to MO59K, and
displayed a dose dependent decrease in cell proliferation, being reduced to 20% relative to the
vehicle (DMSO) treated control cells for the highest drug concentration (75 µM). In contrast,
MO59K was sensitive to cisplatin only at high doses (>50 µM). These results clearly indicate
that DNA-PK is a critical factor for cellular protection against cisplatin (Figure 1).
Figure 1. Cell proliferation assay using CyQuant (Invitrogen, USA) in MO59K and MO59J cells treated with cisplatin (5,
10, 25, 50, and 75 µM) for 72 h.
Cell cycle analysis was next performed to verify whether the enhanced cisplatin cytotoxicity
of MO59J cells was due to defective cell cycle checkpoints. MO59K and MO59J cells in
exponential growth phase were exposed to different concentrations (5 to 25 µM) of cisplatin
and the cell cycle profile was analyzed by flow cytometry (24, 48 and 72 h after treatment).
While DNA-PK proficient MO59K cells displayed an efficient accumulation of S-phase cells at
all the concentrations of cisplatin exposure up to 72 h (Figure 2A), DNA-PK mutant MO59J
cells exhibited only a modest S-phase accumulation after 24 h of drug treatment (25 µM
cisplatin) (Figure 2B), which was alleviated at later time points (48 and 72 h).
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Figure 2. Cell cycle analysis for MO59K and MO59J cells treated with 5, 10 and 25 µM of cisplatin for 24, 48 and 72 h.
DMSO was used as control.
Consistent with impaired cell cycle regulation, an increased frequency of apoptosis (43% for
25 µM cisplatin) was observed after cisplatin treatment in MO59J cells; in contrast to MO59K,
DNA-PK deficient MO59J cells showed apoptotic death even at 5 µM of cisplatin (Figure 3A,B).
Figure 3. Frequency of apoptotic MO59K (A) and MO59J (B) cells detected by flow cytometry as a subG1 population
after exposure to different concentrations of cisplatin (5, 10 and 25 μM). The results were obtained at 24, 48 and 72 h
after treatment. 10,000 events were analyzed for each experiment.
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Proliferating cell nuclear antigen (PCNA) is recruited to chromatin rapidly after DNA damage
and the kinetics of disassembly from the chromatin is considered to reflect the DNA repair
efficiency [13, 14]. PCNA expression was evaluated by Western blot in cisplatin- treated
MO59K and MO59J cells. The expression of PCNA was increased in a dose-dependent manner
in MO59K cells after 24 h of drug treatment, while a constant level of PCNA expression was
observed in MO59J cells indicating the lack of S-phase specific PCNA accumulation (Figure
4). Our results from MO59K and MO59J cell lines indicate that DNA-PK is a critical determi‐
nant of cell survival after cisplatin treatment and the lack of S-phase arrest (as seen in MO59J
cells) is presumably responsible for the increased cell death after drug treatment.
Figure 4. Expression of PCNA protein (30 KDa) analyzed by Western blot using specific antibody. MO59K and MO59J
cells were treated with 5, 10 and 25 µM of cisplatin for 3 and 24 h. β-actin was used as control.
Therefore, DNA-PK may be an important molecule conferring cisplatin resistance in glioblas‐
toma cells, with potential use as a molecular target, and we also observed that the combined
effect of cisplatin and LY294002 (an inhibitor of DNA-PK) caused a significant decrease in cell
proliferation and an increase in apoptotic cell death in glioma cell lines [15]. Our studies thus
far performed indicate that the specific targeting of DNA-PK by small molecule inhibitors may
be an effective strategy for the treatment of gliomas.
3. In silico analysis of transcription factors associated with differentially
expressed genes in GBM cells
3.1. Introduction
Transcription factors (TFs) regulate gene expression by binding to specific DNA sequences of
gene promoter regions. Their expression can be deregulated under certain pathological
conditions, such as cancer. Therefore, studies on regulatory elements of the transcription
machinery are essential for understanding the mechanisms involved in the regulation of
oncogenes and tumor suppressor genes. Additionally, knowledge of the essential functions of
TFs, may lead to strategic development of novel chemotherapy regimen for selectively killing
cancer cells.
DNA-PK is a Potential Molecular Therapeutic Target for Glioblastoma
http://dx.doi.org/10.5772/53181
463
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effect of cisplatin and LY294002 (an inhibitor of DNA-PK) caused a significant decrease in cell
proliferation and an increase in apoptotic cell death in glioma cell lines [15]. Our studies thus
far performed indicate that the specific targeting of DNA-PK by small molecule inhibitors may
be an effective strategy for the treatment of gliomas.
3. In silico analysis of transcription factors associated with differentially
expressed genes in GBM cells
3.1. Introduction
Transcription factors (TFs) regulate gene expression by binding to specific DNA sequences of
gene promoter regions. Their expression can be deregulated under certain pathological
conditions, such as cancer. Therefore, studies on regulatory elements of the transcription
machinery are essential for understanding the mechanisms involved in the regulation of
oncogenes and tumor suppressor genes. Additionally, knowledge of the essential functions of
TFs, may lead to strategic development of novel chemotherapy regimen for selectively killing
cancer cells.
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TFs play a critical role in various cellular processes through regulation of genes involved in
cell cycle, proliferation, cell differentiation, and apoptosis. It has been suggested that TFs can
be potential therapeutic targets for treating the patients with prostate [16] and breast cancer
[17]. Recently, in silico prediction for regulation of TFs has been effectively utilized for
diagnostics and therapeutics of breast cancer [17]. Identification and characterization of
activated transcription regulatory elements hold a great promise not only in providing
information on neoplastic mechanisms, but also in predicting targets for therapeutic interven‐
tion [18]. Although enormous amount of data exist for genes that are differentially expressed
in tumor cells, knowledge of TFs associated with these genes is rather limited. Information on
TFs may enable us to understand how differentially expressed genes in tumor cells respond
to anticancer drugs, as a single or combined treatment with DNA repair inhibitors, which
targets DNA repair proteins.
DNA-PK, one of the key components of mammalian NHEJ (non-homologous end joining)
repair process, belongs to PI3K-related protein kinase (PIKK) family [19]. Recent studies have
projected DNA-PK as a potential molecular target for cancer treatment. Many known PI3K
inhibitors such as LY294002, wortmannin and PI-103, inhibit DNA-PK activity with a compa‐
rable potency to that observed for PI3K inhibition [20]. LY294002 is a PI3K (phosphatidylino‐
sitol-3 kinase) inhibitor, well recognized by its antitumor and pro-apoptotic properties in
several cancer cell lines [21]. Although LY294002 alone can inhibit cell proliferation or induce
apoptosis in cancer cells, its cytotoxic effects can be further enhanced when combined with
radio- or chemotherapy [12, 22]. Consequently, PI3K inhibitors including LY294002 have been
investigated as a possible adjuvant for cancer therapy in many tumor models [23-25], and its
synergistic effects with other anti-tumoral drugs deserve to be investigated in cancer cells.
Our recent study demonstrated that a combined treatment of cisplatin (5-50µM) and LY294002
(50µM) for 24 h reduced the survival of U343 GBM cells with elevated apoptotic death at 72 h
[15]. In this study, gene expression analysis was also performed using a glass slide microarray
containing 4,300 cDNA clones from the human IMAGE Consortium cDNA library [http://
image.llnl.gov/image/] essentially following the procedures published earlier [26]. Statistical
analysis of the results [27] showed that 25µM cisplatin alone caused significant changes in the
expression of 108 genes (28 up- and 80 down-regulated), while LY294002 alone altered the
expression of 33 genes (6 up- and 27 down-regulated); additionally, 274 genes (97 up- and 177
down-regulated) were modulated by the combined treatment of cisplatin and LY294002. The
complete gene lists are available at http//www.rge.fmrp.usp.br/passos/cislygbm/. The drug
combination induced 2.6-fold higher numbers of modulated genes, relative to cisplatin alone,
and these genes participate in several biological processes, such as DNA repair, cell death, and
cell cycle control/proliferation, metabolism, transcription regulation, and cellular adhesion.
Using the gene sets obtained in the above-mentioned study, we performed an in silico analysis
of TFs for the differentially expressed genes obtained in the following comparisons: 25µM
cisplatin versus control, and 25µM cisplatin plus 50µM LY294002 versus control; these lists
contained 108 and 274 differentially expressed genes (SAM analysis, FDR ≤ 0.05), respectively.
Among the 274 genes, 97 (35.4%) genes were up-regulated and 177 (64.6%) genes were down-
regulated. Both up- and down-regulated genes were submitted separately to in silico analysis
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through the FatiGO tool, Babelomics v3.2 [28]. For comparisons, the entire list of genes present
in the microarray was subjected to analysis (4,300 transcripts).The data were analyzed by the
two-tailed Fisher’s exact test, with significance threshold for the p-values set at 0.05. Similar
procedures were performed for the list of 108 genes (set of differentially expressed genes under
25µM cisplatin treatment). Information regarding the biological functions was obtained at
SOURCE (http://smd.stanford.edu/cgi-bin/source/sourceSearch), and NCBI AceView (http://
www.ncbi.nlm.nih.gov/IEB/Research/Acembly/).
3.2. TFs associated with up–regulated genes
Among the predicted TFs associated with up-regulated genes after treatment with cisplatin
alone, the most significant ones are AHR (p = 9.9E–3, 7.7% of associated genes), HNF4 (p =
9.6E–3, 81% of associated genes), NFkappaB (p = 5.8E–3, 11.5% of associated genes), MRF2 (p
= 1.9E–3, 53.8%), and SOX5 (p = 1.6E–2, 7.7% of associated genes). These TFs have been linked
with distinct biological functions, including differentiation, homeostasis, cell growth, senes‐
cence and apoptosis. AHR regulates an array of physiological responses including xenobiotic
metabolism, vasculature development, immunosuppression, T-cell differentiation, reproduc‐
tion, and cell cycle progression [29]. Most genes known to be controlled by HNF4α are involved
in lipid, carbohydrate or amino acid transport and metabolism, indicating a central role in
energy homeostasis [30]. MRF2 (ARID5B) plays a vital role in regulating embryonic develop‐
ment, cell growth and differentiation through tissue-specific repression of differentiation-
specific gene expression [31, 32]. Aberrant ARID5B expression in developing fetus could halt
B-lymphocyte maturation and contribute to leukemogenesis [33]. SOX5 is involved in gene
regulation and maintenance of chromatin structure during diverse developmental processes.
Recently, SOX5 has been found associated with induced acute cellular senescence [34], while




List #1 List #2
GATA-3 30.1 16.3 1.85 1.7E–3
FOXP3 60.2 46.0 1.31 8.0E–3
FOXJ2 46.2 32.6 1.42 9.5E–3
C/EBP 18.3 9.8 1.87 1.5E–2
LXR, PXR, CAR COUP,
RAR
62.4 54.6 1.14 1.6E–2
Table 1. Transcription factors (Term) associated with up-regulated genes in cisplatin and LY294002 treated U343
cells. “Percentage with term” corresponds to the amount of genes that was associated to each TF in each list: List #1
represents up-regulated genes obtained by statistical analysis, and List #2 represents all the genes present in the
microarray slide. “Enrichment index” was calculated for each Term by dividing the percentage in the List #1 by that in
the List #2.
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several cancer cell lines [21]. Although LY294002 alone can inhibit cell proliferation or induce
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[15]. In this study, gene expression analysis was also performed using a glass slide microarray
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tion, and cell cycle progression [29]. Most genes known to be controlled by HNF4α are involved
in lipid, carbohydrate or amino acid transport and metabolism, indicating a central role in
energy homeostasis [30]. MRF2 (ARID5B) plays a vital role in regulating embryonic develop‐
ment, cell growth and differentiation through tissue-specific repression of differentiation-
specific gene expression [31, 32]. Aberrant ARID5B expression in developing fetus could halt
B-lymphocyte maturation and contribute to leukemogenesis [33]. SOX5 is involved in gene
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For the combined treatment (cisplatin and LY294002), the predicted TFs associated with up-
regulated genes showed different TFs (Table 1), indicating that the drug combination in‐
duced quantitative and qualitative differences in transcript expression profiles displayed by
GBM treated cells.
All the TFs that were associated with up-regulated genes showed enrichment indexes greater
than 1 (in the range of 1.14 to 1.87), indicating that these TFs were more specifically associated
with the up-regulated genes as compared to the entire array of genes (Table 1). Biological
functions of the predicted TFs associated with up- and down-regulated genes after the
combined treatment (cisplatin and LY294002) in U343 cells are described below:
GATA-3  (Trans-acting T-cell-specific  transcription factor)  gene encodes a  protein,  which be‐
longs to the GATA family of transcription factors.  The protein contains two GATA-type
zinc fingers and is an important regulator of T-cell development and plays an important
role in endothelial cell biology; GATA-3 is essential in the embryonic development of the
parathyroid, auditory system and kidneys, and defects in this gene cause HDR syndrome
(hypoparathyroidism with sensorineural deafness and renal dysplasia) [37]. GATA-3 anal‐
ysis and the phenotypic spectrum obtained for nine Japanese families with the HDR syn‐
drome suggest that this syndrome is primarily caused by GATA-3 haploinsufficiency [38].
This TF plays a dual role in transcription regulation in a positive and negative manner. In
accordance with this, we found the association of GATA-3 with up-regulated genes (EI =
1.85) after drug treatment in U343 cells.
Another TF, FOXP3 (Forkhead box P3), a positive regulator of transcription, plays a critical role
in the control of immune response. This TF was associated with up-regulated genes (EI = 1.31)
in drug-treated U343 cells. Defects in this gene lead to X-linked autoimmunity-immunodefi‐
ciency syndrome [39]. In several neoplasias, such as breast [40], ovarian [41], skin [42] and
stomach, FOXP3 was found over-expressed [43], or mutated in prostate cancer [44]. It is well
established that tumor cells acquire molecular and biochemical changes which make them
potentially vulnerable to the immune system [45]. Alterations in the immune system can be
applied for cancer detection and therapies [46]. Interestingly, [47] demonstrated a dependency
on functional TP53 for DNA damage induced activation of FOXP3 in human breast and colon
carcinoma cells. However, the precise role of FOXP3 in drug responses is still unknown.
FOXJ2 (Forkhead box J2) was also associated with up-regulated genes (EI = 1.42); this TF is often
described as a positive regulator of transcription [48] and is a member of Forkhead Box TFs,
many of which have been reported to participate in tumor migration and invasion. Wang et
al. [49] showed that the expression of FOXJ2 was high in primary breast cancer tissues without
lymph nodes metastases; moreover, FOXJ2 may play a role in maintenance and survival of
developing and adult neurons, but its function in the central nervous system is still unclear.
Knockdown of this TF in cultured primary astrocytes by siRNA showed that FOXJ2 played an
important role in lipopolysaccharide-induced inflammatory responses [50]. Nonetheless, there
is no information in the literature about its function in relation to chemotherapeutic drugs.
C/EBP (CCAAT/enhancer-binding protein) family plays important roles in many processes such
as cell differentiation, metabolism, and development. C/EBP (CEBPA) gene, CCAAT/enhancer
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binding protein alpha, involved in cell cycle arrest [51], and also plays a role in DNA damage
response dependent on TP53 [52]. The protein acts as a dominant-negative inhibitor by forming
hetero-dimers with other C/EBP members, such as C/EBP and LAP (liver activator protein), and
preventing their DNA binding activity. Another member, GADD153 (CHOP), is a critical
initiator of ER stress-induced apoptosis, and its knockdown prevents perturbations in the AKT
(protein kinase B)/FOXO3a (forkhead box, class O, 3a) pathway in response to ER stress [53].
C/EBP β, a member of a subfamily of basic leucine zipper (bZIP) protein family, play a potential
role in the proliferation and invasion of glioma, being considered as a novel molecular target
for therapy, as well as a predictive marker for survival of patients with glioma [54]. In the
present study, C/EBP showed an association with up-regulated genes (EI = 1.87), suggesting
a possible role in DNA damage responses under drug treatment, and most probably, via AKT
pathway, which is a target for LY294002.
Three TFs (LXR, PXR and CAR) were related to the same percentage (62.4%) of up-regulated
genes, presenting EI = 1.14. The liver X receptors (LXR), LXRA and LXRB, comprise a subfamily
of the nuclear receptor superfamily and are key regulators of macrophage function, controlling
transcriptional programs involved in lipid homeostasis and inflammation. Polymorphism of
LXR gene is associated with obesity since this gene is involved in cellular lipid metabolic
process [55]. PXR, also named NR1I2 (Nuclear receptor subfamily 1, group I, member 2) is a TF
that acts in both positive and negative regulation of transcription, as well as in xenobiotic
transport and metabolic process, in addition to exogenous drug catabolic process; this gene
seems to be also implicated in breast cancer development [56, 57]. Similarly to PXR, CAR
(NR1I3, Nuclear receptor subfamily 1, group I, member 3) is also a key regulator of xenobiotic and
endobiotic metabolism [58]. Identification of TFs related to liver and xenobiotic metabolism
regulating the over-expressed genes suggests that these genes may play a role in drug
responses. However, this interesting possibility needs further validation.
The foregoing account demonstrates that all the TFs that are associated with up-regulated
genes after combined treatment (cisplatin and LY294002) are regulators of important biological
processes, such as cell differentiation, metabolism, development, and immune response, but
the literature is still scarce regarding the role of above mentioned TFs in cellular response
mechanisms to chemotherapeutic drugs. In spite of this, the increment observed in the number
of associated genes (in terms of EI index, which ranged from 1.14 to 1.87) tends to suggest the
involvement of these TFs in the outcome of cellular response to combined treatment.
3.3. TFs associated with down–regulated genes
Similar to the prediction of TFs associated with up-regulated genes, we performed the same
kind of analysis for determining the TFs associated with down-regulated genes. None of the
TF was found associated with down-regulated genes after treatment with cisplatin alone.
However, for the combined treatment (cisplatin and LY294002), six TFs were predicted (Table
2). All TFs displayed enrichment indexes greater than 1 (ranging from 1.10 to 1.80), indicating
that the enrichment was greater in the list of down-regulated genes (list #1) in comparison to
all the genes (list #2) included in the array.
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ciency syndrome [39]. In several neoplasias, such as breast [40], ovarian [41], skin [42] and
stomach, FOXP3 was found over-expressed [43], or mutated in prostate cancer [44]. It is well
established that tumor cells acquire molecular and biochemical changes which make them
potentially vulnerable to the immune system [45]. Alterations in the immune system can be
applied for cancer detection and therapies [46]. Interestingly, [47] demonstrated a dependency
on functional TP53 for DNA damage induced activation of FOXP3 in human breast and colon
carcinoma cells. However, the precise role of FOXP3 in drug responses is still unknown.
FOXJ2 (Forkhead box J2) was also associated with up-regulated genes (EI = 1.42); this TF is often
described as a positive regulator of transcription [48] and is a member of Forkhead Box TFs,
many of which have been reported to participate in tumor migration and invasion. Wang et
al. [49] showed that the expression of FOXJ2 was high in primary breast cancer tissues without
lymph nodes metastases; moreover, FOXJ2 may play a role in maintenance and survival of
developing and adult neurons, but its function in the central nervous system is still unclear.
Knockdown of this TF in cultured primary astrocytes by siRNA showed that FOXJ2 played an
important role in lipopolysaccharide-induced inflammatory responses [50]. Nonetheless, there
is no information in the literature about its function in relation to chemotherapeutic drugs.
C/EBP (CCAAT/enhancer-binding protein) family plays important roles in many processes such
as cell differentiation, metabolism, and development. C/EBP (CEBPA) gene, CCAAT/enhancer
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binding protein alpha, involved in cell cycle arrest [51], and also plays a role in DNA damage
response dependent on TP53 [52]. The protein acts as a dominant-negative inhibitor by forming
hetero-dimers with other C/EBP members, such as C/EBP and LAP (liver activator protein), and
preventing their DNA binding activity. Another member, GADD153 (CHOP), is a critical
initiator of ER stress-induced apoptosis, and its knockdown prevents perturbations in the AKT
(protein kinase B)/FOXO3a (forkhead box, class O, 3a) pathway in response to ER stress [53].
C/EBP β, a member of a subfamily of basic leucine zipper (bZIP) protein family, play a potential
role in the proliferation and invasion of glioma, being considered as a novel molecular target
for therapy, as well as a predictive marker for survival of patients with glioma [54]. In the
present study, C/EBP showed an association with up-regulated genes (EI = 1.87), suggesting
a possible role in DNA damage responses under drug treatment, and most probably, via AKT
pathway, which is a target for LY294002.
Three TFs (LXR, PXR and CAR) were related to the same percentage (62.4%) of up-regulated
genes, presenting EI = 1.14. The liver X receptors (LXR), LXRA and LXRB, comprise a subfamily
of the nuclear receptor superfamily and are key regulators of macrophage function, controlling
transcriptional programs involved in lipid homeostasis and inflammation. Polymorphism of
LXR gene is associated with obesity since this gene is involved in cellular lipid metabolic
process [55]. PXR, also named NR1I2 (Nuclear receptor subfamily 1, group I, member 2) is a TF
that acts in both positive and negative regulation of transcription, as well as in xenobiotic
transport and metabolic process, in addition to exogenous drug catabolic process; this gene
seems to be also implicated in breast cancer development [56, 57]. Similarly to PXR, CAR
(NR1I3, Nuclear receptor subfamily 1, group I, member 3) is also a key regulator of xenobiotic and
endobiotic metabolism [58]. Identification of TFs related to liver and xenobiotic metabolism
regulating the over-expressed genes suggests that these genes may play a role in drug
responses. However, this interesting possibility needs further validation.
The foregoing account demonstrates that all the TFs that are associated with up-regulated
genes after combined treatment (cisplatin and LY294002) are regulators of important biological
processes, such as cell differentiation, metabolism, development, and immune response, but
the literature is still scarce regarding the role of above mentioned TFs in cellular response
mechanisms to chemotherapeutic drugs. In spite of this, the increment observed in the number
of associated genes (in terms of EI index, which ranged from 1.14 to 1.87) tends to suggest the
involvement of these TFs in the outcome of cellular response to combined treatment.
3.3. TFs associated with down–regulated genes
Similar to the prediction of TFs associated with up-regulated genes, we performed the same
kind of analysis for determining the TFs associated with down-regulated genes. None of the
TF was found associated with down-regulated genes after treatment with cisplatin alone.
However, for the combined treatment (cisplatin and LY294002), six TFs were predicted (Table
2). All TFs displayed enrichment indexes greater than 1 (ranging from 1.10 to 1.80), indicating
that the enrichment was greater in the list of down-regulated genes (list #1) in comparison to
all the genes (list #2) included in the array.






List #1 List #2
GATA-3 23.6 16.3 1.45 2.2E–2
Evi-1 50 38.1 1.31 3.9E–2
HNF-1 90.2 84.0 1.10 4.8E–2
USF1 26.4 20.1 1.31 5.1E–2
CDX 82.2 67.3 1.22 5.6E–2
AP-1 27.6 15.5 1.80 5.6E–2
Table 2. Transcription factors (Term) associated to down-regulated genes in treated U343 cells (cisplatin combined to
LY294002) vs. control. “Percentage with term” corresponds to the amount of genes that was associated to each TF in
each list: list #1 represents the down-regulated genes obtained in the statistical analysis, and list #2 represents all
genes present in the microarray slide. An “Enrichment index” was calculated for each Term by dividing the percentage
in the list #1 by that in the list #2.
GATA-3, as already described above, was found associated with both up- and down-regulated
genes. This could be due to the dual activity of this TF, which acts as a positive or negative
regulator of transcription. GATA-3 also participates in the negative regulation of cell prolifer‐
ation process, which can be triggered as a response to drug treatments. Accordingly, we found
GATA-3 association with down-regulated genes (EI = 1.45) after drug treatment in U343 cells.
EVI-1, also known as RUNX1 (Runt-related transcription factor 1), is a positive regulator of
transcription related to peripheral nervous system, neuron development, hematopoietic stem
cell proliferation, and angiogenesis, among other functions. Due to its role in hematopoietic
and nervous systems, deregulation of this TF results in hematological disorders [59-62] and
central nervous system diseases [63]. Recently, Satoh et al. [64] reported that the C-terminal
deletion of RUNX1 attenuates DNA-damage repair responses in hematopoietic stem/progen‐
itor cells, and additionally, they found that RUNX1 directly regulates the transcription of
GADD45A gene, which is involved in cell cycle arrest. Association of EVI-1 with down-
regulated genes (EI = 1.31) presumably indicates an impaired function of this TF in U343 cells,
since it is expected to positively regulate the gene targets.
HNF-1 is also named HNF1A (Hepatocyte Nuclear Factor 1 Alpha) and TCF-1 (Transcription Factor
1). This TF, previously related to diseases such as diabetes and neoplasias [65-70], encodes a
protein involved in the WNT signaling pathway [71]. The activation of this pathway has been
pointed as one of the main causes of colon cancer; in addition, it has been reported that HNF1A
plays an important role in transduction of this pathway in the intestine [72]. Furthermore, Roth
et al. [73] demonstrated alterations in the regulation of WNT signaling pathway in glioma cells.
Inhibition of genes participating in the WNT pathway promote blockage of tumor growth
[74].This is compatible with reduction in cell survival after drug treatment in GBM cells which
may be most likely due to down-regulation of several genes regulated by HNF1A.
USF1 (Upstream transcription factor 1), another TF predicted in our analysis, is a gene with
known functions in cellular responses under stress conditions, such as UV and hypoxia. In
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breast tumors, a role for USF1 in regulating the expression of estrogen receptor alpha (ERalpha)
has been demonstrated [75]. Recently, Baron et al. [76] demonstrated a role for USF-1 in
maintaining genome integrity in response to UV-induced DNA photolesions. Additionally,
using a mouse knock out model, the authors showed that the loss of USF-1 compromises DNA
repair, suggesting that USF-1 may play a similar role in human cells. However, in the present
study, USF1 was found associated with down-regulated genes (EI = 1.31) in U343 and the role
of USF1 remains to be investigated in tumor cells.
CDX represents a gene family of caudal-related homeobox TFs, composed of the following
members: CDX1, CDX2, and CDX4. All these members participate in the regulation of
intestine-specific gene expression, and also in anterior-posterior pattern specification and
blood vessel development. These TFs have been found associated with several neoplasias,
including esophageal [77, 78], gallbladder [79], liver [80], colorectal [81-83], and pancreatic [84],
but their role in drug responses is still unknown.
AP-1 (presented EI = 1.8) is a TF complex formed by proteins of the JUN family dimerized with
members of the FOS gene family, which consists of 4 members (FOS, FOSB, FOSL1, and
FOSL2) that encode leucine zipper proteins. All these genes are oncogenes with established
roles in neoplastic cell transformation [85-87], prostatic [88], colorectal [89, 90], liver [91, 92],
stomach [93], and breast cancers [94]. Interestingly, Hamdi et al. [95] demonstrated the roles
of AP-1 components, ATF3 and FRA1 (FOSL1), in JNK- and ERK-dependent cell cycle arrest
and apoptosis after cisplatin or UV-light treatments, by activating both JNK and ERK pathways
in human glioblastoma cells lacking functional TP53. Recently, Meise et al. [96] showed that
FOSL1 (FRA1) was up-regulated in glioblastoma cells following nimustine (ACNU) treatment.
Thus, it becomes apparent that the AP-1 complex also participates in drug responses, and could
be activated by combined treatment of cisplatin and LY294002 in GBM cells.
Therefore, TFs associated with down-regulated genes are critical participants in several
biological processes such as neuron development, WNT signaling pathway, cellular response
under stress conditions, and neoplastic cell transformation. It seems that all these TFs work in
a concerted manner to regulate several genes leading to initiation of cellular responses after
the combined treatment of cisplatin and LY294002 in GBM cells. Since most of the TFs predicted
by us were not included in the gene arrays, expression of these TFS after drug treatment could
not be verified. Further experiments are certainly warranted to understand their concerted
roles in understanding the cellular response mechanisms to cisplatin and LY294002.
TFs and cis-regulatory elements are considered key components for transcription regulation
[97]. Specific TFs can be involved in the control of co-expressed genes [98], and these genes
tend to participate in related pathways, for example, cell cycle control and apoptosis [99, 100].
Thus, search for the common TFs that control the transcription of a specific group of genes
such as those involved in DNA repair or replication may provide biomarkers, which can be
potential targets for therapeutic intervention [101]. Interestingly, some of the predicted TFs
were recently reported to be associated with DNA repair/DNA damage responses in human
cells, but few were reported in GBM. Nevertheless, the TFs predicted by in silico analysis
described above may be useful for understanding how the transcription machinery responds
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regulator of transcription. GATA-3 also participates in the negative regulation of cell prolifer‐
ation process, which can be triggered as a response to drug treatments. Accordingly, we found
GATA-3 association with down-regulated genes (EI = 1.45) after drug treatment in U343 cells.
EVI-1, also known as RUNX1 (Runt-related transcription factor 1), is a positive regulator of
transcription related to peripheral nervous system, neuron development, hematopoietic stem
cell proliferation, and angiogenesis, among other functions. Due to its role in hematopoietic
and nervous systems, deregulation of this TF results in hematological disorders [59-62] and
central nervous system diseases [63]. Recently, Satoh et al. [64] reported that the C-terminal
deletion of RUNX1 attenuates DNA-damage repair responses in hematopoietic stem/progen‐
itor cells, and additionally, they found that RUNX1 directly regulates the transcription of
GADD45A gene, which is involved in cell cycle arrest. Association of EVI-1 with down-
regulated genes (EI = 1.31) presumably indicates an impaired function of this TF in U343 cells,
since it is expected to positively regulate the gene targets.
HNF-1 is also named HNF1A (Hepatocyte Nuclear Factor 1 Alpha) and TCF-1 (Transcription Factor
1). This TF, previously related to diseases such as diabetes and neoplasias [65-70], encodes a
protein involved in the WNT signaling pathway [71]. The activation of this pathway has been
pointed as one of the main causes of colon cancer; in addition, it has been reported that HNF1A
plays an important role in transduction of this pathway in the intestine [72]. Furthermore, Roth
et al. [73] demonstrated alterations in the regulation of WNT signaling pathway in glioma cells.
Inhibition of genes participating in the WNT pathway promote blockage of tumor growth
[74].This is compatible with reduction in cell survival after drug treatment in GBM cells which
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and apoptosis after cisplatin or UV-light treatments, by activating both JNK and ERK pathways
in human glioblastoma cells lacking functional TP53. Recently, Meise et al. [96] showed that
FOSL1 (FRA1) was up-regulated in glioblastoma cells following nimustine (ACNU) treatment.
Thus, it becomes apparent that the AP-1 complex also participates in drug responses, and could
be activated by combined treatment of cisplatin and LY294002 in GBM cells.
Therefore, TFs associated with down-regulated genes are critical participants in several
biological processes such as neuron development, WNT signaling pathway, cellular response
under stress conditions, and neoplastic cell transformation. It seems that all these TFs work in
a concerted manner to regulate several genes leading to initiation of cellular responses after
the combined treatment of cisplatin and LY294002 in GBM cells. Since most of the TFs predicted
by us were not included in the gene arrays, expression of these TFS after drug treatment could
not be verified. Further experiments are certainly warranted to understand their concerted
roles in understanding the cellular response mechanisms to cisplatin and LY294002.
TFs and cis-regulatory elements are considered key components for transcription regulation
[97]. Specific TFs can be involved in the control of co-expressed genes [98], and these genes
tend to participate in related pathways, for example, cell cycle control and apoptosis [99, 100].
Thus, search for the common TFs that control the transcription of a specific group of genes
such as those involved in DNA repair or replication may provide biomarkers, which can be
potential targets for therapeutic intervention [101]. Interestingly, some of the predicted TFs
were recently reported to be associated with DNA repair/DNA damage responses in human
cells, but few were reported in GBM. Nevertheless, the TFs predicted by in silico analysis
described above may be useful for understanding how the transcription machinery responds
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to chemotherapeutic agents in GBM cells. Further studies are required to get insights regarding
the role of TFs identified by us in modulating the drug response of GBM cells.
3.4. Signaling pathways involved in drug responses
In addition, data obtained on differentially expressed genes between treated (cisplatin
combined to LY294002) and control U343 cells were submitted to a pathway analysis, using
tools available in the Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 [102]. The KEGG pathway analysis was selected and pathways presenting p-
values ≤ 0.05 were chosen.
Signaling pathway analysis was performed by means of tools available in DAVID, as previ‐
ously described. This analysis allowed the identification of common biological pathways
mapped in the KEGG pathway database, in which the up-regulated genes in treated U343 cells
are involved. Three pathways were significantly associated with up regulated genes (Table
3), among which two are related to the inositol molecule (inositol phosphate metabolism and
phosphatidylinositol signaling system); three genes (PIK3C3, PIP5K1B, OCRL) were included
as participants of both pathways. The TP53 signaling pathway was also associated which
included three important genes: ATR, CCNG1 and SESN1. These results are consistent with
earlier studies demonstrating the activation of these signaling pathways under drug treat‐
ments [103-105].
KEGG term Genes* p-value
hsa00562: Inositol phosphate metabolism PIK3C3, PIP5K1B, OCRL 3.3E–2
hsa04115: TP53 signaling pathway ATR, CCNG1, SESN1 5.0E–2
hsa04070: Phosphatidylinositol signaling system PIK3C3, PIP5K1B, OCRL 5.0E–2
* Genes participating in each pathway
Table 3. Cellular signaling pathways associated with up-regulated genes in treated U343 cells (cisplatin combined to
LY294002), as analyzed by tools available in DAVID.
The PIK3C3 gene (Phosphoinositide-3-kinase, class 3) participates in the innate immune response
and cell cycle. This gene also plays an essential role in regulating functional autophagy and is
crucial for normal liver and heart function [106]. PIP5K1B (Phosphatidylinositol-4-phosphate 5-
kinase, type I, beta) is involved in the biosynthesis of phosphatidylinositol 4,5-bisphosphate. The
OCRL gene (Oculocerebrorenal syndrome of Lowe) encodes a phosphatase enzyme with a
demonstrated role in actin polymerization, and it is an important participant in the trans-Golgi
network. Mutations in this gene cause oculocerebrorenal syndrome of Lowe and also Dent
disease [107].
The protein encoded by the ATR gene (Ataxia telangiectasia and Rad3 related) act in the cell cycle
checkpoint and is required for cell cycle arrest and DNA damage repair in response to DNA
damage. The ATR gene belongs to the PI3/PI4-kinase family, as well as ATM and DNA-PK,
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and is known as playing an important role in cellular response to cisplatin [108-110]. The
aberrantly activated antiapoptotic phospatidyl-3-inositol-kinase (PI3K)/Akt signaling is
induced by cisplatin and restricts the efficiency of chemotherapy [49]. The CCNG1 gene (cyclin
G1) plays a role in cell cycle and growth, brain development and G2/M checkpoint, acting in
the negative regulation of apoptotic process. Altered regulation of this gene was observed in
breast cancer [111], and leukemia [112]. SESN1 (Sestrin 1) is responsible for the negative
regulation of cell proliferation, acting in cell cycle arrest in response to DNA damage stimulus.
This gene was found differentially induced by genotoxic stress (UV, gamma-irradiation and
cytotoxic drugs) in a TP53-dependent manner, presenting properties common to the GADD
family of growth arrest and DNA damage-inducible stress-response genes [113].
Therefore, we found relevant pathways related to TP53 (cell cycle arrest and DNA repair) in
response to DNA damage, as well as to the inositol phosphate metabolism and signaling.
Furthermore, several predicted TFs associated with modulated genes participate in “basal vital
processes”, and these processes include the inositol metabolism and signaling, highlighting
the importance of these pathways in cellular response mechanisms after drug treatment.
However, it is not known whether the observed sensitivity of GBM to cisplatin and LY294002
is due to disruption of some of the above-mentioned vital processes through inhibition of PI3K
dependent signaling pathways. A likely possibility that needs consideration is that several
sub-pathways can be inactivated/activated due to loss of major tumor suppressor genes such
as PTEN, which negatively regulates PI3K/AKT pathways [114] in TP53 proficient U343 GBM
cell line. [115]. Furthermore, TP53 pathway, which has been extensively studied in cancer, was
also involved in U343 cell line after drug exposure.
3.5. Conclusion
Identification of TFs associated with a set of differentially expressed genes is an interesting
approach that may allow to interpret mechanisms triggered in a cellular milieu after a given
treatment condition. In the context of cancer research, differential expression of genes and
pathways in response to drug treatment may either result in tumor growth reduction or cell
killing.
Beside the relevance of our findings, some methodological limitations should be mentioned
regarding in silico prediction of TFs. Numerous TF binding sites exist for each of the gene
targets and it is hard to predict which binding site is critical for transcriptional regulation. It
is possible that a considerable fraction of these binding sites are nonfunctional and may
constitute biological noise [116]. Other choices, such as ChIP experiments, may overcome this
concern by detecting indirect TF-DNA interactions through protein/protein interaction [117].
Even though most of the predicted TFs we identified in our study have not been specifically
shown to be associated with GBM in previous studies, they can be considered as potential
predictors for evaluating the effectiveness of drug response in GBM. Further verification and
validation of the TFs involved in GBM may provide useful information for developing novel
therapeutic strategies for brain tumors.
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1. Introduction
Malignant glioma (MG), consisting of anaplastic glioma (AA, WHO grade III) and glioblas‐
tomamultiforme (GBM, WHO grade IV, 60-70%), is the most common and destructive brain
tumor [1]. Despite systemic treatment, surgical resection followed by radiotherapy and che‐
motherapy, the prognosis of patients with GBM remains poor with a median survival of 12
to 15 months and a 5-year survival rate of 9.8% [2, 3]. The dismal outcome fuels the need to
understand the molecular basis of gliomagenesis and identify novel therapeutic targets for
MG treatment.
With a developing understanding of core aberrant signaling pathways in MG, molecular tar‐
geted therapy has shown certain promise as a more rational strategy. Established targets, in‐
cluding receptor tyrosine kinases (RTK) such as EGFR, PDGFR and VEGFR, as well as
mTOR, farnesyl transferase and PI3K, have drawn particular interests both in fundamental
and clinical research. However, single targeted agents so far have not displayed desirable
clinical outcomes as expected, with response rates of 0 to 15% and no prolongation of 6-
month progression-free survival [4–6]. This disappointing outcome is primarily due to the
nature of cancer with multi-genetic abnormality and inter/intra-tumor heterogeneity. There‐
fore, multiple targeting strategies are essential to achieve better clinical benefits.
MicroRNA (miRNA), a type of endogenous small non-coding RNA which negatively modu‐
lates gene expression in post-transcriptional level, has rapidly become a topical issue since it
was firstly discovered in C. elegans two decades ago[7]. Increasing researches have reported
that dysregulation of miRNA is closely associated with tumorigenesis and tumor progres‐
sion. In gliomas, a group of miRNAs have been characterized as oncogenic and tumor-sup‐
pressive molecules. With a unique feature of multi-targeting, miRNA may become a new
powerful weapon fighting against MG. Although much remains to be learned about formu‐
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lating miRNAs as nucleic acid drugs, we feel that identification of miRNAs as therapeutic
targets for gliomas is now within sight.
In this chapter, we will critically review issues relevant to contemporary researches on miR‐
NAs and MG. Based upon other teams’ and our data, this review will present findings on
oncogenic and tumor-suppressive properties of miRNA in MG, focusing on the mechanisms
of dysregulation, the involvement with core pathways of MG and the functional heterogene‐
ity in different context. Besides, we will formulate evidences for miRNA-based clinical ap‐
plication in diagnosis and therapeutics of MG. The developing cognition of miRNAs will
ultimately lead to innovative clinical approaches for MG.
2. Oncogenic and tumor-suppressive miRNAs in malignant gliomas
The very first oncogenic miRNA indentified in GBM is miR-21 as early as 2005 [8], although
whose target genes were not fully understood at that time. In 2008, another group identified
a set of targets of this miRNA which constitute a tumor-suppressive network including
TGF-β, p53 and mitochondrial-apoptotic pathways [9]. This is one of the examples showing
the multi-targeting nature of miRNAs in oncology. Beyond multi-targeting, these findings
also prompt a hypothesis that miRNAs may have pathway preference in some cases.
Coincidently, also in 2005, S.A. Ciafreet al. firstly described that brain-enriched miR-128 and
miR-181 family were frequently down-regulated in primary GBMs and cell lines [10], whose
tumor-suppressive roles of these miRNAs were subsequently validated in the next few
years [11–14].
In 2008, a milestone has been made in glioma research, accomplished by The Cancer Ge‐
nome Atlas (TCGA) Research Network. Through integrative analysis of DNA copy number,
gene expression and DNA methylation aberrations, TCGA defined three major pathways in
GBM, which are RTK, p53 and RB signaling pathways, as shown in Figure 1 [15]. These
pathways cannot be more familiar to every oncologist: frequently activated RTK signaling in
cancer supports cell proliferation and survival, whereas p53 and RB signaling monitor cell
cycle transition and couple to apoptosis and senescence pathways, which are commonly
suppressed in cancer. To date, increasing oncogenic and tumor-suppressive miRNAs in
MGs have been uncovered. In combination with genomic sketch of GBM described by
TCGA, we have a deeper insight into the interactions within the core pathways of MG,
which are controlled in coding and non-coding levels (Figure 1).
Here we do not pay our attention to the detail of each single miRNA, since several reviews
have provided considerable details about their expression and function [16–18]. In this pa‐
per, we prefer to focus on how these miRNAs become aberrant, and which malignant phe‐
notypes they contribute to.
As well as every protein coding gene, non-coding miRNA genes may similarly undergo
over or lost expression, amplification, deletion, insertion, translocation and mutation, which
lead to aberration of miRNAs. The mechanisms of miRNA aberration have not yet been ex‐
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tensively studied. Nevertheless, there have been some clues showing that transcriptional ac‐
tivity, single nucleotide polymorphism (SNP) and chromosome deletion contribute to
aberrant genotype and malignant phenotype of MG.
The most interesting research addressing miRNA transcriptional regulation machinery in
MGs is the TP53 and miR-25/32 feedback circuitry [19]. Carlo M. Croce’s and co-workers
found that miR-25 and miR-32 are negatively regulated by TP53 via repressing their tran‐
scriptional factors MYC and E2F1. Intriguingly, by directly targeting MDM2 and TSC1, these
miRNAs help stabilize P53 protein and suppress tumorigenicity in U87 GBM cells. Thus, a
fine tuned recurrent autoregulatory circuit form. However, in the non-functional mutant
TP53 context, miR-25/32 support cell proliferation per contra. These findings not only pro‐
vide insights into the interaction between miRNAs and TP53 tumor-suppressive pathway,
but also hint that a given miRNA may have distinct function in different genetic and bio‐
chemical status.
It is unexpected that miRNA genes rarely exhibit SNP or mutation within the major mature
sequence segment, although which can be commonly found in the precursor (including the
minor mature sequence which is formerly called the star sequence) and primary miRNA
segments. Through mining human SNP database, Peng Jin’s group identified a G>U poly‐
morphism located in the eighth nucleotide of the mature miR-125a-5p. The U allele blocks
the processing from pri-miRNA to miRNA precursor by altering the secondary structure,
and impairs miRNA-mediated translational suppression [20]. MiR-125s have been demon‐
strated to be tumor-suppressive in GBM [21–23]. However, such nucleotide alteration has
not yet been described in glioma clinical data. The rs11614913 SNP, which locates in the seg‐
ment producing minor mature miR-196a-3p (termed miR-196a* previously), was firstly
found to be associated with the risk of glioma in Chinese population [24]. Recent clinical
study indicates that the rs2910164 in segment containing minor mature miR-146a-3p se‐
quence is also relative to the risk and prognosis in adult glioma [25]. These findings improve
our understandings of miRNA-related pathogenesis and diagnostics in gliomas. Further re‐
search is required to fully comprehend the exact mechanisms underlying the relationship
between miRNA gene SNPs and clinical outcomes, which may have huge clinical potential.
Chromosome alteration undoubtedly contributes to miRNA aberration. Particularly in dif‐
fuse astrocytoma (DA, WHO II) and AA, chromosome 7q32 is a hotspot that frequently am‐
plifies. This region embraces eight miRNAs: miR-593, miR-129-1,miR-335, miR-182, miR-96,
miR-183, miR-29a and miR-29b-1. Among these miRNAs, our group recently reported that
miR-335 is the most striking target in AA [26]. We have demonstrated that miR-335 confers
invasive and proliferative malignant phenotype on astrocytoma via targeting DAAM1. Dis‐
rupting miR-335 by cholesterylated miRNA inhibitor abrogates invasion and elicits apopto‐
sis both in vitro and in vivo. Chromosome amplification in cancer often creates abnormal
high level of coding and non-coding products that subsequently infests the well-balanced
signaling. Currently, drug screening and discovery in oncology specifically focus on over-
expressed protein and over-activated kinase. We believe that miRNA, such as miR-335, may
also be the target for drug development in the future.
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Figure 1. Interaction between microRNAs and core pathways in malignant gliomas.
3. Dual scripts for a miRNA
In the last session we have mentioned that miR-25/32 functions differently depended on
TP53 status in GBM. It is not the sole evidence that a given miRNA plays distinct roles in
respective models. In fact, miRNAs show complicated functional heterogeneity.
One of the examples is miR-135a/b. Remco Nagel et al. found increased expression levels of
miR-135a and miR-135b during colorectal cancer progression, which target the tumor sup‐
pressor gene Adenomatous Polyposis Coli (APC)[27]. The oncogenic role of miR-135a was
further confirmed by BR Zetter’s group. They demonstrated that paclitaxel resistance is as‐
sociated with up-regulation of miR-135a in multiple solid tumor cell lines. Knocking-down
of miR-135a acquires susceptibility to paclitaxel[28]. However, in classic Hodgkin lympho‐
ma (cHL), miR-135a directly regulates JAK2, thus suppressing the expression of BCL2L1 (al‐
so known as BCL-XL) and inducing apoptosis. Furthermore, higher level of miR-135a
indicates better disease-free survival in cHL patients [29]. Likewise our group has also char‐
acterized that miR-135a functions as a selective killer of MG. We have reported that glial
cell-enriched miR-135a is frequently down-regulated in MG and negatively correlates with
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the pathological grading of gliomas. Ectopic delivery of miR-135a selectively triggers mito‐
chondrial dependent apoptosis in MG in vitro and in vivo. Interestingly, this lethal effect is
neutral in normal glial cells and neurons [30].
MiR-335 gives us another example of the dual role nature of miRNAs. An early study identi‐
fied that miR-335 suppresses breast cancer metastasis and migration through targeting
SOX4 and TNC [31]. However, as mentioned above, our recent research found that this miR‐
NA promotes invasion and proliferation in AA [26]. In this way, miRNAs seems to have
cell-type-dependent functional heterogeneity. The definition of “tumor-suppressive” and
“oncogenic” should be carefully employed depended on the cell types and diseases.
Even within the same cell type, the functional behavior of a given miRNA can also be di‐
verse. Previously we have reported that activation of cAMP/PKA pathway, manipulated by
Cholera toxin, induces cellular differentiation of MG, showing malignant phenotype rever‐
sion and potent GFAP (glial fibrillary acidic protein) expression [32]. As it has been well
characterized, we found that IL-6/JAK2/STAT3 contributes to GFAP expression in this mod‐
el [33]. Notably, epigenetic mechanism is also involved. In this context, the so-called onco‐
genic miR-335 in MG induced by Cholera toxin enhances GFAP expression in MG cell lines
and primary cultures [34]. Multi-targeting is one of the natures of miRNAs. Signaling net‐
works composed of target genes and their relative molecules may both contribute to tumor-
suppressive and oncogenic function. It seems that the oncogenic functions of miR-335 are
hindered under a high endogenous level of cAMP, rewiring to pro-differentiation pathways.
To sum up, the role of a given miRNA depends on the script which is assigned by the cell
type, the genomic context and in part the cellular biochemical status. These observations re‐
mind that disease state as well as the genomic subclass of MGs should be considered in the
preclinical study especially for drug discovery involved miRNAs.
4. Involvement of miRNAs as novel biomarkers in malignant gliomas
Biomarkers are distinctive biological indicators that serve for diagnosis, prognosis and med‐
ication. Traditional biomarkers include mRNAs, proteins and metabolites. At present, miR‐
NAs are emerging as novel and practical biomarkers in oncology. Due to their surprising
stability, miRNAs can not only be detected in fresh and frozen tissues, but also in body flu‐
ids and even formalin-fixed paraffin-embedded samples. In the study of Roland Schroers,
miR-15b and miR-21 are found in cerebrospinal fluid and demonstrated to be markers of
glioma [35]. Although much remains to be studied, e.g. to discover more accurate and specif‐
ic markers for respective glioma types, this finding provides a new opportunity to develop
less invasive and early diagnostic approach for gliomas.
Besides diagnosis, miRNAs may be promising biomarkers for prognosis. Jun Li’s group has
reported that miR-182 is markedly up-regulated in various glioma cell lines and primary
glioma specimens. Furthermore, higher level of miR-182 is associated with poor overall sur‐
vival of patients with malignant glioma [36]. A more comprehensive study was recently car‐
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ried out by Sujaya Srinivasan, et al. They analyzed miRNA expression profile of GBM
patients (n = 222) from TCGA database and found a ten-miRNA expression signature that
predicts survival for GBM. In detail, three miRNAs (miR-20a, miR-106a and miR-17-5p)
were identified as protective markers and seven miRNAs (hsa-miR-31, hsa-miR-222, hsa-
miR-148a, hsa-miR-221, hsa-miR-146b, hsa-miR-200b and hsa-miR-193a) were risky [37].
Recent studies have raised a possibility that miRNAs may function as predictive markers for
therapeutics. Temozolomide (TMZ) is a well-known alkylating agent against gliomas, which
methylates guanines in the O-6 position. Accumulating O-6 methyl guanines lead to DNA
mismatch during replication and ultimately result in cell death. Although MGMT (methyl-
guanine methyl transferase) promoter methylation has been proved to be a strongest marker
to predict the TMZ response in low-grade and high-grade gliomas [38–40], it may not be the
only indicator. Recent research indicates that miR-181b/c, miR-195, miR-455-3p and
miR-10a-3p, rather than MGMT promoter methylation, predict response to concomitant che‐
moradiotherapy and acquired TMZ resistance in GBM cell line and patients [41, 42]. In addi‐
tion, increasing evidences indicate that miRNAs also contribute to other drug response. For
instance, up-regulated miR-21 confers teniposide and paclitaxel resistance on GBM cells [43,
44]. Various highly efficient MGMT inhibitors have been developed for sensitizing tumor to
TMZ [45]. The emerging roles of miRNAs in drug resistance of TMZ and other antineoplas‐
tic agents give us a novel angle to include miRNAs as therapeutic targets.
5. Perspectives on miRNAs as nucleic acid drugs in malignant gliomas
5.1. MiRNAs replacement therapy and suppressive therapy
Human body has an extremely complicated internal environment, relying on balance and
stability of which human keep their health. Once the homeostasis is disrupted by down-reg‐
ulation or up-regulation of some important molecules including miRNAs, human will suffer
from all kinds of diseases. Based on the disequilibrium status, the ideal protocols to cure dis‐
eases are believed to replace what is lost and to repress what is excessive, which are respec‐
tively called replacement therapy and suppressive therapy. For the former, estrogen
replacement therapy is the most representative example, which is generally used in meno‐
pausal women with menopausal syndrome caused by ovarian hormones loss and has
shown a positive effect [46]. For the latter, a typical case is a famous anti-angiogenesis drug
Avastin, the humanized anti-vascular endothelial growth factor (VEGF) monoclonal anti‐
body for cancer therapy [47]. Besides, Gefitinib and Glivec specially inhibiting EGFR tyro‐
sine kinase, have both achieved high clinical benefit rates in treating cancer especially lung
carcinoma and chronic myelocytic leukemia[48,49], further indicating the efficacy of sup‐
pressive therapy via targeting core molecules in tumorigenesis.
Notably, increasing evidences demonstrated that gliomagenesis is also closely associated
with deregulation of miRNAs, such as up-regulation of oncogenic miRNAs and down-regu‐
lation of tumor suppressive miRNAs. Therefore, targeting these aberrant miRNAs has tre‐
mendous potential as a therapeutic strategy by down- or up-regulating altered genes.
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Specially, miRNA mimics can be synthesized to replace lessened ones critical in gliomagene‐
sis, and miRNA inhibitors can be designed to suppress the function of up-regulated onco‐
genic miRNAs. Just less than two decades after discovering the role of miRNAs in oncology,
the replacement and suppressive therapies of miRNA are already being used in preclinical
researches. We have proved that artificially rectification of abnormally expressed miRNAs
inhibited growth of glioma xenografts in mice and prolonged the median survival of rat
with orthotopic glioma[26,30], opening a new sight for glioma treatment.
5.2. MiRNA-targeting cocktail therapy
Glioma is a complicated disease of altered genes. TCGA has reported multiple chromosomal
aberrations, nucleotide substitutions and epigenetic modifications that construct three core
pathways (as shown in Figure 1] [15]. Furthermore, glioma is a disease of altered miRNAs.
A genome-wide expression profiling of 26 GBMs, 13 AAs and 7 normal brain samples iden‐
tifies multiple deregulated miRNAs in MGs [50]. In addition, large scale of sequencing anal‐
ysis of GBMs has identified extensive genetic heterogeneity between GBM samples from
different patients [51], implying the possibility of miRNA's heterogeneity. The multiplicity
of deregulated miRNAs and the heterogeneity of deregulated miRNAs expression profiling
may foster therapeutic failure and tumor adaptation to solo miRNA-targeting therapy.
To date, researchers just verified the efficiency of targeting solo miRNA as if by prior agree‐
ment. What will happen if target several pivotal miRNAs simultaneously? Given the multi‐
plicity of deregulated miRNAs in glioma, a cocktail consisting of special miRNA mimics
and/or inhibitors may kill multiple birds with one stone. In another word, components in
cocktail may have an additive effect or even a synergistic effect against MGs. Furthermore,
considering individual differences, one cocktail may not fit for each patient with MGs. If we
can design a specific miRNA cocktail based on individual deregulated miRNAs, miRNA in‐
dividualized treatment will be within our sights. Certainly, additional preliminary eviden‐
ces are needed to verify the feasibility and availability of miRNA-targeting cocktail
therapeutics.
5.3. Engineering miRNA
Engineering miRNA (emiRNA) is artificially designed in sequence, endowed with function‐
al similarity to natural miRNA and functional specificity according to human’s will. In a
sense, emiRNA is a branch of small interfering RNA (siRNA) that possesses multi-targeting
power just as natural miRNA.
Leastwise, there are two strategies to design emiRNA: (a) adjustment based on the natural
miRNA sequence; (b) de novo design.
In the sessions above, we have discussed the fact that a given miRNA may play distinct role
in different models, e.g. different genetic background, different cell type and different sec‐
ond messenger level. Even in a “conclusive”circumstance that a certain miRNA strongly
kills a type of cancer cell, we still need to evaluate its pharmacodynamics in the cancer tissue
and toxic side effect to the normal tissue before clinical application. If a natural sequence
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plicity of deregulated miRNAs in glioma, a cocktail consisting of special miRNA mimics
and/or inhibitors may kill multiple birds with one stone. In another word, components in
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ces are needed to verify the feasibility and availability of miRNA-targeting cocktail
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al similarity to natural miRNA and functional specificity according to human’s will. In a
sense, emiRNA is a branch of small interfering RNA (siRNA) that possesses multi-targeting
power just as natural miRNA.
Leastwise, there are two strategies to design emiRNA: (a) adjustment based on the natural
miRNA sequence; (b) de novo design.
In the sessions above, we have discussed the fact that a given miRNA may play distinct role
in different models, e.g. different genetic background, different cell type and different sec‐
ond messenger level. Even in a “conclusive”circumstance that a certain miRNA strongly
kills a type of cancer cell, we still need to evaluate its pharmacodynamics in the cancer tissue
and toxic side effect to the normal tissue before clinical application. If a natural sequence
Evolvement of microRNAs as Therapeutic Targets for Malignant Gliomas
http://dx.doi.org/10.5772/52672
489
miRNA shows remarkable antitumor effect but exhibits unsatisfying selectivity, does it
mean we should totally abandon this target? The problem may be solved by emiRNA tech‐
nology. Different dominant target genes and their roles in different models determine the
functional heterogeneity of a given miRNA. If we are able to find out the undesired targets
that lead to unsatisfying selectivity, perhaps by keeping the seed region of the miRNA and
adjusting its 3’ nucleotide sequence, we could either avoid the interaction between the miR‐
NA and the undesired target genes, or enhance the binding to our goal targets.
In broader context, we could design an artificial miRNA in a de nove way. Cancers are
known as a type of multigenic disease. By comprehensive sequencing, RTK/RAS/PI[3]K, p53
and RBsignalings are characterized as the core pathways in GBM [15]. In virtue of bioinfor‐
matics, it is possible to design a miRNA that contemporaneously targets the key compo‐
nents of two or more pathways by carefully examining their mutual microRNA recognition
elements (MREs).
However, numbers of scientific problems need to be addressed before putting emiRNA into
practice. We still have limited knowledge about the details of miRNA biogenesis and the
MRE language passing on along evolution. Someday the secret will be unlocked and emiR‐
NA may be a practical weapon against cancers.
5.4. MiRNA formulation
Another attractive issue of translating miRNA into clinical application is formulation. Al‐
though whose length is quite short in the RNA world, miRNA as well as siRNA is a type of
high molecular weight drug in pharmaceutical point of view. Additionally, electric charge
contributed by phosphate groups of the nucleic acid backbone make it inadequate for CNS
delivery. Fortunately, new technical progress brings miRNA formulation within sight.
In the earlier period, viral vector including retrovirus, adenovirus, herpes simplex virus and
adeno-associated virus were broadly used due to their high efficiency for both gene delivery
and expression. However, limitations associated with safety, genomic stability and immuno‐
genicity motivate scientists to focus on non-viral systems. At present, remarkable achieve‐
ments have been made in chemical modifications and conjugations of small RNA. For
example, locked nucleic acid (LNA) technology not only increases melting temperature of
RNA-RNA duplex thus enhancing the binding affinity between small RNA and target tran‐
script, but also improves the half-life of small RNA in serum, which is critical for therapeutic
use [52]. Cholesterylation, viz. modification with cholesteryl functionality, which improves
the cellular uptake of small RNA, is now extensively used for miRNA mimics/inhibitors and
siRNA in preclinical research [53]. Two reviews have provided clear and comprehensive in‐
troduction of the progress on chemical small RNA encapsulation [54, 55]. Particularly, a re‐
cent study from Paula Hammond and colleagues reported a self-assembled microsponges of
small RNA hairpin polymersin corporated more than half a million copies of siRNA in a sin‐
gle nanoparticle [56]. This novel technology allow one thousand times lower concentration
to achieve same degree of gene silencing efficiency as conventional strategies, showing great
clinical application potential. In the near future, small RNA formulation will further benefit
from evolution of nanotechnology and biomaterial technology.
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6. Concluding remark
Glioma is not the type of high incidence disease; however the depressive clinical outcomes
still threaten human health. Special location, rapid proliferation, invasive growth and mas‐
sive angiogenesis are the key issues that limit treatment for MG. In addition, extremely com‐
plicated histopathological and genomic classifications perplex fundamental and clinical
research.
With the evolution of new generation high through-put sequencing technology, clearer in‐
sights of driver mutations and core pathways in various cancers are gradually revealed in
the recent period [57–59]. According to these cancer genomic studies, we realize that not on‐
ly aberrant coding genes lead to cancers, but also non-coding components underneath the
iceberg. Twenty-year’s research on miRNA opens a new world of genetics and oncology.
More and more groups are dedicated to study the role of miRNA in cancer including glio‐
ma. Albeit fragmentary, accumulating data will offer deeper insights of glioma with more
systematic considerations.
Compared with other non-coding protagonists, e.g. histone modification and DNA methyla‐
tion, miRNA is the easiest role to be specifically manipulated, either by over-expression or
inhibition, which determines miRNA to be the star with enormous clinical potential. Al‐
though we have not drawn an elaborate picture of miRNA biogenesis, especially how pri‐
mary sequence and intra-cellular microenvironment influence secondary structure and
eventually contribute to processing and maturation, as well as the communication principles
between miRNA and MRE, we believe that technologies nowadays are poised to uncover
the law of miRNA in oncology. We envision that this intrinsic biomolecule will be the thera‐
peutic target for cancer.
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1. Introduction
MicroRNAs (miRNAs)are short 18–25 nucleotide small non-coding RNA molecules that
function to silence gene expression via sophisticated post-transcriptional regulation[1]. Since
their discovery in the early 1990s, these small molecules have been shown to play an important
regulatory role in a wide range of biological and pathological processes. Over 30% of human
messenger RNAs (mRNAs) are regulated by miRNAs[2]. miRNAs generated by the canonical
biogenesis pathway are transcribed as precursor RNAs from intergenic, intronic or polycis‐
tronic genomic loci by RNA polymerase II (Pol II). The primary miRNA (pri-miRNA) transcript
forms a stem–loop structure that is recognized and processed by the Drosha and DGCR8 RNase
III complex or the spliceosome apparatus in the nucleus. In the non-canonical miRNA
pathway, miRNAs are transcribed directly as endogenous short hairpin RNAs (endo-shRNAs)
or derive directly through splicing from introns that can refold into hairpins (mirtrons). The
trimmed precursor (pre-miRNA) hairpins from both canonical and non-canonical miRNA
pathways are then transported by an exportin 5 and RAN-GTP-dependent process to the
cytosol, where they are typically further processed by the Dicer and transactivation-response
RNA-binding protein (TRBP) RNase III enzyme complex to form the mature double-stranded
~22-nucleotide miRNA. Argonaute proteins (for example, AGO2)
then unwind the miRNA duplex and facilitate incorporation of the miRNA-targeting strand
(also known as the guide strand) into the AGO-containing RNA-induced silencing complex
(RISC). The RISC– miRNA assembly is then guided to specific target sequences in mRNAs.
The initial recognition of mRNAs by the RISC–miRNA complex is driven primarily by
Watson–Crick base-pairing of nucleotides 2 to 8 in the mature miRNA (termed the seed
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sequence) with specific mRNA target sequences chiefly located in the 3′ untranslated region,
and additional base-pairing affords greater affinity and targeting efficiency(Figure1)[3].
Given the pivotal regulatory role of miRNAs in a broad range of biological processes, it is not
surprising that miRNAs play a role in human cancers, including brain tumor. First, about 50%
of human miRNAs are located in cancer-associated genomic regions and fragile sites, sug‐
gesting that they might be the target genes underlying such aberrant intervals [5]. Second, the
advent of high-throughput detection method has promoted expression profiling of miRNAs
in normal and tumor tissues. Compared to normal tissues, anomalous levels of miRNA subsets
have been found in almost all tumor types examined [6, 7]. Third, miRNAs with tumor-
suppressive gene and oncogene-like properties have been described.
Since the first description of aberrant miRNA expression in glioblastomas and pituitary
adenomas in 2005 [8, 9], there have been increasing reports each year about miRNA deregu‐
lation and function in various brain tumors. In this chapter, we summarize the current findings
of miRNA study in brain cancers and discuss the diagnostic and therapeutic potential of
miRNAs, mainly in glioma.
Figure 1. The miRNA biogenesis pathway[4]
2. MiRNAs profile in brain tumor
CBTRUS obtained incidence data from 48 population-based cancer registries that include cases
of malignant and non–malignant (benign and uncertain) primary brain and central nervous
system tumors in the United States in 2004-2007. The most frequently reported histology is the
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predominately non–malignant meningioma, which accounts for 34% of all tumors, followed
by glioblastoma (17%). The predominately non-malignant pituitary and nerve sheath tumors
account for 13% and 9% of all tumors, respectively. Acoustic neuromas (defined by ICD-O-3
site code C72.4 and histology code 9560) account for 63% of all nerve sheath tumors(Figure2).
Only recently, the miRNAs attracted increasing attention as potential diagnostic or even
therapeutic tools in brain tumors. Profiling techniques to identify global expression patterns
of miRNAs in brain tumors have been widely used to uncover aberrantly expressed micro‐
RNAs in tumor genomes. Ciafrè et al. found nine (miR-10b, miR-130a, miR-221, miR-125b-1,
miR-125b-2, miR-9-2, miR-21, miR-25, miR-123) and four miRNAs (miR-128a, miR-181c,
miR-181a, miR-181b), respectively, out of 245 miRNAs to be up-/down-regulated in human
glioblastoma samples, and nine (miR-221, miR-23a, miR-24-2, miR-24-1, miR-23b,
miR-21,miR-222-prec, miR-191, miR-220) and seven miRNAs(miR-181a, miR-181b, miR-128b,
miR-197, miR-181c,miR-125b-2, miR-125b-1), respectively, to be up-/down-regulated in
human glioblastoma cell lines[10]. Chan et al.[8] demonstrated five (miR-21, miR-138, miR-347,
miR-291-5′, miR-135) and three miRNAs (miR-198, miR-188,miR-202), respectively, out of 180
miRNAs to be up- and downregulated in glioblastoma samples. Sasayama et al.[11] found
miR-10b, miR-21, miR-183, miR-92b and miR-106b to be up-, and miR- 302c*, miR-379, miR-329,
miR-134 and miR-369-3p to be downregulated in human glioblastoma samples. Other studies
reported several miRNAs to be significantly deregulated in glioma samples of Chinese patients
(including miR-34a, miR-15b, miR-200a and miR-146b) [12], or miR-29b, miR-125a and miR-149
to be downregulated in glioblastomas [13]. In an array study with 192 miRNAs, 13 miRNAs
(miR-101, miR-128a, miR-132, miR-133a, miR-133b, miR-149, miR-153, miR-154*, miR-185,
miR-29b, miR-323, miR-328, miR-330) were found to be downregulated and three miRNAs to
be upregulated (miR-21, miR-155, miR-210) in glioblastoma multiforme [14]. Another micro‐
array study identified 55 miRNAs out of 756 miRNAs to be upregulated and 29miRNAs to be
downregulated in malignant astrocytomas (primary and secondary glioblastoma and ana‐
plastic astrocytoma, respectively) compared to controls [15].
In additional to gliomas, miRNA profiling also had been discovered in some other brain
tumors. Ferretti et al were the first to identify signatures of a set of 248 miRNAs in a panel of
primary medulloblastomas and normal cerebellar controls using high throughput expression
profiles. They showed different expression profiles between normal brain and tumor and
between distinct tumor histotypes. In particular, they detected an upregulation of mir-21 and
miR-17-92 cluster (miR-17-5p, miR-20a and miR-19a) and a downregulation of miR-128a/b,
let-7, miR-124a, miR-103, miR-134, miR-138, miR-149, miR-181b, miR-9 and miR-125a, most of
them previously reported to be dysregulated in other brain tumor cell lines or nervous system
cancers [16]. Moreover, Recent microarray data reported a possible role of miRNAs in pituitary
adenomas. The first connection between pituitary adenomas and miRNAs was established by
Bottoni et al in 2005, that showed a downregulation of mir-15a and miR-16-1 in GH-secreting
and in PRL-secreting adenomas compared to normal pituitary tissue[8]. In 2007 Bottoni et al
explored the miRNAome of pituitary tumors by microarray. They found that 30 miRNAs are
differentially expressed between normal pituitary gland and pituitary adenomas. Among
them, miR-150, miR-152, miR-191, and miR-192 were found to be upregulated in pituitary
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adenomas, and miR-132, miR-128a, miR-136, miR-16-1, and let-7 are downregulated[17]. As
for meningioma, Feng Zhi et al found a list of 14 miRNAs that were differentially expressed
in meningioma compared to normal adjacent tissue(NAT)samples. Twelve miRNAs, including
miR-17-5p, miR-22-3p, miR-24-3p, miR-26b-5p, miR-27a-3p, miR-27b-3p, miR-96-5p,
miR-146a-5p, miR-155-5p, miR-186-5p, miR-190a and miR-199a were shown to be upregulated
by a factor greater than twofold, whereas two miRNAs, including miR-29c-3p and miR-219-5p,
were significantly downregulated[18].
3. Abberant miRNAs as prognostic and/or diagnostic marker for brain
tumor patients
The use of miRNAs as tumor biomarkers has gained growing interest in the last few years.
Accumulating evidence indicates that miRNA expression can be used as a prognostic and/or
diagnostic marker for brain tumor patients. Niyazi et al. separated 35 glioblastoma patients
into long- and short-term survivors. Then, they found that some miRNAs were significantly
different in two group, including miR-3163, miR-539, miR-1305, miR-1260 and let-7a. this is
the first dataset defining a prognostic role of miRNA expression patterns in patients with
glioblastoma[19]. Moreover, Ma also identified that MiR-196b is overexpressed and confers a
poor prognosis via promoting cellular proliferation in glioblastoma patients[20]. Costa et al
identified miRNAs that are over-expressed in ependymomas, such as miR-135a and
miR-17-5p, and downregulated, such as miR-383 and miR-485-5p. We have also uncovered
Figure 2. Distribution of All Primary Brain and CNS Tumors by Histology (N=226,791) CBTRUS Statistical Report: NPCR
and SEER Data from 2004-2007
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associations between expression of specific miRNAs which portend a worse prognosis. For
example, we have identified a cluster of miRNAs on human chromosome 14q32 that is
associated with time to relapse. We also found that miR-203 is an independent marker for
relapse compared to the parameters that are currently used. Additionally, we have identified
three miRNAs (let-7d, miR-596 and miR-367) that strongly correlate to overall survival[21].
4. Deregulated miRNAs regulated brain tumor cell phenotype
Increasing evidence supports the supposition that miRNAs play an important role in different
types of cancers and in various aspects of cancer biology. Abnormal miR levels in tumors have
important pathogenetic consequences: miRNAs may act as oncogenes or suppressor genes[22].
For examples, Calin et al. [23] identified two clustered miRNAs (miR-15a and miR-16-1) on
the minimal deletion region of chromosome 13q14 and showed that the levels of these miRNAs
were significantly reduced in the majority (68%) of B-cell chronic lymphocytic leukemia (CLL).
Both miRNAs target the anti-apoptotic gene BCL2, which is frequently overexpressed in CLL
[24]. These findings indicate that downregulation of miR-15a and miR-16-1 elevates BCL2
level, contributing to CLL formation and suggesting a tumor-suppressive role for both
miRNAs. In contrast, miR-17-92 showed marked upregulation in B-cell lymphomas. Enforced
expression of miR-17-92 cluster acted with c-myc to accelerate the onset of B-cell lymphoma
in a mouse model [25]. The data suggest that miR-17-92 cluster is a potential oncogene.
Recent evidence supports the ability of miRNAs to regulate brain tumor cell phenotype. We
had done some work to identified that miR-221 and miR-222 regulated their target expression
to co-modulated glioma cell phenotype, including proliferation, cell cycle, apoptosis and
invasion(Figure3)[26-28], and so on.
MiRNAs also regulated radio- and chemo-resistence of glioma. Hierarchical clustering
analysis of expression 1100 miRNAs in three glioma cell lines treated with clinically relevant
doses of radiation (2Gy) revealed significant (3-4 fold) up-regulation of several miRNA that
are implicated in stimulation of survival and proliferation of tumor cells [29]. The set of up-
regulated miRNAs includes miR-1285, miR-151-5p, and miR-24-1 that display beneficial effects
on tumors by inhibiting the core tumor suppressor p53 (miR-1285) and supporting migration,
local metastasis (miR-151-5p), and antiapoptosis (miR-24-1) [30]. Overall, activation of these
miRNAs might possibly increase tumor radioresistance in subsequent radiotherapy sessions
and stimulate motility of cancer cells thereby at least partially explaining the evidence on
enhanced migration of malignant glioma cells in response to radiotherapy [31]. The radiation
treatment of glioma cell lines with normal capacity to repair radiation-induced double strand
breaks (DSB) of DNA caused activation of let-7 [29], a family of miRNA that suppresses
proliferation of gliomblastoma cells [30] (Fig. 4). In contrast, in the radiosensitive human
glioma cell line M059J that is deficient in DNA-dependent protein kinase (DNA-PK) and has
a low activity of ATM, two key members of the non-homologous end joining pathway of DNA-
DSB repair, let-7 miRNA was down-regulated [30].
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adenomas, and miR-132, miR-128a, miR-136, miR-16-1, and let-7 are downregulated[17]. As
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the first dataset defining a prognostic role of miRNA expression patterns in patients with
glioblastoma[19]. Moreover, Ma also identified that MiR-196b is overexpressed and confers a
poor prognosis via promoting cellular proliferation in glioblastoma patients[20]. Costa et al
identified miRNAs that are over-expressed in ependymomas, such as miR-135a and
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Figure 2. Distribution of All Primary Brain and CNS Tumors by Histology (N=226,791) CBTRUS Statistical Report: NPCR
and SEER Data from 2004-2007
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associations between expression of specific miRNAs which portend a worse prognosis. For
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expression of miR-17-92 cluster acted with c-myc to accelerate the onset of B-cell lymphoma
in a mouse model [25]. The data suggest that miR-17-92 cluster is a potential oncogene.
Recent evidence supports the ability of miRNAs to regulate brain tumor cell phenotype. We
had done some work to identified that miR-221 and miR-222 regulated their target expression
to co-modulated glioma cell phenotype, including proliferation, cell cycle, apoptosis and
invasion(Figure3)[26-28], and so on.
MiRNAs also regulated radio- and chemo-resistence of glioma. Hierarchical clustering
analysis of expression 1100 miRNAs in three glioma cell lines treated with clinically relevant
doses of radiation (2Gy) revealed significant (3-4 fold) up-regulation of several miRNA that
are implicated in stimulation of survival and proliferation of tumor cells [29]. The set of up-
regulated miRNAs includes miR-1285, miR-151-5p, and miR-24-1 that display beneficial effects
on tumors by inhibiting the core tumor suppressor p53 (miR-1285) and supporting migration,
local metastasis (miR-151-5p), and antiapoptosis (miR-24-1) [30]. Overall, activation of these
miRNAs might possibly increase tumor radioresistance in subsequent radiotherapy sessions
and stimulate motility of cancer cells thereby at least partially explaining the evidence on
enhanced migration of malignant glioma cells in response to radiotherapy [31]. The radiation
treatment of glioma cell lines with normal capacity to repair radiation-induced double strand
breaks (DSB) of DNA caused activation of let-7 [29], a family of miRNA that suppresses
proliferation of gliomblastoma cells [30] (Fig. 4). In contrast, in the radiosensitive human
glioma cell line M059J that is deficient in DNA-dependent protein kinase (DNA-PK) and has
a low activity of ATM, two key members of the non-homologous end joining pathway of DNA-
DSB repair, let-7 miRNA was down-regulated [30].
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Moreover, MiRNAs were shown to be also involved in the regulation of chemoresistence of
glioma by modulating some relevant proteins that are involved in drug metabolism and drug
transporter. MiRNAs also affect chemotherapeutic agents induced DNA damage repair (Fig. 4).
5. MiRNAs in gliomas and glioblastoma
MiRNAs affect biological character of varies cells by regulating their targets. So, deregulated
miRNAs regulated brain tumor cell phenotype by regulating their targets, including prolifer‐
ation, cell cycle, apoptosis, invasion, and so on.
Figure 3. miR-221 and miR-222 regulated their target expression to co-modulated glioma cell phenotype. (A: MTT
assay show that knockdown of miR-221/222 lowed proliferated rate of glioma cell; B: knockdown of miR-221/222
induce G1 arrest in glioma cell ;C: Annexin V analysis showed that knockdown of miR-221/222 significantly increased
glioma cell apoptosis; D: The transwell assay revealed that knockdown of miR-221/222 significantly decreased glioma
cell invasion.
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5.1. MiR-221 and miR-222
MiR-221 and miR-222 are both up-regulated in several glioma derived cell lines and in glioma
samples [26-28]. They are clustered within a 1-kb genomic interval on chromosome X, so they
could be generated from the same primary transcript [26].
Two members of the Kip/Cip family of CDK inhibitors and key negative regulators of the cell
cycle, p57 and p27, have been identified as putative direct targets of these miRNAs. According
to this theory, the 3'-UTR of p57 harbors one site expected to be recognized by both miR-221
and miR-222, whereas the 3'-UTR of p27 contains two sites for both miRNAs. Transfection of
both miR-221 and miR-222 greatly reduce the levels of p57 and p27 proteins, while downre‐
gulation of either microRNA 221 or 222 in glioblastoma cells caused an increase in p27 levels
and enhanced expression of the luciferase reporter gene fused to the p27 3'-UTR. These results
suggest that miR-221 and miR-222 could promote cell proliferation and S-phase entry together
with further cooperative events and that miRNA 221 and 222 inhibition may be a potential
therapeutic target to reduce the aggressive growth of glioblastoma by restoring normal levels
of their target proteins [32]. The inverse correlation between mir-221/222 and p27 levels, the
impairment of growth potential and the G1 to S shift in the cell cycle of glioma cells after
inhibition of mir-221/222, were later confirmed by Zhang et al. They extended their study to
in vivo trials and showed that miR-221/222 knocked-down through antisense oligonucleotides
Figure 4. MicroRNAs are involved in the regulation of DNA repair in cancer cells after treatment with ionizing radia‐
tion (radiotherapy) and DNA alkylating drugs such as temozolomide and carmistine[30].
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strongly reduced glioma subcutaneous mice xenografts growth through up regulation of p27
[26] and enhanced radiosensitivity of glioblastoma cell lines [33]. Further evidence showed
that knockdown of miR-221/222 induced a change of mitochondrial membrane potential and
caspase-mediated apoptosis on glioblastoma cells. Indeed, mir-221/222 directly downregulate
the proapoptotic protein PUMA, which leads in turn to decrease Bcl-2 and increase BAX. these
results confirm the oncogenic role of mir-221/222 on glioblastoma [27]. Our recent studies
identified that mir-221/222 increased cell invasion and reduced gap junction intercellular
communication (GJIC) by regulating TIMP3 and Cx43[28,34].
5.2. MiR-21
Microarray profiling studies, further validated by Northern blotting qRT-PCR and real-time
PCR analysis, showed that miRNA-21 is strongly elevated in glioma and glioblastoma tumor
samples and glioma cell lines when compared to non-neoplastic control samples, and upre‐
gulation is particularly prominent in grade IV astrocytomas [35-37]. High expression of miR-21
was significantly associated with poor patient survival, suggesting that, in combination with
other aberrant expressed miRNAs (low expression of miR-181b or miR-106a), miRNA-21
profiling has potential application as novel diagnostic and prognostic indicator [37].
Suppression of mir-21 in glioblastoma cells decreased the metabolic activity of cell culture and
cell number, and was associated with a marked increase in apoptosis and caspase activation
[35]. MiR-21 knockdown also leads to a considerable reduction of glioma volumes in mouse
xenografts [38]. Knockdown mir-21 inhibited proliferation and cell invasion and induced
apoptosis through the activation of caspase-3 and -9 in glioma cell lines, which may be related
to a mir-21-dependent modulation of multiple potential target genes, such as TIMP3 [39,40].
From an in silico constructed study of miR-21 predicted targets and further pathway analysis
of computer generated lists of the identified target genes, emerged that mir-21 targets multiple
components of the p53, transforming growth factor-β (TGF-β) and mitochondrial apoptosis
pathways, that contribute to its tumor promoting and antiapoptotic activity. The phenotypic
effects observed upon downregulation of miR-21 in glioblastoma cells, reflect the repression
of these pathways and result in significant increase in apoptotic cells, reduced growth and cell
cycle arrest at G0-G1 [41]. Further bioinformatics analysis evidenced that multiple genes
involved in apoptosis pathways (such as PDCD4, MTAP, and SOX5), carry putative miR-21
binding sites. PDCD4 mRNA is a direct functional target of miR-21 and its expression inversely
correlates with mir-21 in a number of glioblastoma cell lines (T98G, A172, U87, and U251).
Consistent with these observations, downregulation of mir-21 restored protein level of PDCD4
while, ectopic overexpression of mir-21, inhibits PDCD4-dependent apoptosis [42]. Mir-21
controls tumor invasiveness and microvascular proliferation by regulating the expression of
two of the major inhibitors of matrix metalloproteinases (MMPs): RECK and TIMP3. Mir-21
knockdown decreases RECK and TIMP3 protein levels and MMPs activity both in vivo and in
vitro leading to a reduction of glioma cell motility and invasion [43]. Although PTEN tumor
suppressor gene has been validated as a miR-21 target by computational analysis, down-
regulation of mir-21 leads to an inhibition of tumor growth in glioblastoma cell lines and
xenograft tumors independently of PTEN mutational status [44,45]. MiRNA expression profile
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scanning data after inhibition of miR-21, strongly indicated that BID, FAS, PRS6, and SOCS4
tumor suppressor genes were upregulated and evidenced a suppression of EGFR, activated
Akt, cyclin D, and Bcl-2. This study highlighted that miR-21 targets multiple pathways
responsible of inhibition of glioma growth in absence of PTEN [46].
Further findings strengthened the hypothesis that miR-21 represents a promising target to
improve the efficacy of chemotherapy. In a recent study mir-21 was shown to play a key role
in promoting human glioblastoma cells U87MG resistance against the antitumoral agent
temozolomide (TMZ). Indeed, ectopic overexpression of mir-21 significantly reduced TMZ-
induced apoptosis in this cell line through a suppression of Bax/Bcl-2 ratio and caspase-3
activity. These results confirm the hypothesis that mir-21 overexpression during glioma
progression could be responsible of clinical resistance to chemotherapy with the promising
alkylating agent TMZ [47]. Li et al demonstrated that mir-21 is also involved in glioblastoma
cell chemoresistance to the chemotherapeutic agent VM-26, as shown by the observation that
miR-21 knockdown sensitized GBM cells to VM-26. This is likely to happen because mir-21
regulates and inhibit LRRFIP1 gene expression by direct interaction [48]. This gene encodes a
protein, also known as the TRAF-interacting protein (TRIP), that inhibits NF-κB signaling, a
pathway that is known to be responsible for protection against apoptosis [49] and tumor
chemoresistance [50]. Additionally, suppression of miRNA-21 expression in glioblastoma cell
lines enhances sensitivity of cancer cells to antineoplastic cytotoxic therapy with neural
precursor cells (NPC) expressing a secretable variant of the cytotoxic agent tumor necrosis
factor related apoptosis inducing ligand (S-TRAIL). The synergistic effect was observed both
in vitro, through an increased caspase associated cytotoxic death, and in vivo, where miR-21
knockdown and NPC-mediated S-TRAIL reduce cancer growth in tumor xenografts [38]. A
recent study that evaluated the potential role of mir-21 as a therapeutic tool to enhance the
cytotoxic effect of standard chemotherapy showed that co-delivery of miR-21 and 5-fluorour‐
acil (5-FU) by using a poly(amidoamine) (PAMAM) dendrimer as a carrier, significantly
improved the cytotoxicity of the antitumor agent leading to an higher apoptosis rate and a
reduction of the migration ability of tumor cells [51]. Finally, downregulation of miR-21,
contributes to the antitumor effects of IFN-β on glioma cell and intracranial tumor xenografts
and the activation of the transcription factor STAT3 may have a key role in the IFN-β mediated
suppression of mir-21 [52].
5.3. Mir-34a
Mir-34a, transcriptional target of p53 located within chromosome 1p36, has been proposed as
a potential tumor suppressor. MiR-34a is also downregulated in glioblastoma tissues and cell
lines compared to normal brain tissues and is markedly reduced in p53-mutant cells compared
to cells expressing wild-type p53 [53,54].
MiR-34a possesses hundreds of predicted mRNA targets which could mediate its inhibitory
effects on tumor growth. A few of these have been experimentally verified and include
oncogenes such as MYC, CCND1, CDK6, SIRT1 [55] and c-Met [56]. It was shown to directly
inhibit c-Met in glioma and medulloblastoma cells and Notch-1/Notch-2 in glioma cells and
stem cells by binding to the 3'-UTRs of their mRNA. Furthermore, mir-34a inversely correlates
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strongly reduced glioma subcutaneous mice xenografts growth through up regulation of p27
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samples and glioma cell lines when compared to non-neoplastic control samples, and upre‐
gulation is particularly prominent in grade IV astrocytomas [35-37]. High expression of miR-21
was significantly associated with poor patient survival, suggesting that, in combination with
other aberrant expressed miRNAs (low expression of miR-181b or miR-106a), miRNA-21
profiling has potential application as novel diagnostic and prognostic indicator [37].
Suppression of mir-21 in glioblastoma cells decreased the metabolic activity of cell culture and
cell number, and was associated with a marked increase in apoptosis and caspase activation
[35]. MiR-21 knockdown also leads to a considerable reduction of glioma volumes in mouse
xenografts [38]. Knockdown mir-21 inhibited proliferation and cell invasion and induced
apoptosis through the activation of caspase-3 and -9 in glioma cell lines, which may be related
to a mir-21-dependent modulation of multiple potential target genes, such as TIMP3 [39,40].
From an in silico constructed study of miR-21 predicted targets and further pathway analysis
of computer generated lists of the identified target genes, emerged that mir-21 targets multiple
components of the p53, transforming growth factor-β (TGF-β) and mitochondrial apoptosis
pathways, that contribute to its tumor promoting and antiapoptotic activity. The phenotypic
effects observed upon downregulation of miR-21 in glioblastoma cells, reflect the repression
of these pathways and result in significant increase in apoptotic cells, reduced growth and cell
cycle arrest at G0-G1 [41]. Further bioinformatics analysis evidenced that multiple genes
involved in apoptosis pathways (such as PDCD4, MTAP, and SOX5), carry putative miR-21
binding sites. PDCD4 mRNA is a direct functional target of miR-21 and its expression inversely
correlates with mir-21 in a number of glioblastoma cell lines (T98G, A172, U87, and U251).
Consistent with these observations, downregulation of mir-21 restored protein level of PDCD4
while, ectopic overexpression of mir-21, inhibits PDCD4-dependent apoptosis [42]. Mir-21
controls tumor invasiveness and microvascular proliferation by regulating the expression of
two of the major inhibitors of matrix metalloproteinases (MMPs): RECK and TIMP3. Mir-21
knockdown decreases RECK and TIMP3 protein levels and MMPs activity both in vivo and in
vitro leading to a reduction of glioma cell motility and invasion [43]. Although PTEN tumor
suppressor gene has been validated as a miR-21 target by computational analysis, down-
regulation of mir-21 leads to an inhibition of tumor growth in glioblastoma cell lines and
xenograft tumors independently of PTEN mutational status [44,45]. MiRNA expression profile
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scanning data after inhibition of miR-21, strongly indicated that BID, FAS, PRS6, and SOCS4
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Further findings strengthened the hypothesis that miR-21 represents a promising target to
improve the efficacy of chemotherapy. In a recent study mir-21 was shown to play a key role
in promoting human glioblastoma cells U87MG resistance against the antitumoral agent
temozolomide (TMZ). Indeed, ectopic overexpression of mir-21 significantly reduced TMZ-
induced apoptosis in this cell line through a suppression of Bax/Bcl-2 ratio and caspase-3
activity. These results confirm the hypothesis that mir-21 overexpression during glioma
progression could be responsible of clinical resistance to chemotherapy with the promising
alkylating agent TMZ [47]. Li et al demonstrated that mir-21 is also involved in glioblastoma
cell chemoresistance to the chemotherapeutic agent VM-26, as shown by the observation that
miR-21 knockdown sensitized GBM cells to VM-26. This is likely to happen because mir-21
regulates and inhibit LRRFIP1 gene expression by direct interaction [48]. This gene encodes a
protein, also known as the TRAF-interacting protein (TRIP), that inhibits NF-κB signaling, a
pathway that is known to be responsible for protection against apoptosis [49] and tumor
chemoresistance [50]. Additionally, suppression of miRNA-21 expression in glioblastoma cell
lines enhances sensitivity of cancer cells to antineoplastic cytotoxic therapy with neural
precursor cells (NPC) expressing a secretable variant of the cytotoxic agent tumor necrosis
factor related apoptosis inducing ligand (S-TRAIL). The synergistic effect was observed both
in vitro, through an increased caspase associated cytotoxic death, and in vivo, where miR-21
knockdown and NPC-mediated S-TRAIL reduce cancer growth in tumor xenografts [38]. A
recent study that evaluated the potential role of mir-21 as a therapeutic tool to enhance the
cytotoxic effect of standard chemotherapy showed that co-delivery of miR-21 and 5-fluorour‐
acil (5-FU) by using a poly(amidoamine) (PAMAM) dendrimer as a carrier, significantly
improved the cytotoxicity of the antitumor agent leading to an higher apoptosis rate and a
reduction of the migration ability of tumor cells [51]. Finally, downregulation of miR-21,
contributes to the antitumor effects of IFN-β on glioma cell and intracranial tumor xenografts
and the activation of the transcription factor STAT3 may have a key role in the IFN-β mediated
suppression of mir-21 [52].
5.3. Mir-34a
Mir-34a, transcriptional target of p53 located within chromosome 1p36, has been proposed as
a potential tumor suppressor. MiR-34a is also downregulated in glioblastoma tissues and cell
lines compared to normal brain tissues and is markedly reduced in p53-mutant cells compared
to cells expressing wild-type p53 [53,54].
MiR-34a possesses hundreds of predicted mRNA targets which could mediate its inhibitory
effects on tumor growth. A few of these have been experimentally verified and include
oncogenes such as MYC, CCND1, CDK6, SIRT1 [55] and c-Met [56]. It was shown to directly
inhibit c-Met in glioma and medulloblastoma cells and Notch-1/Notch-2 in glioma cells and
stem cells by binding to the 3'-UTRs of their mRNA. Furthermore, mir-34a inversely correlates
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with c-Met, Notch1, Notch2 and CDK6 protein expression in glioma cells. Transfection of
microRNA34a in brain tumor cells strongly inhibits cell proliferation, cell cycle progression,
cell survival, cell invasion, and in vivo glioma xenograft growth but do not affect cell cycle or
death when transfected to human astrocytes, which showed normal expression levels of
microRNA 34a. Restoration of c-Met or Notch-1 and Notch-2 expression by constructs lacking
3'-UTR regions partially reverted cell cycle arrest and apoptosis induced by miR-34a in glioma
cells or stem cells, confirming the hypothesis that the antitumor effects of miR-34a are achieved
via targeting of multiple oncogenes [53]. Interestingly, mir-34a also affect glioma stem cell
differentiation and growth. Luan et al recently reported silent information regulator 1 (Sirt1)
as a direct negative target of mir34a in glioma cell lines at a posttranscriptional level [54]. Sirt1
is a NAD-dependent deacetylase that regulates apoptosis in response to oxidative and
genotoxic stress, and has recently been involved in tumorigenesis acting as an oncogene [57].
5.4. Mir-128
Mir-128, a brain enriched microRNA, is downregulated in glioma cell lines and tissue when
compared to normal brain samples [58]. Mir-128 overexpression decreased glioma cell
proliferation in vitro and glioma xenograft growth in vivo, and is inversely correlated to Bmi-1
expression. Mir-128 directly targets and downregulates Bmi-1 by binding its 3'-UTR region
[59] and leads to a concomitant overexpression of p21CIP1 and a decrease in phosphorylated
Akt [58]. Bmi-1 expression is a critical factor of normal stem cell maintenance and glioblastoma
self-renewal and loss of Bmi-1-mediated self-renewal of neural stem cells has been shown to
be associated with upregulation of p21CIP1 [60] and decreased Akt activation [61]. Consis‐
tently with these observations, miR-128 overexpression in human glioma neurosphere cultures
possessing a glioma ‘stem-like’ cell phenotype, evidenced that miR-128 specifically blocked
glioma self-renewal reducing neurosphere number and size. In conclusion, mir-128 downre‐
gulation is likely to enhance glioma tumorigenesis by promoting an undifferentiated pheno‐
type and self renewing state through Bmi-1 increased expression [58]. By bioinformatical
analysis, E2F3a, a transcription factor involved in cell cycle progression [62], has been identi‐
fied as a direct target of this miRNA. Indeed, Mir-128 and E2F3a levels are negatively correlated
and mir-128 overexpression has similar inhibitory effects on proliferation of glioma cell lines
as E2F3a knocking down Ectopic overexpression of E2F3a partially reversed the effects of
mir-128, suggesting that mir-128 could exert its antitumor effects at least partially by inhibiting
E2F3a expression. Among its target genes angiopoietin-related protein 5 (ARP5) was identified
with bioinformatical tools and then confirmed to be inversely correlated to mir-128 levels in
glioblastoma cells and tissue and downregulated after ectopic overexpression of this miRNA
[58]. ARP5 seems to be a key regulator of cell proliferation, remodeling and regeneration [63]
and could be a member of a group of genes regulated by mir-128 that coordinately contribute
to glioma and GBM pathology [59].
5.5. Mir-451
Mir-451 was found to be upregulated in glioma samples compared to normal brain on
microarray-based miRNAome profiling [64]. MiR-451 showed a striking spatial distribution,
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with groups of positive cells concentrated around a subset of blood vessels. Moreover, high
levels of mir-451 are correlated to a poor prognosis in glioma patients. Mir-451 could regulate
the balance of proliferation and migration in glioma cells in response to changes in glucose
levels and metabolic stress. It regulates 5'-adenosine monophosphate activated protein kinase
(AMPK) pathway in response to glucose levels in glioma cells, through the modulation of the
activity of its upstream activator LKB1 [65]. Activation of LKB1 is a potent anti-proliferative
signal, and also influences cell polarity, a process known to affect cell motility [66].
MiR-451 regulates LKB1 activity by directly targeting CAB39, a component of the active
LKB1complex, leading to a downregulation of CAB39 protein levels. Down-regulation of
mir-451 levels in response to glucose deprivation leads to intense activation of LKB1 and
downstream pathways, allowing cells to survive metabolic stress and promoting cancer cell
migration. Conversely, when glucose is sufficient, elevated miR-451 levels lead to reduced
LKB1/AMPK pathway activation. This facilitates cell proliferation but makes cells more
sensitive to glucose deprivation. Thus mir-451 could be a key regulator of adaptive response
of cancer cells to altered energy availability [65].
In partial contrast with these studies a recent report found mir-451 to be downregulated in
glioma cell lines. Transfection of mir-451 to glioma cell lines was able to inhibit cell growth,
induced G0/G1 phase arrest, increased cell apoptosis and most notably diminished the invasive
capacity of these cells as evidenced by transwell invasion assay. These tumor suppressive
effects may be due to modulated expression of a panel of proteins including CyclinD1, p27,
MMP 2/9 and Bcl-2, probably via regulation of the PI3K/AKT signaling pathway. Indeed,
expression of Akt1 protein decreased after mir-451 transfection [67].
5.6. Mir-7
Mir-7, a miRNA modulated during neural differentiation of embryonic stem cells is a putative
tumor suppressor gene in glioblastoma. It inhibits EGFR gene expression by directly binding
its mRNA at 3'-UTR. Furthermore, miRNA-7 suppresses the activation of Akt pathway and
reduces phospho-Akt levels by directly targeting its upstream regulators IRS-1 and IRS-2 [68].
They also identified Raf1 as a direct target of miR-7 by microarray analysis, Western blot and
luciferase reporter assays of glioblastoma cells transfected with miR-7 [69]. Inhibition of Akt
activation seems to occur independently of mir-7-mediated repression of EGFR pathway.
Consistenly with these findings miRNA-7 was markedly downregulated in glioblastoma
tissue when compared to normal brain. The proposed mechanism that explains the lower
expression of this miRNA is a processing defect in generating pre-miR-7 from pri-miR-7 in
glioblastoma. Pre-miRNA-7 transfection decreased viability and invasiveness of glioblastoma
lines and glioblastoma derived stem cells and led to an increase in the sub-G0 apoptotic
fraction, a decrease in the S fraction and determined a G2-M arrest, most likely by affecting
EGFR and Akt pathways, which have an established key role in gliomagenesis [68]. Indeed,
EGFR is frequently amplified and highly expressed in glioblastomas [26]. In a recent report
mir-7 was also shown to directly inhibit p21-activated kinase 1 (Pak1) in non-brain cancer cells
[70]. Pak1 is a widely upregulated signaling kinase in multiple human cancers, and it is
involved in the regulation of many signaling pathways, including EGFR and Akt, thus
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with c-Met, Notch1, Notch2 and CDK6 protein expression in glioma cells. Transfection of
microRNA34a in brain tumor cells strongly inhibits cell proliferation, cell cycle progression,
cell survival, cell invasion, and in vivo glioma xenograft growth but do not affect cell cycle or
death when transfected to human astrocytes, which showed normal expression levels of
microRNA 34a. Restoration of c-Met or Notch-1 and Notch-2 expression by constructs lacking
3'-UTR regions partially reverted cell cycle arrest and apoptosis induced by miR-34a in glioma
cells or stem cells, confirming the hypothesis that the antitumor effects of miR-34a are achieved
via targeting of multiple oncogenes [53]. Interestingly, mir-34a also affect glioma stem cell
differentiation and growth. Luan et al recently reported silent information regulator 1 (Sirt1)
as a direct negative target of mir34a in glioma cell lines at a posttranscriptional level [54]. Sirt1
is a NAD-dependent deacetylase that regulates apoptosis in response to oxidative and
genotoxic stress, and has recently been involved in tumorigenesis acting as an oncogene [57].
5.4. Mir-128
Mir-128, a brain enriched microRNA, is downregulated in glioma cell lines and tissue when
compared to normal brain samples [58]. Mir-128 overexpression decreased glioma cell
proliferation in vitro and glioma xenograft growth in vivo, and is inversely correlated to Bmi-1
expression. Mir-128 directly targets and downregulates Bmi-1 by binding its 3'-UTR region
[59] and leads to a concomitant overexpression of p21CIP1 and a decrease in phosphorylated
Akt [58]. Bmi-1 expression is a critical factor of normal stem cell maintenance and glioblastoma
self-renewal and loss of Bmi-1-mediated self-renewal of neural stem cells has been shown to
be associated with upregulation of p21CIP1 [60] and decreased Akt activation [61]. Consis‐
tently with these observations, miR-128 overexpression in human glioma neurosphere cultures
possessing a glioma ‘stem-like’ cell phenotype, evidenced that miR-128 specifically blocked
glioma self-renewal reducing neurosphere number and size. In conclusion, mir-128 downre‐
gulation is likely to enhance glioma tumorigenesis by promoting an undifferentiated pheno‐
type and self renewing state through Bmi-1 increased expression [58]. By bioinformatical
analysis, E2F3a, a transcription factor involved in cell cycle progression [62], has been identi‐
fied as a direct target of this miRNA. Indeed, Mir-128 and E2F3a levels are negatively correlated
and mir-128 overexpression has similar inhibitory effects on proliferation of glioma cell lines
as E2F3a knocking down Ectopic overexpression of E2F3a partially reversed the effects of
mir-128, suggesting that mir-128 could exert its antitumor effects at least partially by inhibiting
E2F3a expression. Among its target genes angiopoietin-related protein 5 (ARP5) was identified
with bioinformatical tools and then confirmed to be inversely correlated to mir-128 levels in
glioblastoma cells and tissue and downregulated after ectopic overexpression of this miRNA
[58]. ARP5 seems to be a key regulator of cell proliferation, remodeling and regeneration [63]
and could be a member of a group of genes regulated by mir-128 that coordinately contribute
to glioma and GBM pathology [59].
5.5. Mir-451
Mir-451 was found to be upregulated in glioma samples compared to normal brain on
microarray-based miRNAome profiling [64]. MiR-451 showed a striking spatial distribution,
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with groups of positive cells concentrated around a subset of blood vessels. Moreover, high
levels of mir-451 are correlated to a poor prognosis in glioma patients. Mir-451 could regulate
the balance of proliferation and migration in glioma cells in response to changes in glucose
levels and metabolic stress. It regulates 5'-adenosine monophosphate activated protein kinase
(AMPK) pathway in response to glucose levels in glioma cells, through the modulation of the
activity of its upstream activator LKB1 [65]. Activation of LKB1 is a potent anti-proliferative
signal, and also influences cell polarity, a process known to affect cell motility [66].
MiR-451 regulates LKB1 activity by directly targeting CAB39, a component of the active
LKB1complex, leading to a downregulation of CAB39 protein levels. Down-regulation of
mir-451 levels in response to glucose deprivation leads to intense activation of LKB1 and
downstream pathways, allowing cells to survive metabolic stress and promoting cancer cell
migration. Conversely, when glucose is sufficient, elevated miR-451 levels lead to reduced
LKB1/AMPK pathway activation. This facilitates cell proliferation but makes cells more
sensitive to glucose deprivation. Thus mir-451 could be a key regulator of adaptive response
of cancer cells to altered energy availability [65].
In partial contrast with these studies a recent report found mir-451 to be downregulated in
glioma cell lines. Transfection of mir-451 to glioma cell lines was able to inhibit cell growth,
induced G0/G1 phase arrest, increased cell apoptosis and most notably diminished the invasive
capacity of these cells as evidenced by transwell invasion assay. These tumor suppressive
effects may be due to modulated expression of a panel of proteins including CyclinD1, p27,
MMP 2/9 and Bcl-2, probably via regulation of the PI3K/AKT signaling pathway. Indeed,
expression of Akt1 protein decreased after mir-451 transfection [67].
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tumor suppressor gene in glioblastoma. It inhibits EGFR gene expression by directly binding
its mRNA at 3'-UTR. Furthermore, miRNA-7 suppresses the activation of Akt pathway and
reduces phospho-Akt levels by directly targeting its upstream regulators IRS-1 and IRS-2 [68].
They also identified Raf1 as a direct target of miR-7 by microarray analysis, Western blot and
luciferase reporter assays of glioblastoma cells transfected with miR-7 [69]. Inhibition of Akt
activation seems to occur independently of mir-7-mediated repression of EGFR pathway.
Consistenly with these findings miRNA-7 was markedly downregulated in glioblastoma
tissue when compared to normal brain. The proposed mechanism that explains the lower
expression of this miRNA is a processing defect in generating pre-miR-7 from pri-miR-7 in
glioblastoma. Pre-miRNA-7 transfection decreased viability and invasiveness of glioblastoma
lines and glioblastoma derived stem cells and led to an increase in the sub-G0 apoptotic
fraction, a decrease in the S fraction and determined a G2-M arrest, most likely by affecting
EGFR and Akt pathways, which have an established key role in gliomagenesis [68]. Indeed,
EGFR is frequently amplified and highly expressed in glioblastomas [26]. In a recent report
mir-7 was also shown to directly inhibit p21-activated kinase 1 (Pak1) in non-brain cancer cells
[70]. Pak1 is a widely upregulated signaling kinase in multiple human cancers, and it is
involved in the regulation of many signaling pathways, including EGFR and Akt, thus
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interfering with cell motility, proliferation, and apoptosis [71]. Furthermore, in glioblastomas,
PAK1 upregulation is a negative prognostic marker and its knockdown results in impaired
cell invasion [72]. These preliminary results suggest mir-7 could have a potential and prom‐
ising therapeutic role in brain tumors.
5.7. Mir-181
Mir-181a and mir-181b are well known brain-enriched miRNAs [73]. Downregulation of
mir-181a and mir-181b was detected in both glioma samples and cell lines [74]. Transfection
of both these miRNAs on glioma cell lines results in cell growth inhibition, invasion reduction
and apoptosis induction, miR-181b being more effective than miR-181a [74]. In a recent miRNA
expression profiling conducted on a set of 124 astrocytoma samples and 60 normal adjacent
tissue samples by qRT-PCR, Zhi et al found that downregulation of miR-181b is significantly
associated with poor patient survival independently of other clinicopathological factors. Thus,
mir-181b has a great potential for being used as a diagnostic and prognostic marker and to
better select patients for adjuvant therapy [39].
In a recent study MiR-181b and miR-181c downregulation was found to be significantly
associated to a  positive response to concomitant  chemoradiotherapy with temozolomide
in glioblastoma patients,  suggesting they could be used as predictive factors for therapy
efficacy [75].
5.8. Mir-124/137
MiRNA-124 and miRNA-137 are downregulated in anaplastic astrocytomas and glioblastoma
multiforme relative to non-neoplastic brain tissue [9-10]. Consequently, growth factor signal‐
ing could promote brain tumor formation through suppression of miR-124 and/or miR-137
expression and inhibition of neural stem cells/tumor stem cell differentiation. Transfection of
mir-124 and mir-137 to neural stem cells and tumor-derived stem cells leads to induction of
cellular markers of differentiation, G1 cell cycle arrest and reductions of the expression of the
cell cycle regulator CDK6, a direct target of both miRNAs. These changes are accompanied by
reduced self-renewal and tumorigenicity. Overexpression of miR-124 or miR-137 also reduced
the expression of phosphorylated RB, a downstream target of CDK6 [76]. These results suggest
that ectopic expression of miRNA-124 and miRNA-137 could represent a valid therapy for
glioblastoma multiforme treatment inducing differentiation of tumor cells and cell cycle arrest.
5.9. MiR-125
Mir-125b downregulated in glioma cell lines after treatment with ATRA (all-trans-retinoic
acid), a regulator of neural differentiation and proliferation. Ectopic overexpression of
mir-125b stimulated glioma cell proliferation, partially recovering the cell growth inhibition
induced by ATRA treatment, while mir-125b knockdown promoted ATRA-mediated cell
apoptosis. Furthermore, Bmf was identified as a direct target of miR-125b, and they are
inversely correlated [77]. Bmf interacts with the prosurvival Bcl-2 proteins, regulating cellular
apoptotic pathways [78]. Indeed, transfection with miR-125b increase BCL-2 levels in glioma
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cells, and expression of BCL-2 was significantly decreased when cells were transfected with
miR-125b inhibitor. Thus, Bmf may play an important role in the process of miR-125b influ‐
encing cell apoptosis [77].
Recently, Cortez et al identified that mir-125a downregulated in glioblastomas and particulary
in glioma stem cells CD133+. Overexpression of mir-125a inhibits invasion properties of
glioblastomas, probably through a direct downregulation of podoplanin (PDPN), a membrane
sialo-glycoprotein related to invasion and malignancy [79].
5.10. MiR-326
Kefas et al evidenced a feedback loop between miRNA-326 and Notch pathway, frequently
deregulated in gliomas. Notch-1 knockdown induced mir-326 upregulation in glioma stem
cells, and ectopic overexpression of mir-326 decreased Notch pathway members level and
activity. Forced expression of mir-326 also inhibited cell proliferation, viability and invasive‐
ness and induced apoptosis in both established and stem cell-like glioma lines, these effects
are at least partially explained through downregulation of the Notch pathway. Moreover, it
reduced tumorigenicity in mouse glioma xenografts. Together with the observation that
mir-326 is downregulated in glioblastomas, these findings suggest that miR-326 is a potential
tumor suppressor in glioma cells and that reversing Notch/miR-326 axis toward miR-326
prevalence appears to be a potential therapy for brain tumors [80].
5.11. Mir-26a
Mir-26a up-regulated in high-grade gliomas. MiR-26a is a direct negative regulator of PTEN
and significantly represses PTEN expression. MiR-26a overexpression was attributed to the
amplification of miR-26a-2 locus (chromosome 12q), one of the two miR-26a loci present in the
human genome (mir-26a-1 and miR-26a-2) and is correlated with monoallelic PTEN deletion.
It was suggested a temporal sequence to the molecular evolution of miR-26a-amplified
gliomas, with PTEN loss most likely preceding miR-26a-2 amplification and, concordantly,
miR-26a overexpression in genetically engineered PTEN+/- mice precluded loss of their
remaining PTEN allele. Amplification of mir-26a is likely to promote the silencing of the
remaing PTEN transcript in PTEN+/- tumors, event analogous to a loss of heterozygosity.
Furthermore, in a murine glioma model, PTEN repression mediated by overexpression of
miR-26a, enhanced de novo tumor formation. Akt pathway activation and suppression of its
negative regulator PTEN are particularly important and frequently occur in glioma develop‐
ment. These observations document a new epigenetic mechanism for PTEN regulation in
gliomagenesis, further highlighting that dysregulation of Akt signaling is crucial to the glioma
development and could be modulated through manipulation of miRNA expression [64].
Moreover, MiR-26a is a frequent target of the 12q13.3-14.1 amplicon that also contain CDK4
and CENTG1, two oncogenes that regulate the RB1 and PI3 kinase/AKT pathways, respec‐
tively. The presence of this amplification is negatively correlated to patient survival. PTEN,
RB1, and MAP3K2/MEKK2 were detected as functional targets of mir-26a in glioblastoma.
Ectopic overexpression of miR-26a increased GBM cell growth, decreased apoptosis and
enhanced gliomagenesis in vivo. Thus, miR-26a decreases PTEN expression, activates AKT,
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interfering with cell motility, proliferation, and apoptosis [71]. Furthermore, in glioblastomas,
PAK1 upregulation is a negative prognostic marker and its knockdown results in impaired
cell invasion [72]. These preliminary results suggest mir-7 could have a potential and prom‐
ising therapeutic role in brain tumors.
5.7. Mir-181
Mir-181a and mir-181b are well known brain-enriched miRNAs [73]. Downregulation of
mir-181a and mir-181b was detected in both glioma samples and cell lines [74]. Transfection
of both these miRNAs on glioma cell lines results in cell growth inhibition, invasion reduction
and apoptosis induction, miR-181b being more effective than miR-181a [74]. In a recent miRNA
expression profiling conducted on a set of 124 astrocytoma samples and 60 normal adjacent
tissue samples by qRT-PCR, Zhi et al found that downregulation of miR-181b is significantly
associated with poor patient survival independently of other clinicopathological factors. Thus,
mir-181b has a great potential for being used as a diagnostic and prognostic marker and to
better select patients for adjuvant therapy [39].
In a recent study MiR-181b and miR-181c downregulation was found to be significantly
associated to a  positive response to concomitant  chemoradiotherapy with temozolomide
in glioblastoma patients,  suggesting they could be used as predictive factors for therapy
efficacy [75].
5.8. Mir-124/137
MiRNA-124 and miRNA-137 are downregulated in anaplastic astrocytomas and glioblastoma
multiforme relative to non-neoplastic brain tissue [9-10]. Consequently, growth factor signal‐
ing could promote brain tumor formation through suppression of miR-124 and/or miR-137
expression and inhibition of neural stem cells/tumor stem cell differentiation. Transfection of
mir-124 and mir-137 to neural stem cells and tumor-derived stem cells leads to induction of
cellular markers of differentiation, G1 cell cycle arrest and reductions of the expression of the
cell cycle regulator CDK6, a direct target of both miRNAs. These changes are accompanied by
reduced self-renewal and tumorigenicity. Overexpression of miR-124 or miR-137 also reduced
the expression of phosphorylated RB, a downstream target of CDK6 [76]. These results suggest
that ectopic expression of miRNA-124 and miRNA-137 could represent a valid therapy for
glioblastoma multiforme treatment inducing differentiation of tumor cells and cell cycle arrest.
5.9. MiR-125
Mir-125b downregulated in glioma cell lines after treatment with ATRA (all-trans-retinoic
acid), a regulator of neural differentiation and proliferation. Ectopic overexpression of
mir-125b stimulated glioma cell proliferation, partially recovering the cell growth inhibition
induced by ATRA treatment, while mir-125b knockdown promoted ATRA-mediated cell
apoptosis. Furthermore, Bmf was identified as a direct target of miR-125b, and they are
inversely correlated [77]. Bmf interacts with the prosurvival Bcl-2 proteins, regulating cellular
apoptotic pathways [78]. Indeed, transfection with miR-125b increase BCL-2 levels in glioma
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cells, and expression of BCL-2 was significantly decreased when cells were transfected with
miR-125b inhibitor. Thus, Bmf may play an important role in the process of miR-125b influ‐
encing cell apoptosis [77].
Recently, Cortez et al identified that mir-125a downregulated in glioblastomas and particulary
in glioma stem cells CD133+. Overexpression of mir-125a inhibits invasion properties of
glioblastomas, probably through a direct downregulation of podoplanin (PDPN), a membrane
sialo-glycoprotein related to invasion and malignancy [79].
5.10. MiR-326
Kefas et al evidenced a feedback loop between miRNA-326 and Notch pathway, frequently
deregulated in gliomas. Notch-1 knockdown induced mir-326 upregulation in glioma stem
cells, and ectopic overexpression of mir-326 decreased Notch pathway members level and
activity. Forced expression of mir-326 also inhibited cell proliferation, viability and invasive‐
ness and induced apoptosis in both established and stem cell-like glioma lines, these effects
are at least partially explained through downregulation of the Notch pathway. Moreover, it
reduced tumorigenicity in mouse glioma xenografts. Together with the observation that
mir-326 is downregulated in glioblastomas, these findings suggest that miR-326 is a potential
tumor suppressor in glioma cells and that reversing Notch/miR-326 axis toward miR-326
prevalence appears to be a potential therapy for brain tumors [80].
5.11. Mir-26a
Mir-26a up-regulated in high-grade gliomas. MiR-26a is a direct negative regulator of PTEN
and significantly represses PTEN expression. MiR-26a overexpression was attributed to the
amplification of miR-26a-2 locus (chromosome 12q), one of the two miR-26a loci present in the
human genome (mir-26a-1 and miR-26a-2) and is correlated with monoallelic PTEN deletion.
It was suggested a temporal sequence to the molecular evolution of miR-26a-amplified
gliomas, with PTEN loss most likely preceding miR-26a-2 amplification and, concordantly,
miR-26a overexpression in genetically engineered PTEN+/- mice precluded loss of their
remaining PTEN allele. Amplification of mir-26a is likely to promote the silencing of the
remaing PTEN transcript in PTEN+/- tumors, event analogous to a loss of heterozygosity.
Furthermore, in a murine glioma model, PTEN repression mediated by overexpression of
miR-26a, enhanced de novo tumor formation. Akt pathway activation and suppression of its
negative regulator PTEN are particularly important and frequently occur in glioma develop‐
ment. These observations document a new epigenetic mechanism for PTEN regulation in
gliomagenesis, further highlighting that dysregulation of Akt signaling is crucial to the glioma
development and could be modulated through manipulation of miRNA expression [64].
Moreover, MiR-26a is a frequent target of the 12q13.3-14.1 amplicon that also contain CDK4
and CENTG1, two oncogenes that regulate the RB1 and PI3 kinase/AKT pathways, respec‐
tively. The presence of this amplification is negatively correlated to patient survival. PTEN,
RB1, and MAP3K2/MEKK2 were detected as functional targets of mir-26a in glioblastoma.
Ectopic overexpression of miR-26a increased GBM cell growth, decreased apoptosis and
enhanced gliomagenesis in vivo. Thus, miR-26a decreases PTEN expression, activates AKT,
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and promotes tumor growth. Using human U87 GBM cells that lack functional PTEN, mir-26a
overexpression increased cell growth and decreased apoptosis despite the absence of PTEN,
most probably by downregulating RB1 and MAP3K2, a gene that encodes MEKK2[81]. MEKK2
is a mitogen-activated protein kinase kinase involved in JNK activation pathway that promote
apoptosis in GBM cells [82].
5.12. Mir-10b
Mir-10b is upregulated in glioma samples and glioma cell lines compared to non-neoplastic
brain tissues. RhoC and urokinasetype plasminogen activator receptor (uPAR), which are
known to contribute to glioma invasion and migration, were correlated with mir-10b expres‐
sion in gliomas, probably via inhibition of the translation of the mRNA encoding homeobox
D10 (HOXD10], which in turn represses the expression of these genes [83]. These results
suggest that mir-10 could be involved in regulation of the invasion and migration abilities of
gliomas.
5.13. Mir-15b
Mir-15b was shown to be elevated in a panel of glioma cell lines. Transfection of glioma cells
with miR-15b significantly increased G0/G1 cells and decreased the percentage of cells in S
phase, while inhibition of mir-15b increased G0/G1 cell amount. Thus, miR-15b regulates cell
cycle progression in glioma cells by targeting cell cycle-related factors as CCNE1 (cyclin E1],
a validated downstream target of mir-15b [84].
5.14. Mir-146b
Mir-146b, a miRNA found to be downregulated in human glioma tissue, could exert an
antitumor activity by reducing the expression of a matrix metalloproteinase gene, MMP16, one
of its direct downstream targets. Indeed, transfection of U373 glioma cells with miR-146b
precursor decreased tumor cell migration and invasion, while inhibition of miR-146b by LNA
modified anti-miR-146b produced the opposite effect, without affecting cell proliferation [85].
5.15. Mir-296
Recent studies support a role of mir-296 in promoting angiogenesis in gliomas. When brain mi‐
crovascular endothelial cells were co-cultured with U87 glioma cells or when vascular endothe‐
lial growth factor (VEGF) was added to cultured human brain microvascular endothelial cells,
miR-296 was upregulated. Moreover, mir-296 levels were higher in endothelial cells isolated
from human brain tumors compared to normal brain endothelial cells. Downregulation of
miR-296 in endothelial cells resulted in the inhibition of morphologic characteristics associated
with angiogenesis and reduced angiogenesis in glioma xenografts in vivo. This probably hap‐
pens through the downregulation of the hepatocyte growth factor-regulated tyrosine kinase
substrate (HGS), a validated target of mir-296, thus leading to a reduced HGS-mediated degra‐
dation of the platelet derived growth factor receptor (PDGFR) and vascular endothelial growth
factor receptor (VEGFR). This result points out an interesting feedback loop, where VEGF indu‐
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ces miR-296 expression, which in turn increases cell response to VEGF. Consequently, manipu‐
lating mir-296 expression, could enable to control a key step in cancer angiogenesis [86].
5.16. Mir-29
Mir-29b was found to be significantly downregulated in glioblastoma samples and cells and
CD133+ tumor stem cells. Forced overexpression of this miRNA inhibited invasion and
proliferation and induced apoptosis in glioblastoma cells. Mir-29b as well mir-125a directly
targets podoplanin (PDPN), a putative marker of neural stem cells, related to invasion and
malignancy in glioblastoma [13].
5.17. MiR-17-92 cluster
MiR-17-92 cluster, located within the locus 13q31-q32, encloses five miRNAs (miR-92-1,
miR-19a, miR-20a, miR-19b, miR-17-5p), which have been frequently involved in tumorigen‐
esis [87]. This cluster was detected to be amplified in glioblastoma samples. Furthermore,
expression of miR-17-92 cluster is downregulated upon induction of differentiation of GBM
spheroid cultures by using ATRA. Induction of differentiation leads to deregulation of most
of the key pathways associated with self-renewal such as insulin-like growth factor 1 signaling,
vitamin D receptor/retinoic acid X receptor activation, Wnt/β-catenin signaling and retinoic
acid receptor activation. Inhibition of miR-17-92 cluster leads to decreased cell viability and
decreased cell proliferation probably through a de-repression of CDKN1, E2F1, PTEN and
CTGF which are upregulated. Particularly, connective tissue growth factor (CTGF) gene was
shown to be a direct target of miR-17-92 in glioblastoma spheroids by luciferase reporter assays
[88]. CTGF binds vascular endothelial growth factor (VEGFA), which is a central mediator of
angiogenesis [89], and inhibits VEGFA-induced angiogenesis [90]. Conversely, VEGFA was
shown to inhibit MiR-17-92 [91], thus explaining the concomitant downregulation of VEGFA
and miR-17-92 upon induction of differentiation. In conclusion, the interaction between CTGF,
VEGFA and miR-17-92 might have a key role in gliomagenesis by targeting multiple regulatory
pathways [88].
5.18. Let-7
Let-7 expression is not downregulated in human glioblastoma tissues and cell lines, let-7
ectopic overexpression by transfection on U251 and U87 human glioblastoma cells, reduced
in vitro proliferation and migration and also in vivo tumor growth after xenotransplantation
into nude mice. Furthermore, let-7 miRNA reduced the expression of total RAS, N-RAS, and
K-RAS in glioblastoma cells [92]. These results suggest that let-7 miRNA is able to impair
glioblastoma growth and cellular migration via RAS inhibition.
6. MicroRNAs and tumor stem cells
Glioma stem cells (GSCs) have been recently identified [93]. They express common neural stem
cell (NSC) markers (CD133, Nestin, Musashi, and Sox2) and display multiple-lineage differ‐
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and promotes tumor growth. Using human U87 GBM cells that lack functional PTEN, mir-26a
overexpression increased cell growth and decreased apoptosis despite the absence of PTEN,
most probably by downregulating RB1 and MAP3K2, a gene that encodes MEKK2[81]. MEKK2
is a mitogen-activated protein kinase kinase involved in JNK activation pathway that promote
apoptosis in GBM cells [82].
5.12. Mir-10b
Mir-10b is upregulated in glioma samples and glioma cell lines compared to non-neoplastic
brain tissues. RhoC and urokinasetype plasminogen activator receptor (uPAR), which are
known to contribute to glioma invasion and migration, were correlated with mir-10b expres‐
sion in gliomas, probably via inhibition of the translation of the mRNA encoding homeobox
D10 (HOXD10], which in turn represses the expression of these genes [83]. These results
suggest that mir-10 could be involved in regulation of the invasion and migration abilities of
gliomas.
5.13. Mir-15b
Mir-15b was shown to be elevated in a panel of glioma cell lines. Transfection of glioma cells
with miR-15b significantly increased G0/G1 cells and decreased the percentage of cells in S
phase, while inhibition of mir-15b increased G0/G1 cell amount. Thus, miR-15b regulates cell
cycle progression in glioma cells by targeting cell cycle-related factors as CCNE1 (cyclin E1],
a validated downstream target of mir-15b [84].
5.14. Mir-146b
Mir-146b, a miRNA found to be downregulated in human glioma tissue, could exert an
antitumor activity by reducing the expression of a matrix metalloproteinase gene, MMP16, one
of its direct downstream targets. Indeed, transfection of U373 glioma cells with miR-146b
precursor decreased tumor cell migration and invasion, while inhibition of miR-146b by LNA
modified anti-miR-146b produced the opposite effect, without affecting cell proliferation [85].
5.15. Mir-296
Recent studies support a role of mir-296 in promoting angiogenesis in gliomas. When brain mi‐
crovascular endothelial cells were co-cultured with U87 glioma cells or when vascular endothe‐
lial growth factor (VEGF) was added to cultured human brain microvascular endothelial cells,
miR-296 was upregulated. Moreover, mir-296 levels were higher in endothelial cells isolated
from human brain tumors compared to normal brain endothelial cells. Downregulation of
miR-296 in endothelial cells resulted in the inhibition of morphologic characteristics associated
with angiogenesis and reduced angiogenesis in glioma xenografts in vivo. This probably hap‐
pens through the downregulation of the hepatocyte growth factor-regulated tyrosine kinase
substrate (HGS), a validated target of mir-296, thus leading to a reduced HGS-mediated degra‐
dation of the platelet derived growth factor receptor (PDGFR) and vascular endothelial growth
factor receptor (VEGFR). This result points out an interesting feedback loop, where VEGF indu‐
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ces miR-296 expression, which in turn increases cell response to VEGF. Consequently, manipu‐
lating mir-296 expression, could enable to control a key step in cancer angiogenesis [86].
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CD133+ tumor stem cells. Forced overexpression of this miRNA inhibited invasion and
proliferation and induced apoptosis in glioblastoma cells. Mir-29b as well mir-125a directly
targets podoplanin (PDPN), a putative marker of neural stem cells, related to invasion and
malignancy in glioblastoma [13].
5.17. MiR-17-92 cluster
MiR-17-92 cluster, located within the locus 13q31-q32, encloses five miRNAs (miR-92-1,
miR-19a, miR-20a, miR-19b, miR-17-5p), which have been frequently involved in tumorigen‐
esis [87]. This cluster was detected to be amplified in glioblastoma samples. Furthermore,
expression of miR-17-92 cluster is downregulated upon induction of differentiation of GBM
spheroid cultures by using ATRA. Induction of differentiation leads to deregulation of most
of the key pathways associated with self-renewal such as insulin-like growth factor 1 signaling,
vitamin D receptor/retinoic acid X receptor activation, Wnt/β-catenin signaling and retinoic
acid receptor activation. Inhibition of miR-17-92 cluster leads to decreased cell viability and
decreased cell proliferation probably through a de-repression of CDKN1, E2F1, PTEN and
CTGF which are upregulated. Particularly, connective tissue growth factor (CTGF) gene was
shown to be a direct target of miR-17-92 in glioblastoma spheroids by luciferase reporter assays
[88]. CTGF binds vascular endothelial growth factor (VEGFA), which is a central mediator of
angiogenesis [89], and inhibits VEGFA-induced angiogenesis [90]. Conversely, VEGFA was
shown to inhibit MiR-17-92 [91], thus explaining the concomitant downregulation of VEGFA
and miR-17-92 upon induction of differentiation. In conclusion, the interaction between CTGF,
VEGFA and miR-17-92 might have a key role in gliomagenesis by targeting multiple regulatory
pathways [88].
5.18. Let-7
Let-7 expression is not downregulated in human glioblastoma tissues and cell lines, let-7
ectopic overexpression by transfection on U251 and U87 human glioblastoma cells, reduced
in vitro proliferation and migration and also in vivo tumor growth after xenotransplantation
into nude mice. Furthermore, let-7 miRNA reduced the expression of total RAS, N-RAS, and
K-RAS in glioblastoma cells [92]. These results suggest that let-7 miRNA is able to impair
glioblastoma growth and cellular migration via RAS inhibition.
6. MicroRNAs and tumor stem cells
Glioma stem cells (GSCs) have been recently identified [93]. They express common neural stem
cell (NSC) markers (CD133, Nestin, Musashi, and Sox2) and display multiple-lineage differ‐
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entiation potential and a greater tumorigenic activity in rodent xenografts. GSCs also show an
increased angiogenic potential through a higher expression of vascular endothelial growth
factor (VEGF). GSCs are strongly resistant to radiation [94]and chemotherapy [95].
A recent study by Lavon et al showed a similar expression pattern of mir-21, mir-124, and
mir-137 in gliomas and stem cells. Among them we mention the miR-17 family cluster that
contains 3 miRNAs upregulated in gliomas and NPCs (mir-17-92, mir-106b-25, mir-106a); the
mir-183-182 cluster, also upregulated in gliomas and NPCs; the large 7+46 bipartite miRNA
cluster on chromosome 14, as most of miRNAs located within this region have been shown to
be downregulated in the same samples [96]. This latter cluster is located within a region which
shows a frequent loss of heterozygosity in glioblastomas [97]. Finally, mir302-367 cluster on
chromosome 4q25 and mir371-373 cluster on chromosome 19q13, are upregulated in gliomas
and NPCs. These data confirm the hypothesis that brain cancers arise from multipotent GSCs,
thus explaining the phenotypic heterogeneity of tumors.
Many groups investigated the role of miRNAs in GSCs so far: in a first report Silber et al found
that mir-124 and mir-137 are reduced in grade III and IV gliomas compared to normal brain.
Besides, transfection of these two miRNAs in neural stem cells and glioma cancer cell lines
leads to induction of cellular markers of differentiation, G1 cell cycle arrest and reductions of
CDK6, thus indicating a hypothetical tumor suppressor role of micro-124 and microRNA-137
in GSCs [29]. As previously mentioned in this review, mir-128 was identified as a negative
regulator of glioma self renewal when ectopically overexpressed on human glioma neuro‐
sphere cultures [58].
A recent analysis showed that mir-451 is significantly downregulated in CD133+cells. Trans‐
fection of miR-451 inhibits proliferation and neurosphere formation in GSCs, highlighting that
it can act as a tumor suppressor: two target sites for SMAD protein in the upstream promoter
region of miR-451 have been found, leading to draw the conclusion that this miRNA is
activated by SMAD pathway. Transfection of SMAD in GBM cells inhibited their growth,
suggesting it could induce differentiation of glioma CD133+stem cells through up-regulation
of miR-451, thus reducing their tumorigenicity [98].In conclusion, a stable and selective
delivery of these miRNAs to GSCs could represent a great advance for brain tumor therapy.
MiR -125b is required for stem cell fission, allowing them to bypass the G1/S checkpoint and
making them insensitive to chemotherapy [99]. It has been found to be significantly downre‐
gulated in CD133+glioma stem cells compared to CD133-ones, leading to the hypothesis that
it may be involved in cell differentiation. As expected, transfection of mir-125b to CD133+cells,
decreased the number of proliferating cells and induced G0-G1 arrest: this effect occurs
through a mir-125b-dependent downregulation of CDC25A and CDK6, two cell cycle regula‐
tory proteins [47]. Moreover, miR-29b and miR-125a, are under-expressed in glioblastoma
CD133+cells compared with their counterpart CD133-cells (see above), suggesting a potential
role for these microRNAs in regulation of signaling pathways related to maintenance of stem
cell properties and self-renewal of cancer cells [79].
Some miRNAs could have a role in the regulation of key pathways of GSCs. We already
mentioned above the existence of a regulatory feedback loop between the tumor suppressor
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mir-326 and Notch pathway, shifted towards a prevalence of Notch activity in brain tumor
cells and GSCs [80] Recently, pyruvate kinase type M2 (PKM2) has been identified as a putative
target of mir-326, as levels of PKM2 and mir-326 are inversely correlated in glioma cells. PKM2,
highly expressed on cancer cells and GSCs, plays the role of mediator in mir-326 metabolic
effects: experimental knockdown of this molecule led to an impairment of glioma invasiveness
and clonogenicity and decreased ATP levels, suggesting that PKM2 could represent a valid
target for glioma therapy [100].
Mir-34a downregulated in gliomas and GSCs. When transfected into GSCs, it decreased the
expression of the stem cell markers CD133 and nestin and caused an higher immunostaining
for astrocytes and oligodendrocytes markers, besides modestly inhibiting several malignancy
end-points (migration, survival, proliferation, cell cycle progression). Remarkably, miR-34a
levels in glioma stem cells are significantly lower than in differentiated wild-type p53 glioma
cell lines, suggesting that restoration of miR-34a expression for therapeutic purposes could
achieve strong anti-tumor effects not only by targeting differentiated glioma cells, but also by
inducing glioma stem cell differentiation [56].
7. MicroRNAs in medulloblastoma
Medulloblastoma (MB) is the most common brain malignancy observed in childhood (WHO
grade IV) [101]. Ferretti et al were the first showed that miRNAs profiles is different between
primary medulloblastomas and normal cerebellar controls. These aberrant miRNAs have a
potentially role in MB development: e.g., let-7 microRNAs has been shown to inhibit Ras
oncogene expression [102], reported to be a key factor for MB metastatic behavior [103];
miR-17-92 cluster cooperates with myc, frequently overexpressed in MB, to induce neoplastic
transformation [104]; miR-9 and miR-125a, both downregulated in MB, are involved in cell
proliferation and, when transfected into MB cells, promote apoptosis and impair anchorage-
independent growth by downregulating the truncated isoform of the neurotropin receptor
TrkC (t-TrkC). T-TrkC expression levels are higher in MB, inversely correlate with miR-9 and
miR-125a levels and are responsible of enhanced cell proliferation and worse prognosis. Mir-9
and mir-124 have a common molecular target, REST/NRSF (RE1 silencing transcription factor/
neuron-restrictive silencer factor) complex [105]. These observations suggest that Mir-9 and
mir-124 could play an important role in cerebellar tumorigenesis as REST inactivation has been
reported to inhibit tumor growth [106] and is overexpressed in many MBs [107]. Consequently,
a REST/mir-124 axis shifted towards a prevalence of REST activity, could block neuronal
differen-tiation and promote neoplastic transformation [108].
Mir-124 also modulates medulloblastoma growth by targeting CDK6, a key pro-proliferative
factor overexpressed in 30% of medulloblastomas, which represents an adverse prognostic
marker for clinical outcome [109]. The role of mir-124 in MB development was later confirmed
by Li et al who additionally demonstrated that ectopic expression of mir-124 in medulloblas‐
toma cell lines inhibits cell growth by directly targeting SLC16A1, a protein upregulated in
MBs, that serve as a carrier to export lactic acid extracellularly, thus maintaining homeostasis
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in GSCs [29]. As previously mentioned in this review, mir-128 was identified as a negative
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sphere cultures [58].
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fection of miR-451 inhibits proliferation and neurosphere formation in GSCs, highlighting that
it can act as a tumor suppressor: two target sites for SMAD protein in the upstream promoter
region of miR-451 have been found, leading to draw the conclusion that this miRNA is
activated by SMAD pathway. Transfection of SMAD in GBM cells inhibited their growth,
suggesting it could induce differentiation of glioma CD133+stem cells through up-regulation
of miR-451, thus reducing their tumorigenicity [98].In conclusion, a stable and selective
delivery of these miRNAs to GSCs could represent a great advance for brain tumor therapy.
MiR -125b is required for stem cell fission, allowing them to bypass the G1/S checkpoint and
making them insensitive to chemotherapy [99]. It has been found to be significantly downre‐
gulated in CD133+glioma stem cells compared to CD133-ones, leading to the hypothesis that
it may be involved in cell differentiation. As expected, transfection of mir-125b to CD133+cells,
decreased the number of proliferating cells and induced G0-G1 arrest: this effect occurs
through a mir-125b-dependent downregulation of CDC25A and CDK6, two cell cycle regula‐
tory proteins [47]. Moreover, miR-29b and miR-125a, are under-expressed in glioblastoma
CD133+cells compared with their counterpart CD133-cells (see above), suggesting a potential
role for these microRNAs in regulation of signaling pathways related to maintenance of stem
cell properties and self-renewal of cancer cells [79].
Some miRNAs could have a role in the regulation of key pathways of GSCs. We already
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and clonogenicity and decreased ATP levels, suggesting that PKM2 could represent a valid
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Mir-34a downregulated in gliomas and GSCs. When transfected into GSCs, it decreased the
expression of the stem cell markers CD133 and nestin and caused an higher immunostaining
for astrocytes and oligodendrocytes markers, besides modestly inhibiting several malignancy
end-points (migration, survival, proliferation, cell cycle progression). Remarkably, miR-34a
levels in glioma stem cells are significantly lower than in differentiated wild-type p53 glioma
cell lines, suggesting that restoration of miR-34a expression for therapeutic purposes could
achieve strong anti-tumor effects not only by targeting differentiated glioma cells, but also by
inducing glioma stem cell differentiation [56].
7. MicroRNAs in medulloblastoma
Medulloblastoma (MB) is the most common brain malignancy observed in childhood (WHO
grade IV) [101]. Ferretti et al were the first showed that miRNAs profiles is different between
primary medulloblastomas and normal cerebellar controls. These aberrant miRNAs have a
potentially role in MB development: e.g., let-7 microRNAs has been shown to inhibit Ras
oncogene expression [102], reported to be a key factor for MB metastatic behavior [103];
miR-17-92 cluster cooperates with myc, frequently overexpressed in MB, to induce neoplastic
transformation [104]; miR-9 and miR-125a, both downregulated in MB, are involved in cell
proliferation and, when transfected into MB cells, promote apoptosis and impair anchorage-
independent growth by downregulating the truncated isoform of the neurotropin receptor
TrkC (t-TrkC). T-TrkC expression levels are higher in MB, inversely correlate with miR-9 and
miR-125a levels and are responsible of enhanced cell proliferation and worse prognosis. Mir-9
and mir-124 have a common molecular target, REST/NRSF (RE1 silencing transcription factor/
neuron-restrictive silencer factor) complex [105]. These observations suggest that Mir-9 and
mir-124 could play an important role in cerebellar tumorigenesis as REST inactivation has been
reported to inhibit tumor growth [106] and is overexpressed in many MBs [107]. Consequently,
a REST/mir-124 axis shifted towards a prevalence of REST activity, could block neuronal
differen-tiation and promote neoplastic transformation [108].
Mir-124 also modulates medulloblastoma growth by targeting CDK6, a key pro-proliferative
factor overexpressed in 30% of medulloblastomas, which represents an adverse prognostic
marker for clinical outcome [109]. The role of mir-124 in MB development was later confirmed
by Li et al who additionally demonstrated that ectopic expression of mir-124 in medulloblas‐
toma cell lines inhibits cell growth by directly targeting SLC16A1, a protein upregulated in
MBs, that serve as a carrier to export lactic acid extracellularly, thus maintaining homeostasis
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of tumor cells, where aerobic glycolysis is known to be accelerated [110].At the same time,
downregulation of miR-218 could account for an overexpression of the pro-oncogene EGFR,
which activates MAPK pathway and CTNND2, which in turn encodes the gene of β-catenin
that activates the APC/Wnt signal transduction pathway and leads to tumor growth [111].
Hedgehog (Hh) patched (Ptch1) signalling pathway is a key regulator of the development of
cerebellar granule cell progenitors and its constitutive activation makes cells susceptible of
malignant transformation into medulloblastoma [112]. Hh is a secreted protein that binds to
the transmembrane receptor Ptch1 transducing an intracellular signal through the protoon‐
cogene Smoothened (Smo) to the downstream transcription factors Gli1, Gli2, and Gli3 [113].
Ferretti et al found that miR-125b, miR-326 and miR-324-5p target and repress activator
downstream components of the Hh signalling pathway (Smo and Gli1); consistent with these
findings, 50% of MBs showed a downregulation of these miRNAs together with an overex‐
pression of Gli1. Deletion of chromosome 17p, the most frequent mutation in medulloblasto‐
ma, could account for several genetic defects, including miR-324-5p, p53 and HIC1 tumor
suppressors loss, which cooperate in Hh-dependent tumorigenesis: loss of these genes,
together with other molecular events, contribute to a persistent hyperactivation of Hh
signalling during cerebellar granule cell progenitors development, leading to higher prolifer‐
ative activity and susceptibility to malignant MBs [114].
Recently, Hedgehog signalling pathway has been identified as a target of miR-17-92 cluster.
Indeed, miRNAs from the miR-17-92 cluster are specifically overexpressed in mouse MB
models with specific initiating mutations in Ptch1 and in human MB subgroups with an
activated SHH signaling pathway. To evaluate its oncogenic potential, miR-17-92 was
retrovirally transduced into mouse granule neuron progenitors cells (GNPs) before orthotopic
transplantation into immunocompromised mice. Interestingly, only cells with an SHH
signaling defect (Ptc+/-) developed MBs. Tumor cells from this model exhibited markers of
activated SHH signaling as elevated Math1 and Gli1 mRNA levels, and lost expression of the
wild-type Ptc allele, reinforcing the hypothesis of a functional link between the SHH pathway
and this miRNA cluster [115]. Some studies showed that miR-17-92 is most highly expressed
in SHH-driven medulloblastomas, and higher levels of miR-17-92 are also related to an
overexpression of the oncogene MYC. Moreover, transfection of miR-17-92 maintains mouse
CGNP cells in a proliferative state in the absence of SHH, and synergizes with SHH to promote
cell growth, while treatment of the same cells with SHH results in upregulation of miR-17-92,
confirming that this cooperation is crucial in MB tumorigenesis [116].
Notch pathway plays a key role in regulating granule-cell progenitor differentiation and an
increased copy number of Notch-2 was detected in 15% of medulloblastomas [117]. Expression
of the downstream effector of Notch, HES1, normally declines during neuronal differentiation,
while persistent activation of this factor prevents differentiation of precursor cells [118]. Garzia
et al identified mir-199-5p as capable of directly targeting and repress expression of HES1 in
MB cell lines. Ectopic expression of this miRNA reduced MB cell proliferation, population
expressing stem cell marker CD133 and xenograft tumor growth in mouse models. Their
studies also suggest that the documented downregulation of miR-199b-5p in metastatic tumors
may be related to epigenetic silencing [119].
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Venkataraman et al recently showed that several miRNAs known to be involved in CNS
development, are downregulated in medulloblastoma cell line cultures and tissues. A specific
one, miR-128a, is able to decrease tumor growth and proliferation if ectopically re-expressed
on MB cells. Bmi-1 has been identified as a putative target of miR-128a, a critical factor in
cerebellar development frequently upregulated in MBs. MiR-128a seems to normally down‐
regulate Bmi-1 oncogene, leading to increased levels of p16, a cell cycle inhibitor. Furthermore,
Bmi-1 could be involved in regulating reactive oxygen species by decreasing superoxide
generation, thus leading to a lower redox state in cancer stem cells [120]; this event is known
to be partially responsible of tumor resistance against common therapies [121].
Finally, mir-34a appeared to be a tumor suppressor gene also in medulloblastomas other than
in glioblastomas. Indeed, transient transfection of miR-34a into medulloblastoma cell lines,
strongly inhibited cell proliferation, cell cycle progression, cell survival and cell invasion most
probably through a direct inhibition of c-Met [56].
8. MiRNAs in pituitary tumors
Pituitary adenomas are benign and frequent neoplasms, accounting for about 15% of primary
intracranial tumors [122]. Bottoni et al found that 30 miRNAs are differentially expressed
between normal pituitary gland and pituitary adenomas. Furthermore, their expression is
inversely correlated with tumor size. They probably act through a negative regulation of RARS
(arginyl-tRNA synthetase), which is in turn upregulated in pituitary adenomas and modulates
the expression of factors influencing pituitary tumor growth [123]. Mir-15a and mir-16-1 are
located within chromosome region 13q14. Interestingly, loss of 13q region of chromosome 13
was frequently detected in pituitary tumors, confirming that this region likely contains tumor
suppressor genes [124].
These findings support the hypothesis that miRNA-16-1 plays a key role in tumor growth [195],
most probably by interacting with BCL2 [125], which is overexpressed in about one third of
pituitary adenomas [126]. MiRNAome could also function as a signature for specific histotypes
of pituitary adenomas. Overexpression of miR-23a, miR-23b, and miR-24-2 and lower expres‐
sion of mir-26b are more typical of GH-secreting and PRL-secreting adenomas, differentiating
them from non-functioning adenomas (NFA), characterized by mir-26 upregulation and
miRNA-24-2 downregulation. Moreover, NFA express higher concentration of miR-137 and
lower of miR-127, miR-129, miR-203, and miR-134 compared to GH-secreting adenomas.
Finally, ACTH-secreting adenomas are defined by a strong expression of mir-30 cluster
(miR-30a, miR-30b, miR-30c, and miR-30d), supporting the hypothesis that miRNAs could be
useful diagnostic markers to distinguish pituitary tumor histotypes [127].More recently,
Amaral et al evaluated the expression of microRNAs in ACTH-secreting pituitary tumors: they
found that let-7a, miR-21, miR-141, miR-143, miR-145, and miR-150, besides miR-15 and
miR-16, are downregulated in corticotropinomas compared to normal pituitary tissue and that
a lower expression of mir-141 is linked to a better chance of remission after surgery [128].
Moreover, downregulation of Mir-143 could be involved in tumorigenesis by activating MAPK
pathway via ERK5 [129].
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Quian et al showed that let-7 expression is decreased in more than one third of pituitary
adenomas and is related to higher tumor grade, thus it may act as a tumor suppressor. Levels
of let-7 were found to be inversely correlated to HMGA2 expression [130], confirming some
previous studies which showed that HMGA2 is repressed by let-7 [131]. High levels of HMGA2
have been detected in most types of pituitary adenomas [132] and they are significantly
associated with tumor grade, extent of invasion, tumor size and Ki-67 proliferation index,
probably through regulation of E-cadherin, E2F1, cyclin A, and p53 expression. Accordingly,
let-7 may be useful as a novel anticancer agent in the future [130]. A recent study on the role
of miRNAs in NFAs and GH-secreting pituitary tumors was performed by Butz et al, showing
that a group of miRNAs (miR-128a, miR-155, and miR-516a-3p) targets the 3'-untranslated
region of Wee1, a nuclear protein kinase that acts as a tumor suppressor, and which was found
to be significantly decreased in pituitary tumor samples [133].
9. Therapeutic potential of miRNAs
Current evidence indicates that miRNA deregulation is common in human cancers. The
discovery of miRNAs with oncogenic or tumor-suppressive function raises the possibility of
exploiting these RNA molecules for therapeutic intervention and the development of novel
therapies. The oncogenic miRNAs can be downregulated using antisense miRNA oligonu‐
cleotides (AMOs or antagomirs) or miRNA sponges[134,135], whereas tumor-suppressive
miRNAs may be targeted by replacement with miRNA mimetics.
AMOs  are  synthetic  oligonucleotides  with  sequence  complementary  either  to  mature
miRNA or its precursor and have been widely used to inhibit miRNA activities in vitro
and in vivo[136]. A number of chemical modifications to AMOs have been developed to
improve specific binding to target miRNAs and to resist nuclease degradation. These in‐
clude modifications at the 20-hydroxyl position (20-O-methyl (20OMe),  20-Omethoxyeth‐
yl(20MOE),  20-fluoro  (20F)  and  locked  nucleic  acids  (LNA)),  on  the  phosphorothioate
backbone,  and  conjugation  with  cholesterol  [137].  Of  these  modifications,LNA  shows
high  stability,  strong  affinity  for  target  miRNAs  and  low  toxicity  in  biological  system
and has emerged as a strong candidate for targeting miRNAs in vivo.  One clinical  trial
using  LNA  anti-miRNA  in  treating  human  disease  has  been  initiated  recently.  Using
LNA antimiR-21, Corsten et al. demonstrated that miR-21 knockdown in glioma cells led
to  an  increase  of  apoptotic  cell  death  and  a  significant  reduction  of  glioma  growth  in
vivo,  suggesting that  miR-21 is  a  potential  therapeutic  target.  They further showed that
combination of miR-21 suppression and the cytotoxic agent tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) resulted in enhanced caspase activity and synergistic
killing of glioma cells in vitro. When these treated glioma cells were implanted intracra‐
nially  into  nude mice,  tumor  cells  were  completely  eradicated  after  day  6  of  implanta‐
tion,  compared  to  reduced  tumor  volume  with  either  treatment  alone.  This  finding
suggests that miR-21 knockdown sensitizes glioma cells to apoptosis agent,  and that the
combined treatment is a promising approach for glioma elimination [138].
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Angiogenesis is a process essential for malignant glioma growth. By co-culturing glioma cells
with microvascular endothelial cells, Wurdinger et al. showed that glioma cells could induce
changes of miRNA expression in endothelial cells, with miR-296 being significantly upregu‐
lated. Enhanced expression of miR-296 was also observed in endothelial cells treated with
glioma-conditioned medium or proangiogenic growth factor VEGF or EGF, as well as in
endothelial cells isolated from glioma samples. These results suggested a role for miR-296 in
angiogenesis. It was further demonstrated that miR-296 contributed to angiogenesis by
targeting hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), which controls
the levels of growth factor receptors (VEGFR2 and PDGFRb) by directing these macromole‐
cules to lysosomes for degradation. Importantly, intravenous administration of antimiR- 296
AMO significantly reduced angiogenesis in glioma xenografts in vivo[139]. These results
suggest that inhibition of angiogenesis by targeting miR-296 in endothelial cells may represent
an alternative approach in glioma therapy.
10. Conclusion
MiRNAs are an astonishing new class of gene regulators, and it had been demonstrated
that these molecules play a crucial role in cancer development and progression in a vari‐
ety of malignancies, including brain tumors. Most importantly, in a clinical context, there
is  first  evidence  that  miRNAs  might  provide  new  options  to  improve  diagnostics  and
therapy in the two most common malignant primary brain tumors in adults (glioblasto‐
ma)  and  children  (medulloblastoma).  In  vitro  and  in  vivo  data  suggest  that  miRNAs
could be used to discriminate brain tumors from normal brain tissue, and to identify dif‐
ferent astrocytoma grades. More important, clinico-pathological features seem to correlate
with miRNA expression in these tumors.  Furthermore,  there  is  increasing evidence that
miRNAs might help to generate targeted therapies and to overcome resistance to conven‐
tional anticancer strategies for example in glioblastomas. Of course, it has to be acknowl‐
edged  at  this  stage  that  translation  of  these  preliminary  “in  vitro  data”  into  “hard
clinical facts” is not feasible. But these findings provide a very promising basis for future
studies to determine the effect of miRNA modulation on chemotherapy in “in vivo stud‐
ies”.  Although  therapeutic  delivery  of  miRNAs  is  still  a  developing  field,  and  there  is
much more work to  be  done before  these  molecules  can be  securely  applied in  clinical
settings,  miRNA modulation may one day have a therapeutic application in patients.  In
summary,  the  presented  data  supports  the  enormous  clinical  potential  of  miRNAs  in
brain tumors, and mandate further intensive investigations in this field.
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Quian et al showed that let-7 expression is decreased in more than one third of pituitary
adenomas and is related to higher tumor grade, thus it may act as a tumor suppressor. Levels
of let-7 were found to be inversely correlated to HMGA2 expression [130], confirming some
previous studies which showed that HMGA2 is repressed by let-7 [131]. High levels of HMGA2
have been detected in most types of pituitary adenomas [132] and they are significantly
associated with tumor grade, extent of invasion, tumor size and Ki-67 proliferation index,
probably through regulation of E-cadherin, E2F1, cyclin A, and p53 expression. Accordingly,
let-7 may be useful as a novel anticancer agent in the future [130]. A recent study on the role
of miRNAs in NFAs and GH-secreting pituitary tumors was performed by Butz et al, showing
that a group of miRNAs (miR-128a, miR-155, and miR-516a-3p) targets the 3'-untranslated
region of Wee1, a nuclear protein kinase that acts as a tumor suppressor, and which was found
to be significantly decreased in pituitary tumor samples [133].
9. Therapeutic potential of miRNAs
Current evidence indicates that miRNA deregulation is common in human cancers. The
discovery of miRNAs with oncogenic or tumor-suppressive function raises the possibility of
exploiting these RNA molecules for therapeutic intervention and the development of novel
therapies. The oncogenic miRNAs can be downregulated using antisense miRNA oligonu‐
cleotides (AMOs or antagomirs) or miRNA sponges[134,135], whereas tumor-suppressive
miRNAs may be targeted by replacement with miRNA mimetics.
AMOs  are  synthetic  oligonucleotides  with  sequence  complementary  either  to  mature
miRNA or its precursor and have been widely used to inhibit miRNA activities in vitro
and in vivo[136]. A number of chemical modifications to AMOs have been developed to
improve specific binding to target miRNAs and to resist nuclease degradation. These in‐
clude modifications at the 20-hydroxyl position (20-O-methyl (20OMe),  20-Omethoxyeth‐
yl(20MOE),  20-fluoro  (20F)  and  locked  nucleic  acids  (LNA)),  on  the  phosphorothioate
backbone,  and  conjugation  with  cholesterol  [137].  Of  these  modifications,LNA  shows
high  stability,  strong  affinity  for  target  miRNAs  and  low  toxicity  in  biological  system
and has emerged as a strong candidate for targeting miRNAs in vivo.  One clinical  trial
using  LNA  anti-miRNA  in  treating  human  disease  has  been  initiated  recently.  Using
LNA antimiR-21, Corsten et al. demonstrated that miR-21 knockdown in glioma cells led
to  an  increase  of  apoptotic  cell  death  and  a  significant  reduction  of  glioma  growth  in
vivo,  suggesting that  miR-21 is  a  potential  therapeutic  target.  They further showed that
combination of miR-21 suppression and the cytotoxic agent tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) resulted in enhanced caspase activity and synergistic
killing of glioma cells in vitro. When these treated glioma cells were implanted intracra‐
nially  into  nude mice,  tumor  cells  were  completely  eradicated  after  day  6  of  implanta‐
tion,  compared  to  reduced  tumor  volume  with  either  treatment  alone.  This  finding
suggests that miR-21 knockdown sensitizes glioma cells to apoptosis agent,  and that the
combined treatment is a promising approach for glioma elimination [138].
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Angiogenesis is a process essential for malignant glioma growth. By co-culturing glioma cells
with microvascular endothelial cells, Wurdinger et al. showed that glioma cells could induce
changes of miRNA expression in endothelial cells, with miR-296 being significantly upregu‐
lated. Enhanced expression of miR-296 was also observed in endothelial cells treated with
glioma-conditioned medium or proangiogenic growth factor VEGF or EGF, as well as in
endothelial cells isolated from glioma samples. These results suggested a role for miR-296 in
angiogenesis. It was further demonstrated that miR-296 contributed to angiogenesis by
targeting hepatocyte growth factor-regulated tyrosine kinase substrate (HGS), which controls
the levels of growth factor receptors (VEGFR2 and PDGFRb) by directing these macromole‐
cules to lysosomes for degradation. Importantly, intravenous administration of antimiR- 296
AMO significantly reduced angiogenesis in glioma xenografts in vivo[139]. These results
suggest that inhibition of angiogenesis by targeting miR-296 in endothelial cells may represent
an alternative approach in glioma therapy.
10. Conclusion
MiRNAs are an astonishing new class of gene regulators, and it had been demonstrated
that these molecules play a crucial role in cancer development and progression in a vari‐
ety of malignancies, including brain tumors. Most importantly, in a clinical context, there
is  first  evidence  that  miRNAs  might  provide  new  options  to  improve  diagnostics  and
therapy in the two most common malignant primary brain tumors in adults (glioblasto‐
ma)  and  children  (medulloblastoma).  In  vitro  and  in  vivo  data  suggest  that  miRNAs
could be used to discriminate brain tumors from normal brain tissue, and to identify dif‐
ferent astrocytoma grades. More important, clinico-pathological features seem to correlate
with miRNA expression in these tumors.  Furthermore,  there  is  increasing evidence that
miRNAs might help to generate targeted therapies and to overcome resistance to conven‐
tional anticancer strategies for example in glioblastomas. Of course, it has to be acknowl‐
edged  at  this  stage  that  translation  of  these  preliminary  “in  vitro  data”  into  “hard
clinical facts” is not feasible. But these findings provide a very promising basis for future
studies to determine the effect of miRNA modulation on chemotherapy in “in vivo stud‐
ies”.  Although  therapeutic  delivery  of  miRNAs  is  still  a  developing  field,  and  there  is
much more work to  be  done before  these  molecules  can be  securely  applied in  clinical
settings,  miRNA modulation may one day have a therapeutic application in patients.  In
summary,  the  presented  data  supports  the  enormous  clinical  potential  of  miRNAs  in
brain tumors, and mandate further intensive investigations in this field.
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1. Introduction
Carbonic anhydrases (CAs) are zinc-containing metalloenzymes present in prokaryotes and
eukaryotes (Sly and Hu 1995). CAs have been investigated since 1930´s (Meldrum and
Roughton 1933). They are important in normal human physiology, e.g., in gluconeogenesis,
lipogenesis, ureagenesis, bone resorption, and formation of gastric juice and cerebrospinal
fluid (Sly and Hu 1995, Pastoreková et al. 2004). There are at least 15 members in human alpha-
CA family: Five active family members are cytosolic (CA I-III, VII, and XIII), four are membrane
associated (CA IV, IX, XII, and XIV), two are mitochondrial (CA VA and VB), and one is a
secretory form (CA VI). In addition, there are three acatalytic forms, which are called CA-
related protein (CARPs). CAs can be categorized to catalytically active or inactive, intracellular
or extracellular, and wide-spread or restricted to few tissues.
Their main physiological fuction is to catalyze the conversion of CO2 to bicarbonate ion and




In addition to their functions in normal physiology, the roles of CAs in different diseases have
been extensively investigated during the last decades. They are involved in certain neurolog‐
ical and hereditary disorders, oedema, and most importantly, in cancer. There are at least three
tumor associated isoforms; CA II, IX and XII. Especially carbonic anhydrase IX (CA IX) has
been associated to neoplastic growth and cancer. The following chapter will discuss the role
of CA IX in brain tumors.
© 2013 Nordfors et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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2. Carbonic anhydrase IX
Carbonic anhydrase IX was first found by Pastroreková et al. (1992) and the CA9 gene was
cloned by the Pastrorek et al. (1994). Previously, a research group from Netherlands described
a monoclonal antibody, named G250, which stained cell membranes of renal cell carcinoma,
but did not stain normal epithelium (Oosterwijk et al. 1986). They continued their studies to
establish G250 as a tool in cancer diagnostics and treatment. Afterwards, the protein recog‐
nized by the G250 antibody was characterized to be CA IX (Grabmaier et al. 2000).
CA 9 gene was originally located to the chromosome 17q21.2 by fluorescence in situ hybridi‐
zation (Opavský et al. 1996), but it was later localized to the chromosome 9p13-p12 by radiation
hybrid mapping (http://www.ncbi.nlm.nih.gov/gene/768). CA9 gene consists of eleven exons
and ten introns (Opavský et al. 1996), and encodes a protein containing 466 amino acids. It has
a proteoglycan (PG) domain, central catalytic (CA) domain, transmembrane anchor, and short
COOH- terminal cytoplasmic tail. CA IX was initially called MN, found from human carcino‐
ma cell line, and later associated to neoplastic growth in carcinomas of ovary, uterine cervix
and endometrium (Závada et al. 1993). A detailed characterisation of human CA IX protein
has has shown that the recombinant CA IX protein exhibits the highest catalytic activity ever
measured for any CA isozyme (Hilvo et al. 2008).
3. Carbonic anhydrase IX in normal tissue
The expression of  CA IX in normal  tissues  has  been thoroughly investigated.  In  mouse
tissues, the highest expression has been detected in gastric mucosa, moderate expression in
colon and brain, whereas low expression has been reported in pancreas and small intes‐
tine (Hilvo et al. 2004). The similar distribution pattern has been detected in human tissues;
high  CA  IX  staining  has  been  discovered  in  GI-tract,  especially  in  the  epithelia  of  the
gallbladder and gastric mucosa (Pastorek et al. 1994, Pastoreková et al. 1997, Saarnio et al.
1998a). Furthermore, Saarnio et al. (1998b) have reported the most intensive signals of CA
IX  in  the  epitelium  of  the  duodenum and  jejunum,  whereas  the  expression  diminishes
towards the large intestine. Mesothelium, epithelial cells of the esophagus, and pancreatic
and biliary ducts express CA IX (Turner et al. 1997, Pastoreková et al. 1997, Kivelä et al.
2000, Ivanov et al. 2001). CA IX has been detected in the male reproductive organs, whereas
the female reproductive tract express only low amounts of CA IX (Liao et al. 1994; Karhumaa
et al. 2001). Generally, expression of CA IX is generally low in the human brain, although
positive signal has been reported in the epithelial cells of the choroid plexus (Ivanov et al.
2001, Proescholdt et al. 2005). Similarly, lower levels of CA IX mRNA have been reported
in the normal brain as compared to brain neoplasms (Said et al. 2007a).
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4. Carbonic anhydrase IX in neoplastic tissue
The von Hippel–Lindau (VHL) tumor suppressor gene was the first link to the major pathway
controlling CA IX expression (Wykoff et al. 2000). Importantly, CA IX turned out to be one of
the enzymes regulated by the hypoxia pathway, in which hypoxia inducible factor 1 (HIF-1)
plays a role as a key transcription factor, especially in hypoxic tumors. Under normoxia, the
encoded VHL protein (pVHL) binds to hydroxylated hypoxia inducible factor 1 – alpha and
causes degradation by the ubiquitin-mediated proteasome system, inactivating the down‐
stream target genes. (Ivanov et al.1998). HIF-1 is stabilized under hypoxic conditions and binds
to hypoxia-responsive elements in many genes, e.g VEGF, erythropoietin, and glucose
transporter. This leads to the induction of erythropoiesis, angiogenesis, and glycolysis
(Carmeliet et al. 1998). HIF-1 also activates CA9 gene and CA IX expression level increases
dramatically in hypoxic conditions. In line with this, high CA IX expression is often found in
perinecrotic regions of tumors (Wykoff et al. 2000). The similar induction of CA IX has been
proposed to take place in brain tumors. CA IX mRNA has been studied in human malignant
glioma cell lines and distinct patterns of hypoxic expression of CA IX have been observed (Said
et al. 2007b). The finding indicated that low oxygen concentration is probably the driving force
for the increased CA IX expression due to the presence of a hypoxia responsive element (HRE)
in the CA9 promoter (Wykoff et al. 2000). The activation of hypoxia-inducible genes is
illustrated in Figure 1.
Figure 1. Activation of hypoxia-inducible genes. Under normoxia, HIFα is degraded by ubiquitin-proteasome system.
Prolyl-4-hydroxylases (PHD) hydroxylate two conserved proline residues of HIF-1α, then von Hippel-Lindau protein
(VHL) binds to the hydroxylated HIF-1α. Under hypoxia, PHDs are inactive in the absence of dioxygen, and HIF-1α is not
recognized by VHL protein. HIF-1α accumulates and is translocated to the nucleus. HIF-1β constitutive subunit dimeriz‐
es with HIF-1α, resulting in the active transcription factor, which binds to hypoxia response element (HRE). Therefore
the transcription of target genes, such as CA9 and GLUT1, is induced. Adapted from Pastoreková et al. (2008) and
Haapasalo (2011).
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The overexpression of CAIX in majority of renal cell carcinomas (RCCs) is due to the loss of
functional VHL protein, which causes the stabilization of HIF-1. (Gnarra et al. 1994, Wykoff et
al. 2000). In other words, the CAs are no longer regulated by hypoxia. On the contrary, the
majority of tumors do not contain VHL mutations, and in these, CA IX is usually found in focal
perinecrotic areas, supporting the role of hypoxia in CA IX regulation (Wykoff et al. 2000).
Furthermore, it has been suggested that HIF activates genes that change the expression profile
of tumor cells suffering from hypoxia; thus, either leading to adaptation to the hypoxic stress
or resulting in cell death. If this adaptation is successful, the surviving tumor cell population
is associated with increasingly aggressive behaviour involving invasion and metastases,
resistance to anti-cancer treatment, and finally, worse patient prognosis. (Harris 2002). This
mechanism is supported by various immunohistochemical studies in which the CA IX
expression is located in in the perinecrotic regions of solid tumors.
The mechanisms behind the role of CA IX in cancer have been studied widely. The hypoxia,
measured by needle electrores, has been shown to correlate with CA IX expression in cervical
cancer (Loncaster et al. 2001). This finding has been further clarified in genetic analysis,
showing that CA9 was the most induced gene among the 32 identified hypoxia responsive
genes, which included VEGF, in human solid tumors (Lal et al. 2002). In vitro, CA9 has been
shown to be hypoxia-regulated in glioblastoma cells (Said et al. 2008).
The pivotal feature of the malignant tumor cells is their capability to maintain the normal
intracellular pH, whereas the extracellular pH is significantly acidic. CA IX increases the
extracellular acidification by shifting the site of CO2 hydration from intra- to extracellular
(Svastová et al. 2004). This in turn increases the capability of tumor cells to survive and invade,
and the selective sulfonamide inhibitors disturb this process. Acetazolamide, a potent CA
inhibitor, has been shown to suppress the invasion of renal cancer cells in vitro (Parkkila et al.
2000b). Interestingly, CA IX has an optimal catalytic activity for CO2 hydration to bicarbonate
and proton in acidic pH (Innocenti et al. 2009). Furthermore, when studied in cancer-derived
cell lines, CA IX diminishes the intracellular pH gradient in the hypoxic core of three-dimen‐
sional tumor spheroids (Swietach et al. 2008). These findings support the theory that CA IX is
an essential factor for tumor cells in adaptation to hypoxia and their survival, and is illustared
in Figure 2.
Even though the expression of CA IX is mainly regulated by hypoxia, it has been shown that
acidosis increases CA IX expression via a hypoxia-independent mechanism (Ihnatko et al.
2006). CA IX has been proposed to be regulated by low oxygen concentrations or constitutive,
oncogene-related mechanisms (Said et al. 2007a). Furthermore, CA IX modulates E-cadherin
mediated cell adhesion by decreasing the binding of this cell adhesion molecule to beta-catenin
(Svastová et al. 2003). This, in turn, could possibly benefit the cancer cells by an increase in cell
motility and invasion. As mentioned before, acetazolamide can suppress the invasion of renal
cancer cells in vitro (Parkkila et al. 2000b). However, the inhibition of CA IX in RNAi-treated
breast cancer cells reduced the invasion capacity only slightly (Robertson et al. 2004). There is
also evidence that CA IX expression is a negative predictive factor when evaluating the
treatment efficacy in oestrogen receptor-positive tumors treated with adjuvant tamoxifen after
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primary chemo-endocrine therapy (Generali et al. 2006). The role of CA IX in resistance to
chemotherapy could be explained by the effects of pH on tamoxifen uptake.
Ectopic expression of CA IX is induced in various tumors. These include the malignancies of
breast, cervix uteri, esophagus, kidney, and lung (Liao et al. 1994, McKiernan et al. 1997, Liao
et al. 1997, Turner et al. 1997, Vermylen et al. 1999, Bartosová et al. 2002). When these tumors
are considered, CA IX is absent in the corresponding normal tissue. Conversely, CA IX
expression is usually absent or reduced in tumors which have originated from CA IX-positive
tissues. These include carcinomas of stomach and gallbladder (Saarnio et al. 2001, Leppilampi
et al. 2003). This makes the CA IX a promising molecule as a prognostic factor as well as a
potential target for therapeutic methods.
In cervical cancer, the CA IX expression correlates to tumor hypoxia and poor patient prog‐
nosis, and could be used in the selection of suitable patients for hypoxia-modification therapies
(Loncaster et al. 2001). In lung cancer CA IX is a marker of poor prognosis (Swinson et al.
2003, Kim et al. 2004), and it has been associated to proteins linked to angiogenesis, disruption
of cell-cell adhesion and inhibition of apoptosis (Giatromanolaki et al. 2001). CA IX could also
been used as a differentiation tool between preneoplastic lesions and lung cancer (Vermylen
et al. 1998) and a high concentration of CA IX in plasma serves as a independent prognostic
Figure 2. Example of pH regulation in a cancer cell under hypoxia. This is controlled by HIF-1 mediated gene activa‐
tion. The rapid metabolic rate requires glucose which is transported to the cell by the glucose transporter (GLUT1).
Glycolysis produces lactate and protons, which are transported to extracellular space by the H+/monocarboxylate
transporter 4 (MCT4). The transmebrane CA IX (and XII), and cytosolic CA II prevent intracellular acidification and
maintain the physiological pH. Anion exchangers (AE) transport bicarbonate to cytosol, which then buffers the pro‐
tons produced by the active metabolism. Resulting CO2 is secreted from the cell by diffusion. The Na+/H+ exchanger 1
(NHE1) participates in the secretion of proton. The HIF-mediated machinery and oncogenic pathways result in secre‐
tion of protons and CO2 to extracellular space, thus promoting the breakdown of the extracellular matrix and invasion
of tumor cells. Adapted from Pastoreková et al. (2008) and Haapasalo (2011).
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expression is located in in the perinecrotic regions of solid tumors.
The mechanisms behind the role of CA IX in cancer have been studied widely. The hypoxia,
measured by needle electrores, has been shown to correlate with CA IX expression in cervical
cancer (Loncaster et al. 2001). This finding has been further clarified in genetic analysis,
showing that CA9 was the most induced gene among the 32 identified hypoxia responsive
genes, which included VEGF, in human solid tumors (Lal et al. 2002). In vitro, CA9 has been
shown to be hypoxia-regulated in glioblastoma cells (Said et al. 2008).
The pivotal feature of the malignant tumor cells is their capability to maintain the normal
intracellular pH, whereas the extracellular pH is significantly acidic. CA IX increases the
extracellular acidification by shifting the site of CO2 hydration from intra- to extracellular
(Svastová et al. 2004). This in turn increases the capability of tumor cells to survive and invade,
and the selective sulfonamide inhibitors disturb this process. Acetazolamide, a potent CA
inhibitor, has been shown to suppress the invasion of renal cancer cells in vitro (Parkkila et al.
2000b). Interestingly, CA IX has an optimal catalytic activity for CO2 hydration to bicarbonate
and proton in acidic pH (Innocenti et al. 2009). Furthermore, when studied in cancer-derived
cell lines, CA IX diminishes the intracellular pH gradient in the hypoxic core of three-dimen‐
sional tumor spheroids (Swietach et al. 2008). These findings support the theory that CA IX is
an essential factor for tumor cells in adaptation to hypoxia and their survival, and is illustared
in Figure 2.
Even though the expression of CA IX is mainly regulated by hypoxia, it has been shown that
acidosis increases CA IX expression via a hypoxia-independent mechanism (Ihnatko et al.
2006). CA IX has been proposed to be regulated by low oxygen concentrations or constitutive,
oncogene-related mechanisms (Said et al. 2007a). Furthermore, CA IX modulates E-cadherin
mediated cell adhesion by decreasing the binding of this cell adhesion molecule to beta-catenin
(Svastová et al. 2003). This, in turn, could possibly benefit the cancer cells by an increase in cell
motility and invasion. As mentioned before, acetazolamide can suppress the invasion of renal
cancer cells in vitro (Parkkila et al. 2000b). However, the inhibition of CA IX in RNAi-treated
breast cancer cells reduced the invasion capacity only slightly (Robertson et al. 2004). There is
also evidence that CA IX expression is a negative predictive factor when evaluating the
treatment efficacy in oestrogen receptor-positive tumors treated with adjuvant tamoxifen after
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primary chemo-endocrine therapy (Generali et al. 2006). The role of CA IX in resistance to
chemotherapy could be explained by the effects of pH on tamoxifen uptake.
Ectopic expression of CA IX is induced in various tumors. These include the malignancies of
breast, cervix uteri, esophagus, kidney, and lung (Liao et al. 1994, McKiernan et al. 1997, Liao
et al. 1997, Turner et al. 1997, Vermylen et al. 1999, Bartosová et al. 2002). When these tumors
are considered, CA IX is absent in the corresponding normal tissue. Conversely, CA IX
expression is usually absent or reduced in tumors which have originated from CA IX-positive
tissues. These include carcinomas of stomach and gallbladder (Saarnio et al. 2001, Leppilampi
et al. 2003). This makes the CA IX a promising molecule as a prognostic factor as well as a
potential target for therapeutic methods.
In cervical cancer, the CA IX expression correlates to tumor hypoxia and poor patient prog‐
nosis, and could be used in the selection of suitable patients for hypoxia-modification therapies
(Loncaster et al. 2001). In lung cancer CA IX is a marker of poor prognosis (Swinson et al.
2003, Kim et al. 2004), and it has been associated to proteins linked to angiogenesis, disruption
of cell-cell adhesion and inhibition of apoptosis (Giatromanolaki et al. 2001). CA IX could also
been used as a differentiation tool between preneoplastic lesions and lung cancer (Vermylen
et al. 1998) and a high concentration of CA IX in plasma serves as a independent prognostic
Figure 2. Example of pH regulation in a cancer cell under hypoxia. This is controlled by HIF-1 mediated gene activa‐
tion. The rapid metabolic rate requires glucose which is transported to the cell by the glucose transporter (GLUT1).
Glycolysis produces lactate and protons, which are transported to extracellular space by the H+/monocarboxylate
transporter 4 (MCT4). The transmebrane CA IX (and XII), and cytosolic CA II prevent intracellular acidification and
maintain the physiological pH. Anion exchangers (AE) transport bicarbonate to cytosol, which then buffers the pro‐
tons produced by the active metabolism. Resulting CO2 is secreted from the cell by diffusion. The Na+/H+ exchanger 1
(NHE1) participates in the secretion of proton. The HIF-mediated machinery and oncogenic pathways result in secre‐
tion of protons and CO2 to extracellular space, thus promoting the breakdown of the extracellular matrix and invasion
of tumor cells. Adapted from Pastoreková et al. (2008) and Haapasalo (2011).
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biomarker in patients with non-small cell lung cancer (Ilie et al. 2010). CA IX expression is
sensitive for diagnostics of mesothelioma and metastatic clear cell renal cell carcinoma of the
lung (Ramsey et al. 2012). Furthermore, CA IX expression has been associated with poor
prognosis for patients with head and neck cancer (Beasley et al. 2001, Koukourakis et al.
2001), esophageal cancer (Birner et al. 2011), ovarian cancer (Hynninen et al. 2006, Choschzick
et al. 2011), soft tissue sarcoma (Måseide et al. 2004), and bladder carcinoma (Hoskin et al.
2003). It has been confirmed in several studies that CA IX correlates with poor prognosis in
breast cancer (Chia et al. 2001, Brennan et al. 2006, Hussain et al. 2007) and is related to
overexpression of c-erbB2 (Bartosová et al. 2002).
The most widely investigated tumor type, considering CA IX, is renal cell carcinoma (RCC) in
which CA IX represents a useful marker (Liao et al. 1997, McKiernan et al. 1997, Parkkila et al.
2000a). In its most common subtype, clear cell carcinoma, CA IX expression is higher than in
other renal cell cancer types (Sandlund et al. 2007). In addition, patients with both conventional
renal cell cancer and low CA IX expression had a less favourable prognosis. In renal cancer
CA IX is a promising therapeutic target for novel oncological applications, including immu‐
notherapy and radioisotopic methods (Pastoreková et al. 2006, Bleumer et al. 2006). CA IX and
CA XII are functionally involved in tumor growth (Chiche et al. 2009). Renal cell cancer in
vivo experiments showed that CA9 gene silencing alone led to a 40% reduction in xenograft
tumor volume, and silencing of both CA9 and CA12 resulted in an 85% reduction in tumor
volume.
5. Carbonic anhydrases in adult brain tumors
The incidence of brain tumors is similar in different countries and rather stable over the past
two decades (Pollack et al. 2011). There are about 50 new pediatric and 1000 adult brain tumors
every year in Finland with five million habitants (Statistics Finland 2011). The etiology of brain
tumors has been under intense investigation but no clear evidence between different environ‐
mental, nutritional or lifestyle and carcinogenesis have been found (Baldwin et al. 2004). Most
common primary CNS tumors of the adult are gliomas and meningiomas. Glioblastoma is a
highly malignant and unfortunately common, glial tumor and the 5-year survival of the
patients is less than 10 % (Stupp et al. 2009). On the other hand, almost all (90-98%) patients
with meningioma are alive after five years (Statistics Finland 2011).
The expression of carbonic anhydrases in brain tumors has been previously reported (Parkkila
AK et al. 1995). The first findings assessed CA II, which was stained positively by immuno‐
histochemistry in astrocytic tumors, oligodendrogliomas and medulloblastomas. The expres‐
sion of CA IX was first reported by Ivanov et. al (2001). In this first study, they screened tumors
of different genetic background as well as several malignant cell lines for the expression of CA
IX. mRNA analysis revealed high-to-moderate levels of expression of CA9 and CA12 in glioma
cell lines. Immunolocalization of CA IX was further studied in 11 gliomas; low-grade gliomas
were not stained for CA IX, whereas grade III-IV gliomas were all CA IX positive. In addition,
3 oligodendrogliomas were included in the analysis and they failed to express CA IX. Fur‐
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thermore, all hemangioblastomas (3 tumors), meningiomas (5 tumors), and two out of three
choroid plexus tumors were positive for CA IX.
This overview of different tumors was followed by a study of Proescholdt et al. (2005) on CA
IX and CA XII, which combined brain tumors of different histology and grade of malignancy.
The material consisted of total of 112 tumor samples (grade I-IV astrocytomas, meningiomas,
metastases, primitive neuroectodermal tumors (PNETs), and hemangioblastomas). Generally,
low-grade astrocytomas did not show any positive staining for CA IX and the expression
increased with increasing WHO grade. The strongest staining of all glioma samples was
observed in the glioblastomas, and almost all of the samples (97%) were positive. In these, the
staining was detected around necrotic areas. However, more diffuse staining pattern without
any association to necrosis was detected and CA IX expression was found in almost all tumor
cells, including those near blood vessels, suggesting the induction also without the hypoxia-
inducible mechanism. In the meningiomas, increased CA IX staining, with diffuse and evenly
distributed pattern, was found in comparison to the normal brain. The authors found the most
widespread CA IX and XII staining of all tumors in hemangioblastoma samples.
As to brain tumors, the first large study to describe the expression of CA IX in human diffusely
infiltrating astrocytomas was published year after (Haapasalo et al. 2006). The study material
consisted of 362 diffusely infiltrating astrocytoma samples (grades II-IV), which were obtained
from surgically operated patients. Cellular CA IX immunopositivity was observed in 78% of
diffusely infiltrating astrocytomas and the percentages according the WHO grade were as
follows; 65% of grade II astrocytomas, 73% of grade 3 astrocytomas, and 82% of grade 4
astrocytomas. The immunohistochemial results were verified by mRNA analysis. The
statistical comparison of cytoplasmic CA IX intensity and tumor grade revealed significantly
higher CA IX intensity in tumors of higher malignancy grade. Again, CA IX was expressed in
areas close to the necrotic regions and cytoplasmic staining was seen in the neoplastic cells of
the infiltrative zone. When important clinicopathologial features were assessed, CA IX showed
no association with p53 expression nor did it correlate with epidermal growth factor receptor–
amplification, apoptosis, or cell proliferation by Ki-67/MIB-1. There was a significant correla‐
tion between increasing CA IX intensity and increasing patient age. For the first time, CA IX
positivity was associated to shortened patient survival in univariate analysis: CA IX intensity
divided the tumors into four significantly differing prognostic subsets (Figure 3). The survival
difference was even significant within grade II and grade IV tumors separately. Most impor‐
tantly, statistical analysis of the data revealed that the patient age, tumor grade, and CA IX
intensity all had independent prognostic value when evaluated by Cox multivariate analysis.
The finding that CA IX predicts poor prognosis has been confirmed by others. Korkolopoulou
et al. (2007) showed that increasing CA IX immunopositivity was associated with a shortened
survival in univariate analysis. Furthermore, they reported similar independent prognostica‐
tors in multivariate analysis including CA IX, tumor grade and patient age. The perinecrotic
distribution of CA IX immunostaining was detected and intensity increased in parallel with
the extent of necrosis and histological grade. In concordance, Sathornsumetee et al. (2008)
conducted a trial, in which patients with recurrent malignant astrocytomas treated with a
combination of VEGF -neutralizing antibodies were retrospectively evaluated. Survival
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biomarker in patients with non-small cell lung cancer (Ilie et al. 2010). CA IX expression is
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prognosis for patients with head and neck cancer (Beasley et al. 2001, Koukourakis et al.
2001), esophageal cancer (Birner et al. 2011), ovarian cancer (Hynninen et al. 2006, Choschzick
et al. 2011), soft tissue sarcoma (Måseide et al. 2004), and bladder carcinoma (Hoskin et al.
2003). It has been confirmed in several studies that CA IX correlates with poor prognosis in
breast cancer (Chia et al. 2001, Brennan et al. 2006, Hussain et al. 2007) and is related to
overexpression of c-erbB2 (Bartosová et al. 2002).
The most widely investigated tumor type, considering CA IX, is renal cell carcinoma (RCC) in
which CA IX represents a useful marker (Liao et al. 1997, McKiernan et al. 1997, Parkkila et al.
2000a). In its most common subtype, clear cell carcinoma, CA IX expression is higher than in
other renal cell cancer types (Sandlund et al. 2007). In addition, patients with both conventional
renal cell cancer and low CA IX expression had a less favourable prognosis. In renal cancer
CA IX is a promising therapeutic target for novel oncological applications, including immu‐
notherapy and radioisotopic methods (Pastoreková et al. 2006, Bleumer et al. 2006). CA IX and
CA XII are functionally involved in tumor growth (Chiche et al. 2009). Renal cell cancer in
vivo experiments showed that CA9 gene silencing alone led to a 40% reduction in xenograft
tumor volume, and silencing of both CA9 and CA12 resulted in an 85% reduction in tumor
volume.
5. Carbonic anhydrases in adult brain tumors
The incidence of brain tumors is similar in different countries and rather stable over the past
two decades (Pollack et al. 2011). There are about 50 new pediatric and 1000 adult brain tumors
every year in Finland with five million habitants (Statistics Finland 2011). The etiology of brain
tumors has been under intense investigation but no clear evidence between different environ‐
mental, nutritional or lifestyle and carcinogenesis have been found (Baldwin et al. 2004). Most
common primary CNS tumors of the adult are gliomas and meningiomas. Glioblastoma is a
highly malignant and unfortunately common, glial tumor and the 5-year survival of the
patients is less than 10 % (Stupp et al. 2009). On the other hand, almost all (90-98%) patients
with meningioma are alive after five years (Statistics Finland 2011).
The expression of carbonic anhydrases in brain tumors has been previously reported (Parkkila
AK et al. 1995). The first findings assessed CA II, which was stained positively by immuno‐
histochemistry in astrocytic tumors, oligodendrogliomas and medulloblastomas. The expres‐
sion of CA IX was first reported by Ivanov et. al (2001). In this first study, they screened tumors
of different genetic background as well as several malignant cell lines for the expression of CA
IX. mRNA analysis revealed high-to-moderate levels of expression of CA9 and CA12 in glioma
cell lines. Immunolocalization of CA IX was further studied in 11 gliomas; low-grade gliomas
were not stained for CA IX, whereas grade III-IV gliomas were all CA IX positive. In addition,
3 oligodendrogliomas were included in the analysis and they failed to express CA IX. Fur‐
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thermore, all hemangioblastomas (3 tumors), meningiomas (5 tumors), and two out of three
choroid plexus tumors were positive for CA IX.
This overview of different tumors was followed by a study of Proescholdt et al. (2005) on CA
IX and CA XII, which combined brain tumors of different histology and grade of malignancy.
The material consisted of total of 112 tumor samples (grade I-IV astrocytomas, meningiomas,
metastases, primitive neuroectodermal tumors (PNETs), and hemangioblastomas). Generally,
low-grade astrocytomas did not show any positive staining for CA IX and the expression
increased with increasing WHO grade. The strongest staining of all glioma samples was
observed in the glioblastomas, and almost all of the samples (97%) were positive. In these, the
staining was detected around necrotic areas. However, more diffuse staining pattern without
any association to necrosis was detected and CA IX expression was found in almost all tumor
cells, including those near blood vessels, suggesting the induction also without the hypoxia-
inducible mechanism. In the meningiomas, increased CA IX staining, with diffuse and evenly
distributed pattern, was found in comparison to the normal brain. The authors found the most
widespread CA IX and XII staining of all tumors in hemangioblastoma samples.
As to brain tumors, the first large study to describe the expression of CA IX in human diffusely
infiltrating astrocytomas was published year after (Haapasalo et al. 2006). The study material
consisted of 362 diffusely infiltrating astrocytoma samples (grades II-IV), which were obtained
from surgically operated patients. Cellular CA IX immunopositivity was observed in 78% of
diffusely infiltrating astrocytomas and the percentages according the WHO grade were as
follows; 65% of grade II astrocytomas, 73% of grade 3 astrocytomas, and 82% of grade 4
astrocytomas. The immunohistochemial results were verified by mRNA analysis. The
statistical comparison of cytoplasmic CA IX intensity and tumor grade revealed significantly
higher CA IX intensity in tumors of higher malignancy grade. Again, CA IX was expressed in
areas close to the necrotic regions and cytoplasmic staining was seen in the neoplastic cells of
the infiltrative zone. When important clinicopathologial features were assessed, CA IX showed
no association with p53 expression nor did it correlate with epidermal growth factor receptor–
amplification, apoptosis, or cell proliferation by Ki-67/MIB-1. There was a significant correla‐
tion between increasing CA IX intensity and increasing patient age. For the first time, CA IX
positivity was associated to shortened patient survival in univariate analysis: CA IX intensity
divided the tumors into four significantly differing prognostic subsets (Figure 3). The survival
difference was even significant within grade II and grade IV tumors separately. Most impor‐
tantly, statistical analysis of the data revealed that the patient age, tumor grade, and CA IX
intensity all had independent prognostic value when evaluated by Cox multivariate analysis.
The finding that CA IX predicts poor prognosis has been confirmed by others. Korkolopoulou
et al. (2007) showed that increasing CA IX immunopositivity was associated with a shortened
survival in univariate analysis. Furthermore, they reported similar independent prognostica‐
tors in multivariate analysis including CA IX, tumor grade and patient age. The perinecrotic
distribution of CA IX immunostaining was detected and intensity increased in parallel with
the extent of necrosis and histological grade. In concordance, Sathornsumetee et al. (2008)
conducted a trial, in which patients with recurrent malignant astrocytomas treated with a
combination of VEGF -neutralizing antibodies were retrospectively evaluated. Survival
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analysis revealed that high CA IX expression was associated with poor survival outcome.
VEGF was associated with radiographic response but not with survival. Interestingly, they
tested both CA IX and HIF simultaneously in a Cox model as separate factors, and only CA IX
remained as a statistically significant factor. One opposite result has been published in glioma
patient cohort (Flynn et al. 2008). In this study, no significant correlations between the CA IX
expression and patient survival or tumor grade were found, although the patients with CA
IX-positive tumors seemed to have a trend towards a worse prognosis. This might be due to
different immunostaining method used. The most reliable method for CA IX immunostaining
having no cross-reactivity with other CAs (Saarnio et al. 1998b), is based on M75 antibodies
used by us and e.g. Korkolopoulou et al. (2007). Flynn et al. (2008) had also smaller number of
patients. Yoo et. al (2010) assessed the issue again, and showed that CA IX expression was a
predictive factor for poor survival and correlated positively with increasing WHO grade.
The expression of CA IX has been studied in other gliomas as well. Järvelä et al. (2008) showed
by immunohistochemistry that 80% of studied 86 oligodendroglial tumors stained positively
for CA IX. In addition, CA IX predicted poor prognosis in univariate analysis and in multi‐
variate analysis CA IX expression, patient age and histological component (pure oligoden‐
droglioma vs. mixed oligoastrocytoma) showed independent prognostic values. Abraham et
Figure 3. Prognostic significance of CA IX in diffusely infiltrating astrocytomas (grades II-IV). Kaplan-Meier curves are
shown (p = 0.0011, log-rank test). Haapasalo J et al. (2006)
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al. (2012) have recently assessed the expression of all hypoxia related molecules HIF-1, VEGF,
Glut-1, and CA IX, in oligodendrogliomas. They found that all these proteins were statistically
significantly different between grade II and III oligodendrogliomas, anaplastic oligodendro‐
gliomas having stronger expression. Ingterestingly, low CA IX expression predicted better
prognosis in anaplastic oligodendrogliomas but not in grade II oligodendrogliomas, whereas
the prognostic significance was not reported in the whole tumor material.
As for mostly benign tumors, Yoo et al. (2007) showed that 50% of all meningiomas contained
regions of hypoxia as judged by expression of CA IX. CA IX expression was significantly
associated with higher-grade histology and tended to be more common in recurrent tumors.
Futhermore, Korhonen et al. (2009) reported 11.6% cytosolic CA IX expression in meningiomas.
CA IX positivity was neither associated with the studied clinicopathological factors nor
survival.
Recently, Jensen et al. (2012) assessed the molecular markers of hypoxia, vascularity, and
proliferation in meningeomas, including CA IX. As expected, VEGF, HIF, CA IX, and Glut-1
were positively correlated. There was an association between higher-grade tumors with higher
scores for CA IX, VEGF, and HIF-1alpha, but CA IX was not associated to overall survival.
CA IX is also significantly upregulated in craniopharyngiomas and is associated with increased
cyst size (Proescholdt et al. 2011). The mechanisms of CA IX regulation remain unknown, since
neither hypoxia nor p53 appear to play a role in these tumors. The authors state, that inhibition
of CA IX may be a potential target for the adjuvant treatment in patients with cystic cranio‐
pharyngiomas.
6. CA IX in pediatric brain tumors
Pediatric cancers are still the main cause of death in children aged 1-14 years in the UK and
Finland (Gatta et al. 2005, Statistics Finland 2011). After leukemia brain tumors are the second
most common tumor group. Approximately 60-70% of the patients with brain tumors are alive
five years from the diagnosis (Pokhrel and Hakulinen 2009). The most common pediatric brain
tumors are pilocytic astrosytoma, medulloblastoma and ependymoma. Neurosurgical
operation is the most important treatment modality. Inoperable or highly malignant tumors
are treated also with radio- and chemotherapy. CNS is vulnerable, especially when evolving.
Most of the patients do survive but the tumor and the different treatment modalities can cause
side effects that reduce the quality of life. Supratentorial tumors, tumor reoperations, shunt
revisions and chemotherapy increase the risk of these problems (Reimers et al. 2003, Pietilä et
al. 2012). There is only a limited scope for improvement with conventional chemotherapy and
thus, there is an urgent need of therapeutic agents for these patients. CA IX is one novel
molecule that might serve as a prognostic/diagnostic tool, and perhaps, a target for various
therapeutic methods.
Some publications have assessed the CA IX expression in pediatric brain tumors. Ivanov et al.
(2001) screened a small amount of brain tumors and found the following inmmunohistochem‐
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analysis revealed that high CA IX expression was associated with poor survival outcome.
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tested both CA IX and HIF simultaneously in a Cox model as separate factors, and only CA IX
remained as a statistically significant factor. One opposite result has been published in glioma
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IX-positive tumors seemed to have a trend towards a worse prognosis. This might be due to
different immunostaining method used. The most reliable method for CA IX immunostaining
having no cross-reactivity with other CAs (Saarnio et al. 1998b), is based on M75 antibodies
used by us and e.g. Korkolopoulou et al. (2007). Flynn et al. (2008) had also smaller number of
patients. Yoo et. al (2010) assessed the issue again, and showed that CA IX expression was a
predictive factor for poor survival and correlated positively with increasing WHO grade.
The expression of CA IX has been studied in other gliomas as well. Järvelä et al. (2008) showed
by immunohistochemistry that 80% of studied 86 oligodendroglial tumors stained positively
for CA IX. In addition, CA IX predicted poor prognosis in univariate analysis and in multi‐
variate analysis CA IX expression, patient age and histological component (pure oligoden‐
droglioma vs. mixed oligoastrocytoma) showed independent prognostic values. Abraham et
Figure 3. Prognostic significance of CA IX in diffusely infiltrating astrocytomas (grades II-IV). Kaplan-Meier curves are
shown (p = 0.0011, log-rank test). Haapasalo J et al. (2006)
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significantly different between grade II and III oligodendrogliomas, anaplastic oligodendro‐
gliomas having stronger expression. Ingterestingly, low CA IX expression predicted better
prognosis in anaplastic oligodendrogliomas but not in grade II oligodendrogliomas, whereas
the prognostic significance was not reported in the whole tumor material.
As for mostly benign tumors, Yoo et al. (2007) showed that 50% of all meningiomas contained
regions of hypoxia as judged by expression of CA IX. CA IX expression was significantly
associated with higher-grade histology and tended to be more common in recurrent tumors.
Futhermore, Korhonen et al. (2009) reported 11.6% cytosolic CA IX expression in meningiomas.
CA IX positivity was neither associated with the studied clinicopathological factors nor
survival.
Recently, Jensen et al. (2012) assessed the molecular markers of hypoxia, vascularity, and
proliferation in meningeomas, including CA IX. As expected, VEGF, HIF, CA IX, and Glut-1
were positively correlated. There was an association between higher-grade tumors with higher
scores for CA IX, VEGF, and HIF-1alpha, but CA IX was not associated to overall survival.
CA IX is also significantly upregulated in craniopharyngiomas and is associated with increased
cyst size (Proescholdt et al. 2011). The mechanisms of CA IX regulation remain unknown, since
neither hypoxia nor p53 appear to play a role in these tumors. The authors state, that inhibition
of CA IX may be a potential target for the adjuvant treatment in patients with cystic cranio‐
pharyngiomas.
6. CA IX in pediatric brain tumors
Pediatric cancers are still the main cause of death in children aged 1-14 years in the UK and
Finland (Gatta et al. 2005, Statistics Finland 2011). After leukemia brain tumors are the second
most common tumor group. Approximately 60-70% of the patients with brain tumors are alive
five years from the diagnosis (Pokhrel and Hakulinen 2009). The most common pediatric brain
tumors are pilocytic astrosytoma, medulloblastoma and ependymoma. Neurosurgical
operation is the most important treatment modality. Inoperable or highly malignant tumors
are treated also with radio- and chemotherapy. CNS is vulnerable, especially when evolving.
Most of the patients do survive but the tumor and the different treatment modalities can cause
side effects that reduce the quality of life. Supratentorial tumors, tumor reoperations, shunt
revisions and chemotherapy increase the risk of these problems (Reimers et al. 2003, Pietilä et
al. 2012). There is only a limited scope for improvement with conventional chemotherapy and
thus, there is an urgent need of therapeutic agents for these patients. CA IX is one novel
molecule that might serve as a prognostic/diagnostic tool, and perhaps, a target for various
therapeutic methods.
Some publications have assessed the CA IX expression in pediatric brain tumors. Ivanov et al.
(2001) screened a small amount of brain tumors and found the following inmmunohistochem‐
Carbonic Anhydrase IX in Adult and Pediatric Brain Tumors
http://dx.doi.org/10.5772/52358
541
istry results: most of the 7 central/peripheral PNETs expressed the CA IX, all of 6 studied
epedymomas were posivive. Preusser et al. (2005) assessed the CA IX in intracranial ependy‐
momas: 84 out of 100 tumors expressed CA IX, and it was associated with a bizarre angiogen‐
esis and necrosis. However, CA IX failed to reach a prognostic significance in univariate
analysis. The most common, solid, extracranial pediatric nervous tumor is neuroblastoma.
Dungwa et al. (2012) found positive membranous/cytoplasmic CA IX expression in 21 (23%)
of 91 neuroblastomas but was absent in ganglioneuromas. Neuroblastomas with 1p deletion
and MYCN amplification had even stronger membranous expression. 18% of the neuroblas‐
tomas showed nuclear CA IX expression in 10% or more tumoral cells. Nuclear CA IX
expression associated with worse overall –and event-free survival.
We have previously studied CA IX in 39 medulloblastomas and PNETs (Nordfors et al. 2010).
CA IX positivity was found in 23% of tumors and the expression was linked to necrosis. CA
IX expression was analysed in concordance with various clinical features and molecular
markers. Proliferation (Ki-67/MIB-1), apoptosis or expression of Bcl-2, p53 or c-erbB-2 were
not associated with CA IX in any of the groups except for the correlation between positive c-
erbB-2 and positive CA IX expression in PNETs. CA IX was also positively associated with
female gender. There was no significant difference in the expression of CA IX between primary
and recurrent tumors in any of the groups. Moreover, there was no correlation between the
tumor type (MBs/PNETs) and CA IX intensity. Interestingly, CA IX-positivity was a marker
of worse outcome in patients with MB/PNET in univariate and multivariate analyses (Figure
4). Generally, CA IX is associated with higher grade, necrosis, and worse CA IX seems to have
several inductors. CA IX is often found in perinecrotic areas. Because necrosis is an uncommon
feature and is not considered to be a significant prognostic factor in MBs, the induction of CA
IX in MBs/PNETs may also involve hypoxia-independent mechanisms. In addition, there is
the evidence that CA IX is expressed in grade I pilocytic astrocytomas, and the immunoposi‐
tivity for CA IX is associated to histopathological features of degeneration and increased
proliferation (our unpublished results).
In children, possible side-effects of therapeutic interventions may be more severe and the exact
biology of hypoxia and its clinical relevance in childhood tumors is still unclear. Thus, further
studies will be needed before novel agents concerning hypoxia can be introduced into pediatric
oncology.
7. Future aspects
The tumor tissue specific CA IX expression has led researchers to propose several novel
treatment strategies. A promising treatment strategy is to use CA selective inhibitors
(Pastoreková et al. 2004). Tumor cells probably use CAs as key enzymes to adapt to the hostile
environment caused by metabolic stress of cancer cells, and thus, acidification facilitates the
spread and invasion of cancer cells (Svastová et al. 2004). High CA IX expression might increase
the capability of cells to infiltrate the neighboring tissue. The inhibition of this process would
potentially disturb the invasion processes of cancer cells.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications542
Another possible treatment option is to use cancer-specific antibodies. The CA and proteo‐
glycan domains give the molecule a unique extracellular structure. CA IX expression is high
in renal cell carcinoma (Liao et al. 1997) and this has enabled therapeutic trials with high-dose
radiolabeled CA IX antibody (cG250) and CA IX-loaded dendritic cells. Unfortunately, a
significant breakthrough in clinical trials remains to be achieved and in RCC trials are still in
phase II (Stillebroer et al. 2010).
CA IX could also be used as a potential target for immune therapy. Greiner et al. (2006)
found a significant correlation between high mRNA levels of CA IX and a longer overall
survival  in  acute  myeloid  leukemia.  This  might  be  due  to  the  induction  of  a  strong
antileukemic immune response by CA IX. Similar findings have been found in metastatic
RCC patients (Uemura et al. 2006). Vaccination with tumor-RNA pulsed dendritic cells led
to increased numbers of CA IX peptide-specific cytotoxic T76 lymphocytes and IgG levels
without any major adverse event. Metastasis of three patients shrank or even disappeared
and  the  overall  survival  was  longer  for  six  patients.  However,  further  studies  are  re‐
quired to confirm these findings in larger study cohorts.
Bevacizumab, an anti-VEGF antibody, inhibits the developing vasculature of tumors, but
resistance is common. Antiangiogenic therapy induces hypoxia and thus, CA IX. Curious‐
ly, McIntyre et al. (2012) knocked down CAIX expression in a colon cancer and a glioblas‐
toma  cell  lines  and  combined  the  results  with  bevacizumab.  They  found  that  CAIX
expression was associated with increased necrosis and apoptosis in vivo and in vitro. Added
Figure 4. Prognostic significance of CA IX in medulloblastomas/PNETs. Kaplan-Meier curves are shown (P = 0.041, log-
rank test). Nordfors et al. (2010)
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istry results: most of the 7 central/peripheral PNETs expressed the CA IX, all of 6 studied
epedymomas were posivive. Preusser et al. (2005) assessed the CA IX in intracranial ependy‐
momas: 84 out of 100 tumors expressed CA IX, and it was associated with a bizarre angiogen‐
esis and necrosis. However, CA IX failed to reach a prognostic significance in univariate
analysis. The most common, solid, extracranial pediatric nervous tumor is neuroblastoma.
Dungwa et al. (2012) found positive membranous/cytoplasmic CA IX expression in 21 (23%)
of 91 neuroblastomas but was absent in ganglioneuromas. Neuroblastomas with 1p deletion
and MYCN amplification had even stronger membranous expression. 18% of the neuroblas‐
tomas showed nuclear CA IX expression in 10% or more tumoral cells. Nuclear CA IX
expression associated with worse overall –and event-free survival.
We have previously studied CA IX in 39 medulloblastomas and PNETs (Nordfors et al. 2010).
CA IX positivity was found in 23% of tumors and the expression was linked to necrosis. CA
IX expression was analysed in concordance with various clinical features and molecular
markers. Proliferation (Ki-67/MIB-1), apoptosis or expression of Bcl-2, p53 or c-erbB-2 were
not associated with CA IX in any of the groups except for the correlation between positive c-
erbB-2 and positive CA IX expression in PNETs. CA IX was also positively associated with
female gender. There was no significant difference in the expression of CA IX between primary
and recurrent tumors in any of the groups. Moreover, there was no correlation between the
tumor type (MBs/PNETs) and CA IX intensity. Interestingly, CA IX-positivity was a marker
of worse outcome in patients with MB/PNET in univariate and multivariate analyses (Figure
4). Generally, CA IX is associated with higher grade, necrosis, and worse CA IX seems to have
several inductors. CA IX is often found in perinecrotic areas. Because necrosis is an uncommon
feature and is not considered to be a significant prognostic factor in MBs, the induction of CA
IX in MBs/PNETs may also involve hypoxia-independent mechanisms. In addition, there is
the evidence that CA IX is expressed in grade I pilocytic astrocytomas, and the immunoposi‐
tivity for CA IX is associated to histopathological features of degeneration and increased
proliferation (our unpublished results).
In children, possible side-effects of therapeutic interventions may be more severe and the exact
biology of hypoxia and its clinical relevance in childhood tumors is still unclear. Thus, further
studies will be needed before novel agents concerning hypoxia can be introduced into pediatric
oncology.
7. Future aspects
The tumor tissue specific CA IX expression has led researchers to propose several novel
treatment strategies. A promising treatment strategy is to use CA selective inhibitors
(Pastoreková et al. 2004). Tumor cells probably use CAs as key enzymes to adapt to the hostile
environment caused by metabolic stress of cancer cells, and thus, acidification facilitates the
spread and invasion of cancer cells (Svastová et al. 2004). High CA IX expression might increase
the capability of cells to infiltrate the neighboring tissue. The inhibition of this process would
potentially disturb the invasion processes of cancer cells.
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Another possible treatment option is to use cancer-specific antibodies. The CA and proteo‐
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significant breakthrough in clinical trials remains to be achieved and in RCC trials are still in
phase II (Stillebroer et al. 2010).
CA IX could also be used as a potential target for immune therapy. Greiner et al. (2006)
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without any major adverse event. Metastasis of three patients shrank or even disappeared
and  the  overall  survival  was  longer  for  six  patients.  However,  further  studies  are  re‐
quired to confirm these findings in larger study cohorts.
Bevacizumab, an anti-VEGF antibody, inhibits the developing vasculature of tumors, but
resistance is common. Antiangiogenic therapy induces hypoxia and thus, CA IX. Curious‐
ly, McIntyre et al. (2012) knocked down CAIX expression in a colon cancer and a glioblas‐
toma  cell  lines  and  combined  the  results  with  bevacizumab.  They  found  that  CAIX
expression was associated with increased necrosis and apoptosis in vivo and in vitro. Added
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to this, acidity seemed to inhibit CAIX activity, and this may be the mechanism whereby
excess  acid  self-limits  the  build-up  of  extracellular  acid.  It  seems  that  inhibition  of  the
hypoxic  adaptation  to  antiangiogenic  therapy  enhances  bevacizumab  treatment  and
highlights the value of developing small molecules or antibodies which inhibit CAIX for
combination therapy.
8. Conclusions
CA IX has been linked to several cancer tissues, whereas the normal tissue is mostly negative.
This seems to be the case also when different brain tumors are concerned. Malignant astrocy‐
tomas and oligodendrogliomas express CA IX and it has been shown as a useful prognostica‐
tor. Being a hypoxia/necrosis marker, CA IX can be used as a diagnostic tool in the grading of
astrocytomas and oligodendrogliomas. Tumor biopsies containing a small amount of tissue
for diagnosis, are especially good targets. In addition, CA IX is associated to more malignant
phenotype in meningiomas and some other mostly benign brain tumors.
CA IX is present in the most common malignant brain tumor of children, medulloblastoma,
as well as in PNETs. Interestingly, in these tumors CA IX predicts poor prognosis and could
be used as a marker when planning the cancer therapy. Added to this, CA IX has been shown
to be expressed in other pediatric brain tumors, such as ependymomas and pilocytic astrocy‐
tomas, where it is linked to degenerative histopathological features.
CA IX is associated with hypoxia, necrosis, and angiogenesis – features traditionally linked to
the tumorigenesis of brain tumors. Several studies show that CA IX could be used as a target
molecule in adult and pediatric brain tumors. Further clinical trials for cancer treatment are
needed aiming to either eradicate the tumor cell population or turn the tumor into a more
chronic and stable disease.
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1. Introduction
The outstanding progress in advanced molecular technologies has provided a tremendous
amount of data that has altered the way in which we classify and categorize pediatric brain
tumors. From the initial identification of chromosomal aberrations by karyotyping and com‐
parative genomic hybridization, we have rapidly moved to expression array studies and to
integrative genomic approaches which allowed the stratification of several pediatric brain
tumors into molecular subgroups. These data have not only increased our understanding of
the molecular pathogenesis of pediatric brain tumors, but have also identified prognostic
markers and opened new avenues for targeted therapies.
One of the most important discoveries in pediatric astrocytomas was the duplication and the
mutation of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene, found in pi‐
locytic astrocytomas and malignant astrocytomas, respectively. Clinical trials using BRAF
signaling pathway inhibitors are currently ongoing.
Until recently, the biology of diffuse intrinsic pontine glioma (DIPG) was poorly under‐
stood. Overexpression of epidermal growth factor receptor (EGFR) and platelet-derived
growth factor receptor alpha (PDGFRα) amplification have now been reported in multiple
studies in DIPG and clinical trials with the respective inhibitors (nimotuzumab for EGFR
and dasatinib for PDGFRα), alone or in combination with other drugs, are in progress.
Integrated genomics has shown that medulloblastoma, the most common malignant pedia‐
tric brain tumor, comprises four distinct molecular and clinical variants. The stratification of
patients into the Wnt subgroup, the sonic hedgehog (SHH) subgroup, Group 3 and Group 4
may lead to the identification of those patients that will most likely benefit from targeted
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therapies, like SMO inhibitors. Moreover, this molecular classification may help identify pa‐
tients predicted to have a poor prognosis, who may benefit from intensified therapies, and
patients with a favorable prognosis that potentially benefit from reduced radiation and che‐
motherapy regimens. It is already known from four independent studies that the Wnt sub‐
group patients have a very good prognosis while patients in Group 3 have a high incidence
of metastasis and a dismal prognosis.
The transcriptional profiling of two large independent cohorts of posterior fossa ependymo‐
mas also identified two groups with distinct molecular and clinical features. Group A epen‐
dymomas have a balanced genome, occur in younger patients and tumors are located
laterally. These patients have a worse clinical outcome and higher incidence of metastasis
and recurrence. In contrast, Group B ependymomas occur in the midline and have a better
prognosis. Since ependymomas are usually refractory to current chemotherapeutic agents,
these discoveries may shed some light into the pathways involved in tumor initiation and
progression and also identify new targets for therapy.
We are now facing the next-generation (Next-Gen) sequencing era which will provide further
insights into the dysregulated signaling pathways in each tumor type. The identification of
driver mutations will allow a better understanding of tumorigenesis and lead to the develop‐
ment of more accurate preclinical models. Moreover, the profiling of transcriptomes, genetic
and epigenetic events of large cohorts of tumors will eventually shed some light into the cells of
origin of specific subgroups and also the important driver events for tumor initiation, mainte‐
nance and progression. On the clinical side, this knowledge will allow the stratification of pa‐
tients into appropriate risk groups and the tailoring of treatments according to each tumor’s
genomic landscape. In this chapter we describe the latest advances in molecular genomics of
the most common pediatric brain tumors as well as its prognostic significance and relevance to
the clinic. We also highlight the most recent clinical trials using molecular targeted therapies
and discuss further possible avenues in the treatment of pediatric brain cancer.
2. Astrocytomas
Astrocytomas are a common brain tumor in children. According to the 2007 classification of the
World Health Organization (WHO) they can be classified into four grades (WHO grade I-IV),
which reflect their biological and clinical behavior. Pilocytic astrocytomas (WHO grade I) rep‐
resent the most frequent brain tumor in the pediatric population and have excellent survival
rates over 95% [1]. On the other hand, glioblastomas (WHO grade IV) are aggressive tumors,
often non-responsive to treatments and with survival rates ranging from 10% to 30% [1]. We
will focus on the molecular biology of these two types of pediatric astrocytomas.
2.1. Pilocytic astrocytoma
The first-line treatment for pilocytic astrocytoma (PA) is surgical resection. Although most
children with these tumors survive for a long time, some will experience tumor recurrence,
especially if the tumor resection is incomplete. Recurrent and progressive tumors are treated
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with radiation and/or chemotherapy but, until recently, the mechanisms of recurrence and
malignant transformation were poorly understood.
Early studies on chromosomal aberrations in PAs showed normal karyotypes in most cas‐
es. Trisomy of chromosomes 5 and 7 and 7q gains were some of the few cytogenetic ab‐
normalities  found  [2].  Using  an  array-based  comparative  genomic  hybridization  (array-
CGH),  Pfister  et  al.  studied  a  large  series  of  pediatric  low-grade  astrocytomas  and
uncovered mechanisms of mitogen-activated protein kinase (MAPK) activation in these tu‐
mors. The authors identified a tandem duplication of the BRAF gene locus (7q34) in more
than 50% of the PAs and, in a smaller percentage (~6%) of tumors, a BRAF activating mu‐
tation V600E (a valine to glutamate change at hotspot codon 600) [3]. Later, it was demon‐
strated that the constitutive activation of BRAF was due to a fusion between a novel gene
(KIAA1549) and the BRAF oncogene and also that this fusion was related to a better clini‐
cal outcome in incompletely resected low-grade astrocytomas [4]. Other, less frequent, re‐
ported gene fusions in PAs include the fusion of BRAF  with the FAM131B  gene and the
fusion between a Raf kinase family member (RAF1) and SLIT-ROBO Rho GTPase-activat‐
ing protein 3 (SRGAP3) gene [5]. The combined analysis of BRAF and isocitrate dehydro‐
genase 1 (IDH1) was shown to be both sensitive and specific to separate PAs from diffuse
astrocytomas (WHO grade II). PAs contained the KIAA1549:BRAF  fusion in 70% of cases
but no IDH2  or IDH2  mutations while diffuse astrocytomas exhibited 76% of cases with
IDH1  mutations but no BRAF  fusion [6]. There is also an interesting correlation between
tumor location and the type of MAPK alteration. Posterior fossa tumors usually have in‐
creased  incidence  of  KIAA1549:BRAF  fusion  while  supratentorial  tumors  have  high  fre‐
quency  of  BRAFV600E  mutation.  Approximately  80-90%  of  PA  cases  reported  in  the
literature have at least one alteration in the MAPK pathway. Interestingly, all the altera‐
tions described in the MAPK pathway seem to be mutually exclusive suggesting that  a
single hit may be sufficient to induce transformation [5].
With the discovery of constitutive activation of MAPK pathway and BRAF alterations in
most PAs, there has been an increasing interest in using these targets for novel therapeutic
approaches. A number of phase I and phase II clinical trials are ongoing to test small mole‐





MEK inhibitor AZD6244 Phase I NCT01386450, NCT01089101
RAF inhibitor
(multikinase inhibitor)
Sorafenib Phase II NCT01338857 (suspended)
mTOR inhibitor Everolimus Phase II NCT01158651, NCT00782626
Table 1. Pediatric clinical trials for pilocytic astrocytomas using targeted therapies
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Glioblastoma multiforme (GBM) is the most common brain tumor in adults and is less fre‐
quent in the pediatric population. Despite improvements in neurosurgery and neuro-oncol‐
ogy, children diagnosed with GBM still have a dismal outcome with low survival rates even
with aggressive therapeutic regimens. Although the histology of pediatric and adult GBMs
appears identical, the molecular biology of these tumors is different. Therefore, the develop‐
ment of effective therapies for GBM in children should probably not rely on advances made
in adult tumors.
Mutations in phosphatase and tensin homolog (PTEN) and amplifications of EGFR are com‐
mon in adult malignant gliomas but less frequent in the pediatric setting. However, when
compared to pediatric low-grade gliomas, pediatric GBMs have a significant higher expres‐
sion of EGFR, although with no reported mutations and few deletions (~17%) in EGFRvIII
[7]. While in adult GBMs the activation of the AKT pathway is a result of PTEN mutations,
in pediatric tumors these are infrequent, although overexpression of AKT and its association
with poor survival has been reported [8,9]. In a study with a large cohort of pediatric high-
grade gliomas (HGGs) (37 GBMs out of 63 tumor samples), Bax et al. identified PDGFRα
amplification and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion as the most
frequent focal events. Interestingly, the patients with high-grade tumors and a stable ge‐
nomic profile had a better survival, independent of the histological grade or type [10]. Sever‐
al studies showed that IDH1 mutations, common in adult secondary GBM (98%), are rare in
pediatric GBM [7]. TP53 (tumor protein 53) mutations were reported in pediatric high-grade
tumors with an increased frequency in older children (40%) when compared to those less
than 3 years (12%) [11]. Overexpression of p53, but not TP53 mutations, was also associated
with a significant reduction in the 5 year progression-free survival [12]. A recent study used
high resolution single nucleotide polymorphism (SNP) arrays to identify novel chromoso‐
mal alterations in pediatric GBM, including amplifications of 7q21-22 and 1q43-44 and loss
of heterozygosity (LOH) in15q15.1-15q23 and 17p13-17p11.2. Genes involved in cell-cycle
regulation and cell death pathways were the predominant targets of LOHs [13].
It has been shown that overexpression of O6-methylguanine-DNA methyltransferase
(MGMT) is rare in HGGs but it has also been reported that it is associated with a poor over‐
all survival in children. The MGMT gene encodes a DNA-repair enzyme that can reduce the
efficacy of alkylating agents. When the MGMT gene is silenced by promoter methylation,
DNA repair in tumor tissue is compromised and patients have a better survival [7].
Finaly, a very recent study uncovered an interesting interplay between genetic and epige‐
netic events in pediatric GBM. The authors performed whole-exome sequencing in 48 pedia‐
tric GBMs and identified 44% of tumors harbouring somatic mutations in genes involved in
the chromatin remodeling pathway, including the histone H3 gene (H3F3A), the α-thalassae‐
mia/mental retardation syndrome X-linked (ATRX) gene and the death-domain associated
protein (DAXX) gene [14]. Interestingly, the H3F3A mutations were found to be specific of
GBMs and more prevalent in the pediatric population. Moreover, 54% of all cases and 86%
of patients with H3F3A and/or ATRX mutations, also showed TP53 somatic mutations [14].
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The novel targeted therapies that are currently under clinical investigation for high-grade
gliomas, including GBM, are reviewed in reference [15].
3. Diffuse intrinsic pontine glioma
Despite decades of clinical research, the prognosis of diffuse intrinsic pontine glioma (DIPG)
remains dismal with more than 90% of affected children dying within two years of diagnosis
[16]. The only known effective treatment is radiation therapy although in most patients it
has a transient effect. Different combinations of chemotherapy, radiation and radiosensitiz‐
ers were attempted but failed to improve long-term survival [17]. The indication for biopsy
in DIPG has been reserved for atypical tumors (prominent enhancement in magnetic resso‐
nance imaging (MRI), low T2/FLAIR signal and/or high signal on diffuse imaging). Howev‐
er, the recognition that it is crucial to understand the biology of DIPG in order to design
more rational drug treatments, led to a plea for routine biopsies in these patients. Some
groups are already performing regular image-guided stereotactic biopsies in patients with
DIPGs [18,19] and, furthermore, biopsies have been included in a clinical trial to decide
which patients with DIPG would benefit from targeted therapy with erlotinib, an EGFR in‐
hibitor [20]. Autopsies became another important source of DIPG tissue collection. Recent
studies showed that up to 50% of parents agree with the autopsy and, if done within a short
period of time after death, it is possible to obtain good quality DNA and RNA and even cul‐
ture primary DIPG cell lines [21-23].
The paradigm shift to obtain tissue from patients with DIPG not only increased our knowl‐
edge in the molecular biology of the disease but also raised important clinical considera‐
tions. Paugh et al. described differences at the copy number and expression level in both
adult and pediatric HGGs, including DIPGs. They showed that gain of chromosome 1q and
PDGFRα amplification were frequent in children while chromosome 7 gain, 10q loss and
EGFR amplification were characteristic of adult HGGs [24]. The identification of these two
distinct biological entities has important clinical implications since pediatric clinical trials
over the past decades have been designed with drugs known to have some activity in adult
HGGs. It is now clear that DIPG has to be considered and treated as a separate disease. The
same group compared the copy number alterations (CNAs) in DIPGs and nonbrainstem pe‐
diatric glioblastomas concluding that they are also genomically distinct. They identified re‐
ceptor tyrosine kinase and retinoblastoma protein (RB) amplifications in 47% and 30% of
DIPG cases, respectively, and found high frequency of focal amplifications of PDGFRα, MET
and insuline-like growth factor receptor 1 (IGF1R) [25]. Furthermore, Zarghooni et al., using
SNP arrays, showed that DIPGs have distinct CNAs from pediatric supratentorial high-
grade astrocytomas, with gains in PDGFRα and poly (ADP-ribose) polymerase-1 (PARP-1)
amongst the most frequent [26]. Another group showed other differences between these tu‐
mors including frequent losses of 17p and 14q in DIPGs [27]. A very recent study used DNA
from tumor tissue obtained at diagnosis by steriotactic biopsies and identified oncogenic
mutations in TP53 (40%), PI3KCA (15%) and ATM/MPL (5%). In fact, PI3KCA represents the
first mutated oncogene described in DIPG [28].
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The novel targeted therapies that are currently under clinical investigation for high-grade
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Another level of gene expression regulation in DIPG occurs through epigenetic mechanisms,
including histone modifications. Very recent sudies used whole-genome sequencing in large
cohorts of DIPGs to identify somatic mutations in the H3F3A gene. Khuong-Quang et al. re‐
ported mutations in H3.3 that resulted in the substitution of lysine by methionine at amino
acid 27 (K27M-H3.3) in 71% of cases and the presence of these mutations were associated
with a worse survival independent of patient age and histological grade [29]. Furthermore,
gains or amplifications in PDGFRα and MYC/PVT1 were exclusively seen in K27M-H3.3 mu‐
tants. The authors also described TP53 mutations in 77% and ATRX mutations in 9% of
DIPGs [29]. Interestingly, both the mutated and wild-type H3.3 subgroups showed high fre‐
quency of TP53 mutation. In another study, Wu et al. identified mutations in H3F3A (enco‐
des histone H3.3) and HIST1H3B (encodes histone H3.1) in 78% of DIPGs and 22% of
nonbrainstem pediatric glioblastomas [30]. The different H3 mutations were mutually exclu‐
sive and seemed to be a feature of pediatric HGGs.
The discoveries from the molecular biology of DIPGs identified several drugable targets al‐
lowing the development of molecular target-based trials that are summarized in Table 2.
Some of these trials have shown a subset of patients with survival longer than expected and,
therefore, several other trials are ongoing, some of them including combined therapies
[17,31].
Finally, DIPG treatment involves another challenge which is drug distribution. Probably
due to an intact blood-brain barrier, penetration of drugs in the pons seems to be poor, a fact
demonstrated by the lack of gadolinium enhancement in the MRI in most DIPGs. Therefore,
it is crucial to improve drug delivery either by disrupting the blood-brain barrier (e.g. fo‐
cused ultrasound or drugs that increase permeability such as manitol), by local delivery (tu‐
mor injection or convection enhanced delivery) or even nanoparticles [17]. These techniques
may promote high drug concentrations in the pons, including agents that normally don’t
cross the blood-brain barrier.
Drug Clinical Trial 1 year Overall Survival (OS) Reference
Imatinib Phase I 45.5% 2007 [32]
Tipifarnib Phase I 36.4% 2008 [33]
Gefitinib Phase I 48% 2010 [34]
Vandetanib Phase I 37% 2010 [35]
Erlotinib Phase I 50% 2011 [20]
Gefitinib Phase II 56% 2011 [36]
Nimotuzumab Phase II Median OS 9.6 months 2011 [37]
Table 2. Clinical trials for diffuse intrinsic pontine glioma (DIPG) using targeted therapies
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4. Medulloblastoma
Medulloblastoma, the commonest malignant brain tumor in the pediatric population, is no
longer considered a single disease. Recent efforts of multiple independent groups have
reached to a consensus that medulloblastoma comprises four distinct molecular variants
named WNT, SHH, Group 3 and Group 4 [38]. The subgroups have different demographics,
genetic profiles and prognosis [39]. This may explain why patients with the same histologi‐
cal disease have different clinical outcomes and a variable response to current treatments in‐
cluding surgery, whole-brain radiation and intensive chemotherapy. Figure 1 summarizes
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Figure 1. Features of the four medulloblastoma subgroups, including molecular genetics and clinical outcome
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Figure 1. Features of the four medulloblastoma subgroups, including molecular genetics and clinical outcome




WNT medulloblastomas are frequent in older children and teenagers and are rarely seen in
infants. Patients within this subgroup have usually an excellent outcome with survival rates
over 90%. However, Remke et al. showed that this is only true for pediatric cases as adult
WNT patients exhibit survival rates of approximately 80% [40]. Histologically, WNT tumors
are almost always of the classic variant and they rarely disseminate.
This subgroup is enriched in genes of the WNT pathway. Although few gains and losses
were reported in the WNT genome, mutations in CTNNB1 are frequent and usually occur
with deletion of one copy of chromosome 6 (monosomy 6). Patients with CTNNB1 mutation
have accumulation of β-catenin in the nucleus and better survival rates. Positive nuclear im‐
munostaining for β-catenin is now currently accepted as a marker of WNT medulloblasto‐
mas [41,42], although DKK1 and DKK2 were also proposed as markers for this subgroup
[42,43]. The overall good outcome of WNT tumors suggests that this subgroup may be a
good candidate for de-escalation therapy in future clinical trials.
4.2. SHH medulloblastomas
SHH medulloblastomas are frequently found in infants and adults (approximately 60% of
cases in each age group) but are rare in childhood. In the SHH subgroup, prognostic factors
such as M-stage and desmoplasia are age-dependent. Metastasis at presentation represents a
negative prognostic factor only in adults while desmoplasia is associated with worse out‐
come only in pediatric cases [44]. From a histological point of view this subgroup is unique
since it includes tumors of the four main variants (classic, nodular desmoplastic, large-cell
anaplastic and medulloblastoma with extensive nodularity).
SHH medulloblastomas are characterized by aberrant expression of SHH pathway genes in‐
cluding SMO, PTCH1, SUFU and GLI2. Amplifications of MYCN and YAP1 are also seen in
this subgroup. Additionally, deletion of chromosome 9q is a common and highly restricted
event in SHH tumors, most likely secondary to PTCH1 mutation on chromosome 9q22 [45].
Of notice is the fact that the transcriptomes of pediatric and adult SHH tumors have differ‐
ent expression profiles with increased levels of genes related to extracellular matrix function
in the first group and elevated levels of HOX family genes and genes involved in tissue de‐
velopment in the second group [44,46]. In an attempt to simplify the molecular subgrouping
of medulloblastomas, different laboratories used formalin-fixed paraffin-embedded tissues
(FFPE) to test a variety of markers for SHH medulloblastomas including SFRP1, GLI1 and
GAB1 [42,43,47].
The clinical and molecular distinction of infant and adult SHH medulloblastomas suggests a
disparate underlying biology and raises the question of possible different responses to cur‐
rent targeted therapies.
4.3. Group 3 medulloblastomas
Group 3 medulloblastomas are restricted to pediatric patients. Indeed, two recent studies
concluded that Group 3 tumors are extremely rare in adults [40,48]. Another feature of this
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subgroup is its aggressive behavior with high incidence of metastasis, frequent large-cell
anaplastic histology and an invariable dismal prognosis (approximately 20 to 30% overall
survival). It has been shown that Group 3 medulloblastomas consist of two distinct subtypes
one of which harbors frequent amplifications of the MYC gene and has the worse outcome
[49]. Although Group 3 and 4 have some common genetic features, including gain of chro‐
mosome 7, losses of chromosomes 5q and 10q and gain of chromosome 1q are more frequent
in Group 3 tumors. NPR3 and KCNA1 were proposed as biomarkers for Group 3 and Group
4, respectively [42].
Until recently, there were no known targetable pathways in Group 3 medulloblastomas and
the suggested intensification of treatment for these patients would necessarily result in in‐
creased toxicity and morbidity (see below).
4.4. Group 4 medulloblastomas
Group 4 tumors represent simultaneously the most common and the less well-understood
subgroup of medulloblastomas. They are found across all age groups and have an inter‐
mediate prognosis although the adult patients show a reduced survival when compared to
their pediatric counterparts. Group 4 medulloblastomas are usually of the classic variant
and they rarely present with metastasis. The most frequent genetic aberration in Group 4 tu‐
mors, present in up to 80% of cases, is isochromosome 17q (i17q) although MYCN amplifica‐
tions were also reported. The expression of follistatin-related protein 5 (FSTL5) was
identified as a marker of high-risk Group 4 patients [50].
4.5. From genomic revolution to clinical trials in medulloblastoma
Despite important advances in medulloblastoma treatment, approximately 40% of children
will have recurrence and 30% will die from the disease. Moreover, the survivors are often
left with significant disabilities due to cytotoxic side effects of chemotherapy and radiation
to the developing central nervous system (CNS). Identifying the genetic events that drive
medulloblastoma is, therefore, critical to develop more effective and less toxic therapies.
Except for SHH inhibitors that have shown some promise in SHH patients [51], there were
no other targetable genes or pathways for WNT, Group 3 and Group 4 medulloblastomas.
However, very recently published studies from four independent groups dissected the ge‐
nomic landscape of medulloblastoma using large cohorts of patients and the latest high-
throughput technology.
Using SNP arrays in a large cohort of over 1,000 medulloblastoma samples, Northcott et al.
reported that somatic CNAs are a common event in medulloblastoma and are subgroup-
specific [52]. In Group 3 tumors the authors identified recurrent PVT1 gene fusions with
MYC and NDRG1 through chromothripsis, a process of erroneous DNA repair after chromo‐
some shattering. This process of catastrophic DNA rearrangement has been previously
shown in SHH medulloblastomas with TP53 mutations [53]. The most frequent somatic
CNA was a duplication of SNCAIP, a gene on chromosome 5q23.2 involved in Parkinson’s
disease. Interestingly, SNCAIP duplication is restricted to Group 4α, a subtype of Group 4
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with a relatively balanced genome when compared to Group 4β [52]. The authors also re‐
ported novel targetable pathways that could be the basis for future clinical trials, including
PI3K pathway in SHH, TGF-β pathway in Group 3 and NF-κB pathway in Group 4 [52].
Another interesting observation, consistent with the first published study using genome se‐
quencing in medulloblastoma [54], is the low number of somatic mutations found in these
tumors when compared to adult solid tumors and the increased mutation frequency with
age [52,55-57]. Jones et al. also identified tetraploidy as an early event in Group 3 and Group
4 medulloblastomas, concomitant with TP53 mutations in some tumors [55].
The genome sequencing of independent cohorts of medulloblastoma samples and matched
blood, identified previously known mutated genes (CTNNB1, PTCH1, MLL2, SMARCA4,
TP53) but also allowed the discovery of new recurrent somatic mutations (DDX3X,
CTDNEP1, KDM6A, TBR1, GPS2, BCOR, LDB1, EZH2, CHD7, ZMYM3), often subgroup-spe‐
cific [52,55-57]. Notably, these studies identified genes involved in histone modification and
chromatin remodeling complexes across all subgroups, which may explain the complexity
and heterogeneity seen in medulloblastoma.
The ongoing genomic revolution in medulloblastoma is moving the next generation of clini‐
cal trials towards targeted treatments according to the molecular subgroup. SHH inhibitors,
including GDC-0449 and NVP-LDE225, already proved its efficacy in tumor growth reduc‐
tion but the reported acquired resistance suggests that a combination of targeted therapies
may be a key approach to improve response [58]. Phase II clinical trials using GDC-0449 are
now recruiting pediatric and adult patients with recurrent or refractory medulloblastoma
and phase I trials with NVP-LDE225 are recruiting patients with advanced solid tumors in‐
cluding medulloblastoma. Under debate is the de-escalation of therapy in WNT patients and
the intensification of treatment and/or targeted therapy for Group 3 patients [59,60]. Finaly,
the discovery of a significant number of chromatin modifier genes across medulloblastoma
subgroups suggests that histone deacetylase inhibitors may constitute a good therapeutic
option in the future.
5. Ependymoma
Ependymoma, the third most common brain tumor in childhood, is still incurable in up to
45% of patients [61]. The gold standard of treatment is maximal safe surgical resection fol‐
lowed by radiation since chemotherapy is usually ineffective. Ependymomas can arise in
different regions of the CNS including the cerebral hemispheres, the posterior fossa and the
spinal cord. This diversity is extended to its demographic, genetic, clinical and prognostic
characteristics. Both children and adults can be affected although posterior fossa tumors are
more common in children and supratentorial and spinal tumors occur more frequently in
adults. The clinical behavior of ependymoma is variable with some patients experiencing a
fatal clinical course while others have a long recurrence-free survival. The lack of novel tar‐
geted treatments for ependymoma can be explained by the paucity of cell lines and animal
models of the disease.
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The genetic heterogeneity of ependymoma has been highlighted by different studies with
some cohorts of tumors showing frequent chromosomal alterations and others displaying a
balanced genome. Korshunov et al. identified gain of chromosome 1q, CDKN2A homozy‐
gous deletion and age at diagnosis as independent factors of worse prognosis in ependymo‐
ma [62]. Johnson et al. described subgroups of ependymoma clustered by their CNAs,
messenger RNA (mRNA) and microRNA (miRNA) profiles and, interestingly, tumors were
segregated by their CNS location [63]. Furthermore, the authors were able to generate a
mouse model of supratentorial ependymoma presenting strong evidence that the radial glial
cells are likely the cells of origin of this tumor [63]. More recently, Witt et al. transcriptionaly
profiled two large independent cohorts of posterior fossa tumors identifying two distinct
subgroups, Group A and Group B ependymomas [64]. Group A tumors comprise only pos‐
terior fossa ependymomas while Group B tumors include posterior fossa tumors that clus‐
tered with spinal ependymomas. Patients with Group A ependymomas are younger
(median age 2.5 years), with the majority of tumors located laterally and with a balanced ge‐
nome. These patients have higher incidence of recurrence and metastasis and a worse prog‐
nosis (5 year overall survival of 69%). Patients with Group B ependymomas are older
(median age 20 years), with tumors in the midline (95%) and a high degree of genomic insta‐
bility (Figure 2). Although several cytogenetic abnormalities were found in this group, in‐
cluding loss of chromosomes 1, 2, 3, 6, 8, 10, 14q, 17q, 22q, and gain of chromosomes 4, 5q, 7,
9, 11, 12, 15q, 18, 20, and 21q, patients have a good prognosis (5 year overall survival of
95%). The genes that characterize Group B ependymomas are involved in microtubule as‐
sembly and oxidative metabolism while Group A tumors include several pathways associat‐
ed with cancer. The authors identified LAMA2 and NELL2 as markers of Group A and
Group B ependymomas, respectively [64]. Using unsupervised cluster analysis of gene ex‐
pression signatures, others also described two groups of infratentorial ependymomas
(Group 1 and Group 2) that overlap with Group A and Group B of Witt et al., respectively
[65]. The distinct genetic profiles of posterior fossa ependymomas suggest that novel target‐
ed therapies against subgroup-specific pathways maybe the key strategy to improve surviv‐
al, particularly in Group A patients.
The interesting observation that up to 50% of pediatric ependymomas have a balanced ge‐
nome [62] raises the possibility that epigenetic mechanisms may play a role in ependymoma
pathogenesis. Most studies have focused on promoter hypermethylation of candidate genes
known to be tumor suppressor genes in ependymoma or frequently methylated in other
cancers. HIC-1 and RASSF1A promoter hypermethylation were described in 83% and 86% of
ependymomas, respectively. They are known to be tumor suppressor genes, silenced by hy‐
permethylation in many human cancers [66]. Promoter hypermethylation of other genes, in‐
cluding CDKN2A (21%), CDKN2B (32%), p14ARF (21%), and MGMT (27%) were also
reported in studies with large cohorts of tumor samples [66]. More recently, Rogers et al.
used an array-based analysis to determine the methylation profile of 98 ependymomas [67].
The authors found that supratentorial and spinal ependymomas have a hypermethylated
phenotype and that the genes identified are involved in cell growth and apoptosis. The in‐
crease in promoter methylation of CpG islands across a large number of genes has been de‐
scribed in other cancers as CpG island methylator phenotype (CIMP). Although it has been
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with a relatively balanced genome when compared to Group 4β [52]. The authors also re‐
ported novel targetable pathways that could be the basis for future clinical trials, including
PI3K pathway in SHH, TGF-β pathway in Group 3 and NF-κB pathway in Group 4 [52].
Another interesting observation, consistent with the first published study using genome se‐
quencing in medulloblastoma [54], is the low number of somatic mutations found in these
tumors when compared to adult solid tumors and the increased mutation frequency with
age [52,55-57]. Jones et al. also identified tetraploidy as an early event in Group 3 and Group
4 medulloblastomas, concomitant with TP53 mutations in some tumors [55].
The genome sequencing of independent cohorts of medulloblastoma samples and matched
blood, identified previously known mutated genes (CTNNB1, PTCH1, MLL2, SMARCA4,
TP53) but also allowed the discovery of new recurrent somatic mutations (DDX3X,
CTDNEP1, KDM6A, TBR1, GPS2, BCOR, LDB1, EZH2, CHD7, ZMYM3), often subgroup-spe‐
cific [52,55-57]. Notably, these studies identified genes involved in histone modification and
chromatin remodeling complexes across all subgroups, which may explain the complexity
and heterogeneity seen in medulloblastoma.
The ongoing genomic revolution in medulloblastoma is moving the next generation of clini‐
cal trials towards targeted treatments according to the molecular subgroup. SHH inhibitors,
including GDC-0449 and NVP-LDE225, already proved its efficacy in tumor growth reduc‐
tion but the reported acquired resistance suggests that a combination of targeted therapies
may be a key approach to improve response [58]. Phase II clinical trials using GDC-0449 are
now recruiting pediatric and adult patients with recurrent or refractory medulloblastoma
and phase I trials with NVP-LDE225 are recruiting patients with advanced solid tumors in‐
cluding medulloblastoma. Under debate is the de-escalation of therapy in WNT patients and
the intensification of treatment and/or targeted therapy for Group 3 patients [59,60]. Finaly,
the discovery of a significant number of chromatin modifier genes across medulloblastoma
subgroups suggests that histone deacetylase inhibitors may constitute a good therapeutic
option in the future.
5. Ependymoma
Ependymoma, the third most common brain tumor in childhood, is still incurable in up to
45% of patients [61]. The gold standard of treatment is maximal safe surgical resection fol‐
lowed by radiation since chemotherapy is usually ineffective. Ependymomas can arise in
different regions of the CNS including the cerebral hemispheres, the posterior fossa and the
spinal cord. This diversity is extended to its demographic, genetic, clinical and prognostic
characteristics. Both children and adults can be affected although posterior fossa tumors are
more common in children and supratentorial and spinal tumors occur more frequently in
adults. The clinical behavior of ependymoma is variable with some patients experiencing a
fatal clinical course while others have a long recurrence-free survival. The lack of novel tar‐
geted treatments for ependymoma can be explained by the paucity of cell lines and animal
models of the disease.
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The genetic heterogeneity of ependymoma has been highlighted by different studies with
some cohorts of tumors showing frequent chromosomal alterations and others displaying a
balanced genome. Korshunov et al. identified gain of chromosome 1q, CDKN2A homozy‐
gous deletion and age at diagnosis as independent factors of worse prognosis in ependymo‐
ma [62]. Johnson et al. described subgroups of ependymoma clustered by their CNAs,
messenger RNA (mRNA) and microRNA (miRNA) profiles and, interestingly, tumors were
segregated by their CNS location [63]. Furthermore, the authors were able to generate a
mouse model of supratentorial ependymoma presenting strong evidence that the radial glial
cells are likely the cells of origin of this tumor [63]. More recently, Witt et al. transcriptionaly
profiled two large independent cohorts of posterior fossa tumors identifying two distinct
subgroups, Group A and Group B ependymomas [64]. Group A tumors comprise only pos‐
terior fossa ependymomas while Group B tumors include posterior fossa tumors that clus‐
tered with spinal ependymomas. Patients with Group A ependymomas are younger
(median age 2.5 years), with the majority of tumors located laterally and with a balanced ge‐
nome. These patients have higher incidence of recurrence and metastasis and a worse prog‐
nosis (5 year overall survival of 69%). Patients with Group B ependymomas are older
(median age 20 years), with tumors in the midline (95%) and a high degree of genomic insta‐
bility (Figure 2). Although several cytogenetic abnormalities were found in this group, in‐
cluding loss of chromosomes 1, 2, 3, 6, 8, 10, 14q, 17q, 22q, and gain of chromosomes 4, 5q, 7,
9, 11, 12, 15q, 18, 20, and 21q, patients have a good prognosis (5 year overall survival of
95%). The genes that characterize Group B ependymomas are involved in microtubule as‐
sembly and oxidative metabolism while Group A tumors include several pathways associat‐
ed with cancer. The authors identified LAMA2 and NELL2 as markers of Group A and
Group B ependymomas, respectively [64]. Using unsupervised cluster analysis of gene ex‐
pression signatures, others also described two groups of infratentorial ependymomas
(Group 1 and Group 2) that overlap with Group A and Group B of Witt et al., respectively
[65]. The distinct genetic profiles of posterior fossa ependymomas suggest that novel target‐
ed therapies against subgroup-specific pathways maybe the key strategy to improve surviv‐
al, particularly in Group A patients.
The interesting observation that up to 50% of pediatric ependymomas have a balanced ge‐
nome [62] raises the possibility that epigenetic mechanisms may play a role in ependymoma
pathogenesis. Most studies have focused on promoter hypermethylation of candidate genes
known to be tumor suppressor genes in ependymoma or frequently methylated in other
cancers. HIC-1 and RASSF1A promoter hypermethylation were described in 83% and 86% of
ependymomas, respectively. They are known to be tumor suppressor genes, silenced by hy‐
permethylation in many human cancers [66]. Promoter hypermethylation of other genes, in‐
cluding CDKN2A (21%), CDKN2B (32%), p14ARF (21%), and MGMT (27%) were also
reported in studies with large cohorts of tumor samples [66]. More recently, Rogers et al.
used an array-based analysis to determine the methylation profile of 98 ependymomas [67].
The authors found that supratentorial and spinal ependymomas have a hypermethylated
phenotype and that the genes identified are involved in cell growth and apoptosis. The in‐
crease in promoter methylation of CpG islands across a large number of genes has been de‐
scribed in other cancers as CpG island methylator phenotype (CIMP). Although it has been
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correlated to a worse outcome in other cancers, the authors could not find an association be‐
tween methylation and prognosis in ependymomas [67].
Figure 2. Features of the posterior fossa ependymoma subgroups, including genetic profile, clinical features and
prognosis.
Another less frequent epigenetic event in cancer genomes is hypomethylation. This loss of
DNA methylation occurs mainly in repetitive elements (Alu repeats). In a recent study, Xie
et al. used a genome-wide approach to study the methylation profiles of Alu repeat sequen‐
ces in pediatric intracranial ependymomas [68]. Notably, they identified a global loss of
methylation in the regions flanking, rather than within, Alu sequences, and this was corre‐
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lated with a more agressive tumor phenotype. The biological significance of this finding is
yet to be unraveled.
The increased knowledge of the genetic and epigenetic events that drive ependymoma may
lead to more effective targeted therapies aimed to repair molecular functions and dysregu‐
lated pathways. However, there are currently no clinical trials evaluating specific molecular
therapies in ependymoma. Despite the recent achievements in ependymoma research, great‐
er progress is needed to decifer the molecular and biological mechanisms of this disease
and, ultimately, to improve patient’s clinical outcome.
6. Conclusion
Major steps have been made to a better understanding of the molecular genetics underlying
the most common pediatric brain tumors. An important advance was to recognize that adult
and pediatric brain tumors are distinct and, therefore, need different therapeutic ap‐
proaches. This knowledge opened new avenues for targeted therapies and clinical trials
based on tumor-specific molecular subgrouping are currently ongoing. When compared to
standard chemotherapy and radiation, the use of biological agents has several advantages.
They can target cancer cells and spare normal cells in the developing CNS of children and
also be used to delay radiotherapy, which is responsible for long-term side effects of treat‐
ment. Many of the newer agents are small molecules, with low molecular weight, which fa‐
cilitates blood-brain barrier penetration. However, despite the enthusiasm with the phase I
and phase II clinical trials using biological agents as monotherapy, mainly for progressive
and recurrent brain tumors, efficacy has not yet been proven. In the future, combination
therapies will likely be needed to target multiple pathways involved in tumorigenesis and
to overcome the cytostatic effect of several biological agents. As the amount of data generat‐
ed by high-throughput studies increases the drugable targets for each pediatric brain tumor,
the number of clinical trials will continue to expand aiming a better control of the disease
with less morbidity and extended survival.
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1. Introduction
Glioblastoma multiforme (GBM) is one of the most frequent tumors in the central nervous
system and the most malignant tumor among gliomas. In the past two decades, cytogenetic
and molecular genetic studies have identified a number of recurrent chromosomal abnor‐
malities and genetic alterations in malignant gliomas, particularly in GBM [1]. It was already
described that GBM harbors combinations of the following genetic alterations: loss of heter‐
ozygozity of 10q, EGFR amplification, TP53 mutations, p16INK4a deletion and PTEN muta‐
tions [2]. New integrative genomics studies provided a comprehensive view of the
complicated genomic landscape of GBM, revealing a set of core signaling pathways com‐
monly activated in GBM involving TP53, RB, and RTK (receptor tyrosine kinase) pathways
[3, 4]. The majority of GBM tumors present genetic alterations in all three pathways, which
helps to stimulate cell proliferation and enhance cell survival while allowing tumor cells to
escaping from cell-cycle checkpoints, senescence, and apoptosis. This approach also identi‐
fied previously unknown genetic alterations in IDH1/2, NF1, ERBB2, and NFKBIA genes [1].
The current GBM treatment involves aggressive management including surgery, adjuvant
temozolomide-based chemotherapy, and radiotherapy [5], but GBM patients still present a
dismal prognosis, and the median survival is 14.6 months from diagnosis [6]. Although radi‐
otherapy has been found to significantly prolong survival rates for GBM patients, radiore‐
sistance is a typical characteristic of this tumor [7].
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Current genome-wide studies and the molecular characterization of GBM have allowed the
identification of potential new targets, development of novel therapeutic small molecules
and monoclonal antibodies and initiation of clinical trials with these targets [6, 8-10]. How‐
ever, there is a wide molecular diversity and heterogeneity associated with the aberrantly
GBM signaling pathways, culminating in the relative lack of success of these new ap‐
proaches [10]. Recently, an alternative strategy involves the selective targeting of GBM stem
cells, which are resistant to chemo- and radiotherapy. But still, almost all small-molecule in‐
hibitors designed to target these cells failed to demonstrate the effectiveness of this strategy,
compared with the conventional therapy [11].
Considering that most of the treatment protocols are still ineffective, novel approaches are
needed towards killing of GBM cells. Transcription machinery, as well as its regulatory ele‐
ments is also a feasible new target for the application of molecular therapies. Transcription
of DNA is dependent on the spatially and temporally coordinated interaction between tran‐
scriptional machinery involving RNA polymerase II, transcription factors (TFs)) and tran‐
scriptional regulatory components (promoter elements, enhancers, silencers and locus
control regions) [12, 13]. The low level of transcription, directed by the general transcription
factors associated to RNA polymerase core enzyme, is known as basal transcription [14].
However, there is a rapidly expanding number of ‘context-dependent’ transcription factors
that bind DNA and these TFs are capable of positively or negatively regulating the tran‐
scription process depending on the context of their binding sites, the complement of protein
interactions and other environmental influences [15].
Postgenomic analyses of major transcription factor families, in both malignant and nonma‐
lignant cell types, have opened new discussions about TF function. The mechanisms by
which TFs act in cancer cell systems appear to exhibit a restricted repertoire of skills and
plasticity displayed by normal cell systems [16]. The evolution of a restricted malignant
transcriptome can be seen clearly in the nuclear receptor superfamily, but is also apparent in
the MYC and AP-1 networks [17]. Oncogenic transcriptional rigidity reflects the simultane‐
ous deregulation of target loci such that proliferative and survival signals are enhanced and
antimitotic inputs are either limited or lost. Co-repressor proteins significantly contribute
with the disruption of these processes [16]. Therefore, understanding mechanisms involved
in gene regulation and transcriptional network may lead to a better knowledge about the
crucial functions of TFs, providing information to explore possibilities of their application as
molecular targets in cancer therapy [18].
A valuable tool to study the transcription machinery is the DNA microarray technology [19],
which measures the transcript expression of thousands of genes to identify changes in ex‐
pression profiles at different biological conditions [20-24], thus allowing to compare differ‐
ent cell types under diverse treatment conditions. The influence of TP53 status on
transcriptional profiles was previously described in tumor cell lines [25, 26]. Expression sig‐
natures of irradiated GBM cells were already performed for cell lines that are proficient and
deficient for TP53 [27, 28].
Recently, information on the regulation of gene expression can also be used within the con‐
text of functional enrichment tests, and different databases containing TFs binding sites and
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications578
other regulatory motifs are available, allowing to scan promoter regions of genes to detect
the presence of target motifs [29]. This information allow to determining whether a set of
pre-selected genes is under control of TFs. FatiGO + [30] is a web-based tool capable of asso‐
ciating TFs that are common to a gene set used as parameters. This TF prediction method
was already applied to a GBM dataset obtained from public repositories of microarray ex‐
periments, and the up-regulation of two predicted TFs, E2F1 and E2F4, was validated for
several GBM cell lines [31], demonstrating the suitability of this method.
In the current study, we aimed to identify TFs that could be predicted from significant dif‐
ferentially expressed genes (previously obtained in microarray experiments in irradiated
GBM cells) using an in silico analysis.
We found few predicted TFs that were common between GBM cell lines, while several ex‐
clusive TFs were found for each cell line, indicating that the transcriptional response to ion‐
izing radiation is very particular to each cell line examined in our microarray study, a fact
that can be due to the genetic heterogeneity inherent to GBM cells. In spite of this, there was
a convergence of biological functions among cell lines; the most relevant processes were re‐
lated to apoptosis, cell proliferation, cell cycle, DNA repair, oxidative stress, among others.
Furthermore, the present results also showed several TFs that were already reported as asso‐
ciated to cancer and stress responses.
2. Materials and methods
2.1. Briefly characterization of the experiment that provided the statistically modulated
genes used for TF prediction
2.1.1. Cell culture and irradiation
Human GBM T98G and U87MG cell lines were supplied by the American Type Culture Col‐
lection (ATCC) (Rockville, Maryland, USA) and gently donated by Dr. Mari C. Sogayar
(Universidade de São Paulo, Brazil). U343MG-a (U343), a cell line established from a pri‐
mary malignant astrocytoma in an adult [32], was kindly donated by Dr. James T. Rutka
(The Arthur and Sonia Labatt Brain Tumour Research Center, Canada); U251MG cell lines
was also purchased from the ATCC (Rockville, MD, USA) and gently donated by Dr. Guido
Lenz (Universidade Federal do Rio Grande do Sul, Brazil) [33]. All cell lines grown in the
presence of DMEM + HAM F10 medium (Sigma-Aldrich, St. Louis, USA) plus 10% fetal calf
serum (Cultilab, Campinas, Brazil), and kept at 37°C and 5% CO2, until they reach semi‐
confluency. Cells were sub-cultured and 1x106 cells were seeded in 25 cm2 flasks, being incu‐
bated at 37°C for 48 h, and irradiated with 8 Gy of gamma-rays (60Co source, dose rate of 2.0
Gy / min., Unit Gammatron S-80, Siemens, 1.25 MeV, HC-FMRP/USP).
2.1.2. cDNA microarrays method and analysis
Two experiments with irradiated and sham-irradiated GBM cells were carried out using a
glass slide microarrays containing ~4300 clones of cDNA probe (in replicates) from the hu‐
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Current genome-wide studies and the molecular characterization of GBM have allowed the
identification of potential new targets, development of novel therapeutic small molecules
and monoclonal antibodies and initiation of clinical trials with these targets [6, 8-10]. How‐
ever, there is a wide molecular diversity and heterogeneity associated with the aberrantly
GBM signaling pathways, culminating in the relative lack of success of these new ap‐
proaches [10]. Recently, an alternative strategy involves the selective targeting of GBM stem
cells, which are resistant to chemo- and radiotherapy. But still, almost all small-molecule in‐
hibitors designed to target these cells failed to demonstrate the effectiveness of this strategy,
compared with the conventional therapy [11].
Considering that most of the treatment protocols are still ineffective, novel approaches are
needed towards killing of GBM cells. Transcription machinery, as well as its regulatory ele‐
ments is also a feasible new target for the application of molecular therapies. Transcription
of DNA is dependent on the spatially and temporally coordinated interaction between tran‐
scriptional machinery involving RNA polymerase II, transcription factors (TFs)) and tran‐
scriptional regulatory components (promoter elements, enhancers, silencers and locus
control regions) [12, 13]. The low level of transcription, directed by the general transcription
factors associated to RNA polymerase core enzyme, is known as basal transcription [14].
However, there is a rapidly expanding number of ‘context-dependent’ transcription factors
that bind DNA and these TFs are capable of positively or negatively regulating the tran‐
scription process depending on the context of their binding sites, the complement of protein
interactions and other environmental influences [15].
Postgenomic analyses of major transcription factor families, in both malignant and nonma‐
lignant cell types, have opened new discussions about TF function. The mechanisms by
which TFs act in cancer cell systems appear to exhibit a restricted repertoire of skills and
plasticity displayed by normal cell systems [16]. The evolution of a restricted malignant
transcriptome can be seen clearly in the nuclear receptor superfamily, but is also apparent in
the MYC and AP-1 networks [17]. Oncogenic transcriptional rigidity reflects the simultane‐
ous deregulation of target loci such that proliferative and survival signals are enhanced and
antimitotic inputs are either limited or lost. Co-repressor proteins significantly contribute
with the disruption of these processes [16]. Therefore, understanding mechanisms involved
in gene regulation and transcriptional network may lead to a better knowledge about the
crucial functions of TFs, providing information to explore possibilities of their application as
molecular targets in cancer therapy [18].
A valuable tool to study the transcription machinery is the DNA microarray technology [19],
which measures the transcript expression of thousands of genes to identify changes in ex‐
pression profiles at different biological conditions [20-24], thus allowing to compare differ‐
ent cell types under diverse treatment conditions. The influence of TP53 status on
transcriptional profiles was previously described in tumor cell lines [25, 26]. Expression sig‐
natures of irradiated GBM cells were already performed for cell lines that are proficient and
deficient for TP53 [27, 28].
Recently, information on the regulation of gene expression can also be used within the con‐
text of functional enrichment tests, and different databases containing TFs binding sites and
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other regulatory motifs are available, allowing to scan promoter regions of genes to detect
the presence of target motifs [29]. This information allow to determining whether a set of
pre-selected genes is under control of TFs. FatiGO + [30] is a web-based tool capable of asso‐
ciating TFs that are common to a gene set used as parameters. This TF prediction method
was already applied to a GBM dataset obtained from public repositories of microarray ex‐
periments, and the up-regulation of two predicted TFs, E2F1 and E2F4, was validated for
several GBM cell lines [31], demonstrating the suitability of this method.
In the current study, we aimed to identify TFs that could be predicted from significant dif‐
ferentially expressed genes (previously obtained in microarray experiments in irradiated
GBM cells) using an in silico analysis.
We found few predicted TFs that were common between GBM cell lines, while several ex‐
clusive TFs were found for each cell line, indicating that the transcriptional response to ion‐
izing radiation is very particular to each cell line examined in our microarray study, a fact
that can be due to the genetic heterogeneity inherent to GBM cells. In spite of this, there was
a convergence of biological functions among cell lines; the most relevant processes were re‐
lated to apoptosis, cell proliferation, cell cycle, DNA repair, oxidative stress, among others.
Furthermore, the present results also showed several TFs that were already reported as asso‐
ciated to cancer and stress responses.
2. Materials and methods
2.1. Briefly characterization of the experiment that provided the statistically modulated
genes used for TF prediction
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lection (ATCC) (Rockville, Maryland, USA) and gently donated by Dr. Mari C. Sogayar
(Universidade de São Paulo, Brazil). U343MG-a (U343), a cell line established from a pri‐
mary malignant astrocytoma in an adult [32], was kindly donated by Dr. James T. Rutka
(The Arthur and Sonia Labatt Brain Tumour Research Center, Canada); U251MG cell lines
was also purchased from the ATCC (Rockville, MD, USA) and gently donated by Dr. Guido
Lenz (Universidade Federal do Rio Grande do Sul, Brazil) [33]. All cell lines grown in the
presence of DMEM + HAM F10 medium (Sigma-Aldrich, St. Louis, USA) plus 10% fetal calf
serum (Cultilab, Campinas, Brazil), and kept at 37°C and 5% CO2, until they reach semi‐
confluency. Cells were sub-cultured and 1x106 cells were seeded in 25 cm2 flasks, being incu‐
bated at 37°C for 48 h, and irradiated with 8 Gy of gamma-rays (60Co source, dose rate of 2.0
Gy / min., Unit Gammatron S-80, Siemens, 1.25 MeV, HC-FMRP/USP).
2.1.2. cDNA microarrays method and analysis
Two experiments with irradiated and sham-irradiated GBM cells were carried out using a
glass slide microarrays containing ~4300 clones of cDNA probe (in replicates) from the hu‐
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man IMAGE Consortium cDNA library [34]; kindly provided by Dr. Catherine Nguyen (IN‐
SERM-CNRS, Marseille, France)], and prepared according to the protocol described by
Hegde et al [35]. Microarrays were spotted onto glass slides (Corning, Lowell, MA, USA) by
using a Generation III Array Spotter (Amersham Molecular Dynamics, Sunnyvale, USA) ac‐
cording to the manufacturer’s instructions.
Total RNA extraction was performed for all cell lines, 30 min. and 6 h after irradiation, using
the Trizol reagent (Invitrogen, Carlsbad, USA) according to manufacturer’s instructions.
Each cDNA sample was spotted twice in the slide (duplicate spots). The cDNA complex
probes were prepared using the CyScribe Post Labeling Kit (Amersham Biosciences, Buck‐
inghamshire, UK) as previously described [23]. Hybridizations were carried out using an
automatic system (Automatic Slide Processor, Amersham Biosciences, UK) and signals were
immediately captured after the final wash procedure, using a Generation III laser scanner
(Amersham Biosciences, UK). This array platform was already used in several studies
[22-26, 36].
2.1.3. Data acquisition and gene expression analysis
The provided microarray data was filtered and normalized [25, 36]. Following the normali‐
zation procedure, microarray data was exported to tab-delimited tables in MEV format and
analyzed in MEV (v. 3.1) software [37].
The gene set submitted to SAM (Significance Analysis of Microarray [20]) were previously
obtained by a t-test (α=5%) comparing irradiated (8 Gy) versus unirradiated (controls) T98G,
U251MG, U343MG-a and U87MG cell lines, separately, considering two time points (30 min.






U343MG-a (30 min.) 7 116 +1.53 to -2.42
U343MG-a (6 h) 3 11 +1.83 to -1.39
U87MG (30 min.) 56 73 +1.88 to - 2.95
U87MG (6 h) 86 54 +1.68 to -1.95
T98G (30 min) 32 0 +2.26 to +1.13
T98G (6 h) 16 7 +2.70 to -1.63
U251MG (30 min.) 12 69 +1.85 to -1.40
U251MG (6 h) 17 20 +2.28 to -2.18
Table 1. Overall quantitative results on significant differentially expressed genes obtained by the DNA microarray
method, and analysis performed by SAM – Significance Analysis of Microarray (FDR < 5 %), for the comparison
irradiated versus un-irradiated cells.RNA samples from U87, U343, T98 and U251 cells were collected at 30 min. and 6
h following irradiation with 8 Gy of gamma-rays. Fold-change (+) or (-) means up- and down-regulation in transcript
expression, respectively.
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The list of significantly modulated genes was obtained for a FDR < 5%. U343 cells showed
123 and 14 significantly differentially expressed genes at 30 min and 6 h after irradiation,
respectively, whereas U87 showed 129 genes at 30 min and 140 genes at 6 h; T98G cell line
displayed 32 and 23 significantly up-regulated genes at 30 min. and 6 h, respectively, where‐
as U251 showed 81 genes at 30 min. and 37 genes at 6 h (Table 2).
2.2. Transcriptional factor analysis
The  analysis  of  TFs  related  to  the  significant  differentially  expressed  genes  (SAM)  was
performed by applying the FatiGO + [30].  This  program uses the TRANSFAC [38],  and
CisRed  [39]  transcription  factors  database,  including  their  respective  binding  sites  and
regulated genes.
FatiGO + analyzes if the pre –selected set of genes (provided after SAM analysis), are under
control of the same TF, and search for significant enrichments to each TF that is associated to
the gene list compared to the complete reference list, containing ~4300 clones that were spot‐
ted onto the microarray slide [29].
The p-values obtained in the analysis of regulatory elements have been established by the
program using the Fisher's exact test for multiple comparisons (unadjusted p-value). The
Enrichment Index (EI) calculated for each TF corresponds to the increment obtained regard‐
ing the number of genes (%) statistically modulated (SAM) that are associated to a specific
TF (List #1) divided by the total number of genes (%) in the array set that were predicted as
targets for the same TF (List #2):
EI = % gene List #1/ % gene list #2
The TFs were selected according to unadjusted p-values < 0.05. The genes were submitted
to FatiGO + v3.2,  using the Gene symbol identifier and the selected gene distance of 10
kb. After selecting the TFs associated to modulated genes (SAM), a search was conducted
in  PubMed (http://www.ncbi.nlm.  Nih.gov /  sites  /  entrez /)  looking for  biological  func‐
tions of those TFs.
2.3. Quantitative real-time PCR (qPCR)
We analyzed the transcript expression of HEB, a predict TF that was found associated to
57.7% of up-regulated genes in U87 cells, 30 min. after IR. The reverse transcription step
was carried out in the remaining RNA samples from microarray experiments, with the Su‐
perscript III Reverse Transcriptase kit (Invitrogen, USA), according to manufacturer’s in‐
structions.  The  integrity  of  cDNA  samples  was  validated  by  the  amplification  of  the
endogenous B2M gene and visualization in agarose gel electrophoresis. qPCR was carried
out using SYBR green master mix (Applied Biosystems, Foster City, USA) and the expres‐
sion levels  were  estimated by the  Relative  Expression Software  Tool  (REST)  [49],  using
10000 interactions as setup parameter. All primers (Integrated DNA Technologies, Coral‐
ville, USA) were designed in Primer3 software [50] and are displayed on Table 2. The re‐
actions were carried out in the Applied Biosystems 7500 Real-Time PCR System (Applied
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automatic system (Automatic Slide Processor, Amersham Biosciences, UK) and signals were
immediately captured after the final wash procedure, using a Generation III laser scanner
(Amersham Biosciences, UK). This array platform was already used in several studies
[22-26, 36].
2.1.3. Data acquisition and gene expression analysis
The provided microarray data was filtered and normalized [25, 36]. Following the normali‐
zation procedure, microarray data was exported to tab-delimited tables in MEV format and
analyzed in MEV (v. 3.1) software [37].
The gene set submitted to SAM (Significance Analysis of Microarray [20]) were previously
obtained by a t-test (α=5%) comparing irradiated (8 Gy) versus unirradiated (controls) T98G,
U251MG, U343MG-a and U87MG cell lines, separately, considering two time points (30 min.
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Table 1. Overall quantitative results on significant differentially expressed genes obtained by the DNA microarray
method, and analysis performed by SAM – Significance Analysis of Microarray (FDR < 5 %), for the comparison
irradiated versus un-irradiated cells.RNA samples from U87, U343, T98 and U251 cells were collected at 30 min. and 6
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The list of significantly modulated genes was obtained for a FDR < 5%. U343 cells showed
123 and 14 significantly differentially expressed genes at 30 min and 6 h after irradiation,
respectively, whereas U87 showed 129 genes at 30 min and 140 genes at 6 h; T98G cell line
displayed 32 and 23 significantly up-regulated genes at 30 min. and 6 h, respectively, where‐
as U251 showed 81 genes at 30 min. and 37 genes at 6 h (Table 2).
2.2. Transcriptional factor analysis
The  analysis  of  TFs  related  to  the  significant  differentially  expressed  genes  (SAM)  was
performed by applying the FatiGO + [30].  This  program uses the TRANSFAC [38],  and
CisRed  [39]  transcription  factors  database,  including  their  respective  binding  sites  and
regulated genes.
FatiGO + analyzes if the pre –selected set of genes (provided after SAM analysis), are under
control of the same TF, and search for significant enrichments to each TF that is associated to
the gene list compared to the complete reference list, containing ~4300 clones that were spot‐
ted onto the microarray slide [29].
The p-values obtained in the analysis of regulatory elements have been established by the
program using the Fisher's exact test for multiple comparisons (unadjusted p-value). The
Enrichment Index (EI) calculated for each TF corresponds to the increment obtained regard‐
ing the number of genes (%) statistically modulated (SAM) that are associated to a specific
TF (List #1) divided by the total number of genes (%) in the array set that were predicted as
targets for the same TF (List #2):
EI = % gene List #1/ % gene list #2
The TFs were selected according to unadjusted p-values < 0.05. The genes were submitted
to FatiGO + v3.2,  using the Gene symbol identifier and the selected gene distance of 10
kb. After selecting the TFs associated to modulated genes (SAM), a search was conducted
in  PubMed (http://www.ncbi.nlm.  Nih.gov /  sites  /  entrez /)  looking for  biological  func‐
tions of those TFs.
2.3. Quantitative real-time PCR (qPCR)
We analyzed the transcript expression of HEB, a predict TF that was found associated to
57.7% of up-regulated genes in U87 cells, 30 min. after IR. The reverse transcription step
was carried out in the remaining RNA samples from microarray experiments, with the Su‐
perscript III Reverse Transcriptase kit (Invitrogen, USA), according to manufacturer’s in‐
structions.  The  integrity  of  cDNA  samples  was  validated  by  the  amplification  of  the
endogenous B2M gene and visualization in agarose gel electrophoresis. qPCR was carried
out using SYBR green master mix (Applied Biosystems, Foster City, USA) and the expres‐
sion levels  were  estimated by the  Relative  Expression Software  Tool  (REST)  [49],  using
10000 interactions as setup parameter. All primers (Integrated DNA Technologies, Coral‐
ville, USA) were designed in Primer3 software [50] and are displayed on Table 2. The re‐
actions were carried out in the Applied Biosystems 7500 Real-Time PCR System (Applied
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Biosystems, USA) equipment, using primer sets with an annealing temperature near 60°C
and an amplicon of 100–120 bp. The PCR cycle was the following: pre-heating at 50°C for
2 min., 10 min. at 95°C (denaturation step), followed by 40 cycles at 95°C for 15 sec., and
at 60°C for 60 sec. The dissociation curves were set up as following: 95°C for 15 sec., 60°C




B2M – forward 5’- AGGCTATCCAGCGTACTCCA - 3’
112
B2M – reverse 5’ - TCAATGTCGGATGGATGAAA - 3’
HEB – forward 5’ - CCGCTTGAGTTATCCTCCAC - 3’
116
HEB – reverse 5’ - GTGAGGCAGCAACGTAAGGT - 3’
Table 2. Primer sequences used in Real Time qPCR; the housekeeping B2M gene was used as internal control.
2.4. Western Blot (WB)
Protein extraction was performed with the Trizol reagent (Invitrogen, Carlsbad-USA) ac‐
cording to the manufacturer's instructions, using the same samples for RNA extraction.
These samples were obtained from U87 cells collected at 30 min. post-irradiation. The ex‐
pression of HEB was analyzed by Western blot, using ACTB as internal control. Samples
were prepared with 30 µg of total protein. After electrophoresis, proteins were transferred
from the gel to the membrane Invitrolon PVDF using the XCell IITM Blot Module system
(Invitrogen, Carlsbad - USA). The immunodetection and protein visualization were con‐
ducted with the WesternBreeze Chromogenic kit (Invitrogen, Carlsbad - USA). The antibod‐
ies used in this study were anti-HEB (Santa Cruz, Santa Cruz, USA), and anti-ACTB (Cell
Signaling, Danvers, USA), dilution of 1:1000.
We performed densitometric analysis of WB bands using the GelPro Analyzer (MediaCyber‐
netics, Rockville, USA) 4.0, and the relative expression of HEB was calculated relatively to
ACTB.
3. Results
In the FatiGO + analysis, the lists of statistically modulated genes (SAM) were up-loaded in
order to find TFs that were significantly associated with up-regulated and down-regulated
genes for non-adjusted p-values < 0.05 (Table 3).
A Venn diagram was constructed based on the numbers of predicted TFs from data set pre‐
viously obtained for each cell line (microarray experiments) (Fig. 1). TFs predicted for 30
min and 6 h were pooled together. Each cell line showed a number of exclusive TFs, but we
also observed common TFs between cell lines. Out of 18 exclusive TFs found for U87MG cell
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line, PEBP (p = 0.008), Bach2 (p = 0.007), Freac-4 (p = 0.003), HLV (p = 0.006), Evi-1 (p = 0.009)
displayed the lowest p-values, while PPARG and SEF-1 displayed the highest EI (31.3). U343
presented 9 exclusive TFs; High values of EI were found for MAF (33.1), E2F:DP-1 (22.0), PR
(45.5) and STAT3 (38.5), and ARP-1 was the TF presenting the lowest p-value (0.009). T98G
cells displayed only 6 exclusive TFs: EBF, Pax, Pbx1b, C/EBP, Poly A downstream element
and Pax-9; two of them, EBF and PolyA showed low p-values, 0.005 and 0.007, respectively.
Regarding U251MG cells, 13 TFs were predicted, and only APOLYA presented a high EI
(27.8) (Table 3).
Interestingly, STAT3 was the common TF found for TP53 wild-type cells; however, this TF
was associated with up-regulated genes in U87, and with down-regulated genes in U343.
Only one TF (VBP) was common among three cell lines (U87, U343 and U251), being associ‐
ated with down-regulated genes. Among the TP53 mutant cell lines, ATF4 was common be‐
tween T98 and U251, associated with up-regulated genes (30 min. and 6 h). Two TFs were
found common between U343 and U251, TEF (associated to down-regulated genes, 30 min.)
and MAF (associated to up-regulated, 6 h). Finally, C/BPGamma was commonly predicted
for up-regulated genes in U87 (30 min.) and U251 (6 h) cell lines (Fig. 1).
Therefore, our results showed that most of the predicted TFs were exclusive to each cell line
and few TFs were common among the GBM cell lines; these results indicate that the tran‐
scriptional response to ionizing radiation is very particular to each cell line, and most proba‐
bly this can be due to the genetic heterogeneity of GBM cells.
By using the real time qPCR method, we confirmed the expression of HEB to validate the in
silico prediction for this TF. By using the REST 2009 software, we found that HEB was statis‐
tically up-regulated (+2.6) when comparing irradiated and sham-irradiated U87 cell lines (30
min.) (Fig. 2A). Primer efficiency was also determined for B2M (0.9615) and HEB (0.9652).
We also look for HEB protein expression by Western Blot; both ACTB and HEB antibodies
were used for irradiated and sham-irrradiated U87, 30 min after irradiation (Fig.2B). The rel‐
ative expression values calculated by densitometric analysis showed that HEB expression
was 1.7 higher in irradiated (8 Gy) cells, relatively to the control value (Fig. 2C).
U343MG-a







ARP-1 14.8 6.7 2.2 0.009
TEF 37.5 25.3 1.5 0.013
VBP 19.3 10.4 1.9 0.013
Imperfect Hogness/Goldberg
BOX
2.3 0.2 14.2 0.016
Muscle initiator sequence-20 20.5 12.2 1.7 0.031
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cording to the manufacturer's instructions, using the same samples for RNA extraction.
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from the gel to the membrane Invitrolon PVDF using the XCell IITM Blot Module system
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Signaling, Danvers, USA), dilution of 1:1000.
We performed densitometric analysis of WB bands using the GelPro Analyzer (MediaCyber‐
netics, Rockville, USA) 4.0, and the relative expression of HEB was calculated relatively to
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In the FatiGO + analysis, the lists of statistically modulated genes (SAM) were up-loaded in
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Interestingly, STAT3 was the common TF found for TP53 wild-type cells; however, this TF
was associated with up-regulated genes in U87, and with down-regulated genes in U343.
Only one TF (VBP) was common among three cell lines (U87, U343 and U251), being associ‐
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and few TFs were common among the GBM cell lines; these results indicate that the tran‐
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By using the real time qPCR method, we confirmed the expression of HEB to validate the in
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tically up-regulated (+2.6) when comparing irradiated and sham-irradiated U87 cell lines (30
min.) (Fig. 2A). Primer efficiency was also determined for B2M (0.9615) and HEB (0.9652).
We also look for HEB protein expression by Western Blot; both ACTB and HEB antibodies
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ative expression values calculated by densitometric analysis showed that HEB expression
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Elk-1 44.3 33.1 1.3 0.038
Sox-5 4.6 1.5 3.1 0.048
ACAAT 12.5 6.7 1.9 0.049
6 h (↑)
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Evi-1 97.4 81.6 1.2 0.009
VBP 23.7 10.4 2.3 0.015
TCF-4 55.3 37.2 1.5 0.028
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C/EBPgamma 92.3 64.4 1.4 0.041
6 h (↓)
HES1 45.5 15.6 2.9 0.019
Lmo2 complex 27.3 6.0 4.5 0.026
ATATA 18.2 2.9 6.2 0.041
Table 3. Transcription factors associated with statistically modulated genes (SAM, FDR ≤ 5 %), as predicted by the
FATIGO + v3.2., analysis performed for U343MG-a, U87MG, T98G and U251MG cell lines (30 min. and 6 h post-
irradiation). We used gene lists that showed patterns of repression (↓) and induction (↑) in irradiated cells compared
with mock-irradiated. The Enrichment Index (EI) calculated for each TF corresponds to the increment regarding the
number of genes (%) statistically modulated (SAM) that are associated to a specific TF (List #1) divided by the total
number of genes (%) in the array set that were predicted as targets for the same TF (List #2). The gene distance for the
analysis of the TFs was 10 kb.
Figure 1. Venn diagram showing predicted TFs associated with significant differentially expressed genes (from micro‐
array experiments) selected for four GBM cell lines, comparing irradiated versus sham-irradiated cells, collected at 30
min. and 6 h following irradiation. TF prediction was carried out using FatiGO + v3.2.
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Figure 2. HEB expression. A) HEB expression levels obtained by the qPCR method. This TF was found associated with
up-regulated genes in U87 cells, 30 min. after irradiation. Boxes represent the interquartile range; the dotted line rep‐
resents the median value; whiskers represent the minimum and maximum observations. B) Protein expression ana‐
lyzed by Western Blot using antibodies for HEB (Santa Cruz) and ACTB (Cell Signalling) as endogenous control. C)
Densitometric analysis of Western Blot bands using the Gel Pro Analyzer 4.0 software displayed for HEB expression
relatively to ACTB.
4. Discussion
Recently,  genome wide technologies,  such as DNA microarrays, provide a huge amount
of information about gene expression,  but  require additional  bioinformatics  analyses for
data interpretation. In order to reduce complex signatures to a small number of activated
transcriptional elements, new bioinformatics tools have been developed. To date, genome-
wide TF-binding regions and sites were identified using a variety of indirect methods and
data sets,  revealing abundant binding sites for different TFs in mammalian cells [40-43].
Using  lists  of  differentially  expressed  genes  that  were  generated  by  microarray  experi‐
ments, it is possible to predict TFs that can target common binding sites to a gene set. In
the current study, we performed an in silico analysis (FatiGO + v3.2.) to identify TFs from
a list of significant differentially expressed genes selected for irradiated GBM cell lines in
microarray experiments. Only few predicted TFs were common to GBM cell lines, while
several TFs were exclusive to each cell line, indicating that the transcriptional response to
ionizing radiation is very peculiar to each cell line examined in our microarray study. The
most relevant predicted TFs are discussed below. While few predicted TFs were shared
between  different  cell  lines,  several  TFs  were  found  exclusive  to  each  cell  line,  except
U251.
4.1. Commonly predicted TFs for two or three GBM cell lines
We found few TFs that were predicted for more than one cell line: MAF, TEF, ATF4, STAT3,
VBP and C/EBPGamma. Most of these TFs (STAT3, TEF and VBP) are related to apoptosis,
while other biological classes were also found, such as oxidative stress (ATF4), differentia‐
tion (MAF) and nucleotide excision repair (C/EBPGamma).
STAT3, signal transducer and activator of transcription 3 (acute-phase response factor), is part
of the STAT family of cytoplasmic latent transcription factors, and was predicted for the
TP53 wild type cells, U87 (up-regulated genes, 6 h) and U343 (down-regulated genes, 6 h).










C/EBPgamma 92.3 64.4 1.4 0.041
6 h (↓)
HES1 45.5 15.6 2.9 0.019
Lmo2 complex 27.3 6.0 4.5 0.026
ATATA 18.2 2.9 6.2 0.041
Table 3. Transcription factors associated with statistically modulated genes (SAM, FDR ≤ 5 %), as predicted by the
FATIGO + v3.2., analysis performed for U343MG-a, U87MG, T98G and U251MG cell lines (30 min. and 6 h post-
irradiation). We used gene lists that showed patterns of repression (↓) and induction (↑) in irradiated cells compared
with mock-irradiated. The Enrichment Index (EI) calculated for each TF corresponds to the increment regarding the
number of genes (%) statistically modulated (SAM) that are associated to a specific TF (List #1) divided by the total
number of genes (%) in the array set that were predicted as targets for the same TF (List #2). The gene distance for the
analysis of the TFs was 10 kb.
Figure 1. Venn diagram showing predicted TFs associated with significant differentially expressed genes (from micro‐
array experiments) selected for four GBM cell lines, comparing irradiated versus sham-irradiated cells, collected at 30
min. and 6 h following irradiation. TF prediction was carried out using FatiGO + v3.2.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications586
Figure 2. HEB expression. A) HEB expression levels obtained by the qPCR method. This TF was found associated with
up-regulated genes in U87 cells, 30 min. after irradiation. Boxes represent the interquartile range; the dotted line rep‐
resents the median value; whiskers represent the minimum and maximum observations. B) Protein expression ana‐
lyzed by Western Blot using antibodies for HEB (Santa Cruz) and ACTB (Cell Signalling) as endogenous control. C)
Densitometric analysis of Western Blot bands using the Gel Pro Analyzer 4.0 software displayed for HEB expression
relatively to ACTB.
4. Discussion
Recently,  genome wide technologies,  such as DNA microarrays, provide a huge amount
of information about gene expression,  but  require additional  bioinformatics  analyses for
data interpretation. In order to reduce complex signatures to a small number of activated
transcriptional elements, new bioinformatics tools have been developed. To date, genome-
wide TF-binding regions and sites were identified using a variety of indirect methods and
data sets,  revealing abundant binding sites for different TFs in mammalian cells [40-43].
Using  lists  of  differentially  expressed  genes  that  were  generated  by  microarray  experi‐
ments, it is possible to predict TFs that can target common binding sites to a gene set. In
the current study, we performed an in silico analysis (FatiGO + v3.2.) to identify TFs from
a list of significant differentially expressed genes selected for irradiated GBM cell lines in
microarray experiments. Only few predicted TFs were common to GBM cell lines, while
several TFs were exclusive to each cell line, indicating that the transcriptional response to
ionizing radiation is very peculiar to each cell line examined in our microarray study. The
most relevant predicted TFs are discussed below. While few predicted TFs were shared
between  different  cell  lines,  several  TFs  were  found  exclusive  to  each  cell  line,  except
U251.
4.1. Commonly predicted TFs for two or three GBM cell lines
We found few TFs that were predicted for more than one cell line: MAF, TEF, ATF4, STAT3,
VBP and C/EBPGamma. Most of these TFs (STAT3, TEF and VBP) are related to apoptosis,
while other biological classes were also found, such as oxidative stress (ATF4), differentia‐
tion (MAF) and nucleotide excision repair (C/EBPGamma).
STAT3, signal transducer and activator of transcription 3 (acute-phase response factor), is part
of the STAT family of cytoplasmic latent transcription factors, and was predicted for the
TP53 wild type cells, U87 (up-regulated genes, 6 h) and U343 (down-regulated genes, 6 h).
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Phosphorylated STAT3 leads to transcriptional activation of downstream genes involved in
processes such as cell proliferation, suppression of apoptosis, and angiogenesis [44, 45]. It
was demonstrated that STAT3 is constitutively activated and overexpressed in human glio‐
mas; STAT3 activation correlates with malignancy [46, 47], while STAT3 inhibition reduces
the lethality of GBM tumors in vivo [48], and its inhibition have been tested in phase 0 trial
in head and neck cancers [49].
Thyrotroph embryonic factor (TEF) and human hepatic leukemia factor (HLF) are members
of the PAR (proline and acidic amino acid-rich) subfamily of basic region/leucine zipper (bZIP)
transcription factors. The chicken vitellogenin gene-binding protein (VBP) is also a bZIP TF
member and is considered as the chicken homologue of TEF. TEF was predicted from down-
regulated genes in U343 and U251 (30 min.), and its homolog, VBP, from down-regulated
genes in U87 (6 h), U343 (30 min.) and U251 (30 min.). PAR bZIP proteins have recently been
shown to be involved in amino acid and neurotransmitter metabolism in both liver and
brain [50]. PAR bZIP proteins are also able to transactivate the promoter of bcl-gS which is
directly involved in apoptosis induction. Consistently, transfection of TEF induces the ex‐
pression of endogenous bcl-gS in cancer cells, independently on TP53 [51].
Activating transcription factor 4 (tax-responsive enhancer element B67); activating transcription
factor 4C (ATF4) belongs to the large ATF/CREB family of transcription factors [52] and was
predicted from up-regulated genes in T98 (30 min) and U251 (6 h). Up-regulation of ATF4 is
directly involved in the endoplasmic reticulum (ER) stress through induction of CHOP in
GBM treated with Nelfinavir (protease inhibitor class of drugs) [53] or in concert with PERK,
GADD34 and EIF2alpha in Hela cells submitted to hypoxia [54]. Therefore, activation of
ATF4 was already reported in GBM treated cells.
MAF, the v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) is a unique
subclass of bZIP proteins and was predicted from up-regulated genes in U343 and U251 at 6
h. Depending on the binding site and binding partner, the encoded protein can be a tran‐
scriptional activator or repressor. Members of the MAF family appear to play important
roles in the regulation of differentiation [55]. MAF was found up-regulated in various can‐
cers, such as colon cancer (but only in tumors that presented high levels of COX-2 expres‐
sion) [56], a small subset of myelomas, hairy cell leukemia, T- and NK-cell neoplasms and
small cell lymphomas [57].
C/EBPGamma, a member of the CCAAT/enhancer-binding protein (C/EBP) family of tran‐
scription factors was predicted from up-regulated genes in U87 (30 min.) and U251 (6 h).
This TF regulates the expression of ERCC5 [58], and is a participant of DNA repair [59], par‐
ticularly in the nucleotide excision repair [60].
The predicted TFs represent the overall GBM response to irradiation, since they were select‐
ed for more than one cell line, and as mentioned above, their functions are directly associat‐
ed with stress responses involving apoptosis, DNA repair and ER stress. Moreover, as an
example of STAT3, which is in clinical trial [49], predicted TFs may constitute potential tar‐
gets to be investigated and validated in cancer treatment.
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4.2. Exclusively predicted TFs for irradiated U343 cell line
Few predicted TFs (PR, E2F4:DP-1, and ARP-1) associated with statistically significant
modulated genes in irradiated U343 cells were found exclusive to this cell line. The func‐
tions of these TFs are mainly associated with cell cycle/ tumor growth, being involved in
various types of cancer. The overexpression of E2F4 and its binding partner DP-1 revealed a
dual function of E2F4, which acts as an activator as well as a repressor, being implicated in
positive regulation of the cell cycle [61]. In a previous work, the up-regulation of E2F4 was
confirmed for several GBM cell lines [31], demonstrating the potential of this TF as molecu‐
lar target in cancer therapy.
Progesterone receptor (PR), a nuclear receptor transcription factor was associated with
down-regulated genes in U343 cells (6 h). Steroid hormones participate in several physiolog‐
ical and pathological processes in the brain, including the regulation of tumor cell growth
[62-64]. Progesterone exerts many of its effects by the interaction with specific intracellular
receptors [62, 65].
ARP-1, also known as orphan nuclear receptor chicken ovalbumin upstream promoter tran‐
scription factor II (COUP-TFII) is a member of the steroid/thyroid nuclear hormone receptor
superfamily [66] and can act as transcriptional repressor or activator. ARP-1 plays critical
roles in organogenesis [67-70], and is a major angiogenesis regulator within the tumor mi‐
croenvironment during pancreatic tumor progression and metastasis [71]. Besides, ARP-1
was associated with therapy response in oligodendroglial tumors with 1p/19q loss [72]. In
the present study, this TF was predicted from down-regulated genes (30 min. and 6 h), indi‐
cating its possible involvement in radiation responses restricted to U343 cell line.
4.3. Exclusively predicted TFs for irradiated U87 cell line
A high number of TFs with low p-value (Bach2, PEBP, Freac-4, HLF and Evi-1) and high EI
(PPARG and SEF-1) was associated with significant expressed genes in U87 cell line.
PPARG is a member of the peroxisome proliferator activated receptor (PPAR) family, a sub‐
family of the nuclear receptor superfamily [73]. The protein level of this receptor has been
recently identified as a significant prognostic marker [74]. Interestingly, recent studies have
shown that PPARG is expressed in normal and malignant human brain, and the treatment
with PPARG agonists induces growth arrest and apoptosis in brain tumor cells in vitro and
in animal models in vivo [75-77]. Recent findings show that PPARG agonists regulate growth
and expansion of brain tumor stem cells [78] and also altered the expression of stemness
genes [79]. Unfortunately, clinical trials also failed to demonstrate the effectiveness of such
agonists as a monotherapy for cancer treatment, a fact which stimulates the search for com‐
bination treatments to enhance their effects [80].
Basic leucine zipper transcription factor 2 (Bach2) is an evolutionarily related member of the
BTB-basic region leucine zipper transcription factor family. Bach2 can function as transcrip‐
tional activator and repressor [81]. This TF down-regulates cell proliferation of the neuro‐
blastoma cell line N1E-115 and negatively affects their potential to differentiate, being
considered as gatekeeper of the differentiated status [82]. Bach2 presents high frequency of
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small cell lymphomas [57].
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This TF regulates the expression of ERCC5 [58], and is a participant of DNA repair [59], par‐
ticularly in the nucleotide excision repair [60].
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ed for more than one cell line, and as mentioned above, their functions are directly associat‐
ed with stress responses involving apoptosis, DNA repair and ER stress. Moreover, as an
example of STAT3, which is in clinical trial [49], predicted TFs may constitute potential tar‐
gets to be investigated and validated in cancer treatment.
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4.2. Exclusively predicted TFs for irradiated U343 cell line
Few predicted TFs (PR, E2F4:DP-1, and ARP-1) associated with statistically significant
modulated genes in irradiated U343 cells were found exclusive to this cell line. The func‐
tions of these TFs are mainly associated with cell cycle/ tumor growth, being involved in
various types of cancer. The overexpression of E2F4 and its binding partner DP-1 revealed a
dual function of E2F4, which acts as an activator as well as a repressor, being implicated in
positive regulation of the cell cycle [61]. In a previous work, the up-regulation of E2F4 was
confirmed for several GBM cell lines [31], demonstrating the potential of this TF as molecu‐
lar target in cancer therapy.
Progesterone receptor (PR), a nuclear receptor transcription factor was associated with
down-regulated genes in U343 cells (6 h). Steroid hormones participate in several physiolog‐
ical and pathological processes in the brain, including the regulation of tumor cell growth
[62-64]. Progesterone exerts many of its effects by the interaction with specific intracellular
receptors [62, 65].
ARP-1, also known as orphan nuclear receptor chicken ovalbumin upstream promoter tran‐
scription factor II (COUP-TFII) is a member of the steroid/thyroid nuclear hormone receptor
superfamily [66] and can act as transcriptional repressor or activator. ARP-1 plays critical
roles in organogenesis [67-70], and is a major angiogenesis regulator within the tumor mi‐
croenvironment during pancreatic tumor progression and metastasis [71]. Besides, ARP-1
was associated with therapy response in oligodendroglial tumors with 1p/19q loss [72]. In
the present study, this TF was predicted from down-regulated genes (30 min. and 6 h), indi‐
cating its possible involvement in radiation responses restricted to U343 cell line.
4.3. Exclusively predicted TFs for irradiated U87 cell line
A high number of TFs with low p-value (Bach2, PEBP, Freac-4, HLF and Evi-1) and high EI
(PPARG and SEF-1) was associated with significant expressed genes in U87 cell line.
PPARG is a member of the peroxisome proliferator activated receptor (PPAR) family, a sub‐
family of the nuclear receptor superfamily [73]. The protein level of this receptor has been
recently identified as a significant prognostic marker [74]. Interestingly, recent studies have
shown that PPARG is expressed in normal and malignant human brain, and the treatment
with PPARG agonists induces growth arrest and apoptosis in brain tumor cells in vitro and
in animal models in vivo [75-77]. Recent findings show that PPARG agonists regulate growth
and expansion of brain tumor stem cells [78] and also altered the expression of stemness
genes [79]. Unfortunately, clinical trials also failed to demonstrate the effectiveness of such
agonists as a monotherapy for cancer treatment, a fact which stimulates the search for com‐
bination treatments to enhance their effects [80].
Basic leucine zipper transcription factor 2 (Bach2) is an evolutionarily related member of the
BTB-basic region leucine zipper transcription factor family. Bach2 can function as transcrip‐
tional activator and repressor [81]. This TF down-regulates cell proliferation of the neuro‐
blastoma cell line N1E-115 and negatively affects their potential to differentiate, being
considered as gatekeeper of the differentiated status [82]. Bach2 presents high frequency of
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loss of heterozygosity of the Bach2 gene in human B cell lymphomas [83]. Consistent with
its putative role as a tumor suppressor, Bach2 enhances apoptosis in response to oxidative
stress [84, 85].
The transcription Factor PEBP, also called Raf kinase inhibitor protein (RKIP) is a mem‐
ber of the phosphatidylethanolamine-binding protein (PEBP) family. RKIP plays a pivotal
modulatory role in several protein kinase signaling cascades. RKIP regulates the activity
of the Raf/MEK/ERK, which is responsible for proliferation and differentiation of diverse
cell types [86].  It  has been reported that RKIP was poorly expressed in primary tumors,
being absent in various metastatic cancers; its induction sensitize resistant tumor cells to
apoptosis by various chemo- and immunotherapeutic drugs, as well as inhibitors of meta‐
stasis  [87].The  absence  of  RKIP  is  also  associated  with  highly  malignant  behavior  and
poor survival of patients [88].
The forkhead domain is a monomeric DNA binding motif that defines a rapidly growing
family  of  eukaryotic  transcriptional  regulators.  We  found Freac-4,  also  known as  Fork‐
head Box D1 (FOXD1) associated with down-regulated genes in U87 cells (6 h). This gene
was found repressed in chemoresistant tumors, as analyzed by microarrays [89]. Howev‐
er, FOXD1 and FOXD2 were highly expressed in prostate cancer and lymph node meta‐
stases, among various cancer types [90]. In another study, using kidney-derived cell lines,
it was suggested that FOXD1 may be regulated by TP53, WTAR (a mutated form of WT1)
and WT1 [91].
As already mentioned, HLF is a member of PAR bZIP transcription factors, and was associ‐
ated with down-regulated genes, 6 h after irradiation in U87. PAR bZIP proteins are also in‐
volved in apoptosis induction [51].The fused gene E2A-HLF was responsible for the
development of lymphoid malignancies in 60 % of the transgenic mice [92].
Activator protein one (AP1) transcription factors are a family of jun and fos proteins, whose
subunits present diverse pro/anti-cancer effects, like inhibition or increase in proliferation,
inhibition of apoptosis and angiogenesis [93, 94]. AP-1 is one of the genes early activated af‐
ter radiation in primary human B cells [95]. The inhibition of AP-1 blocks the proliferation of
breast tumor cells by suppressing the growth factor signaling [96]. The modulation of AP-1
activity may be a new attempt to reduce the malignant transformation. However, only the
function involved with malignancy should be targeted [97], since AP-1 presents oncogenic
and anti-oncogenic properties. This TF was associated to U87 cells (up-regulated genes, 30
min.) and (down-regulated genes, 6 h).
The EVI1 gene encodes a zinc finger transcription factor with important roles in normal de‐
velopment and leukemogenesis. Reports in animal model and findings in in vitro studies.
showed that EVI1 affected cellular proliferation, differentiation, and apoptosis [98]. EVI-1
was also found overexpressed in infratentorial ependymomas, it can promote proliferation
of ependymal tumor cells, and its expression indicates an unfavorable prognosis [99].
U87 cell line presented several predicted TFs with significant p values and higher enrich‐
ment index than other cell lines. Most of the predicted TFs are related to apoptosis (PPARG,
Batch2, PEBP, HLF, AP1 and EVI1), but they were associated with up- or down-regulated
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genes. Overall, the biological functions of these TFs are related to cell proliferation, differen‐
tiation and tumor growth, indicating the relevance of their deregulation in cancer develop‐
ment and malignancy, and possibly, in tumor responses to anti-cancer therapies.
4.4. Exclusively predicted TFs for irradiated T98G cell line
Only two TFs were predicted for T98G cells: EBF and C/EBP. The early B-cell factors (EBF)
are a family of four highly conserved DNA-binding transcription factors with an atypical
zinc-finger and helix-loop-helix motif. Zardo and colleagues found that the EBF3 locus on
the human chromosome 10q is deleted or methylated in brain tumors [100]. Functional stud‐
ies revealed that EBF3 activates genes involved in cell cycle arrest and apoptosis, while in
opposite, it represses genes involved in cell survival and proliferation [101]. Therefore, EBFs
represent a novel tumor suppressor whose inactivation blocks normal development and
contributes to tumorigenesis of diverse types of human cancer [102].
CEBP is also known as basic leucine zipper transcription factor, CCAAT/enhancer binding
protein alpha (CEBPA), which directly interacts with CDK2 and CDK4 and arrests cell pro‐
liferation by inhibition of these kinases [103]. CEBPA is crucial for normal granulopoiesis,
and dominant-negative mutations of CEBPA gene were found in patients with myeloblastic
subtypes (M1 and M2) of acute myeloid leukemia [104]. CEBPA also plays a role in DNA
damage response dependent on TP53, as observed in keratinocytes [105]. C/EBPA was
found silenced in human squamous cell carcinoma (SCC), and loss of C/EBPA confers sus‐
ceptibility to UVB-induced skin SCCs involving defective cell cycle arrest in response to
UVB [106]. Interestingly, these findings indicate the role of CEBP in DNA damage respons‐
es, and possibly, the potential of this TF to be explored as therapeutic molecular target.
4.5. Validation of TF prediction
As a predicted TF associated with up-regulated genes, HEB (p-value = 0.021 and EI = 1.5)
was chosen to be studied in terms of expression levels, aiming to validate the in silico analy‐
sis, although for a single TF. Interestingly, we showed that HEB transcript expression was
up-regulated (+2.6) in irradiated U87 cell line, 30 min. after irradiation, while HEB protein
expression analyzed by Western blot was 1.7 higher in irradiated (8 Gy) cells, relatively to
un-exposed controls.
HEB is a member of the class A basic helix-loop-helix (bHLH) family that participates in the
nervous system development [107, 108]. According to O'Neil et al. [109], the repression of
E47/HEB has been associated with the induction of leukemia in mice. In another study, it
was demonstrated the induction of HEB in gliomas compared with non-neoplastic brain tis‐
sue [110]. Moreover, HEB seems to be involved in cell proliferation control of neural stem
cells and also progenitor cells, being important to sustain their undifferentiated state during
embryonic and adult neurogenesis [108]. Although HEB expression has not yet been corre‐
lated with radiation responses in GBM cells, in the present study, we found its association
with significant differentially expressed genes at 30 min. following irradiation in U87 cell
line; interestingly, we also showed that HEB transcript and protein expression was induced
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loss of heterozygosity of the Bach2 gene in human B cell lymphomas [83]. Consistent with
its putative role as a tumor suppressor, Bach2 enhances apoptosis in response to oxidative
stress [84, 85].
The transcription Factor PEBP, also called Raf kinase inhibitor protein (RKIP) is a mem‐
ber of the phosphatidylethanolamine-binding protein (PEBP) family. RKIP plays a pivotal
modulatory role in several protein kinase signaling cascades. RKIP regulates the activity
of the Raf/MEK/ERK, which is responsible for proliferation and differentiation of diverse
cell types [86].  It  has been reported that RKIP was poorly expressed in primary tumors,
being absent in various metastatic cancers; its induction sensitize resistant tumor cells to
apoptosis by various chemo- and immunotherapeutic drugs, as well as inhibitors of meta‐
stasis  [87].The  absence  of  RKIP  is  also  associated  with  highly  malignant  behavior  and
poor survival of patients [88].
The forkhead domain is a monomeric DNA binding motif that defines a rapidly growing
family  of  eukaryotic  transcriptional  regulators.  We  found Freac-4,  also  known as  Fork‐
head Box D1 (FOXD1) associated with down-regulated genes in U87 cells (6 h). This gene
was found repressed in chemoresistant tumors, as analyzed by microarrays [89]. Howev‐
er, FOXD1 and FOXD2 were highly expressed in prostate cancer and lymph node meta‐
stases, among various cancer types [90]. In another study, using kidney-derived cell lines,
it was suggested that FOXD1 may be regulated by TP53, WTAR (a mutated form of WT1)
and WT1 [91].
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ated with down-regulated genes, 6 h after irradiation in U87. PAR bZIP proteins are also in‐
volved in apoptosis induction [51].The fused gene E2A-HLF was responsible for the
development of lymphoid malignancies in 60 % of the transgenic mice [92].
Activator protein one (AP1) transcription factors are a family of jun and fos proteins, whose
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inhibition of apoptosis and angiogenesis [93, 94]. AP-1 is one of the genes early activated af‐
ter radiation in primary human B cells [95]. The inhibition of AP-1 blocks the proliferation of
breast tumor cells by suppressing the growth factor signaling [96]. The modulation of AP-1
activity may be a new attempt to reduce the malignant transformation. However, only the
function involved with malignancy should be targeted [97], since AP-1 presents oncogenic
and anti-oncogenic properties. This TF was associated to U87 cells (up-regulated genes, 30
min.) and (down-regulated genes, 6 h).
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of ependymal tumor cells, and its expression indicates an unfavorable prognosis [99].
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ment index than other cell lines. Most of the predicted TFs are related to apoptosis (PPARG,
Batch2, PEBP, HLF, AP1 and EVI1), but they were associated with up- or down-regulated
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in irradiated U87 cell line, 30 min. after irradiation. This finding, although restrict to one TF,
indicates the validity of the TF prediction by in silico analysis.
5. Conclusions: Lessons from TF prediction in irradiated GBM cells
The present findings about prediction of TFs associated to differentially expressed genes
in GBM cell lines showed that few TFs were shared among different GBM cell lines, while
several TFs were found exclusive to each cell  line,  indicating that the transcriptional re‐
sponse to ionizing radiation is very particular to each cell line, probably due to the genet‐
ic  heterogeneity,  which  is  characteristic  of  GBM  cell  lines.  In  spite  of  this  observation,
several biological functions were similar among cell lines, such as apoptosis, cell prolifera‐
tion,  cell  cycle control,  DNA repair,  ER stress,  and differentiation.  Furthermore,  most of
the predicted TFs were already reported as differentially expressed, deleted or mutated in
cancer,  including  GBM.  However,  apart  the  similarity  of  biological  functions,  different
pathways  seems to  be  associated to  the  predicted TFs.  Interestingly,  we could not  find
TP53 as a TF associated to the data set (List #1) analyzed in the present study, even for
the GBM cells that were wild-type for TP53  gene, and even considering the presence of
TP53 cDNA clone in the microarray slide. It is possible that the TP53 protein could not be
activated in GBM cells, impairing its action as transcription factor, as previously suggest‐
ed by other authors [111].
The most intriguing finding refers to apoptotic related TFs. Probably, predicted TFs related
to apoptosis control, and found associated with expressed genes at early time (30 minutes)
following irradiation, are related to survival in GBM cells; this is supported by reports
showing that in general, these cells are very resistant to undergo apoptosis, even under con‐
ditions of drug treatment or radiation exposure [112-114]. In fact, GBM cells seem to be ca‐
pable of activating several pathways to escaping from cell killing by anticancer therapies.
Even considering the relevance of our findings, some methodological limitations should be
mentioned regarding in silico prediction of TFs. Despite the great advancement in terms of
DNA binding sites detection, it is hard to determine which sites are functional regulatory
elements that influence transcription. It is possible that a considerable fraction of these bind‐
ing sites are nonfunctional and may constitute biological noise [115]. Other choices, such as
ChIP experiments, may overcome this concern by detecting indirect TF-DNA interactions
through protein/protein interaction [116].
In spite of the limitation mentioned above, in a previous study, we validated the expression
of E2F [31] and the HEB expression was confirmed in the present study, both of them in
GBM cell lines. In addition, we selected predicted TFs that were associated with stress re‐
sponse genes, and importantly, the TFs were reported as deregulated or mutated in different
cancer types, thus indicating the relevance of further studies to better exploring the role of
TFs in the context of therapeutic strategies based on molecular targets.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications592
Author details
P. R. D. V. Godoy1, S. S. Mello1, F. S. Donaires1, E. A. Donadi2, G. A. S. Passos3 and
E. T. Sakamoto-Hojo1,4
1 Department of Genetics, Faculty of Medicine, University of São Paulo, Ribeirão Preto, SP,
Brazil
2 Department of Medic Clinic, Faculty of Medicine, University of São Paulo, Ribeirão Preto,
SP, Brazil
3 Department of Genetics, Faculty of Medicine and Faculty of Dentistry, University of São
Paulo, Ribeirão Preto, SP, Brazil
4 Department of Biology, Faculty of Philosophy, Sciences and Letters-USP, University of São
Paulo, Ribeirão Preto, SP, Brazil
References
[1] Chen, J, RM McKay, and LF Parada, Malignant glioma: lessons from genomics,
mouse models, and stem cells. Cell, 2012. 149(1): p. 36-47.
[2] Ohgaki, H, Genetic pathways to glioblastomas. Neuropathology, 2005. 25(1): p. 1-7.
[3] McLendon, R et al., Comprehensive genomic characterization defines human glio‐
blastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-8.
[4] Parsons, DW, et al., An integrated genomic analysis of human glioblastoma multi‐
forme. Science, 2008. 321(5897): p. 1807-12.
[5] Stupp, R, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glio‐
blastoma. N Engl J Med, 2005. 352(10): p. 987-96.
[6] Ohka, F, A Natsume, and T Wakabayashi, Current trends in targeted therapies for
glioblastoma multiforme. Neurol Res Int, 2012. 2012: p. 878425.
[7] Stupp, R, et al., Chemoradiotherapy in malignant glioma: standard of care and future
directions. J Clin Oncol, 2007. 25(26): p. 4127-36.
[8] Sathornsumetee, S, et al., Molecularly targeted therapy for malignant glioma. Cancer,
2007. 110(1): p. 13-24.
[9] Perry, J, et al., Novel therapies in glioblastoma. Neurol Res Int, 2012. 2012: p. 428565.
[10] Polivka, J, Jr., et al., New molecularly targeted therapies for glioblastoma multiforme.
Anticancer Res, 2012. 32(7): p. 2935-46.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
593
in irradiated U87 cell line, 30 min. after irradiation. This finding, although restrict to one TF,
indicates the validity of the TF prediction by in silico analysis.
5. Conclusions: Lessons from TF prediction in irradiated GBM cells
The present findings about prediction of TFs associated to differentially expressed genes
in GBM cell lines showed that few TFs were shared among different GBM cell lines, while
several TFs were found exclusive to each cell  line,  indicating that the transcriptional re‐
sponse to ionizing radiation is very particular to each cell line, probably due to the genet‐
ic  heterogeneity,  which  is  characteristic  of  GBM  cell  lines.  In  spite  of  this  observation,
several biological functions were similar among cell lines, such as apoptosis, cell prolifera‐
tion,  cell  cycle control,  DNA repair,  ER stress,  and differentiation.  Furthermore,  most of
the predicted TFs were already reported as differentially expressed, deleted or mutated in
cancer,  including  GBM.  However,  apart  the  similarity  of  biological  functions,  different
pathways  seems to  be  associated to  the  predicted TFs.  Interestingly,  we could not  find
TP53 as a TF associated to the data set (List #1) analyzed in the present study, even for
the GBM cells that were wild-type for TP53  gene, and even considering the presence of
TP53 cDNA clone in the microarray slide. It is possible that the TP53 protein could not be
activated in GBM cells, impairing its action as transcription factor, as previously suggest‐
ed by other authors [111].
The most intriguing finding refers to apoptotic related TFs. Probably, predicted TFs related
to apoptosis control, and found associated with expressed genes at early time (30 minutes)
following irradiation, are related to survival in GBM cells; this is supported by reports
showing that in general, these cells are very resistant to undergo apoptosis, even under con‐
ditions of drug treatment or radiation exposure [112-114]. In fact, GBM cells seem to be ca‐
pable of activating several pathways to escaping from cell killing by anticancer therapies.
Even considering the relevance of our findings, some methodological limitations should be
mentioned regarding in silico prediction of TFs. Despite the great advancement in terms of
DNA binding sites detection, it is hard to determine which sites are functional regulatory
elements that influence transcription. It is possible that a considerable fraction of these bind‐
ing sites are nonfunctional and may constitute biological noise [115]. Other choices, such as
ChIP experiments, may overcome this concern by detecting indirect TF-DNA interactions
through protein/protein interaction [116].
In spite of the limitation mentioned above, in a previous study, we validated the expression
of E2F [31] and the HEB expression was confirmed in the present study, both of them in
GBM cell lines. In addition, we selected predicted TFs that were associated with stress re‐
sponse genes, and importantly, the TFs were reported as deregulated or mutated in different
cancer types, thus indicating the relevance of further studies to better exploring the role of
TFs in the context of therapeutic strategies based on molecular targets.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications592
Author details
P. R. D. V. Godoy1, S. S. Mello1, F. S. Donaires1, E. A. Donadi2, G. A. S. Passos3 and
E. T. Sakamoto-Hojo1,4
1 Department of Genetics, Faculty of Medicine, University of São Paulo, Ribeirão Preto, SP,
Brazil
2 Department of Medic Clinic, Faculty of Medicine, University of São Paulo, Ribeirão Preto,
SP, Brazil
3 Department of Genetics, Faculty of Medicine and Faculty of Dentistry, University of São
Paulo, Ribeirão Preto, SP, Brazil
4 Department of Biology, Faculty of Philosophy, Sciences and Letters-USP, University of São
Paulo, Ribeirão Preto, SP, Brazil
References
[1] Chen, J, RM McKay, and LF Parada, Malignant glioma: lessons from genomics,
mouse models, and stem cells. Cell, 2012. 149(1): p. 36-47.
[2] Ohgaki, H, Genetic pathways to glioblastomas. Neuropathology, 2005. 25(1): p. 1-7.
[3] McLendon, R et al., Comprehensive genomic characterization defines human glio‐
blastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-8.
[4] Parsons, DW, et al., An integrated genomic analysis of human glioblastoma multi‐
forme. Science, 2008. 321(5897): p. 1807-12.
[5] Stupp, R, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glio‐
blastoma. N Engl J Med, 2005. 352(10): p. 987-96.
[6] Ohka, F, A Natsume, and T Wakabayashi, Current trends in targeted therapies for
glioblastoma multiforme. Neurol Res Int, 2012. 2012: p. 878425.
[7] Stupp, R, et al., Chemoradiotherapy in malignant glioma: standard of care and future
directions. J Clin Oncol, 2007. 25(26): p. 4127-36.
[8] Sathornsumetee, S, et al., Molecularly targeted therapy for malignant glioma. Cancer,
2007. 110(1): p. 13-24.
[9] Perry, J, et al., Novel therapies in glioblastoma. Neurol Res Int, 2012. 2012: p. 428565.
[10] Polivka, J, Jr., et al., New molecularly targeted therapies for glioblastoma multiforme.
Anticancer Res, 2012. 32(7): p. 2935-46.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
593
[11] Natsume, A, et al., Glioma-initiating cells and molecular pathology: implications for
therapy. Brain Tumor Pathol, 2011. 28(1): p. 1-12.
[12] Thomas, MC and CM Chiang, The general transcription machinery and general co‐
factors. Crit Rev Biochem Mol Biol, 2006. 41(3): p. 105-78.
[13] Maston, GA, SK Evans, and MR Green, Transcriptional regulatory elements in the
human genome. Annu Rev Genomics Hum Genet, 2006. 7: p. 29-59.
[14] Hampsey, M, Molecular genetics of the RNA polymerase II general transcriptional
machinery. Microbiol Mol Biol Rev, 1998. 62(2): p. 465-503.
[15] Gaston, K and PS Jayaraman, Transcriptional repression in eukaryotes: repressors
and repression mechanisms. Cell Mol Life Sci, 2003. 60(4): p. 721-41.
[16] Battaglia, S, O Maguire, and MJ Campbell, Transcription factor co-repressors in can‐
cer biology: roles and targeting. Int J Cancer, 2010. 126(11): p. 2511-9.
[17] Thorne, JL, MJ Campbell, and BM Turner, Transcription factors, chromatin and can‐
cer. Int J Biochem Cell Biol, 2009. 41(1): p. 164-75.
[18] Mees, C, J Nemunaitis, and N Senzer, Transcription factors: their potential as targets
for an individualized therapeutic approach to cancer. Cancer Gene Ther, 2009. 16(2):
p. 103-12.
[19] Kel, A, et al., Beyond microarrays: find key transcription factors controlling signal
transduction pathways. BMC Bioinformatics, 2006. 7 Suppl 2: p. S13.
[20] Tusher, VG, R Tibshirani, and G Chu, Significance analysis of microarrays applied to
the ionizing radiation response. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5116-21.
[21] Sakamoto-Hojo, ET, et al., Gene expression profiles in human cells submitted to gen‐
otoxic stress. Mutat Res, 2003. 544(2 3): p. 403-13.
[22] Fachin, AL, et al., Gene expression profiles in human lymphocytes irradiated in vitro
with low doses of gamma rays. Radiat Res, 2007. 168(6): p. 650-65.
[23] Fachin, AL, et al., Gene expression profiles in radiation workers occupationally ex‐
posed to ionizing radiation. J Radiat Res (Tokyo), 2009. 50(1): p. 61-71.
[24] Carminati, PO, et al., Alterations in gene expression profiles correlated with cisplatin
cytotoxicity in the glioma U343 cell line. Genet Mol Biol, 2010. 33(1): p. 159-68.
[25] Godoy, PRDV, et al. Portrait of transcriptional expression profiles displayed by dif‐
ferent glioblastoma cell lines. in: M Garami. (ed.) Molecular Targets of CNS Tumors.
Rijeka: InTech; 2011. p. 277-300.
[26] da Silva, GN, et al., Expression of genes related to apoptosis, cell cycle and signaling
pathways are independent of TP53 status in urinary bladder cancer cells. Mol Biol
Rep, 2011. 38(6): p. 4159-70.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications594
[27] Otomo, T, et al., Microarray analysis of temporal gene responses to ionizing radiation
in two glioblastoma cell lines: up-regulation of DNA repair genes. J Radiat Res (To‐
kyo), 2004. 45(1): p. 53-60.
[28] Godoy, PRDV, et al., Glioblastoma cell lines differing in TP53 status (mutant or wild-
type) display different molecular signaling responses to gamma-irradiation Submit‐
ted, 2013.
[29] Al-Shahrour, F, et al., FatiGO +: a functional profiling tool for genomic data. Integra‐
tion of functional annotation, regulatory motifs and interaction data with microarray
experiments. Nucleic Acids Res, 2007. 35(Web Server issue): p. W91-6.
[30] Al-Shahrour, F, et al., BABELOMICS: a suite of web tools for functional annotation
and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res,
2005. 33(Web Server issue): p. W460-4.
[31] Donaires, FS, et al., Transcriptional factors associated to over-expressed genes in glio‐
blastoma multiforme, as predicted by in silico analysis on publicly microarray data‐
set Submitted, 2013.
[32] Dirks, PB, et al., Retinoic acid and the cyclin dependent kinase inhibitors synergisti‐
cally alter proliferation and morphology of U343 astrocytoma cells. Oncogene, 1997.
15(17): p. 2037-48.
[33] Filippi-Chiela, EC, et al., Autophagy interplay with apoptosis and cell cycle regula‐
tion in the growth inhibiting effect of resveratrol in glioma cells. PLoS ONE, 2011.
6(6): p. e20849.
[34] Lennon, G, et al., The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of
Genomes and Their Expression. Genomics, 1996. 33(1): p. 151-152.
[35] Hegde, P, et al., A concise guide to cDNA microarray analysis. Biotechniques, 2000.
29(3): p. 548-50, 552-4, 556 passim.
[36] Mello, SS, et al., Delayed effects of exposure to a moderate radiation dose on tran‐
scription profiles in human primary fibroblasts. Environ Mol Mutagen, 2011. 52(2): p.
117-29.
[37] Saeed, AI, et al., TM4: a free, open-source system for microarray data management
and analysis. Biotechniques, 2003. 34(2): p. 374-8.
[38] Wingender, E, et al., TRANSFAC: an integrated system for gene expression regula‐
tion. Nucleic Acids Res, 2000. 28(1): p. 316-9.
[39] Robertson, G, et al., cisRED: a database system for genome-scale computational dis‐
covery of regulatory elements. Nucleic Acids Res, 2006. 34(Database issue): p.
D68-73.
[40] Ferretti, V, et al., PReMod: a database of genome-wide mammalian cis-regulatory
module predictions. Nucleic Acids Res, 2007. 35(Database issue): p. D122-6.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
595
[11] Natsume, A, et al., Glioma-initiating cells and molecular pathology: implications for
therapy. Brain Tumor Pathol, 2011. 28(1): p. 1-12.
[12] Thomas, MC and CM Chiang, The general transcription machinery and general co‐
factors. Crit Rev Biochem Mol Biol, 2006. 41(3): p. 105-78.
[13] Maston, GA, SK Evans, and MR Green, Transcriptional regulatory elements in the
human genome. Annu Rev Genomics Hum Genet, 2006. 7: p. 29-59.
[14] Hampsey, M, Molecular genetics of the RNA polymerase II general transcriptional
machinery. Microbiol Mol Biol Rev, 1998. 62(2): p. 465-503.
[15] Gaston, K and PS Jayaraman, Transcriptional repression in eukaryotes: repressors
and repression mechanisms. Cell Mol Life Sci, 2003. 60(4): p. 721-41.
[16] Battaglia, S, O Maguire, and MJ Campbell, Transcription factor co-repressors in can‐
cer biology: roles and targeting. Int J Cancer, 2010. 126(11): p. 2511-9.
[17] Thorne, JL, MJ Campbell, and BM Turner, Transcription factors, chromatin and can‐
cer. Int J Biochem Cell Biol, 2009. 41(1): p. 164-75.
[18] Mees, C, J Nemunaitis, and N Senzer, Transcription factors: their potential as targets
for an individualized therapeutic approach to cancer. Cancer Gene Ther, 2009. 16(2):
p. 103-12.
[19] Kel, A, et al., Beyond microarrays: find key transcription factors controlling signal
transduction pathways. BMC Bioinformatics, 2006. 7 Suppl 2: p. S13.
[20] Tusher, VG, R Tibshirani, and G Chu, Significance analysis of microarrays applied to
the ionizing radiation response. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5116-21.
[21] Sakamoto-Hojo, ET, et al., Gene expression profiles in human cells submitted to gen‐
otoxic stress. Mutat Res, 2003. 544(2 3): p. 403-13.
[22] Fachin, AL, et al., Gene expression profiles in human lymphocytes irradiated in vitro
with low doses of gamma rays. Radiat Res, 2007. 168(6): p. 650-65.
[23] Fachin, AL, et al., Gene expression profiles in radiation workers occupationally ex‐
posed to ionizing radiation. J Radiat Res (Tokyo), 2009. 50(1): p. 61-71.
[24] Carminati, PO, et al., Alterations in gene expression profiles correlated with cisplatin
cytotoxicity in the glioma U343 cell line. Genet Mol Biol, 2010. 33(1): p. 159-68.
[25] Godoy, PRDV, et al. Portrait of transcriptional expression profiles displayed by dif‐
ferent glioblastoma cell lines. in: M Garami. (ed.) Molecular Targets of CNS Tumors.
Rijeka: InTech; 2011. p. 277-300.
[26] da Silva, GN, et al., Expression of genes related to apoptosis, cell cycle and signaling
pathways are independent of TP53 status in urinary bladder cancer cells. Mol Biol
Rep, 2011. 38(6): p. 4159-70.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications594
[27] Otomo, T, et al., Microarray analysis of temporal gene responses to ionizing radiation
in two glioblastoma cell lines: up-regulation of DNA repair genes. J Radiat Res (To‐
kyo), 2004. 45(1): p. 53-60.
[28] Godoy, PRDV, et al., Glioblastoma cell lines differing in TP53 status (mutant or wild-
type) display different molecular signaling responses to gamma-irradiation Submit‐
ted, 2013.
[29] Al-Shahrour, F, et al., FatiGO +: a functional profiling tool for genomic data. Integra‐
tion of functional annotation, regulatory motifs and interaction data with microarray
experiments. Nucleic Acids Res, 2007. 35(Web Server issue): p. W91-6.
[30] Al-Shahrour, F, et al., BABELOMICS: a suite of web tools for functional annotation
and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res,
2005. 33(Web Server issue): p. W460-4.
[31] Donaires, FS, et al., Transcriptional factors associated to over-expressed genes in glio‐
blastoma multiforme, as predicted by in silico analysis on publicly microarray data‐
set Submitted, 2013.
[32] Dirks, PB, et al., Retinoic acid and the cyclin dependent kinase inhibitors synergisti‐
cally alter proliferation and morphology of U343 astrocytoma cells. Oncogene, 1997.
15(17): p. 2037-48.
[33] Filippi-Chiela, EC, et al., Autophagy interplay with apoptosis and cell cycle regula‐
tion in the growth inhibiting effect of resveratrol in glioma cells. PLoS ONE, 2011.
6(6): p. e20849.
[34] Lennon, G, et al., The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of
Genomes and Their Expression. Genomics, 1996. 33(1): p. 151-152.
[35] Hegde, P, et al., A concise guide to cDNA microarray analysis. Biotechniques, 2000.
29(3): p. 548-50, 552-4, 556 passim.
[36] Mello, SS, et al., Delayed effects of exposure to a moderate radiation dose on tran‐
scription profiles in human primary fibroblasts. Environ Mol Mutagen, 2011. 52(2): p.
117-29.
[37] Saeed, AI, et al., TM4: a free, open-source system for microarray data management
and analysis. Biotechniques, 2003. 34(2): p. 374-8.
[38] Wingender, E, et al., TRANSFAC: an integrated system for gene expression regula‐
tion. Nucleic Acids Res, 2000. 28(1): p. 316-9.
[39] Robertson, G, et al., cisRED: a database system for genome-scale computational dis‐
covery of regulatory elements. Nucleic Acids Res, 2006. 34(Database issue): p.
D68-73.
[40] Ferretti, V, et al., PReMod: a database of genome-wide mammalian cis-regulatory
module predictions. Nucleic Acids Res, 2007. 35(Database issue): p. D122-6.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
595
[41] Bieda, M, et al., Unbiased location analysis of E2F1-binding sites suggests a wide‐
spread role for E2F1 in the human genome. Genome Res, 2006. 16(5): p. 595-605.
[42] Birney, E, et al., Identification and analysis of functional elements in 1% of the hu‐
man genome by the ENCODE pilot project. Nature, 2007. 447(7146): p. 799-816.
[43] Cawley, S, et al., Unbiased mapping of transcription factor binding sites along hu‐
man chromosomes 21 and 22 points to widespread regulation of noncoding RNAs.
Cell, 2004. 116(4): p. 499-509.
[44] Bowman, T, et al., Stat3-mediated Myc expression is required for Src transformation
and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A, 2001. 98(13): p. 7319-24.
[45] Brennan, C, et al., Glioblastoma subclasses can be defined by activity among signal
transduction pathways and associated genomic alterations. PLoS ONE, 2009. 4(11): p.
e7752.
[46] Lo, HW, et al., Constitutively activated STAT3 frequently coexpresses with epider‐
mal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes
them to Iressa and alkylators. Clin Cancer Res, 2008. 14(19): p. 6042-54.
[47] Weissenberger, J, et al., IL-6 is required for glioma development in a mouse model.
Oncogene, 2004. 23(19): p. 3308-16.
[48] Doucette, TA, et al., Signal transducer and activator of transcription 3 promotes an‐
giogenesis and drives malignant progression in glioma. Neuro Oncol, 2012.
[49] Sen, M, et al., First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and
Neck Tumors: Implications for Cancer Therapy. Cancer Discov, 2012. 2(8): p. 694-705.
[50] Gachon, F, et al., The loss of circadian PAR bZip transcription factors results in epi‐
lepsy. Genes Dev, 2004. 18(12): p. 1397-412.
[51] Benito, A, et al., A novel role for proline- and acid-rich basic region leucine zipper
(PAR bZIP) proteins in the transcriptional regulation of a BH3-only proapoptotic
gene. J Biol Chem, 2006. 281(50): p. 38351-7.
[52] De Angelis, R, et al., Functional interaction of the subunit 3 of RNA polymerase II
(RPB3) with transcription factor-4 (ATF4). FEBS Lett, 2003. 547(1-3): p. 15-9.
[53] Tian, X, et al., Modulation of CCAAT/enhancer binding protein homologous protein
(CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme
cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol
Chem, 2011. 286(33): p. 29408-16.
[54] Blais, JD, et al., Activating transcription factor 4 is translationally regulated by hy‐
poxic stress. Mol Cell Biol, 2004. 24(17): p. 7469-82.
[55] Blank, V and NC Andrews, The Maf transcription factors: regulators of differentia‐
tion. Trends Biochem Sci, 1997. 22(11): p. 437-41.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications596
[56] Asting, AG, et al., COX-2 gene expression in colon cancer tissue related to regulating
factors and promoter methylation status. BMC Cancer, 2011. 11: p. 238.
[57] Natkunam, Y, et al., Characterization of c-Maf transcription factor in normal and
neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia. Am J
Clin Pathol, 2009. 132(3): p. 361-71.
[58] Crawford, EL, et al., CEBPG regulates ERCC5/XPG expression in human bronchial
epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogen‐
esis, 2007. 28(12): p. 2552-9.
[59] Mullins, DN, et al., CEBPG transcription factor correlates with antioxidant and DNA
repair genes in normal bronchial epithelial cells but not in individuals with broncho‐
genic carcinoma. BMC Cancer, 2005. 5: p. 141.
[60] O'Donovan, A, et al., Isolation of active recombinant XPG protein, a human DNA re‐
pair endonuclease. J Biol Chem, 1994. 269(23): p. 15965-8.
[61] Lee, BK, AA Bhinge, and VR Iyer, Wide-ranging functions of E2F4 in transcriptional
activation and repression revealed by genome-wide analysis. Nucleic Acids Res,
2011. 39(9): p. 3558-73.
[62] Graham, JD and CL Clarke, Physiological action of progesterone in target tissues. En‐
docr Rev, 1997. 18(4): p. 502-19.
[63] Grunberg, SM, et al., Treatment of unresectable meningiomas with the antiprogester‐
one agent mifepristone. J Neurosurg, 1991. 74(6): p. 861-6.
[64] Schrell, UM, et al., Hormonal dependency of cerebral meningiomas. Part 1: Female
sex steroid receptors and their significance as specific markers for adjuvant medical
therapy. J Neurosurg, 1990. 73(5): p. 743-9.
[65] Mahesh, VB, DW Brann, and LB Hendry, Diverse modes of action of progesterone
and its metabolites. J Steroid Biochem Mol Biol, 1996. 56(1-6 Spec No): p. 209-19.
[66] Tsai, SY and MJ Tsai, Chick ovalbumin upstream promoter-transcription factors
(COUP-TFs): coming of age. Endocr Rev, 1997. 18(2): p. 229-40.
[67] Lee, CT, et al., The nuclear orphan receptor COUP-TFII is required for limb and skel‐
etal muscle development. Mol Cell Biol, 2004. 24(24): p. 10835-43.
[68] Takamoto, N, et al., COUP-TFII is essential for radial and anteroposterior patterning
of the stomach. Development, 2005. 132(9): p. 2179-89.
[69] You, LR, et al., Suppression of Notch signalling by the COUP-TFII transcription fac‐
tor regulates vein identity. Nature, 2005. 435(7038): p. 98-104.
[70] You, LR, et al., Mouse lacking COUP-TFII as an animal model of Bochdalek-type
congenital diaphragmatic hernia. Proc Natl Acad Sci U S A, 2005. 102(45): p. 16351-6.
[71] Qin, J, et al., COUP-TFII regulates tumor growth and metastasis by modulating tu‐
mor angiogenesis. Proc Natl Acad Sci U S A, 2010. 107(8): p. 3687-92.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
597
[41] Bieda, M, et al., Unbiased location analysis of E2F1-binding sites suggests a wide‐
spread role for E2F1 in the human genome. Genome Res, 2006. 16(5): p. 595-605.
[42] Birney, E, et al., Identification and analysis of functional elements in 1% of the hu‐
man genome by the ENCODE pilot project. Nature, 2007. 447(7146): p. 799-816.
[43] Cawley, S, et al., Unbiased mapping of transcription factor binding sites along hu‐
man chromosomes 21 and 22 points to widespread regulation of noncoding RNAs.
Cell, 2004. 116(4): p. 499-509.
[44] Bowman, T, et al., Stat3-mediated Myc expression is required for Src transformation
and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A, 2001. 98(13): p. 7319-24.
[45] Brennan, C, et al., Glioblastoma subclasses can be defined by activity among signal
transduction pathways and associated genomic alterations. PLoS ONE, 2009. 4(11): p.
e7752.
[46] Lo, HW, et al., Constitutively activated STAT3 frequently coexpresses with epider‐
mal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes
them to Iressa and alkylators. Clin Cancer Res, 2008. 14(19): p. 6042-54.
[47] Weissenberger, J, et al., IL-6 is required for glioma development in a mouse model.
Oncogene, 2004. 23(19): p. 3308-16.
[48] Doucette, TA, et al., Signal transducer and activator of transcription 3 promotes an‐
giogenesis and drives malignant progression in glioma. Neuro Oncol, 2012.
[49] Sen, M, et al., First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and
Neck Tumors: Implications for Cancer Therapy. Cancer Discov, 2012. 2(8): p. 694-705.
[50] Gachon, F, et al., The loss of circadian PAR bZip transcription factors results in epi‐
lepsy. Genes Dev, 2004. 18(12): p. 1397-412.
[51] Benito, A, et al., A novel role for proline- and acid-rich basic region leucine zipper
(PAR bZIP) proteins in the transcriptional regulation of a BH3-only proapoptotic
gene. J Biol Chem, 2006. 281(50): p. 38351-7.
[52] De Angelis, R, et al., Functional interaction of the subunit 3 of RNA polymerase II
(RPB3) with transcription factor-4 (ATF4). FEBS Lett, 2003. 547(1-3): p. 15-9.
[53] Tian, X, et al., Modulation of CCAAT/enhancer binding protein homologous protein
(CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme
cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol
Chem, 2011. 286(33): p. 29408-16.
[54] Blais, JD, et al., Activating transcription factor 4 is translationally regulated by hy‐
poxic stress. Mol Cell Biol, 2004. 24(17): p. 7469-82.
[55] Blank, V and NC Andrews, The Maf transcription factors: regulators of differentia‐
tion. Trends Biochem Sci, 1997. 22(11): p. 437-41.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications596
[56] Asting, AG, et al., COX-2 gene expression in colon cancer tissue related to regulating
factors and promoter methylation status. BMC Cancer, 2011. 11: p. 238.
[57] Natkunam, Y, et al., Characterization of c-Maf transcription factor in normal and
neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia. Am J
Clin Pathol, 2009. 132(3): p. 361-71.
[58] Crawford, EL, et al., CEBPG regulates ERCC5/XPG expression in human bronchial
epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogen‐
esis, 2007. 28(12): p. 2552-9.
[59] Mullins, DN, et al., CEBPG transcription factor correlates with antioxidant and DNA
repair genes in normal bronchial epithelial cells but not in individuals with broncho‐
genic carcinoma. BMC Cancer, 2005. 5: p. 141.
[60] O'Donovan, A, et al., Isolation of active recombinant XPG protein, a human DNA re‐
pair endonuclease. J Biol Chem, 1994. 269(23): p. 15965-8.
[61] Lee, BK, AA Bhinge, and VR Iyer, Wide-ranging functions of E2F4 in transcriptional
activation and repression revealed by genome-wide analysis. Nucleic Acids Res,
2011. 39(9): p. 3558-73.
[62] Graham, JD and CL Clarke, Physiological action of progesterone in target tissues. En‐
docr Rev, 1997. 18(4): p. 502-19.
[63] Grunberg, SM, et al., Treatment of unresectable meningiomas with the antiprogester‐
one agent mifepristone. J Neurosurg, 1991. 74(6): p. 861-6.
[64] Schrell, UM, et al., Hormonal dependency of cerebral meningiomas. Part 1: Female
sex steroid receptors and their significance as specific markers for adjuvant medical
therapy. J Neurosurg, 1990. 73(5): p. 743-9.
[65] Mahesh, VB, DW Brann, and LB Hendry, Diverse modes of action of progesterone
and its metabolites. J Steroid Biochem Mol Biol, 1996. 56(1-6 Spec No): p. 209-19.
[66] Tsai, SY and MJ Tsai, Chick ovalbumin upstream promoter-transcription factors
(COUP-TFs): coming of age. Endocr Rev, 1997. 18(2): p. 229-40.
[67] Lee, CT, et al., The nuclear orphan receptor COUP-TFII is required for limb and skel‐
etal muscle development. Mol Cell Biol, 2004. 24(24): p. 10835-43.
[68] Takamoto, N, et al., COUP-TFII is essential for radial and anteroposterior patterning
of the stomach. Development, 2005. 132(9): p. 2179-89.
[69] You, LR, et al., Suppression of Notch signalling by the COUP-TFII transcription fac‐
tor regulates vein identity. Nature, 2005. 435(7038): p. 98-104.
[70] You, LR, et al., Mouse lacking COUP-TFII as an animal model of Bochdalek-type
congenital diaphragmatic hernia. Proc Natl Acad Sci U S A, 2005. 102(45): p. 16351-6.
[71] Qin, J, et al., COUP-TFII regulates tumor growth and metastasis by modulating tu‐
mor angiogenesis. Proc Natl Acad Sci U S A, 2010. 107(8): p. 3687-92.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
597
[72] Shaw, EJ, et al., Gene expression in oligodendroglial tumors. Cell Oncol (Dordr),
2011. 34(4): p. 355-67.
[73] Issemann, I and S Green, Activation of a member of the steroid hormone receptor su‐
perfamily by peroxisome proliferators. Nature, 1990. 347(6294): p. 645-50.
[74] Robbins, GT and D Nie, PPAR gamma, bioactive lipids, and cancer progression.
Front Biosci, 2012. 17: p. 1816-34.
[75] Cellai, I, et al., Antineoplastic effects of rosiglitazone and PPARgamma transactiva‐
tion in neuroblastoma cells. Br J Cancer, 2006. 95(7): p. 879-88.
[76] Grommes, C, et al., Inhibition of in vivo glioma growth and invasion by peroxisome
proliferator-activated receptor gamma agonist treatment. Mol Pharmacol, 2006. 70(5):
p. 1524-33.
[77] Strakova, N, et al., Peroxisome proliferator-activated receptors (PPAR) agonists affect
cell viability, apoptosis and expression of cell cycle related proteins in cell lines of
glial brain tumors. Neoplasma, 2005. 52(2): p. 126-36.
[78] Chearwae, W and JJ Bright, PPARgamma agonists inhibit growth and expansion of
CD133+ brain tumour stem cells. Br J Cancer, 2008. 99(12): p. 2044-53.
[79] Pestereva, E, S Kanakasabai, and JJ Bright, PPARgamma agonists regulate the ex‐
pression of stemness and differentiation genes in brain tumour stem cells. Br J Can‐
cer, 2012. 106(10): p. 1702-12.
[80] Veliceasa, D, FT Schulze-Hoepfner, and OV Volpert, PPARgamma and Agonists
against Cancer: Rational Design of Complementation Treatments. PPAR Res, 2008.
2008: p. 945275.
[81] Oyake, T, et al., Bach proteins belong to a novel family of BTB-basic leucine zipper
transcription factors that interact with MafK and regulate transcription through the
NF-E2 site. Mol Cell Biol, 1996. 16(11): p. 6083-95.
[82] Shim, KS, et al., Bach2 is involved in neuronal differentiation of N1E-115 neuroblas‐
toma cells. Exp Cell Res, 2006. 312(12): p. 2264-78.
[83] Sasaki, S, et al., Cloning and expression of human B cell-specific transcription factor
BACH2 mapped to chromosome 6q15. Oncogene, 2000. 19(33): p. 3739-49.
[84] Hoshino, H, et al., Oxidative stress abolishes leptomycin B-sensitive nuclear export
of transcription repressor Bach2 that counteracts activation of Maf recognition ele‐
ment. J Biol Chem, 2000. 275(20): p. 15370-6.
[85] Muto, A, et al., Identification of Bach2 as a B-cell-specific partner for small maf pro‐
teins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. Em‐
bo J, 1998. 17(19): p. 5734-43.
[86] Yeung, K, et al., Suppression of Raf-1 kinase activity and MAP kinase signalling by
RKIP. Nature, 1999. 401(6749): p. 173-7.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications598
[87] Wu, K and B Bonavida, The activated NF-kappaB-Snail-RKIP circuitry in cancer reg‐
ulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs.
Crit Rev Immunol, 2009. 29(3): p. 241-54.
[88] Martinho, O, et al., Downregulation of RKIP is associated with poor outcome and
malignant progression in gliomas. PLoS ONE, 2012. 7(1): p. e30769.
[89] Ju, W, et al., Identification of genes with differential expression in chemoresistant ep‐
ithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res,
2009. 18(2-3): p. 47-56.
[90] van der Heul-Nieuwenhuijsen, L, NF Dits, and G Jenster, Gene expression of fork‐
head transcription factors in the normal and diseased human prostate. BJU Int, 2009.
103(11): p. 1574-80.
[91] Pierrou, S, et al., Cloning and characterization of seven human forkhead proteins:
binding site specificity and DNA bending. Embo J, 1994. 13(20): p. 5002-12.
[92] Smith, KS, et al., Disrupted differentiation and oncogenic transformation of lym‐
phoid progenitors in E2A-HLF transgenic mice. Mol Cell Biol, 1999. 19(6): p. 4443-51.
[93] Shaulian, E and M Karin, AP 1 in cell proliferation and survival. Oncogene, 2001.
20(19): p. 2390-400.
[94] Schreiber, M, et al., Control of cell cycle progression by c-Jun is p53 dependent.
Genes Dev, 1999. 13(5): p. 607-19.
[95] Wilson, RE, et al., Early response gene signalling cascades activated by ionising radi‐
ation in primary human B cells. Oncogene, 1993. 8(12): p. 3229-37.
[96] Liu, Y, et al., Inhibition of AP-1 transcription factor causes blockade of multiple sig‐
nal transduction pathways and inhibits breast cancer growth. Oncogene, 2002. 21(50):
p. 7680-9.
[97] Libermann, TA and LF Zerbini, Targeting transcription factors for cancer gene thera‐
py. Curr Gene Ther, 2006. 6(1): p. 17-33.
[98] Wieser, R, The oncogene and developmental regulator EVI1: expression, biochemical
properties, and biological functions. Gene, 2007. 396(2): p. 346-57.
[99] Koos, B, et al., The transcription factor evi-1 is overexpressed, promotes proliferation,
and is prognostically unfavorable in infratentorial ependymomas. Clin Cancer Res,
2011. 17(11): p. 3631-7.
[100] Zardo, G, et al., Integrated genomic and epigenomic analyses pinpoint biallelic gene
inactivation in tumors. Nat Genet, 2002. 32(3): p. 453-8.
[101] Zhao, LY, et al., An EBF3-mediated transcriptional program that induces cell cycle
arrest and apoptosis. Cancer Res, 2006. 66(19): p. 9445-52.
[102] Liao, D, Emerging roles of the EBF family of transcription factors in tumor suppres‐
sion. Mol Cancer Res, 2009. 7(12): p. 1893-901.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
599
[72] Shaw, EJ, et al., Gene expression in oligodendroglial tumors. Cell Oncol (Dordr),
2011. 34(4): p. 355-67.
[73] Issemann, I and S Green, Activation of a member of the steroid hormone receptor su‐
perfamily by peroxisome proliferators. Nature, 1990. 347(6294): p. 645-50.
[74] Robbins, GT and D Nie, PPAR gamma, bioactive lipids, and cancer progression.
Front Biosci, 2012. 17: p. 1816-34.
[75] Cellai, I, et al., Antineoplastic effects of rosiglitazone and PPARgamma transactiva‐
tion in neuroblastoma cells. Br J Cancer, 2006. 95(7): p. 879-88.
[76] Grommes, C, et al., Inhibition of in vivo glioma growth and invasion by peroxisome
proliferator-activated receptor gamma agonist treatment. Mol Pharmacol, 2006. 70(5):
p. 1524-33.
[77] Strakova, N, et al., Peroxisome proliferator-activated receptors (PPAR) agonists affect
cell viability, apoptosis and expression of cell cycle related proteins in cell lines of
glial brain tumors. Neoplasma, 2005. 52(2): p. 126-36.
[78] Chearwae, W and JJ Bright, PPARgamma agonists inhibit growth and expansion of
CD133+ brain tumour stem cells. Br J Cancer, 2008. 99(12): p. 2044-53.
[79] Pestereva, E, S Kanakasabai, and JJ Bright, PPARgamma agonists regulate the ex‐
pression of stemness and differentiation genes in brain tumour stem cells. Br J Can‐
cer, 2012. 106(10): p. 1702-12.
[80] Veliceasa, D, FT Schulze-Hoepfner, and OV Volpert, PPARgamma and Agonists
against Cancer: Rational Design of Complementation Treatments. PPAR Res, 2008.
2008: p. 945275.
[81] Oyake, T, et al., Bach proteins belong to a novel family of BTB-basic leucine zipper
transcription factors that interact with MafK and regulate transcription through the
NF-E2 site. Mol Cell Biol, 1996. 16(11): p. 6083-95.
[82] Shim, KS, et al., Bach2 is involved in neuronal differentiation of N1E-115 neuroblas‐
toma cells. Exp Cell Res, 2006. 312(12): p. 2264-78.
[83] Sasaki, S, et al., Cloning and expression of human B cell-specific transcription factor
BACH2 mapped to chromosome 6q15. Oncogene, 2000. 19(33): p. 3739-49.
[84] Hoshino, H, et al., Oxidative stress abolishes leptomycin B-sensitive nuclear export
of transcription repressor Bach2 that counteracts activation of Maf recognition ele‐
ment. J Biol Chem, 2000. 275(20): p. 15370-6.
[85] Muto, A, et al., Identification of Bach2 as a B-cell-specific partner for small maf pro‐
teins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. Em‐
bo J, 1998. 17(19): p. 5734-43.
[86] Yeung, K, et al., Suppression of Raf-1 kinase activity and MAP kinase signalling by
RKIP. Nature, 1999. 401(6749): p. 173-7.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications598
[87] Wu, K and B Bonavida, The activated NF-kappaB-Snail-RKIP circuitry in cancer reg‐
ulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs.
Crit Rev Immunol, 2009. 29(3): p. 241-54.
[88] Martinho, O, et al., Downregulation of RKIP is associated with poor outcome and
malignant progression in gliomas. PLoS ONE, 2012. 7(1): p. e30769.
[89] Ju, W, et al., Identification of genes with differential expression in chemoresistant ep‐
ithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res,
2009. 18(2-3): p. 47-56.
[90] van der Heul-Nieuwenhuijsen, L, NF Dits, and G Jenster, Gene expression of fork‐
head transcription factors in the normal and diseased human prostate. BJU Int, 2009.
103(11): p. 1574-80.
[91] Pierrou, S, et al., Cloning and characterization of seven human forkhead proteins:
binding site specificity and DNA bending. Embo J, 1994. 13(20): p. 5002-12.
[92] Smith, KS, et al., Disrupted differentiation and oncogenic transformation of lym‐
phoid progenitors in E2A-HLF transgenic mice. Mol Cell Biol, 1999. 19(6): p. 4443-51.
[93] Shaulian, E and M Karin, AP 1 in cell proliferation and survival. Oncogene, 2001.
20(19): p. 2390-400.
[94] Schreiber, M, et al., Control of cell cycle progression by c-Jun is p53 dependent.
Genes Dev, 1999. 13(5): p. 607-19.
[95] Wilson, RE, et al., Early response gene signalling cascades activated by ionising radi‐
ation in primary human B cells. Oncogene, 1993. 8(12): p. 3229-37.
[96] Liu, Y, et al., Inhibition of AP-1 transcription factor causes blockade of multiple sig‐
nal transduction pathways and inhibits breast cancer growth. Oncogene, 2002. 21(50):
p. 7680-9.
[97] Libermann, TA and LF Zerbini, Targeting transcription factors for cancer gene thera‐
py. Curr Gene Ther, 2006. 6(1): p. 17-33.
[98] Wieser, R, The oncogene and developmental regulator EVI1: expression, biochemical
properties, and biological functions. Gene, 2007. 396(2): p. 346-57.
[99] Koos, B, et al., The transcription factor evi-1 is overexpressed, promotes proliferation,
and is prognostically unfavorable in infratentorial ependymomas. Clin Cancer Res,
2011. 17(11): p. 3631-7.
[100] Zardo, G, et al., Integrated genomic and epigenomic analyses pinpoint biallelic gene
inactivation in tumors. Nat Genet, 2002. 32(3): p. 453-8.
[101] Zhao, LY, et al., An EBF3-mediated transcriptional program that induces cell cycle
arrest and apoptosis. Cancer Res, 2006. 66(19): p. 9445-52.
[102] Liao, D, Emerging roles of the EBF family of transcription factors in tumor suppres‐
sion. Mol Cancer Res, 2009. 7(12): p. 1893-901.
In silico Analysis of Transcription Factors Associated to Differentially Expressed Genes in Irradiated...
http://dx.doi.org/10.5772/53299
599
[103] Wang, H, et al., C/EBPalpha arrests cell proliferation through direct inhibition of
Cdk2 and Cdk4. Mol Cell, 2001. 8(4): p. 817-28.
[104] Pabst, T, et al., Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer
binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet, 2001.
27(3): p. 263-70.
[105] Yoon, K and RC Smart, C/EBPalpha is a DNA damage-inducible p53-regulated medi‐
ator of the G1 checkpoint in keratinocytes. Mol Cell Biol, 2004. 24(24): p. 10650-60.
[106] Thompson, EA, et al., C/EBPalpha expression is downregulated in human nonmela‐
noma skin cancers and inactivation of C/EBPalpha confers susceptibility to UVB-in‐
duced skin squamous cell carcinomas. J Invest Dermatol, 2011. 131(6): p. 1339-46.
[107] Ravanpay, AC and JM Olson, E protein dosage influences brain development more
than family member identity. J Neurosci Res, 2008. 86(7): p. 1472-81.
[108] Uittenbogaard, M and A Chiaramello, Expression of the bHLH transcription factor
Tcf12 (ME1) gene is linked to the expansion of precursor cell populations during
neurogenesis. Brain Res Gene Expr Patterns, 2002. 1(2): p. 115-21.
[109] O'Neil, J, et al., TAL1/SCL induces leukemia by inhibiting the transcriptional activity
of E47/HEB. Cancer Cell, 2004. 5(6): p. 587-96.
[110] Riemenschneider, MJ, TH Koy, and G Reifenberger, Expression of oligodendrocyte
lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol, 2004.
107(3): p. 277-82.
[111] Shu, HK, et al., The intrinsic radioresistance of glioblastoma-derived cell lines is asso‐
ciated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci U S A,
1998. 95(24): p. 14453-8.
[112] Rubel, A, et al., The membrane targeted apoptosis modulators erucylphosphocholine
and erucylphosphohomocholine increase the radiation response of human glioblasto‐
ma cell lines in vitro. Radiat Oncol, 2006. 1: p. 6.
[113] Honda, N, et al., Radiosensitization by overexpression of the nonphosphorylation
form of IkappaB-alpha in human glioma cells. J Radiat Res, 2002. 43(3): p. 283-92.
[114] Yamagishi, N, J Miyakoshi, and H Takebe, Enhanced radiosensitivity by inhibition of
nuclear factor kappa B activation in human malignant glioma cells. Int J Radiat Biol,
1997. 72(2): p. 157-62.
[115] Struhl, K, Gene regulation. A paradigm for precision. Science, 2001. 293(5532): p.
1054-5.
[116] Chen, X, et al., Integration of external signaling pathways with the core transcription‐
al network in embryonic stem cells
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications600
Section 8
Stem Cells
[103] Wang, H, et al., C/EBPalpha arrests cell proliferation through direct inhibition of
Cdk2 and Cdk4. Mol Cell, 2001. 8(4): p. 817-28.
[104] Pabst, T, et al., Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer
binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet, 2001.
27(3): p. 263-70.
[105] Yoon, K and RC Smart, C/EBPalpha is a DNA damage-inducible p53-regulated medi‐
ator of the G1 checkpoint in keratinocytes. Mol Cell Biol, 2004. 24(24): p. 10650-60.
[106] Thompson, EA, et al., C/EBPalpha expression is downregulated in human nonmela‐
noma skin cancers and inactivation of C/EBPalpha confers susceptibility to UVB-in‐
duced skin squamous cell carcinomas. J Invest Dermatol, 2011. 131(6): p. 1339-46.
[107] Ravanpay, AC and JM Olson, E protein dosage influences brain development more
than family member identity. J Neurosci Res, 2008. 86(7): p. 1472-81.
[108] Uittenbogaard, M and A Chiaramello, Expression of the bHLH transcription factor
Tcf12 (ME1) gene is linked to the expansion of precursor cell populations during
neurogenesis. Brain Res Gene Expr Patterns, 2002. 1(2): p. 115-21.
[109] O'Neil, J, et al., TAL1/SCL induces leukemia by inhibiting the transcriptional activity
of E47/HEB. Cancer Cell, 2004. 5(6): p. 587-96.
[110] Riemenschneider, MJ, TH Koy, and G Reifenberger, Expression of oligodendrocyte
lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol, 2004.
107(3): p. 277-82.
[111] Shu, HK, et al., The intrinsic radioresistance of glioblastoma-derived cell lines is asso‐
ciated with a failure of p53 to induce p21(BAX) expression. Proc Natl Acad Sci U S A,
1998. 95(24): p. 14453-8.
[112] Rubel, A, et al., The membrane targeted apoptosis modulators erucylphosphocholine
and erucylphosphohomocholine increase the radiation response of human glioblasto‐
ma cell lines in vitro. Radiat Oncol, 2006. 1: p. 6.
[113] Honda, N, et al., Radiosensitization by overexpression of the nonphosphorylation
form of IkappaB-alpha in human glioma cells. J Radiat Res, 2002. 43(3): p. 283-92.
[114] Yamagishi, N, J Miyakoshi, and H Takebe, Enhanced radiosensitivity by inhibition of
nuclear factor kappa B activation in human malignant glioma cells. Int J Radiat Biol,
1997. 72(2): p. 157-62.
[115] Struhl, K, Gene regulation. A paradigm for precision. Science, 2001. 293(5532): p.
1054-5.
[116] Chen, X, et al., Integration of external signaling pathways with the core transcription‐
al network in embryonic stem cells





Andrés Felipe Cardona and León Darío Ortíz
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52633
1. Introduction
The incidence of primary tumors of the central nervous system (CNS) has been estimated in
15.8/100,000 and 17.2/100,000 individuals for men and women, respectively [1,2], which
globally represents approximately 190,000 new cases per year. They represent the 3rd most
common cause of death from cancer in middle-aged men, and the 4th most common in
women between 15 and 34 years of age [3,4]. The most frequent tumors called gliomas ex‐
hibit glial characteristics on pathologic examination [1,3]. Despite advances in the knowl‐
edge of the molecular biology of gliomas, effective therapeutic strategies remain elusive.
After multimodality treatment with surgery, radiation and chemotherapy, the overall sur‐
vival (OS) of patients with Glioblastoma (GB), the most frequent glioma, is around 14.6
months and the survival at 2 years is 26% [5, 6, 7, 8]. Although it is recognized that there are
progenitor cells that can differentiate into neuronal and glial cells, the concept of a brain tu‐
mor stem cells is more controversial. In 2002, Altman and colleagues proposed the theory of
post-natal neurogenesis that, associated with the finding of progenitor cells in glial tumors,
suggested that these cells could be targeted for more effective therapies[9]. One of the diffi‐
culties is that there are no specific phenotypic markers for these cancer stem cells, and,
therefore, their identification is limited to a functional characterization.
Nonetheless, pluripotent cells obtained from human brain tumors that express the CD133
surface marker (or Prominin 1; PROM1 is the founding member of pentaspantransmem‐
brane glycoproteins) have the ability for sustained self-renewal, proliferation and tumor ini‐
tiation/propagation. Furthermore, this functionally defined glioma stem cells form a niche
around the blood vessels, being highly pro- angiogenic; those are regulated by hypoxia and
are resistant to conventional oncologic treatment like radiotherapy and/or chemotherapy
[10, 11]. In addition, they have important migration and invasion capabilities while actively
interacting with the immune system. Therefore, therapeutic opportunities include targeting
of stem cell specific pathways, induction of differentiation of stem cells, blocking microen‐
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vironment signals (including angiogenesis factors), and harnessing the immune system to
recognize and attack stem cells. Significant challenges continues since the presence of cancer
stem cells within the tumor is highly heterogenous, they can remain quiescent for years, and
they may share biological features with normal stem cells [12, 13].
We present here a detailed review of the published literature on cancer stem cells of gliomas
and meduloblastomas, and their possible relationships with the response to chemo-radio‐
therapy and to future therapeutic interventions. Similarly, we discuss their role in the pro‐
gression of the disease, and we provide an analysis of the functional properties of neuronal
progenitor cells and of their tumor homologues that lose their regulatory capacity during
the process of neurogenesis.
2. Identification of progenitor cells in the brain and the relationship with
glial tumors
Cancer only develops after mutations occurs in a few cells. These abnormal cells lose the ca‐
pacity for self -regulation and have the potential for uncontrolled proliferation [12]. Two hy‐
pothetical models have been invoked to explain this phenomenon. The first is the
“stochastic” which predicts that all cells have a homogeneous capacity to initiate a neoplasm
with areas in which the elements are activated in a synchronic and constitutive manner [12].
The second model is the “hierarchic” which assumes that only a sub-group of cells in the
tumor has the potential to proliferate and to generate new neoplasic focus; the other cells act
as support or representate well-differentiated or terminal tumor cells. This model explains
the findings of the pluripotent progenitor cells in acute myeloid leukemia, in cerebral tu‐
mors, and in cancer of the breast, prostate and colon [13, 14]. Nevertheless, those two mod‐
els are not exclusive and it is likely that there is a combination of both scenarios in most
types of cancer. Fig. (1) Summarizes the principal molecular alterations of cerebral tumors of
glial origin.
Early studies by Nottebohm et al. reported the discovery of neural embryonic tissue in the
cerebral parenchyma of birds [15],followed by reports of similar findings in rodents, pri‐
mates and humans [16]. As a consequence, it is generally accepted that neurogenesis persists
during adulthood, particularly at the level of the dentate gyrus of the hippocampus (in the
hilus and in several planes of the granular laminae) and in the upper region of the deep lat‐
eral ventricles, neighboring the striated body, as shown in Fig. (2).These cells constitute
about 0.2% of the elements forming the encephalon, primitively associated with the telence‐
phalon and generally expressing the glial fibrillary acidic protein (GFAP) [16, 17]. They have
a putative role in, and are capable of regenerating the neurogenetic structure in vivo and in
vitro; generally enjoying a state of relative quiescence with a cell cycle of about 28 days (type
B cells or pluripotent astrocytes) [18].
Usually, the pluripotent progenitor cells have a capacity of generating other second-order
progenitor elements that divide every 12 hours (rapid proliferation phase). These cells,
termed type C (immature precursors), maintain multipotent capacity and generate other
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neuronal precursors with greater maturity, termed type A cells (migrant neuroblasts). This
type A cells are capable of migrating in groups across the rostral portion of the lateral ven‐
tricle up to the olfactory bulb where they are integrated as new interneurons in different lay‐
ers of the cortex (Fig. 2) [19].The subventricular stem cells are conserved in eutherian
mammals, but only in man is the cellular displacement not grouped, but rather individual;
and follow a destiny that, as-yet, has not been clarified [20]. Analogously to the subventricu‐
lar zone, the hippocampus granular region amplifies some lesser-known precursor cells
termed type D, which have limited migratory capacity (short distances) [20].
From the neurochemical perspective, the type B cells express intermediate filaments such as
vimentin and nestin, and are characteristically negative for the neuronal markers PSA-
NCAM (Poly-Sialated Neural Cell Adhesion Molecule) and TuJ1 (class III beta-tubulin) [21].
They frequently express PDGFR-α (platelet-derived growth factor receptor) which appears
to act as a regulator of balance for the differentiation between the oligodendrocytes and neu‐
rons during the phase of asymmetric neurogenesis. The type B cells, while being highly sen‐
sitive to stimulation by epidermal growth factor (EGF) and FGF2 (fibroblast growth factor
type 2) [20], show constitutive positivity for CD133.
The expression of CD133 marker has been observed in normal progenitor cells, glial tumors
and central nervous system neoplasms (“neurosphere” model) [22, 23]. CD133 is a 130 KDa
surface glycoprotein with 5 transmembrane domains [24]. There are several isoforms of
CD133 regulated by methylation, but their specific regulatory roles in transcription are still
unknown [24]. Some reports suggest that their position in the membrane has some relation‐
ship with the dynamic organization of cell structure and, as such, determines cell polarity,
migration and interaction with other neighboring cells, especially with those belonging to
the tumor endothelium [21, 25]. The CD133 positive (CD133+) cells have a series of mecha‐
nisms that contribute to preferential activation of regulatory points of the cell cycle, increas‐
ing its resistance to standard chemotherapy and radiation therapy. [26]. This finding and
other routes of abnormal activation such as Wnt/β-catenin (Wnt was coined as a combina‐
tion of Wg and Int and can be pronounced as 'wint'), Notch (The notch signaling pathway is
a highly conserved cell signaling system present in most multicellular organism), SHh (son‐
ic-hedgehog), PTEN (phosphatase and tensin homolog) and Bmi-1 (polycomb ring finger
oncogene) explain, at least in part, why progenitor cells of glial tumors are resistant to radio‐
therapy [26, 27]. In addition, these cells exhibit primary resistance to chemotherapy agents
like carboplatin, paclitaxel and etoposide [28, 29].
GB are remarkably heterogeneous tumors, both phenotypically and genetically, and it is
very unlikely that a single antigen will selectively identify a single population of uniquely
tumorigenic cells that is common to all GBs. It is important to note that CD133-negative
brain tumor cells can also generate tumors in murine cancer models, and those new cells can
express CD133 in celular membrane [30]. In human tissue, another investigation have
shown that A2B5, a glial progenitor marker, is expressed in human gliomas, up to 61.7% of
tumoral cells, viewed on flow cytometry [31]. It would be considered that the role of CD133+
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uncertain, but most of studies and models agree with the importance of CD133+ cells in tu‐
morgenesis on the brain [16-29].
A study that evaluated the genetic expression of the BCRP1/ABCG2 (also known as Abcg2
murine/ABCG2 human) and MGMT (O-6-methylguanine-DNA methyltransferase) in glial
progenitors found a significant increase in their activity, similar to various apoptosis sup‐
pressors such as Bcl-2 (B-cell lymphoma 2, apoptosis checkpoint), FLIP (inhibitory protein),
BCL-XL ("B-cell lymphoma-extra large", involved in the signal transduction pathway of the
FAS-L.) and of some inhibitors of pro-apoptosis proteins such as XIAP (Co-chaperone of The
hsp90, immunophilin homolog XAP2), cIAP1 (cellular inhibitor of apoptosis 1), cIAP2 (cellu‐
lar inhibitor of apoptosis 2), NAIP (neuronal apoptosis inhibitory protein) and survivin (ba‐
culoviral inhibitor of apoptosis repeat-containing 5 or BIRC5) [23]. Furthermore, the
inhibition of the caspases 3, 7 and 9 is significantly higher in recurrent GB rich in CD133+
cells than in its counterpart in which lower counts are observed [32].
Nestin, an intermediate class IV filament that is produced in considerable quantities in nor‐
mal and tumor progenitor cells during brain development and in glial neoplasms [33, 34], is
a constituent part of the cytoskeleton, has the responsibility for the maintenance of the cell
morphology and facilitates adhesion, proliferation and migration. In adults, nestin is ex‐
pressed in the subventricular progenitor cells, in some remnants near the choroid plexus
and in the prosencephalon [35]. As in high grade gliomas, nestin is re-expressed in multiple
cell lines of the brain during other circumstances such as acute ischemia, trauma and menin‐
go-encephalitis [36]. In neoplasms, the co-expression of nestin and vimentin is related to
substantial increase in invasive capacity (associated with multifocality), the facility to repair
external attack (nuclear nestin regulates chromatin), and motility. This combination of mark‐
ers could be useful in assessing the prognosis, especially since its presence is associated to a
more aggressive tumor phenotype, rich in progenitor cells [37].
The normal and tumor precursor cells share the expression of multiple markers, the capacity
of unlimited regeneration, exponential proliferation and open differentiation. Additionally,
they have similar telomerase activity and resistance to apoptosis, as well as a higher capaci‐
ty to transport substances to membrane level [38]. The latter characteristic facilitates the exo‐
cyte of anti-neoplastic molecules via proteins of the ABC family, such as MDR-1 (Gene that
encodes P-glycoprotein; ABCB1, ATP-binding cassette, sub-family B member 1), MRP-1 (hu‐
man multidrug resistance protein or ABCC1), ABCA2, ABCA3 and ABCG2 (Genes that enc‐
odes the ATP-binding cassette sub-family A member 2 protein, sub-family A member 3
protein and sub-family G member 2 protein; respectively) [21, 38, 39].
3. Molecular changes that favor tumor progenitor cells
The progenitor cells of brain tumors have certain characteristics that differentiate them from
their normal counterparts. By definition, the cancer stem cells need to have the capacity to
develop tumors following orthotopic implantation (if the tumor is an identical phenotypic
copy of the original tumor). They exhibit a sustained capacity for self-renewal and are capa‐
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ble of showing polyclonality [33]. Reilly et al. established a murine model that combined
mutations in the p53 gene and in the gene specific for neurofibromatosis (Nf1, neurofibro‐
min 11), capable of activating the Ras (a protein superfamily of small GTPases) pathway to
favor the formation of astrocytomas. They found that the deletion of any tumor suppressor
gene and/or the activation of oncogenes such as Ras and Akt (serine/threonine protein kin‐
ase) in the undifferentiated cells that express CD133 or nestin, resulted in the formation of
glial tumors [40].
Another important alteration is view on PDGF. The effect of PDGF on the nestin-positive
progenitor cells is equivalent to that which occurs when the loss of CDKN2A (cyclin-de‐
pendent kinase inhibitor 2A), which codes for the INK4a (tumour suppressor protein) and
ARF (ADP-ribosylation factor 11) is combined with the increase in the expression of EGFR
in the immature and in the mature cells [36,41]. Further, during embryogenesis neural pro‐
genitors have been shown to express the A isoform of the PDGFR, while its mature homo‐
logue (glia and neurons) is expressed on the PDGF surface. PDGFR-B is found in small
quantities in pluriultipotent cells, but only increases as the cells differentiate and mature, es‐
pecially into oligodendrocytes, and in the presence of phosphorylated PDGFR-A [42]. Infu‐
sion of PDGF-A in the subventricular region of certain rodents suppresses the production of
neuroblasts and generates a hyperplasia of type B cells which frequently results in the devel‐
opment of astrocytomas and oligodendrogliomas. Additionally, activation, via the PDGF
signaling, in the regions of the brain rich in precursor cells contributes to tumorigenesis,
which seems to be favored by autocrine and paracrine stimulation of PDGF-A, PDGF-B and
the OLIG2 (oligodendrocyte lineage transcription factor 2) transcription factors [42, 43].
Some of the signaling pathways included in the evolution of progenitor cells and in their
differentiation are altered in the gliomas. The Notch pathway is essential for the mainte‐
nance of tumor cell architecture. It is expressed from embryogenesis and interacts, normally
or abnormally, with multiple ligands such as DLL-1, 3 and 4 (delta-like 1, 3 and 4 respective‐
ly), together with the Jag-1 and Jag-2 proteins (jagged 1 and 2 respectively). The Notch sig‐
naling pathway controls neural differentiation and is known to maintain CNS character and
to inhibit neurogenesis. The Notch–Hes (Hairy and enhancer of split) pathway is necessary
for self-renewing cell division and, thus, maintenance of the neural precursor population
[44-47]. Another recent studies have shown that Fbw7 acts as a molecular switch that antag‐
onizes Notch activity and JNK/c-Jun signaling to enable neural stem cell differentiation and
progenitor survival [48]. In tumor progenitors, the Notch receptors has been shown acting
as a trigger for stimulation of differentiation [49] and, in preclinical studies, it has been
shown experimental therapeutic implications [50]. Differentiation is mediated by tumor ne‐
crosis factor- α (TNF-α) activator enzyme and by the C-secretase, which is responsible for
the signal transcription to the nucleus for unlinking responses via transcription factor CBF1/
Su(H)/LAG1 (CSL) (homologous Drosophila gene Suppressor of Hairless /Longevity assur‐
ance gene 1 or cardiolipinsynthetase) [49]. This interaction results in the activation of target
genes responsible for preempting differentiation and apopotosis [49] and gives the opportu‐
nity for developing therapeutic options [49, 50]. The Notch signaling pathway prevents the
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with K-Ras (v-Ki-ras2; Kirsten rat sarcoma viral oncogene homolog) in promoting colony
formation [49-51].
A study demonstrated that the inhibition of the Notch-1 receptor induces apoptosis and inhib‐
its the proliferation of glial cell tumors that express CD133 [52]. This provides an opportunity
to modulate the pathways responsible of treatment resistance, since there are compounds
available that act as decoys, as inhibitors of Υ-secretase, as intracellular bait directed against
MAML-1 (mastermind-like 1), or simply as inhibitors of the Ras pathway [53, 54].
Epithelial Growth Factor is another important issue in the molecular changes on progenitor
cells. Using the model of the neurosphere [22], Singh et al. inoculated cells isolated from
high grade glioma into the cranium of immuno-suppressed rodents and observed that the
minimum number of cells required to produce a neoplasm was 1x105. However, when the
experiment was repeated using CD133+ cells stimulated by EGF, the number required was
reduced to 100-fold [25, 55]. It is important to note that CD133 expression occurs not only in
the neural and neoplastic progenitor cells but also in endothelial stem cells that participate
in blood vessel formation necessary for the development of normal brain and for tumorigen‐
esis [55, 56]. In preclinical models, activated EGFR signaling induce behaviors characteristic
of GB on stem cells, including enhanced proliferation, survival and migration, even in the
absence of EGF ligand. wtEGFR block neuronal differentiation and is associated with a dra‐
matic increase in chemotaxis in the presence of EGF. EGFRvIII expression lead to an increase
in neural stem cells proliferation and survival, while it simultaneously blocked neuronal dif‐
ferentiation and promoted glial fate. It gives an opportunity for terapeutic development on
this EGF field [57].
4. The micro-environment of progenitor cells and glial tumors
The presence of progenitor cells in Acute Myeloid Leukemia highlights the importance of
the micro-environment in maintaining its function, and the quiescent state [9, 12, 14]. The
perivascular niche of the glial tumor progenitor cells is highly specialized and depends, in
great part, on the capillaries that are similar to those in the periventricular region of the hu‐
man brain. At the proximity to the endothelial cells, enables inter-cellular communication
that causes enrichment with brain derived neurotrophic factor (BDNF), vascular endothelial
growth factor C (VEGF-C) and pigment factor derived from the endothelium (PEDF) [9];
molecules that facilitate, principally, migration and neoplasic proliferation. Even more, there
is consistent evidence that the extra-cellular matrix is responsible for key points in the regu‐
lation of tumor precursors via the tenascin-C gene. Expression of this gene by the cells of the
neural crest translates into anti-adhesive properties that block the interaction of fibronectin
with the syndecans [58]. Further, chondroitin sulfate continues stimulating the progenitor
cell to maintain its primitive state, and impedes evolution of its progeny.
Although the niche affects the biology of the progenitor cells in the tumor, the communica‐
tion is not unidirectional. Several studies have demonstrated that the precursors are able to
promote the replication of endothelial cells, including the necessary stimulus for the forma‐
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tion of complex neovascular structures [59, 60] by increasing the concentrations of VEGF
and BDNF [9, 60, 61]. Complementing these data, Calabrese et al. found, using multi-photon
laser scanning microscopy, that the CD133+/nestin+ cells were always found in the intimal
layer proximal to the vascular endothelium of GB, medulloblastomas, ependymomas and
oligodendrogliomas [61].
Classically, pathology of high-grade gliomas describes a disorganized and aberrant vascular
growth randomly generated to supply the voracity of the tumor. However, several recently
published reviews explain that this architecture is available in the altered form to serve as
lodging for the tumor precursors and their vascular analogues [9, 14].
Glial progenitor cells and their descendants are capable of interfering with the blood vessels
of the brain, using the effect known as “perivascular satellitosis”. Nevertheless, it is infre‐
quent to find extra-axial lesions. Clinically, the microvascular density of GB correlates with
prognosis [62]; a factor that contributes to the response observed in anti-angiogenesis, possi‐
bly dependent on VEGF generated in elevated quantities by the CD133+ cells [63, 64]. Fur‐
ther, the observation that CD133+ GB cells lose their ability to recruit endothelial cells and
form blood vessels after being exposed to low concentrations of bevacizumab suggests that
this effect is controlled, at least in part, by the decrease in the expression of VEGF, VEGFR2
and angiopoietin-2 (Ang-2) [9].
Data from pre-clinical studies and clinical trials indicate that three drugs that block angio‐
genesis may be promising therapy for high-grade gliomas, due to their inhibitory potential
on the niche of tumor progenitors. An estudy demonstrated that endothelial cells increase
brain tumor stem cell survival and targeting the tumor vasculature with bevacizumab re‐
duces the number of cancer stem cells in treated tumors [65]. Bevacizumab (humanized
monoclonal antibody against VEGF receptors 1 and 2) and cediranib (AZD2171, potent in‐
hibitor of VEGF receptor tyrosine kinases type 1, 2 and 3) are being evaluated currently in
clinical trials. [65, 66, 67]Those are agents that act on the VEGF 1, 2 and 3 receptors, suggest‐
ing an improvement in progression- free survival (PFS) and OS in patients with recurrent
high grade gliomas. Cilengitide blocks the αvβ6, αvβ5 y αvβ3 integrins [68] and has been
evaluated in clinical trials [69, 70]. As previously mentioned, the effect of these molecules is
the normalization of the tumor vessels, or the depletion of the blood flow, that interferes
with the maintenance and survival of the precursor and terminal cells of the tumor, thus,
anti-angiogenic therapy may function as a therapy against Glioma Stem Cells. A further nu‐
ance has come from early studies that suggest that glioblastoma cells can form parts of the
tumor vasculature [71]. It is likely that anti-angiogenic drugs might not only inhibit tumor
vascularization to suppress GB growth, but also directly disrupt the niches for the mainte‐
nance of GSCs, therefore weakening the ‘‘tumor roots’’.
5. Role of progenitor cells in meduloblastomas
The two germinal epithelia of the cerebellum are found in the deep ventricular zone of the
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matrix of the first of these regions gives rise to several neuronal and glial cell lines, and the
second, only produces granular cells which are the most numerous elements in all of the
prosencephalon [73]. In humans, peak growth of the cerebellum occurs later in comparison
with the remainder of the CNS, and its principal stage of development is in the third trimes‐
ter of gestation. In other more rudimentary mammalians this event occurs during the two
weeks following birth [74]. Nevertheless, evolution of this neural structure is observed in
children up to the end of the first year of life, and appears to be dependent on the presence
of the CD133+ cells, which are concentrated principally in the white matter and in the rhom‐
bic lips [75].
The evidence that connects the pluripotent neural cells with the tumor elements of the me‐
duloblastoma is merely correlative and is supported by the expression of the calbindin-D
(calcium binding protein D) among the precursors of normal cerebellum and, as well as be‐
ing found in 50% of the meduloblastomas, especially in those of the classical type. In con‐
trast, nodular lesions or desmoplasias express the marker p75, which suggests a dual tumor
origin. This hypothesis is supported by the behavior of the meduloblastomas induced in
murine models that frequently express CD133+ but which have a specific dissimilar evolu‐
tion such as, among other aspects, the aberrant activation of the Hedgehog (Hh) gene [76].
The Hh pathway regulates the development of the cerebellum in many species, but has car‐
dinal importance among humans, where it promotes migration of precursors of granular
cells, and their proliferation incited by the production of the Hh ligand in Purkinje cells. The
mutation in the PTCH (patched homolog 1) receptor which results in constitutive activation
of the Hh pathway is found in a great number of patients with sporadic meduloblastoma, as
well as in those with Gorlin syndrome, an autosomal dominant entity characterized by coex‐
istence of basal cell carcinomas and primitive neuroectodermal tumors [73, 75]. Approxi‐
mately 14% of the mice heterozygous for the PTCH mutation develop medulobastomas, in
which primary alterations of the precursors of the granular cells are frequently found, as
well as changes in the SMO (smoothened) and SUFU (suppressor of fused homolog) genes,
which are generators of this type of neoplasia in vivo [77]. Other animal models have dem‐
onstrated that meduloblastomas initiated by genetic changes in the different pathways of
Hh also result in the activation of this signaling pathway; in particular, the inactivation of
the CXCR6 (chemokine receptor CXCR6) that results in the expression of Gli1, Gli2 (GLI
family zinc finger 1 and 2), Ptc2 (Hh receptor Patched type 2) and Sfrp1(secreted frizzled-
related protein 1) proteins evident in the meduloblastomas, and which are susceptible to in‐
hibition of Hh with molecules such as cyclopamine, or with specific inhibitors such as Hh-
antagonist [78].
Another signaling pathway altered in sporadic and inherited meduloblastomas is the Wing‐
less/Wnt (wingless-type MMTV integration site family member) that regulates the prolifera‐
tion of progenitor cells in the deep ventricular region and in the hippocampus [9]. The loss
of Wnt1, a key effector of β-catenin, causes several abnormalities in the midbrain and in the
cerebellum, and is found over-expressed in classical meduloblastomas [79, 80]. Although its
role in the regulation of the pluripotent progenitors of the cerebellum is not clear, it appears
to depend on similar mutations to those identified in the patients with Turcot syndrome; an
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autosomal recessive condition caused by the loss of function of the adenomatous polyposis
gene, and which is present in 5% of meduloblastomas [80]. The mutations have also been
observed in a small subgroup of patients with primitive neuroectoderm tumors and results
in the decrease in expression of Axin-2 (plays an important role in the regulation of the sta‐
bility of beta-catenin in the Wnt signaling pathway); the gene that acts as negative regulator
of Wnt and which has been detected in a small group of patients with meduloblastoma [81].
The nuclear translocation of the β-catenin resulting in the activation of the Wnt pathway is
observed in 25% of the patients with meduloblastoma and, usually, corresponds to an ele‐
vated presence of the CD133 cells. Paradoxically, and in contrary to what occurs in high-
grade gliomas, their presence is associated with a favorable clinical evolution, related to the
absence of alterations in Hh and aberrations in chromosome 17 [82].
The Notch signaling pathway is observed to be active in the progenitor cells of the deep ven‐
tricular region and in the rhombic region. It promotes proliferation and survival and inhibits
cellular differentiation. The four isoforms of the receptor do not result in the same changes
in the cerebellum. For example, Notch-2 stimulates the proliferation of progenitors of the
granular neuromas, while Notch-1 is associated with their differentiation; a consistent find‐
ing in the classical forms of meduloblastomas [82]. Some primitive neuroectoderm tumors
show increase in the Notch-2 loci and in co-expression of the Hes1 pathway, that correlate
clinically with adverse prognosis; while other studies have provided evidence for alterna‐
tive and abnormal regulation Notch Hh pathway [72]. Finally, hypoxia and the protein
products that this activity generates, promote the proliferation of progenitor cells of the cer‐
ebellum stimulated by the Notch pathway; a finding that has been confirmed in medulo‐
blastomas [83]. Fig. (3) summarizes the principal signaling pathways of the neural
precursors of the cerebellum and of meduloblastomas.
Several subordinate pathways can promote the generation of meduloblastomas from neural
progenitor cells. The REN (renin) gene located on chromosome 17 promotes the differentia‐
tion of granular precursors, suppressing the Hh signals, an alteration that frequently results
in meduloblastoma [73]. The N-myc oncogene (v-mycmyelocytomatosis viral related onco‐
gene, neuroblastoma derived), which plays an essential role in cerebellum growth, is a pri‐
mary constituent of white matter of the Hh pathway in meduloblastoma and is observed to
be amplified in large cell variants, which favor a negative clinical outcome. Other transcrip‐
tion factors associated with the more primitive processes of progenitor cells of the cerebel‐
lum and tumor development are RE-1 (RE1-Silencing Transcription factor), OTX2
(orthodenticle homolog 2) and BMI1 (BMI1 polycomb ring finger oncogene) [72, 73]. A re‐
cent report described the substantial role of molecular alterations of CD15+/CD133− in the
induction of primitive neuroectoderm brain tumors [84].
6. Therapeutic implications of tumor progenitors
The prognostic implications of the presence of stem cells in gliomas has been examined in a
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radiotherapy and temozolamide (TMZ), evaluated the prognostic value of CD133 expression
and of the capacity of the tumor to generate CD133+ cells in culture. The CD133 status, as
determined by immunohistochemistry, had no prognostic value, but the in vitro capacity to
generate precursors was associated to a significant reduction in OS (HR: 2.50; 95%CI:
1.04-6.06; P = 0.004) of 8 (95%CI: 4.0-11.5) and 15 months (95%CI: 11.0-19.0) for tumors with
higher and lower quantity of CD133+ cells, respectively (P = 0.0002). Similarly, the PFS was
also associated to the ability to generate precursors from the tumor (3.5 months for high ver‐
sus 9.0 months for low grade; P = 0.0001). The CD133+ count was also associated with a
higher mortality risk (HR: 1.65; 95%CI: 1.05-2.60; P = 0.0285) [85]. A similar study examining
high grade oligodendrogliomas found that tumors without CD133+ cells had an improved
prognosis, and this marker predicted clinical outcome better than histological assessment
[86]. Another immunohistochemical analysis for nestin and CD133 of both, low grade and
high grade gliomas, revealed that their expression correlates with survival, with tumors that
co-express nestin+/CD133+ carrying a shorter survival [87]. These findings have stimulated
the active search for new therapeutic strategies directed against the precursors of cerebral
tumors, and their microenvironment.
Therapeutic interventions directed against cerebral tumor progenitor cells can be divided in‐
to three groups: firstly, directed towards provoking differentiation of the precursors; sec‐
ondly, designed to eliminate the progenitor cells inhibiting their multi-potentiality and
quiescence; thirdly, directed towards attacking the tumor microenvironment [88, 89].
The therapies that provoke differentiation of the progenitors focus on the capacity to reverse
the malignant state and, essentially, to recover the auto-regenerative property [90]. To-date,
two groups of medications affect differentiation: derivatives of retinoic acid and compounds
directed against epigenetic changes (histone deacetylators).
Among the compounds directed towards eliminating progenitor cells, the therapies of note
are those that are directed against tumor markers of progenitor cells expressed in cellular
membrane (antibodies against CD133+) [9], the inhibitors of the Hh pathway (cyclopamine,
NBT-272) [91], PPAR-γ agonists [92], TMZ [93], inhibitors of mTOR (sirolimus, everolimus,
temsirolimus, deforolimus) [94], derivatives of bone morphogenetic protein (BMP) [95], tar‐
get molecules directed against check-points that avoid damage induced by radiotherapy in
the progenitors (Chk1 and Chk2, checkpoint homolog type 1 and 2) [15], imatinib [96, 97]
and inhibitors of the ABCB super-family [98]. Similarly, it is important to mention the drugs
that modify the micro-environment, among which are the angiogenesis blocking drugs such
as bevacizumab [65], cediranib [67] and cilengitide [68, 69] and, equally, the inhibitors of
PI3K (phosphoinositide-3-kinase) that could act turning the medulloblastoma progenitors
closest to the vascular niche more sensitive to irradiation, as in vitro studies show for human
endothelial cells precursors [99]. Fig. (4) highlights some strategies directed against the cell
precursors of brain tumors.
The effect of retinoic acid on the CD133+ cells appears to be related to the repression of the
Wnt/β-catenin pathway that slows the proliferation accompanying over-expression of Axin
[100]. The same strategy is used in a preclinical model to test the effectiveness of combining
13-cis-retenoic acid with vorinostat (SAHA) in medulloblastoma cells in culture. Retinoic
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acid acts on the transcriptional activation of BMP-2 (Bone morphogenetic protein 2), and SA‐
HA facilitates the apopotosis controlling chromatin; effects that lead to an increase in the
sensitivity to cisplatin and etoposide [101]. Heat shock protein 90 (HSP90) operates as a sup‐
plier of β-catenin during its conformational maturation phase. The inhibitor 17-allylami‐
no-17-demethoxygeldanamycin (17-AAG) modifies the HSP90 phenotype and affects the
aberrant expression of the β-catenin. This enables the inhibition (in vivo and in vitro) of the
growth of several cell lines of glioma and their progenitors CD133+, and translates into an
increase in the effect of radiation on the GB; a finding that is more evident during exposure
to TMZ [102].
With respect to the preponderant role of Hh in the development of normal and tumor pro‐
genitor cells, Bar et al explored the effectiveness of cyclopamine in a subpopulation of pri‐
mordial GB cells [103]. In the study, 26% of the samples showed Gli (transcription factors
mediating the Hh pathway isolated from Glioblastoma) over-expression, a target function of
this pathway that was inhibited satisfactorily in 60% of the cases. The outcome was a signifi‐
cant decrease in the CD133+ progenitor growth. In parallel, the administration of cyclopa‐
mine on neurospheres inhibited the generation of new colonies, suggesting a regression of
the clonogenic capacity of the glioma progenitors.
Beier et al. demonstrated that TMZ is incapable of inducing death of the CD133+ cells. Pro‐
liferation was effectively inhibited by reducing its metabolism in vitro by 72% following 7
days of incubation [93]. Depending on the subtype of cells, TMZ induces arrest in the G2-M
transition or delay in the cell cycle at G2. However, in all the cultures, the cells at sub-G0
peak of apopotosis, was <8%. Genetical analysis shows that the pattern of presentation of
the promoter of the MGMT gene was greater among the negative cells, which does not ex‐
plain the susceptibility of the progenitors to the alkylating agent [93].
Glial progenitors and their progeny conserve a mechanism of homogeneous differentiation
promoted by BMP (bone morphogenetic protein) and its ligands, reducing slightly the quan‐
tity of CD133+ cells and favoring the increase in the astroglia and of the cellular elements,
similar to neurons. An study observed in some in vivo models that the therapeutic stimulus
of the different isoforms of BMP delays tumor growth and the potential for vascular inva‐
sion of the GB [104].
Cancer stem cells from GB specimens seems to be immune suppressive as they inhibit mito‐
gen T cell proliferation from normal donors [105].Therefore targeting specifically cancer
stem cells may revert the immune suppressive microenvironment induced by these cells, al‐
lowing a synergistic effect when combined with immune therapy. On the other hand GB de‐
rived stem cells may be a source of unique antigens that can be used for dendritic cell
vaccination, as has been demonstrated in the animal model [106].
As previously mentioned, the use of bevacizumab attenuates the capacity of the tumor pro‐
genitors to promote angiogenesis, and it will be seen not only following the regulation of
acidosis and hypoxia but also by the activation of oncogenes such as PTEN and EGFR [64,
107]. Cediranib, a pan-inhibitor of VEGF receptor, normalizes the blood vessels of the tumor
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production of the CD133+ progenitors and the endothelium precursor cells is reduced [66].
Cilengitide reduces the expression of αvβ3 integrin in the tumor micro-environment. The
migratory and proliferative capacity of the precursors is reduced by up to 60%; an effect that
appears to be dependent on the dose and on the co-expression of other surface antigens of
the endothelial cells (CD144 and von Willebrand factor) [68-70].
Aldehyde dehydrogenase function is used by cancer stem cells to repopulate a tumor mass
after chemotherapy cytoreduction. As in hematopoyetic stem cells, it would be spected that
inhibition of Aldehyde dehydrogenase helps differentiate cells. With the inhibition of alde‐
hyde dehydrogenase, stem cell division to non-stem daughter cells tends to become blocked.
Exist potent aldehyde dehydrogenase inhibitors on the market: chloral hydrate, chloram‐
phenicol, and disulfiram, that could be useful [108].
7. Conclusion
Our understanding about cancer and the relationship with the theory of stem cells is grow‐
ing up as the tumoral incidence around the world does.
Advances in molecular cell biology will give to the oncology physicians and scientist the
tools for understanding the processes underlying tumorgenesis and intracelullar processes
for viability, serving as possible targets in oncotherapy, diagnosis and prognosis.
Molecular characteristics that give susceptibility for brain tumors to some therapies encour‐
age the clinicians to become experts for giving the best therapeutic choices according to mo‐
lecular guidance for radio/chemotherapy or other alternatives, like biological therapy,
immunotherapy and experimental treatment options.
Future about stem cells as a chapter of brain tumors is on the road for establish individual‐
ized treatment profiles, depending on clinical, pathological and molecular characteristics of
patients and tumors, a traslational analysis from the molecules to the patients.
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1. Introduction
Glioblastomas are the most common primary malignant neoplasms in the adult brain, and
have the characteristics of glial cells [1]. The WHO histopathological classification guidelines
categorize gliomas according to their histopathological grades; low-grade gliomas are not
anaplastic and are associated with a favorable patient prognosis, while high-grade gliomas
exhibit increased cellularity, nuclear atypia, mitotic activity, microvascular proliferation,
and necrosis. Glioblastomas are the highest grade of the gliomas. Surgical treatment is the
main therapy used for glioblastomas, with radiotherapy and chemotherapy performed as
adjuvant care. Despite intensive research and recent advances in treatment, the prognosis
for patients with glioblastoma remains poor, with a five-year survival rate of approximately
3% [2, 3]. In addition to having rapid growth rates, glioblastomas aggressively invade the
adjacent normal brain tissues, they are often surgically unresectable, and recurrent glioblas‐
tomas are resistant to conventional radiotherapy and chemotherapy.
Nestin is a class VI intermediate filament protein that was first described as a neural stem/
progenitor cell marker [4, 5]. Neuroepithelial stem cells can differentiate into neurons, oligoden‐
drocytes, and astrocytes, and nestin has been shown to be down-regulated or to completely dis‐
appear during such differentiation. Nestin-positive neuroepithelial stem cells are detected in the
subventricular zone of the human adult brain and they remain mitotically active throughout
adulthood [6]. Unlike other intermediate filament proteins, nestin plays important roles in cellu‐
lar processes, including stemness, migration, and cell cycle regulation.
Nestin expression has been reported in various types of tumor cells originating from the
central nervous system, including glioblastomas. Several reports have indicated a close rela‐
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tionship between neuroepithelial stem cells and glioblastoma cells at their origin because
both cell types express the same stem cell markers, such as CD133 and nestin. High-grade
gliomas express higher nestin levels compared to low-grade gliomas [7, 8]. We have report‐
ed that knockdown of nestin using short hairpin RNA (shRNA) suppressed cell growth, mi‐
gration, and invasion [9]; therefore, nestin may serve as a novel candidate for molecular
targeted therapy for glioblastomas. In the present chapter, we summarize the available data
regarding the expression and roles of nestin in normal brain tissues and brain tumor tissues,
and discuss the possibility of using nestin as a novel therapeutic target in brain tumors,
mainly for glioblastomas.
2. Structure and characterization of nestin
Nestin is a large protein (>1600 amino acids) that contains a short N-terminal and an unusu‐
ally long C-terminal. It interacts with other intermediate filament proteins, including vimen‐
tin, desmin, and internexin, to form heterodimers and mixed polymers; however, in contrast
to other intermediate filament proteins, nestin cannot form homopolymers [10]. The nestin
gene has four exons and three introns; in humans, neural cell-specific expression is reported‐
ly regulated by the second intron, whereas nestin expression in tumor endothelium is en‐
hanced by the first intron [11]. Nestin is known to be phosphorylated on Thr316 by cdc2
kinase [12] and/or cyclin-dependent kinase 5 [13], and to modulate mitosis-associated cyto‐
plasmic reorganization during mitosis. However, the roles of glycosylation of nestin have
not been closely examined [14].
During early stages of development, nestin is expressed in dividing cells in the central nerv‐
ous system (CNS), peripheral nervous system, and in myogenic and other tissues. During
differentiation in normal brain tissue, nestin expression is downregulated and replaced by
expression of tissue-specific intermediate filament proteins; therefore, nesting is widely used
as a neuronal stem cell marker. Nestin is also expressed in immature non-neuronal cells and
progenitor cells in normal tissues [15-17]. High levels of nestin expression have been detect‐
ed in oligodendroglial lineage cells, ependymocytes, Sertoli cells, enteroglia, hair follicle
cells, podocytes of renal glomeruli, pancreatic stellate cells, pericytes, islets, optic nerve, and
odontoblasts [18-23].
In pathological conditions, nestin is re-expressed during repair processes, as well as in vari‐
ous neoplasms and proliferating endothelial cells. Nestin expression has been observed in
repair processes in the CNS, muscle, liver, and infarcted myocardium [24-26]. Furthermore,
increased nestin expression has been reported in various tumor cells, including CNS tumors,
pancreatic cancer, gastrointestinal stromal tumors (GISTs), prostate cancers, breast cancers,
malignant melanomas, dermatofibrosarcoma protuberances, and thyroid tumors [27-31]. In
several tumors, expression of nestin has been reported to be closely correlated with poor
prognosis. Nestin is specifically expressed in proliferating small-sized vascular endothelial
cells in glioblastomas and in colorectal, prostate, and pancreatic cancers [7, 32-34].
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3. Nestin in normal fetal and adult brain tissues
Many lines of evidence have shown nestin-positive brain cells to be neural stem/progenitor
cells; therefore, a great deal of research has involved the use of nestin to detect neural stem
cells [35-37]. Children, but not adult humans, exhibit nestin-positive cells in the subventricu‐
lar zone of the third ventricle [6], and the human embryonic midbrain stem cell line
NGC-407 showed degradation of nestin after induction of differentiation [38]. However, in
adult mice, nestin-positive cells were detected in CA2 lesions of the hippocampus after tran‐
sient ischemia [39]. Another study reported that nestin-positive neuroepithelial stem cells
are detected in the subventricular zone of the human adult brain and remain mitotically ac‐
tive throughout adulthood [40]. Nestin has been used for research in the field of neural pro‐
genitor cells; for example, neural progenitor cell-specific gene transfection was successfully
performed using a nestin-driven gene transfection system [41-46]. A recent study has shown
that nestin is also a stem/progenitor cell marker in the pituitary gland [47].
4. Nestin in various types of brain tumors
Nestin expression in brain tumor cells has been reported in schwannomas [48], ependymo‐
mas [49, 50], neurocytomas [51], adamantinomatous craniopharyngiomas [52], pituitary ade‐
nomas [53], medulloblastomas [54-59], oligodendrogliomas [60], and glioblastomas [7, 8, 48,
61] (Table 1). Tissue microarrays of 257 brain tumors have revealed frequent nestin expres‐
sion in gliomas and schwannomas [48]. Another analysis included 379 tumors, and the re‐
sults further revealed that nestin immunoreactivity is associated with poor outcome in
intracranial ependymomas, and that nestin is an independent marker for poor progression-
free survival and overall survival [49].
Expression of nestin has also been reported in tanycytic ependymoma, a rare variant of
ependymoma [50], and central neurocytoma cases express nestin, as determined by PCR
[51]. Co-expression of nestin, microtubule-associated protein 2 (MAP2), and GFAP has been
reported in adamantinomatous craniopharyngiomas [52]. In pituitary adenomas, CD133-
positive cells ubiquitously co-express CD34, nestin, and VEGFR2, and may play a role in the
neovascularization of tumors [53]. Human medulloblastoma cell lines [54] and medulloblas‐
toma stem cells [55-58] express nestin, and secreted protein acidic and rich in cysteine
(SPARC) has been shown to induce neuronal differentiation in medulloblastoma cells with
elevations of nestin, NeuN, and neurofilament [59]. One study found that oligodendroglio‐
mas express no or weak nestin, but high Olig2 and alpha-internexin [60]. Oligoastrocytomas
moderately express nestin, while astrocytoma and glioblastoma strongly express nestin.
Nestin is an intermediate filament protein and is localized in the cytoplasm in most brain
tumors; however, in human neuroblastoma and medulloblastoma cell lines, nestin has been
observed in nuclei [62], suggesting that nestin may directly bind to DNA or intranucleic pro‐
teins. Altogether, these findings demonstrate that nestin is expressed in a wide variety of
brain tumors and that this expression correlates with their functions or cell behaviors.
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Brain tumors Expression pattern and roles
Schwannomas Frequent nestin expression [48]
Ependymomas Poor progression-free survival and overall survival [49]
Neurocytomas [51] N/D
Adamantinomatous craniopharyngiomas Expressed in the invasion niche [52]
Pituitary adenomas Coexpressed with CD133 [53]
Medulloblastomas Expressed in tumor stem cells [55-58]
Oligodendrogliomas [60] N/D
Gliomas High grade [7,8]
Worse overall survival [48,61]
Glioblastomas Infiltration into surrounding tissue [8]
 Tumor stem cells [72-77]
N/D: Not determined.
Table 1. Expression and roles of nestin in brain tumors
5. Nestin in glioblastoma
5.1. Nestin in low-grade gliomas and glioblastomas
Immunohistochemical analysis has demonstrated nestin expression in the cytoplasm of glio‐
blastoma cells (Figure 1). Large-scale and multicenter studies have shown high immunor‐
eactivity of nestin in glioma cases to be correlated with high grade [7, 8] and worse overall
survival [48, 61] (Table 1). Furthermore, expression of nestin and MIB-1 labeling indices in
immunohistochemical analyses may correlate with aggressiveness of pilocytic astrocytoma
and pilomyxoid astrocytoma [63]. An analysis of several stem cell markers—including
CD133, nestin, B lymphoma Mo-MLV insertion region 1 homolog (BMI-1), Maternal embry‐
onic leucine zipper kinase (MELK), and Notch 1-4—was performed using quantitative RT-
PCR in 42 glioblastoma samples; MELK was most upregulated, followed by nestin [64]. In
contrast, others have reported that nestin immunoreactivity is mostly due to an acute glial
reaction and is not specific to the neoplasm [65], and that nestin expression in gliomas does
not correlate with prognosis [66].
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Figure 1. Expression of nestin in glioblastomas. Bar, 100 μm
Immunostaining of nestin in glioblastoma cells has been demonstrated to delineate between
invading tumor and the adjacent gray and white matter; therefore, nestin is considered to be
a useful marker for examining the infiltration of glioblastomas into surrounding tissues [8].
Furthermore, knockdown of nestin in human glioblastoma cells has been shown to suppress
cell migration and invasion, and to increase F-actin expression and cell adhesion to extracel‐
lular matrices [9].
Nestin-positive non-tumorous brain cells migrate into the glioblastoma cells and delay as‐
trocytic or elongated bipolar morphology and glomerulus-like microvasculature [67]; there‐
fore, nestin-positive cells have been considered an important component of the tumor
microenvironment. CD133-positive and nestin-positive niches are perivascularly localized in
all glioma tissues, and the presence of these niches increases significantly with increasing tu‐
mor grade [68]. Mice were engineered to co-express platelet-derived growth factor B recep‐
tor and Bcl-2 under the control of the glioneuronal-specific nestin promoter, and this
resulted in the development of low- and high-grade gliomas [69]. Another study found that
human glioblastoma subclones characterized by high nestin levels formed tumors in vivo at
a significantly faster rate than subclones with low nestin expression, suggesting that induc‐
tion of nestin plays an important role in glioblastoma carcinogenesis [70]. However, the op‐
posite result has also been reported [71].
5.2. Nestin in glioma stem cells
Cancer stem cells appear to be responsible for tumor metastasis, resistance to radiotherapy
and chemotherapy, and disease relapse; thus, their analysis and therapeutic targeting are be‐
lieved to be crucial. Many studies have shown that there is a small population of cancer
stem cells in glioblastomas, and that nestin is one of the stem/progenitor cell markers of glio‐
blastomas [72-77]. CD133, Oct4, Sox2, and Nanog have also been considered to be stem cell
markers in glioblastomas [78, 79]. However, CD133-negative and nestin-negative glioblasto‐
ma cells show tumorigenic potential in vivo [71]; thus, there remains some controversy over
which specific markers should be used to detect glioblastoma stem cells. An in vitro study
has shown that neurospheres of glioblastoma cells exhibit high expressions of nestin,
CD133, and Oct4 compared to the expressions in monolayer cells [80]. One study reported
that radiation induces increased expressions of stem cell markers, including nestin, CD133,
and Musashi [81]; in contrast, another study has shown that radiation induced accumulation
of CD133-positive glioblastoma cells, but not nestin [82]. Glioblastoma stem cells are main‐
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blastomas [72-77]. CD133, Oct4, Sox2, and Nanog have also been considered to be stem cell
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ma cells show tumorigenic potential in vivo [71]; thus, there remains some controversy over
which specific markers should be used to detect glioblastoma stem cells. An in vitro study
has shown that neurospheres of glioblastoma cells exhibit high expressions of nestin,
CD133, and Oct4 compared to the expressions in monolayer cells [80]. One study reported
that radiation induces increased expressions of stem cell markers, including nestin, CD133,
and Musashi [81]; in contrast, another study has shown that radiation induced accumulation
of CD133-positive glioblastoma cells, but not nestin [82]. Glioblastoma stem cells are main‐
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tained in vivo in a niche characterized by hypoxia, and hypoxia reportedly increases the ex‐
pressions of nestin, CD133, podoplanin, and Bmi-1 [83]. Together, these available data
suggest that there is close relationship between nestin and stemness in glioblastoma.
Expression of nestin in cancer stem cells of glioblastoma may indicate the origin and func‐
tion of these cells. Potential cancer stem cell origins include migration of neural stem cells
toward the tumor, migration of mesenchymal stem cells from bone marrow, or dedifferen‐
tiation of tumor cells [84]; each of these hypotheses have been proven experimentally. In
brain tumors, long-term cultured human neural stem cells undergo spontaneous transfor‐
mation to tumor-initiating cells [37]. In contrast, Nanog promotes dedifferentiation of p53-
deficient mouse astrocytes into glioblastoma stem cells [85]. These results indicate that
glioblastoma stem cells may arise from both the transformation of nestin-positive neural
stem cells and differentiated astrocytes. Retinoic acid treatment for glioblastoma stem cells
was demonstrated to reduce the expression of neural stem cell markers, such as nestin,
CD133, Msi-1, and Sox-2 [86].
Xenografts developed from human anaplastic astrocytoma and glioblastoma tumor-derived
spheres in the brain of a nude mouse revealed co-expression of PCNA, VCAM-1, caspase-3,
and nestin [87]. Cells positive for both caspase-3 and nestin were located adjacent to or
around the blood vessels. Glioblastoma stem cells expressed nestin/CD31 or CD133/CD31,
and these cells were capable of differentiating into endothelial cells [88]. Dong et al. have
shown that human glioma stem/progenitor cells transdifferentiate into vascular endothelial
cells in vitro and in vivo [89]. Glioblastoma stem cells have close relationships with the an‐
giogenic switch, intratumor hypoxia, and the neoplastic microvascular network. These find‐
ings provide new insights for targeted therapy against glioblastomas.
5.3. Regulation of nestin in glioblastoma cells
Glioblastomas usually show hyperactivation of the PI3K-Akt pathway. Exogeneous expres‐
sion of the Akt-binding domain of Girdin inhibits its Akt-mediated phosphorylation, and re‐
portedly diminishes migration and the expression of the stem cell markers nestin and SOX2
[90]. Nestin expression in glioblastomas is correlated with proangiogenic chemokines
(CXCL12 and its receptor CXCR4) and growth factors (VEGF and PDGF-B and its receptor
PDGFRbeta) [91]. Hypoxia and radiation are both inducers of stem cells, and were associat‐
ed with increased expression of nestin [81, 83]. In glioblastoma cases, a 9-gene profile that
included podoplanin and insulin-like growth factor binding protein 2 was found to predict
the prognosis, and was also positively associated with expressions of nestin and CD133 [92].
Additionally, the enhancer lesion of nestin is known to be located in the second intron in
neural cells, and this lesion is highly conserved in mouse, rat, and human [93].
5.4. Nestin in interstitial tissues and angiogenesis of glioblastoma
Glioblastoma-conditioned medium has been shown to induce human mesenchymal stem
cells (hMSCs) to increase expressions of nestin, CD151, VE-cadherin, desmin, α-smooth
muscle actin, and nerval/glial antigen 2—indicating pericyte-like differentiation, rather than
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differentiation to endothelial cells or smooth muscle cells [94]. hMSCs migrate towards glio‐
blastoma and are incorporated into tumor microvessels.
Much evidence has shown that expression of nestin in vascular endothelial cells is associat‐
ed with proliferation and angiogenesis [32, 95-98]. In glioblastomas, expression of nestin in
both tumor cells and endothelial cells was increased according to increasing tumor grade
[7]. A recent study has indicated that the capillaries in gliomas may come from the differen‐
tiation of glioblastoma stem cells, and that the glioblastoma stem cells are accumulated
around the capillaries [99]. In contrast, CD105 has been proposed to be a more useful marker
of tumor angiogenesis in glioblastomas than nestin [100]. The morphology of nestin-positive
cells in brain tumors is reportedly more typical of neural stem cells, and less than 0.1% of
these cells co-express the endothelial marker CD34 [101].
5.5. Nestin as a therapeutic target for glioblastoma
We have reported that knockdown of nestin using shRNA suppresses cell migration and in‐
vasion [9]. Lu et al. demonstrated that blocking the expression of nestin in glioblastomas via
intratumor injection of shRNA significantly slowed tumor growth and volume [70]; there‐
fore, nestin may serve as a novel candidate for molecular targeted therapy for glioblastomas
[9]. The phytoalexin resveratrol suppresses cell growth, migration, invasion, and expression
of nestin in glioblastoma cells [102]. It has been shown that peptides can bind to a nestin iso‐
type that is specifically expressed in glioma stem cells, which enables them to target nestin-
positive cells in human glioma tissue [103]. Future studies should focus on developing
delivery systems to target these anti-nestin reagents to brain tumors, and on the estimation
of the side-effects for normal brain stem cells that express nestin.
6. Conclusion
The neuronal stem cell marker nestin regulates cell growth, migration, invasion, and stem‐
ness, and has been found to be expressed in a wide variety of brain tumors. Nestin may be a
candidate for the development of promising therapeutic and diagnostic modalities for glio‐
blastoma.
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A dramatic increase in knowledge regarding the molecular biology of brain tumors 
has been established over the past few years.  In particular recent new avenues 
regarding the role of stem cells and microRNAs along with further understanding of 
the importance of angiogenesis, immunotherapy and explanations for the resistance 
of the tumors to chemotherapeutic agents and radiation therapy has been developed.  
It is hopeful that this new information will lead to efficacious treatment strategies for 
these tumors which remain a challenge.  In this book a review of the latest information 
on these topics along with a variety of new therapeutic treatment strategies with an 
emphasis on molecular targeted therapies is provided.
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